FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Hunter, JC Nguyen, D Aden, B Al Bandar, Z Al Dhaheri, W Abu Elkheir, K Khudair, A Al Mulla, M El Saleh, F Imambaccus, H Al Kaabi, N Sheikh, FA Sasse, J Turner, A Wareth, LA Weber, S Al Ameri, A Abu Amer, W Alami, NN Bunga, S Haynes, LM Hall, AJ Kallen, AJ Kuhar, D Pham, H Pringle, K Tong, SX Whitaker, BL Gerber, SI Al Hosani, FI AF Hunter, Jennifer C. Duc Nguyen Aden, Bashir Al Bandar, Zyad Al Dhaheri, Wafa Abu Elkheir, Kheir Khudair, Ahmed Al Mulla, Mariam El Saleh, Feda Imambaccus, Hala Al Kaabi, Nawal Sheikh, Farrukh Amin Sasse, Jurgen Turner, Andrew Wareth, Laila Abdel Weber, Stefan Al Ameri, Asma Abu Amer, Wesal Alami, Negar N. Bunga, Sudhir Haynes, Lia M. Hall, Aron J. Kallen, Alexander J. Kuhar, David Huong Pham Pringle, Kimberly Tong, Suxiang Whitaker, Brett L. Gerber, Susan I. Al Hosani, Farida Ismail TI Transmission of Middle East Respiratory Syndrome Coronavirus Infections in Healthcare Settings, Abu Dhabi SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SAUDI-ARABIA; FAMILY CLUSTER; OUTBREAK; FACILITIES; RIYADH; JEDDAH AB Middle East respiratory syndrome coronavirus (MERS-CoV) infections sharply increased in the Arabian Peninsula during spring 2014. In Abu Dhabi, United Arab Emirates, these infections occurred primarily among healthcare workers and patients. To identify and describe epidemiologic and clinical characteristics of persons with healthcare-associated infection, we reviewed laboratory-confirmed MERS-CoV cases reported to the Health Authority of Abu Dhabi during January 1, 2013 May 9, 2014. Of 65 case-patients identified with MERS-CoV infection, 27 (42%) had healthcare-associated cases. Epidemiologic and genetic sequencing findings suggest that 3 healthcare clusters of MERS-CoV infection occurred, including 1 that resulted in 20 infected persons in 1 hospital. MERS-CoV in healthcare settings spread predominantly before MERS-CoV infection was diagnosed, underscoring the importance of increasing awareness and infection control measures at first points of entry to healthcare facilities. C1 [Hunter, Jennifer C.; Duc Nguyen; Alami, Negar N.; Bunga, Sudhir; Haynes, Lia M.; Hall, Aron J.; Kallen, Alexander J.; Kuhar, David; Huong Pham; Pringle, Kimberly; Tong, Suxiang; Whitaker, Brett L.; Gerber, Susan I.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Aden, Bashir; Al Bandar, Zyad; Al Dhaheri, Wafa; Abu Elkheir, Kheir; Khudair, Ahmed; Al Mulla, Mariam; El Saleh, Feda; Al Hosani, Farida Ismail] Hlth Author Abu Dhabi, Abu Dhabi, U Arab Emirates. [Imambaccus, Hala; Al Kaabi, Nawal; Sheikh, Farrukh Amin; Sasse, Jurgen; Turner, Andrew; Wareth, Laila Abdel; Weber, Stefan] Abu Dhabi Hlth Serv Co, Abu Dhabi, U Arab Emirates. [Al Ameri, Asma; Abu Amer, Wesal] Sheikh Khalifa Med City, Mol Diagnost Lab, Abu Dhabi, U Arab Emirates. RP Hunter, JC (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A24, Atlanta, GA 30329 USA. EM xdd9@cdc.gov FU US CDC; Health Authority of Abu Dhabi FX These activities were was supported by the US CDC and Health Authority of Abu Dhabi. NR 27 TC 9 Z9 9 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2016 VL 22 IS 4 BP 647 EP 656 DI 10.3201/eid2204.151615 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DH3LM UT WOS:000372688500009 PM 26981708 ER PT J AU Islam, MS Sazzad, HMS Satter, SM Sultana, S Hossain, MJ Hasan, M Rahman, M Campbell, S Cannon, DL Stroher, U Daszak, P Luby, SP Gurley, ES AF Islam, M. Saiful Sazzad, Hossain M. S. Satter, Syed Moinuddin Sultana, Sharmin Hossain, M. Jahangir Hasan, Murshid Rahman, Mahmudur Campbell, Shelley Cannon, Deborah L. Stroeher, Ute Daszak, Peter Luby, Stephen P. Gurley, Emily S. TI Nipah Virus Transmission from Bats to Humans Associated with Drinking Traditional Liquor Made from Date Palm Sap, Bangladesh, 2011-2014 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID OUTBREAK; ENCEPHALITIS; INFECTION; MALAYSIA; ACCESS; INDIA AB Nipah virus (NiV) is a paramyxovirus, and Pteropus spp. bats are the natural reservoir. From December 2010 through March 2014, hospital-based encephalitis surveillance in Bangladesh identified 18 clusters of NiV infection. The source of infection for case-patients in 3 clusters in 2 districts was unknown. A team of epidemiologists and anthropologists investigated these 3 clusters comprising 14 case-patients, 8 of whom died. Among the 14 case-patients, 8 drank fermented date palm sap (tari) regularly before their illness, and 6 provided care to a person infected with NiV. The process of preparing date palm trees for tari production was similar to the process of collecting date palm sap for fresh consumption. Bat excreta was reportedly found inside pots used to make tari. These findings suggest that drinking tari is a potential pathway of NiV transmission. Interventions that prevent bat access to date palm sap might prevent tari-associated NiV infection. C1 [Islam, M. Saiful; Sazzad, Hossain M. S.; Satter, Syed Moinuddin; Hossain, M. Jahangir; Hasan, Murshid; Luby, Stephen P.; Gurley, Emily S.] Icddr B, Dhaka, Bangladesh. [Sultana, Sharmin; Rahman, Mahmudur] Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh. [Hossain, M. Jahangir] MRC, London, England. [Campbell, Shelley; Cannon, Deborah L.; Stroeher, Ute] Ctr Dis Control & Prevent, Atlanta, GA USA. [Daszak, Peter] EcoHlth Alliance, New York, NY USA. [Luby, Stephen P.] Stanford Univ, Ctr Innovat Global Hlth, Stanford, CA 94305 USA. RP Islam, MS (reprint author), Icddr B, Ctr Communicable Dis, 68 Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh. EM saiful@icddrb.org RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X FU US Centers for Disease Control and Prevention (CDC) [5U01CI000628-01]; US National Institutes of Health (NIH) [07-015-0712-52200]; National Science Foundation/NIH Ecology and Evolution of Infectious Diseases from the Fogarty International Center [2R01-TW005869] FX The study was funded by the US Centers for Disease Control and Prevention (CDC) cooperative agreement no. 5U01CI000628-01, the US National Institutes of Health (NIH) grant no. 07-015-0712-52200 (Bangladesh-NIH/Emerging Infectious Disease), and National Science Foundation/NIH Ecology and Evolution of Infectious Diseases grant no. 2R01-TW005869 from the Fogarty International Center. ICDDR,B also acknowledges with gratitude the commitment of CDC, NIH, and the government of Bangladesh to its research efforts. icddr,b is also grateful to the governments of Australia, Bangladesh, Canada, Sweden, and the United Kingdom for providing core/unrestricted support. NR 39 TC 3 Z9 4 U1 1 U2 12 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2016 VL 22 IS 4 BP 664 EP 670 DI 10.3201/eid2204.151747 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DH3LM UT WOS:000372688500011 PM 26981928 ER PT J AU Lamers, MM Raj, VS Shafei, M Ali, SS Abdillh, SM Gazo, M Nofal, S Lu, XY Erdman, DD Koopmans, MP Abdallat, M Haddadin, A Haagmans, BL AF Lamers, Mart M. Raj, V. Stalin Shafei, Mah'd Ali, Sami Sheikh Abdillh, Sultan M. Gazo, Mahmoud Nofal, Samer Lu, Xiaoyan Erdman, Dean D. Koopmans, Marion P. Abdallat, Mohammad Haddadin, Aktham Haagmans, Bart L. TI Deletion Variants of Middle East Respiratory Syndrome Coronavirus from Humans, Jordan, 2015 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SAUDI-ARABIA; TRANSMISSION; OUTBREAK; PROTEIN; RIYADH; 4A AB We characterized Middle East respiratory syndrome coronaviruses from a hospital outbreak in Jordan in 2015. The viruses from Jordan were highly similar to isolates from Riyadh, Saudi Arabia, except for deletions in open reading frames 4a and 3. Transmissibility and pathogenicity of this strain remains to be determined. C1 [Lamers, Mart M.; Raj, V. Stalin; Koopmans, Marion P.; Haagmans, Bart L.] Erasmus Univ, Med Ctr, Rotterdam, Netherlands. [Shafei, Mah'd; Ali, Sami Sheikh; Abdillh, Sultan M.; Gazo, Mahmoud; Nofal, Samer; Abdallat, Mohammad; Haddadin, Aktham] Jordan Minist Hlth, Amman, Jordan. [Lu, Xiaoyan; Erdman, Dean D.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Haagmans, BL (reprint author), Erasmus MC, Dept Virosci, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.; Haddadin, A (reprint author), Jordan Minist Hlth, Lab Directorate, CPHL, Natl Influenza Ctr, Amman, Jordan. EM draktham@gmail.com; b.haagmans@erasmusmc.nl OI Victor, Stalin Raj/0000-0003-2250-8481 FU ZonMW, TOP Project [91213066]; EU [643476]; Erasmus Graduate Program Infection and, Immunity (NWO grant) [022.005.032] FX This study was supported by ZonMW, TOP Project (grant no. 91213066), EU H2020 COMPARE (grant agreement no. 643476), and the Erasmus Graduate Program Infection and, Immunity (NWO grant no.022.005.032). NR 14 TC 4 Z9 4 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2016 VL 22 IS 4 BP 716 EP 719 DI 10.3201/eid2204.152065 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DH3LM UT WOS:000372688500021 PM 26981770 ER PT J AU Ao, TT Rahman, M Haque, F Chakraborty, A Hossain, MJ Haider, S Alamgir, ASM Sobel, J Luby, SP Gurley, ES AF Ao, Trong T. Rahman, Mahmudur Haque, Farhana Chakraborty, Apurba Hossain, M. Jahangir Haider, Sabbir Alamgir, A. S. M. Sobel, Jeremy Luby, Stephen P. Gurley, Emily S. TI Low-Cost National Media-Based Surveillance System for Public Health Events, Bangladesh SO EMERGING INFECTIOUS DISEASES LA English DT Article AB We assessed a media-based public health surveillance system in Bangladesh during 2010-2011. The system is a highly effective, low-cost, locally appropriate, and sustainable outbreak detection tool that could be used in other low-income, resource-poor settings to meet the capacity for surveillance outlined in the International Health Regulations 2005. C1 [Ao, Trong T.; Sobel, Jeremy; Luby, Stephen P.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rahman, Mahmudur; Haque, Farhana; Chakraborty, Apurba; Haider, Sabbir; Alamgir, A. S. M.] Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh. [Haque, Farhana; Chakraborty, Apurba; Hossain, M. Jahangir; Luby, Stephen P.; Gurley, Emily S.] Icddr B, GPO Box 128, Dhaka 1000, Bangladesh. RP Gurley, ES (reprint author), Icddr B, GPO Box 128, Dhaka 1000, Bangladesh. EM egurley@icddrb.org RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X FU US Centers for Disease Control and Prevention (CDC) FX The evaluation was funded by the US Centers for Disease Control and Prevention (CDC). Core support to icddr,b was provided by the governments of Australia, Bangladesh, Canada, Sweden, and the United Kingdom. NR 6 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2016 VL 22 IS 4 BP 720 EP 722 DI 10.3201/eid2204.150330 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DH3LM UT WOS:000372688500022 PM 26981877 ER PT J AU Carias, C O'Hagan, JJ Jewett, A Gambhir, M Cohen, NJ Haber, Y Pesik, N Swerdlow, DL AF Carias, Cristina O'Hagan, Justin J. Jewett, Amy Gambhir, Manoj Cohen, Nicole J. Haber, Yoni Pesik, Nicki Swerdlow, David L. TI Exportations of Symptomatic Cases of MERS-CoV Infection to Countries outside the Middle East SO EMERGING INFECTIOUS DISEASES LA English DT Article ID CORONAVIRUS AB In 2012, an outbreak of infection with Middle East respiratory syndrome coronavirus (MERS-CoV), was detected in the Arabian Peninsula. Modeling can produce estimates of the expected annual number of symptomatic cases of MERS-CoV infection exported and the likelihood of exportation from source countries in the Middle East to countries outside the region. C1 [Carias, Cristina; O'Hagan, Justin J.] IHRC Inc, Atlanta, GA USA. [Carias, Cristina; O'Hagan, Justin J.; Jewett, Amy; Gambhir, Manoj; Cohen, Nicole J.; Haber, Yoni; Pesik, Nicki; Swerdlow, David L.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C18, Atlanta, GA 30329 USA. [Gambhir, Manoj] Monash Univ, Melbourne, Vic 3004, Australia. RP Carias, C (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C18, Atlanta, GA 30329 USA. EM vnn9@cdc.gov RI Haber, Shimon/H-2095-2016; Niren MD, Neil/H-2184-2016 OI Haber, Shimon/0000-0003-2841-5366; Niren MD, Neil/0000-0003-2841-5366 NR 15 TC 3 Z9 3 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2016 VL 22 IS 4 BP 723 EP 725 DI 10.3201/eid2204.150976 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DH3LM UT WOS:000372688500023 PM 26981926 ER PT J AU Huang, X Huang, Q Dun, ZJ Huang, W Wu, SY Liang, JH Deng, XL Zhang, YH AF Huang, Xi Huang, Qiong Dun, Zhongjun Huang, Wei Wu, Shuyu Liang, Junhua Deng, Xiaoling Zhang, Yonghui TI Nontyphoidal Salmonella Infection, Guangdong Province, China, 2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; FOODBORNE INFECTIONS; BURDEN; ILLNESS; GASTROENTERITIS; ENGLAND; DISEASE AB We used active and passive surveillance to estimate nontyphoidal Salmonella (NTS) infection during 2012 in Guangdong Province, China. Under passive surveillance, for every reported NTS infection, an estimated 414.8 cases occurred annually. Under active surveillance, an estimated 35.8 cases occurred. Active surveillance provides remarkable advantages in incidence estimate. C1 [Huang, Xi; Huang, Qiong; Liang, Junhua; Deng, Xiaoling; Zhang, Yonghui] Guangdong Prov Ctr Dis Control & Prevent, Guangzhou, Guangdong, Peoples R China. [Dun, Zhongjun] Guangdong Prov Inst Publ Hlth, Guangzhou, Guangdong, Peoples R China. [Huang, Wei] Liwan Dist Ctr Dis Control & Prevent, Guangzhou, Guangdong, Peoples R China. [Wu, Shuyu] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Zhang, YH (reprint author), Guangdong Prov Ctr Dis Control & Prevent, 160 Qunxian Rd,Dashi Av, Guangzhou 510430, Guangdong, Peoples R China. EM zyh@cdcp.org.cn FU China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases [1U2GHH00018-01]; Guangdong Medical Research Foundation [A2013069] FX The study was supported by the China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases (subproject 6) (1U2GHH00018-01) and Guangdong Medical Research Foundation (sponsored projectA2013069). NR 14 TC 0 Z9 1 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2016 VL 22 IS 4 BP 726 EP 729 DI 10.3201/eid2204.151372 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DH3LM UT WOS:000372688500024 PM 26982074 ER PT J AU Schultz, MG Bloch, AB AF Schultz, Myron G. Bloch, Alan B. TI In Memoriam: Sandy Ford (1950-2015) SO EMERGING INFECTIOUS DISEASES LA English DT Biographical-Item C1 US PHS, Atlanta, GA USA. Ctr Dis Control & Prevent, Atlanta, GA USA. RP Bloch, AB (reprint author), 1639 Colebook Circle, Decatur, GA 30033 USA. EM abb1@abblconsulting.com NR 2 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2016 VL 22 IS 4 BP 764 EP 765 DI 10.3201/eid2204.151336 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DH3LM UT WOS:000372688500041 PM 27358969 ER PT J AU Breedlove, B AF Breedlove, Byron TI From Farm to Fable SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Breedlove, Byron] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C19, Atlanta, GA 30329 USA. RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C19, Atlanta, GA 30329 USA. EM wbb1@cdc.gov OI Breedlove, Byron/0000-0002-1026-1963 NR 11 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2016 VL 22 IS 4 BP 768 EP 769 DI 10.3201/eid2204.AC2204 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DH3LM UT WOS:000372688500042 PM 27358970 ER PT J AU Bryant, KA Harris, AD Gould, CV Humphreys, E Lundstrom, T Murphy, DM Olmsted, R Oriola, S Zerr, D AF Bryant, Kristina A. Harris, Anthony D. Gould, Carolyn V. Humphreys, Eve Lundstrom, Tammy Murphy, Denise M. Olmsted, Russell Oriola, Shannon Zerr, Danielle TI Necessary Infrastructure of Infection Prevention and Healthcare Epidemiology Programs: A Review SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Review ID BLOOD-STREAM INFECTION; URINARY-TRACT-INFECTION; CONTROL LINK-NURSE; ANTIMICROBIAL STEWARDSHIP; UNITED-STATES; NOSOCOMIAL INFECTIONS; DISEASES SOCIETY; NATIONAL-HEALTH; SAFETY NETWORK; US HOSPITALS C1 [Bryant, Kristina A.] Univ Louisville, Sch Med, Louisville, KY 40292 USA. [Harris, Anthony D.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Gould, Carolyn V.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Humphreys, Eve] Soc Healthcare Epidemiol Amer, Arlington, VA USA. [Lundstrom, Tammy] Premier Hlth, Dayton, OH USA. [Murphy, Denise M.] Main Line Hlth, Philadelphia, PA USA. [Olmsted, Russell] Trinity Hlth, Livonia, MI USA. [Oriola, Shannon] Scripps Mem Hosp, La Jolla, CA USA. [Zerr, Danielle] Univ Washington, Seattle, WA 98195 USA. RP Bryant, KA (reprint author), 571 S Floyd St,Ste 321, Louisville, KY 40202 USA. EM K0brya01@louisville.edu NR 54 TC 1 Z9 1 U1 0 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2016 VL 37 IS 4 BP 371 EP 380 DI 10.1017/ice.2015.333 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DH5AD UT WOS:000372796200001 PM 26832072 ER PT J AU Thompson, ND Wise, M Belflower, R Kanago, M Kainer, MA Lovell, C Patel, PR AF Thompson, Nicola D. Wise, Matthew Belflower, Ruth Kanago, Meredith Kainer, Marion A. Lovell, Chris Patel, Priti R. TI Evaluation of Manual and Automated Bloodstream Infection Surveillance in Outpatient Dialysis Centers SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article C1 [Thompson, Nicola D.; Wise, Matthew; Belflower, Ruth; Patel, Priti R.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-16, Atlanta, GA 30333 USA. [Kanago, Meredith; Kainer, Marion A.] Emerging Infect Program, Tennessee Dept Hlth, Nashville, TN USA. [Lovell, Chris] Dialysis Clin Inc, Nashville, TN USA. RP Thompson, ND (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-16, Atlanta, GA 30333 USA. EM ndthompson@cdc.gov FU Office of Disease Prevention and Health Promotion, US Department of Health and Human Services FX Office of Disease Prevention and Health Promotion, US Department of Health and Human Services. NR 6 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2016 VL 37 IS 4 BP 472 EP 474 DI 10.1017/ice.2015.336 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DH5AD UT WOS:000372796200016 PM 26763179 ER PT J AU Marks, SM Hirsch-Moverman, Y Salcedo, K Graviss, EA Oh, P Seaworth, B Flood, J Armstrong, L Armitige, L Mase, S AF Marks, S. M. Hirsch-Moverman, Y. Salcedo, K. Graviss, E. A. Oh, P. Seaworth, B. Flood, J. Armstrong, L. Armitige, L. Mase, S. CA TB Epidemiologic Studies Consortii TI Characteristics and costs of multidrug-resistant tuberculosis inpatient care in the United States, 2005-2007 SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE TB; drug resistance; cost, hospitalization; HIV/AIDS AB OBJECTIVE: A population-based study of 135 multi-drug-resistant tuberculosis (MDR-TB) patients reported to the Centers for Disease Control and Prevention (CDC) during 2005-2007 found 73% were hospitalized. We analyzed factors associated with hospitalization. METHODS: We assessed statistically significant multi variable associations with US in-patient TB diagnosis, frequency of hospitalization, length of hospital stay, and in-patient direct costs to the health care system. RESULTS: Of 98 hospitalized patients, 83 (85%) were foreign-born. Blacks, diabetics, or smokers were more likely, and patients with disseminated disease less likely, to receive their TB diagnosis while hospitalized. Patients aged >= 65 years, those with the acquired immune deficiency syndrome (AIDS), or with private insurance, were hospitalized more frequently. Excluding deaths, length of stay was greater for patients aged >= 65 years, those with extensively drug-resistant TB (XDR-TB), those residing in Texas, those with AIDS, those who were unemployed, or those who had TB resistant to all first-line medications vs. others. Average hospitalization cost per XDR-TB patient (US$285 000) was 3.5 times that per MDR-TB patient (US$81 000), in 2010 dollars. Hospitalization episode costs for MDR-TB rank third highest and those for XDR-TB highest among the principal diagnoses. CONCLUSIONS: Hospitalization was common and remains a critical care component for patients who were older, had comorbidities, or required complex management due to XDR-TB. MDR-TB in-patient costs are among the highest for any disease. C1 [Marks, S. M.; Armstrong, L.; Mase, S.] CDC, US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Hirsch-Moverman, Y.] Columbia Univ, Int Ctr AIDS Care & Treatment Programs, New York, NY USA. [Salcedo, K.; Oh, P.; Flood, J.] Calif Dept Publ Hlth, Div Communicable Dis Control, Ctr Infect Dis, Richmond, CA USA. [Graviss, E. A.] Methodist Hosp Res Inst, Houston, TX USA. [Seaworth, B.; Armitige, L.] Univ Texas Hlth Ctr Tyler, Texas Dept State Hlth Serv, Tyler, TX USA. Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Mailstop E-10,1600 Clifton Rd, Atlanta, GA 30333 USA. RP Marks, SM (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Mailstop E-10,1600 Clifton Rd, Atlanta, GA 30333 USA. EM smarks@cdc.gov FU Intramural CDC HHS [CC999999] NR 19 TC 4 Z9 4 U1 1 U2 4 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD APR PY 2016 VL 20 IS 4 BP 435 EP 441 DI 10.5588/ijtld.15.0575 PG 7 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA DH8HL UT WOS:000373034000005 PM 26970150 ER PT J AU Angra, P Ridderhof, J Tahseen, S Van Deun, A AF Angra, P. Ridderhof, J. Tahseen, S. Van Deun, A. TI Read the new microscopy handbook: even the Ziehl-Neelsen technique has changed SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Letter C1 [Angra, P.; Ridderhof, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tahseen, S.] Natl TB Control Program, Islamabad, Pakistan. [Van Deun, A.] Inst Trop Med, B-2000 Antwerp, Belgium. RP Angra, P (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM pea6@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD APR PY 2016 VL 20 IS 4 BP 567 EP 567 DI 10.5588/ijtld.16.0009 PG 1 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA DH8HL UT WOS:000373034000024 PM 26970169 ER PT J AU Monroe, BP Yager, P Blanton, J Birhane, MG Wadhwa, A Orciari, L Petersen, B Wallace, R AF Monroe, Benjamin P. Yager, Pamela Blanton, Jesse Birhane, Meseret G. Wadhwa, Ashutosh Orciari, Lillian Petersen, Brett Wallace, Ryan TI Rabies surveillance in the United States during 2014 SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Article ID POSTEXPOSURE PROPHYLAXIS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; RECOMMENDATIONS; VACCINATION; AMERICA; USA AB During 2014, 50 states and Puerto Rico reported 6,033 rabid animals and 1 human case of rabies to the CDC, representing a 2.83% increase from the 5,865 rabid animals and 3 human cases of rabies reported in 2013. Of the 6,034 cases of rabies, 5,588 (92.61%) involved wildlife. Relative contributions by the major animal groups were as follows: 1,822 (30.20%) raccoons, 1,756 (29.10%) bats, 1,588 (26.32%) skunks, 311 (5.15%) foxes, 272 (4.51%) cats, 78 (1.29%) cattle, and 59 (0.98%) dogs. Compared with 2013, there was a substantial increase in the number of samples submitted for rabies testing. The 1 human case of rabies involved a 52-year-old male in Missouri. Infection was determined to be a result of a rabies virus variant associated with Perimyotis subflavus; however, no specific exposure event was identified. C1 [Monroe, Benjamin P.; Yager, Pamela; Blanton, Jesse; Birhane, Meseret G.; Wadhwa, Ashutosh; Orciari, Lillian; Petersen, Brett; Wallace, Ryan] CDC, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. RP Monroe, BP (reprint author), CDC, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ihd2@cdc.gov NR 27 TC 5 Z9 5 U1 6 U2 13 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 EI 1943-569X J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD APR 1 PY 2016 VL 248 IS 7 BP 777 EP 788 PG 12 WC Veterinary Sciences SC Veterinary Sciences GA DI0WC UT WOS:000373217000015 PM 27003019 ER PT J AU Kakumanu, ML Ponnusamy, L Sutton, HT Meshnick, SR Nicholson, WL Apperson, CS AF Kakumanu, Madhavi L. Ponnusamy, Loganathan Sutton, Haley T. Meshnick, Steven R. Nicholson, William L. Apperson, Charles S. TI Development and Validation of an Improved PCR Method Using the 23S-5S Intergenic Spacer for Detection of Rickettsiae in Dermacentor variabilis Ticks and Tissue Samples from Humans and Laboratory Animals SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID SPOTTED-FEVER GROUP; AMBLYOMMA-AMERICANUM; UNITED-STATES; PHYLOGENETIC ANALYSIS; MOLECULAR-DETECTION; ACARI IXODIDAE; NORTH-CAROLINA; PATHOGENS; IDENTIFICATION; PREVALENCE AB A novel nested PCR assay was developed to detect Rickettsia spp. in ticks and tissue samples from humans and laboratory animals. Primers were designed for the nested run to amplify a variable region of the 23S-5S intergenic spacer (IGS) of Rickettsia spp. The newly designed primers were evaluated using genomic DNA from 11 Rickettsia species belonging to the spotted fever, typhus, and ancestral groups and, in parallel, compared to other Rickettsia-specific PCR targets (ompA, gltA, and the 17-kDa protein gene). The new 23S-5S IGS nested PCR assay amplified all 11 Rickettsia spp., but the assays employing other PCR targets did not. The novel nested assay was sensitive enough to detect one copy of a cloned 23S-5S IGS fragment from "Candidatus Rickettsia amblyommii." Subsequently, the detection efficiency of the 23S-5S IGS nested assay was compared to those of the other three assays using genomic DNA extracted from 40 adult Dermacentor variabilis ticks. The nested 23S-5S IGS assay detected Rickettsia DNA in 45% of the ticks, while the amplification rates of the other three assays ranged between 5 and 20%. The novel PCR assay was validated using clinical samples from humans and laboratory animals that were known to be infected with pathogenic species of Rickettsia. The nested 23S-5S IGS PCR assay was coupled with reverse line blot hybridization with species-specific probes for high-throughput detection and simultaneous identification of the species of Rickettsia in the ticks. "Candidatus Rickettsia amblyommii," R. montanensis, R. felis, and R. bellii were frequently identified species, along with some potentially novel Rickettsia strains that were closely related to R. bellii and R. conorii. C1 [Kakumanu, Madhavi L.; Ponnusamy, Loganathan; Sutton, Haley T.; Apperson, Charles S.] N Carolina State Univ, Dept Entomol, Raleigh, NC 27695 USA. [Meshnick, Steven R.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Nicholson, William L.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Apperson, Charles S.] N Carolina State Univ, Comparat Med Inst, Raleigh, NC 27695 USA. RP Apperson, CS (reprint author), N Carolina State Univ, Dept Entomol, Raleigh, NC 27695 USA.; Apperson, CS (reprint author), N Carolina State Univ, Comparat Med Inst, Raleigh, NC 27695 USA. EM apperson@ncsu.edu OI Kakumanu, Madhavi/0000-0002-4325-3679 FU HHS \ CDC \ National Institute for Occupational Safety and Health (NIOSH) [5R01OH009874] FX HHS vertical bar CDC vertical bar National Institute for Occupational Safety and Health (NIOSH) provided funding to Steven R. Meshnick under grant number 5R01OH009874. NR 47 TC 1 Z9 1 U1 3 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2016 VL 54 IS 4 BP 972 EP 979 DI 10.1128/JCM.02605-15 PG 8 WC Microbiology SC Microbiology GA DI2OX UT WOS:000373337100017 PM 26818674 ER PT J AU Juarez, SI Nunez, AE Aranda, MM Mojica, D Kim, AA Parekh, B AF Juarez, Sandra I. Nunez, Aurelio E. Aranda, Margginna M. Mojica, Dalis Kim, Andrea A. Parekh, Bharat TI Field Evaluation of Four Rapid Tests for Diagnosis of HIV Infection in Panama SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID PERFORMANCE AB Four HIV rapid tests were subjected to field validation in Panama and compared to an enzyme-linked immunosorbent assay/Multispot-based testing algorithm. The sensitivities of Determine, Uni-Gold, SD Bioline, and INSTI were 99.8%. The specificities of Determine, SD-Bioline, and Uni-Gold were 100%, and the specificity of INSTI was 99.8%. On the basis of these data, we determined that these rapid tests can be used in an appropriate algorithm to diagnose HIV infection and are suitable for use in testing and counseling settings in Panama. C1 [Juarez, Sandra I.] Ctr Dis Control & Prevent, Div Global HIV & TB, Cent Amer Reg, Guatemala City, Guatemala. [Nunez, Aurelio E.; Aranda, Margginna M.] Minist Hlth, Natl STI HIV AIDS Program, Panama City, Panama. [Mojica, Dalis] Gorgas Mem Inst, Cent Reference Lab Publ Hlth, Panama City, Panama. [Kim, Andrea A.; Parekh, Bharat] Ctr Dis Control & Prevent, Int Lab Branch, DGHT CGH, Atlanta, GA USA. RP Juarez, SI (reprint author), Ctr Dis Control & Prevent, Div Global HIV & TB, Cent Amer Reg, Guatemala City, Guatemala. EM sjuarezgarrido@cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR); SECOMISCA [SG/SICA/COMISCA/CDC 5U19GH00064] FX This study was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through a cooperative agreement with SECOMISCA under grant number SG/SICA/COMISCA/CDC 5U19GH00064 and the guidance and technical expertise provided by the Centers for Disease Control and Prevention (CDC). NR 15 TC 1 Z9 1 U1 1 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2016 VL 54 IS 4 BP 1127 EP 1129 DI 10.1128/JCM.02654-15 PG 3 WC Microbiology SC Microbiology GA DI2OX UT WOS:000373337100038 PM 26763970 ER PT J AU Benedict, K Purfield, AE Mohle-Boetani, J Wheeler, C Park, BJ AF Benedict, Kaitlin Purfield, Anne E. Mohle-Boetani, Janet Wheeler, Charlotte Park, Benjamin J. TI Awareness and Environmental Exposures Related to Coccidioidomycosis Among Inmates at Two California Prisons, 2013 SO JOURNAL OF CORRECTIONAL HEALTH CARE LA English DT Article DE coccidioidomycosis; Valley fever; Coccidioides; prisons; California AB Coccidioidomycosis (Valley fever) is a major cause of illness in inmates in some California prisons. This article discusses an investigation conducted at two prisons to describe potential environmental exposures. The study did not identify modifiable risk factors; limiting the type or duration of outdoor activity in these prisons may not decrease coccidioidomycosis morbidity. C1 [Benedict, Kaitlin; Purfield, Anne E.] Ctr Dis Control & Prevent, Atlanta, GA 30033 USA. [Mohle-Boetani, Janet; Wheeler, Charlotte; Park, Benjamin J.] Calif Correct Hlth Care Serv, Publ Hlth Branch, Elk Grove, CA USA. RP Benedict, K (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30033 USA. EM jsy8@cdc.gov NR 11 TC 0 Z9 0 U1 1 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1078-3458 EI 1940-5200 J9 J CORRECT HEALTH CAR JI J. Correct. Health Care PD APR PY 2016 VL 22 IS 2 BP 157 EP 163 DI 10.1177/1078345816635577 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH5IK UT WOS:000372819900008 PM 26984139 ER PT J AU Breysse, P AF Breysse, Patrick TI A, T, S, D, What? SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article AB As part of our continuing effort to highlight innovative approaches to improving the health and environment of communities, the journal is pleased to publish a bimonthly column from the Agency for Toxic Substances and Disease Registry (ATSDR). ATSDR is a federal public health agency of the U.S. Department of Health and Human Services (HHS) and shares a common office of the Director with the National Center for Environmental Health (NCEH) at the Centers for Disease Control and Prevention (CDC). ATSDR serves the public by using the best science, taking responsive public health actions, and providing trusted health information to prevent harmful exposures and diseases related to toxic substances. The purpose of this column is to inform readers of ATSDR's activities and initiatives to better understand the relationship between exposure to hazardous substances in the environment and their impact on human health and how to protect public health. We believe that the column will provide a valuable resource to our readership by helping to make known the considerable resources and expertise that ATSDR has available to assist communities, states, and others to assure good environmental health practice for all is served. The conclusions of this article are those of the author(s) and do not necessarily represent the views of ATSDR, CDC, or HHS. Patrick Breysse joined CDC in December 2014 as the director of NCEH/ATSDR. He leads CDC's efforts to investigate the relationship between environmental factors and health. C1 [Breysse, Patrick] CDC, NCEH, ATSDR, 4770 Buford Highway,MS F-61, Atlanta, GA 30341 USA. RP Breysse, P (reprint author), CDC, NCEH, ATSDR, 4770 Buford Highway,MS F-61, Atlanta, GA 30341 USA. EM pjb7@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD APR PY 2016 VL 78 IS 8 BP 28 EP 29 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DH8HD UT WOS:000373033200006 PM 27188070 ER PT J AU Kalis, MA Zaidel, BW AF Kalis, Martin A. Zaidel, Bernice W. TI New Emergency Response Training for Environmental Health Professionals SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article AB NEHA strives to provide up-to-date and relevant information on environmental health and to build partnerships in the profession. In pursuit of these goals, we feature a column from the Environmental Health Services Branch (EHSB) of the Centers for Disease Control and Prevention (CDC) in every issue of the Journal. In these columns, EHSB and guest authors share insights and information about environmental health programs, trends, issues, and resources. The conclusions in this article are those of the author(s) and do not necessarily represent the views of CDC. Martin Kalis is a public health advisor with CDC's EHSB. He is the program manager for CDC's Environmental Health Training in Emergency Response (EHTER). Bernice Zaidel is the assistant director of curriculum development and evaluation at the Federal Emergency Management Agency's Center for Domestic Preparedness (CDP). She is CDP's lead for partnering with EHSB and developing EHTER courses. C1 [Kalis, Martin A.] CDC, EHSB, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-58, Atlanta, GA 30341 USA. RP Kalis, MA (reprint author), CDC, EHSB, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-58, Atlanta, GA 30341 USA. EM mkalis@cdc.gov NR 0 TC 1 Z9 1 U1 0 U2 2 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD APR PY 2016 VL 78 IS 8 BP 30 EP 31 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DH8HD UT WOS:000373033200007 PM 27188071 ER PT J AU Bemis, K Thornton, A Rodriguez-Lainz, A Lowenthal, P Escobedo, M Sosa, LE Tibbs, A Sharnprapai, S Moser, KS Cochran, J Lobato, MN AF Bemis, Kelley Thornton, Andrew Rodriguez-Lainz, Alfonso Lowenthal, Phil Escobedo, Miguel Sosa, Lynn E. Tibbs, Andrew Sharnprapai, Sharon Moser, Kathleen S. Cochran, Jennifer Lobato, Mark N. TI Civil Surgeon Tuberculosis Evaluations for Foreign-Born Persons Seeking Permanent US Residence SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Screening; Immigration; Public health; Surveillance; Tuberculosis ID UNITED-STATES; PULMONARY TUBERCULOSIS; IMMIGRANTS; REFUGEES AB Foreign-born persons in the United States seeking to adjust their status to permanent resident must undergo screening for tuberculosis (TB) disease. Screening is performed by civil surgeons (CS) following technical instructions by the Centers for Disease Control and Prevention. From 2011 to 2012, 1,369 practicing CS in California, Texas, and New England were surveyed to investigate adherence to the instructions. A descriptive analysis was conducted on 907 (66 %) respondents. Of 907 respondents, 739 (83 %) had read the instructions and 565 (63 %) understood that a chest radiograph is required for status adjustors with TB symptoms; however, only 326 (36 %) knew that a chest radiograph is required for immunosuppressed status adjustors. When suspecting TB disease, 105 (12 %) would neither report nor refer status adjustors to the health department; 91 (10 %) would neither start treatment nor refer for TB infection. Most CS followed aspects of the technical instructions; however, educational opportunities are warranted to ensure positive patient outcomes. C1 [Bemis, Kelley; Thornton, Andrew] CDC, CSTE Appl Epidemiol Fellowship Program, Atlanta, GA 30333 USA. [Bemis, Kelley; Sosa, Lynn E.] Connecticut Dept Publ Hlth, TB Control Program, Hartford, CT USA. [Thornton, Andrew; Rodriguez-Lainz, Alfonso; Escobedo, Miguel] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Thornton, Andrew; Moser, Kathleen S.] Cty San Diego Hlth & Human Serv Agcy, San Diego, CA USA. [Lowenthal, Phil] Calif Dept Publ Hlth, TB Control Branch, Richmond, CA USA. [Tibbs, Andrew; Sharnprapai, Sharon; Cochran, Jennifer] Massachusetts Dept Publ Hlth, Div TB Prevent & Control, Jamaica Plain, MA USA. [Lobato, Mark N.] Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd Mailstop E-10, Atlanta, GA 30333 USA. RP Lobato, MN (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd Mailstop E-10, Atlanta, GA 30333 USA. EM Mark.Lobato@ct.gov FU Centers for Disease Control and Prevention (CDC) [5U38HM000414] FX The authors are grateful to the New England Tuberculosis Consortium for contributions to the design and implementation of the survey, the Massachusetts Department of Health for efforts in survey follow-up, and the Texas Department of State Health Services. We would also like to acknowledge Jennifer Flood for input throughout the design of this evaluation as well as Melissa Lin, Tracy Renaud, and Jeffrey Lawliss, U.S. Citizenship and Immigration Services for their assistance. Finally, we thank the Division of Global Migration and Quarantine, CDC for their generous contribution of time and thoughts. This evaluation was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (CSTE) and funded by the Centers for Disease Control and Prevention (CDC) Cooperative Agreement Number 5U38HM000414. NR 19 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD APR PY 2016 VL 18 IS 2 BP 301 EP 307 DI 10.1007/s10903-015-0169-1 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH9LR UT WOS:000373118100003 PM 25672993 ER PT J AU Simon, AE Akinbami, LJ AF Simon, Alan E. Akinbami, Lara J. TI Asthma Action Plan Receipt among Children with Asthma 2-17 Years of Age, United States, 2002-2013 SO JOURNAL OF PEDIATRICS LA English DT Article ID SELF-MANAGEMENT; QUALITY; LIFE AB Objective To examine national trends in the receipt of asthma action plans, an intervention recommended by the National Asthma Education and Prevention Program guidelines. Study design We used data from the sample child component of the National Health Interview Survey from 2002, 2003, 2008, and 2013 to examine the percentage of children 2-17 years of age with asthma (n=3714) that have ever received an asthma action plan. Bivariate and multivariate (with adjustment for sociodemographic characteristics and asthma outcomes consistent with greater disease severity) logistic regressions were conducted to examine trends from 2002 to 2013 and to examine, with 2013 data only, the relationship between having received an asthma action plan and both sociodemographic characteristics and indicators of asthma severity. Results The percentage of children with asthma that had ever received an asthma action plan increased from 41.7% in 2002 to 50.7% in 2013 (P<.001 for trend). In 2013, a greater percentage of non-Hispanic black (58.4%) than non-Hispanic white (47.4%) children (P=.028), privately insured (56.2%) vs those with public insurance only (46.3%) (P=.016), and users of inhaled preventive asthma medication vs those that did not (P<.001) had ever received an asthma action plan. Adjusted results were similar. Conclusion The percentage of US children with asthma that had ever received an asthma action plan increased between 2002 and 2013, although one-half had never received an asthma action plan in 2013. Some sociodemographic and asthma severity measures are related to receipt of an asthma action plan. C1 [Simon, Alan E.; Akinbami, Lara J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Akinbami, Lara J.] US PHS, Rockville, MD USA. RP Simon, AE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. NR 22 TC 1 Z9 1 U1 2 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD APR PY 2016 VL 171 BP 283 EP + DI 10.1016/j.jpeds.2016.01.004 PG 8 WC Pediatrics SC Pediatrics GA DH4KC UT WOS:000372753600055 PM 26858189 ER PT J AU Sabatino, SA Thompson, TD Guy, GP de Moor, JS Tangka, FK AF Sabatino, Susan A. Thompson, Trevor D. Guy, Gery P., Jr. de Moor, Janet S. Tangka, Florence K. TI Mammography Use Among Medicare Beneficiaries After Elimination of Cost Sharing SO MEDICAL CARE LA English DT Article DE cost sharing; early detection of cancer; Medicare; mammography ID TASK-FORCE RECOMMENDATIONS; PREVENTIVE SERVICES; COLORECTAL CANCERS; UNITED-STATES; BREAST-CANCER; HEALTH PLANS; CARE; COVERAGE; WOMEN; INTERVENTIONS AB Background: We examined mammography use before and after Medicare eliminated cost sharing for screening mammography in January 2011. Methods: Using National Health Interview Survey data, we examined changes in mammography use between 2010 and 2013 among Medicare beneficiaries aged 65-74 years. Logistic regression and predictive margins were used to examine changes in use after adjusting for covariates. Results: In 2013, 74.7% of women reported a mammogram within 2 years, a 3.5 percentage point increase (95% confidence interval, -0.3, 7.2) compared with 2010. Increases occurred among women aged 65-69 years, unmarried women, and women with usual sources of care and 2-5 physician visits in the prior year. After adjustment, mammography use increased in 2013 versus 2010 (74.8% vs. 71.3%, P=0.039). Interactions between year and income, insurance, race, or ethnicity were not significant. Conclusions: There was a modest increase in mammography use from 2010 to 2013 among Medicare beneficiaries aged 65-74 years, possibly consistent with an effect of eliminating Medicare cost sharing during this time. Findings suggest that eliminating cost sharing might increase use of recommended screening services. C1 [Sabatino, Susan A.; Thompson, Trevor D.; Guy, Gery P., Jr.; Tangka, Florence K.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway F-76, Atlanta, GA 30341 USA. [de Moor, Janet S.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Sabatino, SA (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway F-76, Atlanta, GA 30341 USA. EM ssabatino@cdc.gov FU US government FX The National Health Interview Survey and manuscript preparation were funded by the US government. NR 34 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD APR PY 2016 VL 54 IS 4 BP 394 EP 399 DI 10.1097/MLR.0000000000000495 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DH6XK UT WOS:000372935200009 PM 26759983 ER PT J AU Davis, KR Dunn, AC Burnett, C McCullough, L Dimond, M Wagner, J Smith, L Carter, A Willardson, S Nakashima, AK AF Davis, Kenneth R. Dunn, Angela C. Burnett, Cindy McCullough, Laine Dimond, Melissa Wagner, Jenni Smith, Lori Carter, Amy Willardson, Sarah Nakashima, Allyn K. TI Campylobacter jejuni Infections Associated with Raw Milk Consumption - Utah, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID COWS C1 [Davis, Kenneth R.; Burnett, Cindy; McCullough, Laine; Dimond, Melissa; Nakashima, Allyn K.] Utah Dept Hlth, Salt Lake City, UT 84116 USA. [Dunn, Angela C.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Wagner, Jenni; Smith, Lori] Utah Publ Hlth Lab, Salt Lake City, UT USA. [Carter, Amy] Weber Morgan Hlth Dept, Ogden, UT USA. [Willardson, Sarah] Davis Cty Hlth Dept, Clearfield, UT USA. RP Davis, KR (reprint author), Utah Dept Hlth, Salt Lake City, UT 84116 USA. EM krdavis@utah.gov NR 9 TC 1 Z9 1 U1 3 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 1 PY 2016 VL 65 IS 12 BP 301 EP 305 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH8IO UT WOS:000373036900001 PM 27031585 ER PT J AU Brown, LG Hoover, ER Ripley, D Matis, B Nicholas, D Hedeen, N Faw, B AF Brown, Laura G. Hoover, E. Rickamer Ripley, Danny Matis, Bailey Nicholas, David Hedeen, Nicole Faw, Breda TI Retail Deli Slicer Cleaning Frequency - Six Selected Sites, United States, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PATHOGENS C1 [Brown, Laura G.; Hoover, E. Rickamer] CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Ripley, Danny] Tennessee Dept Hlth, Nashville, TN USA. [Matis, Bailey] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Nicholas, David] New York State Dept Hlth, Albany, NY 12237 USA. [Hedeen, Nicole] Minnesota Dept Hlth, Minneapolis, MN 55414 USA. [Faw, Breda] Calif Dept Publ Hlth, Sacramento, CA USA. RP Brown, LG (reprint author), CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM lrgreen@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 1 PY 2016 VL 65 IS 12 BP 306 EP 310 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH8IO UT WOS:000373036900002 PM 27031689 ER PT J AU Tepper, NK Goldberg, HI Bernal, MIV Rivera, B Frey, MT Malave, C Renquist, CM Bracero, NJ Dominguez, KL Sanchez, RE Shapiro-Mendoza, CK Rodriguez, BRC Simeone, RM Pesik, NT Barfield, WD Ko, JY Galang, RR Perez-Padilla, J Polen, KND Honein, MA Rasmussen, SA Jamieson, DJ AF Tepper, Naomi K. Goldberg, Howard I. Bernal, Manuel I. Vargas Rivera, Brenda Frey, Meghan T. Malave, Claritsa Renquist, Christina M. Bracero, Nabal Jose Dominguez, Kenneth L. Sanchez, Ramon E. Shapiro-Mendoza, Carrie K. Rodriguez, Blanca R. Cuevas Simeone, Regina M. Pesik, Nicki T. Barfield, Wanda D. Ko, Jean Y. Galang, Romeo R. Perez-Padilla, Janice Polen, Kara N. D. Honein, Margaret A. Rasmussen, Sonja A. Jamieson, Denise J. TI Estimating Contraceptive Needs and Increasing Access to Contraception in Response to the Zika Virus Disease Outbreak - Puerto Rico, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNINTENDED PREGNANCIES; NO-COST C1 [Tepper, Naomi K.; Goldberg, Howard I.; Shapiro-Mendoza, Carrie K.; Barfield, Wanda D.; Ko, Jean Y.; Jamieson, Denise J.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Bernal, Manuel I. Vargas; Rivera, Brenda] Puerto Rico Dept Hlth, Mayaguez, PR USA. [Frey, Meghan T.; Renquist, Christina M.; Simeone, Regina M.; Polen, Kara N. D.; Honein, Margaret A.] CDC, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Malave, Claritsa] Off Reg Operat, Hlth Resources & Serv Adm, Rockville, MD 20857 USA. [Bracero, Nabal Jose] Univ Puerto Rico, Mayaguez, PR USA. [Bracero, Nabal Jose] Amer Coll Obstetricians & Gynecologists, Puerto Rico Sect, Washington, DC 20024 USA. [Dominguez, Kenneth L.; Galang, Romeo R.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Sanchez, Ramon E.] Univ Puerto Rico, Family Planning Program Title X Clin Preven, Mayaguez, PR USA. [Rodriguez, Blanca R. Cuevas] PROFAMILIAS, Santiago, Chile. [Pesik, Nicki T.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Galang, Romeo R.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Perez-Padilla, Janice] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Rasmussen, Sonja A.] CDC, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Tepper, NK (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM zikamch@cdc.gov NR 9 TC 13 Z9 14 U1 5 U2 19 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 1 PY 2016 VL 65 IS 12 BP 311 EP 314 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH8IO UT WOS:000373036900003 PM 27031817 ER PT J AU Petersen, EE Polen, KND Meaney-Delman, D Ellington, SR Oduyebo, T Cohn, A Oster, AM Russell, K Kawwass, JF Karwowski, MP Powers, AM Bertolli, J Brooks, JT Kissin, D Villanueva, J Munoz-Jordan, J Kuehnert, M Olson, CK Honein, MA Rivera, M Jamieson, DJ Rasmussen, SA AF Petersen, Emily E. Polen, Kara N. D. Meaney-Delman, Dana Ellington, Sascha R. Oduyebo, Titilope Cohn, Amanda Oster, Alexandra M. Russell, Kate Kawwass, Jennifer F. Karwowski, Mateusz P. Powers, Ann M. Bertolli, Jeanne Brooks, John T. Kissin, Dmitry Villanueva, Julie Munoz-Jordan, Jorge Kuehnert, Matthew Olson, Christine K. Honein, Margaret A. Rivera, Maria Jamieson, Denise J. Rasmussen, Sonja A. TI Update: Interim Guidance for Health Care Providers Caring for Women of Reproductive Age with Possible Zika Virus Exposure - United States, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SEXUAL TRANSMISSION; INFECTION; SEMEN; MICRONESIA; GUIDELINES; TRAVELERS; HIV-1 C1 [Petersen, Emily E.; Ellington, Sascha R.; Oduyebo, Titilope; Kawwass, Jennifer F.; Kissin, Dmitry; Olson, Christine K.; Rivera, Maria; Jamieson, Denise J.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Polen, Kara N. D.; Honein, Margaret A.] CDC, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Meaney-Delman, Dana] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Off Director, Atlanta, GA 30333 USA. [Oduyebo, Titilope; Russell, Kate; Karwowski, Mateusz P.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Cohn, Amanda] CDC, Off Director, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Oster, Alexandra M.; Bertolli, Jeanne; Brooks, John T.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Russell, Kate] CDC, Influenza Div, NCIRD, Atlanta, GA 30333 USA. [Kawwass, Jennifer F.] Emory Univ, Div Reprod Endocrinol & Infertil, Dept Gynecol & Obstet, Sch Med, Atlanta, GA 30322 USA. [Karwowski, Mateusz P.] CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Powers, Ann M.; Munoz-Jordan, Jorge] CDC, Div Vector Borne Dis, NCEZID, Atlanta, GA 30333 USA. [Villanueva, Julie] CDC, Div Preparedness & Emerging Infect, NCEZID, Atlanta, GA 30333 USA. [Kuehnert, Matthew] CDC, Div Healthcare Qual Promot, NCEZID, Atlanta, GA 30333 USA. [Rasmussen, Sonja A.] CDC, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Petersen, EE (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM ZikaMCH@cdc.gov NR 35 TC 44 Z9 46 U1 3 U2 12 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 1 PY 2016 VL 65 IS 12 BP 315 EP 322 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH8IO UT WOS:000373036900004 PM 27031943 ER PT J AU Oster, AM Russell, K Stryker, JE Friedman, A Kachur, RE Petersen, EE Jamieson, DJ Cohn, AC Brooks, JT AF Oster, Alexandra M. Russell, Kate Stryker, Jo Ellen Friedman, Allison Kachur, Rachel E. Petersen, Emily E. Jamieson, Denise J. Cohn, Amanda C. Brooks, John T. TI Update: Interim Guidance for Prevention of Sexual Transmission of Zika Virus - United States, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Oster, Alexandra M.; Stryker, Jo Ellen; Brooks, John T.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Russell, Kate] CDC, Epidem Intelligence Serv, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Russell, Kate] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Friedman, Allison; Kachur, Rachel E.] CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Petersen, Emily E.; Jamieson, Denise J.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Cohn, Amanda C.] CDC, Off Director, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Oster, AM (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM AOster@cdc.gov OI Russell, Kate/0000-0001-9343-3355 NR 10 TC 26 Z9 29 U1 1 U2 13 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 1 PY 2016 VL 65 IS 12 BP 323 EP 325 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH8IO UT WOS:000373036900005 PM 27032078 ER PT J AU Dirlikov, E Rodriguez, C Morales, S Martinez, LC Mendez, JB Sanchez, AC Burgos, JH Santiago, Z Cuevas-Ruis, RI Camacho, SA Mercado, ER Guzman, JF Ryff, K Luna-Pinto, C Arguin, PM Chenet, SM Silva-Flannery, L Ljolje, D Velazquez, JC Thomas, D Garcia, BR AF Dirlikov, Emilio Rodriguez, Carmen Morales, Shirley Martinez, Laura Castro Mendez, Juan B. Sanchez, Anibal Cruz Burgos, Jesus Hernandez Santiago, Zobeida Cuevas-Ruis, Rosa Ivette Camacho, Sheila Adorno Mercado, Enid Roman Guzman, Jessica Falcon Ryff, Kyle Luna-Pinto, Carolina Arguin, Paul M. Chenet, Stella M. Silva-Flannery, Luciana Ljolje, Dragan Velazquez, Julio Cadiz Thomas, Dana Garcia, Brenda Rivera TI Imported Cases of Malaria - Puerto Rico, July-October 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Dirlikov, Emilio] CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA. [Dirlikov, Emilio; Rodriguez, Carmen; Martinez, Laura Castro; Mendez, Juan B.; Sanchez, Anibal Cruz; Burgos, Jesus Hernandez; Santiago, Zobeida; Cuevas-Ruis, Rosa Ivette; Camacho, Sheila Adorno; Mercado, Enid Roman; Guzman, Jessica Falcon; Ryff, Kyle; Velazquez, Julio Cadiz; Thomas, Dana; Garcia, Brenda Rivera] Puerto Rico Dept Hlth, Mayaguez, PR USA. [Morales, Shirley] Cook Cty Dept Publ Hlth, Maywood, IL 60153 USA. [Guzman, Jessica Falcon; Thomas, Dana] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Luna-Pinto, Carolina] CDC, San Juan Quarantine Stn, Atlanta, GA 30333 USA. [Arguin, Paul M.; Chenet, Stella M.; Silva-Flannery, Luciana; Ljolje, Dragan] CDC, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. RP Dirlikov, E (reprint author), CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA. EM klt9@cdc.gov NR 4 TC 1 Z9 1 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 1 PY 2016 VL 65 IS 12 BP 326 EP 327 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH8IO UT WOS:000373036900006 PM 27030910 ER PT J AU Huang, JY Louis, FJ Dixon, MG Sefu, M Kightlinger, L Martel, LD Jayaraman, GC Gueye, AS AF Huang, Jennifer Y. Louis, Frantz Jean Dixon, Meredith G. Sefu, Marcel Kightlinger, Lon Martel, Lise D. Jayaraman, Gayatri C. Gueye, Abdou Salam TI Baseline Assessment of the Use of Ebola Rapid Diagnostic Tests - Forecariah, Guinea, October-November 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Huang, Jennifer Y.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Louis, Frantz Jean] CDC, Div Global HIV & TB Haiti, Ctr Global Hlth, Atlanta, GA 30333 USA. [Dixon, Meredith G.] CDC, Div Global Hlth Protect, WIDB FETP, Ctr Global Hlth, Atlanta, GA 30333 USA. [Sefu, Marcel] CDC, Div Global Hlth Protect, FETP Democrat Republ Congo, Ctr Global Hlth, Atlanta, GA 30333 USA. [Kightlinger, Lon] CDC, South Dakota Dept Hlth, Ctr Global Hlth, Atlanta, GA 30333 USA. [Martel, Lise D.] CDC, Div Global Hlth Protect, Guinea Off, Ctr Global Hlth, Atlanta, GA 30333 USA. [Jayaraman, Gayatri C.] WHO, Global Outbreak Alert & Response Network, Geneva, Switzerland. [Gueye, Abdou Salam] CDC, Div Global HIV & TB, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Huang, JY (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM Jhuang3@cdc.gov NR 8 TC 2 Z9 2 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 1 PY 2016 VL 65 IS 12 BP 328 EP 329 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH8IO UT WOS:000373036900007 PM 27030992 ER PT J AU Meaney-Delman, D Rasmussen, SA Staples, JE Oduyebo, T Ellington, SR Petersen, EE Fischer, M Jamieson, DJ AF Meaney-Delman, Dana Rasmussen, Sonja A. Staples, J. Erin Oduyebo, Titilope Ellington, Sascha R. Petersen, Emily E. Fischer, Marc Jamieson, Denise J. TI Zika Virus and Pregnancy What Obstetric Health Care Providers Need to Know SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID FRENCH-POLYNESIA; PERINATAL TRANSMISSION; UNITED-STATES; FEBRUARY 2014; INFECTION; BRAZIL; OUTBREAK; BRAIN; WOMEN; MICRONESIA AB Zika virus is a flavivirus transmitted by Aedes (Stegomyia) species of mosquitoes. In May 2015, the World Health Organization confirmed the first local transmission of Zika virus in the Americas in Brazil. The virus has spread rapidly to other countries in the Americas; as of January 29, 2016, local transmission has been detected in at least 22 countries or territories, including the Commonwealth of Puerto Rico and the U.S. Virgin Islands. Zika virus can infect pregnant women in all three trimesters. Although pregnant women do not appear to be more susceptible to or more severely affected by Zika virus infection, maternal-fetal transmission has been documented. Several pieces of evidence suggest that maternal Zika virus infection is associated with adverse neonatal outcomes, most notably microcephaly. Because of the number of countries and territories with local Zika virus transmission, it is likely that obstetric health care providers will care for pregnant women who live in or have traveled to an area of local Zika virus transmission. We review information on Zika virus, its clinical presentation, modes of transmission, laboratory testing, effects during pregnancy, and methods of prevention to assist obstetric health care providers in caring for pregnant women considering travel or with a history of travel to areas with ongoing Zika virus transmission and pregnant women residing in areas with ongoing Zika virus transmission. C1 [Meaney-Delman, Dana; Rasmussen, Sonja A.; Staples, J. Erin; Oduyebo, Titilope; Ellington, Sascha R.; Petersen, Emily E.; Fischer, Marc; Jamieson, Denise J.] Ctr Dis Control & Prevent, Atlanta, GA 30345 USA. RP Meaney-Delman, D (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,Mailstop C12, Atlanta, GA 30345 USA. EM Vmo0@cdc.gov NR 45 TC 17 Z9 19 U1 8 U2 47 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2016 VL 127 IS 4 BP 642 EP 648 DI 10.1097/AOG.0000000000001378 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DH4YF UT WOS:000372791000004 PM 26889662 ER PT J AU Cohen, C Moyes, J Tempia, S Groome, M Walaza, S Pretorius, M Naby, F Mekgoe, O Kahn, K von Gottberg, A Wolter, N Cohen, AL von Mollendorf, C Venter, M Madhi, SA AF Cohen, Cheryl Moyes, Jocelyn Tempia, Stefano Groome, Michelle Walaza, Sibongile Pretorius, Marthi Naby, Fathima Mekgoe, Omphile Kahn, Kathleen von Gottberg, Anne Wolter, Nicole Cohen, Adam L. von Mollendorf, Claire Venter, Marietjie Madhi, Shabir A. TI Epidemiology of Acute Lower Respiratory Tract Infection in HIV-Exposed Uninfected Infants SO PEDIATRICS LA English DT Article ID IMMUNODEFICIENCY-VIRUS-INFECTION; INVASIVE PNEUMOCOCCAL DISEASE; SOUTH-AFRICAN CHILDREN; ANTIRETROVIRAL THERAPY; INCREASED RISK; MORTALITY; PNEUMONIA; MORBIDITY; MOTHERS; WOMEN AB BACKGROUND: Increased morbidity and mortality from lower respiratory tract infection (LRTI) has been suggested in HIV-exposed uninfected (HEU) children; however, the contribution of respiratory viruses is unclear. We studied the epidemiology of LRTI hospitalization in HIV-unexposed uninfected (HUU) and HEU infants aged <6 months in South Africa. METHODS: We prospectively enrolled hospitalized infants with LRTI from 4 provinces from 2010 to 2013. Using polymerase chain reaction, nasopharyngeal aspirates were tested for 10 viruses and blood for pneumococcal DNA. Incidence for 2010-2011 was estimated at 1 site with population denominators. RESULTS: We enrolled 3537 children aged <6 months. HIV infection and exposure status were determined for 2507 (71%), of whom 211 (8%) were HIV infected, 850 (34%) were HEU, and 1446 (58%) were HUU. The annual incidence of LRTI was elevated in HEU (incidence rate ratio [IRR] 1.4; 95% confidence interval [CI] 1.3-1.5) and HIV infected (IRR 3.8; 95% CI 3.3-4.5), compared with HUU infants. Relative incidence estimates were greater in HEU than HUU, for respiratory syncytial virus (RSV; IRR 1.4; 95% CI 1.3-1.6) and human metapneumovirus-associated (IRR 1.4; 95% CI 1.1-2.0) LRTI, with a similar trend observed for influenza (IRR 1.2; 95% CI 0.8-1.8). HEU infants overall, and those with RSV-associated LRTI had greater odds (odds ratio 2.1, 95% CI 1.1-3.8, and 12.2, 95% CI 1.7-infinity, respectively) of death than HUU. CONCLUSIONS: HEU infants were more likely to be hospitalized and to die in-hospital than HUU, including specifically due to RSV. This group should be considered a high-risk group for LRTI. C1 [Cohen, Cheryl; Moyes, Jocelyn; Walaza, Sibongile; von Gottberg, Anne; Wolter, Nicole; von Mollendorf, Claire; Madhi, Shabir A.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa. [Cohen, Cheryl; Moyes, Jocelyn; Walaza, Sibongile; von Mollendorf, Claire] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa. [Groome, Michelle; Madhi, Shabir A.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Fac Hlth Sci, Johannesburg, South Africa. [Groome, Michelle; Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa. [Kahn, Kathleen] Univ Witwatersrand, MRC, Wits Rural Publ Hlth & Hlth Transit Res Unit Agin, Sch Publ Hlth,Fac Hlth Sci, Johannesburg, South Africa. [von Gottberg, Anne; Wolter, Nicole] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa. [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Tempia, Stefano; Cohen, Adam L.] US Ctr Dis Control & Prevent South Africa, Influenza Programme, Pretoria, South Africa. [Venter, Marietjie] US Ctr Dis Control & Prevent South Africa, Global Dis Detect, Pretoria, South Africa. [Pretorius, Marthi; Venter, Marietjie] Univ Pretoria, Dept Med Virol, Zoonosis Res Unit, ZA-0001 Pretoria, South Africa. [Naby, Fathima] Univ KwaZulu Natal, Pietermaritzburg Metropolitan Hosp, Dept Paediat, Kwa Zulu, South Africa. [Mekgoe, Omphile] Klerksdorp Hosp, Dept Paediat, Flamwood, Northwest Provi, South Africa. [Kahn, Kathleen] Umea Univ, Ctr Global Hlth Res, Umea, Sweden. [Kahn, Kathleen] INDEPTH Network, Accra, Ghana. RP Cohen, C (reprint author), Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Private Bag X4, ZA-2131 Johannesburg, Gauteng, South Africa. EM cherylc@nicd.ac.za RI Venter, Marietjie/P-9604-2016 OI Venter, Marietjie/0000-0003-2696-824X FU National Institute for Communicable Diseases/National Health Laboratory Service; US Centers for Disease Control and Prevention (CDC; Atlanta, Georgia); Preparedness and Response to Avian and Pandemic Influenza in South Africa [U51/IP000155-04] FX This study received funding from the National Institute for Communicable Diseases/National Health Laboratory Service and was supported in part by funds from the US Centers for Disease Control and Prevention (CDC; Atlanta, Georgia), Preparedness and Response to Avian and Pandemic Influenza in South Africa (Cooperative Agreement U51/IP000155-04). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC. The funders had no role in study design, implementation, manuscript writing, or the decision to submit for publication. The corresponding author had full access to all the data in the study and takes final responsibility for the decision to submit for publication. NR 50 TC 7 Z9 7 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2016 VL 137 IS 4 AR e20153272 DI 10.1542/peds.2015-3272 PG 10 WC Pediatrics SC Pediatrics GA DI0OU UT WOS:000373197500034 ER PT J AU Perella, D Wang, CB Civen, R Viner, K Kuguru, K Daskalaki, I Schmid, DS Lopez, AS Tseng, HF Newbern, EC Mascola, L Bialek, SR AF Perella, Dana Wang, Chengbin Civen, Rachel Viner, Kendra Kuguru, Karen Daskalaki, Irini Schmid, D. Scott Lopez, Adriana S. Tseng, Hung Fu Newbern, E. Claire Mascola, Laurene Bialek, Stephanie R. TI Varicella Vaccine Effectiveness in Preventing Community Transmission in the 2-Dose Era SO PEDIATRICS LA English DT Article ID WILD-TYPE STRAINS; UNITED-STATES; ELEMENTARY-SCHOOL; OUTBREAK; CHILDREN; EPIDEMIOLOGY; SURVEILLANCE; ZOSTER; IMPLEMENTATION; CHICKENPOX AB OBJECTIVES: We examined overall and incremental effectiveness of 2-dose varicella vaccination in preventing community transmission of varicella among children aged 4 to 18 years in 2 active surveillance sites. One-dose varicella vaccine effectiveness (VE) was examined in those aged 1 to 18 years. METHODS: From May 2009 through June 2011, varicella cases identified during active surveillance in Antelope Valley, CA and Philadelphia, PA were enrolled into a matched case-control study. Matched controls within 2 years of the patient's age were selected from immunization registries. A standardized questionnaire was administered to participants' parents, and varicella vaccination history was obtained from health care provider, immunization registry, or parent records. We used conditional logistic regression to estimate varicella VE against clinically diagnosed and laboratory-confirmed varicella. RESULTS: A total of 125 clinically diagnosed varicella cases and 408 matched controls were enrolled. Twenty-nine cases were laboratory confirmed. One-dose VE (1-dose versus unvaccinated) was 75.6% (95% confidence interval [CI], 38.7%-90.3%) in preventing any clinically diagnosed varicella and 78.1% (95% CI, 12.7%-94.5%) against moderate or severe, clinically diagnosed disease (>= 50 lesions). Among subjects aged >= 4 years, 2-dose VE (2-dose versus unvaccinated) was 93.6% (95% CI, 75.6%-98.3%) against any varicella and 97.9% (95% CI, 83.0%-99.7%) against moderate or severe varicella. Incremental effectiveness (2-dose versus 1-dose) was 87.5% against clinically diagnosed varicella and 97.3% against laboratory-confirmed varicella. CONCLUSIONS: Two-dose varicella vaccination offered better protection against varicella from community transmission among school-aged children compared with 1-dose vaccination. C1 [Perella, Dana; Viner, Kendra; Daskalaki, Irini; Newbern, E. Claire] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Wang, Chengbin; Schmid, D. Scott; Lopez, Adriana S.; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Civen, Rachel; Kuguru, Karen; Mascola, Laurene] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Tseng, Hung Fu] Kaiser Permanente, Southern Calif Permanente Med Grp, Pasadena, CA USA. RP Perella, D (reprint author), Philadelphia Dept Publ Hlth, Acute Communicable Dis Program, 500 S Broad St,2nd Floor, Philadelphia, PA 19146 USA. EM dana.perella@phila.gov FU American Recovery and Reinvestment Act (ARRA) [RFA-IP04-11601ARRA09] FX Supported by the American Recovery and Reinvestment Act (ARRA), Section 317 Immunization Program: Strengthening the Evidence Base Measuring Effectiveness of Two Doses of Varicella Vaccine, U01 (RFA-IP04-11601ARRA09). NR 36 TC 0 Z9 0 U1 1 U2 1 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2016 VL 137 IS 4 AR e20152802 DI 10.1542/peds.2015-2802 PG 9 WC Pediatrics SC Pediatrics GA DI0OU UT WOS:000373197500022 ER PT J AU Sampath, A Maduro, G Schillinger, JA AF Sampath, Amitha Maduro, Gil Schillinger, Julia A. TI Infant Deaths Due To Herpes Simplex Virus, Congenital Syphilis, and HIV in New York City SO PEDIATRICS LA English DT Article ID POPULATION-BASED SURVEILLANCE; RECURRENT GENITAL HERPES; NEONATAL HERPES; UNITED-STATES; CONTROLLED-TRIAL; GLYCOPROTEIN-D; INFECTIONS; VACCINE; MORTALITY; TYPE-2 AB BACKGROUND: Neonatal infection with herpes simplex virus (HSV) is not a nationally reportable disease; there have been few population-based measures of HSV-related infant mortality. We describe infant death rates due to neonatal HSV as compared with congenital syphilis (CS) and HIV, 2 reportable, perinatally transmitted diseases, in New York City from 1981 to 2013. METHODS: We identified neonatal HSV-, CS-, and HIV-related deaths using International Classification of Diseases (ICD) codes listed on certificates of death or stillbirth issued in New York City. Deaths were classified as HSV-related if certificates listed (1) any HSV ICD-9/ICD-10 codes for deaths <= 42 days of age, (2) any HSV ICD-9/ICD-10 codes and an ICD code for perinatal infection for deaths at 43 to 365 days of age, or (3) an ICD-10 code for congenital HSV. CS-and HIV-related deaths were those listing any ICD code for syphilis or HIV. RESULTS: There were 34 deaths due to neonatal HSV (0.82 deaths per 100 000 live births), 38 from CS (0.92 per 100 000), and 262 from HIV (6.33 per 100 000). There were no CS-related deaths after 1996, and only 1 HIV-related infant death after 2004. The neonatal HSV-related death rate during the most recent decade (2004-2013) was significantly higher than in previous years. CONCLUSIONS: The increasing neonatal HSV-related death rate may reflect increases in neonatal herpes incidence; an increasing number of pregnant women have never had HSV type 1 and are therefore at risk of acquiring infection during pregnancy and transmitting to their infant. C1 [Sampath, Amitha] New York City Dept Hlth & Mental Hyg, Bur Publ Hlth Training, New York, NY USA. [Maduro, Gil] New York City Dept Hlth & Mental Hyg, Bur Vital Stat, New York, NY USA. [Schillinger, Julia A.] New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, New York, NY USA. [Schillinger, Julia A.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV Hepatitis Sexually Transmitted Dis &, Atlanta, GA USA. RP Schillinger, JA (reprint author), Bur STD Prevent & Control, 42-09 28th St,CN 73, Long Isl City, NY 11101 USA. EM jschilli@health.nyc.gov NR 47 TC 0 Z9 0 U1 4 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2016 VL 137 IS 4 AR e20152387 DI 10.1542/peds.2015-2387 PG 9 WC Pediatrics SC Pediatrics GA DI0OU UT WOS:000373197500017 ER PT J AU Mirabelli, MC Preisser, JS Loehr, LR Agarwal, SK Barr, RG Couper, DJ Hankinson, JL Hyun, N Folsom, AR London, SJ AF Mirabelli, Maria C. Preisser, John S. Loehr, Laura R. Agarwal, Sunil K. Barr, R. Graham Couper, David J. Hankinson, John L. Hyun, Noorie Folsom, Aaron R. London, Stephanie J. TI Lung function decline over 25 years of follow-up among black and white adults in the ARIC study cohort SO RESPIRATORY MEDICINE LA English DT Article DE Aging; Epidemiology; Lung function tests; Respiratory; Spirometry ID OBSTRUCTIVE PULMONARY-DISEASE; ATHEROSCLEROSIS RISK; LONGITUDINAL DATA; GENDER-DIFFERENCES; UNITED-STATES; SMOKING; MORTALITY; HEALTH; COMMUNITIES; ATTRITION AB Background: Interpretation of longitudinal information about lung function decline from middle to older age has been limited by loss to follow-up that may be correlated with baseline lung function or the rate of decline. We conducted these analyses to estimate age-related decline in lung function across groups of race, sex, and smoking status while accounting for dropout from the Atherosclerosis Risk in Communities Study. Methods: We analyzed data from 13,896 black and white participants, aged 45-64 years at the 1987-1989 baseline clinical examination. Using spirometry data collected at baseline and two follow-up visits, we estimated annual population-averaged mean changes in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) by race, sex, and smoking status using inverse-probability-weighted independence estimating equations conditioning-on-being-alive. Results: Estimated rates of FEV1 decline estimated using inverse-probability-weighted independence estimating equations conditioning on being alive were higher among white than black participants at age 45 years (e.g., male never smokers: black: -29.5 ml/year; white: -51.9 ml/year), but higher among black than white participants by age 75 (black: -51.2 ml/year; white: -26). Observed differences by race were more pronounced among men than among women. By smoking status, FEV1 declines were larger among current than former or never smokers at age 45 across all categories of race and sex. By age 60, FEV1 decline was larger among former and never than current smokers. Estimated annual declines generated using unweighted generalized estimating equations were smaller for current smokers at younger ages in all four groups of race and sex compared with results from weighted analyses that accounted for attrition. Conclusions: Using methods accounting for dropout from an approximately 25-year health study, estimated rates of lung function decline varied by age, race, sex, and smoking status, with largest declines observed among current smokers at younger ages. Published by Elsevier Ltd. C1 [Mirabelli, Maria C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Air Pollut & Resp Hlth Branch, 4770 Buford Highway NE,Mailstop F-60, Atlanta, GA 30341 USA. [Preisser, John S.; Couper, David J.; Hyun, Noorie] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, 3101 McGavran Greenberg Hall,CB 7420,135 Dauer Dr, Chapel Hill, NC 27599 USA. [Loehr, Laura R.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, 170 Rosenau Hall,CB 7400,135 Dauer Dr, Chapel Hill, NC 27599 USA. [Agarwal, Sunil K.] Johns Hopkins Univ, Dept Med, 2020 E Monument St,Room B-321, Baltimore, MD 21287 USA. [Barr, R. Graham] Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA. [Hankinson, John L.] Hankinson Consulting Inc, 1860 Barnett Shoals Rd,Suite 103,PMB 505, Athens, GA 30605 USA. [Folsom, Aaron R.] Univ Minnesota, Div Epidemiol & Community Hlth, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA. [London, Stephanie J.] NIEHS, Epidemiol Branch, NIH, Dept Hlth & Human Serv, 111 TW Alexander Dr,POB 12233,MD A3-05, Res Triangle Pk, NC 27709 USA. RP Mirabelli, MC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Air Pollut & Resp Hlth Branch, 4770 Buford Highway NE,Mailstop F-60, Atlanta, GA 30341 USA. EM mmirabelli@cdc.gov OI Mirabelli, Maria/0000-0002-3540-0085; London, Stephanie/0000-0003-4911-5290 FU National Heart, Lung, and Blood Institute [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C]; NIH, National Institute of Environmental Health Sciences FX The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). Dr. London is supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 35 TC 2 Z9 2 U1 1 U2 3 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 EI 1532-3064 J9 RESP MED JI Respir. Med. PD APR PY 2016 VL 113 BP 57 EP 64 DI 10.1016/j.rmed.2016.02.003 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA DH8ZO UT WOS:000373085700009 PM 26905512 ER PT J AU Groom, HC Henninger, ML Smith, N Koppolu, P Cheetham, TC Glanz, JM Hambidge, SJ Jackson, LA Kharbanda, EO Klein, NP McCarthy, NL Nordin, JD Weintraub, ES Naleway, AL AF Groom, Holly C. Henninger, Michelle L. Smith, Ning Koppolu, Padma Cheetham, T. Craig Glanz, Jason M. Hambidge, Simon J. Jackson, Lisa A. Kharbanda, Elyse O. Klein, Nicola P. McCarthy, Natalie L. Nordin, James D. Weintraub, Eric S. Naleway, Allison L. TI Influenza Vaccination During Pregnancy Influenza Seasons 2002-2012, Vaccine Safety Datalink SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID H1N1 VIRUS-INFECTION; NEW-YORK-CITY; UNITED-STATES; PANDEMIC INFLUENZA; A H1N1; WOMEN; COVERAGE; RECOMMENDATIONS; OUTCOMES AB Introduction: Pregnant women are at risk for influenza-related complications and have been recommended for vaccination by the Advisory Committee on Immunization Practices (ACIP) since 1990. Annual rates of influenza coverage of pregnant women have been consistently low. The Vaccine Safety Datalink was used to assess influenza vaccine coverage over 10 consecutive years (2002-2012); assess patterns related to changes in ACIP recommendations; identify predictors of vaccination; and compare the results with those published by national U.S. surveys. Methods: Retrospective cohort study of 721,898 pregnancies conducted in 2014. Coverage rates were assessed for all pregnancies and for live births only. Multivariate regression analysis identified predictors associated with vaccination. Results: Coverage increased from 8.8% to 50.9% in 2002-2012. Seasonal coverage rates increased slowly following the 2004 ACIP influenza vaccine recommendation (to remove the first trimester restriction), but spiked significantly during the 2009 H1N1 influenza pandemic. Significant predictors of vaccination during pregnancy included older age; vaccination in a previous season; high-risk conditions in addition to pregnancy; pregnancy during either the 2004-2005 or 2009-2010 seasons; entering the influenza season after the first trimester of pregnancy; and a pregnancy with longer overlap with the influenza season (p < 0.001 for each). Conclusions: Influenza vaccination coverage among pregnant women increased between the 2002-2003 and 2011-2012 seasons, although it was still below the developmental Healthy People 2020 goal of 80%. The 2004 ACIP language change positively impacted first-trimester vaccination uptake. Vaccine Safety Datalink data estimates were consistent with U.S. estimates. (C) 2016 American Journal of Preventive Medicine. All rights reserved. C1 [Groom, Holly C.; Henninger, Michelle L.; Smith, Ning; Koppolu, Padma; Naleway, Allison L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Cheetham, T. Craig] Kaiser Permanente So Calif, Res & Evaluat, Pasadena, CA 91101 USA. [Glanz, Jason M.; Hambidge, Simon J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Glanz, Jason M.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Hambidge, Simon J.] Denver Hlth, Ambulatory Care Serv, Denver, CO USA. [Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA. [Kharbanda, Elyse O.; Nordin, James D.] HealthPartners Inst Educ & Res, Minneapolis, MN USA. [Klein, Nicola P.] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. [McCarthy, Natalie L.; Weintraub, Eric S.] CDC, Immunizat Safety Off, Atlanta, GA 30333 USA. RP Groom, HC (reprint author), 3800 N Interstate Ave, Portland, OR 97227 USA. EM holly.c.groom@kpchr.org NR 30 TC 3 Z9 3 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2016 VL 50 IS 4 BP 480 EP 488 DI 10.1016/j.amepre.2015.08.017 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DH1RP UT WOS:000372562900007 PM 26526159 ER PT J AU Will, JC Zhang, ZF Ritchey, MD Loustalot, F AF Will, Julie C. Zhang, Zefeng Ritchey, Matthew D. Loustalot, Fleetwood TI Medication Adherence and Incident Preventable Hospitalizations for Hypertension SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID CARE-SENSITIVE CONDITIONS; CORONARY-ARTERY-DISEASE; ANTIHYPERTENSIVE AGENTS; AFRICAN-AMERICANS; RISK; OUTCOMES; IMPACT; DISPARITIES; POPULATION; THERAPY AB Introduction: Potentially preventable hospitalizations (PPHs) for hypertension (HTN) is one indicator of possible failed ambulatory care. Rates of PPHs for HTN have remained fairly level since the late 1980s, which may reflect a lack of understanding of the drivers of these hospitalizations. Anti-HTN medication non-adherence has been studied as a potential risk factor for other cardiovascular disease outcomes but not for PPHs for HTN. Methods: A cohort analysis was conducted during 2005-2012 of people with HTN enrolled in commercial and employee health plans with claims in the MarketScan database. PPH for HTN was defined according to specifications published by the Agency for Healthcare Research and Quality. The proportion of days covered (PDC) algorithm was used to assess adherence to antihypertensives. Crude- and multivariate-adjusted incident PPHs for HTN rates were calculated, as well as third-party payments for selected PPH for HTN-related expenses. Results: During 9,344,528 person-years of follow-up (mean=3 years), 6,008 incident PPHs for HTN were identified among 3,099,291 people. The crude rate for good adherence (PDC >= 80%) was 23.2 per 100,000 person-years compared with 102.6 per 100,000 person-years for poor adherence (PDC <40%). Over the 8-year study, PPH for HTN-associated payments equaled $41 million. Payments for those with poor adherence were four times higher than for those with good adherence. Conclusions: Poor anti-HTN medication adherence is strongly associated with PPHs for HTN. Improving the percentage of people who achieve good medication adherence is one possible approach to reducing the burden of PPHs for HTN in the U.S. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Will, Julie C.; Zhang, Zefeng; Ritchey, Matthew D.; Loustalot, Fleetwood] CDC, Div Heart Dis & Stroke Prevent, 4700 Buford Highway NE,MS F-72, Atlanta, GA 30341 USA. RP Will, JC (reprint author), CDC, Div Heart Dis & Stroke Prevent, 4700 Buford Highway NE,MS F-72, Atlanta, GA 30341 USA. EM juliewill21@gmail.com NR 40 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2016 VL 50 IS 4 BP 489 EP 499 DI 10.1016/j.amepre.2015.08.021 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DH1RP UT WOS:000372562900008 PM 26526163 ER PT J AU Mays, D Arrazola, RA Tworek, C Rolle, IV Neff, LJ Portnoy, DB AF Mays, Darren Arrazola, Rene A. Tworek, Cindy Rolle, Italia V. Neff, Linda J. Portnoy, David B. TI Openness to Using Non-cigarette Tobacco Products Among US Young Adults SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID HARM PERCEPTIONS; COLLEGE-STUDENTS; UNITED-STATES; SMOKING; PREVALENCE; AWARENESS; USERS AB Introduction: National data indicate that the prevalence of non-cigarette tobacco product use is highest among young adults; however, little is known about their openness to use these products in the future and associated risk factors. This study sought to characterize openness to using non cigarette tobacco products and associated factors among U.S. young adults. Methods: In 2014, National Adult Tobacco Survey data (2012-2013) were analyzed to characterize openness to using the following tobacco products among all young adults aged 18-29 years (N=5,985): cigars; electronic cigarettes ("e-cigarettes"); hookah; pipe tobacco; chew, snuff, or dip; snus; and dissolvables. Among those who were not current users of each product, multivariable logistic regression was used to examine associations between demographics, cigarette smoking status, lifetime use of other non-cigarette products, perceived harm and addictiveness of smoking, and receipt of tobacco industry promotions and openness to using each product. Results: Among all young adults, openness to using non-cigarette tobacco products was greatest for hookah (28.2%); e-cigarettes (25.5%); and cigars (19.1%). In multivariable analyses, which included non-current users of each product, non-current ever, current, and former smokers were more likely than never smokers to be open to using most examined products, as were men and adults aged 18-24 years. Receipt of tobacco industry promotions was associated with openness to using e-cigarettes; chew, snuff, or dip; and snus. Conclusions: There is substantial openness to trying non-cigarette tobacco products among U.S. young adults. Young adults are an important population to consider for interventions targeting non-cigarette tobacco product use. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Mays, Darren] US FDA, Tobacco Regulatory Sci Fellowship Program, Silver Spring, MD 20993 USA. [Mays, Darren] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. [Arrazola, Rene A.; Rolle, Italia V.; Neff, Linda J.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Tworek, Cindy; Portnoy, David B.] US FDA, Off Sci, Ctr Tobacco Prod, 10903 New Hampshire Ave,Bldg 71,Room G335, Silver Spring, MD 20993 USA. RP Portnoy, DB (reprint author), US FDA, Off Sci, Ctr Tobacco Prod, 10903 New Hampshire Ave,Bldg 71,Room G335, Silver Spring, MD 20993 USA. EM david.portnoy@fda.hhs.gov OI Portnoy, David/0000-0003-2175-9457 FU U.S. Food and Drug Administration (FDA) Center for Tobacco Products; U.S. CDC Office on Smoking and Health FX The 2012-2013 National Adult Tobacco Survey was supported by the U.S. Food and Drug Administration (FDA) Center for Tobacco Products and the U.S. CDC Office on Smoking and Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official positions or policies of the FDA or CDC. The information in this article is not a formal dissemination of information by either the FDA or CDC. The authors thank Dr. Sean Hu (CDC); Lieutenant Kimberly Nguyen (CDC); Dr. Bridget Ambrose (FDA); Dr. Hannah Day (FDA); and Mr. Enver Holder-Hayes (FDA) for their assistance in data stewardship of the 2012-2013 National Adult Tobacco Survey. NR 26 TC 2 Z9 2 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2016 VL 50 IS 4 BP 528 EP 534 DI 10.1016/j.amepre.2015.08.015 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DH1RP UT WOS:000372562900012 PM 26549502 ER PT J AU Okomo-Adhiambo, M Mishin, VP Sleeman, K Saguar, E Guevara, H Reisdorf, E Griesser, RH Spackman, KJ Mendenhall, M Carlos, MP Healey, B St George, K Laplante, J Aden, T Chester, S Xu, X Gubareva, LV AF Okomo-Adhiambo, M. Mishin, V. P. Sleeman, K. Saguar, E. Guevara, H. Reisdorf, E. Griesser, R. H. Spackman, K. J. Mendenhall, M. Carlos, M. P. Healey, B. St George, K. Laplante, J. Aden, T. Chester, S. Xu, X. Gubareva, L. V. TI Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance SO ANTIVIRAL RESEARCH LA English DT Article DE Assay standardization; Neuraminidase inhibition; Oseltamivir; Zanamivir; Peramivir ID DRUG SUSCEPTIBILITY ASSESSMENT; GLOBAL UPDATE; VIRUSES; OSELTAMIVIR; A(H3N2); RESISTANCE; PERAMIVIR; WORLDWIDE; CLUSTER AB Background: Monitoring influenza virus susceptibility to neuraminidase (NA) inhibitors (NAIs) is vital for detecting drug-resistant variants, and is primarily assessed using NA inhibition (NI) assays, supplemented by NA sequence analysis. However, differences in NI testing methodologies between surveillance laboratories results in variability of 50% inhibitory concentration (IC50) values, which impacts data sharing, reporting and interpretation. In 2011, the Centers for Disease Control and Prevention (CDC), in collaboration with the Association for Public Health Laboratories (APHL) spearheaded efforts to standardize fluorescence-based NI assay testing in the United States (U.S.), with the goal of achieving consistency of IC50 data. Methods: For the standardization process, three participating state public health laboratories (PHLs), designated as National Surveillance Reference Centers for Influenza (NSRC-Is), assessed the NAI susceptibility of the 2011-12 CDC reference virus panel using stepwise procedures, with support from the CDC reference laboratory. Next, the NSRC-Is assessed the NAI susceptibility of season 2011-12 U.S. influenza surveillance isolates (n = 940), with a large subset (n = 742) tested in parallel by CDC. Subsequently, U.S. influenza surveillance isolates (n = 9629) circulating during the next three influenza seasons (2012-15), were independently tested by the three NSRC-Is (n = 7331) and CDC (n = 2298). Results: The NI assay IC(50)s generated by respective NSRC-Is using viruses and drugs prepared by CDC were similar to those obtained with viruses and drugs prepared in-house, and were uniform between laboratories. IC(50)s for U.S. surveillance isolates tested during four consecutive influenza seasons (2011-15) were consistent from season to season, within and between laboratories. Conclusion: These results show that the NI assay is robust enough to be standardized, marking the first time IC50 data have been normalized across multiple laboratories, and used for U.S. national NAI susceptibility surveillance. Published by Elsevier B.V. C1 [Okomo-Adhiambo, M.; Mishin, V. P.; Sleeman, K.; Xu, X.; Gubareva, L. V.] Ctr Dis Control & Prevent CDC, Influenza Div, NCIRD, Atlanta, GA USA. [Saguar, E.; Guevara, H.] CDPH, Richmond, CA USA. [Reisdorf, E.; Griesser, R. H.] Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA. [Spackman, K. J.; Mendenhall, M.] USLPH, Taylorsville, UT USA. [Carlos, M. P.; Healey, B.] Maryland Dept Hlth & Mental Hyg MD DHMH Labs Adm, Baltimore, MD USA. [St George, K.; Laplante, J.] New York State Dept Hlth NYSDOH, Wadsworth Ctr, Albany, NY USA. [Aden, T.; Chester, S.] APHL, Silver Spring, MD USA. [Gubareva, L. V.] Mail Stop G-16,1600 Clifton Rd, Atlanta, GA 30333 USA. [Sleeman, K.] CDC, Div Global HIV AIDS, CGH, Atlanta, GA 30333 USA. [Aden, T.] Battelle Mem Inst, Atlanta, GA USA. RP Gubareva, LV (reprint author), Mail Stop G-16,1600 Clifton Rd, Atlanta, GA 30333 USA. EM lgubareva@cdc.gov FU CDC Pandemic Influenza Scientific Agenda (PISA) FX We wish to acknowledge the CDC Pandemic Influenza Scientific Agenda (PISA) for the partial funding of this initiative. We acknowledge the late Dr. Alexander Klimov, Influenza Division, CDC, for his leadership and support of this project. We acknowledge, our colleagues in the Molecular Epidemiology Team, Virus Reference Team, and Sequencing Activity Team, Virology Surveillance and Diagnosis Branch, Influenza Division, CDC, for their valuable support and contributions to this project. We acknowledge the USLPH, Taylorsville, UT, and the WSLH, Madison, WI, for their participation in this project. We also acknowledge the CDPH, Richmond, CA, for their participation in this project, including the late Dr. David P. Schnurr, Cindy Wong, Nohemi Reyes-Martin, and Debra Wadford for their support. We acknowledge the MD DHMH Laboratories Administration Virus Isolation Team and Fellows for their contributions, including Brittany Wells, for providing the MD DHMH data reported in this manuscript. We acknowledge Pamela Moleta (NTLN/APHL) for her support, and also thank our collaborators in the U.S. public health laboratories for submission of influenza virus isolates and clinical specimens. NR 26 TC 1 Z9 1 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 EI 1872-9096 J9 ANTIVIR RES JI Antiviral Res. PD APR PY 2016 VL 128 BP 28 EP 35 DI 10.1016/j.antiviral.2016.01.009 PG 8 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA DH4OJ UT WOS:000372765000004 PM 26808479 ER PT J AU Humrighouse, BW Emery, BD Kelly, AJ Metcalfe, MG Mbizo, J McQuiston, JR AF Humrighouse, B. W. Emery, B. D. Kelly, A. J. Metcalfe, M. G. Mbizo, J. McQuiston, J. R. TI Haematospirillum jordaniae gen. nov., sp nov., isolated from human blood samples. SO ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY LA English DT Article DE Haematospirillum jordaniae; Pathogen; Bacteria; Blood; Gram-negative; Clinical ID RIBOSOMAL-RNA; LIPID-COMPOSITION; IDENTIFICATION; CLASSIFICATION; BACTERIA; DATABASE AB A Gram-negative, aerobic, motile, spiral-shaped bacterium, strain H5569(T), was isolated from a human blood sample. Phenotypic and molecular characteristics of the isolate were investigated. Optimal growth was found to occur at 35 A degrees C under aerobic conditions on Heart Infusion Agar supplemented with 5 % rabbit blood. The major fatty acids present in the cells were identified as C-16:0, C-16:1 omega 7c and C-18:1 omega 7c. The predominant respiratory quinone was found to be ubiquinone-Q10. The G+C content of genomic DNA for strain H5569(T) was found to be 49.9 %. Based on 16S rRNA gene sequence analysis results, 13 additional isolates were also analysed in this study. Phylogenetic analysis based on 16S rRNA gene sequences revealed that the organism, represented by strain H5569(T), forms a distinct lineage within the family Rhodospirillaceae, closely related to two Novispirillum itersonii subspecies (93.9-94.1 %) and two Caenispirillum sp. (91.2-91.6 %). Based on these results, the isolate H5569(T) is concluded to represent a new genus and species for which the name Haematospirillum jordaniae gen. nov., sp. nov. is proposed. The type strain is H5569(T) (=DSMT 28903 = CCUG 66838(T)). C1 [Humrighouse, B. W.; Emery, B. D.; Kelly, A. J.; McQuiston, J. R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Bacterial Special Pathogens Branch, Special Bacteriol Reference Lab, Atlanta, GA USA. [Metcalfe, M. G.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Mbizo, J.] Univ W Florida, Coll Sci Engn & Hlth, Dept Publ Hlth Clin & Hlth Sci, Pensacola, FL 32514 USA. RP Humrighouse, BW (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Bacterial Special Pathogens Branch, Special Bacteriol Reference Lab, Atlanta, GA USA. EM Bhumrighouse@cdc.gov NR 22 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0003-6072 EI 1572-9699 J9 ANTON LEEUW INT J G JI Antonie Van Leeuwenhoek PD APR PY 2016 VL 109 IS 4 BP 493 EP 500 DI 10.1007/s10482-016-0654-0 PG 8 WC Microbiology SC Microbiology GA DH1NL UT WOS:000372551500002 PM 26857139 ER PT J AU Kingry, LC Rowe, LA Respicio-Kingry, LB Beard, CB Schriefer, ME Petersen, JM AF Kingry, Luke C. Rowe, Lori A. Respicio-Kingry, Laurel B. Beard, Charles B. Schriefer, Martin E. Petersen, Jeannine M. TI Whole genome multilocus sequence typing as an epidemiologic tool for Yersinia pestis SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE wgMLST; Whole genome sequencing; Yersinia pestis; Molecular epidemiology; Plague ID PRIMARY PNEUMONIC PLAGUE; BACTERIAL PATHOGENS; UNITED-STATES; EVOLUTION; CAMPYLOBACTER; CHINA; MLST; ERA AB Human plague is a severe and often fatal zoonotic disease caused by Yersinia pestis. For public health investigations of human cases, nonintensive whole genome molecular typing tools, capable of defining epidemiologic relationships, are advantageous. Whole genome multilocus sequence typing (wgMLST) is a recently developed methodology that simplifies genomic analyses by transforming millions of base pairs of sequence into character data for each gene. We sequenced 13 US Y. pestis isolates with known epidemiologic relationships. Sequences were assembled de novo, and multilocus sequence typing alleles were assigned by comparison against 3979 open reading frames from the reference strain CO92. Allele-based cluster analysis accurately grouped the 13 isolates, as well as 9 publicly available Y. pestis isolates, by their epidemiologic relationships. Our findings indicate wgMLST is a simplified, sensitive, and scalable tool for epidemiologic analysis of Y. pestis strains. Published by Elsevier Inc. C1 [Kingry, Luke C.; Respicio-Kingry, Laurel B.; Beard, Charles B.; Schriefer, Martin E.; Petersen, Jeannine M.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Bacterial Dis Branch, Ft Collins, CO 80523 USA. [Rowe, Lori A.] Ctr Dis Control & Prevent, Div Sci Resources, Biotechnol Core Facil Branch, Atlanta, GA 30329 USA. RP Petersen, JM (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Bacterial Dis Branch, Ft Collins, CO 80523 USA. EM nzp0@cdc.gov OI Kingry, Luke/0000-0002-5724-2575 FU Intramural CDC HHS [CC999999] NR 38 TC 3 Z9 3 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 EI 1879-0070 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD APR PY 2016 VL 84 IS 4 BP 275 EP 280 DI 10.1016/j.diagmicrobio.2015.12.003 PG 6 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA DH4PV UT WOS:000372768800001 PM 26778487 ER PT J AU Benitez, AJ Winchell, JM AF Benitez, Alvaro J. Winchell, Jonas M. TI Rapid detection and typing of pathogenic nonpneumophila Legionella spp. isolates using a multiplex real-time PCR assay SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Real-time PCR; Legionella spp.; Detection; Typing; HRM Analysis ID RESOLUTION MELT ANALYSIS; LEGIONNAIRES-DISEASE; PONTIAC FEVER; GENUS LEGIONELLA; MIP GENE; PNEUMOPHILA; PNEUMONIA; WATER; ANISA; SEROGROUPS AB We developed a single tube multiplex real-time PCR assay that allows for the rapid detection and typing of 9 nonpneumophila Legionella spp. isolates that are clinically relevant. The multiplex assay is capable of simultaneously detecting and discriminating L. micdadei, L. bozemanii, L dumoffii, L. longbeachae, L. feeleii, L. anisa, L parisiensis, L. tucsonensis serogroup (sg) 1 and 3, and L. sainthelensis sg 1 and 2 isolates. Evaluation of the assay with nucleic acid from each of these species derived from both clinical and environmental isolates and typing strains demonstrated 100% sensitivity and 100% specificity when tested against 43 other Legionella spp. Typing of L. anisa, L parisiensis, and L. tucsonensis sg 1 and 3 isolates was accomplished by developing a real-time PCR assay followed by high-resolution melt (HRM) analysis targeting the ssrA gene. Further typing of L. bozemanii, L. longbeachae, and L. feeleii isolates to the serogroup level was accomplished by developing a real-time PCR assay followed by HRM analysis targeting the mip gene. When used in conjunction with other currently available diagnostic tests, these assays may aid in rapidly identifying specific etiologies associated with Legionella outbreaks, clusters, sporadic cases, and potential environmental sources. Published by Elsevier Inc. C1 [Benitez, Alvaro J.; Winchell, Jonas M.] Ctr Dis Control & Prevent, Pneumonia Response & Surveillance Lab, Resp Dis Branch, Div Bacterial Dis,Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Winchell, JM (reprint author), Ctr Dis Control & Prevent, Pneumonia Response & Surveillance Lab, Resp Dis Branch, Div Bacterial Dis,Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. EM jwinchell@cdc.gov NR 38 TC 2 Z9 2 U1 4 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 EI 1879-0070 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD APR PY 2016 VL 84 IS 4 BP 298 EP 303 DI 10.1016/j.diagmicrobio.2016.01.007 PG 6 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA DH4PV UT WOS:000372768800005 PM 26867966 ER PT J AU Subramanian, S Tangka, FKL Beebe, MC Trebino, D Weir, HK Babcock, F AF Subramanian, Sujha Tangka, Florence K. L. Beebe, Maggie Cole Trebino, Diana Weir, Hannah K. Babcock, Frances TI The cost of cancer registry operations: Impact of volume on cost per case for core and enhanced registry activities SO EVALUATION AND PROGRAM PLANNING LA English DT Article DE Cost; Cancer registry; Economics ID DRUG-ABUSE TREATMENT; PROGRAM; DATCAP AB Background: Cancer registration data is vital for creating evidence-based policies and interventions. Quantifying the resources needed for cancer registration activities and identifying potential efficiencies are critically important to ensure sustainability of cancer registry operations. Methods: Using a previously validated web-based cost assessment tool, we collected activity-based cost data and report findings using 3 years of data from 40 National Program of Cancer Registry grantees. We stratified registries by volume: low-volume included fewer than 10,000 cases, medium-volume included 10,000-50,000 cases, and high-volume included >50,000 cases. Results: Low-volume cancer registries incurred an average of $93.11 to report a case (without in-kind contributions) compared with $27.70 incurred by high-volume registries. Across all registries, the highest cost per case was incurred for data collection and abstraction ($8.33), management ($6.86), and administration ($4.99). Low- and medium-volume registries have higher costs than high-volume registries for all key activities. Conclusions: Some cost differences by volume can be explained by the large fixed costs required for administering and performing registration activities, but other reasons may include the quality of the data initially submitted to the registries from reporting sources such as hospitals and pathology laboratories. Automation or efficiency improvements in data collection can potentially reduce overall costs. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Subramanian, Sujha; Trebino, Diana] RTI Int, Canc Econ & Policy, Waltham, MA USA. [Beebe, Maggie Cole] RTI Int, Hlth Care Financing & Payment Program, Waltham, MA USA. [Trebino, Diana] RTI Int, Waltham, MA USA. [Tangka, Florence K. L.; Weir, Hannah K.; Babcock, Frances] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Subramanian, S (reprint author), RTI Int, Canc Econ & Policy, Waltham, MA USA. EM ssubramanian@rti.org FU Intramural CDC HHS [CC999999] NR 15 TC 6 Z9 6 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7189 EI 1873-7870 J9 EVAL PROGRAM PLANN JI Eval. Program Plan. PD APR PY 2016 VL 55 BP 1 EP 8 DI 10.1016/j.evalprogplan.2015.11.005 PG 8 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA DG9EM UT WOS:000372385600001 PM 26702880 ER PT J AU Menendez, CKC Amandus, HE Wu, N Hendricks, SA AF Menendez, Cammie K. Chaumont Amandus, Harlan E. Wu, Nan Hendricks, Scott A. TI Compliance to two city convenience store ordinance requirements SO INJURY PREVENTION LA English DT Article ID ROBBERY RISK; PREVENTION AB Background Robbery-related homicides and assaults are the leading cause of death in retail businesses. Robbery reduction approaches focus on compliance to Crime Prevention Through Environmental Design (CPTED) guidelines. Purpose We evaluated the level of compliance to CPTED guidelines specified by convenience store safety ordinances effective in 2010 in Dallas and Houston, Texas, USA. Methods Convenience stores were defined as businesses less than 10 000 square feet that sell grocery items. Store managers were interviewed for store ordinance requirements from August to November 2011, in a random sample of 594 (289 in Dallas, 305 in Houston) convenience stores that were open before and after the effective dates of their city's ordinance. Data were collected in 2011 and analysed in 2012-2014. Results Overall, 9% of stores were in full compliance, although 79% reported being registered with the police departments as compliant. Compliance was consistently significantly higher in Dallas than in Houston for many requirements and by store type. Compliance was lower among single owner-operator stores compared with corporate/franchise stores. Compliance to individual requirements was lowest for signage and visibility. Conclusions Full compliance to the required safety measures is consistent with industry 'best practices' and evidence-based workplace violence prevention research findings. In Houston and Dallas compliance was higher for some CPTED requirements but not the less costly approaches that are also the more straightforward to adopt. C1 [Menendez, Cammie K. Chaumont; Amandus, Harlan E.; Wu, Nan; Hendricks, Scott A.] NIOSH, Div Safety Res, Ctr Dis Control & Prevent, 1095 Willowdale Rd,M-S 1811, Morgantown, WV 26505 USA. RP Menendez, CKC (reprint author), NIOSH, Div Safety Res, Ctr Dis Control & Prevent, 1095 Willowdale Rd,M-S 1811, Morgantown, WV 26505 USA. EM cmenendez@cdc.gov FU National Institute for Occupational Safety and Health FX National Institute for Occupational Safety and Health. NR 22 TC 0 Z9 0 U1 3 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 EI 1475-5785 J9 INJURY PREV JI Inj. Prev. PD APR PY 2016 VL 22 IS 2 BP 117 EP 122 DI 10.1136/injuryprev-2015-041582 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH1EP UT WOS:000372527500006 ER PT J AU Perelygina, L Plotkin, S Russo, P Hautala, T Bonilla, F Ochs, H Joshi, AY Routes, JM Patel, K Wehr, C Sullivan, K AF Perelygina, Ludmila Plotkin, Stanley Russo, Pierre Hautala, Timo Bonilla, Francisco Ochs, Hans Joshi, Avni Y. Routes, John M. Patel, Kiran Wehr, Claudia Sullivan, Kathleen TI RUBELLA VIRUS IN CUTANEOUS GRANULOMAS IN IMMUNE DEFICIENT PATIENTS SO JOURNAL OF CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT CIS Annual Meeting on Immune Deficiency and Dysregulation North American Conference CY APR 14-17, 2016 CL Boston, MA SP Clin Immunol Soc C1 [Perelygina, Ludmila] CDC, Atlanta, GA 30333 USA. [Plotkin, Stanley] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Russo, Pierre] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Hautala, Timo] Oulu Univ Hosp, Oulu, Finland. [Bonilla, Francisco] Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA. [Ochs, Hans] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA. [Joshi, Avni Y.] Mayo Clin, Rochester, MN USA. [Routes, John M.] Med Coll Wisconsin, Dept Allergy & Clin Immunol, Milwaukee, WI 53226 USA. [Patel, Kiran] UCSF, San Francisco, CA USA. [Wehr, Claudia] Univ Freiburg, Hugstetter Str 55, D-79106 Freiburg, Germany. [Sullivan, Kathleen] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0271-9142 EI 1573-2592 J9 J CLIN IMMUNOL JI J. Clin. Immunol. PD APR PY 2016 VL 36 IS 3 MA 4425 BP 263 EP 264 PG 2 WC Immunology SC Immunology GA DG6AT UT WOS:000372165300079 ER PT J AU Mond, J Tumpey, T DeMario, L AF Mond, James Tumpey, Terrence DeMario, Lucy TI PROTECTIVE LEVELS OF NEUTRALIZING ANTIBODIES TO INFLUENZA ARE PRESENT IN AN IVIG (RI-002) PREPARED WITH STANDARDIZED AND ELEVATED LEVELS OF NEUTRALIZING ANTIBODIES TO RSV SO JOURNAL OF CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT CIS Annual Meeting on Immune Deficiency and Dysregulation North American Conference CY APR 14-17, 2016 CL Boston, MA SP Clin Immunol Soc C1 [Mond, James; DeMario, Lucy] ADMA Biol Inc, Ramsey, NJ USA. [Tumpey, Terrence] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0271-9142 EI 1573-2592 J9 J CLIN IMMUNOL JI J. Clin. Immunol. PD APR PY 2016 VL 36 IS 3 MA 4463 BP 273 EP 273 PG 1 WC Immunology SC Immunology GA DG6AT UT WOS:000372165300102 ER PT J AU Carias, C Greening, B Campbell, CG Meltzer, MI Hamel, MJ AF Carias, Cristina Greening, Bradford, Jr. Campbell, Caresse G. Meltzer, Martin I. Hamel, Mary J. TI Preventive malaria treatment for contacts of patients with Ebola virus disease in the context of the west Africa 2014-15 Ebola virus disease response: an economic analysis SO LANCET INFECTIOUS DISEASES LA English DT Article ID PLASMODIUM-FALCIPARUM MALARIA; ARTESUNATE-AMODIAQUINE; COST-EFFECTIVENESS; CASE-MANAGEMENT; STRATEGIES; EPIDEMIC; KIKWIT; BURDEN; CONGO; FEVER AB Background After the detection of an Ebola virus disease outbreak in west Africa in 2014, one of the elements of the response was to contact trace and isolate patients in specialised Ebola treatment units (ETUs) at onset of fever. We aimed to assess the economic feasibility of administering preventive malaria treatment to all contacts of patients with Ebola virus disease, to prevent the onset of febrile malaria and subsequent admission to ETUs. Methods We used a decision tree model to analyse the costs of preventive malaria treatment (artemisinin-based combination treatment [ACT]) for all contacts of patients with Ebola virus disease (in terms of administration and averted ETU-stay costs) and benefits (in terms of averted ETU admissions) in west Africa, from a health-care provider perspective. The period of analyses was 1 year, which is roughly similar to the duration of the 2014-15 west Africa Ebola outbreak response. We calculated the intervention's cost per ETU admission averted (average cost-effectiveness ratio) by season (wet and dry), country (Liberia, Sierra Leone, and Guinea), and age of contact (<5 years, 5-14 years, and >= 15 years). We did sensitivity analyses to assess how results varied with malaria parasite prevalence (in children aged 2-10 years), daily cost of ETU stay (for Liberian malaria incidence levels), and compliance and effectiveness of preventive malaria treatment. Findings Administration of ACTs to contacts of patients with Ebola virus disease was cost saving for contacts of all ages in Liberia, Sierra Leone, and Guinea, in both seasons, from a health-care provider perspective. In the wet season, preventive malaria treatment was estimated to reduce the probability of a contact being admitted to an ETU by a maximum of 36% (in Guinea, for contacts aged <5 years), and a minimum of 10% (in Guinea and Sierra Leone, for those aged >= 15 years). Assuming 85% compliance and taking into account the African population pyramid, the intervention is expected to be cost saving in contacts of all age groups in areas with malaria parasite prevalence in children aged 2-10 years as low as 10%. In Liberia during the wet season, malaria preventive treatment was cost saving even when average daily bed-stay costs were as low as US$5 for children younger than 5 years, $9 for those aged 5-14 years, and $22 for those aged 15 years or older. Interpretation Administration of preventive malaria treatment to contacts of patients with Ebola virus disease should be considered by public health officials when addressing Ebola virus disease outbreaks in countries and seasons where malaria reaches high levels of transmission. C1 [Carias, Cristina; Greening, Bradford, Jr.; Campbell, Caresse G.; Meltzer, Martin I.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Carias, Cristina; Greening, Bradford, Jr.; Campbell, Caresse G.; Meltzer, Martin I.] Ctr Dis Control & Prevent, Modeling Unit, Emergency Operat Ctr, Ebola Response 2014, Atlanta, GA 30333 USA. [Hamel, Mary J.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Carias, Cristina] IHRC Inc, Atlanta, GA USA. RP Carias, C (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C-18, Atlanta, GA 30333 USA. EM vnn9@cdc.gov RI Greening, Bradford/K-5533-2014 OI Greening, Bradford/0000-0003-2727-2287 FU Centers for Disease Control and Prevention FX Centers for Disease Control and Prevention. NR 39 TC 1 Z9 1 U1 2 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD APR PY 2016 VL 16 IS 4 BP 449 EP 458 DI 10.1016/S1473-3099(15)00465-X PG 10 WC Infectious Diseases SC Infectious Diseases GA DH0CH UT WOS:000372449600038 PM 26706716 ER PT J AU Kroelinger, CD Vladutiu, CJ Jones, JR AF Kroelinger, Charlan D. Vladutiu, Catherine J. Jones, Jessica R. TI Recognizing Excellence in Maternal and Child Health (MCH) Epidemiology: The 2014 National MCH Epidemiology Awards SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Maternal and child health epidemiology; Perinatal epidemiology; National awards ID PERSONAL HISTORY; SOCIAL MEDICINE AB Purpose The impact of programs, policies, and practices developed by professionals in the field of maternal and child health (MCH) epidemiology is highlighted biennially by 16 national MCH agencies and organizations, or the Coalition for Excellence in MCH Epidemiology. Description In September 2014, multiple leading agencies in the field of MCH partnered to host the national CityMatCH Leadership and MCH Epidemiology Conference in Phoenix, Arizona. The conference offered opportunities for peer exchange; presentation of new scientific methodologies, programs, and policies; dialogue on changes in the MCH field; and discussion of emerging MCH issues relevant to the work of local, state, and national MCH professionals. During the conference, the National MCH Epidemiology Awards were presented to individuals, teams, institutions, and leaders for significantly contributing to the improved health of women, children, and families. Assessment During the conference, the Coalition presented seven deserving health researchers and research groups with national awards in the areas of advancing knowledge, effective practice, outstanding leadership, young professional achievement, and lifetime achievement. The article highlights the accomplishments of these national-level awardees. Conclusion Recognition of deserving professionals strengthens the field of MCH epidemiology, and sets the standard for exceptional research, mentoring, and practice. C1 [Kroelinger, Charlan D.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Maternal & Child Hlth Epidemiol Program, Natl MCH Epidemiol Awards Select Comm,Div Reprod, 4770 Buford Hwy NE,MS F-74, Atlanta, GA 30341 USA. [Vladutiu, Catherine J.; Jones, Jessica R.] Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, 5600 Fishers Lane 18-23, Rockville, MD 20857 USA. RP Kroelinger, CD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Maternal & Child Hlth Epidemiol Program, Natl MCH Epidemiol Awards Select Comm,Div Reprod, 4770 Buford Hwy NE,MS F-74, Atlanta, GA 30341 USA. EM ckroelinger@cdc.gov FU Intramural CDC HHS [CC999999] NR 3 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2016 VL 20 IS 4 BP 760 EP 768 DI 10.1007/s10995-015-1916-6 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG6BR UT WOS:000372167700004 PM 26723200 ER PT J AU Barradas, DT Wasserman, MP Daniel-Robinson, L Bruce, MA DiSantis, KI Navarro, FH Jones, WA Manzi, NM Smith, MW Goodness, BM AF Barradas, Danielle T. Wasserman, Martin P. Daniel-Robinson, Lekisha Bruce, Marino A. DiSantis, Katherine Isselmann Navarro, Frederick H. Jones, Warren A. Manzi, Nadine M. Smith, Mark W. Goodness, Brian M. TI Hospital Utilization and Costs Among Preterm Infants by Payer: Nationwide Inpatient Sample, 2009 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Preterm birth; Low birth weight; Insurance ID NEONATAL INTENSIVE-CARE; BIRTH-WEIGHT INFANTS; PRENATAL-CARE; WOMEN AB Objectives To describe hospital utilization and costs associated with preterm or low birth weight births (preterm/LBW) by payer prior to implementation of the Affordable Care Act and to identify areas for improvement in the quality of care received among preterm/LBW infants. Methods Hospital utilization-defined as mean length of stay (LOS, days), secondary diagnoses for birth hospitalizations, primary diagnoses for rehospitalizations, and transfer status-and costs were described among preterm/LBW infants using the 2009 Nationwide Inpatient Sample. Results Approximately 9.1 % of included hospitalizations (n = 4,167,900) were births among preterm/LBW infants; however, these birth hospitalizations accounted for 43.4 % of total costs. Rehospitalizations of all infants occurred at a rate of 5.9 % overall, but accounted for 22.6 % of total costs. This pattern was observed across all payer types. The prevalence of rehospitalizations was nearly twice as high among preterm/LBW infants covered by Medicaid (7.6 %) compared to commercially-insured infants (4.3 %). Neonatal transfers were more common among preterm/LBW infants whose deliveries and hospitalizations were covered by Medicaid (7.3 %) versus commercial insurance (6.5 %). Uninsured/self-pay preterm and LBW infants died in-hospital during the first year of life at a rate of 91 per 1000 discharges-nearly three times higher than preterm and LBW infants covered by either Medicaid (37 per 1000) or commercial insurance (32 per 1000). Conclusions When comparing preterm/LBW infants whose births were covered by Medicaid and commercial insurance, there were few differences in length of hospital stays and costs. However, opportunities for improvement within Medicaid and CHIP exist with regard to reducing rehospitalizations and neonatal transfers. C1 [Barradas, Danielle T.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, 4770 Buford Hwy NE,MS F-74, Atlanta, GA 30341 USA. [Wasserman, Martin P.; Bruce, Marino A.; DiSantis, Katherine Isselmann; Navarro, Frederick H.; Jones, Warren A.; Manzi, Nadine M.] Provider Resources Inc, Healthcare Qual & Dispar Div, Erie, PA USA. [Daniel-Robinson, Lekisha] Ctr Medicare & Medicaid Serv, Ctr Medicaid & CHIP Serv, Children & Adults Hlth Programs Grp, Div Qual Evaluat & Hlth Outcomes, Baltimore, MA USA. [Smith, Mark W.; Goodness, Brian M.] Truven Hlth Analyt, Ann Arbor, MI USA. RP Barradas, DT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, 4770 Buford Hwy NE,MS F-74, Atlanta, GA 30341 USA. EM dbarradas@cdc.gov FU Intramural CDC HHS [CC999999] NR 17 TC 0 Z9 0 U1 4 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2016 VL 20 IS 4 BP 808 EP 818 DI 10.1007/s10995-015-1911-y PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG6BR UT WOS:000372167700009 PM 26740227 ER PT J AU Masterson, EA Themann, CL Luckhaupt, SE Li, J Calvert, GM AF Masterson, Elizabeth A. Themann, Christa L. Luckhaupt, Sara E. Li, Jia Calvert, Geoffrey M. TI Hearing difficulty and tinnitus among US workers and non-workers in 2007 SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE occupational hearing loss; ringing in the ears; tinnitus; hazardous noise; noise-induced hearing loss; surveillance ID UNITED-STATES; NATIONAL-HEALTH; NOISE; PREVALENCE; EXPOSURE; INDUSTRY AB BackgroundHearing loss and tinnitus are two potentially debilitating physical conditions affecting many people in the United States. The purpose of this study was to estimate the prevalence of hearing difficulty, tinnitus, and their co-occurrence within U.S. populations. MethodsData from the 2007 National Health Interview Survey (NHIS) were examined. Weighted prevalence and adjusted prevalence ratios for self-reported hearing difficulty, tinnitus, and their co-occurrence were estimated and compared by demographic, among workers with and without occupational noise exposure, and across industries and occupations. ResultsSeven percent of U.S. workers never exposed to occupational noise had hearing difficulty, 5% had tinnitus and 2% had both conditions. However, among workers who had ever been exposed to occupational noise, the prevalence was 23%, 15%, and 9%, respectively (P<0.0001). ConclusionsHearing difficulty and tinnitus are prevalent in the U.S.; especially among noise-exposed workers. Improved strategies for hearing conservation or better implementation are needed. Published 2016. This article is a U.S. Government work and is in the public domain in the USA. C1 [Masterson, Elizabeth A.; Themann, Christa L.; Luckhaupt, Sara E.; Li, Jia; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Masterson, EA (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 1090 Tusculum Ave,MS R17, Cincinnati, OH 45226 USA. EM emasterson@cdc.gov NR 40 TC 2 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD APR PY 2016 VL 59 IS 4 BP 290 EP 300 DI 10.1002/ajim.22565 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG7UP UT WOS:000372289500004 PM 26818136 ER PT J AU Ingasia, LA Cheruiyot, J Okoth, SA Andagalu, B Kamau, E AF Ingasia, Luicer A. Cheruiyot, Jelagat Okoth, Sheila Akinyi Andagalu, Ben Kamau, Edwin TI Genetic variability and population structure of Plasmodium falciparum parasite populations from different malaria ecological regions of Kenya SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Plasmodium falciparum; Kenya; Genetic diversity; Population structure ID WESTERN KENYA; LINKAGE DISEQUILIBRIUM; MICROSATELLITE MARKERS; RURAL KENYA; DIVERSITY; TRANSMISSION; RESISTANCE; HIGHLANDS; SELECTION; DECLINE AB Transmission intensity, movement of human and vector hosts, biogeographical features, and malaria control measures are some of the important factors that determine Plasmodium falciparum parasite genetic variability and population structure. Kenya has different malaria ecologies which might require different disease intervention methods. Refined parasite population genetic studies are critical for informing malaria control and elimination strategies. This study describes the genetic diversity and population structure of P. falciparum parasites from the different malaria ecological zones in Kenya. Twelve multi-locus microsatellite (MS) loci previously described were genotyped in 225 P. falciparum isolates collected between 2012 and 2013 from five sites; three in lowland endemic regions (Kisumu, Kombewa, and Malindi) and two in highland, epidemic regions (Kisii and Kericho). Parasites from the lowland endemic and highland epidemic regions of western Kenya had high genetic diversity compared to coastal lowland endemic region of Kenya [Malindi]. The Kenyan parasites had a mean genetic differentiation index (F-ST) of 0.072 (p = 0.011). Themulti-locus genetic analysis of the 12 MS revealed all the parasites had unique haplotypes. Significant linkage disequilibrium (LD) was observed in all the five parasite populations. Kisumu had the most significant index of association values (0.16; p < 0.0001) whereas Kisii had the least significant index of association values (0.03; p < 0.0001). Our data suggest high genetic diversity in Kenyan parasite population with the exception of parasite from Malindi where malaria has been on the decline. The presence of significant LD suggests that there is occurrence of inbreeding in the parasite population. Parasite populations from Kisii showed the strongest evidence for epidemic population structure whereas the rest of the regions showed panmixia. Defining the genetic diversity of the parasites in different ecological regions of Kenya after introduction of the artemether-lumefantrine is important in refining the spread of drug resistant strains and malaria transmission for more effective control and eventual elimination of malaria in Kenya. (C) 2015 Published by Elsevier B.V. C1 [Ingasia, Luicer A.; Cheruiyot, Jelagat; Andagalu, Ben; Kamau, Edwin] US Army Med Res Directorate Kenya, Dept Emerging & Infect Dis, Kenya Med Res Inst KEMRI, Walter Reed Project, Kisumu, Kenya. [Okoth, Sheila Akinyi] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Ctr Global Hlth, Atlanta, GA USA. [Okoth, Sheila Akinyi] Atlanta Res & Educ Fdn, VA Med Ctr, Decatur, GA USA. RP Kamau, E (reprint author), US Army Med Res Directorate Kenya, Dept Emerging & Infect Dis, Kenya Med Res Inst KEMRI, Walter Reed Project, Kisumu, Kenya. EM edwin.kamau.mil@mail.mil FU Armed Forces Health Surveillance Center, Division of Global Emerging Infections Surveillance and Response System Operations FX This work was supported by the Armed Forces Health Surveillance Center, Division of Global Emerging Infections Surveillance and Response System Operations. NR 39 TC 1 Z9 1 U1 3 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 EI 1567-7257 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD APR PY 2016 VL 39 BP 372 EP 380 DI 10.1016/j.meegid.2015.10.013 PG 9 WC Infectious Diseases SC Infectious Diseases GA DG4DZ UT WOS:000372022700047 PM 26472129 ER PT J AU Fitzpatrick, M Brooks, JT Kaplan, JE AF Fitzpatrick, Meghan Brooks, John T. Kaplan, Jonathan E. TI Epidemiology of HIV-Associated Lung Disease in the United States SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE HIV; epidemiology; smoking; pneumonia; Pneumocystis; pulmonary disease; chronic obstructive; lung cancer ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; PNEUMOCYSTIS-CARINII-PNEUMONIA; MYCOBACTERIUM-AVIUM COMPLEX; PULMONARY ARTERIAL-HYPERTENSION; COMMUNITY-ACQUIRED PNEUMONIA; QUALITY-OF-LIFE; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; DEFINING OPPORTUNISTIC ILLNESSES; CRYPTOCOCCUS-GATTII INFECTIONS AB The epidemiology of HIV infection and its pulmonary complications in the United States has evolved significantly over nearly 20 years since the advent of combination antiretroviral therapy. While infectious complications are less of a threat to patients whose immune systems have been restored, many HIV-infected persons in the United States remain at high risk for opportunistic infection because they are unaware of their HIV infection, have difficulty maintaining linkage to care, or maintain inadequate viral control. Bacterial pneumonia and Pneumocystis pneumonia remain significantly more prevalent among HIV-infected persons, and together with seasonal influenza are areas where public health efforts to increase antiretroviral therapy, appropriate prophylaxis, and vaccination may decrease burden of disease. Noninfectious pulmonary complications of chronic HIV infection are increasingly recognized in the United States and elsewhere. Chronic obstructive pulmonary disease, asthma, pulmonary hypertension, sleep-disordered breathing, and primary lung cancer may all be more common among persons with HIV; of concern, disease burden in U.S. HIV-infected persons may be underestimated due to lack of diagnostic testing for these conditions. Smoking is among the most prevalent preventable causes of morbidity and mortality affecting persons living with HIV infection, and has particular import to pulmonary disease. As of 2009, 42% of HIV-infected adults in medical care in the United States smoked tobacco (over twice the national rate in the general population). Successful efforts to promote smoking cessation among HIV-infected persons are of critical importance to decrease the burden of chronic pulmonary disease. C1 [Fitzpatrick, Meghan] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Kaplan, Jonathan E.] Ctr Dis Control & Prevent, Div Global HIV & TB, Atlanta, GA USA. RP Fitzpatrick, M (reprint author), Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, 3459 Fifth Ave,628 NW, Pittsburgh, PA 15213 USA. EM fitzpatrickme2@upmc.edu NR 184 TC 0 Z9 0 U1 1 U2 5 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 EI 1098-9048 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD APR PY 2016 VL 37 IS 2 BP 181 EP 198 DI 10.1055/s-0036-1572556 PG 18 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DG4VK UT WOS:000372071000005 PM 26974297 ER PT J AU Berrios-Torres, SI AF Berrios-Torres, Sandra I. TI Evidence-Based Update to the U.S. Centers for Disease Control and Prevention and Healthcare Infection Control Practices Advisory Committee Guideline for the Prevention of Surgical Site Infection: Developmental Process SO SURGICAL INFECTIONS LA English DT Article ID KNEE ARTHROPLASTY; UNITED-STATES; RECOMMENDATIONS; STRENGTH; QUALITY; HIP; SYSTEMS; GRADE AB Recommendations in the "Guideline for Prevention of Surgical Site Infection, 1999" were based on experts' selective interpretation of the scientific evidence. Effective 2009, the U.S. Centers for Disease Control and Prevention (CDC) and its Healthcare Infection Control Practices Advisory Committee (HICPAC) updated their guideline development process. This is a narrative summary of the updated process focusing on key changes and challenges specific to the Guideline for Prevention of Surgical Site Infection. The guideline development process now incorporates evidence-based methodology and provides explicit links between the evidence and the recommendations using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method. There is also participation by professional surgical societies, an updated guideline structure (core and procedure-specific sections), additional planned related manuscripts (introductions to the guideline and research opportunities), and new proposed venues for publication. The new CDC and HICPAC "Guideline for the Prevention of Surgical Site Infection" represents a substantial advancement from recommendations for infection control practices based on expert opinion to evidence-based practices. The new structure is meant to facilitate future updates, in particular, those addressing specialty or procedure-specific surgical site infection prevention questions. Increased presence by the surgical community through the professional surgical societies' engagement in the guideline development process, lead authorship of related manuscripts, and proposed publication in the surgical literature not only increase adherence by the surgical community, but also promote an ongoing collaboration with public health and other partners in a multidisciplinary approach to SSI prevention. C1 [Berrios-Torres, Sandra I.] US Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Berrios-Torres, SI (reprint author), 3525 Del Mar Hts Rd,139, San Diego, CA 92014 USA. EM sandra.berrios@stanfordalumni.org NR 26 TC 1 Z9 1 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 EI 1557-8674 J9 SURG INFECT JI Surg. Infect. PD APR 1 PY 2016 VL 17 IS 2 BP 256 EP 261 DI 10.1089/sur.2015.264 PG 6 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA DG6FL UT WOS:000372178200020 PM 26891203 ER PT J AU Nnadi, CD Anderson, LF Armstrong, LR Stagg, HR Pedrazzoli, D Pratt, R Heilig, CM Abubakar, I Moonan, PK AF Nnadi, Chimeremma D. Anderson, Laura F. Armstrong, Lori R. Stagg, Helen R. Pedrazzoli, Debora Pratt, Robert Heilig, Charles M. Abubakar, Ibrahim Moonan, Patrick K. TI Mind the gap: TB trends in the USA and the UK, 2000-2011 SO THORAX LA English DT Article ID FOREIGN-BORN PERSONS; UNITED-STATES; LATENT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; IMMIGRATION; REGRESSION; COUNTRIES; RATES; IMPLEMENTATION; ELIMINATION AB Background TB remains a major public health concern, even in low-incidence countries like the USA and the UK. Over the last two decades, cases of TB reported in the USA have declined, while they have increased substantially in the UK. We examined factors associated with this divergence in TB trends between the two countries. Methods We analysed all cases of TB reported to the US and UK national TB surveillance systems from 1 January 2000 through 31 December 2011. Negative binominal regression was used to assess potential demographic, clinical and risk factor variables associated with differences in observed trends. Findings A total of 259 609 cases were reported. From 2000 to 2011, annual TB incidence rates declined from 5.8 to 3.4 cases per 100 000 in the USA, whereas in the UK, TB incidence increased from 11.4 to 14.4 cases per 100 000. The majority of cases in both the USA (56%) and the UK (64%) were among foreign-born persons. The number of foreign-born cases reported in the USA declined by 15% (7731 in 2000 to 6564 in 2011) while native-born cases fell by 54% (8442 in 2000 to 3883 in 2011). In contrast, the number of foreign-born cases reported in the UK increased by 80% (3380 in 2000 to 6088 in 2011), while the number of native-born cases remained largely unchanged (2158 in 2000 to 2137 in 2011). In an adjusted negative binomial regression model, significant differences in trend were associated with sex, age, race/ethnicity, site of disease, HIV status and previous history of TB (p<0.01). Among the foreign-born, significant differences in trend were also associated with time since UK or US entry (p<0.01). Interpretation To achieve TB elimination in the UK, a re-evaluation of current TB control policies and practices with a focus on foreign-born are needed. In the USA, maintaining and strengthening control practices are necessary to sustain the progress made over the last 20 years. C1 [Nnadi, Chimeremma D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30336 USA. [Nnadi, Chimeremma D.; Armstrong, Lori R.; Pratt, Robert; Heilig, Charles M.; Moonan, Patrick K.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30336 USA. [Anderson, Laura F.; Abubakar, Ibrahim] Publ Hlth England, TB Sect, London, England. [Stagg, Helen R.; Abubakar, Ibrahim] UCL, Res Dept Infect & Populat Hlth, London, England. [Pedrazzoli, Debora] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, TB Ctr, TB Modelling Grp, London WC1, England. [Pedrazzoli, Debora] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, CMMID, London WC1, England. RP Moonan, PK (reprint author), Ctr Dis Control & Prevent, Div Global HIV & TB, 1600 Clifton Rd NE, Atlanta, GA 30336 USA. EM pmoonan@cdc.gov OI Stagg, Helen/0000-0003-4022-3447; Heilig, Charles/0000-0003-1075-1310 FU Health Protection Agency, Centers for Disease Control and Prevention FX Health Protection Agency, Centers for Disease Control and Prevention. NR 45 TC 1 Z9 1 U1 1 U2 7 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0040-6376 EI 1468-3296 J9 THORAX JI Thorax PD APR PY 2016 VL 71 IS 4 BP 356 EP 363 DI 10.1136/thoraxjnl-2015-207915 PG 8 WC Respiratory System SC Respiratory System GA DG7TD UT WOS:000372285700010 PM 26907187 ER PT J AU Furukawa, NW Teshale, EH Cosmas, L Ochieng, M Gikunju, S Fields, BS Montgomery, JM AF Furukawa, N. W. Teshale, E. H. Cosmas, L. Ochieng, M. Gikunju, S. Fields, B. S. Montgomery, J. M. TI Serologic evidence for hepatitis E virus infection among patients with undifferentiated acute febrile illness in Kibera, Kenya SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Hepatitis E; Kibera; Kenya; Acute febrile illness; Enzyme immunoassay; Nucleic acid testing ID E OUTBREAK; MALARIA; ANTIBODIES; DIAGNOSIS; ETIOLOGY; FEVER; HIV AB Background: Hepatitis E (HEV) is an emerging cause of viral hepatitis mainly transmitted through the fecal-oral route. Residents of the Kibera slum of Nairobi, Kenya are at risk for fecal-orally transmitted infections. Objective: To quantify the incidence and prevalence of HEV infection among acute febrile illness (AFI) cases using a population-based infectious disease surveillance network. Study design: Cross-sectional serum samples from AFI case-patients between 2009 and 2012 were matched to the age and gender distribution of the Kibera population and tested by IgM and IgG enzyme immunoassays (EIA) and nucleic acid testing (NAT). Serum from healthy residents was also tested by EIA. Results: Of the 482 AFI serum samples tested, 124 (25.7%) and 182 (37.8%) were IgM and IgG reactive, respectively. On multivariate analysis, IgM reactivity was associated with HIV (RR 1.66, 95% CI 1.07, 2.60; p = 0.024) while IgG reactivity was associated with increasing age (p < 0.001) and HIV (RR 1.93, 95%CI 1.52, 2.46; p<0.001). AFI case-patients were more likely to be IgM (p = 0.002) and IgG (p<0.001) reactive compared to healthy residents. The seroincidence by HEV-specific IgM was 84.0 per 1000 person years, however, all 482 samples were negative by NAT. Conclusions: Serologic evidence for HEV in Kibera suggests a high burden of infection, but NAT did not confirm HEV viremia. Additional testing is needed to determine whether EIAs are susceptible to false positivity in undifferentiated AFI populations before their widespread use. (C) 2016 Elsevier B.V. All rights reserved. C1 [Furukawa, N. W.] Univ Washington, Dept Med, Seattle, WA USA. [Teshale, E. H.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Cosmas, L.; Fields, B. S.; Montgomery, J. M.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Nairobi, Kenya. [Ochieng, M.; Gikunju, S.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Nairobi, Kenya. RP Furukawa, NW (reprint author), Univ Washington, Dept Internal Med, 1959 NE Pacific St,Box 356421, Seattle, WA 98195 USA. EM furukn1@uw.edu FU CDC-Hubert Global Health Fellowship FX Funding from the CDC-Hubert Global Health Fellowship. NR 21 TC 0 Z9 0 U1 0 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD APR PY 2016 VL 77 BP 106 EP 108 DI 10.1016/j.jcv.2016.02.021 PG 3 WC Virology SC Virology GA DG0WR UT WOS:000371787100021 PM 26925954 ER PT J AU Barbero, C Gilchrist, S Chriqui, JF Martin, MA Wennerstrom, A VanderVeur, J Prewitt, K Brownstein, JN AF Barbero, Colleen Gilchrist, Siobhan Chriqui, Jamie F. Martin, Molly A. Wennerstrom, Ashley VanderVeur, Jennifer Prewitt, Kim Brownstein, J. Nell TI Do State Community Health Worker Laws Align with Best Available Evidence? SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Community health worker; Evidence-informed policy; Health policy; Health law ID BLOOD-PRESSURE AB Community health workers (CHWs) are expected to improve patient care and population health while reducing health care costs. Law is a tool states are using to build a supportive infrastructure for the CHW workforce. This study assessed the extent existing state law pertaining to the CHW workforce aligned with best available evidence. We used the previously developed Quality and Impact of Component (QuIC) Evidence Assessment method to identify and prioritize those components that could comprise an evidence-informed CHW policy at the state level. We next assessed the extent codified statutes and regulations in effect as of December 31, 2014 for the 50 states and D.C. included the components identified in the evidence assessment. Fourteen components of an evidence-informed CHW policy were identified; eight had best, three had promising, and three had emerging evidence bases. Codified law in 18 states (35.3 % of 51) pertained to the CHW workforce. Fifteen of these 18 states authorized at least one of the 14 components from the evidence assessment (maximum: nine components, median: 2.5). The most frequently authorized component was a defined scope of practice for CHWs (authorized by eight states) followed by a standard core competency curriculum and inclusion of CHWs in multidisciplinary health care teams (each authorized by six states). States could consider the components presented in this article when developing new or strengthening existing law. C1 [Barbero, Colleen; VanderVeur, Jennifer; Brownstein, J. Nell] Ctr Dis Control & Prevent, 4770 Buford Highway,Northeast Mail Stop F-75, Atlanta, GA 30341 USA. [Gilchrist, Siobhan] IHRC Inc, 2 Ravina Dr Suite 1750, Atlanta, GA 30346 USA. [Chriqui, Jamie F.; Martin, Molly A.] Univ Illinois, 453 Westside Res Off Bldg,1747 West Roosevelt Rd, Chicago, IL 60608 USA. [Wennerstrom, Ashley] Tulane Univ, Sch Med, Dept Internal Med, 1430 Tulane Ave,SL-16, New Orleans, LA 70112 USA. [Prewitt, Kim] Washington Univ, Brown Sch Social Work, 700 Rosedale Ave,CB 1009, St Louis, MO 63112 USA. RP Barbero, C (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,Northeast Mail Stop F-75, Atlanta, GA 30341 USA. EM vrm5@cdc.gov FU Centers for Disease Control and Prevention [11IPA1103219] FX Centers for Disease Control and Prevention (#11IPA1103219). NR 27 TC 2 Z9 2 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 EI 1573-3610 J9 J COMMUN HEALTH JI J. Community Health PD APR PY 2016 VL 41 IS 2 BP 315 EP 325 DI 10.1007/s10900-015-0098-x PG 11 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DG0ZB UT WOS:000371793700015 PM 26455578 ER PT J AU Fortenberry, GZ Beckman, J Schwartz, A Prado, JB Graham, LS Higgins, S Lackovic, M Mulay, P Bojes, H Waltz, J Mitchell, Y Leinenkugel, K Oriel, MS Evans, E Calvert, GM AF Fortenberry, Gamola Z. Beckman, John Schwartz, Abby Prado, Joanne Bonnar Graham, Lucia S. Higgins, Sheila Lackovic, Michelle Mulay, Prakash Bojes, Heidi Waltz, Justin Mitchell, Yvette Leinenkugel, Kathy Oriel, Michel S. Evans, Elizabeth Calvert, Geoffrey M. TI Magnitude and characteristics of acute paraquat- and diquat-related illnesses in the US: 1998-2013 SO ENVIRONMENTAL RESEARCH LA English DT Article DE Paraquat; Diquat; Pesticides; Acute Poisonings; Surveillance ID CLINICAL-FEATURES; FORMULATION; MANAGEMENT; INGESTION AB Background: Paraquat and diquat are among the most commonly used herbicides in the world. Objectives: Determine the magnitude, characteristics, and root causes for acute paraquat- and diquatrelated illnesses in the US Methods: Illnesses associated with paraquat or diquat exposure occurring from 1998 through 2011 were identified from the Sentinel Event Notification System for Occupational Risks (SENSOR)-Pesticides Program, the California Department of Pesticide Regulation (CDPR) Pesticide Illness Surveillance Program (PISP), and the Incident Data System (IDS). Cases identified by the National Poison Data System (NPDS) were reviewed for the years 1998-2003 and 2006-2013. Results: A total of 300 paraquat- and 144 diquat-related acute illnesses were identified by SENSOR, PISP, and IDS. NPDS identified 693 paraquat- and 2128 diquat-related acute illnesses. In SENSOR/PISP/IDS, illnesses were commonly low severity (paraquat=41%; diquat=81%); however, SENSOR/PISP/IDS identified 24 deaths caused by paraquat and 5 deaths associated with diquat. Nineteen paraquat-related deaths were due to ingestion, seven of which were unintentional, often due to improper storage in beverage bottles. In SENSOR/PISP/IDS, paraquat and diquat-related acute illnesses were work-related in 68% (n=203) and 29% (n=42) of cases, respectively. When herbicide application site was known, the vast majority of acute paraquat-related illnesses (81%) arose from agricultural applications. Common root causes of illness were failure to use adequate personal protective equipment (PPE), application equipment failure, and spill/splash of herbicide. Conclusions: Although the magnitude of acute paraquat/diquat-related illnesses was relatively low, several fatalities were identified. Many illnesses could be prevented through stricter compliance with label requirements (e.g. ensuring proper herbicide storage and PPE use), and through enhanced training of certified applicators. Published by Elsevier Inc. C1 [Fortenberry, Gamola Z.; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Beckman, John] Inst Publ Hlth, Oakland, CA USA. [Beckman, John] Calif Dept Publ Hlth, Richmond, CA USA. [Schwartz, Abby] Michigan Dept Hlth & Human Serv, Lansing, MI USA. [Prado, Joanne Bonnar] Washington State Dept Hlth, Olympia, WA USA. [Graham, Lucia S.; Oriel, Michel S.] Calif Dept Pesticide Regulat, Sacramento, CA USA. [Higgins, Sheila] North Carolina Dept Hlth & Human Serv, Raleigh, NC USA. [Lackovic, Michelle] Louisiana Dept Hlth & Hosp, New Orleans, LA USA. [Mulay, Prakash] Florida Dept Hlth, Tallahassee, FL USA. [Bojes, Heidi] Texas Dept State Hlth Serv, Austin, TX USA. [Waltz, Justin] Oregon Hlth Author, Portland, OR USA. [Mitchell, Yvette] New York State Dept Hlth, Albany, NY USA. [Leinenkugel, Kathy] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA. [Evans, Elizabeth] US EPA, Off Pesticide Programs, Washington, DC 20460 USA. RP Calvert, GM (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. EM jac6@cdc.gov FU National Institute for Occupational Safety and Health, United States; United States Environmental Protection Agency (EPA) [DW-75-95840001-2] FX Funding was provided by the National Institute for Occupational Safety and Health, United States, the United States Environmental Protection Agency (EPA Interagency Agreement identification number DW-75-95840001-2), and the participating state agencies that provided data. NR 24 TC 1 Z9 2 U1 2 U2 10 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD APR PY 2016 VL 146 BP 191 EP 199 DI 10.1016/j.envres.2016.01.003 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DF2TE UT WOS:000371196000023 PM 26775000 ER PT J AU Spencer, S Chung, J Thompson, M Piedra, PA Jewell, A Avadhanula, V Mei, MH Jackson, ML Meece, J Sundaram, M Belongia, EA Cross, R Johnson, E Bullotta, A Rinaldo, C Gaglani, M Murthy, K Clipper, L Berman, L Flannery, B AF Spencer, Sarah Chung, Jessie Thompson, Mark Piedra, Pedro A. Jewell, Alan Avadhanula, Vasanthi Mei, Minghua Jackson, Michael L. Meece, Jennifer Sundaram, Maria Belongia, Edward A. Cross, Rachel Johnson, Emileigh Bullotta, Arlene Rinaldo, Charles Gaglani, Manjusha Murthy, Kempapura Clipper, Lydia Berman, LaShondra Flannery, Brendan TI Factors associated with real-time RT-PCR cycle threshold values among medically attended influenza episodes SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE Influenza; RT-PCR; cycle threshold value ID REVERSE TRANSCRIPTION-PCR; VACCINE EFFECTIVENESS; SEASONAL INFLUENZA; VIRUS DETECTION; ADULT PATIENTS; UNITED-STATES; VIRAL LOADS; QUANTIFICATION; INFECTION; DIAGNOSIS AB We evaluated the cycle threshold (CT) values of 1,160 influenza A positive and 806 influenza B positive specimens from two seasons of the US Flu VE Network to identify factors associated with CT values. Low CT values (high genomic load) were associated with shorter intervals between illness onset and specimen collection, young age (ages 3-8 years old), and self-rated illness severity for both influenza A and B. Low CT values were also associated with reported fever/feverishness and age 65 years for influenza A. J. Med. Virol. 88:719-723, 2016. (c) 2015 Wiley Periodicals, Inc. C1 [Spencer, Sarah; Chung, Jessie; Thompson, Mark; Berman, LaShondra; Flannery, Brendan] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. [Spencer, Sarah; Chung, Jessie] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Piedra, Pedro A.; Jewell, Alan; Avadhanula, Vasanthi; Mei, Minghua] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Piedra, Pedro A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Jackson, Michael L.] Grp Hlth Res Inst, Seattle, WA USA. [Meece, Jennifer; Sundaram, Maria; Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Cross, Rachel; Johnson, Emileigh] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Bullotta, Arlene; Rinaldo, Charles] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Gaglani, Manjusha; Murthy, Kempapura; Clipper, Lydia] Scott & White Healthcare, Temple, TX USA. RP Spencer, S (reprint author), Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA.; Spencer, S (reprint author), Ctr Dis Control & Prevent, 1600 Clifton RD MS A32, Atlanta, GA 30329 USA. EM vmf5@cdc.gov FU Centers for Disease Control and Prevention; Group Health Research Institute [U01 IP000474]; Marshfield Clinic Research Foundation [U01 IP000466]; University of Pittsburgh [U01 IP000471]; Scott and White Healthcare [U01 IP000467]; University of Michigan [U01 IP000473] FX Grant sponsor: Centers for Disease Control and Prevention; Group Health Research Institute; Grant number: U01 IP000474; Grant sponsor: Marshfield Clinic Research Foundation; Grant number: U01 IP000466; Grant sponsor: University of Pittsburgh; Grant number: U01 IP000471; Grant sponsor: Scott and White Healthcare; Grant number: U01 IP000467; Grant sponsor: University of Michigan; Grant number: U01 IP000473. NR 25 TC 1 Z9 1 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 EI 1096-9071 J9 J MED VIROL JI J. Med. Virol. PD APR PY 2016 VL 88 IS 4 BP 719 EP 723 DI 10.1002/jmv.24373 PG 5 WC Virology SC Virology GA DC4IL UT WOS:000369184300020 PM 26334765 ER PT J AU Meyer, RE Liu, G Gilboa, SM Ethen, MK Aylsworth, AS Powell, CM Flood, TJ Mai, CT Wang, Y Canfield, MA AF Meyer, Robert E. Liu, Gang Gilboa, Suzanne M. Ethen, Mary K. Aylsworth, Arthur S. Powell, Cynthia M. Flood, Timothy J. Mai, Cara T. Wang, Ying Canfield, Mark A. CA Natl Birth Defects Prevention TI Survival of children with trisomy 13 and trisomy 18: A multi-state population-based study SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE trisomy 13; trisomy 18; survival; mortality; epidemiology ID PRENATAL-DIAGNOSIS; PATAU-SYNDROME; BIRTH-DEFECTS; UNITED-STATES; INFANTS; PREVALENCE; MANAGEMENT; MORTALITY AB Trisomy 13 (T13) and trisomy 18 (T18) are among the most prevalent autosomal trisomies. Both are associated with a very high risk of mortality. Numerous instances, however, of long-term survival of children with T13 or T18 have prompted some clinicians to pursue aggressive treatment instead of the traditional approach of palliative care. The purpose of this study is to assess current mortality data for these conditions. This multi-state, population-based study examined data obtained from birth defect surveillance programs in nine states on live-born infants delivered during 1999-2007 with T13 or T18. Information on children's vital status and selected maternal and infant risk factors were obtained using matched birth and death certificates and other data sources. The Kaplan-Meier method and Cox proportional hazards models were used to estimate age-specific survival probabilities and predictors of survival up to age five. There were 693 children with T13 and 1,113 children with T18 identified from the participating states. Among children with T13, 5-year survival was 9.7%; among children with T18, it was 12.3%. For both trisomies, gestational age was the strongest predictor of mortality. Females and children of non-Hispanic black mothers had the lowest mortality. Omphalocele and congenital heart defects were associated with an increased risk of death for children with T18 but not T13. This study found survival among children with T13 and T18 to be somewhat higher than those previously reported in the literature, consistent with recent studies reporting improved survival following more aggressive medical intervention for these children. (c) 2015 Wiley Periodicals, Inc. C1 [Meyer, Robert E.] State Ctr Hlth Stat, NC Div Publ Hlth, Birth Defects Monitoring Program, Raleigh, NC 27603 USA. [Liu, Gang] SUNY Albany, Dept Epidemiol & Biostat, Albany, NY 12222 USA. [Gilboa, Suzanne M.; Mai, Cara T.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Ethen, Mary K.; Canfield, Mark A.] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA. [Aylsworth, Arthur S.; Powell, Cynthia M.] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA. [Aylsworth, Arthur S.; Powell, Cynthia M.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA. [Flood, Timothy J.] Arizona Dept Hlth Serv, Birth Defects Monitoring Program, Phoenix, AZ 85007 USA. [Wang, Ying] New York State Dept Hlth, Off Primary Care & Hlth Syst Management, Albany, NY USA. RP Meyer, RE (reprint author), State Ctr Hlth Stat, NC Div Publ Hlth, 222 N Dawson St,Cotton Bldg, Raleigh, NC 27603 USA. EM robert.meyer@dhhs.nc.gov FU Intramural CDC HHS [CC999999] NR 35 TC 11 Z9 11 U1 8 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD APR PY 2016 VL 170 IS 4 BP 825 EP 837 DI 10.1002/ajmg.a.37495 PG 13 WC Genetics & Heredity SC Genetics & Heredity GA DH9EN UT WOS:000373099300003 PM 26663415 ER PT J AU Sullivan, RT Ssewanyana, I Wamala, S Nankya, F Jagannathan, P Tappero, JW Mayanja-Kizza, H Muhindo, MK Arinaitwe, E Kamya, M Dorsey, G Feeney, ME Riley, EM Drakeley, CJ Greenhouse, B AF Sullivan, Richard T. Ssewanyana, Isaac Wamala, Samuel Nankya, Felistas Jagannathan, Prasanna Tappero, Jordan W. Mayanja-Kizza, Harriet Muhindo, Mary K. Arinaitwe, Emmanuel Kamya, Moses Dorsey, Grant Feeney, Margaret E. Riley, Eleanor M. Drakeley, Chris J. Greenhouse, Bryan TI B cell sub-types following acute malaria and associations with clinical immunity (vol 15, 139, 2016) SO MALARIA JOURNAL LA English DT Correction C1 [Sullivan, Richard T.; Jagannathan, Prasanna; Dorsey, Grant; Feeney, Margaret E.; Greenhouse, Bryan] Univ Calif San Francisco, Dept Med, Box 0811, San Francisco, CA 94110 USA. [Ssewanyana, Isaac; Wamala, Samuel; Nankya, Felistas; Mayanja-Kizza, Harriet; Muhindo, Mary K.; Arinaitwe, Emmanuel; Kamya, Moses] Infect Dis Res Collaborat, Tororo, Uganda. [Ssewanyana, Isaac; Riley, Eleanor M.; Drakeley, Chris J.] London Sch Hyg & Trop Med, Dept Immunol & Infect, London WC1, England. [Tappero, Jordan W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mayanja-Kizza, Harriet; Kamya, Moses] Makerere Univ, Sch Med, Kampala, Uganda. RP Sullivan, RT (reprint author), Univ Calif San Francisco, Dept Med, Box 0811, San Francisco, CA 94110 USA. EM richard.sullivan@ucsf.edu RI Riley, Eleanor/C-8960-2013 OI Riley, Eleanor/0000-0003-3447-3570 FU NIAID NIH HHS [P30 AI027763] NR 1 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAR 31 PY 2016 VL 15 AR 188 DI 10.1186/s12936-016-1236-3 PG 1 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DI4QU UT WOS:000373485200005 PM 27036294 ER PT J AU Caini, S Andrade, W Badur, S Balmaseda, A Barakat, A Bella, A Bimohuen, A Brammer, L Bresee, J Bruno, A Castillo, L Ciblak, MA Clara, AW Cohen, C Cutter, J Daouda, C de Lozano, C De Mora, D Dorji, K Emukule, GO Fasce, RA Feng, L de Almeida, WAF Guiomar, R Heraud, JM Holubka, O Huang, QS Kadjo, HA Kiyanbekova, L Kosasih, H Kusznierz, G Lara, J Li, M Lopez, L Hoang, PVM Henriques, CMP Matute, ML Mironenko, A Moreno, B Mott, JA Njouom, R Nurhayati Ospanova, A Owen, R Pebody, R Pennington, K Puzelli, S Le, MTQ Razanajatovo, NH Rodrigues, A Rudi, JM Lin, RTP Venter, M Vernet, MA Wangchuk, S Yang, J Yu, H Zambon, M Schellevis, F Paget, J AF Caini, Saverio Andrade, Winston Badur, Selim Balmaseda, Angel Barakat, Amal Bella, Antonino Bimohuen, Abderrahman Brammer, Lynnette Bresee, Joseph Bruno, Alfredo Castillo, Leticia Ciblak, Meral A. Clara, Alexey W. Cohen, Cheryl Cutter, Jeffery Daouda, Coulibaly de Lozano, Celina De Mora, Domenica Dorji, Kunzang Emukule, Gideon O. Fasce, Rodrigo A. Feng, Luzhao Ferreira de Almeida, Walquiria Aparecida Guiomar, Raquel Heraud, Jean-Michel Holubka, Olha Huang, Q. Sue Kadjo, Herve A. Kiyanbekova, Lyazzat Kosasih, Herman Kusznierz, Gabriela Lara, Jenny Li, Ming Lopez, Liza Phuong Vu Mai Hoang Pessanha Henriques, Claudio Maierovitch Matute, Maria Luisa Mironenko, Alla Moreno, Brechla Mott, Joshua A. Njouom, Richard Nurhayati Ospanova, Akerke Owen, Rhonda Pebody, Richard Pennington, Kate Puzelli, Simona Mai Thi Quynh Le Razanajatovo, Norosoa Harline Rodrigues, Ana Rudi, Juan Manuel Lin, Raymond Tzer Pin Venter, Marietjie Vernet, Marie-Astrid Wangchuk, Sonam Yang, Juan Yu, Hongjie Zambon, Maria Schellevis, Franois Paget, John CA Global Influenza B Study TI Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination? SO PLOS ONE LA English DT Article ID SUB-SAHARAN AFRICA; SEASONAL INFLUENZA; SURVEILLANCE; MADAGASCAR; DRIVERS AB Introduction Determining the optimal time to vaccinate is important for influenza vaccination programmes. Here, we assessed the temporal characteristics of influenza epidemics in the Northern and Southern hemispheres and in the tropics, and discuss their implications for vaccination programmes. Methods This was a retrospective analysis of surveillance data between 2000 and 2014 from the Global Influenza B Study database. The seasonal peak of influenza was defined as the week with the most reported cases (overall, A, and B) in the season. The duration of seasonal activity was assessed using the maximum proportion of influenza cases during three consecutive months and the minimum number of months with >= 80% of cases in the season. We also assessed whether co-circulation of A and B virus types affected the duration of influenza epidemics. Results 212 influenza seasons and 571,907 cases were included from 30 countries. In tropical countries, the seasonal influenza activity lasted longer and the peaks of influenza A and B coincided less frequently than in temperate countries. Temporal characteristics of influenza epidemics were heterogeneous in the tropics, with distinct seasonal epidemics observed only in some countries. Seasons with co-circulation of influenza A and B were longer than influenza A seasons, especially in the tropics. Discussion Our findings show that influenza seasonality is less well defined in the tropics than in temperate regions. This has important implications for vaccination programmes in these countries. High-quality influenza surveillance systems are needed in the tropics to enable decisions about when to vaccinate. C1 [Caini, Saverio; Schellevis, Franois; Paget, John] Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands. [Andrade, Winston; Fasce, Rodrigo A.] Inst Salud Publ Chile, Secc Virus Resp & Exantemat, Santiago, Chile. [Badur, Selim; Ciblak, Meral A.] Istanbul Univ, Istanbul, Turkey. [Balmaseda, Angel] Minist Hlth, Natl Influenza Ctr, Managua, Nicaragua. [Barakat, Amal; Bimohuen, Abderrahman] Minist Hlth, Inst Natl Hyg, Natl Influenza Ctr, Rabat, Morocco. [Bella, Antonino] NIH, Natl Ctr Epidemiol Surveillance & Hlth Promot, Rome, Italy. [Brammer, Lynnette; Bresee, Joseph] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, Atlanta, GA USA. [Bruno, Alfredo; De Mora, Domenica] INSPI, Ctr Ref Nacl Influenza & Otros Virus Resp, Guayaquil, Ecuador. [Castillo, Leticia] Minist Hlth, Natl Influenza Ctr, Guatemala City, Guatemala. [Clara, Alexey W.] US Ctr Dis Control, Cent Amer Reg, Guatemala City, Guatemala. [Cohen, Cheryl] Natl Inst Communicable Dis, CRDM, Johannesburg, South Africa. [Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa. [Cutter, Jeffery; Lin, Raymond Tzer Pin] Minist Hlth, Communicable Dis Div, Singapore, Singapore. [Daouda, Coulibaly; Kadjo, Herve A.] Pasteur Inst Cote Ivoire, Resp Viruses Unit, Abidjan, Cote Ivoire. [de Lozano, Celina] Minist Hlth, Natl Influenza Ctr, San Salvador, El Salvador. [Dorji, Kunzang; Wangchuk, Sonam] Minist Hlth, Dept Publ Hlth, Publ Hlth Lab, Thimphu, Bhutan. [Emukule, Gideon O.; Mott, Joshua A.] US Ctr Dis Control & Prevent, Nairobi, Kenya. [Feng, Luzhao; Li, Ming; Yang, Juan; Yu, Hongjie] Chinese Ctr Dis Control & Prevent, Key Lab Surveillance & Early warning Infect Dis, Div Infect Dis, Beijing, Peoples R China. [Ferreira de Almeida, Walquiria Aparecida; Pessanha Henriques, Claudio Maierovitch] Minist Hlth, Brasilia, DF, Brazil. [Guiomar, Raquel] Natl Inst Hlth, Dept Infect Dis, Natl Influenza Ref Lab, Lisbon, Portugal. [Heraud, Jean-Michel; Razanajatovo, Norosoa Harline] Inst Pasteur Madagascar, Virol Unit, Natl Influenza Ctr, Antananarivo, Madagascar. [Holubka, Olha; Mironenko, Alla] Natl Acad Med Sci Ukraine, LV Gromashevsky Inst Epidemiol & Infect Dis, Kiev, Ukraine. [Huang, Q. Sue; Lopez, Liza] Inst Environm Sci & Res, Wellington, New Zealand. [Kiyanbekova, Lyazzat; Ospanova, Akerke] Astana Ctr Sanit Epidemiol Expertise, Zonal Virol Lab, Astana, Kazakhstan. [Kosasih, Herman; Nurhayati] US Naval, Med Res Unit 2, Jakarta, Indonesia. [Kusznierz, Gabriela; Rudi, Juan Manuel] Inst Nacl Enfermedades Resp Dr Emilio Coni, Santa Fe, Argentina. [Lara, Jenny] Minist Hlth, Natl Influenza Ctr, San Jose, Costa Rica. [Phuong Vu Mai Hoang; Mai Thi Quynh Le] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam. [Matute, Maria Luisa] Minist Hlth, Natl Influenza Ctr, Tegucigalpa, Honduras. [Moreno, Brechla] IC Gorgas, Natl Influenza Ctr, Panama City, Panama. [Njouom, Richard; Vernet, Marie-Astrid] Ctr Pasteur Cameroun, Serv Virol, Yaounde, Cameroon. [Owen, Rhonda; Pennington, Kate] Off Hlth Protect, Dept Hlth, Hlth Policy Protect Branch, Vaccine Preventable Dis Surveillance Sect, Woden, ACT, Australia. [Pebody, Richard] Publ Hlth England, Dept Resp Dis, Colindale, England. [Puzelli, Simona] Natl Inst Hlth, Natl Influenza Ctr, Rome, Italy. [Rodrigues, Ana] Natl Inst Hlth, Dept Epidemiol, Lisbon, Portugal. [Venter, Marietjie] US CDC, Global Dis Detect, Pretoria, South Africa. [Venter, Marietjie] Univ Pretoria, Zoonoses Res Ctr, Dept Med Virol, ZA-0002 Pretoria, South Africa. [Zambon, Maria] Publ Hlth England, Resp Virus Unit, Colindale, England. RP Caini, S (reprint author), Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands. EM s.caini@nivel.nl OI Rizzo, Caterina/0000-0002-5583-7508; HERAUD, Jean-Michel/0000-0003-1107-0859; Pebody, Richard/0000-0002-9069-2885 FU Sanofi Pasteur FX The Global Influenza B Study is supported by an unrestricted research grant from Sanofi Pasteur. The study sponsor had no role in the design of the study; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. The study sponsor had no access to the data in the study. NR 30 TC 3 Z9 3 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 31 PY 2016 VL 11 IS 3 AR e0152310 DI 10.1371/journal.pone.0152310 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH9NC UT WOS:000373121800053 PM 27031105 ER PT J AU Muehlenbachs, A Mathison, BA Olson, PD AF Muehlenbachs, Atis Mathison, Blaine A. Olson, Peter D. TI Malignant Transformation of Hymenolepis nana in a Human Host REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Muehlenbachs, Atis; Mathison, Blaine A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Olson, Peter D.] Nat Hist Museum, Cromwell Rd, London SW7 5BD, England. RP Muehlenbachs, A (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM vkd6@cdc.gov RI Olson, Peter/D-4643-2009 OI Olson, Peter/0000-0002-4183-4533 NR 2 TC 0 Z9 0 U1 2 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 31 PY 2016 VL 374 IS 13 BP 1293 EP 1294 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DH8ZM UT WOS:000373085500021 PM 27028925 ER PT J AU Compton, WM Jones, CM Baldwin, GT AF Compton, Wilson M. Jones, Christopher M. Baldwin, Grant T. TI Nonmedical Prescription-Opioid Use and Heroin Use REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Compton, Wilson M.] Natl Inst Drug Abuse, Bethesda, MD USA. [Jones, Christopher M.] Dept Hlth & Human Serv, Washington, DC USA. [Baldwin, Grant T.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Compton, WM (reprint author), Natl Inst Drug Abuse, Bethesda, MD USA. EM wcompton@nida.nih.gov NR 5 TC 1 Z9 1 U1 4 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 31 PY 2016 VL 374 IS 13 BP 1296 EP 1296 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DH8ZM UT WOS:000373085500026 PM 27028930 ER PT J AU Cavanaugh, JS Modi, S Musau, S McCarthy, K Alexander, H Burmen, B Heilig, CM Shiraishi, RW Cain, K AF Cavanaugh, Joseph S. Modi, Surbhi Musau, Susan McCarthy, Kimberly Alexander, Heather Burmen, Barbara Heilig, Charles M. Shiraishi, Ray W. Cain, Kevin TI Comparative Yield of Different Diagnostic Tests for Tuberculosis among People Living with HIV in Western Kenya SO PLOS ONE LA English DT Article ID SPUTUM SMEAR MICROSCOPY; FINE-NEEDLE-ASPIRATION; PULMONARY TUBERCULOSIS; XPERT MTB/RIF; SOUTH-AFRICA; ANTIRETROVIRAL THERAPY; CONTAMINATION; COLLECTION; SUSPECTS; TB AB Background Diagnosis followed by effective treatment of tuberculosis (TB) reduces transmission and saves lives in persons living with HIV (PLHIV). Sputum smear microscopy is widely used for diagnosis, despite limited sensitivity in PLHIV. Evidence is needed to determine the optimal diagnostic approach for these patients. Methods From May 2011 through June 2012, we recruited PLHIV from 15 HIV treatment centers in western Kenya. We collected up to three sputum specimens for Ziehl-Neelsen (ZN) and fluorescence microscopy (FM), GeneXpert MTB/RIF (Xpert), and culture, regardless of symptoms. We calculated the incremental yield of each test, stratifying results by CD4 cell count and specimen type; data were analyzed to account for complex sampling. Results From 778 enrolled patients, we identified 88 (11.3%) laboratory-confirmed TB cases. Of the 74 cases who submitted 2 specimens for microscopy and Xpert testing, ZN microscopy identified 25 (33.6%); Xpert identified those plus an additional 18 (incremental yield = 24.4%). Xpert testing of spot specimens identified 48 (57.0%) of 84 cases; whereas Xpert testing of morning specimens identified 50 (66.0%) of 76 cases. Two Xpert tests detected 22/24 (92.0%) TB cases with CD4 counts < 100 cells/mu L and 30/45 (67.0%) of cases with CD4 counts >= 100 cells/mu l. Conclusions In PLHIV, Xpert substantially increased diagnostic yield compared to smear microscopy and had the highest yield when used to test morning specimens and specimens from PLHIV with CD4 count < 100 cells/mu L. TB programs unable to replace smear microscopy with Xpert for all symptomatic PLHIV should consider targeted replacement and using morning specimens. C1 [Cavanaugh, Joseph S.; Modi, Surbhi; McCarthy, Kimberly; Alexander, Heather; Heilig, Charles M.; Shiraishi, Ray W.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Musau, Susan; Burmen, Barbara] Kenya Med Res Inst KEMRI, Ctr Global Hlth Res, Kisumu, Kenya. [Cain, Kevin] US Ctr Dis Control & Prevent, Kisumu, Kenya. RP Cavanaugh, JS (reprint author), US Ctr Dis Control & Prevent, Atlanta, GA USA. EM hgi7@cdc.gov OI Heilig, Charles/0000-0003-1075-1310 FU United States Agency for International Development (USAID); U.S. President's Emergency Plan for AIDS Relief (PEPFAR) funds FX This research was supported with funds from the United States Agency for International Development (USAID) through an inter-agency agreement between U.S. CDC and USAID, and with U.S. President's Emergency Plan for AIDS Relief (PEPFAR) funds. NR 38 TC 3 Z9 3 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 29 PY 2016 VL 11 IS 3 AR e0152364 DI 10.1371/journal.pone.0152364 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH9KB UT WOS:000373113900050 PM 27023213 ER PT J AU Cassemiro, KMSD Burlandy, FM Barbosa, MRF Chen, Q Jorba, J Hachich, EM Sato, MIZ Burns, CC da Silva, EE AF de Melo Cassemiro, Klecia Marilia S. Burlandy, Fernanda M. Barbosa, Mikaela R. F. Chen, Qi Jorba, Jaume Hachich, Elayse M. Sato, Maria I. Z. Burns, Cara C. da Silva, Edson E. TI Molecular and Phenotypic Characterization of a Highly Evolved Type 2 Vaccine-Derived Poliovirus Isolated from Seawater in Brazil, 2014 SO PLOS ONE LA English DT Article ID ACTING REPLICATION ELEMENT; ACUTE FLACCID PARALYSIS; WILD POLIOVIRUS; CODING REGION; RECOMBINANT SEQUENCES; MOSAIC STRUCTURE; DNA-SEQUENCES; IDENTIFICATION; OUTBREAK; POLIOMYELITIS AB A type 2 vaccine-derived poliovirus (VDPV), differing from the Sabin 2 strain at 8.6% (78/903) of VP1 nucleotide positions, was isolated from seawater collected from a seaport in Sao Paulo State, Brazil. The P1/capsid region is related to the Sabin 2 strain, but sequences within the 5'-untranslated region and downstream of the P1 region were derived from recombination with other members of Human Enterovirus Species C (HEV-C). The two known attenuating mutations had reverted to wild-type (A481G in the 5'-UTR and Ile143Thr in VP1). The VDPV isolate had lost the temperature sensitive phenotype and had accumulated amino acid substitutions in neutralizing antigenic (NAg) sites 3a and 3b. The date of the initiating OPV dose, estimated from the number of synonymous substitutions in the capsid region, was approximately 8.5 years before seawater sampling, a finding consistent with a long time of virus replication and possible transmission among several individuals. Although no closely related type 2 VDPVs were detected in Brazil or elsewhere, this VDPV was found in an area with a mobile population, where conditions may favor both viral infection and spread. Environmental surveillance serves as an important tool for sensitive and early detection of circulating poliovirus in the final stages of global polio eradication. C1 [de Melo Cassemiro, Klecia Marilia S.; Burlandy, Fernanda M.; da Silva, Edson E.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Enterovirus Lab, Rio De Janeiro, Rio De Janeiro, Brazil. [Barbosa, Mikaela R. F.; Hachich, Elayse M.; Sato, Maria I. Z.] Environm Co Sao Paulo State, Environm Anal Dept, Sao Paulo, Sao Paulo, Brazil. [Chen, Qi; Jorba, Jaume; Burns, Cara C.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP da Silva, EE (reprint author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Enterovirus Lab, Rio De Janeiro, Rio De Janeiro, Brazil. EM edson@ioc.fiocruz.br FU "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico"; "Fundacao Oswaldo Cruz"; CNPq FX KMSMC was supported by the "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico" (URL: http://cnpq.br/). The study was supported by the "Fundacao Oswaldo Cruz" (URL: http://fiocruz.br/) and CNPq. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 72 TC 0 Z9 0 U1 2 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 28 PY 2016 VL 11 IS 3 AR e0152251 DI 10.1371/journal.pone.0152251 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH5EH UT WOS:000372807800036 PM 27019095 ER PT J AU Kiware, SS Russell, TL Mtema, ZJ Malishee, AD Chaki, P Lwetoijera, D Chanda, J Chinula, D Majambere, S Gimnig, JE Smith, TA Killeen, GF AF Kiware, Samson S. Russell, Tanya L. Mtema, Zacharia J. Malishee, Alpha D. Chaki, Prosper Lwetoijera, Dickson Chanda, Javan Chinula, Dingani Majambere, Silas Gimnig, John E. Smith, Thomas A. Killeen, Gerry F. TI A generic schema and data collection forms applicable to diverse entomological studies of mosquitoes SO SOURCE CODE FOR BIOLOGY AND MEDICINE LA English DT Article ID DAR-ES-SALAAM; LINKED-IMMUNOSORBENT-ASSAY; ANOPHELES-GAMBIAE COMPLEX; INSECTICIDE-TREATED NETS; MALARIA VECTOR MOSQUITOS; INFECTED MOSQUITOS; CONTROL PROGRAM; HIGH COVERAGE; TENT TRAP; BED NETS AB Background: Standardized schemas, databases, and public data repositories are needed for the studies of malaria vectors that encompass a remarkably diverse array of designs and rapidly generate large data volumes, often in resource-limited tropical settings lacking specialized software or informatics support. Results: Data from the majority of mosquito studies conformed to a generic schema, with data collection forms recording the experimental design, sorting of collections, details of sample pooling or subdivision, and additional observations. Generically applicable forms with standardized attribute definitions enabled rigorous, consistent data and sample management with generic software and minimal expertise. Forms use now includes 20 experiments, 8 projects, and 15 users at 3 research and control institutes in 3 African countries, resulting in 11 peer-reviewed publications. Conclusion: We have designed generic data schema that can be used to develop paper or electronic based data collection forms depending on the availability of resources. We have developed paper-based data collection forms that can be used to collect data from majority of entomological studies across multiple study areas using standardized data formats. Data recorded on these forms with standardized formats can be entered and linked with any relational database software. These informatics tools are recommended because they ensure that medical entomologists save time, improve data quality, and data collected and shared across multiple studies is in standardized formats hence increasing research outputs. C1 [Kiware, Samson S.; Russell, Tanya L.; Mtema, Zacharia J.; Malishee, Alpha D.; Chaki, Prosper; Lwetoijera, Dickson; Majambere, Silas; Killeen, Gerry F.] Ifakara Hlth Inst, Environm Hlth & Ecol Sci Themat Grp, POB 53, Ifakara, Tanzania. [Kiware, Samson S.] Marquette Univ, Dept Math Stat & Comp Sci, Milwaukee, WI 53201 USA. [Russell, Tanya L.] Univ Queensland, Sch Populat Hlth, Pacific Malaria Initiat Support Ctr, Brisbane, Qld 4006, Australia. [Lwetoijera, Dickson; Majambere, Silas; Killeen, Gerry F.] Univ Liverpool, Liverpool Sch Trop Med, Vector Biol Dept, Pembroke Pl, Liverpool L3 5QA, Merseyside, England. [Chanda, Javan; Chinula, Dingani] Natl Malaria Control Ctr, Lusaka, Zambia. [Gimnig, John E.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. [Smith, Thomas A.] Swiss Trop Inst, Dept Publ Hlth & Epidemiol, Socinstr 57, CH-4002 Basel, Switzerland. RP Kiware, SS (reprint author), Ifakara Hlth Inst, Environm Hlth & Ecol Sci Themat Grp, POB 53, Ifakara, Tanzania.; Kiware, SS (reprint author), Marquette Univ, Dept Math Stat & Comp Sci, Milwaukee, WI 53201 USA. EM skiware@ihi.or.tz NR 59 TC 0 Z9 0 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1751-0473 J9 SOURCE CODE BIOL MED JI Source Code Biol. Med. PD MAR 28 PY 2016 VL 11 AR 4 DI 10.1186/s13029-016-0050-1 PG 11 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA DI0OX UT WOS:000373197800001 PM 27022408 ER PT J AU Salinas, JL Mindra, G Haddad, MB Pratt, R Price, SF Langer, AJ AF Salinas, Jorge L. Mindra, Godwin Haddad, Maryam B. Pratt, Robert Price, Sandy F. Langer, Adam J. TI Leveling of Tuberculosis Incidence - United States, 2013-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Salinas, Jorge L.; Mindra, Godwin] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Salinas, Jorge L.; Mindra, Godwin; Haddad, Maryam B.; Pratt, Robert; Price, Sandy F.; Langer, Adam J.] CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Salinas, JL; Mindra, G (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Salinas, JL; Mindra, G (reprint author), CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM jsalinas@cdc.gov; GMindra@cdc.gov NR 10 TC 21 Z9 21 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 25 PY 2016 VL 65 IS 11 BP 273 EP 278 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH4CS UT WOS:000372733700001 PM 27010173 ER PT J AU Weinberg, MP Cherry, C Lipnitz, J Nienstadt, L King-Todd, A Haddad, MB Russell, M Wong, D Davidson, P McFadden, J Miller, C AF Weinberg, Meghan P. Cherry, Cara Lipnitz, Julie Nienstadt, Linus King-Todd, April Haddad, Maryam B. Russell, Michelle Wong, David Davidson, Peter McFadden, Jevon Miller, Corinne TI Tuberculosis Among Temporary Visa Holders Working in the Tourism Industry - United States, 2012-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Weinberg, Meghan P.; Cherry, Cara] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Weinberg, Meghan P.; Davidson, Peter; McFadden, Jevon; Miller, Corinne] Michigan Dept Hlth & Human Serv, Charter Twp Of Clinton, MI 48036 USA. [Cherry, Cara] Natl Pk Serv, Resource Stewardship & Sci, Off Publ Hlth, Ft Collins, CO USA. [Cherry, Cara] Natl Pk Serv, Resource Stewardship & Sci, Wildlife Hlth Branch, Ft Collins, CO USA. [Lipnitz, Julie] Luce Mackinac Alger Schoolcraft Dist Hlth Dept, St Ignace, MI USA. [Nienstadt, Linus] Coconino Cty Publ Hlth Serv Dist, Flagstaff, AZ USA. [King-Todd, April] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Haddad, Maryam B.] CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Russell, Michelle] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Wong, David] Natl Pk Serv, Off Publ Hlth, Albuquerque, NM USA. [McFadden, Jevon] CDC, Career Epidemiol Field Officer Program, Atlanta, GA 30333 USA. RP Weinberg, MP; Cherry, C (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Weinberg, MP (reprint author), Michigan Dept Hlth & Human Serv, Charter Twp Of Clinton, MI 48036 USA. EM MPWeinberg@cdc.gov; CCherry@cdc.gov NR 9 TC 0 Z9 0 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 25 PY 2016 VL 65 IS 11 BP 279 EP 281 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH4CS UT WOS:000372733700003 PM 27010221 ER PT J AU Finn, LE Gutowski, J Alles, S Mirowitz, N Johnson, C Osterhoudt, KC Patel, A AF Finn, Lauren E. Gutowski, Jennifer Alles, Steve Mirowitz, Naomi Johnson, Caroline Osterhoudt, Kevin C. Patel, Ami TI Photokeratitis Linked to Metal Halide Bulbs in Two Gymnasiums - Philadelphia, Pennsylvania, 2011 and 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Finn, Lauren E.; Gutowski, Jennifer; Alles, Steve; Mirowitz, Naomi; Johnson, Caroline; Patel, Ami] Philadelphia Dept Publ Hlth, Div Dis Control, Philadelphia, PA USA. [Osterhoudt, Kevin C.] Childrens Hosp, Poison Control Ctr, Philadelphia, PA 19104 USA. [Patel, Ami] CDC, Off Publ Hlth Preparedness & Response, Div State & Local Readiness, Atlanta, GA 30333 USA. RP Finn, LE (reprint author), Philadelphia Dept Publ Hlth, Div Dis Control, Philadelphia, PA USA. EM lauren.finn@phila.gov NR 5 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 25 PY 2016 VL 65 IS 11 BP 282 EP 285 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH4CS UT WOS:000372733700004 PM 27010342 ER PT J AU Armstrong, P Hennessey, M Adams, M Cherry, C Chiu, S Harrist, A Kwit, N Lewis, L McGuire, DO Oduyebo, T Russell, K Talley, P Tanner, M Williams, C AF Armstrong, Paige Hennessey, Morgan Adams, Monica Cherry, Cara Chiu, Sophia Harrist, Alexia Kwit, Natalie Lewis, Lillianne McGuire, Dana Olzenak Oduyebo, Titilope Russell, Kate Talley, Pamela Tanner, Mary Williams, Charnetta CA Zika Virus Response Epidemiology TI Travel-Associated Zika Virus Disease Cases Among US Residents - United States, January 2015-February 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UPDATE INTERIM GUIDELINES; INFECTION C1 [Armstrong, Paige; Hennessey, Morgan; Adams, Monica; Cherry, Cara; Chiu, Sophia; Harrist, Alexia; Kwit, Natalie; Lewis, Lillianne; McGuire, Dana Olzenak; Oduyebo, Titilope; Russell, Kate; Talley, Pamela; Tanner, Mary; Williams, Charnetta] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. RP Armstrong, P (reprint author), Care of Fischer M, Zika Virus Response Epidemiol & Lab Team, New York, NY USA. EM mfischer@cdc.gov OI Russell, Kate/0000-0001-9343-3355 NR 10 TC 20 Z9 20 U1 3 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 25 PY 2016 VL 65 IS 11 BP 286 EP 289 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH4CS UT WOS:000372733700005 PM 27023833 ER PT J AU Olson, CK Iwamoto, M Perkins, KM Polen, KND Hageman, J Meaney-Delman, D Igbinosa, II Khan, S Honein, MA Bell, M Rasmussen, SA Jamieson, DJ AF Olson, Christine K. Iwamoto, Martha Perkins, Kiran M. Polen, Kara N. D. Hageman, Jeffrey Meaney-Delman, Dana Igbinosa, Irogue I. Khan, Sumaiya Honein, Margaret A. Bell, Michael Rasmussen, Sonja A. Jamieson, Denise J. TI Preventing Transmission of Zika Virus in Labor and Delivery Settings Through Implementation of Standard Precautions - United States, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Olson, Christine K.; Jamieson, Denise J.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Iwamoto, Martha] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Perkins, Kiran M.; Hageman, Jeffrey; Bell, Michael] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Polen, Kara N. D.; Honein, Margaret A.] CDC, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Meaney-Delman, Dana] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Off Director, Atlanta, GA 30333 USA. [Igbinosa, Irogue I.] CDC, Ctr Surveillance Epidemiol & Lab Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA. [Khan, Sumaiya] CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Rasmussen, Sonja A.] CDC, Ctr Surveillance Epidemiol & Lab Serv, Div Publ Hlth Informat Disseminat, Atlanta, GA 30333 USA. RP Olson, CK (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM zikamch@cdc.gov NR 11 TC 11 Z9 12 U1 3 U2 12 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 25 PY 2016 VL 65 IS 11 BP 290 EP 292 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH4CS UT WOS:000372733700006 PM 27010422 ER PT J AU Cherry, C Leong, K Wallen, R Buttke, D AF Cherry, Cara Leong, Kirsten Wallen, Rick Buttke, Danielle TI Injuries Associated with Bison Encounters - Yellowstone National Park, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Cherry, Cara] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Cherry, Cara] Natl Pk Serv, Off Publ Hlth, Nat Resource Stewardship & Sci, Ft Collins, CO USA. [Leong, Kirsten] Natl Pk Serv, Wildlife Hlth Branch, Nat Resource Stewardship & Sci, Ft Collins, CO USA. [Wallen, Rick] Natl Pk Serv, Human Dimens Biol Resource Management, Nat Resource Stewardship & Sci, Ft Collins, CO USA. [Buttke, Danielle] Yellowstone Natl Pk, Bison Ecol & Management Team, Teyton Cty, WY USA. RP Cherry, C (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Cherry, C (reprint author), Natl Pk Serv, Off Publ Hlth, Nat Resource Stewardship & Sci, Ft Collins, CO USA. EM CCherry@cdc.gov NR 5 TC 0 Z9 0 U1 2 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 25 PY 2016 VL 65 IS 11 BP 293 EP 294 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH4CS UT WOS:000372733700007 PM 27010506 ER PT J AU Gorina, Y AF Gorina, Yelena TI Difference in Life Expectancy Between Females and Males at Birth and at Age 65 Years - National Vital Statistics System, United States, 1990, 2000, 2010, and 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 [Gorina, Yelena] CDC, Natl Vital Stat Syst, Atlanta, GA 30333 USA. RP Gorina, Y (reprint author), CDC, Natl Vital Stat Syst, Atlanta, GA 30333 USA. EM yag9@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 25 PY 2016 VL 65 IS 11 BP 296 EP 296 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH4CS UT WOS:000372733700010 ER PT J AU Leigh, JP Grosse, SD Cassady, D Melnikow, J Hertz-Picciotto, I AF Leigh, J. Paul Grosse, Scott D. Cassady, Diana Melnikow, Joy Hertz-Picciotto, Irva TI Spending by California's Department of Developmental Services for Persons with Autism across Demographic and Expenditure Categories SO PLOS ONE LA English DT Article ID SPECTRUM DISORDERS; INTELLECTUAL DISABILITY; MEDICAL EXPENDITURES; ECONOMIC BURDEN; UNITED-STATES; CHILDREN; PREVALENCE; POPULATION; DIAGNOSIS; FAMILIES AB Background Few autism spectrum disorder (ASD) studies have estimated non-medical costs for treatment or addressed possible differences in provision of services across gender, race-ethnic, age or demographic or expenditure categories, especially among adults. Methods The California Department of Developmental Services (CDDS) provides services to residents with developmental disabilities. CDDS provided aggregate data on primarily non-medical spending for fiscal year 2012-2013 for persons with ASD with or without intellectual disability (ID) (main sample, n = 42,274), and two sub-samples: ASD only (n = 30,164), and ASD+ ID (n = 12,110). Demographic variables included sex, age and race-ethnicity. Spending categories included Employment Support, Community Care Facilities, Day Care, Transportation, and in-home and out-of-home Respite. Results Per-person spending for males and females were approximately the same: $10,488 and $10,791 for males and females for ages 3-17 and $26,491 and $26,627 for ages 18+. Among race/ethnicity categories, the ranking from highest to lowest among ages 3-17 was white non-Hispanics ($11,480), Asian non-Hispanics ($11,036), "Others" ($11,031), Hispanics ($9,571), and African-American non-Hispanics ($9,482). For ages 18+, the ranking was whites ($31,008), African-Americans ($26,831), "Others" ($25,395), Asians ($22,993), and Hispanics ($18,083). The ASD+ ID sub-sample exerted disproportionate influence on findings from the main sample for persons 18+. Combining all ages, the top two expenditure categories for per-person spending were Community Care Facilities ($43,867) and Day Care ($11,244). For most adult age groups, the percentage of recipients participating were highest for Day Care (44.9% - 62.4%) and Transportation (38.6% - 50.9%). Per-person spending for Day Care, Transportation, and Employment Support was relatively low for children but relatively high for adults. Conclusion White non-Hispanics received the highest per-person spending and Hispanics among the least. Amounts within spending categories varied considerably across age groups. Our estimates may be useful as baseline measures for stakeholders preparing for increasing ASD prevalence, especially among adults. C1 [Leigh, J. Paul; Melnikow, Joy] Univ Calif Davis, Sch Med, Ctr Healthcare Policy & Res, Sacramento, CA 95817 USA. [Leigh, J. Paul; Cassady, Diana; Hertz-Picciotto, Irva] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Melnikow, Joy] Univ Calif Davis, Sch Med, Dept Family Med, Sacramento, CA 95817 USA. RP Leigh, JP (reprint author), Univ Calif Davis, Sch Med, Ctr Healthcare Policy & Res, Sacramento, CA 95817 USA.; Leigh, JP (reprint author), Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA. EM pleigh@ucdavis.edu FU Autism Speaks [7636]; National Institute for Occupational Safety and Health [U54OH007550] FX This work was supported by Autism Speaks, #7636, https://www.autismspeaks.org/; and National Institute for Occupational Safety and Health, # U54OH007550, http://www.cdc.gov/niosh/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 55 TC 2 Z9 2 U1 4 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 25 PY 2016 VL 11 IS 3 AR e0151970 DI 10.1371/journal.pone.0151970 PG 23 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH3TE UT WOS:000372708900035 PM 27015098 ER PT J AU Gerloff, NA Khan, SU Zanders, N Balish, A Haider, N Islam, A Chowdhury, S Rahman, MZ Haque, A Hosseini, P Gurley, ES Luby, SP Wentworth, DE Donis, RO Sturm-Ramirez, K Davis, CT AF Gerloff, Nancy A. Khan, Salah Uddin Zanders, Natosha Balish, Amanda Haider, Najmul Islam, Ausraful Chowdhury, Sukanta Rahman, Mahmudur Ziaur Haque, Ainul Hosseini, Parviez Gurley, Emily S. Luby, Stephen P. Wentworth, David E. Donis, Ruben O. Sturm-Ramirez, Katharine Davis, C. Todd TI Genetically Diverse Low Pathogenicity Avian Influenza A Virus Subtypes Co-Circulate among Poultry in Bangladesh SO PLOS ONE LA English DT Article ID HUMAN INFECTION; H5N1 VIRUSES; H7N9 VIRUS; ORIGIN; SURVEILLANCE; ALIGNMENT; DUCKS AB Influenza virus surveillance, poultry outbreak investigations and genomic sequencing were assessed to understand the ecology and evolution of low pathogenicity avian influenza (LPAI) A viruses in Bangladesh from 2007 to 2013. We analyzed 506 avian specimens collected from poultry in live bird markets and backyard flocks to identify influenza A viruses. Virus isolation-positive specimens (n = 50) were subtyped and their coding-complete genomes were sequenced. The most frequently identified subtypes among LPAI isolates were H9N2, H11N3, H4N6, and H1N1. Less frequently detected subtypes included H1N3, H2N4, H3N2, H3N6, H3N8, H4N2, H5N2, H6N1, H6N7, and H7N9. Gene sequences were compared to publicly available sequences using phylogenetic inference approaches. Among the 14 subtypes identified, the majority of viral gene segments were most closely related to poultry or wild bird viruses commonly found in Southeast Asia, Europe, and/or northern Africa. LPAI subtypes were distributed over several geographic locations in Bangladesh, and surface and internal protein gene segments clustered phylogenetically with a diverse number of viral subtypes suggesting extensive reassortment among these LPAI viruses. H9N2 subtype viruses differed from other LPAI subtypes because genes from these viruses consistently clustered together, indicating this subtype is enzootic in Bangladesh. The H9N2 strains identified in Bangladesh were phylogenetically and antigenically related to previous human-derived H9N2 viruses detected in Bangladesh representing a potential source for human infection. In contrast, the circulating LPAI H5N2 and H7N9 viruses were both phylogenetically and antigenically unrelated to H5 viruses identified previously in humans in Bangladesh and H7N9 strains isolated from humans in China. In Bangladesh, domestic poultry sold in live bird markets carried a wide range of LPAI virus subtypes and a high diversity of genotypes. These findings, combined with the seven year timeframe of sampling, indicate a continuous circulation of these viruses in the country. C1 [Gerloff, Nancy A.; Zanders, Natosha; Balish, Amanda; Wentworth, David E.; Donis, Ruben O.; Sturm-Ramirez, Katharine; Davis, C. Todd] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Khan, Salah Uddin; Haider, Najmul; Islam, Ausraful; Chowdhury, Sukanta; Rahman, Mahmudur Ziaur; Gurley, Emily S.; Luby, Stephen P.; Sturm-Ramirez, Katharine] Icddr B, Dhaka, Bangladesh. [Haque, Ainul] Minist Fisheries & Livestock, Dept Livestock Serv, Dhaka, Bangladesh. [Hosseini, Parviez] EcoHlth Alliance, New York, NY USA. RP Davis, CT (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM ctdavis@cdc.gov RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Wentworth, David/0000-0002-5190-980X; Luby, Stephen/0000-0001-5385-899X; Haider, Najmul/0000-0002-5980-3460 FU Government of Bangladesh [PL480]; EcoHealth Alliance; National Institutes of Health/National Science Foundation Ecology and Evolution of Infectious Diseases award from the Fogarty International Center [3R01-TW005869]; Centers for Disease Control; Atlanta Education and Research Foundation; Research Participation Program at the Centers for Disease Control and Prevention (CDC); Oak Ridge Institute for Science and Education; U.S. Department of Energy; Fogarty International Center [3R01-TW005869]; [U01/CI000628] FX Icddr, b is funded by project U01/CI000628 a cooperative agreement with CDC (website TCGwww.cdc.gov;www.icddrb.org). This research was supported by the Government of Bangladesh through grant number PL480. The authors thank the EcoHealth Alliance (www.ecohealthalliance.org) for financial support of staff involved in bird sample collection, which was funded by National Institutes of Health/National Science Foundation Ecology and Evolution of Infectious Diseases award from the Fogarty International Center (3R01-TW005869). This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement with the U.S. Department of Energy (www.orau.org). The authors would like to thank the Atlanta Education and Research Foundation for support (www.atlaref.org).; We gratefully acknowledge the authors, and the originating and submitting laboratories of the sequences from GISAID's EpiFluTM Database, which were used in this analysis. This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement with the U.S. Department of Energy. We would like to thank the Atlanta Education and Research Foundation for support. Icddr,b was funded by project U01CI000628, a cooperative agreement with CDC. We thank the EcoHealth Alliance for financial support of staff involved in sample collection through a NIH/NSF Ecology and Evolution of Infectious Diseases award from the Fogarty International Center (3R01-TW005869). Icddr,b acknowledges with gratitude the commitment of CDC and EcoHealth Alliance to its research efforts. Icddr, b is also grateful to the Governments of Bangladesh, Canada, Sweden and the UK for providing core/unrestricted support. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the Agency for Toxic Substances and Disease Registry. NR 52 TC 1 Z9 1 U1 5 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 24 PY 2016 VL 11 IS 3 AR e0152131 DI 10.1371/journal.pone.0152131 PG 29 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH3SV UT WOS:000372708000094 PM 27010791 ER PT J AU Menegon, M Bardaji, A Martinez-Espinosa, F Botto-Menezes, C Ome-Kaius, M Mueller, I Betuela, I Arevalo-Herrera, M Kochar, S Kochar, SK Jaju, P Hans, D Chitnis, C Padilla, N Castellanos, ME Ortiz, L Sanz, S Piqueras, M Desai, M Mayor, A del Portillo, H Menendez, C Severini, C AF Menegon, Michela Bardaji, Azucena Martinez-Espinosa, Flor Botto-Menezes, Camila Ome-Kaius, Maria Mueller, Ivo Betuela, Inoni Arevalo-Herrera, Myriam Kochar, Swati Kochar, Sanjay K. Jaju, Puneet Hans, Dhiraj Chitnis, Chetan Padilla, Norma Eugenia Castellanos, Maria Ortiz, Lucia Sanz, Sergi Piqueras, Mireia Desai, Meghna Mayor, Alfredo del Portillo, Hernando Menendez, Clara Severini, Carlo TI Microsatellite Genotyping of Plasmodium vivax Isolates from Pregnant Women in Four Malaria Endemic Countries SO PLOS ONE LA English DT Article ID GENETIC DIVERSITY; FALCIPARUM INFECTIONS; POPULATION-STRUCTURE; CONGENITAL MALARIA; NATURAL-SELECTION; CENTRAL INDIA; MARKERS; TRANSMISSION; RELAPSES; EPIDEMIOLOGY AB Plasmodium vivax is the most widely distributed human parasite and the main cause of human malaria outside the African continent. However, the knowledge about the genetic variability of P. vivax is limited when compared to the information available for P. falciparum. We present the results of a study aimed at characterizing the genetic structure of P. vivax populations obtained from pregnant women from different malaria endemic settings. Between June 2008 and October 2011 nearly 2000 pregnant women were recruited during routine antenatal care at each site and followed up until delivery. A capillary blood sample from the study participants was collected for genotyping at different time points. Seven P. vivax microsatellite markers were used for genotypic characterization on a total of 229 P. vivax isolates obtained from Brazil, Colombia, India and Papua New Guinea. In each population, the number of alleles per locus, the expected heterozygosity and the levels of multilocus linkage disequilibrium were assessed. The extent of genetic differentiation among populations was also estimated. Six microsatellite loci on 137 P. falciparum isolates from three countries were screened for comparison. The mean value of expected heterozygosity per country ranged from 0.839 to 0.874 for P. vivax and from 0.578 to 0.758 for P. falciparum. P. vivax populations were more diverse than those of P. falciparum. In some of the studied countries, the diversity of P. vivax population was very high compared to the respective level of endemicity. The level of inter-population differentiation was moderate to high in all P. vivax and P. falciparum populations studied. C1 [Menegon, Michela; Severini, Carlo] Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, Viale Regina Elena 299, I-00161 Rome, Italy. [Bardaji, Azucena; Mueller, Ivo; Sanz, Sergi; Piqueras, Mireia; Mayor, Alfredo; del Portillo, Hernando; Menendez, Clara] Univ Barcelona, Barcelona Ctr Int Hlth Res CRESIB, Hosp Clin, Barcelona, Spain. [Martinez-Espinosa, Flor; Botto-Menezes, Camila] Fundacao Med Trop Amazonas Dr Heitor Vieira Doura, Gerencia Malaria, Manaus, Amazonas, Brazil. [Botto-Menezes, Camila] Univ Estado Amazonas, Manaus, Amazonas, Brazil. [Ome-Kaius, Maria; Mueller, Ivo; Betuela, Inoni] Papua New Guinea Inst Med Res, POB 60, Goroka, Papua N Guinea. [Mueller, Ivo] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia. [Arevalo-Herrera, Myriam] Univ Valle, Ctr Int Vacunas, Fac Hlth, Cali, Colombia. [Kochar, Swati; Kochar, Sanjay K.] Sardar Patel Med Coll, Bikaner, India. [Jaju, Puneet; Hans, Dhiraj; Chitnis, Chetan] Int Ctr Genet Engn & Biotechnol, Malaria Grp, New Delhi, India. [Padilla, Norma; Eugenia Castellanos, Maria; Ortiz, Lucia] Univ Valle Guatemala, Ctr Estudios Salud, Guatemala City, Guatemala. [Desai, Meghna] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA USA. [del Portillo, Hernando] Inst Catalana Rec & Estudis Avancats, Barcelona, Spain. RP Severini, C (reprint author), Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, Viale Regina Elena 299, I-00161 Rome, Italy. EM carlo.severini@iss.it FU EU [FP7-HEALTH-201588]; Malaria in Pregnancy Consortium; Bill and Melinda Gates Foundation FX The PregVax collaborative project was an EU-FP7 funded programme (FP7-HEALTH-201588). This research was also supported by the Malaria in Pregnancy Consortium, which is funded through a grant from the Bill and Melinda Gates Foundation to the Liverpool School of Tropical Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 0 Z9 0 U1 2 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 24 PY 2016 VL 11 IS 3 AR e0152447 DI 10.1371/journal.pone.0152447 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH3SV UT WOS:000372708000144 PM 27011010 ER PT J AU Tebbens, RJD Pallansch, MA Wassilak, SGF Cochi, SL Thompson, KM AF Tebbens, Radboud J. Duintjer Pallansch, Mark A. Wassilak, Steven G. F. Cochi, Stephen L. Thompson, Kimberly M. TI Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame SO BMC INFECTIOUS DISEASES LA English DT Article DE Polio; Eradication; Risk management; Vaccine; Stockpile ID POPULATION IMMUNITY; TRANSMISSION; PROGRESS; OPTIONS AB Background: Following successful eradication of wild polioviruses and planned globally-coordinated cessation of oral poliovirus vaccine (OPV), national and global health leaders may need to respond to outbreaks from reintroduced live polioviruses, particularly vaccine-derived polioviruses (VDPVs). Preparing outbreak response plans and assessing potential vaccine needs from an emergency stockpile require consideration of the different national risks and conditions as they change with time after OPV cessation. Methods: We used an integrated global model to consider several key issues related to managing poliovirus risks and outbreak response, including the time interval during which monovalent OPV (mOPV) can be safely used following homotypic OPV cessation; the timing, quality, and quantity of rounds required to stop transmission; vaccine stockpile needs; and the impacts of vaccine choices and surveillance quality. We compare the base case scenario that assumes aggressive outbreak response and sufficient mOPV available from the stockpile for all outbreaks that occur in the model, with various scenarios that change the outbreak response strategies. Results: Outbreak response after OPV cessation will require careful management, with some circumstances expected to require more and/or higher quality rounds to stop transmission than others. For outbreaks involving serotype 2, using trivalent OPV instead of mOPV2 following cessation of OPV serotype 2 but before cessation of OPV serotypes 1 and (would represent a good option if logistically feasible. Using mOPV for outbreak response can start new outbreaks if exported outside the outbreak population into populations with decreasing population immunity to transmission after OPV cessation, but failure to contain outbreaks resulting in exportation of the outbreak poliovirus may represent a greater risk. The possibility of mOPV use generating new long-term poliovirus excretors represents a real concern. Using the base case outbreak response assumptions, we expect over 25 % probability of a shortage of stockpiled filled mOPV vaccine, which could jeopardize the achievement of global polio eradication. For the long term, responding to any poliovirus reintroductions may require a global IPV stockpile. Despite the risks, our model suggests that good risk management and response strategies can successfully control most potential outbreaks after OPV cessation. Conclusions: Health leaders should carefully consider the numerous outbreak response choices that affect the probability of successfully managing poliovirus risks after OPV cessation. C1 [Tebbens, Radboud J. Duintjer; Thompson, Kimberly M.] Kid Risk Inc, 10524 Moss Pk Rd,Ste 204-364, Orlando, FL 32832 USA. [Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Wassilak, Steven G. F.; Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. RP Tebbens, RJD (reprint author), Kid Risk Inc, 10524 Moss Pk Rd,Ste 204-364, Orlando, FL 32832 USA. EM rdt@kidrisk.org FU US Centers for Disease Control and Prevention [CDC-200-2015-M-61344] FX RJDT and KMT acknowledge support for this work from the US Centers for Disease Control and Prevention under Contract CDC-200-2015-M-61344. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 25 TC 4 Z9 4 U1 2 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD MAR 24 PY 2016 VL 16 AR 137 DI 10.1186/s12879-016-1465-7 PG 19 WC Infectious Diseases SC Infectious Diseases GA DH3RZ UT WOS:000372705500001 ER PT J AU Musial-Siwek, M Jaff'ee, MB Imperiali, B AF Musial-Siwek, Monika Jaff'ee, Marcie B. Imperiali, Barbara TI Probing Polytopic Membrane Protein-Substrate Interactions by Luminescence Resonance Energy Transfer SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY LA English DT Article ID LANTHANIDE-BINDING TAGS; N-LINKED GLYCOSYLATION; IN-VITRO; BACTERIAL OLIGOSACCHARYLTRANSFERASE; CAMPYLOBACTER-JEJUNI; HIGH-AFFINITY; PROBES; MOVEMENT; PEPTIDE; CHANNEL AB Integral membrane proteins play essential roles in all living systems; however, major technical hurdles challenge analyses of this class of proteins. Biophysical approaches that provide structural information to complement and leverage experimentally determined and computationally predicted structures are urgently needed. Herein we present the application of luminescence resonance energy transfer (LRET) for investigating the interactions of the polytopic membrane-bound oligosaccharyl transferases (OTases) with partner substrates. Monomeric OTases, such as the PglBs from Campylobacter jejuni and Campylobacter lari, catalyze transfer of glycans from membrane-associated undecaprenol diphosphate-linked substrates to proteins in the bacterial periplasm. LRET-based distance measurements are enabled by the inclusion of an encoded N-terminal lanthanide-binding, tag (LBT), and LRET between the luminescent (LBT)-Tb3+ donor complex and fluorescently labeled peptide and glycan substrates provides discrete distance measurements across the span of the membrane. LRET-based measurements of detergent-solubilized PglB from C. lari allowed direct comparison with the distances based on the previously reported the C. lari PglB crystal structure, thereby validating the approach in a defined system. Distance measurements between peptide and glycan substrates and the C. jejuni PglB offer new experimental information on substrate binding to the related, but structurally uncharacterized, eukaryotic OTase. C1 [Imperiali, Barbara] MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA. MIT, Dept Chem, Cambridge, MA 02139 USA. [Jaff'ee, Marcie B.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Imperiali, B (reprint author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM imper@mit.edu FU NIH [GM-039334]; NSF [MCB 0744415]; NIH Pre-Doctoral Training Grant [T32GM007287] FX This research was supported by NIH GM-039334 (B.I. and M.M.), NSF Grant MCB 0744415 and the NIH Pre-Doctoral Training Grant T32GM007287 (M.B.J.). We thank Drs. Garrett Whitworth and Vinita Lukose for the synthesis and labeling of UndPP-trisaccharide. NR 34 TC 0 Z9 0 U1 13 U2 38 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0002-7863 J9 J AM CHEM SOC JI J. Am. Chem. Soc. PD MAR 23 PY 2016 VL 138 IS 11 BP 3806 EP 3812 DI 10.1021/jacs.5b13426 PG 7 WC Chemistry, Multidisciplinary SC Chemistry GA DH5TG UT WOS:000372854200029 PM 26918528 ER PT J AU Barcia, C Guillemin, GJ Curtin, JF Zirger, JM AF Barcia, Carlos Guillemin, Gilles J. Curtin, James F. Zirger, Jeffrey M. TI Editorial: Glial Cells: Managers of Neuro-Immunity SO FRONTIERS IN CELLULAR NEUROSCIENCE LA English DT Editorial Material DE glia; neuroinflammation; neuroimmunology; microglia; astroglia; T cells C1 [Barcia, Carlos] Univ Autonoma Barcelona, Inst Neurociencies, Dept Biochem & Mol Biol, Cerdanyola Del Valles, Spain. [Guillemin, Gilles J.] Macquarie Univ, Dept Biomed Sci, Fac Med & Hlth Sci, Sydney, NSW 2109, Australia. [Curtin, James F.] Dublin Inst Technol, Sch Food Sci & Environm Hlth, Dublin, Ireland. [Zirger, Jeffrey M.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Barcia, C (reprint author), Univ Autonoma Barcelona, Inst Neurociencies, Dept Biochem & Mol Biol, Cerdanyola Del Valles, Spain. EM carlos.barcia@uab.es RI Barcia, Carlos/I-8205-2014; OI Barcia, Carlos/0000-0003-0976-4245; Curtin, James/0000-0002-9320-9254 NR 0 TC 0 Z9 0 U1 0 U2 1 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5102 J9 FRONT CELL NEUROSCI JI Front. Cell. Neurosci. PD MAR 23 PY 2016 VL 10 AR 60 DI 10.3389/fncel.2016.00060 PG 2 WC Neurosciences SC Neurosciences & Neurology GA DH1VW UT WOS:000372574000001 PM 27047335 ER PT J AU Shelton, RC Dunston, SK Leoce, N Jandorf, L Thompson, HS Crookes, DM Erwin, DO AF Shelton, Rachel C. Dunston, Sheba King Leoce, Nicole Jandorf, Lina Thompson, Hayley S. Crookes, Danielle M. Erwin, Deborah O. TI Predictors of activity level and retention among African American lay health advisors (LHAs) from The National Witness Project: Implications for the implementation and sustainability of community-based LHA programs from a longitudinal study SO IMPLEMENTATION SCIENCE LA English DT Article DE Lay health advisors; African Americans; Cancer screening; Sustainability; Implementation; Evidence-based programs ID CERVICAL-CANCER EDUCATION; IMPROVE MAMMOGRAPHY UTILIZATION; HELPER THERAPY PRINCIPLE; BREAST-CANCER; PLANNERS PERSPECTIVES; RANDOMIZED-TRIAL; LOW-INCOME; WORKERS; WOMEN; INTERVENTION AB Background: Lay health advisor (LHA) programs are increasingly being implemented in the USA and globally in the context of health promotion and disease prevention. LHAs are effective in addressing health disparities when used to reach medically underserved populations, with strong evidence among African American and Hispanic women. Despite their success and the evidence supporting implementation of LHA programs in community settings, there are tremendous barriers to sustaining LHA programs and little is understood about their implementation and sustainability in "real-world" settings. The purpose of this study was to (1) propose a conceptual framework to investigate factors at individual, social, and organizational levels that impact LHA activity and retention; and (2) use prospective data to investigate the individual, social, and organizational factors that predict activity level and retention among a community-based sample of African American LHAs participating in an effective, evidence-based LHA program (National Witness Project; NWP). Methods: Seventy-six LHAs were recruited from eight NWP sites across the USA. Baseline predictor data was collected from LHAs during a telephone questionnaire administered between 2010 and 2011. Outcome data on LHA participation and program activity levels were collected in the fall of 2012 from NWP program directors. Chi-square and ANOVA tests were used to identify differences between retained and completely inactive LHAs, and LHAs with high/moderate vs. low/no activity levels. Multivariable logistic regression models were conducted to identify variables that predicted LHA retention and activity levels. Results: In multivariable models, LHAs based at sites with academic partnerships had increased odds of retention and high/moderate activity levels, even after adjusting for baseline LHA activity level. Higher religiosity among LHAs was associated with decreased odds of being highly/moderately active. LHA role clarity and self-efficacy were associated with retention and high/moderate activity in multivariable models unadjusted for baseline LHA activity level. Conclusions: Organizational and role-related factors are critical in influencing the retention and activity levels of LHAs. Developing and fostering partnerships with academic institutions will be important strategies to promote successful implementation and sustainability of LHA programs. Clarifying role expectations and building self-efficacy during LHA recruitment and training should be further explored to promote LHA retention and participation. C1 [Shelton, Rachel C.; Dunston, Sheba King] Columbia Univ, Mailman Sch Publ, Dept Sociomed Sci, 722 168th St,Room 941, New York, NY 10032 USA. [Dunston, Sheba King] Ctr Dis Control & Prevent, Off Res & Methodol, Quest Design Res Lab, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. [Leoce, Nicole] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, 722 168th St, New York, NY 10032 USA. [Jandorf, Lina] Icahn Sch Med Mt Sinai, Dept Oncol Sci, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA. [Thompson, Hayley S.] Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Oncol,Populat Studies & Dispar Res Program, 4100 John R-MM03CB, Detroit, MI 48201 USA. [Crookes, Danielle M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, 722 168th St, New York, NY 10032 USA. [Erwin, Deborah O.] New York State Dept Hlth, Roswell Pk Canc Inst, Off Canc Hlth Dispar Res Canc Prevent & Populat S, Elm & Carlton St, Buffalo, NY 14263 USA. RP Shelton, RC (reprint author), Columbia Univ, Mailman Sch Publ, Dept Sociomed Sci, 722 168th St,Room 941, New York, NY 10032 USA. EM rs3108@cumc.columbia.edu FU National Cancer Institute [5R03CA150543-03] FX We are grateful to the NWP National Steering Committee, project directors, coordinators, LHAs, and role models from the National Witness Project who contributed their time to this study. In particular, we would like to thank and acknowledge Detric "Dee" Johnson and Mattye Willis for all of their efforts and support. This research was funded by a grant from the National Cancer Institute (5R03CA150543-03, "Serving as a Lay Health Advisor: The Impact on Self and Community). NR 85 TC 0 Z9 0 U1 6 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAR 22 PY 2016 VL 11 AR 41 DI 10.1186/s13012-016-0403-9 PG 14 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DI0JG UT WOS:000373181400002 PM 27000149 ER PT J AU Casper, M Kramer, MR Quick, H Schieb, LJ Vaughan, AS Greer, S AF Casper, Michele Kramer, Michael R. Quick, Harrison Schieb, Linda J. Vaughan, Adam S. Greer, Sophia TI Changes in the Geographic Patterns of Heart Disease Mortality in the United States 1973 to 2010 SO CIRCULATION LA English DT Article DE mortality; mapping; epidemiology; heart diseases ID RISK-FACTORS; CORONARY MORTALITY; TRENDS; US; HEALTH; RATES; INEQUALITIES; DISPARITIES; BLACKS; WHITES AB Background- Although many studies have documented the dramatic declines in heart disease mortality in the United States at the national level, little attention has been given to the temporal changes in the geographic patterns of heart disease mortality. Methods and Results- Age-adjusted and spatially smoothed county-level heart disease death rates were calculated for 2-year intervals from 1973 to 1974 to 2009 to 2010 for those aged >= 35 years. Heart disease deaths were defined according to the International Classification of Diseases codes for diseases of the heart in the eighth, ninth, and tenth revisions of the International Classification of Diseases. A fully Bayesian spatiotemporal model was used to produce precise rate estimates, even in counties with small populations. A substantial shift in the concentration of high-rate counties from the Northeast to the Deep South was observed, along with a concentration of slow-decline counties in the South and a nearly 2-fold increase in the geographic inequality among counties. Conclusions- The dramatic change in the geographic patterns of heart disease mortality during 40 years highlights the importance of small-area surveillance to reveal patterns that are hidden at the national level, gives communities the historical context for understanding their current burden of heart disease, and provides important clues for understanding the determinants of the geographic disparities in heart disease mortality. C1 [Casper, Michele; Kramer, Michael R.; Quick, Harrison; Schieb, Linda J.; Vaughan, Adam S.; Greer, Sophia] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Kramer, Michael R.; Vaughan, Adam S.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Casper, M (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, MS-F-77,4770 Buford Hwy, Atlanta, GA 30341 USA. EM mcasper@cdc.gov FU Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health [K01HD074726] FX This research was supported in part by appointments for Dr Kramer and Adam Vaughan to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. Dr Kramer was also supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Number K01HD074726. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 53 TC 7 Z9 7 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD MAR 22 PY 2016 VL 133 IS 12 BP 1171 EP 1180 DI 10.1161/CIRCULATIONAHA.115.018663 PG 10 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DG9MC UT WOS:000372406100004 PM 27002081 ER PT J AU Spellberg, B Srinivasan, A Chambers, HF AF Spellberg, Brad Srinivasan, Arjun Chambers, Henry F. TI New Societal Approaches to Empowering Antibiotic Stewardship SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Spellberg, Brad] Los Angeles Cty Univ Southern Calif, Med Ctr, Los Angeles, CA USA. [Spellberg, Brad] Univ So Calif, Keck Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90033 USA. [Srinivasan, Arjun] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Chambers, Henry F.] Univ Calif San Francisco, Div Infect Dis, San Francisco, CA 94143 USA. RP Spellberg, B (reprint author), LAC USC Med Ctr, 2051 Marengo St,C2K122, Los Angeles, CA 90033 USA. EM bspellberg@dhs.lacounty.gov FU NIAID NIH HHS [R01 AI103342, R01 AI117211] NR 7 TC 8 Z9 8 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 22 PY 2016 VL 315 IS 12 BP 1229 EP 1230 DI 10.1001/jama.2016.1346 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DH0YQ UT WOS:000372511100004 PM 26914942 ER PT J AU Sukumaran, L Omer, SB AF Sukumaran, Lakshmi Omer, Saad B. TI Repeat Tdap Vaccination and Adverse Birth Outcomes Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Sukumaran, Lakshmi] Ctr Dis Control & Prevent, Immunizat Safety Off, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA. [Omer, Saad B.] Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. RP Sukumaran, L (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA. EM lsukumaran@cdc.gov NR 1 TC 0 Z9 0 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 22 PY 2016 VL 315 IS 12 BP 1286 EP 1286 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DH0YQ UT WOS:000372511100021 PM 27002457 ER PT J AU Aia, P Kal, M Lavu, E John, LN Johnson, K Coulter, C Ershova, J Tosas, O Zignol, M Ahmadova, S Islam, T AF Aia, Paul Kal, Margaret Lavu, Evelyn John, Lucy N. Johnson, Karen Coulter, Chris Ershova, Julia Tosas, Olga Zignol, Matteo Ahmadova, Shalala Islam, Tauhid TI The Burden of Drug-Resistant Tuberculosis in Papua New Guinea: Results of a Large Population-Based Survey SO PLOS ONE LA English DT Article ID WESTERN PROVINCE AB Background Reliable estimates of the burden of multidrug-resistant tuberculosis (MDR-TB) are crucial for effective control and prevention of tuberculosis (TB). Papua New Guinea (PNG) is a high TB burden country with limited information on the magnitude of the MDR-TB problem. Methods A cross-sectional study was conducted in four PNG provinces: Madang, Morobe, National Capital District and Western Province. Patient sputum samples were tested for rifampicin resistance by the Xpert MTB/RIF assay and those showing the presence of resistance underwent phenotypic susceptibility testing to first-and second-line anti-TB drugs including streptomycin, isoniazid, rifampicin, ethambutol, pyrazinamide, ofloxacin, amikacin, kanamycin and capreomycin. Results Among 1,182 TB patients enrolled in the study, MDR-TB was detected in 20 new (2.7%; 95% confidence intervals [CI] 1.1-4.3%) and 24 previously treated (19.1%; 95% CI: 8.5-29.8%) TB cases. No case of extensively drug-resistant TB (XDR-TB) was detected. Thirty percent (6/20) of new and 33.3%(8/24) of previously treated cases with MDR-TB were detected in a single cluster in Western Province. Conclusion In PNG the proportion of MDR-TB in new cases is slightly lower than the regional average of 4.4% (95% CI: 2.6-6.3%). A large proportion of MDR-TB cases were identified from a single hospital in Western Province, suggesting that the prevalence of MDR-TB across the country is heterogeneous. Future surveys should further explore this finding. The survey also helped strengthening the use of smear microscopy and Xpert MTB/RIF testing as diagnostic tools for TB in the country. C1 [Aia, Paul; Kal, Margaret; Lavu, Evelyn; John, Lucy N.] Natl Dept Hlth, Port Moresby, Papua N Guinea. [Johnson, Karen] Hlth & HIV Implementat Serv Provider, Abt JTA, Port Moresby, Papua N Guinea. [Coulter, Chris] Pathol Queensland, Queensland Mycobacterium Reference Lab, Herston, Qld, Australia. [Ershova, Julia] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Tosas, Olga] Guys & St Thomas NHS Fdn Trust, London, England. [Zignol, Matteo] WHO, Global TB Programme, CH-1211 Geneva, Switzerland. [Ahmadova, Shalala] WHO, Western Pacific Reg Off, Stop TB & Leprosy Eliminat, Manila, Philippines. [Islam, Tauhid] WHO, Port Moresby, Papua N Guinea. RP Islam, T (reprint author), WHO, Port Moresby, Papua N Guinea. EM islamt@wpro.who.int FU Australian Government's aid program through the Australian High Commission PNG; Global Fund to Fight AIDS, Tuberculosis and Malaria FX The study was made possible with funding from the Australian Government's aid program through the Australian High Commission PNG and supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria, technical assistance of WHO's Global TB Programme. NR 13 TC 1 Z9 1 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 22 PY 2016 VL 11 IS 3 AR e0149806 DI 10.1371/journal.pone.0149806 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH3OX UT WOS:000372697400011 PM 27003160 ER PT J AU Veguilla, V Lopez-Gatell, H Lopez-Martinez, I Aparicio-Antonio, R Barrera-Badillo, G Rojo-Medina, J Gross, FL Jefferson, SN Katz, JM Hernandez-Avila, M Alpuche-Aranda, CM AF Veguilla, Vic Lopez-Gatell, Hugo Lopez-Martinez, Irma Aparicio-Antonio, Rodrigo Barrera-Badillo, Gisela Rojo-Medina, Julieta Gross, Felicia Liaini Jefferson, Stacie N. Katz, Jacqueline M. Hernandez-Avila, Mauricio Alpuche-Aranda, Celia M. TI A Large Proportion of the Mexican Population Remained Susceptible to A(H1N1) pdm09 Infection One Year after the Emergence of 2009 Influenza Pandemic SO PLOS ONE LA English DT Article ID SEROLOGIC ASSAYS; H1N1 VIRUS; SEROPREVALENCE AB Background The 2009 H1N1 influenza pandemic initially affected Mexico from April 2009 to July 2010. By August 2010, a fourth of the population had received the monovalent vaccine against the pandemic virus (A(H1N1) pdm09). To assess the proportion of the Mexican population who remained potentially susceptible to infection throughout the summer of 2010, we estimated the population seroprevalence to A(H1N1) pdm09 in a serosurvey of blood donors. Methods We evaluated baseline cross-reactivity to the pandemic strain and set the threshold for seropositivity using pre-pandemic (2005-2008) stored serum samples and sera from confirmed A(H1N1) pdm09 infected individuals. Between June and September 2010, a convenience sample serosurvey of adult blood donors, children, and adolescents was conducted in six states of Mexico. Sera were tested by the microneutralization (MN) and hemagglutination inhibition (HI) assays, and regarded seropositive if antibody titers were equal or exceeded 1: 40 for MN and 1: 20 for HI. Age-standardized seroprevalence were calculated using the 2010 National Census population. Results Sera from 1,484 individuals were analyzed; 1,363 (92%) were blood donors, and 121 (8%) children or adolescents aged <= 19 years. Mean age (standard deviation) was 31.4 (11.5) years, and 276 (19%) were women. A total of 516 (35%) participants declared history of influenza vaccination after April 2009. The age-standardized seroprevalence to A(H1N1) pdm09 was 48% by the MN and 41% by the HI assays, respectively. The youngest quintile, aged 1 to 22 years, had the highest the seroprevalence; 61% (95% confidence interval [CI]: 56, 66%) for MN, and 56% (95% CI: 51, 62%) for HI. Conclusions Despite high transmission of A(H1N1) pdm09 observed immediately after its emergence and extensive vaccination, over a half of the Mexican population remained potentially susceptible to A(H1N1) pdm09 infection. Subsequent influenza seasons with high transmission of A(H1N1) pdm09, as 2011-2012 and 2013-2014, are compatible with these findings. C1 [Veguilla, Vic; Gross, Felicia Liaini; Jefferson, Stacie N.; Katz, Jacqueline M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Lopez-Gatell, Hugo] Secretaria Salud Mexico, Direcc Gen Adjunta Epidemiol, Mexico City, DF, Mexico. [Lopez-Martinez, Irma; Aparicio-Antonio, Rodrigo; Barrera-Badillo, Gisela] Inst Diagnost & Referencia Epidemiol, Dept Virol, Lab Virus Resp, Mexico City, DF, Mexico. [Rojo-Medina, Julieta] Secretaria Salud Mexico, Ctr Nacl Transfus Sanguinea, Mexico City, DF, Mexico. [Hernandez-Avila, Mauricio] Secretaria Salud Mexico, Subsecretaria Prevenc & Promoc Salud, Mexico City, DF, Mexico. [Alpuche-Aranda, Celia M.] Inst Diagnost & Referencia Epidemiol, Direcc Gen Adjunta, Mexico City, DF, Mexico. [Alpuche-Aranda, Celia M.] Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca, Morelos, Mexico. [Hernandez-Avila, Mauricio] Inst Nacl Salud Publ, Direcc Gen, Cuernavaca, Morelos, Mexico. RP Alpuche-Aranda, CM (reprint author), Inst Diagnost & Referencia Epidemiol, Direcc Gen Adjunta, Mexico City, DF, Mexico.; Alpuche-Aranda, CM (reprint author), Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca, Morelos, Mexico. EM celia.alpuche@insp.mx NR 17 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 22 PY 2016 VL 11 IS 3 AR e0150428 DI 10.1371/journal.pone.0150428 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH3OX UT WOS:000372697400013 PM 27003409 ER PT J AU Dizon, DS Krilov, L Cohen, E Gangadhar, T Ganz, PA Hensing, TA Hunger, S Krishnamurthi, SS Lassman, AB Markham, MJ Mayer, E Neuss, M Pal, SK Richardson, LC Schilsky, R Schwartz, GK Spriggs, DR Villalona-Calero, MA Villani, G Masters, G AF Dizon, Don S. Krilov, Lada Cohen, Ezra Gangadhar, Tara Ganz, Patricia A. Hensing, Thomas A. Hunger, Stephen Krishnamurthi, Smitha S. Lassman, Andrew B. Markham, Merry Jennifer Mayer, Erica Neuss, Michael Pal, Sumanta Kumar Richardson, Lisa C. Schilsky, Richard Schwartz, Gary K. Spriggs, David R. Villalona-Calero, Miguel Angel Villani, Gina Masters, Gregory TI Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID CELL LUNG-CANCER; ACUTE LYMPHOBLASTIC-LEUKEMIA; RANDOMIZED CONTROLLED-TRIAL; CHIMERIC ANTIGEN RECEPTOR; SENSITIVE OVARIAN-CANCER; ADVANCED BREAST-CANCER; UNITED-STATES; UNTREATED MELANOMA; PALLIATIVE CARE; PD-1 BLOCKADE C1 [Dizon, Don S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mayer, Erica] Dana Farber Canc Inst, Boston, MA 02115 USA. [Krilov, Lada; Schilsky, Richard] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA. [Cohen, Ezra] Univ Calif San Diego, San Diego, CA 92103 USA. [Ganz, Patricia A.] Univ Calif Los Angeles, Los Angeles, CA USA. [Pal, Sumanta Kumar] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Gangadhar, Tara] Univ Penn, Philadelphia, PA 19104 USA. [Hunger, Stephen] Childrens Hosp Ctr Philadelphia, Philadelphia, PA USA. [Hensing, Thomas A.] Univ Chicago, Evanston, IL USA. [Krishnamurthi, Smitha S.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Lassman, Andrew B.; Schwartz, Gary K.] Columbia Univ, New York, NY USA. [Spriggs, David R.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Villani, Gina] Ralph Lauren Ctr Canc Care & Prevent, New York, NY USA. [Markham, Merry Jennifer] Univ Florida, Gainesville, FL USA. [Villalona-Calero, Miguel Angel] Miami Canc Inst, Miami, FL USA. [Neuss, Michael] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Richardson, Lisa C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Masters, Gregory] Helen F Graham Canc Ctr & Res Inst, Newark, DE USA. RP Krilov, L (reprint author), Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA. EM lada.krilov@asco.org OI Markham, Merry/0000-0003-3567-3494 FU Intramural CDC HHS [CC999999]; NCATS NIH HHS [UL1 TR001427] NR 86 TC 20 Z9 23 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 20 PY 2016 VL 34 IS 9 BP 987 EP + DI 10.1200/JCO.2015.65.8427 PG 27 WC Oncology SC Oncology GA DJ6OZ UT WOS:000374334100018 PM 26846975 ER PT J AU Dowell, D Haegerich, TM Chou, R AF Dowell, Deborah Haegerich, Tamara M. Chou, Roger TI CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 SO MMWR RECOMMENDATIONS AND REPORTS LA English DT Article ID LOW-BACK-PAIN; CHRONIC NONCANCER PAIN; PRESCRIPTION DRUG-ABUSE; EVIDENCE BASED RECOMMENDATIONS; MEDICATION-ASSISTED TREATMENT; CLINICAL-PRACTICE GUIDELINE; EULAR-STANDING-COMMITTEE; MENTAL-HEALTH DISORDERS; PRIMARY-CARE PHYSICIANS; RISK-FACTORS AB This guideline provides recommendations for primary care clinicians who are prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. The guideline addresses 1) when to initiate or continue opioids for chronic pain; 2) opioid selection, dosage, duration, follow-up, and discontinuation; and 3) assessing risk and addressing harms of opioid use. CDC developed the guideline using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework, and recommendations are made on the basis of a systematic review of the scientific evidence while considering benefits and harms, values and preferences, and resource allocation. CDC obtained input from experts, stakeholders, the public, peer reviewers, and a federally chartered advisory committee. It is important that patients receive appropriate pain treatment with careful consideration of the benefits and risks of treatment options. This guideline is intended to improve communication between clinicians and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder, overdose, and death. CDC has provided a checklist for prescribing opioids for chronic pain (http://stacks.cdc.gov/view/cdc/38025) as well as a website (http://www.cdc.gov/drugoverdose/prescribingresources.html) with additional tools to guide clinicians in implementing the recommendations. C1 [Dowell, Deborah; Haegerich, Tamara M.; Chou, Roger] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Dowell, D (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM gdo7@cdc.gov NR 221 TC 124 Z9 125 U1 7 U2 15 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1057-5987 EI 1545-8601 J9 MMWR RECOMM REP JI MMWR Recomm. Rep. PD MAR 18 PY 2016 VL 65 IS 1 BP 1 EP 49 PG 49 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DJ4RM UT WOS:000374195400001 PM 26987082 ER PT J AU Wang, CB Dollard, SC Amin, MM Bialek, SR AF Wang, Chengbin Dollard, Sheila C. Amin, Minal M. Bialek, Stephanie R. TI Cytomegalovirus IgM Seroprevalence among Women of Reproductive Age in the United States SO PLOS ONE LA English DT Article ID CMV INFECTION; BLOOD-DONORS; AVIDITY; PREGNANCY; ANTIBODIES AB Cytomegalovirus (CMV) IgM indicates recent active CMV infection. CMV IgM seroprevalence is a useful marker for prevalence of transmission. Using data from the National Health and Nutrition Examination Survey (NHANES) III 1988-1994, we present estimates of CMV IgM prevalence by race/ethnicity, provide a comparison of IgM seroprevalence among all women and among CMV IgG positive women, and explore factors possibly associated with IgM seroprevalence, including socioeconomic status and exposure to young children. There was no difference in IgM seroprevalence by race/ethnicity among all women (3.1%, 2.2%, and 1.6% for non-Hispanic white, non-Hispanic black and Mexican American, respectively; P = 0.11). CMV IgM seroprevalence decreased significantly with increasing age in non-Hispanic black women (P<0.001 for trend) and marginally among Mexican American women (P = 0.07), while no apparent trend with age was seen in non-Hispanic white women (P = 0.99). Among 4001 IgG+ women, 118 were IgM+, resulting in 4.9% IgM seroprevalence. In IgG+ women, IgM seroprevalence varied significantly by age (5.3%, 7.3%, and 3.7% for women of 12-19, 20-29, and 30-49 years; P = 0.04) and race/ethnicity (6.1%, 2.7%, and 2.0% for non-Hispanic white, non-Hispanic black, and Mexican American; P<0.001). The factors reported associated with IgG seroprevalence were not associated with IgM seroprevalence. The patterns of CMV IgM seroprevalence by age, race/ethnicity, and IgG serostatus may help understanding the epidemiology of congenital CMV infection as a consequence of vertical transmission and are useful for identifying target populations for intervention to reduce CMV transmission. C1 [Wang, Chengbin; Dollard, Sheila C.; Amin, Minal M.; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Wang, CB (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM cwang1@cdc.gov FU Intramural CDC HHS [CC999999] NR 21 TC 2 Z9 2 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 18 PY 2016 VL 11 IS 3 AR e0151996 DI 10.1371/journal.pone.0151996 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH1ZE UT WOS:000372582800129 PM 26990759 ER PT J AU Kapczynski, DR Tumpey, TM Hidajat, R Zsak, A Chrzastek, K Tretyakova, I Pushko, P AF Kapczynski, Darrell R. Tumpey, Terrence M. Hidajat, Rachmat Zsak, Aniko Chrzastek, Klaudia Tretyakova, Irina Pushko, Peter TI Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses SO VACCINE LA English DT Article DE Avian influenza; Virus-like particle; VLP vaccine; Trivalent ID AVIAN INFLUENZA; UNITED-STATES; VACCINES; POULTRY; BIRDS; GENE; HEMAGGLUTININ; ANTIBODIES; SUBTYPES; FERRETS AB Highly pathogenic avian influenza (HPAI) viruses, especially H5N1 strains, represent a public health threat and cause widespread morbidity and mortality in domestic poultry. Recombinant virus-like particles (VLPs) represent a promising novel vaccine approach to control avian influenza including HPAI strains. Influenza VLPs contain viral hemagglutinin (HA), which can be expressed in cell culture within highly immunogenic VLPs that morphologically and antigenically resemble influenza virions, except VLPs are non-infectious. Here we describe a recombinant VLP containing HA proteins derived from three distinct clades of H5N1 viruses as an experimental, broadly protective H5 avian influenza vaccine. A baculovirus vector was configured to co-express the H5 genes from recent H5N1 HPAI isolates A/chicken/Germany/2014 (clade 2.3.4.4), A/chicken/West Java/Subang/29/2007 (clade 2.1.3) and A/chicken/Egypt/121/2012 (clade 2.2.1). Co-expression of these genes in Sf9 cells along with influenza neuraminidase (NA) and retrovirus gag genes resulted in production of triple-clade H555 VLPs that exhibited hemagglutination activity and morphologically resembled influenza virions. Vaccination of chickens with these VLPs resulted in induction of serum antibody responses and efficient protection against experimental challenges with three different viruses including the recent U.S. H5N8 HPAI isolate. We conclude that these novel triple-clade VLPs represent a feasible strategy for simultaneously evoking protective antibodies against multiple variants of H5 influenza virus. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Kapczynski, Darrell R.; Zsak, Aniko; Chrzastek, Klaudia] USDA SEPRL, Athens, GA USA. [Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE, Atlanta, GA USA. [Hidajat, Rachmat; Tretyakova, Irina; Pushko, Peter] Medigen Inc, 8420 Gas House Pike,Suite S, Frederick, MD USA. RP Pushko, P (reprint author), Medigen Inc, 8420 Gas House Pike,Suite S, Frederick, MD USA. EM ppushko@medigen-usa.com FU USDA NIFA [2013-33610-21041]; NIH NIAID [1R01AI111532]; USDA-ARS [6040-32000-062-00D] FX We thank Brian Nickols, Paphael O. Prather, and Noah Horn for their contributions. This project was supported in part by grants 2013-33610-21041 (USDA NIFA), 1R01AI111532 (NIH NIAID) and 6040-32000-062-00D (USDA-ARS). The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the funding agencies. NR 33 TC 2 Z9 2 U1 4 U2 13 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 18 PY 2016 VL 34 IS 13 BP 1575 EP 1581 DI 10.1016/j.vaccine.2016.02.011 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA DH4NS UT WOS:000372763300011 PM 26868083 ER PT J AU Smith, PJ Stokley, S Bednarczyk, RA Orenstein, WA Omer, SB AF Smith, Philip J. Stokley, Shannon Bednarczyk, Robert A. Orenstein, Walter A. Omer, Saad B. TI HPV vaccination coverage of teen girls: The influence of health care providers SO VACCINE LA English DT Article DE HPV; Parental concerns; Provider influence; Attributable risk ID AGED 13-17 YEARS; PATIENT SATISFACTION; IMMUNIZATION RATES; CHILDREN PROGRAM; UNITED-STATES; INTERVENTIONS; VACCINES; SAFETY AB Background: Between 2010 and 2014, the percentage of 13-17 year-old girls administered >= 3 doses of the human papilloma virus (HPV) vaccine ("fully vaccinated") increased by 7.7 percentage points to 39.7%, and the percentage not administered any doses of the HPV vaccine ("not immunized") decreased by 11.3 percentage points to 40.0%. Objective: To evaluate the complex interactions between parents' vaccine-related beliefs, demographic factors, and HPV immunization status. Methods: Vaccine-related parental beliefs and sociodemographic data collected by the 2010 National Immunization Survey-Teen among teen girls (n = 8490) were analyzed. HPV vaccination status was determined from teens' health care provider (HCP) records. Results: Among teen girls either unvaccinated or fully vaccinated against HPV, teen girls whose parent was positively influenced to vaccinate their teen daughter against HPV were 48.2 percentage points more likely to be fully vaccinated. Parents who reported being positively influenced to vaccinate against HPV were 28.9 percentage points more likely to report that their daughter's HCP talked about the HPV vaccine, 27.2 percentage points more likely to report that their daughter's HCP gave enough time to discuss the HPV shot, and 43.4 percentage points more likely to report that their daughter's HCP recommended the HPV vaccine (p < 0.05). Among teen girls administered 1-2 doses of the HPV vaccine, 87.0% had missed opportunities for HPV vaccine administration. Conclusion: Results suggest that an important pathway to achieving higher >= 3 dose HPV vaccine coverage is by increasing HPV vaccination series initiation though HCP talking to parents about the HPV vaccine, giving parents time to discuss the vaccine, and by making a strong recommendation for the HPV. Also, HPV vaccination series completion rates may be increased by eliminating missed opportunities to vaccinate against HPV and scheduling additional follow-up visits to administer missing HPV vaccine doses. Published by Elsevier Ltd. C1 [Smith, Philip J.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, MS A-19,1600 Clifton Rd NE, Atlanta, GA 30333 USA. [Stokley, Shannon] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Bednarczyk, Robert A.; Orenstein, Walter A.; Omer, Saad B.] Emory Univ, Atlanta, GA 30322 USA. RP Smith, PJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, MS A-19,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM pzs6@cdc.gov; zma2@cdc.gov; robert.a.bednarczyk@emory.edu; worenst@emory.edu; somer@emory.edu NR 48 TC 3 Z9 3 U1 3 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 18 PY 2016 VL 34 IS 13 BP 1604 EP 1610 DI 10.1016/j.vaccine.2016.01.061 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA DH4NS UT WOS:000372763300015 PM 26854907 ER PT J AU Pratt, PD Henschel, K Turabelidze, G Grim, A Ellison, JA Orciari, L Yager, P Franka, R Wu, XF Ma, XY Wadhwa, A Smith, TG Petersen, B Shiferaw, M AF Pratt, P. Drew Henschel, Kathleen Turabelidze, George Grim, Autumn Ellison, James A. Orciari, Lillian Yager, Pamela Franka, Richard Wu, Xianfu Ma, Xiaoyue Wadhwa, Ashutosh Smith, Todd G. Petersen, Brett Shiferaw, Miriam TI Human Rabies - Missouri, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 [Pratt, P. Drew; Henschel, Kathleen; Turabelidze, George; Grim, Autumn] Missouri Dept Hlth & Senior Serv, Div Community & Publ Hlth, Jefferson, AR USA. [Ellison, James A.; Orciari, Lillian; Yager, Pamela; Franka, Richard; Wu, Xianfu; Ma, Xiaoyue; Wadhwa, Ashutosh; Smith, Todd G.; Petersen, Brett; Shiferaw, Miriam] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Shiferaw, M (reprint author), CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM MShiferaw@cdc.gov NR 9 TC 3 Z9 3 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 18 PY 2016 VL 65 IS 10 BP 253 EP 256 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG5SX UT WOS:000372140000001 PM 26985578 ER PT J AU Petersen, BW Harms, TJ Reynolds, MG Harrison, LH AF Petersen, Brett W. Harms, Tiara J. Reynolds, Mary G. Harrison, Lee H. TI Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses - Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID COMPLICATIONS; ACAM2000; VECTORS C1 [Petersen, Brett W.; Reynolds, Mary G.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Harms, Tiara J.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Harrison, Lee H.] Univ Pittsburgh, Advisory Comm Immunizat Practices, Pittsburgh, PA 15260 USA. [Harrison, Lee H.] Univ Pittsburgh, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15260 USA. RP Petersen, BW (reprint author), CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. NR 20 TC 1 Z9 1 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 18 PY 2016 VL 65 IS 10 BP 257 EP 262 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG5SX UT WOS:000372140000002 PM 26985679 ER PT J AU Cetron, M AF Cetron, Martin TI Revision to CDC's Zika Travel Notices: Minimal Likelihood for Mosquito-Borne Zika Virus Transmission at Elevations Above 2,000 Meters SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 [Cetron, Martin] CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Cetron, M (reprint author), CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM MCetron@cdc.gov NR 9 TC 4 Z9 5 U1 2 U2 12 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 18 PY 2016 VL 65 IS 10 BP 267 EP 268 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG5SX UT WOS:000372140000004 PM 26985965 ER PT J AU Hill, J Hoyt, J Achieng, F Ouma, P L'lanziva, A Kariuki, S Desai, M Webster, J AF Hill, Jenny Hoyt, Jenna Achieng, Florence Ouma, Peter L'lanziva, Anne Kariuki, Simon Desai, Meghna Webster, Jayne TI User and Provider Acceptability of Intermittent Screening and Treatment and Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine to Prevent Malaria in Pregnancy in Western Kenya SO PLOS ONE LA English DT Article ID RAPID DIAGNOSTIC-TESTS; SULFADOXINE-PYRIMETHAMINE; EFFICACY; WOMEN; METAANALYSIS; THERAPY; MICROSCOPY; MUTATION; TRIAL; GHANA AB Background The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) alongside long-lasting insecticide-treated nets (LLIN) and case management for reducing the risks associated with malaria in pregnancy in areas of moderate-to-high transmission in sub-Saharan Africa. Due to increasing Plasmodium falciparum resistance to SP, the search for alternative drugs or strategies to control malaria in pregnancy is a priority. We assessed the acceptability among pregnant women and health providers of intermittent screening and treatment (ISTp) and IPTp with dihydroartemisinin-piperaquine (DP) as alternative strategies in the context of an un-blinded clinical trial. Methods Qualitative data were collected through ten focus group discussions with women participating in a randomized controlled trial to evaluate ISTp or IPTp with DP (multi-day regimen) versus IPTp with SP (single dose) in western Kenya. Individual in-depth interviews were conducted with 26 health providers working in the trial facilities and trial staff. Results Women appreciated the advantages of being tested with a rapid diagnostic test (RDT) at every ANC visit (although a few women disliked finger pricks) and accepted that they would not receive any antimalarial when tested RDT-negative. There were differences in women's experiences of the efficacy of antimalarials between the trial arms, with more women in the IPTp-SP arm reporting they had experienced malaria episodes. Side effects were experienced among women taking DP and SP. Although women and trial staff reported adherence to the full DP regimen within the trial, health providers were not confident that women would adhere to multi-day regimens in non-trial settings. Health providers recognized the advantages of ISTp in reducing unnecessary exposure to drugs, but lacked confidence in the reliability of RDTs compared to microscopy. Conclusions Our findings indicate that, within a trial context, ISTp-DP and IPTp-DP were generally acceptable among both users and providers and were regarded as potentially valuable alternatives to IPTp-SP. Several challenges were identified the most important of which was concerns with achieving adherence to DP in non-trial settings, requiring operational feasibility studies in routine health systems. Policy adoption of ISTp with RDTs would require a major shift in thinking among health providers due to lack of confidence in RDTs. C1 [Hill, Jenny; Hoyt, Jenna] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England. [Achieng, Florence; Ouma, Peter; L'lanziva, Anne; Kariuki, Simon] Ctr Dis Control, Res & Publ Hlth Collaborat, Kenya Med Res Inst, Kisumu, Kenya. [Desai, Meghna] Ctr Dis Control & Prevent, Atlanta, GA USA. [Webster, Jayne] Univ London London Sch Hyg & Trop Med, Dis Control Dept, Keppel St, London WC1E 7HT, England. RP Hill, J (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England. EM jenny.hill@lstmed.ac.uk FU Malaria in Pregnancy (MiP) Consortium; Bill & Melinda Gates Foundation; United States President's Malaria Initiative; U.S. Agency for International Development; U.S. Centers for Disease Control and Prevention (CDC); CDC; Kenya Medical Research Institute (KEMRI) FX This work was supported by the Malaria in Pregnancy (MiP) Consortium, which is funded through a grant from the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine, UK, and was made possible through support provided by the United States President's Malaria Initiative, U.S. Agency for International Development and U.S. Centers for Disease Control and Prevention (CDC), under the terms of an Interagency Agreement with CDC and through a Cooperative Agreement between the CDC and the Kenya Medical Research Institute (KEMRI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 1 Z9 1 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 17 PY 2016 VL 11 IS 3 AR e0150259 DI 10.1371/journal.pone.0150259 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH1YG UT WOS:000372580300019 PM 26986471 ER PT J AU Warren, TK Jordan, R Lo, MK Ray, AS Mackman, RL Soloveva, V Siegel, D Perron, M Bannister, R Hui, HC Larson, N Strickley, R Wells, J Stuthman, KS Van Tongeren, SA Garza, NL Donnelly, G Shurtleff, AC Retterer, CJ Gharaibeh, D Zamani, R Kenny, T Eaton, BP Grimes, E Welch, LS Gomba, L Wilhelmsen, CL Nichols, DK Nuss, JE Nagle, ER Kugelman, JR Palacios, G Doerffler, E Neville, S Carra, E Clarke, MO Zhang, LJ Lew, W Ross, B Wang, Q Chun, K Wolfe, L Babusis, D Park, Y Stray, KM Trancheva, I Feng, JY Barauskas, O Xu, YL Wong, P Braun, MR Flint, M McMullan, LK Chen, SS Fearns, R Swaminathan, S Mayers, DL Spiropoulou, CF Lee, WA Nichol, ST Cihlar, T Bavari, S AF Warren, Travis K. Jordan, Robert Lo, Michael K. Ray, Adrian S. Mackman, Richard L. Soloveva, Veronica Siegel, Dustin Perron, Michel Bannister, Roy Hui, Hon C. Larson, Nate Strickley, Robert Wells, Jay Stuthman, Kelly S. Van Tongeren, Sean A. Garza, Nicole L. Donnelly, Ginger Shurtleff, Amy C. Retterer, Cary J. Gharaibeh, Dima Zamani, Rouzbeh Kenny, Tara Eaton, Brett P. Grimes, Elizabeth Welch, Lisa S. Gomba, Laura Wilhelmsen, Catherine L. Nichols, Donald K. Nuss, Jonathan E. Nagle, Elyse R. Kugelman, Jeffrey R. Palacios, Gustavo Doerffler, Edward Neville, Sean Carra, Ernest Clarke, Michael O. Zhang, Lijun Lew, Willard Ross, Bruce Wang, Queenie Chun, Kwon Wolfe, Lydia Babusis, Darius Park, Yeojin Stray, Kirsten M. Trancheva, Iva Feng, Joy Y. Barauskas, Ona Xu, Yili Wong, Pamela Braun, Molly R. Flint, Mike McMullan, Laura K. Chen, Shan-Shan Fearns, Rachel Swaminathan, Swami Mayers, Douglas L. Spiropoulou, Christina F. Lee, William A. Nichol, Stuart T. Cihlar, Tomas Bavari, Sina TI Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys SO NATURE LA English DT Article ID INFECTED NONHUMAN-PRIMATES; ANTIVIRAL ACTIVITY; T-705 FAVIPIRAVIR; HIGH-THROUGHPUT; POLYMERASE; INHIBITOR; MODEL; PROTECTION; MACAQUES; PROMOTER AB The most recent Ebola virus outbreak in West Africa, which was unprecedented in the number of cases and fatalities, geographic distribution, and number of nations affected, highlights the need for safe, effective, and readily available antiviral agents for treatment and prevention of acute Ebola virus (EBOV) disease (EVD) or sequelae(1). No antiviral therapeutics have yet received regulatory approval or demonstrated clinical efficacy. Here we report the discovery of a novel small molecule GS-5734, a monophosphoramidate prodrug of an adenosine analogue, with antiviral activity against EBOV. GS-5734 exhibits antiviral activity against multiple variants of EBOV and other filoviruses in cell-based assays. The pharmacologically active nucleoside triphosphate (NTP) is efficiently formed in multiple human cell types incubated with GS-5734 in vitro, and the NTP acts as an alternative substrate and RNA-chain terminator in primer-extension assays using a surrogate respiratory syncytial virus RNA polymerase. Intravenous administration of GS-5734 to nonhuman primates resulted in persistent NTP levels in peripheral blood mononuclear cells (half-life, 14 h) and distribution to sanctuary sites for viral replication including testes, eyes, and brain. In a rhesus monkey model of EVD, once-daily intravenous administration of 10 mg kg(-1) GS-5734 for 12 days resulted in profound suppression of EBOV replication and protected 100% of EBOV-infected animals against lethal disease, ameliorating clinical disease signs and pathophysiological markers, even when treatments were initiated three days after virus exposure when systemic viral RNA was detected in two out of six treated animals. These results show the first substantive post-exposure protection by a small-molecule antiviral compound against EBOV in nonhuman primates. The broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenaviruses, and coronaviruses, suggests the potential for wider medical use. GS-5734 is amenable to large-scale manufacturing, and clinical studies investigating the drug safety and pharmacokinetics are ongoing. C1 [Warren, Travis K.; Soloveva, Veronica; Wells, Jay; Stuthman, Kelly S.; Van Tongeren, Sean A.; Garza, Nicole L.; Donnelly, Ginger; Shurtleff, Amy C.; Retterer, Cary J.; Gharaibeh, Dima; Zamani, Rouzbeh; Kenny, Tara; Eaton, Brett P.; Grimes, Elizabeth; Welch, Lisa S.; Gomba, Laura; Wilhelmsen, Catherine L.; Nichols, Donald K.; Nuss, Jonathan E.; Nagle, Elyse R.; Kugelman, Jeffrey R.; Palacios, Gustavo; Mayers, Douglas L.; Bavari, Sina] US Army, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA. [Warren, Travis K.; Soloveva, Veronica; Gomba, Laura; Nuss, Jonathan E.; Bavari, Sina] US Army, Med Res Inst Infect Dis, Therapeut Dev Ctr, Ft Detrick, MD 21702 USA. [Jordan, Robert; Ray, Adrian S.; Mackman, Richard L.; Siegel, Dustin; Perron, Michel; Bannister, Roy; Hui, Hon C.; Larson, Nate; Strickley, Robert; Doerffler, Edward; Neville, Sean; Carra, Ernest; Clarke, Michael O.; Zhang, Lijun; Lew, Willard; Ross, Bruce; Wang, Queenie; Chun, Kwon; Wolfe, Lydia; Babusis, Darius; Park, Yeojin; Stray, Kirsten M.; Trancheva, Iva; Feng, Joy Y.; Barauskas, Ona; Xu, Yili; Wong, Pamela; Chen, Shan-Shan; Swaminathan, Swami; Lee, William A.; Cihlar, Tomas] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA. [Lo, Michael K.; Flint, Mike; McMullan, Laura K.; Spiropoulou, Christina F.; Nichol, Stuart T.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Braun, Molly R.; Fearns, Rachel] Boston Univ, Sch Med, Boston, MA 02118 USA. [Welch, Lisa S.] LOKET Consulting, Clarksburg, MD 20871 USA. [Mayers, Douglas L.] Cocrystal Pharma, Tucker, GA 30084 USA. RP Bavari, S (reprint author), US Army, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA.; Bavari, S (reprint author), US Army, Med Res Inst Infect Dis, Therapeut Dev Ctr, Ft Detrick, MD 21702 USA.; Cihlar, T (reprint author), Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA. EM tomas.cihlar@gilead.com; sina.bavari.civ@mail.mil OI Palacios, Gustavo/0000-0001-5062-1938 FU Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBD) of the Defense Threat Reduction Agency (DTRA) [CB10218]; NIH [R01AI113321] FX T. Bocan, A. Duplantier, R. Panchal, and C. Kane provided scientific input. B. Norquist assisted with manuscript preparation. C. Cooper provided scientific input with human macrophage cultures for high-content image assessments. S. Tritsch and G. Gomba assisted with GS-5734 dose preparations for efficacy studies. C. Rice provided animal husbandry support services. X. Wei, W. Garner, and L. Zhong provided additional support for statistical analyses. K. Wang, K. Brendza, T. Alfredson, and L. Serafini assisted with analytical methods; S. Bondy and R. Seemayer procured key raw materials; L. Heumann, R. Polniaszeck, E. Rueden, A. Chtchemelinine, K. Brak, and B. Hoang contributed to synthesis; and Y. Zherebina helped with chiral separations. G. Lee supported the RSV antiviral assay, and G. Stepan, S. Ahmadyar, and H. Yu conducted part of the cytotoxicity testing. J. Knox contributed to polymerase modelling. A. L. Rheingold performed the X-ray crystallographic analysis (Supplementary Information). Studies at USAMRIID were in part supported by The Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBD) of the Defense Threat Reduction Agency (DTRA) under plan #CB10218. Work in the Fearns laboratory was supported by NIH R01AI113321. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the US Army or the Centers for Disease Control and Prevention, US Department of Health and Human Services. NR 37 TC 23 Z9 24 U1 10 U2 29 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD MAR 17 PY 2016 VL 531 IS 7594 BP 381 EP + DI 10.1038/nature17180 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DG4TA UT WOS:000372064300055 PM 26934220 ER PT J AU Bushman, M Morton, L Duah, N Quashie, N Abuaku, B Koram, KA Dimbu, PR Plucinski, M Gutman, J Lyaruu, P Kachur, SP de Roode, JC Udhayakumar, V AF Bushman, Mary Morton, Lindsay Duah, Nancy Quashie, Neils Abuaku, Benjamin Koram, Kwadwo A. Dimbu, Pedro Rafael Plucinski, Mateusz Gutman, Julie Lyaruu, Peter Kachur, S. Patrick de Roode, Jacobus C. Udhayakumar, Venkatachalam TI Within-host competition and drug resistance in the human malaria parasite Plasmodium falciparum SO PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES LA English DT Article DE Plasmodium falciparum; malaria; within-host; competition; resistance; chloroquine ID ARTEMISININ RESISTANCE; CHABAUDI INFECTIONS; SELECTIVE SWEEPS; FITNESS; CHEMOTHERAPY; SPREAD; PFCRT; DIVERSITY; EVOLUTION; ANGOLA AB Infections with the malaria parasite Plasmodium falciparum typically comprise multiple strains, especially in high-transmission areas where infectious mosquito bites occur frequently. However, little is known about the dynamics of mixed-strain infections, particularly whether strains sharing a host compete or grow independently. Competition between drug-sensitive and drug resistant strains, if it occurs, could be a crucial determinant of the spread of resistance. We analysed 1341 P. falciparum infections in children from Angola, Ghana and Tanzania and found compelling evidence for competition in mixed-strain infections: overall parasite density did not increase with additional strains, and densities of individual chloroquine-sensitive (CQS) and chloroquine-resistant (CQR) strains were reduced in the presence of competitors. We also found that CQR strains exhibited low densities compared with CQS strains (in the absence of chloroquine), which may underlie observed declines of chloroquine resistance in many countries following retirement of chloroquine as a first-line therapy. Our observations support a key role for within-host competition in the evolution of drug-resistant malaria. Malaria control and resistance-management efforts in high-transmission regions may be significantly aided or hindered by the effects of competition in mixed-strain infections. Consideration of within-host dynamics may spur development of novel strategies to minimize resistance while maximizing the benefits of control measures. C1 [Bushman, Mary; de Roode, Jacobus C.] Emory Univ, Dept Biol, Atlanta, GA 30322 USA. [Bushman, Mary; Morton, Lindsay; Plucinski, Mateusz; Gutman, Julie; Kachur, S. Patrick; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Plucinski, Mateusz] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Duah, Nancy; Quashie, Neils; Abuaku, Benjamin; Koram, Kwadwo A.] Univ Ghana, Noguchi Mem Inst Med Res, Dept Epidemiol, Legon, Ghana. [Quashie, Neils] Univ Ghana, Sch Med, Ctr Trop Clin Pharmacol & Therapeut, Accra, Ghana. [Dimbu, Pedro Rafael] Natl Malaria Control Program, Luanda, Angola. [Lyaruu, Peter] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. RP Bushman, M (reprint author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.; Bushman, M (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. EM mbushma@emory.edu OI Duah, Nancy/0000-0001-8819-1793 FU Molecules to Mankind Fellowship through the Burroughs Wellcome Fund Institutional Program Unifying Population and Laboratory-Based Sciences; Emory University; Emerging Infectious Diseases Laboratory Fellowship - Association of Public Health Laboratories; Centers for Disease Control and Prevention; NIH [R01GM109501] FX M.B. was funded by a Molecules to Mankind Fellowship through the Burroughs Wellcome Fund Institutional Program Unifying Population and Laboratory-Based Sciences and by Emory University; L.M. was funded by an Emerging Infectious Diseases Laboratory Fellowship sponsored by the Association of Public Health Laboratories and the Centers for Disease Control and Prevention; and J.C.d.R. was funded by NIH R01GM109501. NR 58 TC 0 Z9 0 U1 5 U2 14 PU ROYAL SOC PI LONDON PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND SN 0962-8452 EI 1471-2954 J9 P ROY SOC B-BIOL SCI JI Proc. R. Soc. B-Biol. Sci. PD MAR 16 PY 2016 VL 283 IS 1826 AR 20153038 DI 10.1098/rspb.2015.3038 PG 8 WC Biology; Ecology; Evolutionary Biology SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences & Ecology; Evolutionary Biology GA DK4WV UT WOS:000374921900007 PM 26984625 ER PT J AU Ellington, SR Clarke, KEN Kourtis, AP AF Ellington, Sascha R. Clarke, Kristie E. N. Kourtis, Athena P. TI Cytomegalovirus Infection in Human Immunodeficiency Virus (HIV)-Exposed and HIV-Infected Infants: A Systematic Review SO JOURNAL OF INFECTIOUS DISEASES LA English DT Review DE cytomegalovirus; HIV; mother-to-child transmission; HIV-exposed infant ID ACTIVE ANTIRETROVIRAL THERAPY; CONGENITAL CYTOMEGALOVIRUS; DISEASE PROGRESSION; TRANSMISSION; CHILDREN; MOTHERS; TYPE-1; AIDS; BORN; COFACTOR AB Cytomegalovirus is highly prevalent worldwide and an important opportunistic pathogen in human immunodeficiency virus (HIV)-infected individuals. The effects of cytomegalovirus infection on HIV-exposed infants are poorly understood. We conducted a systematic review to assess the relationship between cytomegalovirus and HIV infections among HIV-exposed infants. Limited evidence suggests that HIV-induced immunosuppression in the mother increases the rate of congenital cytomegalovirus infection, while maternal antiretroviral therapy may reduce it. Limited information exists on the direction of the relationship between cytomegalovirus and HIV transmission among HIV-exposed infants. Only 2 studies have addressed this temporal sequence of events, and they suggest that cytomegalovirus can lead to subsequent HIV infection in HIV-exposed infants. Most evidence suggests that early cytomegalovirus infection accelerates HIV disease progression in infants. Gaps remain in understanding the role that cytomegalovirus infection plays in HIV-exposed infants. Decreasing cytomegalovirus transmission prenatally and in infancy might further decrease HIV transmission and lead to better health among HIV-exposed infants. C1 [Ellington, Sascha R.; Clarke, Kristie E. N.; Kourtis, Athena P.] Ctr Dis Control & Prevent, Div Reprod Hlth, MS F74,Chamblee Campus,Bldg 107,Buford Highway, Atlanta, GA 30341 USA. RP Ellington, SR (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, MS F74,Chamblee Campus,Bldg 107,Buford Highway, Atlanta, GA 30341 USA. EM sellington@cdc.gov FU CDC FX This work was supported by the CDC. NR 42 TC 3 Z9 3 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 15 PY 2016 VL 213 IS 6 BP 891 EP 900 DI 10.1093/infdis/jiv549 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DJ4ON UT WOS:000374186000004 PM 26597258 ER PT J AU Campo, DS Xia, GL Dimitrova, Z Lin, YL Forbi, JC Ganova-Raeva, L Punkova, L Ramachandran, S Thai, H Skums, P Sims, S Rytsareva, I Vaughan, G Roh, HJ Purdy, MA Sue, A Khudyakov, Y AF Campo, David S. Xia, Guo-Liang Dimitrova, Zoya Lin, Yulin Forbi, Joseph C. Ganova-Raeva, Lilia Punkova, Lili Ramachandran, Sumathi Thai, Hong Skums, Pavel Sims, Seth Rytsareva, Inna Vaughan, Gilberto Roh, Ha-Jung Purdy, Michael A. Sue, Amanda Khudyakov, Yury TI Accurate Genetic Detection of Hepatitis C Virus Transmissions in Outbreak Settings SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HCV; outbreak; threshold; NGS; nucleotide diversity; phylogenetic analysis; hamming distance; transmission networks ID MOLECULAR EPIDEMIOLOGY; PHYLOGENETIC ANALYSIS; HIV TRANSMISSION; SEQUENCE ALIGNMENT; HEMODIALYSIS UNIT; DNA-SEQUENCES; INFECTION; EVOLUTION; PERFORMANCE; POPULATION AB Hepatitis C is a major public health problem in the United States and worldwide. Outbreaks of hepatitis C virus (HCV) infections are associated with unsafe injection practices, drug diversion, and other exposures to blood and are difficult to detect and investigate. Here, we developed and validated a simple approach for molecular detection of HCV transmissions in outbreak settings. We obtained sequences from the HCV hypervariable region 1 (HVR1), using end-point limiting-dilution (EPLD) technique, from 127 cases involved in 32 epidemiologically defined HCV outbreaks and 193 individuals with unrelated HCV strains. We compared several types of genetic distances and calculated a threshold, using minimal Hamming distances, that identifies transmission clusters in all tested outbreaks with 100% accuracy. The approach was also validated on sequences obtained using next-generation sequencing from HCV strains recovered from 239 individuals, and findings showed the same accuracy as that for EPLD. On average, the nucleotide diversity of the intrahost population was 6.2 times greater in the source case than in any incident case, allowing the correct detection of transmission direction in 8 outbreaks for which source cases were known. A simple and accurate distance-based approach developed here for detecting HCV transmissions streamlines molecular investigation of outbreaks, thus improving the public health capacity for rapid and effective control of hepatitis C. C1 [Campo, David S.; Xia, Guo-Liang; Dimitrova, Zoya; Lin, Yulin; Forbi, Joseph C.; Ganova-Raeva, Lilia; Punkova, Lili; Ramachandran, Sumathi; Thai, Hong; Skums, Pavel; Sims, Seth; Rytsareva, Inna; Vaughan, Gilberto; Roh, Ha-Jung; Purdy, Michael A.; Sue, Amanda; Khudyakov, Yury] Ctr Dis Control & Prevent, Mol Epidemiol & Bioinformat Lab, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Campo, DS (reprint author), Ctr Dis Control & Prevent, Mol Epidemiol & Bioinformat Lab, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM fyv6@cdc.gov RI Roh, Ha-Jung/N-1365-2016; OI Roh, Ha-Jung/0000-0003-1523-6844; Sims, Seth/0000-0003-2126-0197 FU Advanced Molecular Detection Program, Office of Infectious Diseases, CDC FX This work was supported by the Advanced Molecular Detection Program, Office of Infectious Diseases, CDC. NR 50 TC 1 Z9 2 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 15 PY 2016 VL 213 IS 6 BP 957 EP 965 DI 10.1093/infdis/jiv542 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DJ4ON UT WOS:000374186000013 PM 26582955 ER PT J AU Byers, N Ritchey, M Vaidyanathan, A Brandt, AJ Yip, F AF Byers, Nathan Ritchey, Matthew Vaidyanathan, Ambarish Brandt, Amy J. Yip, Fuyuen TI Short-term effects of ambient air pollutants on asthma-related emergency department visits in Indianapolis, Indiana, 2007-2011 SO JOURNAL OF ASTHMA LA English DT Article DE Lagged effects; ozone; particulate matter; sulfur dioxide; time-series ID TIME-SERIES; POLLUTION; QUALITY; MORTALITY; EXPOSURE; HEALTH AB Objective: We estimate the short-term associations between daily changes in ambient air pollutants and daily asthma-related emergency department (ED) visits in Indianapolis, IN. Methods: We identified asthma-related ED visits among Indianapolis residents aged 5 years. We used Poisson regression in a time-series framework to estimate the increased risk for asthma-related ED visits from exposure to ambient SO2, PM2.5 and ozone during the warm season (April-September) and SO2 and PM2.5 during the cold (October-March) season, from 2007 to 2011. Our models controlled for measured confounders, including weather and respiratory infections, as well as unmeasured confounders using a natural cubic spline to account for long-term seasonal trends. Results: During 2007-2011 in Indianapolis, 165056 asthma-related ED visits occurred. We found statistically significant positive associations (p<0.05) between ambient air pollutants and ED visits during the warm season for persons aged 5-44 years. Interquartile range increases in daily ozone concentrations with same day, 2-day lagged, and 3-day moving average were associated with increased risks for ED visits of 3.2% (95% CI: 0.2%, 6.3%), 4.4% (0.1%, 8.9%) and 4.8% (0.2%, 9.6%), respectively. Interquartile range increases in 3-day moving averages for SO2 were associated with an increased risk of 3.3% (95% CI: 0.2%, 6.5%). We identified statistically significant associations (p<0.05) between increased SO2 and PM2.5 levels and decreased ED visits among some age groups, primarily during the cold season, and no significant positive associations between changes in PM2.5 concentration and asthma-related ED visits. Conclusions: During the warm season, increases in ozone and SO2 concentrations were associated with increased asthma morbidity in children and young adults in Indianapolis. These results will enable reliable estimation of the health impacts of increases in these pollutants on asthma-related ED visits in Indianapolis and similar communities. C1 [Byers, Nathan] Indiana Dept Environm Management, Indianapolis, IN USA. [Ritchey, Matthew] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F-72, Atlanta, GA 30341 USA. [Vaidyanathan, Ambarish; Yip, Fuyuen] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Brandt, Amy J.] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. [Byers, Nathan] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. RP Ritchey, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F-72, Atlanta, GA 30341 USA. EM hha7@cdc.gov NR 22 TC 0 Z9 0 U1 4 U2 7 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0277-0903 EI 1532-4303 J9 J ASTHMA JI J. Asthma PD MAR 15 PY 2016 VL 53 IS 3 BP 245 EP 252 DI 10.3109/02770903.2015.1091006 PG 8 WC Allergy; Respiratory System SC Allergy; Respiratory System GA DI5CO UT WOS:000373515900003 PM 26517197 ER PT J AU Guclu, H Read, J Vukotich, CJ Galloway, DD Gao, H Rainey, JJ Uzicanin, A Zimmer, SM Cummings, DAT AF Guclu, Hasan Read, Jonathan Vukotich, Charles J., Jr. Galloway, David D. Gao, Hongjiang Rainey, Jeanette J. Uzicanin, Amra Zimmer, Shanta M. Cummings, Derek A. T. TI Social Contact Networks and Mixing among Students in K-12 Schools in Pittsburgh, PA SO PLOS ONE LA English DT Article ID PANDEMIC INFLUENZA; INFECTIOUS-DISEASE; UNITED-STATES; SPREAD; TRANSMISSION; CHILDREN; OUTBREAKS; PATTERNS; CLOSURE; ADULTS AB Students attending schools play an important role in the transmission of influenza. In this study, we present a social network analysis of contacts among 1,828 students in eight different schools in urban and suburban areas in and near Pittsburgh, Pennsylvania, United States of America, including elementary, elementary-middle, middle, and high schools. We collected social contact information of students who wore wireless sensor devices that regularly recorded other devices if they are within a distance of 3 meters. We analyzed these networks to identify patterns of proximal student interactions in different classes and grades, to describe community structure within the schools, and to assess the impact of the physical environment of schools on proximal contacts. In the elementary and middle schools, we observed a high number of intra-grade and intra-classroom contacts and a relatively low number of inter-grade contacts. However, in high schools, contact networks were well connected and mixed across grades. High modularity of lower grades suggests that assumptions of homogeneous mixing in epidemic models may be inappropriate; whereas lower modularity in high schools suggests that homogenous mixing assumptions may be more acceptable in these settings. The results suggest that interventions targeting subsets of classrooms may work better in elementary schools than high schools. Our work presents quantitative measures of age-specific, school-based contacts that can be used as the basis for constructing models of the transmission of infections in schools. C1 [Guclu, Hasan] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA. [Guclu, Hasan; Galloway, David D.] Univ Pittsburgh, Grad Sch Publ Hlth, Publ Hlth Dynam Lab, Pittsburgh, PA USA. [Guclu, Hasan] Istanbul Medeniyet Univ, Dept Stat, Fac Sci, Istanbul, Turkey. [Read, Jonathan] Univ Liverpool, Inst Infect & Global Hlth, Farr Inst HeRC, Dept Epidemiol & Populat Hlth, Liverpool L69 3GL, Merseyside, England. [Read, Jonathan] Univ Lancaster, Lancaster Med Sch, Lancaster LA1 4YG, England. [Vukotich, Charles J., Jr.; Zimmer, Shanta M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Gao, Hongjiang; Rainey, Jeanette J.; Uzicanin, Amra] US Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Cummings, Derek A. T.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Guclu, H (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA.; Guclu, H (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Publ Hlth Dynam Lab, Pittsburgh, PA USA.; Guclu, H (reprint author), Istanbul Medeniyet Univ, Dept Stat, Fac Sci, Istanbul, Turkey. EM guclu@pitt.edu OI Read, Jonathan/0000-0002-9697-0962 FU US Centers for Disease Control and Prevention (CDC) [1U01CK00179-01] FX This research was supported by Cooperative Agreement number 1U01CK00179-01 from the US Centers for Disease Control and Prevention (CDC, www.cdc.gov). Its contents are solely the responsibility of the authors and do not necessarily represent the official position of CDC. NR 48 TC 1 Z9 1 U1 2 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 15 PY 2016 VL 11 IS 3 AR e0151139 DI 10.1371/journal.pone.0151139 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH1VK UT WOS:000372572800047 PM 26978780 ER PT J AU Cope, JR Conrad, DA Cohen, N Cotilla, M DaSilva, A Jackson, J Visvesvara, GS AF Cope, Jennifer R. Conrad, Dennis A. Cohen, Naiomi Cotilla, Manuel DaSilva, Alexandre Jackson, Jonathan Visvesvara, Govinda S. TI Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE primary amebic meningoencephalitis; Naegleria fowleri; miltefosine ID NAEGLERIA-FOWLERI; TAP WATER AB Primary amebic meningoencephalitis (PAM) is a fulminant central nervous system infection caused by the thermophilic free-living ameba Naegleria fowleri. Few survivals have been documented and adequate treatment is lacking. We report 2 PAM cases, 1 fatal and 1 surviving, treated with the novel antiparasitic agent miltefosine. C1 [Cope, Jennifer R.; DaSilva, Alexandre; Jackson, Jonathan; Visvesvara, Govinda S.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA. [Conrad, Dennis A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Cohen, Naiomi; Cotilla, Manuel] Miami Childrens Hosp, Miami, FL USA. [DaSilva, Alexandre] US FDA, Laurel, MD USA. RP Cope, JR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA. EM jcope@cdc.gov FU Intramural CDC HHS [CC999999] NR 11 TC 5 Z9 5 U1 4 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 15 PY 2016 VL 62 IS 6 BP 774 EP 776 DI 10.1093/cid/civ1021 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DF9XU UT WOS:000371716700015 PM 26679626 ER PT J AU Cantey, PT Weeks, J Edwards, M Rao, S Ostovar, GA Dehority, W Alzona, M Swoboda, S Christiaens, B Ballan, W Hartley, J Terranella, A Weatherhead, J Dunn, JJ Marx, DP Hicks, MJ Rauch, RA Smith, C Dishop, MK Handler, MH Dudley, RWR Chundu, K Hobohm, D Feiz-Erfan, I Hakes, J Berry, RS Stepensaski, S Greenfield, B Shroeder, L Bishop, H de Almeida, M Mathison, B Eberhard, M AF Cantey, Paul T. Weeks, Jessica Edwards, Morven Rao, Suchitra Ostovar, G. Amin Dehority, Walter Alzona, Maria Swoboda, Sara Christiaens, Brooke Ballan, Wassim Hartley, John Terranella, Andrew Weatherhead, Jill Dunn, James J. Marx, Douglas P. Hicks, M. John Rauch, Ronald A. Smith, Christiana Dishop, Megan K. Handler, Michael H. Dudley, Roy W. R. Chundu, Kote Hobohm, Dan Feiz-Erfan, Iman Hakes, Joseph Berry, Ryan S. Stepensaski, Shelly Greenfield, Benjamin Shroeder, Laura Bishop, Henry de Almeida, Marcos Mathison, Blaine Eberhard, Mark TI The Emergence of Zoonotic Onchocerca lupi Infection in the United States - A Case-Series SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Onchocerca lupi; emerging infectious diseases; zoonotic infection ID CANINE OCULAR ONCHOCERCOSIS; MACROFILARICIDAL ACTIVITY; WOLBACHIA ENDOSYMBIONT; DIROFILARIA-IMMITIS; 2 DOGS; DOXYCYCLINE; IVERMECTIN; VOLVULUS; DISEASE; GREECE AB This case-series describes the 6 human infections with Onchocerca lupi, a parasite known to infect cats and dogs, that have been identified in the United States since 2013. Unlike cases reported outside the country, the American patients have not had subconjunctival nodules but have manifested more invasive disease (eg, spinal, orbital, and subdermal nodules). Diagnosis remains challenging in the absence of a serologic test. Treatment should be guided by what is done for Onchocerca volvulus as there are no data for O. lupi. Available evidence suggests that there may be transmission in southwestern United States, but the risk of transmission to humans is not known. Research is needed to better define the burden of disease in the United States and develop appropriately-targeted prevention strategies. C1 [Cantey, Paul T.; Bishop, Henry; de Almeida, Marcos; Mathison, Blaine; Eberhard, Mark] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd,MS A-06, Atlanta, GA 30329 USA. [Weeks, Jessica; Swoboda, Sara; Terranella, Andrew] Indian Hlth Serv Navajo Area, Window Rock, AZ USA. [Edwards, Morven; Weatherhead, Jill; Dunn, James J.; Marx, Douglas P.; Hicks, M. John; Rauch, Ronald A.] Baylor Coll Med, Houston, TX 77030 USA. [Rao, Suchitra; Smith, Christiana; Handler, Michael H.] Univ Colorado, Sch Med, Childrens Hosp Colorado, Aurora, CO USA. [Ostovar, G. Amin; Hobohm, Dan; Feiz-Erfan, Iman] Univ Arizona, Dist Med Grp, Maricopa Med Ctr, Phoenix, AZ USA. [Dehority, Walter; Berry, Ryan S.; Greenfield, Benjamin] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA. [Alzona, Maria] Clin Path Associates, Tempe, AZ USA. [Christiaens, Brooke; Ballan, Wassim; Hartley, John] Phoenix Childrens Hosp, Phoenix, AZ USA. [Dishop, Megan K.] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA. [Dudley, Roy W. R.] McGill Univ, Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada. [Hakes, Joseph] San Juan Reg Med Grp, Farmington, NM USA. [Stepensaski, Shelly] Pathol Associates Albuquerque, Div Dermatopathol, Albuquerque, NM USA. [Shroeder, Laura] North Phoenix Infect Dis, Phoenix, AZ USA. RP Cantey, PT (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd,MS A-06, Atlanta, GA 30329 USA. EM gdn9@cdc.gov OI Dehority, Walter/0000-0003-3785-7537 FU Intramural CDC HHS [CC999999]; NIAID NIH HHS [T32 AI055413] NR 32 TC 2 Z9 2 U1 2 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 15 PY 2016 VL 62 IS 6 BP 778 EP 783 DI 10.1093/cid/civ983 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DF9XU UT WOS:000371716700017 PM 26611778 ER PT J AU Burns, JM Miura, K Sullivan, J Long, CA Barnwell, JW AF Burns, James M., Jr. Miura, Kazutoyo Sullivan, JoAnn Long, Carole A. Barnwell, John W. TI Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys SO MALARIA JOURNAL LA English DT Article DE Blood-stage malaria vaccine; Aotus monkeys; Vaccine carrier protein ID BLOOD-STAGE MALARIA; WHOLE PARASITE; PHASE-3 TRIAL; PROTECTION; IMMUNIZATION; RESPONSES; CHILDREN; ANTIBODY; SPOROZOITES; CHALLENGE AB Background: The production of properly folded, recombinant sub-unit Plasmodium falciparum malaria vaccine candidates in sufficient quantities is often a challenge. Success in vaccine immunogenicity studies in small animal models does not always predict immunogenicity in non-human primates and/or human subjects. The aim of this study was to assess the immunogenicity of a chimeric blood-stage malaria vaccine in Aotus monkeys. This vaccine candidate includes the neutralizing B cell epitopes of P. falciparum merozoite surface protein 1 (rPfMSP1(19)) genetically linked to a highly immunogenic, well-conserved P. falciparum merozoite surface protein 8 (rPfMSP8 (Delta Asn/Asp)) partner. Methods: Aotus nancymaae monkeys were immunized with purified rPfMSP1/8 or rPfMSP8 (Delta Asn/Asp) formulated with Montanide ISA 720 as adjuvant, or with adjuvant alone. Antibody responses to MSP1(19) and MSP8 domains were measured by ELISA following primary, secondary and tertiary immunizations. The functionality of vaccine-induced antibodies was assessed in a standard P. falciparum blood-stage in vitro growth inhibition assay. Non-parametric tests with corrections for multiple comparisons when appropriate were used to determine the significance of differences in antigen-specific IgG titres and in parasite growth inhibition. Results: The chimeric rPfMSP1/8 vaccine was shown to be well tolerated and highly immunogenic with boost-able antibody responses elicited to both PfMSP8 and PfMSP1(19) domains. Elicited antibodies were highly cross-reactive between FVO and 3D7 alleles of PfMSP1(19) and potently inhibited the in vitro growth of P. falciparum blood-stage parasites. Conclusions: Similar to previous results with inbred and outbred mice and with rabbits, the PfMSP1/8 vaccine was shown to be highly effective in eliciting P. falciparum growth inhibitory antibodies upon immunization of non-human primates. The data support the further assessment of PfMSP1/8 as a component of a multivalent vaccine for use in human subjects. As important, the data indicate that rPfMSP8 (Delta Asn/Asp) can be used as a malaria specific carrier protein to: (1) drive production of antibody responses to neutralizing B cell epitopes of heterologous vaccine candidates and (2) facilitate production of properly folded, recombinant P. falciparum subunit vaccines in high yield. C1 [Burns, James M., Jr.; Long, Carole A.] Drexel Univ, Coll Med, Ctr Mol Parasitol, Dept Microbiol & Immunol, 2900 Queen Lane, Philadelphia, PA 19129 USA. [Miura, Kazutoyo; Long, Carole A.] NIAID, Malaria Immunol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA. [Sullivan, JoAnn; Barnwell, John W.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. RP Burns, JM (reprint author), Drexel Univ, Coll Med, Ctr Mol Parasitol, Dept Microbiol & Immunol, 2900 Queen Lane, Philadelphia, PA 19129 USA. EM jburns@drexelmed.edu FU NIH-NIAID [AI035661, AI114292]; Department of Microbiology and Immunology, Drexel University College of Medicine; Intramural Program of NIH-NIAID; PATH Malaria Vaccine Initiative FX This work was supported by NIH-NIAID Grants AI035661 (JMB) and AI114292 (JMB), the Department of Microbiology and Immunology, Drexel University College of Medicine (JMB) and the Intramural Program of NIH-NIAID (CAL). The GIA Reference Center where the GIA assay was performed was supported by the PATH Malaria Vaccine Initiative. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. NR 35 TC 0 Z9 0 U1 2 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAR 15 PY 2016 VL 15 AR 159 DI 10.1186/s12936-016-1226-5 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DG3JT UT WOS:000371966200001 PM 26975721 ER PT J AU Harris, AM Hicks, LA Qaseem, A AF Harris, Aaron M. Hicks, Lauri A. Qaseem, Amir CA Amer Coll Phys Ctr Dis Control Prevention TI Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CLINICAL-PRACTICE GUIDELINE; ACUTE BACTERIAL RHINOSINUSITIS; RANDOMIZED CONTROLLED-TRIAL; ACUTE BRONCHITIS; UNITED-STATES; COMMON COLD; FUSOBACTERIUM-NECROPHORUM; AMBULATORY-CARE; SORE THROAT; PRINCIPLES AB Background: Acute respiratory tract infection (ARTI) is the most common reason for antibiotic prescription in adults. Antibiotics are often inappropriately prescribed for patients with ARTI. This article presents best practices for antibiotic use in healthy adults (those without chronic lung disease or immunocompromising conditions) presenting with ARTI. Methods: A narrative literature review of evidence about appropriate antibiotic use for ARTI in adults was conducted. The most recent clinical guidelines from professional societies were complemented by meta-analyses, systematic reviews, and randomized clinical trials. To identify evidence-based articles, the Cochrane Library, PubMed, MEDLINE, and EMBASE were searched through September 2015 using the following Medical Subject Headings terms: "acute bronchitis," "respiratory tract infection," "pharyngitis," "rhinosinusitis," and "the common cold." High-Value Care Advice 1: Clinicians should not perform testing or initiate antibiotic therapy in patients with bronchitis unless pneumonia is suspected. High-Value Care Advice 2: Clinicians should test patients with symptoms suggestive of group A streptococcal pharyngitis (for example, persistent fevers, anterior cervical adenitis, and tonsillopharyngeal exudates or other appropriate combination of symptoms) by rapid antigen detection test and/or culture for group A Streptococcus. Clinicians should treat patients with antibiotics only if they have confirmed streptococcal pharyngitis. High-Value Care Advice 3: Clinicians should reserve antibiotic treatment for acute rhinosinusitis for patients with persistent symptoms for more than 10 days, onset of severe symptoms or signs of high fever (>39 degrees C) and purulent nasal discharge or facial pain lasting for at least 3 consecutive days, or onset of worsening symptoms following a typical viral illness that lasted 5 days that was initially improving (double sickening). High-Value Care Advice 4: Clinicians should not prescribe antibiotics for patients with the common cold. C1 [Qaseem, Amir] Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA. [Harris, Aaron M.; Hicks, Lauri A.] Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop G-37, Atlanta, GA 30329 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org FU ACP; Centers for Disease Control and Prevention FX Financial support for the development of this guideline comes exclusively from the operating budgets of ACP and the Centers for Disease Control and Prevention. NR 69 TC 23 Z9 23 U1 2 U2 7 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 15 PY 2016 VL 164 IS 6 BP 425 EP + DI 10.7326/M15-1840 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA DG6PG UT WOS:000372207200016 PM 26785402 ER PT J AU Al-Emran, HM Eibach, D Krumkamp, R Ali, M Baker, S Biggs, HM Bjerregaard-Andersen, M Breiman, RF Clemens, JD Crump, JA Espinoza, LMC Deerin, J Dekker, DM Gassama Sow, A Hertz, JT Im, J Ibrango, S von Kalckreuth, V Kabore, LP Konings, F Lofberg, SV Meyer, CG Mintz, ED Montgomery, JM Olack, B Pak, GD Panzner, U Park, SE Razafindrabe, JLT Rabezanahary, H Rakotondrainiarivelo, JP Rakotozandrindrainy, R Raminosoa, TM Schutt-Gerowitt, H Sampo, E Soura, AB Tall, A Warren, M Wierzba, TF May, J Marks, F AF Al-Emran, Hassan M. Eibach, Daniel Krumkamp, Ralf Ali, Mohammad Baker, Stephen Biggs, Holly M. Bjerregaard-Andersen, Morten Breiman, Robert F. Clemens, John D. Crump, John A. Espinoza, Ligia Maria Cruz Deerin, Jessica Dekker, Denise Myriam Gassama Sow, Amy Hertz, Julian T. Im, Justin Ibrango, Samuel von Kalckreuth, Vera Kabore, Leon Parfait Konings, Frank Lofberg, Sandra Valborg Meyer, Christian G. Mintz, Eric D. Montgomery, Joel M. Olack, Beatrice Pak, Gi Deok Panzner, Ursula Park, Se Eun Razafindrabe, Jean Luco Tsiriniaina Rabezanahary, Henintsoa Rakotondrainiarivelo, Jean Philibert Rakotozandrindrainy, Raphael Raminosoa, Tiana Mirana Schuett-Gerowitt, Heidi Sampo, Emmanuel Soura, Abdramane Bassiahi Tall, Adama Warren, Michelle Wierzba, Thomas F. May, Juergen Marks, Florian TI A Multicountry Molecular Analysis of Salmonella enterica Serovar Typhi With Reduced Susceptibility to Ciprofloxacin in Sub-Saharan Africa SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE sub-Saharan Africa; ciprofloxacin; S. Typhi; susceptible ID GLOBAL BURDEN; RESISTANCE; MUTATIONS; PARATYPHI; PREVALENCE; SENEGAL; DAKAR; QEPA; QNR AB Methods.aEuro integral Febrile patients from 9 sites within 6 countries in SSA with a body temperature of a parts per thousand yen38.0A degrees C were enrolled in this study. Blood samples were obtained for bacterial culture, and Salmonella isolates were identified biochemically and confirmed by multiplex polymerase chain reaction (PCR). Antimicrobial susceptibility of all Salmonella isolates was performed by disk diffusion test, and minimum inhibitory concentrations (MICs) against ciprofloxacin were measured by Etest. All Salmonella isolates with reduced susceptibility to ciprofloxacin (MIC > 0.06 A mu g/mL) were screened for mutations in quinolone resistance-determining regions in target genes, and the presence of plasmid-mediated quinolone resistance (PMQR) genes was assessed by PCR. Results.aEuro integral A total of 8161 blood cultures were performed, and 100 (1.2%) S. Typhi, 2 (< 0.1%) Salmonella enterica serovar Paratyphi A, and 27 (0.3%) nontyphoid Salmonella (NTS) were isolated. Multidrug-resistant S. Typhi were isolated in Kenya (79% [n = 38]) and Tanzania (89% [n = 8]) only. Reduced ciprofloxacin-susceptible (22% [n = 11]) S. Typhi were isolated only in Kenya. Among those 11 isolates, all had a Glu133Gly mutation in the gyrA gene combined with either a gyrA (Ser83Phe) or gyrB mutation (Ser464Phe). One Salmonella Paratyphi A isolate with reduced susceptibility to ciprofloxacin was found in Senegal, with 1 mutation in gyrA (Ser83Phe) and a second mutation in parC (Ser57Phe). Mutations in the parE gene and PMQR genes were not detected in any isolate. Conclusions.aEuro integral Salmonella Typhi with reduced susceptibility to ciprofloxacin was not distributed homogenously throughout SSA. Its prevalence was very high in Kenya, and was not observed in other study countries. Continuous monitoring of antimicrobial susceptibility is required to follow the potential spread of antimicrobial-resistant isolates throughout SSA. C1 [Al-Emran, Hassan M.; Eibach, Daniel; Krumkamp, Ralf; Dekker, Denise Myriam; Meyer, Christian G.; May, Juergen] Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany. [Al-Emran, Hassan M.; Eibach, Daniel; Krumkamp, Ralf; Dekker, Denise Myriam; May, Juergen] German Ctr Infect Res, Hamburg, Germany. [Ali, Mohammad; Clemens, John D.; Espinoza, Ligia Maria Cruz; Deerin, Jessica; Im, Justin; von Kalckreuth, Vera; Konings, Frank; Pak, Gi Deok; Panzner, Ursula; Park, Se Eun; Schuett-Gerowitt, Heidi; Warren, Michelle; Wierzba, Thomas F.; Marks, Florian] Int Vaccine Inst, Seoul, South Korea. [Ali, Mohammad] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Baker, Stephen] Univ Oxford, Clin Res Unit, Wellcome Trust Major Overseas Programme, Hosp Trop Dis, Ho Chi Minh City, Vietnam. [Biggs, Holly M.; Crump, John A.; Hertz, Julian T.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC USA. [Biggs, Holly M.; Crump, John A.; Hertz, Julian T.] Duke Univ, Duke Global Hlth Inst, Durham, NC USA. [Bjerregaard-Andersen, Morten; Lofberg, Sandra Valborg] Bandim Hlth Project, Bissau, Guinea Bissau. [Bjerregaard-Andersen, Morten; Lofberg, Sandra Valborg] Res Ctr Vitamins & Vaccines, Copenhagen, Denmark. [Breiman, Robert F.; Montgomery, Joel M.; Olack, Beatrice] Kenya Govt Med Res Ctr, Ctr Dis Control, Nairobi, Kenya. [Breiman, Robert F.; Montgomery, Joel M.; Olack, Beatrice] Prevent Kenya Collaborat, Nairobi, Kenya. [Breiman, Robert F.] Emory Univ, Global Hlth Inst, Atlanta, GA 30322 USA. [Clemens, John D.] Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh. [Crump, John A.] Kilimanjaro Christian Med Ctr, Moshi, Tanzania. [Crump, John A.] Univ Otago, Ctr Int Hlth, Dunedin, New Zealand. [Gassama Sow, Amy; Tall, Adama] Univ Cheikh Anta Diop Dakar, Inst Pasteur Dakar, Dakar, Senegal. [Ibrango, Samuel] Minist Hlth, Ouagadougou, Burkina Faso. [Kabore, Leon Parfait] Schiphra Hosp, Ouagadougou, Burkina Faso. [Meyer, Christian G.] Univ Tubingen, Inst Trop Med, Tubingen, Germany. [Mintz, Eric D.] Nat Ctr Emerging & Zoonot Infect Dis, Ctr Dis Control & Prevent, Atlanta, GA USA. [Razafindrabe, Jean Luco Tsiriniaina; Rabezanahary, Henintsoa; Rakotondrainiarivelo, Jean Philibert; Rakotozandrindrainy, Raphael; Raminosoa, Tiana Mirana] Univ Antananarivo, Antananarivo, Madagascar. [Schuett-Gerowitt, Heidi; Sampo, Emmanuel] Univ Cologne, Inst Med Microbiol, Cologne, Germany. [Soura, Abdramane Bassiahi] Univ Ouagadougou, Ouagadougou, Burkina Faso. RP Al-Emran, HM (reprint author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany. EM al-emran@bnitm.de FU Bill & Melinda Gates Foundation [OPPGH5231, OPP1129380] FX This research was funded by the Bill & Melinda Gates Foundation (OPPGH5231). The International Vaccine Institute (IVI) acknowledges its donors, including the Republic of Korea and the Swedish International Development Cooperation Agency. This publication was made possible through a grant from the Bill & Melinda Gates Foundation (OPP1129380). NR 31 TC 0 Z9 0 U1 2 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 15 PY 2016 VL 62 SU 1 BP S42 EP S46 DI 10.1093/cid/civ788 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DF9WI UT WOS:000371712500008 PM 26933020 ER PT J AU von Kalckreuth, V Konings, F Aaby, P Adu-Sarkodie, Y Ali, M Aseffa, A Baker, S Breiman, RF Bjerregaard-Andersen, M Clemens, JD Crump, JA Espinoza, LMC Deerin, JF Gasmelseed, N Sow, AG Im, J Keddy, KH Cosmas, L May, J Meyer, CG Mintz, ED Montgomery, JM Olack, B Pak, GD Panzner, U Park, SE Rakotozandrindrainy, R Schutt-Gerowitt, H Soura, AB Warren, MR Wierzba, TF Marks, F AF von Kalckreuth, Vera Konings, Frank Aaby, Peter Adu-Sarkodie, Yaw Ali, Mohammad Aseffa, Abraham Baker, Stephen Breiman, Robert F. Bjerregaard-Andersen, Morten Clemens, John D. Crump, John A. Cruz Espinoza, Ligia Maria Deerin, Jessica Fung Gasmelseed, Nagla Sow, Amy Gassama Im, Justin Keddy, Karen H. Cosmas, Leonard May, Juergen Meyer, Christian G. Mintz, Eric D. Montgomery, Joel M. Olack, Beatrice Pak, Gi Deok Panzner, Ursula Park, Se Eun Rakotozandrindrainy, Raphael Schuett-Gerowitt, Heidi Soura, Abdramane Bassiahi Warren, Michelle R. Wierzba, Thomas F. Marks, Florian TI The Typhoid Fever Surveillance in Africa Program (TSAP): Clinical, Diagnostic, and Epidemiological Methodologies SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE typhoid fever; Africa; methodology; surveillance; invasive Salmonella disease ID SALMONELLA-TYPHI; NORTHERN TANZANIA; BONE-MARROW; ANTIMICROBIAL RESISTANCE; INVASIVE BACTERIAL; FUNGAL-INFECTIONS; SOUTH-AFRICA; CHILDREN; VACCINE; DISEASE AB Methods.aEuro integral Standardized procedures were developed and deployed across sites for study site selection, patient enrolment, laboratory procedures, quality control and quality assurance, assessment of healthcare utilization and incidence calculations. Results.aEuro integral Passive surveillance for bloodstream infections among febrile patients was initiated at thirteen sentinel sites in ten countries (Burkina Faso, Ethiopia, Ghana, Guinea-Bissau, Kenya, Madagascar, Senegal, South Africa, Sudan, and Tanzania). Each TSAP site conducted case detection using these standardized methods to isolate and identify aerobic bacteria from the bloodstream of febrile patients. Healthcare utilization surveys were conducted to adjust population denominators in incidence calculations for differing healthcare utilization patterns and improve comparability of incidence rates across sites. Conclusions.aEuro integral By providing standardized data on the incidence of typhoid fever and iNTS disease in sub-Saharan Africa, TSAP will provide vital input for targeted typhoid fever prevention programs. C1 [von Kalckreuth, Vera; Konings, Frank; Ali, Mohammad; Clemens, John D.; Cruz Espinoza, Ligia Maria; Deerin, Jessica Fung; Pak, Gi Deok; Panzner, Ursula; Park, Se Eun; Warren, Michelle R.; Wierzba, Thomas F.; Marks, Florian] Int Vaccine Inst, Seoul, South Korea. [Aaby, Peter; Bjerregaard-Andersen, Morten] Bandim Hlth Project, Bissau, Guinea Bissau. [Adu-Sarkodie, Yaw] Kwame Nkrumah Univ Sci & Technol, Kumasi Ctr Collaborat Res Trop Med, Kumasi, Ghana. [Adu-Sarkodie, Yaw] Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Kumasi, Ghana. [Ali, Mohammad] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Aseffa, Abraham] Armauer Hansen Res Inst, Addis Ababa, Ethiopia. [Baker, Stephen] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam. [Breiman, Robert F.; Cosmas, Leonard; Montgomery, Joel M.] Ctr Dis Control & Prevent, Nairobi, Kenya. [Breiman, Robert F.] Emory Univ, Global Hlth Inst, Atlanta, GA 30322 USA. [Bjerregaard-Andersen, Morten] Res Ctr Vitamins & Vaccines, Copenhagen, Denmark. [Clemens, John D.] Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh. [Crump, John A.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC USA. [Crump, John A.] Duke Univ, Med Ctr, Duke Global Hlth Inst, Durham, NC USA. [Crump, John A.] Kilimanjaro Christian Med Ctr, Moshi, Tanzania. [Crump, John A.] Univ Otago, Ctr Int Hlth, Dunedin, New Zealand. [Gasmelseed, Nagla] Univ Gezira, Wad Madani, Sudan. [Sow, Amy Gassama] Inst Pasteur Senegal, Dakar, Senegal. [Sow, Amy Gassama] Univ Cheikh Anta Diop Dakar, Dakar, Senegal. [Keddy, Karen H.] Univ Witwatersrand, Natl Inst Communicable Dis, Johannesburg, South Africa. [Keddy, Karen H.] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa. [May, Juergen] Bernhard Nocht Inst Trop Med, Dept Infect Epidemiol, Bernhard Nocht Str 74, D-20359 Hamburg, Germany. [Meyer, Christian G.] Univ Tubingen, Inst Trop Med, Tubingen, Germany. [Mintz, Eric D.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Olack, Beatrice] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Rakotozandrindrainy, Raphael] Univ Antananarivo, Madagascar, Germany. [Schuett-Gerowitt, Heidi] Univ Cologne, Inst Med Microbiol, Cologne, Germany. [Soura, Abdramane Bassiahi] Univ Ouagadougou, Inst Superieur Sci Populat, Ouagadougou, Burkina Faso. RP Marks, F (reprint author), Int Vaccine Inst, Seoul, South Korea. EM fmarks@ivi.int RI Aseffa, Abraham/J-3248-2016; Ali, Mohammad/E-2365-2017 OI Aseffa, Abraham/0000-0002-8028-1150; Ali, Mohammad/0000-0003-1410-388X FU Bill & Melinda Gates Foundation [OPPGH5231, OPP1129380]; US National Institutes of Health [R01TW009237, U01 AI062563, R24 TW007988, D43 PA-03-018, U01 AI069484, U01 AI067854, P30 AI064518]; UK Biotechnology and Biological Sciences Research Council [BB/J010367]; Wellcome Trust; Royal Society [100087/Z/12/Z] FX The publication is based on research funded by the Bill & Melinda Gates Foundation (OPPGH5231). IVI acknowledges its donors, including the Republic of Korea and the Swedish International Development Cooperation Agency. Research infrastructure at the Moshi site was supported by the US National Institutes of Health (grant numbers R01TW009237; U01 AI062563; R24 TW007988; D43 PA-03-018; U01 AI069484; U01 AI067854; P30 AI064518), and by the UK Biotechnology and Biological Sciences Research Council (grant number BB/J010367). S. B. is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (100087/Z/12/Z). This publication was made possible by a grant from the Bill & Melinda Gates Foundation (OPP1129380). NR 54 TC 6 Z9 6 U1 2 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 15 PY 2016 VL 62 SU 1 BP S9 EP S16 DI 10.1093/cid/civ693 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DF9WI UT WOS:000371712500003 PM 26933028 ER PT J AU Chilengi, R Simuyandi, M Beach, L Mwila, K Becker-Dreps, S Emperador, DM Velasquez, DE Bosomprah, S Jiang, BM AF Chilengi, Roma Simuyandi, Michelo Beach, Lauren Mwila, Katayi Becker-Dreps, Sylvia Emperador, Devy M. Velasquez, Daniel E. Bosomprah, Samuel Jiang, Baoming TI Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants SO PLOS ONE LA English DT Article ID 1ST 2 YEARS; CHILDHOOD DIARRHEA; AFRICAN INFANTS; INDIAN INFANTS; SERUM ANTIBODY; DOUBLE-BLIND; BREAST-MILK; LIVE; CHILDREN; EFFICACY AB Introduction Live attenuated oral vaccines against rotavirus (RV) have been shown to be less efficacious in children from developing countries. Reasons for this disparity are not fully understood. We assessed the role of maternal factors including breast milk RV-specific IgA, transplacentally acquired infant serum RV-specific IgG and maternal HIV status in seroconversion among Zambian infants routinely immunized with Rotarix (TM) (RV1). Methods 420 mother-child pairs were recruited at infant age 6-12 weeks in Lusaka. Clinical information and samples were collected at baseline and at one month following the second dose of RV1. Determination of breast milk RV-specific IgA and serum RV-specific IgA and IgG was done using standardized ELISA. Seroconversion was defined as a >= 4 fold rise in serum IgA titre from baseline to one-month post RV1 dose 2, while seropositivity of IgA was defined as serum titre >= 40 and antibody variables were modelled on log-base 2. Logistic regression was used to identify predictors of the odds of seroconversion. Results Baseline infant seropositivity was 25.5%(91/357). The seroconversion frequency was 60.2% (130/216). Infants who were IgA seropositive at baseline were less likely to seroconvert compared to their seronegative counterparts (P = 0.04). There was no evidence of an association between maternal HIV status and seroconversion (P = 0.25). Higher titres of breast milk rotavirus-specific IgA were associated with a lower frequency of seroconverson (Nonparametric test for trend Z = -2.84; P<0.01): a two-fold increase in breast milk RV-specific IgA titres was associated with a 22% lower odds of seroconversion (OR = 0.80; 95% CI = 0.68-0.94; P = 0.01). There was seasonal variation in baseline breast milk rotavirus-specific IgA titres, with significantly higher GMTs during the cold dry months (P = 0.01). Conclusion Low immunogenicity of RV1 vaccine could be explained in part by exposure to high antibody titres in breast milk and early exposure to wild-type rotavirus infections. Potential interference of anti-RV specific IgA in breast milk and pre-vaccination serum RV specific-IgA and IgG titres with RV1 seroconversion and effectiveness requires further research. C1 [Chilengi, Roma; Simuyandi, Michelo; Beach, Lauren; Mwila, Katayi; Bosomprah, Samuel] Ctr Infect Dis Res Zambia, Lusaka, Zambia. [Chilengi, Roma; Becker-Dreps, Sylvia] Univ N Carolina, Chapel Hill, NC USA. [Emperador, Devy M.; Velasquez, Daniel E.; Jiang, Baoming] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Chilengi, R (reprint author), Ctr Infect Dis Res Zambia, Lusaka, Zambia.; Chilengi, R (reprint author), Univ N Carolina, Chapel Hill, NC USA. EM Roma.Chilengi@cidrz.org OI Simuyandi, Michelo/0000-0002-7348-2835 FU National Institutes for Health (NIH), USA [1R01AI099601]; NIH [1R56A1108515-01] FX This study is funded by the National Institutes for Health (NIH), USA, through an R01 grant 1R01AI099601. Co-author SD was supported by 1R56A1108515-01 from the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 2 Z9 2 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 14 PY 2016 VL 11 IS 3 AR e0150100 DI 10.1371/journal.pone.0150100 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH1UO UT WOS:000372570600018 PM 26974432 ER PT J AU Cooper, HLF Linton, S Kelley, ME Ross, Z Wolfe, ME Chen, YT Zlotorzynska, M Hunter-Jones, J Friedman, SR Jarlais, DCD Tempalski, B DiNenno, E Broz, D Wejnert, C Paz-Bailey, G AF Cooper, Hannah L. F. Linton, Sabriya Kelley, Mary E. Ross, Zev Wolfe, Mary E. Chen, Yen-Tyng Zlotorzynska, Maria Hunter-Jones, Josalin Friedman, Samuel R. Jarlais, Don C. Des Tempalski, Barbara DiNenno, Elizabeth Broz, Dita Wejnert, Cyprian Paz-Bailey, Gabriela CA National HIV Behav Surveillance TI Risk Environments, Race/Ethnicity, and HIV Status in a Large Sample of People Who Inject Drugs in the United States SO PLOS ONE LA English DT Article ID US METROPOLITAN-AREAS; BEHAVIORAL SURVEILLANCE SYSTEM; SYRINGE EXCHANGE PROGRAMS; OLDER MEXICAN-AMERICANS; ALCOHOL OUTLET DENSITY; LOS-ANGELES-COUNTY; NEW-YORK-CITY; NEIGHBORHOOD POVERTY; DEPRESSIVE SYMPTOMS; RACIAL DISPARITIES AB Introduction We analyzed relationships between place characteristics and being HIV-negative among black, Latino, and white people who inject drugs (PWID) in the US. Methods Data on PWID (N = 9077) were from the Centers for Disease Control and Prevention's 2009 National HIV Behavioral Surveillance. Administrative data were analyzed to describe the 968 ZIP codes, 51 counties, and 19 metropolitan statistical areas (MSAs) where they lived. Multilevel multivariable models examined relationships between place characteristics and HIV status. Exploratory population attributable risk percents (e-PAR %s) were estimated. Results Black and Latino PWID were more likely to be HIV-negative if they lived in less economically disadvantaged counties, or in MSAs with less criminal-justice activity (i.e., lower drug-related arrest rates, lower policing/corrections expenditures). Latino PWID were more likely to be HIV-negative in MSAs with more Latino isolation, less black isolation, and less violent crime. E-PAR%s attributed 8-19% of HIV cases among black PWID and 1-15% of cases among Latino PWID to place characteristics. Discussion Evaluations of structural interventions to improve economic conditions and reduce drug-related criminal justice activity may show evidence that they protect black and Latino PWID from HIV infection. C1 [Cooper, Hannah L. F.; Linton, Sabriya; Kelley, Mary E.; Wolfe, Mary E.; Chen, Yen-Tyng; Zlotorzynska, Maria; Hunter-Jones, Josalin] Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. [Ross, Zev] ZevRoss SpatialAnal, 120 N Aurora St,Suite 3A, Ithaca, NY 14850 USA. [Friedman, Samuel R.; Tempalski, Barbara] Natl Dev & Res Inst, Inst Infect Dis Res, 71 West 23rd St,4th Fl, New York, NY 10010 USA. [Jarlais, Don C. Des] Mt Sinai Beth Israel, Baron Edmond de Rothschild Chem Dependency Inst, 39 Broadway,5th Floor, New York, NY 10006 USA. [DiNenno, Elizabeth; Broz, Dita; Wejnert, Cyprian; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS-E46, Atlanta, GA 30333 USA. RP Cooper, HLF (reprint author), Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM hcoope3@emory.edu FU NIH; National Institute on Drug Abuse [DA035101]; National Institutes of Health [P30 AI050409]; ZevRoss SpatialAnalysis; Centers and Disease Control and Prevention; National HIV Behavioral Surveillance Study Group: Atlanta, GA FX This research was supported by two NIH grants. One from the National Institute on Drug Abuse (http://www.drugabuse.gov/) entitled "Place Characteristics & Disparities in HIV in IDUS: A Multilevel Analysis of NHBS" (DA035101; Cooper, PI), and another from the National Institutes of Health (http://www.nih.gov/) funding the Emory Center for AIDS Research (P30 AI050409; Curran, PI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. ZevRoss SpatialAnalysis provided support in the form of salaries for author ZR but did not have any additional role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.; This research was supported by the Centers and Disease Control and Prevention, and the National HIV Behavioral Surveillance Study Group: Atlanta, GA: Jennifer Taussig, Shacara Johnson, Jeff Todd; Baltimore, MD: Colin Flynn, Danielle German; Boston, MA: Debbie Isenberg, Maura Driscoll, Elizabeth Hurwitz; Chicago, IL: Nikhil Prachand, Nanette Benbow; Dallas, TX: Sharon Melville, Richard Yeager, Jim Dyer, Alicia Novoa; Denver, CO: Mark Thrun, Alia Al-Tayyib; Detroit, MI: Emily Higgins, Eve Mokotoff, Vivian Griffin; Houston, TX: Aaron Sayegh, Jan Risser, Hafeez Rehman; Los Angeles, CA: Trista Bingham, Ekow Kwa Sey; Miami, FL: Lisa Metsch, David Forrest, Dano Beck, Gabriel Cardenas; Nassau-Suffolk, NY: Chris Nemeth, Lou Smith, Carol-Ann Watson; New Orleans, LA: William T. Robinson, DeAnn Gruber, Narquis Barak; New York City, NY: Alan Neaigus, Samuel Jenness, Travis Wendel, Camila Gelpi-Acosta, Holly Hagan; Newark, NJ: Henry Godette, Barbara Bolden, Sally D'Errico; Philadelphia, PA: Kathleen A. Brady, Althea Kirkland, Mark Shpaner; San Diego, CA: Vanessa Miguelino-Keasling, Al Velasco; San Francisco, CA: H. Fisher Raymond; San Juan, PR: Sandra Miranda De Leo'n, Yadira Rolo'n-Colo'n; Seattle, WA: Maria Courogen, Hanne Thiede, Richard Burt; St Louis, MO: Michael Herbert, Yelena Friedberg, Dale Wrigley, Jacob Fisher; Washington, DC: Marie Sansone, Tiffany West-Ojo, Manya Magnus, Irene Kuo; Behavioral Surveillance Team. We would like to thank the NHBS participants for making this study possible. We also thank and acknowledge Mr. Scott Burris and Ms. Mona Bennett for their help documenting laws governing syringe access. NR 85 TC 1 Z9 1 U1 5 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 14 PY 2016 VL 11 IS 3 AR e0150410 DI 10.1371/journal.pone.0150410 PG 21 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH1UO UT WOS:000372570600024 PM 26974165 ER PT J AU Fowlkes, AL Witte, D Beeler, J Audet, SA Broadhead, R Bellini, WJ Cutts, F Helfand, RF AF Fowlkes, Ashley L. Witte, Desiree Beeler, Judy Audet, Susette A. Broadhead, Robin Bellini, William J. Cutts, Felicity Helfand, Rita F. TI Supplemental measles vaccine antibody response among HIV-infected and -uninfected children in Malawi after 1-and 2-dose primary measles vaccination schedules SO VACCINE LA English DT Article DE Measles vaccine; HIV; Supplementary immunization activity; Antibody response; Neutralizing antibody ID EDMONSTON-ZAGREB; AGE; IMMUNOGENICITY; INFANTS; TRIAL AB Background: The long-term antibody response to measles vaccine (MV) administered at age 6 months with or without subsequent doses is not well documented. Methods: Measles serum antibody responses were evaluated after a supplemental dose of measles vaccine (sMV) administered at a median age of 20 months among Malawian children who had previously received 2 doses of measles vaccine (MV) at ages 6 and 9 months (HIV-infected and random sample of HIV-uninfected) or 1 dose at age 9 months (random sample of HIV-uninfected). We compared measles antibody seropositivity between groups by enzyme linked immunoassay and seroprotection by plaque reduction neutralization geometric mean concentrations. Results: Of 1756 children enrolled, 887 (50.5%) received a sMV dose following MV at 9 months of age and had specimens available after sMV receipt, including 401 HIV-uninfected children who received one MV dose at 9 months, 464 HIV-uninfected and 22 HIV-infected children who received two doses of MV at ages 6 and 9 months. Among HIV-uninfected children, protective levels of antibody were found post sMV in 90-99% through ages 24-36 months and were not affected by MV schedule. Geometric mean concentration levels of measles antibody were significantly increased post-sMV among those HIV-uninfected children previously non-responsive to vaccination. Among HIV-infected children, the proportion seroprotected increased initially but by 9 months post-sMV was no higher than pre-sMV. Conclusions: Our findings support early 2-dose MV to provide measles immunity for young infants without risk of interference with antibody responses to subsequent MV doses administered as part of SIAs. Published by Elsevier Ltd. C1 [Fowlkes, Ashley L.; Bellini, William J.; Helfand, Rita F.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Witte, Desiree; Broadhead, Robin] Univ Malawi, Coll Med, Blantyre, Malawi. [Beeler, Judy; Audet, Susette A.] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA. [Cutts, Felicity] London Sch Hyg & Trop Med, London WC1, England. RP Fowlkes, AL (reprint author), MPH, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30329 USA. EM afowlkes@cdc.gov FU World Health Organization [V21/181/130]; Centers for Disease Control and Prevention; Berna Biotech FX World Health Organization (grant V21/181/130 to R.B.); Centers for Disease Control and Prevention; Berna Biotech (formerly Swiss Serum and Vaccine Institute; donation of measles vaccine). NR 17 TC 0 Z9 0 U1 6 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 14 PY 2016 VL 34 IS 12 BP 1459 EP 1464 DI 10.1016/j.vaccine.2016.01.055 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA DG9EG UT WOS:000372385000007 PM 26873052 ER PT J AU Bowyer, JF Sarkar, S Tranter, KM Hanig, JP Miller, DB O'Callaghan, JP AF Bowyer, John F. Sarkar, Sumit Tranter, Karen M. Hanig, Joseph P. Miller, Diane B. O'Callaghan, James P. TI Vascular-directed responses of microglia produced by methamphetamine exposure: indirect evidence that microglia are involved in vascular repair? SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Microglia; Vascular damage; Methamphetamine; Amphetamine; Neurotoxicity; Hyperthermia; Hypertension ID CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; NEURONAL DEGENERATION; INDUCED NEUROTOXICITY; IMMUNE-SYSTEM; ADULT BRAIN; RAT-BRAIN; AMPHETAMINE; ACTIVATION; HYPERTHERMIA AB Background: Brain microglial activations and damage responses are most commonly associated with neurodegeneration or systemic innate immune system activation. Here, we used histological methods to focus on microglial responses that are directed towards brain vasculature, previously undescribed, after a neurotoxic exposure to methamphetamine. Methods: Male rats were given doses of methamphetamine that produce pronounced hyperthermia, hypertension, and toxicity. Identification of microglia and microglia-like cells (pericytes and possibly perivascular cells) was done using immunoreactivity to allograft inflammatory factor 1 (Aif1 a.k.a Iba1) and alpha M integrin (Itgam a.k.a. Cd11b) while vasculature endothelium was identified using rat endothelial cell antigen 1 (RECA-1). Regions of neuronal, axonal, and nerve terminal degeneration were determined using Fluoro-Jade C. Results: Dual labeling of vasculature (RECA-1) and microglia (Iba1) showed a strong association of hypertrophied cells surrounding and juxtaposed to vasculature in the septum, medial dorsal hippocampus, piriform cortex, and thalamus. The Iba1 labeling was more pronounced in the cell body while Cd11b more so in the processes of activated microglia. These regions have been previously identified to have vascular leakage after neurotoxic methamphetamine exposure. Dual labeling with Fluoro-Jade C and Iba1 indicated that there was minimal or no evidence of neuronal damage in the septum and hippocampus where many hypertrophied Iba1-labeled cells were found to be associated with vasculature. Although microglial activation around the prominent neurodegeneration was found in the thalamus, there were also many examples of activated microglia associated with vasculature. Conclusions: The data implicate microglia, and possibly related cell types, in playing a major role in responding to methamphetamine-induced vascular damage, and possibly repair, in the absence of neurodegeneration. Identifying brain regions with hypertrophied/activated microglial-like cells associated with vasculature has the potential for identifying regions of more subtle examples of vascular damage and BBB compromise. C1 [Bowyer, John F.; Sarkar, Sumit; Tranter, Karen M.] US FDA, Div Neurotoxicol, Natl Ctr Toxicol, Jefferson, AR 72079 USA. [Hanig, Joseph P.] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA. [Miller, Diane B.; O'Callaghan, James P.] NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Bowyer, John F.] US FDA, Natl Ctr Toxicol Res, 3900 NCTR Rd,HFT-132, Jefferson, AR 72079 USA. RP Bowyer, JF (reprint author), US FDA, Div Neurotoxicol, Natl Ctr Toxicol, Jefferson, AR 72079 USA.; Bowyer, JF (reprint author), US FDA, Natl Ctr Toxicol Res, 3900 NCTR Rd,HFT-132, Jefferson, AR 72079 USA. EM John.Bowyer@fda.hhs.gov FU FDA [E7519] FX This study was supported by FDA protocol E7519. NR 54 TC 1 Z9 1 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD MAR 12 PY 2016 VL 13 AR 64 DI 10.1186/s12974-016-0526-6 PG 15 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA DG0VJ UT WOS:000371783500001 PM 26970737 ER PT J AU Unger, ER Lin, JMS Tian, H Gurbaxani, BM Boneva, RS Jones, JF AF Unger, E. R. Lin, J. -M. S. Tian, H. Gurbaxani, B. M. Boneva, R. S. Jones, J. F. TI Methods of applying the 1994 case definition of chronic fatigue syndrome - impact on classification and observed illness characteristics SO POPULATION HEALTH METRICS LA English DT Article DE Chronic fatigue syndrome; Case definition; Surveillance methods ID ENCEPHALOMYELITIS CFS/ME; EPIDEMIOLOGY; DISEASE; SF-36 AB Background: Multiple case definitions are in use to identify chronic fatigue syndrome (CFS). Even when using the same definition, methods used to apply definitional criteria may affect results. The Centers for Disease Control and Prevention (CDC) conducted two population-based studies estimating CFS prevalence using the 1994 case definition; one relied on direct questions for criteria of fatigue, functional impairment and symptoms (1997 Wichita; Method 1), and the other used subscale score thresholds of standardized questionnaires for criteria (2004 Georgia; Method 2). Compared to previous reports the 2004 CFS prevalence estimate was higher, raising questions about whether changes in the method of operationalizing affected this and illness characteristics. Methods: The follow-up of the Georgia cohort allowed direct comparison of both methods of applying the 1994 case definition. Of 1961 participants (53 % of eligible) who completed the detailed telephone interview, 919 (47 %) were eligible for and 751 (81 %) underwent clinical evaluation including medical/psychiatric evaluations. Data from the 499 individuals with complete data and without exclusionary conditions was available for this analysis. Results: A total of 86 participants were classified as CFS by one or both methods; 44 cases identified by both methods, 15 only identified by Method 1, and 27 only identified by Method 2 (Kappa 0.63; 95 % confidence interval [CI]: 0.53, 0.73 and concordance 91.59 %). The CFS group identified by both methods were more fatigued, had worse functioning, and more symptoms than those identified by only one method. Moderate to severe depression was noted in only one individual who was classified as CFS by both methods. When comparing the CFS groups identified by only one method, those only identified by Method 2 were either similar to or more severely affected in fatigue, function, and symptoms than those only identified by Method 1. Conclusions: The two methods demonstrated substantial concordance. While Method 2 classified more participants as CFS, there was no indication that they were less severely ill or more depressed. The classification differences do not fully explain the prevalence increase noted in the 2004 Georgia study. Use of standardized instruments for the major CFS domains provides advantages for disease stratification and comparing CFS patients to other illnesses. C1 [Unger, E. R.; Lin, J. -M. S.; Tian, H.; Gurbaxani, B. M.; Boneva, R. S.; Jones, J. F.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect, 1600 Clifton Rd,MS G41, Atlanta, GA 30329 USA. RP Unger, ER (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect, 1600 Clifton Rd,MS G41, Atlanta, GA 30329 USA. EM eru0@cdc.gov NR 31 TC 0 Z9 0 U1 2 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-7954 J9 POPUL HEALTH METR JI Popul. Health Metr. PD MAR 12 PY 2016 VL 14 AR 5 DI 10.1186/s12963-016-0077-1 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG0PM UT WOS:000371767500001 PM 26973437 ER PT J AU Lucchi, NW Ljolje, D Silva-Flannery, L Udhayakumar, V AF Lucchi, Naomi W. Ljolje, Dragan Silva-Flannery, Luciana Udhayakumar, Venkatachalam TI Use of Malachite Green-Loop Mediated Isothermal Amplification for Detection of Plasmodium spp. Parasites SO PLOS ONE LA English DT Article ID MALARIA ELIMINATION; FALCIPARUM-MALARIA; DIAGNOSIS; LAMP; ZANZIBAR; ASSAY AB Malaria elimination efforts are hampered by the lack of sensitive tools to detect infections with low-level parasitemia, usually below the threshold of standard diagnostic methods, microscopy and rapid diagnostic tests. Isothermal nucleic acid amplification assays such as the loop-mediated isothermal amplification (LAMP), are well suited for field use as they do not require thermal cyclers to run the test. However, the use of specialized equipment, as described by many groups, reduces the versatility of the LAMP technique as a simple tool for use in endemic countries. In this study, the use of the malachite green (MG) dye, as a visual endpoint readout, together with a simple mini heat block was evaluated for the detection of malaria parasites. The assay was performed for 1 hour at 63 degrees C and the results scored by 3 independent human readers. The limit of detection of the assay was determined using well-quantified Plasmodium spp. infected reference samples and its utility in testing clinical samples was determined using 190 pre-treatment specimens submitted for reference diagnosis of imported malaria in the United States. Use of a simplified boil and spin methods of DNA extraction from whole blood and filter paper was also investigated. We demonstrate the accurate and sensitive detection of malaria parasites using this assay with a detection limit ranging between 1-8 parasites/mu L, supporting its applicability for the detection of infections with low parasite burden. This assay is compatible with the use of a simple boil and spin sample preparation method from both whole blood and filter papers without a loss of sensitivity. The MG-LAMP assay described here has great potential to extend the reach of molecular tools to settings where they are needed. C1 [Lucchi, Naomi W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Ctr Global Hlth, Atlanta, GA USA. [Ljolje, Dragan; Silva-Flannery, Luciana] Atlanta Res & Educ Fdn, Vet Affairs Med Ctr, Decatur, GA USA. RP Lucchi, NW (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Ctr Global Hlth, Atlanta, GA USA. EM NLucchi@cdc.gov FU Malaria Branch at the Centers for Disease Control and Prevention; Atlanta Research and Education Foundation FX This report was made possible through support provided by the Malaria Branch at the Centers for Disease Control and Prevention and the Atlanta Research and Education Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This report was made possible through support provided by the Malaria Branch at the Centers for Disease Control and Prevention and the Atlanta Research and Education Foundation. We would like to thank Dr. John Barnwell for providing the quantified Plasmodium samples for the study and technical support of the project. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 22 TC 2 Z9 2 U1 4 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 11 PY 2016 VL 11 IS 3 AR e0151437 DI 10.1371/journal.pone.0151437 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DG3SC UT WOS:000371989200054 PM 26967908 ER PT J AU Bitsko, RH Holbrook, JR Robinson, LR Kaminski, JW Ghandour, R Smith, C Peacock, G AF Bitsko, Rebecca H. Holbrook, Joseph R. Robinson, Lara R. Kaminski, Jennifer W. Ghandour, Reem Smith, Camille Peacock, Georgina TI Health Care, Family, and Community Factors Associated with Mental, Behavioral, and Developmental Disorders in Early Childhood - United States, 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PUBLIC-HEALTH C1 [Bitsko, Rebecca H.; Holbrook, Joseph R.; Robinson, Lara R.; Kaminski, Jennifer W.; Peacock, Georgina] CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Ghandour, Reem] US Hlth Resources & Serv Adm, Off Epidemiol & Res, Maternal & Child Hlth Bur, Rockville, MD 20857 USA. [Smith, Camille] CDC, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Bitsko, RH (reprint author), CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM dvk2@cdc.gov NR 10 TC 0 Z9 0 U1 2 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 11 PY 2016 VL 65 IS 9 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF9QR UT WOS:000371696600001 ER PT J AU Gavin, L Pazol, K AF Gavin, Loretta Pazol, Karen TI Update: Providing Quality Family Planning Services - Recommendations from CDC and the US Office of Population Affairs, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ADVISORY-COMMITTEE; UNITED-STATES C1 [Gavin, Loretta] US Dept Hlth & Human Serv, Off Populat Affairs, Rockville, MD USA. [Pazol, Karen] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. RP Gavin, L (reprint author), US Dept Hlth & Human Serv, Off Populat Affairs, Rockville, MD USA. EM lorrie.gavin@hhs.gov NR 19 TC 0 Z9 0 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 11 PY 2016 VL 65 IS 9 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF9QR UT WOS:000371696600003 ER PT J AU Lee, CT Bulterys, M Martel, LD Dahl, BA AF Lee, Christopher T. Bulterys, Marc Martel, Lise D. Dahl, Benjamin A. TI Evaluation of a National Call Center and a Local Alerts System for Detection of New Cases of Ebola Virus Disease - Guinea, 2014-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Lee, Christopher T.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Lee, Christopher T.; Bulterys, Marc; Martel, Lise D.; Dahl, Benjamin A.] CDC Ebola Response Team, Conakry, Guinea. [Lee, Christopher T.] New York City Dept Hlth & Mental Hygiene, Div Epidemiol, New York, NY USA. [Bulterys, Marc] Naval Hlth Res Ctr, San Diego, CA USA. [Bulterys, Marc; Dahl, Benjamin A.] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. [Martel, Lise D.] CDC Guinea Off, Conakry, Guinea. RP Lee, CT (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM klq5@cdc.gov NR 8 TC 0 Z9 0 U1 5 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 11 PY 2016 VL 65 IS 9 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF9QR UT WOS:000371696600002 ER PT J AU Talley, P Holzbauer, S Smith, K Pomputius, W AF Talley, Pamela Holzbauer, Stacy Smith, Kirk Pomputius, William TI Lymphocytic Choriomeningitis Virus Meningoencephalitis from a Household Rodent Infestation - Minnesota, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Talley, Pamela] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Talley, Pamela; Holzbauer, Stacy; Smith, Kirk] Minnesota Dept Hlth, St Paul, MN USA. [Holzbauer, Stacy] CDC, Career Epidemiol Field Officer Program, Atlanta, GA 30333 USA. [Pomputius, William] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA. RP Talley, P (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Talley, P (reprint author), Minnesota Dept Hlth, St Paul, MN USA. EM ptalley@cdc.gov NR 9 TC 0 Z9 0 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 11 PY 2016 VL 65 IS 9 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF9QR UT WOS:000371696600006 ER PT J AU Weiner, LM Fridkin, SK Aponte-Torres, Z Avery, L Coffin, N Dudeck, MA Edwards, JR Jernigan, JA Konnor, R Soe, MM Peterson, K McDonald, LC AF Weiner, Lindsey M. Fridkin, Scott K. Aponte-Torres, Zuleika Avery, Lacey Coffin, Nicole Dudeck, Margaret A. Edwards, Jonathan R. Jernigan, John A. Konnor, Rebecca Soe, Minn M. Peterson, Kelly McDonald, L. Clifford TI Vital Signs: Preventing Antibiotic-Resistant Infections in Hospitals - United States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CLOSTRIDIUM-DIFFICILE INFECTION; ACUTE-CARE HOSPITALS; RISK-FACTORS; PREVALENCE; ENTEROBACTERIACEAE; EPIDEMIOLOGY; PNEUMONIAE AB Background: Health care-associated antibiotic-resistant (AR) infections increase patient morbidity and mortality and might be impossible to successfully treat with any antibiotic. CDC assessed health care-associated infections (HAI), including Clostridium difficile infections (CDI), and the role of six AR bacteria of highest concern nationwide in several types of health care facilities. Methods: During 2014, approximately 4,000 short-term acute care hospitals, 501 long-term acute care hospitals, and 1,135 inpatient rehabilitation facilities in all 50 states reported data on specific infections to the National Healthcare Safety Network. National standardized infection ratios and their percentage reduction from a baseline year for each HAI type, by facility type, were calculated. The proportions of AR pathogens and HAIs caused by any of six resistant bacteria highlighted by CDC in 2013 as urgent or serious threats were determined. Results: In 2014, the reductions in incidence in short-term acute care hospitals and long-term acute care hospitals were 50% and 9%, respectively, for central line-associated bloodstream infection; 0% (short-term acute care hospitals), 11% (long-term acute care hospitals), and 14% (inpatient rehabilitation facilities) for catheter-associated urinary tract infection; 17% (short-term acute care hospitals) for surgical site infection, and 8% (short-term acute care hospitals) for CDI. Combining HAIs other than CDI across all settings, 47.9% of Staphylococcus aureus isolates were methicillin resistant, 29.5% of enterococci were vancomycin-resistant, 17.8% of Enterobacteriaceae were extended-spectrum beta-lactamase phenotype, 3.6% of Enterobacteriaceae were carbapenem resistant, 15.9% of Pseudomonas aeruginosa isolates were multidrug resistant, and 52.6% of Acinetobacter species were multidrug resistant. The likelihood of HAIs caused by any of the six resistant bacteria ranged from 12% in inpatient rehabilitation facilities to 29% in long-term acute care hospitals. Conclusions: Although there has been considerable progress in preventing some HAIs, many remaining infections could be prevented with implementation of existing recommended practices. Depending upon the setting, more than one in four of HAIs excluding CDI are caused by AR bacteria. Implications for Public Health Practice: Physicians, nurses, and health care leaders need to consistently and comprehensively follow all recommendations to prevent catheter-and procedure-related infections and reduce the impact of AR bacteria through antimicrobial stewardship and measures to prevent spread. C1 [Weiner, Lindsey M.; Fridkin, Scott K.; Aponte-Torres, Zuleika; Avery, Lacey; Coffin, Nicole; Dudeck, Margaret A.; Edwards, Jonathan R.; Jernigan, John A.; Konnor, Rebecca; Soe, Minn M.; Peterson, Kelly; McDonald, L. Clifford] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP McDonald, LC (reprint author), CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. EM ljm3@cdc.gov NR 29 TC 0 Z9 0 U1 4 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 11 PY 2016 VL 65 IS 9 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF9QR UT WOS:000371696600004 ER PT J AU Mockenhaupt, FP Barbre, KA Jensenius, M Larsen, CS Barnett, ED Stauffer, W Rothe, C Asgeirsson, H Hamer, DH Esposito, DH Gautret, P Schlagenhauf, P AF Mockenhaupt, F. P. Barbre, K. A. Jensenius, M. Larsen, C. S. Barnett, E. D. Stauffer, W. Rothe, C. Asgeirsson, H. Hamer, D. H. Esposito, D. H. Gautret, P. Schlagenhauf, P. TI Profile of illness in Syrian refugees: A GeoSentinel analysis, 2013 to 2015 SO EUROSURVEILLANCE LA English DT Article ID CUTANEOUS LEISHMANIASIS; DISEASE; TURKEY; SURVEILLANCE; GERMANY; WAR AB Screening of 488 Syrian unaccompanied minor refugees (< 18 years-old) in Berlin showed low prevalence of intestinal parasites (Giardia, 7%), positive schistosomiasis serology (1.4%) and absence of hepatitis B. Among 44 ill adult Syrian refugees examined at GeoSentinel clinics worldwide, cutaneous leishmaniasis affected one in three patients; other noteworthy infections were active tuberculosis (11%) and chronic hepatitis B or C (9%). These data can contribute to evidence-based guidelines for infectious disease screening of Syrian refugees. C1 [Mockenhaupt, F. P.] Charite, Inst Trop Med & Int Hlth, D-13353 Berlin, Germany. [Barbre, K. A.; Esposito, D. H.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Atlanta, GA USA. [Jensenius, M.] Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway. [Larsen, C. S.] Aarhus Univ Hosp, Dept Infect Dis, DK-8000 Aarhus, Denmark. [Barnett, E. D.] Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA USA. [Stauffer, W.] Univ Minnesota, Sch Med, Div Infect Dis & Int Med, St Paul, MN 55108 USA. [Rothe, C.] Univ Med Ctr Hamburg Eppendorf, Bernhard Nocht Clin, Dept Trop Med & Infect Dis, Hamburg, Germany. [Asgeirsson, H.] Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden. [Hamer, D. H.] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02215 USA. [Hamer, D. H.] Boston Univ, Sch Publ Hlth, Ctr Global Hlth & Dev, Boston, MA 02215 USA. [Hamer, D. H.] Boston Med Ctr, Dept Med, Infect Dis Sect, Boston, MA USA. [Gautret, P.] Aix Marseille Univ, Univ Hosp Inst Infect & Trop Dis, Marseille, France. [Schlagenhauf, P.] Univ Zurich, Ctr Travel Med, WHO Collaborating Ctr Travellers Hlth, Epidemiol Biostat & Prevent Inst, Zurich, Switzerland. RP Mockenhaupt, FP (reprint author), Charite, Inst Trop Med & Int Hlth, D-13353 Berlin, Germany. EM frank.mockenhaupt@charite.de NR 19 TC 8 Z9 8 U1 5 U2 20 PU EUR CENTRE DIS PREVENTION & CONTROL PI STOCKHOLM PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN SN 1560-7917 J9 EUROSURVEILLANCE JI Eurosurveillance PD MAR 10 PY 2016 VL 21 IS 10 BP 7 EP 11 AR 30160 DI 10.2807/1560-7917.ES.2016.21.10.30160 PG 5 WC Infectious Diseases SC Infectious Diseases GA DG6LL UT WOS:000372195800002 PM 26987893 ER PT J AU Vynnycky, E Adams, EJ Cutts, FT Reef, SE Navar, AM Simons, E Yoshida, LM Brown, DWJ Jackson, C Strebel, PM Dabbagh, AJ AF Vynnycky, Emilia Adams, Elisabeth J. Cutts, Felicity T. Reef, Susan E. Navar, Ann Marie Simons, Emily Yoshida, Lay-Myint Brown, David W. J. Jackson, Charlotte Strebel, Peter M. Dabbagh, Alya J. TI Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review SO PLOS ONE LA English DT Article ID PREGNANT-WOMEN; DEVELOPING-COUNTRIES; VACCINATION; INFECTION; ELIMINATION; IMPACT; URBAN; AGE AB Background The burden of Congenital Rubella Syndrome (CRS) is typically underestimated in routine surveillance. Updated estimates are needed following the recent WHO position paper on rubella and recent GAVI initiatives, funding rubella vaccination in eligible countries. Previous estimates considered the year 1996 and only 78 (developing) countries. Methods We reviewed the literature to identify rubella seroprevalence studies conducted before countries introduced rubella-containing vaccination (RCV). These data and the estimated vaccination coverage in the routine schedule and mass campaigns were incorporated in mathematical models to estimate the CRS incidence in 1996 and 2000-2010 for each country, region and globally. Results The estimated CRS decreased in the three regions (Americas, Europe and Eastern Mediterranean) which had introduced widespread RCV by 2010, reaching <2 per 100,000 live births (the Americas and Europe) and 25 (95% CI 4-61) per 100,000 live births (the Eastern Mediterranean). The estimated incidence in 2010 ranged from 90 (95% CI: 46-195) in the Western Pacific, excluding China, to 116 (95% CI: 56-235) and 121 (95% CI: 31-238) per 100,000 live births in Africa and SE Asia respectively. Highest numbers of cases were predicted in Africa (39,000, 95% CI: 18,000-80,000) and SE Asia (49,000, 95% CI: 11,00097,000). In 2010, 105,000 (95% CI: 54,000-158,000) CRS cases were estimated globally, compared to 119,000 (95% CI: 72,000-169,000) in 1996. Conclusions Whilst falling dramatically in the Americas, Europe and the Eastern Mediterranean after vaccination, the estimated CRS incidence remains high elsewhere. Well-conducted seroprevalence studies can help to improve the reliability of these estimates and monitor the impact of rubella vaccination. C1 [Vynnycky, Emilia; Adams, Elisabeth J.; Brown, David W. J.] Publ Hlth England, 61 Colindale Ave, London NW9 5EQ, England. [Adams, Elisabeth J.] Aquarius Populat Hlth, London, England. [Adams, Elisabeth J.] Univ Bristol, Sch Social & Community Med, Canynge Hall,39 Whatley Rd, Bristol BS8 2PS, Avon, England. [Navar, Ann Marie] Duke Univ, Med Ctr, Durham, NC USA. [Navar, Ann Marie] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Vynnycky, Emilia; Cutts, Felicity T.; Jackson, Charlotte] London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England. [Simons, Emily; Strebel, Peter M.; Dabbagh, Alya J.] WHO, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. [Reef, Susan E.] Ctr Dis Control & Prevent, 1600 Clifton RD NE, Atlanta, GA 30333 USA. [Yoshida, Lay-Myint] Nagasaki Univ, Inst Trop Med, Nagasaki 852, Japan. [Jackson, Charlotte] UCL, London, England. [Brown, David W. J.] Fiocruz MS, IOC, Influenza & Measles Lab, BR-21045900 Rio De Janeiro, Brazil. RP Vynnycky, E (reprint author), Publ Hlth England, 61 Colindale Ave, London NW9 5EQ, England.; Vynnycky, E (reprint author), London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England. EM emilia.vynnycky@phe.gov.uk OI Jackson, Charlotte/0000-0001-8544-7685 FU World Health Organization; Bill and Melinda Gates Foundation; Child Health Epidemiology Reference Group FX EA and EV were funded by a grant provided by the World Health Organization. AMNB was funded by the Bill and Melinda Gates Foundation in support of the Global Burden of Disease project and the Child Health Epidemiology Reference Group. NR 40 TC 4 Z9 4 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 10 PY 2016 VL 11 IS 3 AR e0149160 DI 10.1371/journal.pone.0149160 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DG3TL UT WOS:000371993000009 PM 26962867 ER PT J AU Kakuru, A Jagannathan, P Muhindo, MK Natureeba, P Awori, P Nakalembe, M Opira, B Olwoch, P Ategeka, J Nayebare, P Clark, TD Feeney, ME Charlebois, ED Rizzuto, G Muehlenbachs, A Havlir, DV Kamya, MR Dorsey, G AF Kakuru, Abel Jagannathan, Prasanna Muhindo, Mary K. Natureeba, Paul Awori, Patricia Nakalembe, Miriam Opira, Bishop Olwoch, Peter Ategeka, John Nayebare, Patience Clark, Tamara D. Feeney, Margaret E. Charlebois, Edwin D. Rizzuto, Gabrielle Muehlenbachs, Atis Havlir, Diane V. Kamya, Moses R. Dorsey, Grant TI Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID PLACEBO-CONTROLLED TRIAL; INTERMITTENT SULFADOXINE-PYRIMETHAMINE; LOW-BIRTH-WEIGHT; DRUG-RESISTANCE; WOMEN; INFECTION; ANEMIA; MALAWI; UGANDA; TRANSMISSION AB BACKGROUND Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa. However, with the spread of resistance to sulfadoxine-pyrimethamine, new interventions are needed. METHODS We conducted a double-blind, randomized, controlled trial involving 300 human immunodeficiency virus (HIV)-uninfected pregnant adolescents or women in Uganda, where sulfadoxine-pyrimethamine resistance is widespread. We randomly assigned participants to a sulfadoxine-pyrimethamine regimen (106 participants), a three-dose dihydroartemisinin-piperaquine regimen (94 participants), or a monthly dihydroartemisinin-piperaquine regimen (100 participants). The primary outcome was the prevalence of histopathologically confirmed placental malaria. RESULTS The prevalence of histopathologically confirmed placental malaria was significantly higher in the sulfadoxine-pyrimethamine group (50.0%) than in the three-dose dihydroartemisinin-piperaquine group (34.1%, P=0.03) or the monthly dihydroartemisinin-piperaquine group (27.1%, P=0.001). The prevalence of a composite adverse birth outcome was lower in the monthly dihydroartemisinin-piperaquine group (9.2%) than in the sulfadoxine-pyrimethamine group (18.6%, P=0.05) or the three-dose dihydroartemisinin-piperaquine group (21.3%, P=0.02). During pregnancy, the incidence of symptomatic malaria was significantly higher in the sulfadoxine-pyrimethamine group (41 episodes over 43.0 person-years at risk) than in the three-dose dihydroartemisinin-piperaquine group (12 episodes over 38.2 person-years at risk, P=0.001) or the monthly dihydroartemisinin-piperaquine group (0 episodes over 42.3 personyears at risk, P<0.001), as was the prevalence of parasitemia (40.5% in the sulfadoxine-pyrimethamine group vs. 16.6% in the three-dose dihydroartemisinin-piperaquine group [P<0.001] and 5.2% in the monthly dihydroartemisinin-piperaquine group [P<0.001]). In each treatment group, the risk of vomiting after administration of any dose of the study agents was less than 0.4%, and there were no significant differences among the groups in the risk of adverse events. CONCLUSIONS The burden of malaria in pregnancy was significantly lower among adolescent girls or women who received intermittent preventive treatment with dihydroartemisinin-piperaquine than among those who received sulfadoxine-pyrimethamine, and monthly treatment with dihydroartemisinin-piperaquine was superior to three-dose dihydroartemisinin-piperaquine with regard to several outcomes. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development; ClinicalTrials. gov number, NCT02163447.) C1 [Kakuru, Abel; Muhindo, Mary K.; Natureeba, Paul; Awori, Patricia; Nakalembe, Miriam; Opira, Bishop; Olwoch, Peter; Ategeka, John; Nayebare, Patience] Makerere Univ, Coll Hlth Sci, Infect Dis Res Collaborat, Kampala, Uganda. [Nakalembe, Miriam] Makerere Univ, Coll Hlth Sci, Dept Obstet & Gynecol, Kampala, Uganda. [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Sch Med, Kampala, Uganda. [Jagannathan, Prasanna; Clark, Tamara D.; Feeney, Margaret E.; Havlir, Diane V.; Dorsey, Grant] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Feeney, Margaret E.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. [Rizzuto, Gabrielle] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. [Charlebois, Edwin D.] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA. [Muehlenbachs, Atis] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Dorsey, G (reprint author), San Francisco Gen Hosp, 1001 Potrero Ave,Bldg 30,Rm 3420, San Francisco, CA 94110 USA. EM gdorsey@medsfgh.ucsf.edu FU Eunice Kennedy Shriver National Institute of Child Health and Human Development FX Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development; ClinicalTrials.gov number, NCT02163447. NR 34 TC 15 Z9 15 U1 0 U2 7 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 10 PY 2016 VL 374 IS 10 BP 928 EP 939 DI 10.1056/NEJMoa1509150 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA DF9DH UT WOS:000371660000006 PM 26962728 ER PT J AU Lima, GFMD Lucchi, NW Silva-Flannery, L Macedo-de-Oliveira, A Hristov, AD Inoue, J Costa-Nascimento, MD Udhayakumar, V Di Santi, SM AF Maciel de Castro Lima, Giselle Fernandes Lucchi, Naomi W. Silva-Flannery, Luciana Macedo-de-Oliveira, Alexandre Hristov, Angelica D. Inoue, Juliana Costa-Nascimento, Maria de Jesus Udhayakumar, Venkatachalam Di Santi, Silvia M. TI Still Searching for a Suitable Molecular Test to Detect Hidden Plasmodium Infection: A Proposal for Blood Donor Screening in Brazil SO PLOS ONE LA English DT Article ID REAL-TIME PCR; POLYMERASE-CHAIN-REACTION; MALARIA PARASITE DETECTION; NESTED PCR; DIAGNOSIS; TRANSFUSION; AMPLIFICATION; STRATEGY; AREAS; VIVAX AB Background Efforts have been made to establish sensitive diagnostic tools for malaria screening in blood banks in order to detect malaria asymptomatic carriers. Microscopy, the malaria reference test in Brazil, is time consuming and its sensitivity depends on microscopist experience. Although molecular tools are available, some aspects need to be considered for large-scale screening: accuracy and robustness for detecting low parasitemia, affordability for application to large number of samples and flexibility to perform on individual or pooled samples. Methodology In this retrospective study, we evaluated four molecular assays for detection of malaria parasites in a set of 56 samples previously evaluated by expert microscopy. In addition, we evaluated the effect of pooling samples on the sensitivity and specificity of the molecular assays. A well-characterized cultured sample with 1 parasite/mu L was included in all the tests evaluated. DNA was extracted with QIAamp DNA Blood Mini Kit and eluted in 50 mu L to concentrate the DNA. Pools were assembled with 10 samples each. Molecular protocols targeting 18S rRNA, included one qPCR genus specific (Lima-genus), one duplex qPCR genus/Pf (PET-genus, PET-Pf) and one duplex qPCR specie-specific (Rougemont: RougPf/Pv and Roug-Pm/Po). Additionally a nested PCR protocol specie-specific was used (Snou-Pf, Snou-Pv, Snou-Pm and Snou-Po). Results The limit of detection was 3.5 p/mu L and 0.35p/mu l for the PET-genus and Lima-genus assays, respectively. Considering the positive (n = 13) and negative (n = 39) unpooled individual samples according to microscopy, the sensitivity of the two genus qPCR assays was 76.9% (Lima-genus) and 72.7% (PET-genus). The Lima-genus and PET-genus showed both sensitivity of 86.7% in the pooled samples. The genus protocols yielded similar results (Kappa value of 1.000) in both individual and pooled samples. Conclusions Efforts should be made to improve performance of molecular tests to enable the detection of low-density parasitemia if these tests are to be utilized for blood transfusion screening. C1 [Maciel de Castro Lima, Giselle Fernandes; Hristov, Angelica D.; Inoue, Juliana; Di Santi, Silvia M.] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, SP, Brazil. [Lucchi, Naomi W.; Silva-Flannery, Luciana; Macedo-de-Oliveira, Alexandre; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA USA. [Silva-Flannery, Luciana] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Costa-Nascimento, Maria de Jesus; Di Santi, Silvia M.] Univ Sao Paulo, Secretaria Estado Saude Sao Paulo, Nucleo Estudos Malaria Superintendencia Controle, Inst Med Trop Sao Paulo, Sao Paulo, SP, Brazil. RP Lima, GFMD (reprint author), Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, SP, Brazil. EM giselledecastro@usp.br FU U.S. Agency for International Development (USAID) through the Amazon Malaria Initiative (AMI); Sao Paulo Research Foundation (FAPESP) [2012/18014-5]; Superintendencia de Controle de Endemias (SUCEN); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) FX Funding was provided by the U.S. Agency for International Development (USAID) through the Amazon Malaria Initiative (AMI). Author who received the funding AMO; Sao Paulo Research Foundation (FAPESP) by grant #2012/18014-5. Author who received the funding SMDS; Superintendencia de Controle de Endemias (SUCEN). Author who received the funding SMDS; and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq). Author who received the funding GFMCL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 0 Z9 0 U1 3 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 9 PY 2016 VL 11 IS 3 AR e0150391 DI 10.1371/journal.pone.0150391 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DG3TF UT WOS:000371992300047 PM 26959994 ER PT J AU Zheng, JD Huo, XX Huai, Y Xiao, L Jiang, H Klena, J Greene, CM Xing, XS Huang, JG Liu, SL Peng, YX Yang, H Luo, J Peng, ZB Liu, LL Chen, MY Chen, H Zhang, YZ Huang, DQ Guan, XH Feng, LZ Zhan, FX Hu, DJ Varma, JK Yu, HJ AF Zheng, Jiandong Huo, Xixiang Huai, Yang Xiao, Lin Jiang, Hui Klena, John Greene, Carolyn M. Xing, Xuesen Huang, Jigui Liu, Shali Peng, Youxing Yang, Hui Luo, Jun Peng, Zhibin Liu, Linlin Chen, Maoyi Chen, Hui Zhang, Yuzhi Huang, Danqin Guan, Xuhua Feng, Luzhao Zhan, Faxian Hu, Dale J. Varma, Jay K. Yu, Hongjie TI Epidemiology, Seasonality and Treatment of Hospitalized Adults and Adolescents with Influenza in Jingzhou, China, 2010-2012 SO PLOS ONE LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY SYNCYTIAL VIRUS; NEURAMINIDASE INHIBITORS; PRIMARY-CARE; RISK-FACTORS; INFECTION; MORTALITY; CORTICOSTEROIDS; METAANALYSIS; VACCINATION AB Background After the 2009 influenza A (H1 N1) pandemic, we conducted hospital-based severe acute respiratory infection (SARI) surveillance in one central Chinese city to assess disease burden attributable to influenza among adults and adolescents. Methods We defined an adult SARI case as a hospitalized patient aged >= 15 years with temperature >= 38.0 degrees C and at least one of the following: cough, sore throat, tachypnea, difficulty breathing, abnormal breath sounds on auscultation, sputum production, hemoptysis, chest pain, or chest radiograph consistent with pneumonia. For each enrolled SARI case-patient, we completed a standardized case report form, and collected a nasopharyngeal swab within 24 hours of admission. Specimens were tested for influenza viruses by real-time reverse transcription polymerase chain reaction (rRT-PCR). We analyzed data from adult SARI cases in four hospitals in Jingzhou, China from April 2010 to April 2012. Results Of 1,790 adult SARI patients enrolled, 40% were aged >= 65 years old. The median duration of hospitalization was 9 days. Nearly all were prescribed antibiotics during theirhospitalization, less than 1% were prescribed oseltamivir, and 28% were prescribed corticosteroids. Only 0.1% reported receiving influenza vaccination in the past year. Of 1,704 samples tested, 16% were positive for influenza. Influenza activity in all age groups showed winter-spring and summer peaks. Influenza-positive patients had a longer duration from illness onset to hospitalization and a shorter duration from hospital admission to discharge or death compared to influenza negative SARI patients. Conclusions There is substantial burden of influenza-associated SARI hospitalizations in Jingzhou, China, especially among older adults. More effective promotion of annual seasonal influenza vaccination and timely oseltamivir treatment among high risk groups may improve influenza prevention and control in China. C1 [Zheng, Jiandong; Jiang, Hui; Peng, Zhibin; Feng, Luzhao; Yu, Hongjie] Chinese Ctr Dis Control & Prevent, Key Lab Surveillance & Early Warning Infect Dis, Div Infect Dis, Beijing, Peoples R China. [Huo, Xixiang; Xing, Xuesen; Liu, Linlin; Chen, Hui; Huang, Danqin; Guan, Xuhua; Zhan, Faxian] Hubei Prov Ctr Dis Control & Prevent, Wuhan, Peoples R China. [Huai, Yang; Klena, John; Greene, Carolyn M.; Zhang, Yuzhi; Hu, Dale J.; Varma, Jay K.] Ctr Dis Control & Prevent, Ctr Global Hlth, China US Collaborat Program Emerging & Reemerging, Beijing, Peoples R China. [Xiao, Lin; Huang, Jigui; Chen, Maoyi] Jingzhou Ctr Dis Control & Prevent, Jingzhou, Peoples R China. [Klena, John; Hu, Dale J.; Varma, Jay K.] Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. [Greene, Carolyn M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Liu, Shali] Jingzhou Cent Hosp, Jingzhou, Peoples R China. [Peng, Youxing] Jingzhou First Peoples Hosp, Jingzhou, Peoples R China. [Yang, Hui] Jingzhou Second Peoples Hosp, Jingzhou, Peoples R China. [Luo, Jun] Jingzhou Maternal & Childrens Hosp, Jingzhou, Peoples R China. [Hu, Dale J.] NIAID, Vaccine Res Program, Div Aids, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. RP Yu, HJ (reprint author), Chinese Ctr Dis Control & Prevent, Key Lab Surveillance & Early Warning Infect Dis, Div Infect Dis, Beijing, Peoples R China. EM yuhj@chinacdc.cn FU Cooperative Agreement Number [5U2GGH000018]; Centers for Disease Control and Prevention FX This study was supported by the Cooperative Agreement Number, 5U2GGH000018, funded by the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Department of Health and Human Services. NR 38 TC 0 Z9 0 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 9 PY 2016 VL 11 IS 3 AR e0150713 DI 10.1371/journal.pone.0150713 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DG3TF UT WOS:000371992300068 PM 26958855 ER PT J AU Mesquita, RD Vionette-Amaral, RJ Lowenberger, C Rivera-Pomar, R Monteiro, FA Minx, P Spieth, J Carvalho, AB Panzera, F Lawson, D Torres, AQ Ribeiro, JMC Sorgine, MHF Waterhouse, RM Montague, MJ Abad-Franch, F Alves-Bezerra, M Amaral, LR Araujo, H Araujo, RN Aravind, L Atella, GC Azambuja, P Berni, M Bittencourt-Cunha, PR Braz, GRC Calderon-Fernandez, G Carareto, CMA Christensen, MB Costa, IR Costa, SG Dansa, M Daumas, CRO De-Paula, IF Dias, FA Dimopoulos, G Emrich, SJ Esponda-Behrens, N Fampa, P Fernandez-Medina, RD da Fonseca, RN Fontenele, M Fronick, C Fulton, LA Gandara, AC Garcia, ES Genta, FA Giraldo-Calderon, GI Gomes, B Gondim, KC Granzotto, A Guarneri, AA Guigo, R Harry, M Hughes, DST Jablonka, W Jacquin-Joly, E Juarez, MP Koerich, LB Lange, AB Latorre-Estivalis, JM Lavore, A Lawrence, GG Lazoski, C Lazzari, CR Lopes, RR Lorenzo, MG Lugon, MD Majerowicz, D Marcet, PL Mariotti, M Masuda, H Megy, K Melo, ACA Missirlis, F Mota, T Noriega, FG Nouzova, M Nunes, RD Oliveir, RLL Oliveira-Silveira, G Ons, S Orchard, I Pagola, L Paiva-Silva, GO Pascual, A Pavan, MG Pedrini, N Peixoto, AA Pereira, MH Pike, A Polycarpo, C Prosdocimi, F Ribeiro-Rodrigues, R Robertson, HM Salerno, AP Salmon, D Santesmasses, D Schama, R Seabra-Junior, ES Silva-Cardoso, L Silva-Neto, MAC Souza-Gomes, M Sterkel, M Taracena, ML Tojo, M Tu, ZJ Tubio, JMC Ursic-Bedoya, R Venancio, TM Walter-Nuno, AB Wilson, D Warren, WC Wilson, RK Huebner, E Dotson, EM Oliveira, PL AF Mesquita, Rafael D. Vionette-Amaral, Raquel J. Lowenberger, Carl Rivera-Pomar, Rolando Monteiro, Fernando A. Minx, Patrick Spieth, John Carvalho, A. Bernardo Panzera, Francisco Lawson, Daniel Torres, Andre Q. Ribeiro, Jose M. C. Sorgine, Marcos H. F. Waterhouse, Robert M. Montague, Michael J. Abad-Franch, Fernando Alves-Bezerra, Michele Amaral, Laurence R. Araujo, HelenaM. Araujo, Ricardo N. Aravind, L. Atella, Georgia C. Azambuja, Patricia Berni, Mateus Bittencourt-Cunha, Paula R. Braz, Gloria R. C. Calderon-Fernandez, Gustavo Carareto, Claudia M. A. Christensen, Mikkel B. Costa, Igor R. Costa, Samara G. Dansa, Marilvia Daumas-Filho, Carlos R. O. De-Paula, Iron F. Dias, Felipe A. Dimopoulos, George Emrich, Scott J. Esponda-Behrens, Natalia Fampa, Patricia Fernandez-Medina, Rita D. da Fonseca, Rodrigo N. Fontenele, Marcio Fronick, Catrina Fulton, Lucinda A. Gandara, Ana Caroline Garcia, Eloi S. Genta, Fernando A. Giraldo-Calderon, Gloria I. Gomes, Bruno Gondim, Katia C. Granzotto, Adriana Guarneri, Alessandra A. Guigo, Roderic Harry, Myriam Hughes, Daniel S. T. Jablonka, Willy Jacquin-Joly, Emmanuelle Juarez, M. Patricia Koerich, Leonardo B. Lange, Angela B. Latorre-Estivalis, Jose Manuel Lavore, Andres Lawrence, Gena G. Lazoski, Cristiano Lazzari, Claudio R. Lopes, Raphael R. Lorenzo, Marcelo G. Lugon, Magda D. Majerowicz, David Marcet, Paula L. Mariotti, Marco Masuda, Hatisaburo Megy, Karine Melo, Ana C. A. Missirlis, Fanis Mota, Theo Noriega, Fernando G. Nouzova, Marcela Nunes, Rodrigo D. Oliveir, Raquel L. L. Oliveira-Silveira, Gilbert Ons, Sheila Orchard, Ian Pagola, Lucia Paiva-Silva, Gabriela O. Pascual, Agustina Pavan, Marcio G. Pedrini, Nicolas Peixoto, Alexandre A. Pereira, Marcos H. Pike, Andrew Polycarpo, Carla Prosdocimi, Francisco Ribeiro-Rodrigues, Rodrigo Robertson, Hugh M. Salerno, Ana Paula Salmon, Didier Santesmasses, Didac Schama, Renata Seabra-Junior, Eloy S. Silva-Cardoso, Livia Silva-Neto, Mario A. C. Souza-Gomes, Matheus Sterkel, Marcos Taracena, Mabel L. Tojo, Marta Tu, Zhijian Jake Tubio, Jose M. C. Ursic-Bedoya, Raul Venancio, Thiago M. Walter-Nuno, Ana Beatriz Wilson, Derek Warren, Wesley C. Wilson, Richard K. Huebner, Erwin Dotson, Ellen M. Oliveira, Pedro L. TI Genome of Rhodnius prolixus, an insect vector of Chagas disease, reveals unique adaptations to hematophagy and parasite infection (vol 112, pg 14936, 2015) SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Correction C1 [Mesquita, Rafael D.; Torres, Andre Q.; Braz, Gloria R. C.; Melo, Ana C. A.] Univ Fed Rio de Janeiro, Inst Quim, Dept Bioquim, BR-21941909 Rio De Janeiro, Brazil. [Mesquita, Rafael D.; Monteiro, Fernando A.; Sorgine, Marcos H. F.; Araujo, HelenaM.; Araujo, Ricardo N.; Atella, Georgia C.; Azambuja, Patricia; Braz, Gloria R. C.; Dias, Felipe A.; da Fonseca, Rodrigo N.; Fontenele, Marcio; Gandara, Ana Caroline; Garcia, Eloi S.; Genta, Fernando A.; Gomes, Bruno; Gondim, Katia C.; Guarneri, Alessandra A.; Koerich, Leonardo B.; Latorre-Estivalis, Jose Manuel; Lazoski, Cristiano; Lorenzo, Marcelo G.; Masuda, Hatisaburo; Melo, Ana C. A.; Nunes, Rodrigo D.; Paiva-Silva, Gabriela O.; Peixoto, Alexandre A.; Pereira, Marcos H.; Polycarpo, Carla; Schama, Renata; Silva-Neto, Mario A. C.; Venancio, Thiago M.; Oliveira, Pedro L.] Inst Nacl Ciencia & Tecnol Entomol Mol, BR-21941591 Rio De Janeiro, Brazil. [Vionette-Amaral, Raquel J.; Sorgine, Marcos H. F.; Alves-Bezerra, Michele; Atella, Georgia C.; Bittencourt-Cunha, Paula R.; Costa, Igor R.; Daumas-Filho, Carlos R. O.; De-Paula, Iron F.; Dias, Felipe A.; Fontenele, Marcio; Gandara, Ana Caroline; Gondim, Katia C.; Jablonka, Willy; Lopes, Raphael R.; Majerowicz, David; Masuda, Hatisaburo; Nunes, Rodrigo D.; Oliveira-Silveira, Gilbert; Paiva-Silva, Gabriela O.; Polycarpo, Carla; Prosdocimi, Francisco; Salmon, Didier; Silva-Cardoso, Livia; Silva-Neto, Mario A. C.; Sterkel, Marcos; Taracena, Mabel L.; Walter-Nuno, Ana Beatriz; Oliveira, Pedro L.] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo Meis, Programa Biol Mol & Biotecnol, BR-21941591 Rio De Janeiro, Brazil. [Lowenberger, Carl] Simon Fraser Univ, Biol Sci, Burnaby, BC V5A 1S6, Canada. [Rivera-Pomar, Rolando; Esponda-Behrens, Natalia; Lavore, Andres; Ons, Sheila; Pagola, Lucia; Pascual, Agustina] Univ Nacl La Plata, Ctr Reg Estudios Genom, RA-1900 La Plata, Argentina. [Rivera-Pomar, Rolando] Univ Nacl Noroeste Buenos Aires, Ctr Bioinvest, RA-2700 Pergamino, Argentina. [Monteiro, Fernando A.; Torres, Andre Q.; Azambuja, Patricia; Costa, Samara G.; Garcia, Eloi S.; Genta, Fernando A.; Gomes, Bruno; Pavan, Marcio G.; Peixoto, Alexandre A.; Schama, Renata] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, BR-21040900 Rio De Janeiro, Brazil. [Minx, Patrick; Spieth, John; Montague, Michael J.; Fronick, Catrina; Fulton, Lucinda A.; Warren, Wesley C.; Wilson, Richard K.] Washington Univ, Sch Med, McDonnell Genome Inst, St Louis, MO 63108 USA. [Carvalho, A. Bernardo; Koerich, Leonardo B.; Lazoski, Cristiano] Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, BR-21941590 Rio De Janeiro, Brazil. [Panzera, Francisco] Univ Republica, Fac Ciencias, Secc Genet Evolut, Montevideo 11400, Uruguay. [Lawson, Daniel; Christensen, Mikkel B.; Hughes, Daniel S. T.; Megy, Karine; Wilson, Derek] European Bioinformat Inst, European Mol Biol Lab, Welcome Trust Genome Campus, Cambridge CB10 1SD, England. [Ribeiro, Jose M. C.] NIAID, Sect Vector Biol, NIH, Rockville, MD 20852 USA. [Waterhouse, Robert M.] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland. [Waterhouse, Robert M.] Swiss Inst Bioinformat, CH-1211 Geneva, Switzerland. [Waterhouse, Robert M.] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA. [Waterhouse, Robert M.] MIT & Harvard, Broad Inst, Cambridge, MA 02142 USA. [Abad-Franch, Fernando] Fundacao Oswaldo Cruz, Inst Leonidas & Maria Deane, Grp Pesquisa Ecol Doencas Transmissiveis Amazonia, BR-69057070 Amazonas, Brazil. [Amaral, Laurence R.; Souza-Gomes, Matheus] Univ Fed Uberlandia, Fac Computacao, Inst Genet & Bioquim, Lab Bioinformat & Anal Mol, BR-38700002 Uberlandia, MG, Brazil. [Araujo, HelenaM.; Berni, Mateus] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, BR-21941591 Rio De Janeiro, Brazil. [Araujo, Ricardo N.; Pereira, Marcos H.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Parasitol, BR-31270901 Belo Horizonte, MG, Brazil. [Aravind, L.] NIH, Natl Lib Med, Natl Ctr Biotechnol Informat, Rockville, MD 20894 USA. [Calderon-Fernandez, Gustavo; Juarez, M. Patricia; Pedrini, Nicolas] Univ Nacl La Plata, CONICET, Fac Ciencias Med, Inst Invest Bioquim La Plata, RA-1900 La Plata, Argentina. [Carareto, Claudia M. A.; Granzotto, Adriana] Univ Estadual Paulista, Dept Biol, BR-15054000 Sao Paulo, Brazil. [Dansa, Marilvia; Lugon, Magda D.; Venancio, Thiago M.] Univ Estadual Norte Fluminense, Ctr Biociencias & Biotecnol, Lab Quim & Funcao Proteinas & Peptideos, BR-28013602 Rio De Janeiro, Brazil. [Dimopoulos, George; Pike, Andrew] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA. [Emrich, Scott J.] Univ Notre Dame, Dept Comp Sci & Engn, Notre Dame, IN 46556 USA. [Fampa, Patricia; Oliveir, Raquel L. L.] Univ Fed Rural Rio de Janeiro, Inst Ciencias Biol & Saude, Dept Biol Anim, BR-23897000 Rio De Janeiro, Brazil. [Fernandez-Medina, Rita D.] Fdn Oswaldo Cruz Rio de Janeiro, Escola Nacl Saude Publ, BR-21040360 Rio De Janeiro, Brazil. [da Fonseca, Rodrigo N.] Univ Fed Rio de Janeiro, Nucleo Pesquisas Ecol Macae, BR-27910970 Rio De Janeiro, Brazil. [Giraldo-Calderon, Gloria I.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA. [Guarneri, Alessandra A.; Latorre-Estivalis, Jose Manuel; Lorenzo, Marcelo G.] Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, BR-30190002 Belo Horizonte, MG, Brazil. [Guigo, Roderic; Mariotti, Marco; Santesmasses, Didac] Barcelona Inst Sci & Technol, Ctr Genom Regulat, Barcelona 08003, Catalonia, Spain. [Guigo, Roderic; Mariotti, Marco; Santesmasses, Didac] Univ Pompeu Fabra, Barcelona 08003, Catalonia, Spain. [Harry, Myriam] CNRS, Inst Rech Dev, Lab Evolut Genome & Speciat, UPR9034 UR 072, F-91198 Gif Sur Yvette, France. [Harry, Myriam] Univ Paris 11, F-91400 Orsay, France. [Jacquin-Joly, Emmanuelle] French Natl Inst Agr Res, Inst Ecol & Environm Sci Paris, F-78000 Versailles, France. [Lange, Angela B.; Orchard, Ian] Univ Toronto, Dept Biol, Mississauga, ON L5L 1C6, Canada. [Lawrence, Gena G.; Marcet, Paula L.; Dotson, Ellen M.] Ctr Dis Control & Prevent, Entomol Branch, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. [Lazzari, Claudio R.] Univ Tours, CNRS, Inst Rech Biol Insecte, UMR7261, F-37200 Tours, France. [Majerowicz, David] Univ Fed Rio de Janeiro, Fac Farm, Dept Biotecnol Farmaceut, BR-21941902 Rio De Janeiro, Brazil. [Missirlis, Fanis] Inst Politecn Nacl Zacatenco, Ctr Invest & Estudios Avanzados, Dept Physiol Biophys & Neurosci, Mexico City 03760, DF, Mexico. [Mota, Theo] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Fisiol & Biofis, BR-31270901 Belo Horizonte, MG, Brazil. [Noriega, Fernando G.; Nouzova, Marcela] Florida Int Univ, Dept Biol Sci, Miami, FL 33199 USA. [Ribeiro-Rodrigues, Rodrigo] Univ Fed Espirito Santo, Nucleo Doencas Infecciosas, BR-29043900 Espirito Santo, Brazil. [Robertson, Hugh M.] Univ Illinois, Dept Entomol, Urbana, IL 61801 USA. [Salerno, Ana Paula; Seabra-Junior, Eloy S.] Inst Fed Educ Ciencia & Tecnol Rio de Janeiro, BR-20270021 Rio De Janeiro, Brazil. [Tojo, Marta] Univ Santiago de Compostela, Inst Invest Sanit, Ctr Resesarch Mol Med & Chron Dis, Dept Physiol,Sch Med, Santiago De Compostela 15782, Spain. [Tu, Zhijian Jake] Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA. [Tubio, Jose M. C.] Univ Cambridge, Dept Vet Med, Cambridge CB3 0ES, England. [Huebner, Erwin] Univ Manitoba, Dept Biol Sci, Winnipeg, MB R3T 2N2, Canada. RP Mesquita, RD (reprint author), Univ Fed Rio de Janeiro, Inst Quim, Dept Bioquim, BR-21941909 Rio De Janeiro, Brazil.; Mesquita, RD (reprint author), Inst Nacl Ciencia & Tecnol Entomol Mol, BR-21941591 Rio De Janeiro, Brazil. RI Pereira, Marcos/A-3774-2012; Prosdocimi, Francisco/F-6847-2012; Venancio, Thiago/B-5003-2011; Guigo, Roderic/D-1303-2010; Carareto, Claudia/D-2814-2012 OI Prosdocimi, Francisco/0000-0002-6761-3069; Guigo, Roderic/0000-0002-5738-4477; NR 1 TC 2 Z9 2 U1 6 U2 14 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAR 8 PY 2016 VL 113 IS 10 BP E1415 EP E1416 DI 10.1073/pnas.1600205113 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DG4AW UT WOS:000372013300016 ER PT J AU Wilmot, KA O'Flaherty, M Capewell, S Ford, ES Vaccarino, V AF Wilmot, Kobina A. O'Flaherty, Martin Capewell, Simon Ford, Earl S. Vaccarino, Viola TI Response to Letter Regarding Article, "Coronary Heart Disease Mortality Declines in the United States From 1979 Through 2011: Evidence for Stagnation in Young Adults, Especially Women" SO CIRCULATION LA English DT Letter C1 [Wilmot, Kobina A.] Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA. [O'Flaherty, Martin; Capewell, Simon] Univ Liverpool, Dept Publ Hlth & Policy, Inst Psychol Hlth & Soc, Clin Epidemiol, Liverpool L69 3BX, Merseyside, England. [Ford, Earl S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Vaccarino, Viola] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Dept Med,Div Cardiol,Sch Med, Atlanta, GA 30322 USA. RP Wilmot, KA (reprint author), Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA. OI O'Flaherty, Martin/0000-0001-8944-4131 NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD MAR 8 PY 2016 VL 133 IS 10 BP E433 EP E433 DI 10.1161/CIRCULATIONAHA.115.020672 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DF6RB UT WOS:000371482300006 PM 26951831 ER PT J AU Diaz, MH Winchell, JM AF Diaz, Maureen H. Winchell, Jonas M. TI The Evolution of Advanced Molecular Diagnostics for the Detection and Characterization of Mycoplasma pneumoniae SO FRONTIERS IN MICROBIOLOGY LA English DT Article DE Mycoplasma pneumoniae; molecular diagnostics; molecular epidemiology; molecular characteristics; whole genome sequencing ID REAL-TIME PCR; COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY-TRACT INFECTIONS; SEQUENCE-BASED AMPLIFICATION; TANDEM-REPEAT ANALYSIS; MACROLIDE RESISTANCE DETERMINATION; HOMOLOGOUS DNA RECOMBINATION; FRAGMENT-LENGTH-POLYMORPHISM; DESORPTION IONIZATION-TIME; POLYMERASE-CHAIN-REACTION AB Over the past decade there have been significant advancements in the methods used for detecting and characterizing Mycoplasma pneumoniae, a common cause of respiratory illness and community-acquired pneumonia worldwide. The repertoire of available molecular diagnostics has greatly expanded from nucleic acid amplification techniques (NAATs) that encompass a variety of chemistries used for detection, to more sophisticated characterizing methods such as multi locus variable-number tandem-repeat analysis (MLVA), Multi-locus sequence typing (MLST), matrix -assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), single nucleotide polymorphism typing, and numerous macrolide susceptibility profiling methods, among others. These many molecular -based approaches have been developed and employed to continually increase the level of discrimination and characterization in order to better understand the epidemiology and biology of M. pneumoniae. This review will summarize recent molecular techniques and procedures and lend perspective to how each has enhanced the current understanding of this organism and will emphasize how Next Generation Sequencing may serve as a resource for researchers to gain a more comprehensive understanding of the genomic complexities of this insidious pathogen. C1 [Diaz, Maureen H.; Winchell, Jonas M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Resp Dis Branch,Pneumonia Response & Surveillance, Atlanta, GA USA. RP Winchell, JM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Resp Dis Branch,Pneumonia Response & Surveillance, Atlanta, GA USA. EM jwinchell@cdc.gov NR 159 TC 4 Z9 4 U1 4 U2 10 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-302X J9 FRONT MICROBIOL JI Front. Microbiol. PD MAR 8 PY 2016 VL 7 AR 232 DI 10.3389/fmicb.2016.00232 PG 17 WC Microbiology SC Microbiology GA DF7KZ UT WOS:000371537900001 PM 27014191 ER PT J AU Voelker, R AF Voelker, Rebecca TI Call for Stepped-up Research on Antidepressant Use During Pregnancy SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT News Item C1 [Voelker, Rebecca] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Voelker, R (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 8 PY 2016 VL 315 IS 10 BP 971 EP 971 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA EM0AP UT WOS:000394981500006 ER PT J AU Voelker, R AF Voelker, Rebecca TI When Patients Are Close-Lipped About Memory Problems SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT News Item C1 [Voelker, Rebecca] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Voelker, R (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 8 PY 2016 VL 315 IS 10 BP 971 EP 971 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA EM0AP UT WOS:000394981500005 ER PT J AU Worrell, CM Wiegand, RE Davis, SM Odero, KO Blackstock, A Cuellar, VM Njenga, SM Montgomery, JM Roy, SL Fox, LM AF Worrell, Caitlin M. Wiegand, Ryan E. Davis, Stephanie M. Odero, Kennedy O. Blackstock, Anna Cuellar, Victoria M. Njenga, Sammy M. Montgomery, Joel M. Roy, Sharon L. Fox, LeAnne M. TI A Cross-Sectional Study of Water, Sanitation, and Hygiene-Related Risk Factors for Soil-Transmitted Helminth Infection in Urban School- and Preschool-Aged Children in Kibera, Nairobi SO PLOS ONE LA English DT Article ID TRICHURIS-TRICHIURA; DEVELOPING-COUNTRIES; DRINKING-WATER; DIARRHEA; HEALTH; SLUM; CONTAMINATION; METAANALYSIS; PREVALENCE; HOOKWORM AB Soil-transmitted helminth (STH) infections affect persons living in areas with poor water, sanitation, and hygiene (WASH). Preschool-aged children (PSAC) and school-aged children (SAC) are disproportionately affected by STH infections. We aimed to identify WASH factors associated with STH infection among PSAC and SAC in Kibera, Kenya. In 2012, households containing a PSAC or SAC were randomly selected from those enrolled in the International Emerging Infections Program, a population-based surveillance system. We administered a household questionnaire, conducted environmental assessments for WASH, and tested three stools from each child for STH eggs using the Kato-Katz method. WASH factors were evaluated for associations with STH infection using univariable and multivariable Poisson regression. Any-STH prevalence was 40.8% among 201 PSAC and 40.0% among 475 SAC enrolled. Using the Joint Monitoring Programme water and sanitation classifications, 1.5% of households reported piped water on premises versus 98.5% another improved water source; 1.3% reported improved sanitation facilities, while 81.7% used shared sanitation facilities, 13.9% had unimproved facilities, and 3.1% reported no facilities (open defecation). On univariable analysis, STH infection was significantly associated with a household toilet located off-premises (prevalence ratio (PR) = 1.33; p = 0.047), while always treating water (PR = 0.81; p = 0.04), covering drinking water containers (PR = 0.75; p = 0.02), using clean towels during hand drying (PR = 0.58; p < 0.01), having finished household floor material (PR = 0.76; p < 0.01), having electricity (PR = 0.70; p < 0.01), and increasing household elevation in 10-meter increments (PR = 0.89; p < 0.01) were protective against STH infection. On multivariable analysis, usually versus always treating water was associated with increased STH prevalence (adjusted prevalence ratio (aPR) = 1.52; p < 0.01), while having finished household floor material (aPR = 0.76; p = 0.03), reported child deworming in the last year (aPR = 0.76; p < 0.01), and 10-meter household elevation increases (aPR = 0.89; p < 0.01) were protective against infection. The intersection between WASH and STH infection is complex; site-specific WASH interventions should be considered to sustain the gains made by deworming activities. C1 [Worrell, Caitlin M.; Wiegand, Ryan E.; Davis, Stephanie M.; Fox, LeAnne M.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Odero, Kennedy O.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Nairobi, Kenya. [Blackstock, Anna; Cuellar, Victoria M.; Roy, Sharon L.] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Atlanta, GA USA. [Njenga, Sammy M.] Kenya Govt Med Res Ctr, Eastern & Southern Africa Ctr Int Parasite Contro, Nairobi, Kenya. [Montgomery, Joel M.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Nairobi, Kenya. RP Worrell, CM (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. EM cworrell@cdc.gov FU U.S. Agency for International Development (USAID); Centers for Disease Control and Prevention [OG11-12021] FX Funding for this study was obtained from the U.S. Agency for International Development (USAID) though an inter-agency agreement with the Centers for Disease Control and Prevention (No. OG11-12021). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 74 TC 0 Z9 0 U1 5 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 7 PY 2016 VL 11 IS 3 AR e0150744 DI 10.1371/journal.pone.0150744 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DG3SL UT WOS:000371990100056 PM 26950552 ER PT J AU Schuh, AJ Amman, BR Apanaskevich, DA Sealy, TK Nichol, ST Towner, JS AF Schuh, Amy J. Amman, Brian R. Apanaskevich, Dmitry A. Sealy, Tara K. Nichol, Stuart T. Towner, Jonathan S. TI No evidence for the involvement of the argasid tick Ornithodoros faini in the enzootic maintenance of marburgvirus within Egyptian rousette bats Rousettus aegyptiacus SO PARASITES & VECTORS LA English DT Article DE Filovirus; Marburgvirus; Marburg virus; Tick; Argasid; Ornithodoros; Egyptian rousette bat; Rousettus aegyptiacus; Transmission; Maintenance ID EXPERIMENTAL TRANSMISSION; FRUIT BATS; VIRUS; REPLICATION; INOCULATION; VECTOR; ACARI; FEVER AB Background: The cave-dwelling Egyptian rousette bat (ERB; Rousettus aegyptiacus) was recently identified as a natural reservoir host of marburgviruses. However, the mechanisms of transmission for the enzootic maintenance of marburgviruses within ERBs are unclear. Previous ecological investigations of large ERB colonies inhabiting Python Cave and Kitaka Mine, Uganda revealed that argasid ticks (Ornithodoros faini) are hematophagous ectoparasites of ERBs. Yet, their potential role as transmission vectors for marburgvirus has not been sufficiently assessed. Findings: In the present study, 3,125 O. faini were collected during April 2013 from the rock crevices of Python Cave, Uganda. None of the ticks tested positive for marburgvirus-specific RNA by Q-RT-PCR. The probability of failure to detect marburgvirus at a conservative prevalence of 0.1 % was 0.05. Conclusions: The absence of marburgvirus RNA in O. faini suggests they do not play a significant role in the transmission and enzootic maintenance of marburgvirus within their natural reservoir host. C1 [Schuh, Amy J.; Amman, Brian R.; Sealy, Tara K.; Nichol, Stuart T.; Towner, Jonathan S.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Viral Special Pathogens Branch, Atlanta, GA USA. [Apanaskevich, Dmitry A.] Georgia So Univ, James H Oliver Jr Inst Coastal Plain Sci, US Natl Tick Collect, Statesboro, GA 30460 USA. RP Towner, JS (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Viral Special Pathogens Branch, Atlanta, GA USA. EM jit8@cdc.gov NR 22 TC 1 Z9 1 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD MAR 5 PY 2016 VL 9 AR 128 DI 10.1186/s13071-016-1390-z PG 3 WC Parasitology SC Parasitology GA DF6HQ UT WOS:000371456900001 PM 26944044 ER PT J AU Cullen, KA Mace, KE Arguin, PM AF Cullen, Karen A. Mace, Kimberly E. Arguin, Paul M. TI Malaria Surveillance - United States, 2013 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID PLASMODIUM-FALCIPARUM; CHEMOPROPHYLAXIS; RESISTANCE; HAITI; KNOWLEDGE; ATTITUDES; TRAVELERS AB Problem/Condition: Malaria in humans is caused by intraerythrocytic protozoa of the genus Plasmodium. These parasites are transmitted by the bite of an infective female Anopheles mosquito. The majority of malaria infections in the United States occur among persons who have traveled to regions with ongoing malaria transmission. However, malaria is also occasionally acquired by persons who have not traveled out of the country through exposure to infected blood products, congenital transmission, laboratory exposure, or local mosquitoborne transmission. Malaria surveillance in the United States is conducted to identify episodes of local transmission and to guide prevention recommendations for travelers. Period Covered: This report summarizes cases in persons with onset of illness in 2013 and summarizes trends during previous years. Description of System: Malaria cases diagnosed by blood film, polymerase chain reaction, or rapid diagnostic tests are mandated to be reported to local and state health departments by health care providers or laboratory staff Case investigations are conducted by local and state health departments, and reports are transmitted to CDC through the National Malaria Surveillance System, National Notifiable Diseases Surveillance System, or direct CDC consultations. CDC conducted antimalarial drug resistance marker testing on blood samples submitted to CDC by health care providers or local/state health departments. Data from these reporting systems serve as the basis for this report: Results: CDC received 1,727 reported cases of malaria, including two congenital cases, with an onset of symptoms in 2013 among persons in the United States. The total number of cases represents a 2% increase from the 1,687 cases reported for 2012. Plasmodium falciparum, P vivax, P malariae, and P. ovale were identified in 61%, 14%, 3%, and 4% of cases, respectively. Forty (2%) patients were infected by two species. The infecting species was unreported or undetermined in 17% of cases. Polymerase chain reaction testing determined or corrected the species for 85 of the 137 (62%) samples evaluated for drug resistance marker testing. Of the 904 patients who reported purpose of travel, 635 (70%) were visiting friends or relatives (VFR). Among the 961 cases in U.S. civilians for whom information on chemoprophylaxis use and travel region was known, 42 (4%) patients reported that they had initiated and adhered to a chemoprophylaxis drug regimen recommended by CDC for the regions to which they had traveled. Thirty:six cases were reported in pregnant women, none of whom had adhered to chemoprophylaxis. Among all reported cases, approximately 270 (16%) were classified as severe illnesses in 2013. Of these, 10 persons with malaria died in 2013, the highest number since 2001. In 2013, a total of 137 blood samples submitted to CDC were tested for molecular markers associated with antimalarial drug resistance. Of the 100 P. falciparum-positive samples, 95 were tested for pyrimethamine resistance: 88 (93%) had genetic polymorphisms associated with pyrimethamine drug resistance, 74 (76%) with sulfadoxine resistance, 53 (53%) with chloroquine resistance, one (1%) with atovaquone resistance, none with mefloquine drug resistance, and none with artemisinin resistance. Interpretation: The overall trend of malaria cases has been increasing since 1973; the number of cases reported in 2013 is the third highest annual total since then. Despite progress in reducing the global burden of malaria, the disease remains endemic in many regions, and the use of appropriate prevention measures by travelers is still inadequate. Public Health Actions: Completion of data elements on the malaria case report form increased slightly in 2013 compared with 2012, but still remains unacceptably low. This incomplete reporting compromises efforts to examine trends in malaria cases and prevent infections. VFRs continue to be a difficult population to reach with effective malaria prevention strategies. Evidence based prevention strategies that effectively target VFRs need to be developed and implemented to have a substantial impact on the numbers of imported malaria cases in the United States. Fewer patients reported taking chemoprophylaxis in 2013 (32%) compared with 2012 (34%), and adherence was poor among those who did take chemoprophylaxis. Proper use of malaria chemoprophylaxis will prevent the majority of malaria illness and reduce the risk for severe disease (http://www.cdc.gov/malaria/travelers/drugs.html). Malaria infections can be fatal if not diagnosed and treated promptly with antimalarial medications appropriate for the patient's age and medical history, the likely country of malaria acquisition, and previous use of antimalarial chemoprophylaxis. Recent molecular laboratory advances have enabled CDC to identify and conduct molecular surveillance of antimalarial drug resistance markers (http://wwvv.cdc.gov/malaria/features/ars.html). These advances will allow CDC to track, guide treatment, and manage drug resistance in malaria parasites both domestically and globally. For this to be successful, specimens should be submitted for all cases diagnosed in the United States. Clinicians should consult the CDC Guidelines for Treatment of Malaria and contact the CDC's Malaria Hotline for case management advice, when needed. Malaria treatment recommendations can be obtained online (http://www.cdc.gov/malaria/diagnosis_treatment) or by calling the Malaria Hotline (770-488-7788 or toll-free at 855-856-4713). C1 [Cullen, Karen A.; Mace, Kimberly E.; Arguin, Paul M.] CDC, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Arguin, PM (reprint author), Ctr Global Hlth, Malaria Branch, Div Parasit Dis & Malaria, London, England. EM pma0@cdc.gov NR 60 TC 2 Z9 2 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD MAR 4 PY 2016 VL 65 IS 2 BP 1 EP 22 PG 22 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DL0PK UT WOS:000375334800001 PM 26938139 ER PT J AU Santibanez, TA Vogt, TM Zhai, YS McIntyre, AF AF Santibanez, Tammy A. Vogt, Tara M. Zhai, Yusheng McIntyre, Anne F. TI Place of influenza vaccination among children United States, 2010-11 through 2013-14 influenza seasons SO VACCINE LA English DT Article DE Influenza; Vaccination; Vaccination setting; Children ID MEDICAL HOME; RECOMMENDATIONS; COVERAGE; VACCINES AB Background: Studies are published on settings adults receive influenza vaccination but few have reported on settings children are vaccinated and how this might be changing over time or vary by socio-demographics. Methods: Data from the National Immunization Survey-Flu were analyzed to assess place of influenza vaccination among vaccinated children 6 months-17 years during the 2010-11, 2011-12, 2012-13, and 2013-14 influenza seasons. The percentage of children vaccinated at each place was calculated overall and by age, race/ethnicity, income, and Metropolitan Statistical Area (MSA). Results: The places children received influenza vaccination varied little over four recent influenza seasons. From the 2010-11 through 2013-14 influenza seasons the percentage of vaccinated children receiving influenza vaccination at a doctor's office was 64.1%, 65.1%, 65.3%, and 65.3%, respectively with no differences from one season to the next. Likewise, for vaccination at clinics or health centers (17.8%, 17.5%, 17.0%. 18.0%), health departments (3.2%, 3.6%, 3.0%, 2.8%), and other non-medical places (1.6%, 1.4%, 1.2%, 1.1%), there were no differences from one season to the next. There were some differences for vaccinations at hospitals, pharmacies, and schools. There was considerable variability in the place of influenza vaccination by age, race/ethnicity, income, and MSA. Fewer Hispanic children were vaccinated at a doctor's office than black, white, and other or multiple race children and fewer black children and children of other or multiple races were vaccinated at a doctor's office than white children. More children at or below the poverty level were vaccinated at a clinic or health center than all of the other income groups. Conclusion: Most vaccinated children receive their influenza vaccination at a doctor's office. Place of vaccination changed little over four recent influenza seasons. Large variability in place of vaccination exists by age, race/ethnicity, income, and MSA. Monitoring place of vaccination can help shape future immunization programs. Published by Elsevier Ltd. C1 [Santibanez, Tammy A.; Vogt, Tara M.; Zhai, Yusheng; McIntyre, Anne F.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. RP Santibanez, TA (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Mailstop A-19, Atlanta, GA 30329 USA. EM afz5@cdc.gov NR 22 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 4 PY 2016 VL 34 IS 10 BP 1296 EP 1303 DI 10.1016/j.vaccine.2016.01.032 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA DG3DO UT WOS:000371949900010 PM 26850756 ER PT J AU Buss, BF Keyser-Metobo, A Rother, J Holtz, L Gall, K Jereb, J Murphy, CN Iwen, PC Robbe-Austerman, S Holcomb, MA Infield, P AF Buss, Bryan F. Keyser-Metobo, Alison Rother, Julie Holtz, Laura Gall, Kristin Jereb, John Murphy, Caitlin N. Iwen, Peter C. Robbe-Austerman, Suelee Holcomb, Melissa A. Infield, Pat TI Possible Airborne Person-to-Person Transmission of Mycobacterium bovis - Nebraska 2014-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; HUMAN TUBERCULOSIS C1 [Buss, Bryan F.] CDC, Career Epidemiol Field Officer Program, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Buss, Bryan F.; Keyser-Metobo, Alison; Gall, Kristin; Holcomb, Melissa A.; Infield, Pat] Nebraska Dept Hlth & Human Serv, Div Publ Hlth, Lincoln, NE USA. [Rother, Julie] Northeast Nebraska Publ Hlth Dept, Wayne, NE USA. [Holtz, Laura] Elkhorn Logan Valley Publ Hlth Dept, Wisner, NE USA. [Jereb, John] CDC, Field Serv & Evaluat Branch, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Murphy, Caitlin N.; Iwen, Peter C.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Lincoln, NE USA. [Iwen, Peter C.] Univ Nebraska Med Ctr, Nebraska Publ Hlth Lab, Lincoln, NE USA. [Robbe-Austerman, Suelee] USDA, Natl Vet Serv Labs, Ames, IA 50010 USA. RP Buss, BF (reprint author), CDC, Career Epidemiol Field Officer Program, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.; Buss, BF (reprint author), Nebraska Dept Hlth & Human Serv, Div Publ Hlth, Lincoln, NE USA. EM feu7@cdc.gov NR 10 TC 4 Z9 4 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 4 PY 2016 VL 65 IS 8 BP 197 EP 201 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4UC UT WOS:000371345500001 PM 26938831 ER PT J AU Curran, KG Gibson, JJ Marke, D Caulker, V Bomeh, J Redd, JT Bunga, S Brunkard, J Kilmarx, PH AF Curran, Kathryn G. Gibson, James J. Marke, Dennis Caulker, Victor Bomeh, John Redd, John T. Bunga, Sudhir Brunkard, Joan Kilmarx, Peter H. TI Cluster of Ebola Virus Disease Linked to a Single Funeral - Moyamba District, Sierra Leone, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HEMORRHAGIC-FEVER C1 [Curran, Kathryn G.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Curran, Kathryn G.; Brunkard, Joan] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Gibson, James J.] CDC, Div Global Hlth Protect, Tanzania Country Off, Ctr Global Hlth, Atlanta, GA 30333 USA. [Marke, Dennis; Caulker, Victor; Bomeh, John] Sierra Leone Minist Hlth & Sanitat, Makene, Sierra Leone. [Redd, John T.] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Bunga, Sudhir] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA. [Kilmarx, Peter H.] CDC, Div Global HIV AIDS Zimbabwe, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Curran, KG (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Curran, KG (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM ydh9@cdc.gov NR 10 TC 2 Z9 2 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 4 PY 2016 VL 65 IS 8 BP 202 EP 205 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4UC UT WOS:000371345500002 PM 26938950 ER PT J AU Khanal, S Sedai, TR Choudary, GR Giri, JN Bohara, R Pant, R Gautam, M Sharapov, UM Goodson, JL Alexander, J Dabbagh, A Strebel, P Perry, RT Bah, S Abeysinghe, N Thapa, A AF Khanal, Sudhir Sedai, Tika Ram Choudary, Ganga Ram Giri, Jagat Narain Bohara, Rajendra Pant, Rajendra Gautam, Mukunda Sharapov, Umid M. Goodson, James L. Alexander, James Dabbagh, Alya Strebel, Peter Perry, Robert T. Bah, Sunil Abeysinghe, Nihal Thapa, Arun TI Progress Toward Measles Elimination - Nepal, 2007-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Khanal, Sudhir; Sedai, Tika Ram; Bah, Sunil; Abeysinghe, Nihal; Thapa, Arun] WHO, IVD, South East Asia Reg Off, Delhi, India. [Choudary, Ganga Ram; Giri, Jagat Narain; Bohara, Rajendra] WHO, Nepal Country Off, Immunizat Preventable Dis, Kathmandu, Nepal. [Pant, Rajendra; Gautam, Mukunda] Minist Hlth & Populat, Dept Hlth Serv, Child Hlth Div, Kathmandu, Nepal. [Sharapov, Umid M.; Goodson, James L.; Alexander, James] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. [Dabbagh, Alya; Strebel, Peter; Perry, Robert T.] WHO Headquarters, IVD, Geneva, Switzerland. RP Khanal, S (reprint author), WHO, IVD, South East Asia Reg Off, Delhi, India. EM khanals@who.int NR 10 TC 2 Z9 2 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 4 PY 2016 VL 65 IS 8 BP 206 EP 210 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4UC UT WOS:000371345500003 PM 26937619 ER PT J AU Meaney-Delman, D Hills, SL Williams, C Galang, RR Iyengar, P Hennenfent, AK Rabe, IB Panella, A Oduyebo, T Honein, MA Zaki, S Lindsey, N Lehman, JA Kwit, N Bertolli, J Ellington, S Igbinosa, I Minta, AA Petersen, EE Mead, P Rasmussen, SA Jamieson, DJ AF Meaney-Delman, Dana Hills, Susan L. Williams, Charnetta Galang, Romeo R. Iyengar, Preetha Hennenfent, Andrew K. Rabe, Ingrid B. Panella, Amanda Oduyebo, Titilope Honein, Margaret A. Zaki, Sherif Lindsey, Nicole Lehman, Jennifer A. Kwit, Natalie Bertolli, Jeanne Ellington, Sascha Igbinosa, Irogue Minta, Anna A. Petersen, Emily E. Mead, Paul Rasmussen, Sonja A. Jamieson, Denise J. TI Zika Virus Infection Among US Pregnant Travelers - August 2015-February 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; INTERIM GUIDELINES; WOMEN C1 [Meaney-Delman, Dana] CDC, Off Director, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Hills, Susan L.; Rabe, Ingrid B.; Panella, Amanda; Lindsey, Nicole; Lehman, Jennifer A.; Mead, Paul] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Williams, Charnetta; Galang, Romeo R.; Oduyebo, Titilope; Kwit, Natalie; Minta, Anna A.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Williams, Charnetta; Galang, Romeo R.; Bertolli, Jeanne] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Iyengar, Preetha] District Columbia Dept Hlth, Washington, DC USA. [Hennenfent, Andrew K.] CDC, CSTE Appl Epidemiol Fellowship, Dist Columbia Dept Hlth, Atlanta, GA 30333 USA. [Oduyebo, Titilope; Ellington, Sascha; Petersen, Emily E.; Jamieson, Denise J.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Honein, Margaret A.] CDC, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Zaki, Sherif] CDC, Div High Consequence Pathogens, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Igbinosa, Irogue] CDC, Div Sci Educ & Dev, Atlanta, GA 30333 USA. [Minta, Anna A.] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Rasmussen, Sonja A.] CDC, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Meaney-Delman, D (reprint author), CDC, Off Director, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM ZikaMCH@cdc.gov NR 13 TC 39 Z9 44 U1 4 U2 20 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 4 PY 2016 VL 65 IS 8 BP 211 EP 214 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4UC UT WOS:000371345500004 PM 26938703 ER PT J AU Hills, SL Russell, K Hennessey, M Williams, C Oster, AM Fischer, M Mead, P AF Hills, Susan L. Russell, Kate Hennessey, Morgan Williams, Charnetta Oster, Alexandra M. Fischer, Marc Mead, Paul TI Transmission of Zika Virus Through Sexual Contact with Travelers to Areas of Ongoing Transmission - Continental United States, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID INTERIM GUIDELINES C1 [Hills, Susan L.; Hennessey, Morgan; Fischer, Marc; Mead, Paul] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Russell, Kate; Hennessey, Morgan; Williams, Charnetta] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Russell, Kate] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Williams, Charnetta] CDC, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Oster, Alexandra M.] CDC, Div HIV AIDS Prevent, NCHHSTP, Atlanta, GA 30333 USA. RP Mead, P (reprint author), CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM pmead@cdc.gov OI Russell, Kate/0000-0001-9343-3355 NR 9 TC 88 Z9 91 U1 9 U2 39 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 4 PY 2016 VL 65 IS 8 BP 215 EP 216 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4UC UT WOS:000371345500005 PM 26937739 ER PT J AU Yeoman, KM Halldin, CN Wood, J Storey, E Johns, D Laney, AS AF Yeoman, K. M. Halldin, C. N. Wood, J. Storey, E. Johns, D. Laney, A. S. TI Current knowledge of US metal and nonmetal miner health: Current and potential data sources for analysis of miner health status SO ARCHIVES OF ENVIRONMENTAL & OCCUPATIONAL HEALTH LA English DT Article DE Health promotion; mining; public health surveillance; respiratory tract diseases ID IRON-ORE MINERS; LUNG-CANCER MORTALITY; DIESEL EXHAUST; RISK-ASSESSMENT; RESPIRATORY SYMPTOMS; RESPONSE ANALYSES; COHORT MORTALITY; TIN MINERS; EXPOSURE; SILICA AB Little is known about the current health status of US metal and nonmetal (MNM) miners, in part because no health surveillance systems exist for this population. The National Institute for Occupational Safety and Health (NIOSH) is developing a program to characterize burden of disease among MNM miners. This report discusses current knowledge and potential data sources of MNM miner health. Recent national surveys were analyzed, and literature specific to MNM miner health status was reviewed. No robust estimates of disease prevalence were identified, and national surveys did not provide information specific to MNM miners. Because substantial gaps exist in the understanding of MNM miners' current health status, NIOSH plans to develop a health surveillance program for this population to guide intervention efforts to reduce occupational and personal risks for chronic illness. C1 [Yeoman, K. M.] NIOSH, Resp Hlth Div, Ctr Dis Control & Prevent, 315 East Montgomery Ave Spokane, Spokane, WA 99207 USA. [Halldin, C. N.; Wood, J.; Storey, E.; Johns, D.; Laney, A. S.] NIOSH, Respiratory Hlth Div, Ctr Dis Control & Prevent, Morgantown, WV USA. RP Yeoman, KM (reprint author), NIOSH, Resp Hlth Div, Ctr Dis Control & Prevent, 315 East Montgomery Ave Spokane, Spokane, WA 99207 USA. EM kyeoman@cdc.gov FU Intramural CDC HHS [CC999999] NR 38 TC 0 Z9 0 U1 4 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1933-8244 EI 2154-4700 J9 ARCH ENVIRON OCCUP H JI Arch. Environ. Occup. Health PD MAR 3 PY 2016 VL 71 IS 2 BP 119 EP 126 DI 10.1080/19338244.2014.998330 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DI4XU UT WOS:000373503500009 PM 25658684 ER PT J AU Rohan, E Zebrack, B Kayser, K Oktay, J AF Rohan, Elizabeth Zebrack, Bradley Kayser, Karen Oktay, Julianne TI Art and Science of Oncology Social Work: Bridging Practice Wisdom and Research SO JOURNAL OF PSYCHOSOCIAL ONCOLOGY LA English DT Meeting Abstract DE Professional Issues; Research C1 Ctr Dis Control & Prevent, Atlanta, GA USA. Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA. Univ Louisville, Kent Sch Social Work, Louisville, KY 40292 USA. Univ Maryland, Sch Social Work, 525 W Redwood St, Baltimore, MD 21201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0734-7332 EI 1540-7586 J9 J PSYCHOSOC ONCOL JI J. Psychosoc. Oncol. PD MAR 3 PY 2016 VL 34 IS 1-2 BP 122 EP 123 PG 2 WC Psychology, Social SC Psychology GA DG5PU UT WOS:000372131100043 ER PT J AU Panuwet, P Hunter, RE D'Souza, PE Chen, XY Radford, SA Cohen, JR Marder, ME Kartavenka, K Ryan, PB Barr, DB AF Panuwet, Parinya Hunter, Ronald E., Jr. D'Souza, Priya E. Chen, Xianyu Radford, Samantha A. Cohen, Jordan R. Marder, M. Elizabeth Kartavenka, Kostya Ryan, P. Barry Barr, Dana Boyd TI Biological Matrix Effects in Quantitative Tandem Mass Spectrometry-Based Analytical Methods: Advancing Biomonitoring SO CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY LA English DT Review DE tandem mass-spectrometry; Analytical method development; matrix effects; biomonitoring; biological analysis ID HUMAN URINE; ION SUPPRESSION; ELECTROSPRAY-IONIZATION; GAS-CHROMATOGRAPHY; ORGANOPHOSPHORUS PESTICIDES; SIGNAL SUPPRESSION; SAMPLE PREPARATION; VALIDATION; QUANTIFICATION; BIOANALYSIS AB The ability to quantify levels of target analytes in biological samples accurately and precisely in biomonitoring involves the use of highly sensitive and selective instrumentation such as tandem mass spectrometers and a thorough understanding of highly variable matrix effects. Typically, matrix effects are caused by co-eluting matrix components that alter the ionization of target analytes as well as the chromatographic response of target analytes, leading to reduced or increased sensitivity of the analysis. Thus, before the desired accuracy and precision standards of laboratory data are achieved, these effects must be characterized and controlled. Here we present our review and observations of matrix effects encountered during the validation and implementation of tandem mass spectrometry-based analytical methods. We also provide systematic, comprehensive laboratory strategies needed to control challenges posed by matrix effects in order to ensure delivery of the most accurate data for biomonitoring studies assessing exposure to environmental toxicants. C1 [Panuwet, Parinya; Hunter, Ronald E., Jr.; D'Souza, Priya E.; Chen, Xianyu; Radford, Samantha A.; Cohen, Jordan R.; Marder, M. Elizabeth; Kartavenka, Kostya; Ryan, P. Barry; Barr, Dana Boyd] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, 201 Dowman Dr, Atlanta, GA 30322 USA. [Chen, Xianyu; Radford, Samantha A.; Ryan, P. Barry] Emory Univ, Dept Chem, 1515 Pierce Dr, Atlanta, GA 30322 USA. [Hunter, Ronald E., Jr.] Ctr Dis Control & Prevent, ORISE, Atlanta, GA USA. RP Panuwet, P (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, 201 Dowman Dr, Atlanta, GA 30322 USA. EM ppanuwe@emory.edu FU American Recovery and Reinvestment Act under NIH [5RC1ES01829902]; National Children's Study [HHSN267200700007C]; PBDE Body Burdens, House Dust Concentrations, and Associations with Thyroid Hormones under NIH [1R21ES019697-01]; Emory Parkinson's disease Collaborative Environmental Research Center under NIEHS [P01 ES016731]; HERCULES: Health and Exposome Research Center at Emory University under NIEHS [1P30ES019776-01A1]; Graduate and Postdoctoral Training in Toxicology NIH grant [T32 ES012870] FX This work was supported in part by the American Recovery and Reinvestment Act of 2009 under NIH grant 5RC1ES01829902, the National Children's Study under contract number HHSN267200700007C, PBDE Body Burdens, House Dust Concentrations, and Associations with Thyroid Hormones under NIH grant 1R21ES019697-01, the Emory Parkinson's disease Collaborative Environmental Research Center under NIEHS grant P01 ES016731, and HERCULES: Health and Exposome Research Center at Emory University under NIEHS grant 1P30ES019776-01A1. Samantha A. Radford was supported by Graduate and Postdoctoral Training in Toxicology NIH grant T32 ES012870. NR 57 TC 5 Z9 6 U1 8 U2 24 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1040-8347 EI 1547-6510 J9 CRIT REV ANAL CHEM JI Crit. Rev. Anal. Chem. PD MAR 3 PY 2016 VL 46 IS 2 BP 93 EP 105 DI 10.1080/10408347.2014.980775 PG 13 WC Chemistry, Analytical SC Chemistry GA DG8VL UT WOS:000372361600002 PM 25562585 ER PT J AU Murchison, AP Friedman, DS Gower, EW Haller, JA Lam, BL Lee, DJ McGwin, G Owsley, C Saaddine, J AF Murchison, Ann P. Friedman, David S. Gower, Emily W. Haller, Julia A. Lam, Byron L. Lee, David J. McGwin, Gerald, Jr. Owsley, Cynthia Saaddine, Jinan CA INSIGHT Study Grp TI A Multi-Center Diabetes Eye Screening Study in Community Settings: Study Design and Methodology SO OPHTHALMIC EPIDEMIOLOGY LA English DT Article DE study design; Diabetes; methodology; tele-ophthalmology; eye screening ID UNITED-STATES; VISUAL IMPAIRMENT; RETINOPATHY; PREVALENCE; ADULTS; CARE; PROGRESSION; DISEASES; PEOPLE AB Purpose: Diabetes is the leading cause of new cases of blindness among adults aged 20-74 years within the United States. The Innovative Network for Sight Research group (INSIGHT) designed the Diabetic Eye Screening Study (DESS) to examine the feasibility and short-term effectiveness of non-mydriatic diabetic retinopathy (DR) screening for adults with diabetes in community-based settings. Methods: Study enrollment began in December 2011 at four sites: an internal medicine clinic at a county hospital in Birmingham, Alabama; a Federally-qualified community healthcare center in Miami-Dade County, Florida; a university-affiliated outpatient pharmacy in Philadelphia, Pennsylvania; and a medical home in Winston-Salem, North Carolina. People 18 years or older with previously diagnosed diabetes were offered free DR screening using non-mydriatic retinal photography that was preceded by a brief questionnaire addressing demographic information and previous eye care use. Visual acuity was also measured for each eye. Images were evaluated at a telemedicine reading center by trained evaluators using the National Health System DR grading classification. Participants and their physicians were sent screening report results and telephoned for a follow-up survey 3 months post-screening to determine whether participants had sought follow-up comprehensive eye care and their experiences with the screening process. Results: Target enrollment at each site was a minimum of 500 persons. Three of the four sites met this enrollment goal. Conclusion: The INSIGHT/DESS is intended to establish the feasibility and short-term effectiveness of DR screening using non-mydriatic retinal photography in persons with diabetes who seek services in community-based clinic and pharmacy settings. C1 [Murchison, Ann P.; Haller, Julia A.] Thomas Jefferson Univ, Wills Eye Hosp, Philadelphia, PA 19107 USA. [Friedman, David S.; Gower, Emily W.] Johns Hopkins Univ Hosp, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21287 USA. [Gower, Emily W.] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA. [Gower, Emily W.] Wake Forest Sch Med, Dept Ophthalmol, Winston Salem, NC USA. [Lam, Byron L.; Lee, David J.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA. [McGwin, Gerald, Jr.; Owsley, Cynthia] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA. [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA. [Saaddine, Jinan] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. RP Murchison, AP (reprint author), Wills Eye Hosp & Res Inst, 840 Walnut St, Philadelphia, PA 19107 USA. EM amurchison@willseye.org FU Centers for Disease Control and Prevention; Johns Hopkins University [5U58DP002653]; University of Alabama at Birmingham [5U58DP002651]; University of Miami [5U58DP002652]; Wills Eye Hospital [5U58DP002655]; Johns Hopkins University: Alcon Research Institute award; University of Alabama at Birmingham: EyeSight Foundation of Alabama; Research to Prevent Blindness Inc.; Buck Trust FX This study was funded by the Centers for Disease Control and Prevention through cooperative agreements with Johns Hopkins University 5U58DP002653), the University of Alabama at Birmingham (5U58DP002651), the University of Miami (5U58DP002652), and the Wills Eye Hospital (5U58DP002655).; Supplemental funding was provided as indicated, listed by institution: Johns Hopkins University: Alcon Research Institute award funds to Dr Friedman; University of Alabama at Birmingham: EyeSight Foundation of Alabama, Research to Prevent Blindness Inc., The Buck Trust. NR 21 TC 1 Z9 1 U1 5 U2 8 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0928-6586 EI 1744-5086 J9 OPHTHAL EPIDEMIOL JI Ophthalmic Epidemiol. PD MAR 3 PY 2016 VL 23 IS 2 BP 109 EP 115 DI 10.3109/09286586.2015.1099682 PG 7 WC Ophthalmology SC Ophthalmology GA DH4FU UT WOS:000372741700007 PM 26949832 ER PT J AU Hark, L Waisbourd, M Myers, JS Henderer, J Crews, JE Saaddine, JB Molineaux, J Johnson, D Sembhi, H Stratford, S Suleiman, A Pizzi, L Spaeth, GL Katz, LJ AF Hark, Lisa Waisbourd, Michael Myers, Jonathan S. Henderer, Jeffrey Crews, John E. Saaddine, Jinan B. Molineaux, Jeanne Johnson, Deiana Sembhi, Harjeet Stratford, Shayla Suleiman, Ayman Pizzi, Laura Spaeth, George L. Katz, L. Jay TI Improving Access to Eye Care among Persons at High-Risk of Glaucoma in Philadelphia - Design and Methodology: The Philadelphia Glaucoma Detection and Treatment Project SO OPHTHALMIC EPIDEMIOLOGY LA English DT Article DE community-based; glaucoma treatment; glaucoma detection; Access to eye care; underserved population ID OPEN-ANGLE GLAUCOMA; VISUAL-FIELD DETERIORATION; QUALITY-OF-LIFE; UNITED-STATES; INTRAOCULAR-PRESSURE; OCULAR HYPERTENSION; SCREENING-PROGRAM; FOLLOW-UP; POPULATION; PREVALENCE AB Purpose: The Wills Eye Glaucoma Research Center initiated a 2-year demonstration project to develop and implement a community-based intervention to improve detection and management of glaucoma in Philadelphia. Methods: The glaucoma detection examination consisted of: ocular, medical, and family history; visual acuity testing; corneal pachymetry; biomicroscopy of the anterior segment; intraocular pressure (IOP) measurement; gonioscopy; funduscopy; automated visual field testing; and fundus-color photography. Treatment included laser surgery and/or IOP-lowering medication. A cost analysis was conducted to understand resource requirements. Outcome measures included; prevalence of glaucoma-related pathology and other eye diseases among high-risk populations; the impact of educational workshops on level of knowledge about glaucoma (assessed by pre- and post-test evaluation); and patient satisfaction of the glaucoma detection examinations in the community (assessed by satisfaction survey). Treatment outcome measures were change in IOP at 4-6 weeks and 4-6 months following selective laser trabeculoplasty treatment, deepening of the anterior chamber angle following laser-peripheral iridotomy treatment, and rate of adherence to recommended follow-up examinations. Cost outcomes included total program costs, cost per case of glaucoma detected, and cost per case of ocular disease detected. Results: This project enrolled 1649 participants (African Americans aged 50+ years, adults 60+ years and individuals with a family history of glaucoma). A total of 1074 individuals attended a glaucoma educational workshop and 1508 scheduled glaucoma detection examination appointments in the community setting. Conclusions: The Philadelphia Glaucoma Detection and Treatment Project aimed to improve access and use of eye care and to provide a model for a targeted community-based glaucoma program. C1 [Hark, Lisa; Waisbourd, Michael; Myers, Jonathan S.; Molineaux, Jeanne; Johnson, Deiana; Sembhi, Harjeet; Stratford, Shayla; Suleiman, Ayman; Spaeth, George L.; Katz, L. Jay] Thomas Jefferson Univ, Wills Eye Hosp, Glaucoma Res Ctr, 840 Walnut St, Philadelphia, PA 19107 USA. [Henderer, Jeffrey] Temple Univ, Sch Med, Dept Ophthalmol, Philadelphia, PA 19122 USA. [Crews, John E.; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Vis Hlth Initiat, Atlanta, GA USA. [Pizzi, Laura] Thomas Jefferson Univ, Sch Pharm, Philadelphia, PA 19107 USA. RP Hark, L (reprint author), Thomas Jefferson Univ, Wills Eye Hosp, Glaucoma Res Ctr, 840 Walnut St, Philadelphia, PA 19107 USA. EM lhark@willseye.org FU US Centers for Disease Control and Prevention (CDC) Cooperative Agreement [1U58DP004060-01] FX The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper. Financial support was provided by the US Centers for Disease Control and Prevention (CDC) Cooperative Agreement #1U58DP004060-01. NR 50 TC 2 Z9 2 U1 1 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0928-6586 EI 1744-5086 J9 OPHTHAL EPIDEMIOL JI Ophthalmic Epidemiol. PD MAR 3 PY 2016 VL 23 IS 2 BP 122 EP 130 DI 10.3109/09286586.2015.1099683 PG 9 WC Ophthalmology SC Ophthalmology GA DH4FU UT WOS:000372741700009 PM 26950056 ER PT J AU Sumner, SA Mercado-Crespo, MC Spelke, MB Paulozzi, L Sugerman, DE Hillis, SD Stanley, C AF Sumner, Steven Allan Mercado-Crespo, Melissa C. Spelke, M. Bridget Paulozzi, Leonard Sugerman, David E. Hillis, Susan D. Stanley, Christina TI Use of Naloxone by Emergency Medical Services during Opioid Drug Overdose Resuscitation Efforts SO PREHOSPITAL EMERGENCY CARE LA English DT Article DE emergency medical services; opioid; naloxone; heroin; resuscitation ID VITAL SIGNS OVERDOSES; HEROIN OVERDOSE; OPIATE OVERDOSE; PAIN RELIEVERS; UNITED-STATES; RHODE-ISLAND; DEATHS; IMPLEMENTATION; INTRANASAL; PATTERNS AB Naloxone administration is an important component of resuscitation attempts by emergency medical services (EMS) for opioid drug overdoses. However, EMS providers must first recognize the possibility of opioid overdose in clinical encounters. As part of a public health response to an outbreak of opioid overdoses in Rhode Island, we examined missed opportunities for naloxone administration and factors potentially influencing EMS providers' decision to administer naloxone. We reviewed medical examiner files on all individuals who died of an opioid-related drug overdose in Rhode Island from January 1, 2012 through March 31, 2014, underwent attempted resuscitation by EMS providers, and had records available to assess for naloxone administration. We evaluated whether these individuals received naloxone as part of their resuscitation efforts and compared patient and scene characteristics of those who received naloxone to those who did not receive naloxone via chi-square, t-test, and logistic regression analyses. One hundred and twenty-four individuals who underwent attempted EMS resuscitation died due to opioid overdose. Naloxone was administered during EMS resuscitation attempts in 82 (66.1%) of cases. Females were nearly three-fold as likely not to receive naloxone as males (OR 2.9; 95% CI 1.2-7.0; p-value 0.02). Additionally, patients without signs of potential drug abuse also had a greater than three-fold odds of not receiving naloxone (OR 3.3; 95% CI 1.2-9.2; p-value 0.02). Older individuals, particularly those over age 50, were more likely not to receive naloxone than victims younger than age 30 (OR 4.8; 95% CI 1.3-17.4; p-value 0.02). Women, older individuals, and those patients without clear signs of illicit drug abuse, were less likely to receive naloxone in EMS resuscitation attempts. Heightened clinical suspicion for opioid overdose is important given the recent increase in overdoses among patients due to prescription opioids. C1 [Sumner, Steven Allan] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway,Mailstop F-63, Atlanta, GA USA. [Mercado-Crespo, Melissa C.; Spelke, M. Bridget; Paulozzi, Leonard; Sugerman, David E.; Hillis, Susan D.] CDC, Atlanta, GA 30333 USA. [Stanley, Christina] Rhode Isl Dept Hlth, Providence, RI 02908 USA. RP Sumner, SA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway,Mailstop F-63, Atlanta, GA USA. EM hvo5@cdc.gov OI Spelke, Bridget/0000-0002-5950-8197 FU Intramural CDC HHS [CC999999] NR 26 TC 1 Z9 1 U1 2 U2 8 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1090-3127 EI 1545-0066 J9 PREHOSP EMERG CARE JI Prehosp. Emerg. Care PD MAR 3 PY 2016 VL 20 IS 2 BP 220 EP 225 DI 10.3109/10903127.2015.1076096 PG 6 WC Emergency Medicine; Public, Environmental & Occupational Health SC Emergency Medicine; Public, Environmental & Occupational Health GA DH5PX UT WOS:000372845300007 PM 26383533 ER PT J AU Sullivan, RT Ssewanyana, I Wamala, S Nankya, F Jagannathan, P Tappero, JW Mayanja-Kizza, H Muhindo, MK Arinaitwe, E Kamya, M Dorsey, G Feeney, ME Riley, EM Drakeley, CJ Greenhouse, B Sullivan, R AF Sullivan, Richard T. Ssewanyana, Isaac Wamala, Samuel Nankya, Felistas Jagannathan, Prasanna Tappero, Jordan W. Mayanja-Kizza, Harriet Muhindo, Mary K. Arinaitwe, Emmanuel Kamya, Moses Dorsey, Grant Feeney, Margaret E. Riley, Eleanor M. Drakeley, Chris J. Greenhouse, Bryan Sullivan, Richard TI B cell sub-types following acute malaria and associations with clinical immunity SO MALARIA JOURNAL LA English DT Article DE Atypical memory B cells; Transitional B cells; Plasmablasts; Plasma cells Plasmodium falciparum; Malaria; Immunity ID PLASMODIUM-FALCIPARUM INFECTION; ERYTHROCYTE-MEMBRANE PROTEIN-1; ACQUIRED-IMMUNITY; MEMORY; CHILDREN; INDIVIDUALS; EXPRESSION; BLOOD; AGE; ACTIVATION AB Background: Repeated exposure to Plasmodium falciparum is associated with perturbations in B cell sub-set homeostasis, including expansion atypical memory B cells. However, B cell perturbations immediately following acute malaria infection have been poorly characterized, especially with regard to their relationship with immunity to malaria. Methods: To better understand the kinetics of B cell sub-sets following malaria, the proportions of six B cell sub-sets were assessed at five time points following acute malaria in four to 5 years old children living in a high transmission region of Uganda. B cell sub-set kinetics were compared with measures of clinical immunity to malaria-lower parasite density at the time of malaria diagnosis and recent asymptomatic parasitaemia. Results: Atypical memory B cell and transitional B cell proportions increased following malaria. In contrast, plasmablast proportions were highest at the time of malaria diagnosis and rapidly declined following treatment. Increased proportions of atypical memory B cells were associated with greater immunity to malaria, whereas increased proportions of transitional B cells were associated with evidence of less immunity to malaria. Conclusions: These findings highlight the dynamic changes in multiple B cell sub-sets following acute, uncomplicated malaria, and how these sub-sets are associated with developing immunity to malaria. C1 [Sullivan, Richard T.; Jagannathan, Prasanna; Dorsey, Grant; Feeney, Margaret E.; Greenhouse, Bryan; Sullivan, Richard] Univ Calif San Francisco, Dept Med, Box 0811, San Francisco, CA 94110 USA. [Ssewanyana, Isaac; Wamala, Samuel; Nankya, Felistas; Mayanja-Kizza, Harriet; Muhindo, Mary K.; Arinaitwe, Emmanuel; Kamya, Moses] Infect Dis Res Collaborat, Tororo, Uganda. [Ssewanyana, Isaac; Riley, Eleanor M.; Drakeley, Chris J.] London Sch Hyg & Trop Med, Dept Immunol & Infect, London WC1, England. [Tappero, Jordan W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mayanja-Kizza, Harriet; Kamya, Moses] Makerere Univ, Sch Med, Kampala, Uganda. RP Sullivan, R (reprint author), Univ Calif San Francisco, Dept Med, Box 0811, San Francisco, CA 94110 USA. EM richard.sullivan@ucsf.edu RI Riley, Eleanor/C-8960-2013 OI Riley, Eleanor/0000-0003-3447-3570 FU Centers for Disease Control and Prevention [U62P024421]; National Institutes of Health International Centers of Excellence in Malaria Research (ICMER) program U19 [AI089674]; NIH [AI093615, AI107200]; UCSF Centers for AIDS Research [P30AI027763]; Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene; Doris Duke Charitable Foundation (Doris Duke Clinical Scientist Development Award) FX We are grateful to all the parents and guardians for giving their consent and to the study participants for their cooperation. We thank all the members of the study team for their tireless effort and excellent work. This work was supported by the Centers for Disease Control and Prevention [Cooperative Agreement No. U62P024421] (JT and GD), National Institutes of Health International Centers of Excellence in Malaria Research (ICMER) program U19 [AI089674] (RTS, IS, MK, MEF, CJD and BG), NIH R01 [AI093615] (MEF), UCSF Centers for AIDS Research [P30AI027763] (MEF), Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene (PJ), NIH R21 [AI107200] (BG), and by the Doris Duke Charitable Foundation (Doris Duke Clinical Scientist Development Award to (BG). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or any funding institution. NR 47 TC 2 Z9 2 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAR 3 PY 2016 VL 15 AR 139 DI 10.1186/s12936-016-1190-0 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DF6KJ UT WOS:000371464200001 PM 26939776 ER PT J AU Robertson, M Wei, SC Beer, L Adedinsewo, D Stockwell, S Dombrowski, JC Johnson, C Skarbinski, J AF Robertson, McKaylee Wei, Stanley C. Beer, Linda Adedinsewo, Demilade Stockwell, Sandra Dombrowski, Julia C. Johnson, Christopher Skarbinski, Jacek TI Delayed entry into HIV medical care in a nationally representative sample of HIV-infected adults receiving medical care in the USA SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE initiation of care; HIV testing; HIV/AIDS; HIV care continuum; Linkage to care ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; UNITED-STATES; EARLY RETENTION; RISK-FACTORS; VIRAL LOAD; DIAGNOSIS; LINKAGE; TRANSMISSION; PREVENTION AB Before widespread antiretroviral therapy (ART), an estimated 17% of people delayed HIV care. We report national estimates of the prevalence and factors associated with delayed care entry in the contemporary ART era. We used Medical Monitoring Project data collected from June 2009 through May 2011 for 1425 persons diagnosed with HIV from May 2004 to April 2009 who initiated care within 12 months. We defined delayed care as entry >three months from diagnosis. Adjusted prevalence ratios (aPRs) were calculated to identify risk factors associated with delayed care. In this nationally representative sample of HIV-infected adults receiving medical care, 7.0% (95% confidence interval [CI]: 5.3-8.8) delayed care after diagnosis. Black race was associated with a lower likelihood of delay than white race (aPR 0.38). Men who have sex with women versus women who have sex with men (aPR 1.86) and persons required to take an HIV test versus recommended by a provider (aPR 2.52) were more likely to delay. Among those who delayed 48% reported a personal factor as the primary reason. Among persons initially diagnosed with HIV (non-AIDS), those who delayed care were twice as likely (aPR 2.08) to develop AIDS as of May 2011. Compared to the pre-ART era, there was a nearly 60% reduction in delayed care entry. Although relatively few HIV patients delayed care entry, certain groups may have an increased risk. Focus on linkage to care among persons who are required to take an HIV test may further reduce delayed care entry. C1 [Robertson, McKaylee; Adedinsewo, Demilade] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Robertson, McKaylee; Wei, Stanley C.; Beer, Linda; Adedinsewo, Demilade; Stockwell, Sandra; Johnson, Christopher; Skarbinski, Jacek] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Wei, Stanley C.] US PHS, Atlanta, GA USA. [Dombrowski, Julia C.] Univ Washington, Dept Med, Seattle, WA USA. [Dombrowski, Julia C.] Publ Hlth Seattle & King Cty HIV STD Program, Seattle, WA USA. RP Robertson, M (reprint author), Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA.; Robertson, M (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM mr1472@hunter.cuny.edu OI Adedinsewo, Demilade/0000-0002-8629-2029 FU Centers for Disease Control and Prevention [PS09-937] FX This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an agreement between the US Department of Energy and CDC. Funding for the Medical Monitoring Project is provided by a cooperative agreement (PS09-937) from the Centers for Disease Control and Prevention. NR 32 TC 1 Z9 1 U1 3 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 EI 1360-0451 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PD MAR 3 PY 2016 VL 28 IS 3 BP 325 EP 333 DI 10.1080/09540121.2015.1096891 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA DE5PD UT WOS:000370682600009 PM 26493721 ER PT J AU Silver, SR Steege, AL Boiano, JM AF Silver, Sharon R. Steege, Andrea L. Boiano, James M. TI Predictors of adherence to safe handling practices for antineoplastic drugs: A survey of hospital nurses SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE Antineoplastic drugs; exposure controls; healthcare; hospital; nurses; oncology ID HEALTH-CARE WORKERS; AMBULATORY ONCOLOGY SETTINGS; CONTAMINATION; AWARENESS; EXPOSURE; GUIDELINES; KNOWLEDGE AB Despite growing awareness of the hazards of exposure to antineoplastic drugs (ADs), surveys continue to find incomplete adherence to recommended safe handling guidelines. A 2011 survey of healthcare workers presents an opportunity to examine factors associated with adherence among 1094 hospital nurses who administered ADs.Data for these hypothesis-generating analyses were taken from an anonymous, web-based survey of healthcare workers. Regression modeling was used to examine associations between a number of predictors (engineering controls, work practices, nurse perceptions, and nurse and hospital characteristics) and three outcomes reported by nurses: use of personal protective equipment (PPE); activities performed with gloves previously worn to administer ADs; and spills of ADs.Adherence to safe handling guidelines was not universal, and AD spills were reported by 9.5% of nurses during the week prior to the survey. Familiarity with safe handling guidelines and training in safe handling were associated with more reported PPE use. Nurse-perceived availability of PPE was associated with more reported PPE use and lower odds of reported spills. Use of closed system drug-transfer devices and luer-lock fittings also decreased the odds of self-reported AD spills, while more frequent AD administration increased the risk. AD administration frequency was also associated with performing more activities with gloves previously worn to administer ADs, and nurse perception of having adequate time for taking safety precautions with fewer such activities.The results suggest that training and familiarity with guidelines for safe handling of ADs, adequate time to adhere to guidelines, and availability of PPE and certain engineering controls are key to ensuring adherence to safe handling practices. Further assessment of training components and engineering controls would be useful for tailoring interventions targeting these areas. C1 [Silver, Sharon R.; Steege, Andrea L.; Boiano, James M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 1090 Tusculum Ave,MS R-15, Cincinnati, OH 45226 USA. RP Silver, SR (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 1090 Tusculum Ave,MS R-15, Cincinnati, OH 45226 USA. EM ssilver@cdc.gov RI Steege, Andrea/H-8900-2016 OI Silver, Sharon/0000-0002-7679-5028; Steege, Andrea/0000-0001-5665-2559 FU National Institute for Occupational Safety and Health FX This project was supported by the National Institute for Occupational Safety and Health NR 31 TC 0 Z9 0 U1 7 U2 11 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD MAR 3 PY 2016 VL 13 IS 3 BP 203 EP 212 DI 10.1080/15459624.2015.1091963 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DC4KL UT WOS:000369189500002 PM 26556549 ER PT J AU Murashov, V Hearl, F Howard, J AF Murashov, Vladimir Hearl, Frank Howard, John TI Working safely with robot workers: Recommendations for the new workplace SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Editorial Material DE Collaborative robots; industrial robots; occupational safety; risk assessment; risk mitigation; service robots; workers; workplace AB The increasing use of robots in performing tasks alongside or together with human co-workers raises novel occupational safety and health issues. The new 21st century workplace will be one in which occupational robotics plays an increasing role. This article describes the increasing complexity of robots and proposes a number of recommendations for the practice of safe occupational robotics. C1 [Murashov, Vladimir; Hearl, Frank; Howard, John] NIOSH, Ctr Dis Control & Prevent, Washington, DC 20201 USA. [Murashov, Vladimir] NIOSH, 395 E St SW, Washington, DC 20201 USA. RP Murashov, V (reprint author), NIOSH, 395 E St SW, Washington, DC 20201 USA. EM vmurashov@cdc.gov FU Intramural CDC HHS [CC999999] NR 58 TC 1 Z9 1 U1 3 U2 20 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD MAR 3 PY 2016 VL 13 IS 3 DI 10.1080/15459624.2015.1116700 PG 11 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DC4KK UT WOS:000369189400001 PM 26554511 ER PT J AU Cauda, E Miller, A Drake, P AF Cauda, Emanuele Miller, Arthur Drake, Pamela TI Promoting early exposure monitoring for respirable crystalline silica: Taking the laboratory to the mine site SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE Exposure; field-based monitoring; mining; portable FTIR; respirable crystalline silica (RCS) ID FLOW RATE SAMPLERS; X-RAY-DIFFRACTION; COAL-DUST; INFRARED SPECTROPHOTOMETRY; QUARTZ; COLLECTION AB The exposure to respirable crystalline silica (RCS) in the mining industry is a recognized occupational hazard. The assessment and monitoring of the exposure to RCS is limited by two main factors: (1) variability of the silica percent in the mining dust and (2) lengthy off-site laboratory analysis of collected samples. The monitoring of respirable dust via traditional or real-time techniques is not adequate. A solution for on-site quantification of RCS in dust samples is being investigated by the Office of Mine Safety and Health Research, a division of the National Institute for Occupational Safety and Health. The use of portable Fourier transform infrared analyzers in conjunction with a direct-on-filter analysis approach is proposed. The progress made so far, the necessary steps in progress, and the application of the monitoring solution to a small data set is presented. When developed, the solution will allow operators to estimate RCS immediately after sampling, resulting in timelier monitoring of RCS for self-assessment of compliance at the end of the shift, more effective engineering monitoring, and better evaluation of control technologies. C1 [Cauda, Emanuele; Miller, Arthur; Drake, Pamela] NIOSH, Off Mine Safety & Hlth Res, Ctr Dis Control & Prevent CDC, Pittsburgh, PA 15236 USA. RP Cauda, E (reprint author), NIOSH, Off Mine Safety & Hlth Res, Ctr Dis Control & Prevent CDC, Pittsburgh, PA 15236 USA. EM ecauda@cdc.gov NR 25 TC 1 Z9 1 U1 7 U2 21 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD MAR 3 PY 2016 VL 13 IS 3 BP D39 EP D45 DI 10.1080/15459624.2015.1116691 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DB1XB UT WOS:000368301200001 PM 26558490 ER PT J AU Gleim, ER Garrison, LE Vello, MS Savage, MY Lopez, G Berghaus, RD Yabsley, MJ AF Gleim, Elizabeth R. Garrison, Laurel E. Vello, Marianne S. Savage, Mason Y. Lopez, Gaylord Berghaus, Roy D. Yabsley, Michael J. TI Factors associated with tick bites and pathogen prevalence in ticks parasitizing humans in Georgia, USA SO PARASITES & VECTORS LA English DT Article DE Epidemiology; Tick-borne pathogens; Tick-borne disease; Rickettsia; Ticks; Georgia ID POLYMERASE-CHAIN-REACTION; LYME-DISEASE PREVENTION; MOUNTAIN-SPOTTED-FEVER; AMBLYOMMA-AMERICANUM; SOUTH-CAROLINA; UNITED-STATES; EHRLICHIA-CHAFFEENSIS; RICKETTSIA-AMBLYOMMII; ETIOLOGIC AGENT; NORTH-CAROLINA AB Background: The incidence and emergence of tick-borne diseases has increased dramatically in the United States during the past 30 years, yet few large-scale epidemiological studies have been performed on individuals bitten by ticks. Epidemiological information, including disease development, may provide valuable information regarding effectiveness of tick bite prevention education, pathogen transmission, human-disease dynamics, and potential implications for under reporting of tick-borne diseases. Methods: Ticks found attached to Georgia residents were submitted for identification and polymerase chain reaction (PCR) testing for Francisella tularensis, Ehrlichia, Anaplasma, Borrelia, and Rickettsia spp. Tick bite victims were interviewed three weeks after the tick bite to identify various epidemiologic factors associated with infestation and if signs suggestive of a tick-borne disease had developed. Fisher's exact test of independence was used to evaluate associations between various factors evaluated in the study. A multivariable logistic regression model was used for the prediction of nonspecific illness post-tick bite. Results: From April 2005-December 2006, 444 participants submitted 597 ticks (426 Amblyomma americanum, 142 Dermacentor variabilis, 19 A. maculatum, 7 Ixodes scapularis, 3 Amblyomma sp.) which originated from 95 counties. Only 25 (34 %) of 74 interviewed individuals purposely took tick bite prevention measures. Ticks that were PCR positive for bacterial organisms were attached to 136 participants. Of the 77 participants who developed non-specific illness, 50 did not have PCR positive ticks, whereas 27 did have PCR positive tick (s). Of those 27 individuals, 12 fit the criteria for a possible tick-borne illness (i.e., tick attached n> 6 h [if known], >= 4 day incubation period, and the individual exhibited clinical symptoms typical of a tick-borne illness without exhibiting cough, sore throat, or sinus congestion). Ticks from these individuals were positive for R. amblyommii (n = 8), E. ewingii (n = 1), R. montana (n = 1), R. rhiphicephali (n = 1), and Rickettsia sp. TR-39 (n=1). Conclusions: Although illnesses reported in this study cannot definitively be connected with tick bites, it does provide insight into development, diagnosis, and treatment of possible tick-borne diseases post-tick bite. The study also provided data on pathogen prevalence, and epidemiologic factors associated with tick bites, as well as tick presence by county in Georgia. C1 [Gleim, Elizabeth R.; Savage, Mason Y.; Yabsley, Michael J.] Univ Georgia, Coll Vet Med, Southeastern Cooperat Wildlife Dis Study, 589 DW Brooks Dr,Wildlife Hlth Bldg, Athens, GA 30602 USA. [Gleim, Elizabeth R.; Yabsley, Michael J.] Univ Georgia, Warnell Sch Forestry & Nat Resources, 180 E Green St, Athens, GA 30602 USA. [Gleim, Elizabeth R.] Emory Univ, Oxford Coll, 150 Few Cr, Oxford, GA 30054 USA. [Garrison, Laurel E.; Vello, Marianne S.] Georgia Dept Human Resources, Div Publ Hlth, 2 Peachtree St NW, Atlanta, GA 30303 USA. [Garrison, Laurel E.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C 25, Atlanta, GA 30333 USA. [Savage, Mason Y.] N Carolina State Univ, Coll Vet Med, 1052 William Moore Dr, Raleigh, NC 27606 USA. [Lopez, Gaylord] Georgia Poison Ctr, 80 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA. [Berghaus, Roy D.] Univ Georgia, Coll Vet Med, Dept Populat Hlth, 501 DW Brooks Dr, Atlanta, GA 30602 USA. RP Gleim, ER (reprint author), Univ Georgia, Coll Vet Med, Southeastern Cooperat Wildlife Dis Study, 589 DW Brooks Dr,Wildlife Hlth Bldg, Athens, GA 30602 USA.; Gleim, ER (reprint author), Univ Georgia, Warnell Sch Forestry & Nat Resources, 180 E Green St, Athens, GA 30602 USA.; Gleim, ER (reprint author), Emory Univ, Oxford Coll, 150 Few Cr, Oxford, GA 30054 USA. EM egleim@gmail.com FU Centers for Disease Control and Prevention/University of Georgia collaborative grant (Ecosystem Health and Human Health: Understanding the Ecological Effects of Prescribed Fire Regimes on the Distribution and Population Dynamics of Tick-Borne Zoonoses) [8212]; Warnell School of Forestry and Natural Resources; J.W. Jones Ecological Research Center; Southeastern Cooperative Wildlife Disease Study FX The authors thank Meghan Weems and Rosmarie Kelly for their assistance with study implementation and participant interviews. Support of ERG was funded in part by Centers for Disease Control and Prevention/University of Georgia collaborative grant (#8212, Ecosystem Health and Human Health: Understanding the Ecological Effects of Prescribed Fire Regimes on the Distribution and Population Dynamics of Tick-Borne Zoonoses), the Warnell School of Forestry and Natural Resources and the J.W. Jones Ecological Research Center. Additional funding was provided by the Southeastern Cooperative Wildlife Disease Study through sponsorship with member states. NR 44 TC 2 Z9 3 U1 3 U2 20 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD MAR 2 PY 2016 VL 9 AR 125 DI 10.1186/s13071-016-1408-6 PG 13 WC Parasitology SC Parasitology GA DF6GZ UT WOS:000371455200001 PM 26935205 ER PT J AU Diaz, MH Cross, KE Benitez, AJ Hicks, LA Kutty, P Bramley, AM Chappell, JD Hymas, W Patel, A Qi, C Williams, DJ Arnold, SR Ampofo, K Self, WH Grijalva, CG Anderson, EJ McCullers, JA Pavia, AT Wunderink, RG Edwards, KM Jain, S Winchell, JM AF Diaz, Maureen H. Cross, Kristen E. Benitez, Alvaro J. Hicks, Lauri A. Kutty, Preeta Bramley, Anna M. Chappell, James D. Hymas, Weston Patel, Anami Qi, Chao Williams, Derek J. Arnold, Sandra R. Ampofo, Krow Self, Wesley H. Grijalva, Carlos G. Anderson, Evan J. McCullers, Jonathan A. Pavia, Andrew T. Wunderink, Richard G. Edwards, Kathryn M. Jain, Seema Winchell, Jonas M. TI Identification of Bacterial and Viral Codetections With Mycoplasma pneumoniae Using the TaqMan Array Card in Patients Hospitalized With Community-Acquired Pneumonia SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE community-acquired pneumonia; multipathogen detection; Mycoplasma pneumoniae ID REQUIRING HOSPITALIZATION; CLINICAL CHARACTERISTICS; RESPIRATORY-INFECTIONS; CHILDREN; CARRIAGE; STREPTOCOCCUS; PATHOGENS AB Mycoplasma pneumoniae was detected in a number of patients with community-acquired pneumonia in a recent prospective study. To assess whether other pathogens were also detected in these patients, TaqMan Array Cards were used to test 216 M pneumoniae-positive respiratory specimens for 25 additional viral and bacterial respiratory pathogens. It is interesting to note that 1 or more codetections, predominantly bacterial, were identified in approximately 60% of specimens, with codetections being more common in children. C1 [Diaz, Maureen H.; Cross, Kristen E.; Benitez, Alvaro J.; Hicks, Lauri A.; Kutty, Preeta; Winchell, Jonas M.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. [Bramley, Anna M.; Jain, Seema] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Chappell, James D.; Williams, Derek J.; Self, Wesley H.; Grijalva, Carlos G.; Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Hymas, Weston; Ampofo, Krow; Pavia, Andrew T.] Univ Utah, Ctr Sci, Salt Lake City, UT USA. [Patel, Anami; Arnold, Sandra R.; McCullers, Jonathan A.] Le Bonheur Childrens Hosp, Memphis, TN USA. [Patel, Anami; Arnold, Sandra R.; McCullers, Jonathan A.] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA. [Qi, Chao; Wunderink, Richard G.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Edwards, Kathryn M.] Vanderbilt Vaccine Res Program, Nashville, TN USA. [Anderson, Evan J.] Emory Univ, Sch Med, Atlanta, GA USA. [McCullers, Jonathan A.] St Jude Childrens Res Hosp, Memphis, TN USA. RP Winchell, JM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS G-03, Atlanta, GA 30333 USA. EM jwinchell@cdc.gov OI Wunderink, Richard/0000-0002-8527-4195 NR 20 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SPR PY 2016 VL 3 IS 2 DI 10.1093/ofid/ofw071 PG 4 WC Infectious Diseases SC Infectious Diseases GA EC3IR UT WOS:000388020200027 ER PT J AU Hales, CM Johnson, E Helgenberger, L Papania, MJ Larzelere, M Gopalani, SV Lebo, E Wallace, G Moturi, E Hickman, CJ Rota, PA Alexander, HS Marin, M AF Hales, Craig M. Johnson, Eliaser Helgenberger, Louisa Papania, Mark J. Larzelere, Maribeth Gopalani, Sameer V. Lebo, Emmaculate Wallace, Greg Moturi, Edna Hickman, Carole J. Rota, Paul A. Alexander, Hinden S. Marin, Mona TI Measles Outbreak Associated With Low Vaccine Effectiveness Among Adults in Pohnpei State, Federated States of Micronesia, 2014 SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE Federated States of Micronesia; measles; measles vaccine; MMR; vaccine effectiveness ID VIRUS; EXPOSURE; ISLAND; GENE AB Background. A measles outbreak in Pohnpei State, Federated States of Micronesia in 2014 affected many persons who had received >= 1 dose of measles-containing vaccine (MCV). A mass vaccination campaign targeted persons aged 6 months to 49 years, regardless of prior vaccination. Methods. We evaluated vaccine effectiveness (VE) of MCV by comparing secondary attack rates among vaccinated and unvaccinated contacts after household exposure to measles. Results. Among 318 contacts, VE for precampaign MCV was 23.1% (95% confidence interval [CI], -425 to 87.3) for 1 dose, 63.4% (95% CI, -103 to 90.6) for 2 doses, and 95.9% (95% CI, 45.0 to 100) for 3 doses. Vaccine effectiveness was 78.7% (95% CI, 10.1 to 97.7) for campaign doses received >= 5 days before rash onset in the primary case and 50.4% (95% CI, -52.1 to 87.9) for doses received 4 days before to 3 days after rash onset in the primary case. Vaccine effectiveness for most recent doses received before 2010 ranged from 51% to 57%, but it increased to 84% for second doses received in 2010 or later. Conclusions. Low VE was a major source of measles susceptibility in this outbreak; potential reasons include historical cold chain inadequacies or waning of immunity. Vaccine effectiveness of campaign doses supports rapid implementation of vaccination campaigns in outbreak settings. C1 [Hales, Craig M.; Papania, Mark J.; Larzelere, Maribeth; Wallace, Greg; Hickman, Carole J.; Rota, Paul A.; Marin, Mona] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Johnson, Eliaser; Alexander, Hinden S.] Federated States Micronesia, Div Primary Hlth Care, Kolonia, Pohnpei State, Micronesia. [Helgenberger, Louisa; Gopalani, Sameer V.] Govt Federated States Micronesia, Dept Hlth & Social Affairs, Palikir, Micronesia. [Lebo, Emmaculate; Moturi, Edna] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Hales, Craig M.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Gopalani, Sameer V.] Federated States Micronesia, Country Liaison Off Northern Micronesia, WHO, Palikir, Micronesia. [Moturi, Edna] United Nations High Commissioner Refugees, Dar Es Salaam, Tanzania. RP Hales, CM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop G37, Atlanta, GA 30333 USA. EM chales@cdc.gov NR 21 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SPR PY 2016 VL 3 IS 2 DI 10.1093/ofid/ofw064 PG 7 WC Infectious Diseases SC Infectious Diseases GA EC3IR UT WOS:000388020200020 ER PT J AU Moturi, E Mahmud, A Kamadjeu, R Mbaeyi, C Farag, N Mulugeta, A Gary, H Ehrhardt, D AF Moturi, Edna Mahmud, Abdirahman Kamadjeu, Raoul Mbaeyi, Chukwuma Farag, Noha Mulugeta, Abraham Gary, Howard, Jr. Ehrhardt, Derek TI Contribution of Contact Sampling in Increasing Sensitivity of Poliovirus Detection During A Polio Outbreak-Somalia, 2013 SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE acute flaccid paralysis; contact stool specimens; eradication; polio; Somalia ID WILD POLIOVIRUS; POLIOMYELITIS; ERADICATION; SURVEILLANCE; EPIDEMIOLOGY; AMERICA; SYRIA AB Background. In May 2013, a wild poliovirus type 1 (WPV1) outbreak reported in Somalia provided an opportunity to examine the contribution of testing contacts to WPV detection. Methods. We reviewed acute flaccid paralysis (AFP) case-patients and linked contacts reported in the Somalia Surveillance Database from May 9 to December 31, 2013. We restricted our analysis to AFP case-patients that had >= 3 contacts and calculated the contribution of each contact to case detection. Results. Among 546 AFP cases identified, 328 AFP cases had >= 3 contacts. Among the 328 AFP cases with >= 3 contacts, 93 WPV1 cases were detected: 58 cases (62%; 95% confidence interval [CI], 52%-72%) were detected through testing stool specimens from AFP case-patients; and 35 cases (38%; 95% CI, 28%-48%) were detected through testing stool specimens from contacts, including 19 cases (20%; 95% CI, 14%-30%) from the first contact, 11 cases (12%; 95% CI, 7%-20%) from the second contact, and 5 cases (5%; 95% CI, 2%-12%) from the third contact. Among the 103 AFP cases with >= 4 contacts, 3 (6%; 95% CI, 2%-16%) of 52 WPV1 cases were detected by testing the fourth contact. No additional WPV1 cases were detected by testing >4 contacts. Conclusions. Stool specimens from 3 to 4 contacts of persons with AFP during polio outbreaks are needed to maximize detection of WPV cases. C1 [Moturi, Edna] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Moturi, Edna; Mahmud, Abdirahman; Mbaeyi, Chukwuma; Farag, Noha; Gary, Howard, Jr.; Ehrhardt, Derek] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. [Kamadjeu, Raoul; Mulugeta, Abraham] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. WHO, Somalia Country Off, Nairobi, Kenya. [Moturi, Edna] United Nations High Commissioner Refugees, Dar Es Salaam, Tanzania. RP Moturi, E (reprint author), United Nations High Commissioner Refugees, Dar Es Salaam, Tanzania.; Moturi, E (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30329 USA. EM kwamsie@gmail.com NR 22 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SPR PY 2016 VL 3 IS 2 DI 10.1093/ofid/ofw111 PG 4 WC Infectious Diseases SC Infectious Diseases GA EC3IR UT WOS:000388020200063 ER PT J AU Zhong, WM Liu, F Wilson, JR Holiday, C Li, ZN Bai, YH Tzeng, WP Stevens, J York, IA Levine, MZ AF Zhong, Weimin Liu, Feng Wilson, Jason R. Holiday, Crystal Li, Zhu-Nan Bai, Yaohui Tzeng, Wen-Pin Stevens, James York, Ian A. Levine, Min Z. TI Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of Influenza A Viruses After Influenza Vaccination in Humans SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE antibody; antibody-dependent cell-mediated cytotoxicity; hemagglutinin; influenza A virus; vaccines ID RANDOMIZED CLINICAL-TRIAL; H5N1 VACCINE; SCID MICE; INFECTION; PROTECTION; IMMUNOGENICITY; H1N1; CHILDREN; RECOGNITION; CHALLENGE AB Background. Detection of neutralizing antibodies (nAbs) to influenza A virus hemagglutinin (HA) antigens by conventional serological assays is currently the main immune correlate of protection for influenza vaccines However, current prepandemic avian influenza vaccines are poorly immunogenic in inducing nAbs despite considerable protection conferred. Recent studies show that Ab-dependent cell-mediated cytotoxicity (ADCC) to HA antigens are readily detectable in the sera of healthy individuals and patients with influenza infection. Methods. Virus neutralization and ADCC activities of serum samples from individuals who received either seasonal or a stockpiled H5N1 avian influenza vaccine were evaluated by hemagglutination inhibition assay, microneutralization assay, and an improved ADCC natural killer (NK) cell activation assay. Results. Immunization with inactivated seasonal influenza vaccine led to strong expansion of both nAbs and ADCC-mediating antibodies (adccAbs) to H3 antigen of the vaccine virus in 24 postvaccination human sera. In sharp contrast, 18 individuals vaccinated with the adjuvanted H5N1 avian influenza vaccine mounted H5-specific antibodies with strong ADCC activities despite moderate virus neutralization capacity. Strength of HA-specific ADCC activities is largely associated with the titers of HA-binding antibodies and not with the fine antigenic specificity of anti-HA nAbs. Conclusions. Detection of both nAbs and adccAbs may better reflect protective capacity of HA-specific antibodies induced by avian influenza vaccines. C1 [Zhong, Weimin; Liu, Feng; Wilson, Jason R.; Holiday, Crystal; Li, Zhu-Nan; Bai, Yaohui; Tzeng, Wen-Pin; Stevens, James; York, Ian A.; Levine, Min Z.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA 30329 USA. RP Zhong, WM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM wzhong@cdc.gov OI York, Ian/0000-0002-3478-3344 NR 40 TC 4 Z9 4 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SPR PY 2016 VL 3 IS 2 DI 10.1093/ofid/ofw102 PG 7 WC Infectious Diseases SC Infectious Diseases GA EC3IR UT WOS:000388020200055 ER PT J AU Abedi, GR Prill, MM Langley, GE Wikswo, ME Weinberg, GA Curns, AT Schneider, E AF Abedi, Glen R. Prill, Mila M. Langley, Gayle E. Wikswo, Mary E. Weinberg, Geoffrey A. Curns, Aaron T. Schneider, Eileen TI Estimates of Parainfluenza Virus-Associated Hospitalizations and Cost Among Children Aged Less Than 5 Years in the United States, 1998-2010 SO JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY LA English DT Article DE bronchiolitis; croup; parainfluenza; pneumonia ID RESPIRATORY SYNCYTIAL VIRUS; YOUNG-CHILDREN; VACCINE; SAFETY; INFECTIONS; PROGRESS; LIVE AB Background. Parainfluenza virus (PIV) is the second leading cause of hospitalization for respiratory illness in young children in the United States. Infection can result in a full range of respiratory illness, including bronchiolitis, croup, and pneumonia. The recognized human subtypes of PIV are numbered 1-4. This study calculates estimates of PIV-associated hospitalizations among US children younger than 5 years using the latest available data. Methods. Data from the National Respiratory and Enteric Virus Surveillance System were used to characterize seasonal PIV trends from July 2004 through June 2010. To estimate the number of PIV-associated hospitalizations that occurred annually among US children aged <5 years from 1998 through 2010, respiratory hospitalizations from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample were multiplied by the proportion of acute respiratory infection hospitalizations positive for PIV among young children enrolled in the New Vaccine Surveillance Network. Estimates of hospitalization charges attributable to PIV infection were also calculated. Results. Parainfluenza virus seasonality follows type-specific seasonal patterns, with PIV-1 circulating in odd-numbered years and PIV-2 and -3 circulating annually. The average annual estimates of PIV-associated bronchiolitis, croup, and pneumonia hospitalizations among children aged <5 years in the United States were 3888 (0.2 hospitalizations per 1000), 8481 per year (0.4 per 1000 children), and 10 186 (0.5 per 1000 children), respectively. Annual charges for PIV-associated bronchiolitis, croup, and pneumonia hospitalizations were approximately $43 million, $58 million, and $158 million, respectively. Conclusions. The majority of PIV-associated hospitalizations in young children occur among those aged 0 to 2 years. When vaccines for PIV become available, immunization would be most effective if realized within the first year of life. C1 [Abedi, Glen R.; Prill, Mila M.; Langley, Gayle E.; Wikswo, Mary E.; Curns, Aaron T.; Schneider, Eileen] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Weinberg, Geoffrey A.] Univ Rochester, Sch Med & Dent, Div Pediat Infect Dis, New York, NY USA. RP Abedi, GR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A34, Atlanta, GA 30333 USA. EM gabedi@cdc.gov FU NCIRD CDC HHS [U01 IP000022, U01 IP000147, U01 IP000017]; PHS HHS [U38 CCU217969, U38 CCU417958, U38 CCU522352] NR 13 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 2048-7193 EI 2048-7207 J9 J PEDIATR INFECT DIS JI J. Pediatr. Infect. Dis. Soc. PD MAR PY 2016 VL 5 IS 1 BP 7 EP 13 DI 10.1093/jpids/piu047 PG 7 WC Infectious Diseases SC Infectious Diseases GA DZ8PS UT WOS:000386133900004 PM 26908486 ER PT J AU Sprecher, A Feldmann, H Hensley, LE Kobinger, G Nichol, ST Strong, J Van Herp, M AF Sprecher, Armand Feldmann, Heinz Hensley, Lisa E. Kobinger, Gary Nichol, Stuart T. Strong, Jim Van Herp, Michel TI Ebola virus is unlikely to become endemic in West Africa SO NATURE MICROBIOLOGY LA English DT Editorial Material ID BATS; INFECTION AB Concern over Ebola becoming endemic in West Africa has appeared in the medical and lay media. Routes of transmission, rates of viral evolution, suitability of humans as hosts and rarity of spillover events make this very unlikely. Without evidence that endemic Ebola is likely, ending epidemics should remain the focus. C1 [Sprecher, Armand; Van Herp, Michel] Med Sans Frontieres, Rue Arbre Benit 46, B-1050 Brussels, Belgium. [Feldmann, Heinz] NIAID, Virol Lab, Div Intramural Res, NIH, 903 S 4th St, Hamilton, MT 59840 USA. [Hensley, Lisa E.] Integrated Res Facil, Frederick, MD USA. [Hensley, Lisa E.] NIAID, 8200 Res Plaza Way, Frederick, MD 21702 USA. [Kobinger, Gary; Strong, Jim] Natl Microbiol Lab, 1015 Arlington St, Winnipeg, MB, Canada. [Nichol, Stuart T.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. RP Sprecher, A (reprint author), Med Sans Frontieres, Rue Arbre Benit 46, B-1050 Brussels, Belgium. EM armand.sprecher@brussels.msf.org NR 16 TC 1 Z9 1 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 2058-5276 J9 NAT MICROBIOL JI NAT. MICROBIOL PD MAR PY 2016 VL 1 IS 3 AR 16007 DI 10.1038/NMICROBIOL.2016.7 PG 2 WC Microbiology SC Microbiology GA DW4HU UT WOS:000383604600019 PM 27572170 ER PT J AU Richards, TB Negoita, S McNeel, TS Holt, DL Topor, M Henley, SJ White, A Li, J Li, CY AF Richards, Thomas B. Negoita, Serban McNeel, Timothy S. Holt, Dylan L. Topor, Marie Henley, S. Jane White, Arica Li, Jun Li, Chunyu TI Adjusted American Joint Committee on Cancer 6th edition stage for analysis of trends in black-white disparities in non-small cell lung cancer, SEER Medicare, 2000-2011 SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Meeting Abstract CT 8th AACR Conference on the Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved CY NOV 13-16, 2015 CL Atlanta, GA SP Amer Assoc Canc Res C1 [Richards, Thomas B.; Henley, S. Jane; White, Arica; Li, Jun; Li, Chunyu] CDC, Atlanta, GA 30333 USA. [Negoita, Serban; Holt, Dylan L.] Westat Corp, Rockville, MD USA. [McNeel, Timothy S.; Topor, Marie] IMS Inc, Calverton, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAR PY 2016 VL 25 IS 3 SU S MA B44 DI 10.1158/1538-7755.DISP15-B44 PG 2 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DR8PH UT WOS:000380159300187 ER PT J AU Shoemaker, ML White, MC AF Shoemaker, Meredith L. White, Mary C. TI Breast and cervical cancer screening among Hispanic and Asian subgroups in the United States: Estimates from the National Health Interview Survey, 2008, 2010 and 2013 SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Meeting Abstract CT 8th AACR Conference on the Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved CY NOV 13-16, 2015 CL Atlanta, GA SP Amer Assoc Canc Res C1 [Shoemaker, Meredith L.; White, Mary C.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAR PY 2016 VL 25 IS 3 SU S MA B85 DI 10.1158/1538-7755.DISP15-B85 PG 2 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DR8PH UT WOS:000380159300308 ER PT J AU Smith, JL Ghaffarzadeh, A Wilson, KM AF Smith, Judith Lee Ghaffarzadeh, Ashley Wilson, Katherine M. TI Adaptation of an effective cervical cancer screening intervention: Assessing barriers and facilitators to screening among Latinas and African American women SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Meeting Abstract CT 8th AACR Conference on the Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved CY NOV 13-16, 2015 CL Atlanta, GA SP Amer Assoc Canc Res C1 [Smith, Judith Lee; Ghaffarzadeh, Ashley; Wilson, Katherine M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAR PY 2016 VL 25 IS 3 SU S MA A32 DI 10.1158/1538-7755.DISP15-A32 PG 2 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DR8PH UT WOS:000380159300044 ER PT J AU Weir, HK Li, CY Henley, J Joseph, D AF Weir, Hannah K. Li, Chunyu Henley, Jane Joseph, Djenaba TI Estimating potential years of life lost and productivity lost due to avoidable premature colorectal cancer deaths in US counties with lower educational attainment SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Meeting Abstract CT 8th AACR Conference on the Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved CY NOV 13-16, 2015 CL Atlanta, GA SP Amer Assoc Canc Res C1 [Weir, Hannah K.; Li, Chunyu; Henley, Jane; Joseph, Djenaba] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAR PY 2016 VL 25 IS 3 SU S MA A89 DI 10.1158/1538-7755.DISP15-A89 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DR8PH UT WOS:000380159300020 ER PT J AU Kim, A Hansen, H Duke, J Davis, K Alexander, R Rowland, A Mitchko, J AF Kim, Annice Hansen, Heather Duke, Jennifer Davis, Kevin Alexander, Robert Rowland, Amy Mitchko, Jane TI Does Digital Ad Exposure Influence Information-Seeking Behavior Online? Evidence From the 2012 Tips From Former Smokers National Tobacco Prevention Campaign SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE tobacco cessation; health; Internet; monitoring and evaluation ID MEDIA CAMPAIGN; SMOKING PREVALENCE; PUBLIC-HEALTH; POPULATION; YOUTH AB Background: Measuring the impact of online health campaigns is challenging. Ad click-through rates are traditionally used to measure campaign reach, but few Internet users ever click on ads. Alternatively, self-reported exposure to digital ads would be prone to recall bias. Furthermore, there may be latency effects whereby people do not click on ads when exposed but visit the promoted website or conduct campaign-related searches later. Online panels that unobtrusively collect panelists' Web behavior data and link ad exposure to website visits and searches can more reliably assess the impact of digital ad exposure. From March to June 2012, the Centers for Disease Control and Prevention aired the national Tips From Former Smokers (Tips 2012) media campaign designed to encourage current smokers to quit. Advertisements ran across media channels, and the digital ads directed users to the Tips 2012 campaign website. Objective: Our aim was to examine whether exposure to Tips 2012 digital ads influenced information-seeking behaviors online. Methods: ComScore mined its panelists' Web behavior data for unique codes that would indicate exposure to Tips 2012 ads, regardless of whether panelists clicked the ad or not. A total of 15,319 US adults were identified as having been exposed to a Tips 2012 campaign ad. An equal number of unexposed adults (N=15,319) were identified and matched on demographics and Internet use behavior to the exposed group. Panelists' Web behavior data were mined for up to 4 weeks after initial Tips 2012 ad exposure to determine whether they visited the Tips 2012 campaign website or other cessation-related websites (eg, nicotine replacement therapy site) or conducted searches for campaign-related topics (eg, quit smoking). Results: The proportion of exposed adults visiting the Tips 2012 sites increased from 0.4% in Week 1 to 0.9% 4 weeks after ad exposure, and these rates were significantly higher than in the unexposed group (0.1% in Week 1 to 0.4% in Week 4, P<.001) across all weeks examined. The proportion of exposed panelists visiting other cessation websites increased from 0.2% in Week 1 to 0.3% 4 weeks after initial ad exposure, and these rates were significantly higher than in the unexposed group (0.0% in Week 1 to 0.2% in Week 4, P=.001 to P=.019) across all weeks examined. There were no significant differences in searches for campaign-related topics between the exposed and unexposed group during most of the weeks examined. Conclusions: These results suggest that online ad exposure is associated with confirmed visits to the Tips 2012 campaign sites and visits to other cessation websites and that these information-seeking behaviors occur up to several weeks after ad exposure. Web behavior data from online panels are useful for examining exposure and behavioral responses to digital campaign ads. C1 [Kim, Annice; Hansen, Heather; Duke, Jennifer; Davis, Kevin] RTI Int, 3040 E Cornwallis Rd,POB 12194, Res Triangle Pk, NC USA. [Alexander, Robert; Rowland, Amy; Mitchko, Jane] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. RP Kim, A (reprint author), RTI Int, 3040 E Cornwallis Rd,POB 12194, Res Triangle Pk, NC USA. EM akim@rti.org FU Centers for Disease Control and Prevention FX This work was funded by the Centers for Disease Control and Prevention. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or RTI International. NR 31 TC 1 Z9 1 U1 5 U2 7 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD MAR PY 2016 VL 18 IS 3 AR e64 DI 10.2196/jmir.4299 PG 12 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA DS4UU UT WOS:000380777900006 PM 26983849 ER PT J AU Chavarro, JE Minguez-Alarcon, L Chiu, YH Gaskins, AJ Souter, I Williams, PL Calafat, AM Hauser, R AF Chavarro, Jorge E. Minguez-Alarcon, Lidia Chiu, Yu-Han Gaskins, Audrey J. Souter, Irene Williams, Paige L. Calafat, Antonia M. Hauser, Russ CA EARTH Study Team TI Soy Intake Modifies the Relation Between Urinary Bisphenol A Concentrations and Pregnancy Outcomes Among Women Undergoing Assisted Reproduction SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID FOOD-FREQUENCY QUESTIONNAIRE; ESTROGEN-RECEPTOR-ALPHA; SEMEN QUALITY; US ADULTS; IN-VITRO; INTRAUTERINE IMPLANTATION; NEONATAL EXPOSURE; FERTILIZED OVA; GENISTEIN; ISOFLAVONES AB Context: Experimental data in rodents suggest that the adverse reproductive health effects of bisphenol A (BPA) can be modified by intake of soy phytoestrogens. Whether the same is true in humans is not known. Objective: The purpose of this study was to evaluate whether soy consumption modifies the relation between urinary BPA levels and infertility treatment outcomes among women undergoing assisted reproduction. Setting: The study was conducted in a fertility center in a teaching hospital. Design: We evaluated 239 women enrolled between 2007 and 2012 in the Environment and Reproductive Health (EARTH) Study, a prospective cohort study, who underwent 347 in vitro fertilization (IVF) cycles. Participants completed a baseline questionnaire and provided up to 2 urine samples in each treatment cycle before oocyte retrieval. IVF outcomes were abstracted from electronic medical records. We used generalized linear mixed models with interaction terms to evaluate whether the association between urinary BPA concentrations and IVF outcomes was modified by soy intake. Main Outcome Measure: Live birth rates per initiated treatment cycle were measured. Results: Soy food consumption modified the association of urinary BPA concentration with live birth rates (P for interaction = .01). Among women who did not consume soy foods, the adjusted live birth rates per initiated cycle in increasing quartiles of cycle-specific urinary BPA concentrations were 54%, 35%, 31%, and 17% (P for trend = .03). The corresponding live birth rates among women reporting pretreatment consumption of soy foods were 38%, 42%, 47%, and 49% (P for trend = 0.35). A similar pattern was found for implantation (P for interaction = .02) and clinical pregnancy rates (P for interaction = .03) per initiated cycle, where urinary BPA was inversely related to these outcomes among women not consuming soy foods but unrelated to them among soy consumers. Conclusion: Soy food intake may protect against the adverse reproductive effects of BPA. As these findings represent the first report suggesting a potential interaction between soy and BPA in humans, they should be further evaluated in other populations. C1 [Chavarro, Jorge E.; Chiu, Yu-Han; Gaskins, Audrey J.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Chavarro, Jorge E.; Gaskins, Audrey J.; Hauser, Russ] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Minguez-Alarcon, Lidia; Hauser, Russ] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Williams, Paige L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Chavarro, Jorge E.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Chavarro, Jorge E.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Souter, Irene; Hauser, Russ] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA. [Souter, Irene; Hauser, Russ] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30329 USA. RP Chavarro, JE (reprint author), Harvard Univ, Sch Publ Hlth Nutr, 665 Huntington Ave, Boston, MA 02115 USA. EM jchavarr@hsph.harvard.edu FU National Institutes of Health [R01ES022955, R01ES009718, R01ES000002, T32DK007703-16, P30DK46200] FX This work was supported by the National Institutes of Health (grants R01ES022955, R01ES009718, R01ES000002, T32DK007703-16, and P30DK46200). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names and commercial sources is for identification only and does not constitute endorsement by the US Department of Health and Human Services or the CDC. NR 51 TC 4 Z9 4 U1 7 U2 8 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAR PY 2016 VL 101 IS 3 BP 1082 EP 1090 DI 10.1210/jc.2015-3473 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP9JA UT WOS:000378811300039 PM 26815879 ER PT J AU Deffrasnes, C Marsh, GA Foo, CH Rootes, CL Gould, CM Grusovin, J Monaghan, P Lo, MK Tompkins, SM Adams, TE Lowenthal, JW Simpson, KJ Stewart, CR Bean, AGD Wang, LF AF Deffrasnes, Celine Marsh, Glenn A. Foo, Chwan Hong Rootes, Christina L. Gould, Cathryn M. Grusovin, Julian Monaghan, Paul Lo, Michael K. Tompkins, S. Mark Adams, Timothy E. Lowenthal, John W. Simpson, Kaylene J. Stewart, Cameron R. Bean, Andrew G. D. Wang, Lin-Fa TI Genome-wide siRNA Screening at Biosafety Level 4 Reveals a Crucial Role for Fibrillarin in Henipavirus Infection SO PLOS PATHOGENS LA English DT Article ID INFLUENZA-VIRUS REPLICATION; RESPIRATORY-SYNCYTIAL-VIRUS; RIBOSOMAL-RNA METHYLATION; IRES-MEDIATED TRANSLATION; HENDRA VIRUS; DENGUE VIRUS; HOST FACTORS; STATISTICAL-METHODS; MATRIX PROTEIN; NIPAH VIRUS AB Hendra and Nipah viruses (genus Henipavirus, family Paramyxoviridae) are highly pathogenic bat-borne viruses. The need for high biocontainment when studying henipaviruses has hindered the development of therapeutics and knowledge of the viral infection cycle. We have performed a genome-wide siRNA screen at biosafety level 4 that identified 585 human proteins required for henipavirus infection. The host protein with the largest impact was fibrillarin, a nucleolar methyltransferase that was also required by measles, mumps and respiratory syncytial viruses for infection. While not required for cell entry, henipavirus RNA and protein syntheses were greatly impaired in cells lacking fibrillarin, indicating a crucial role in the RNA replication phase of infection. During infection, the Hendra virus matrix protein co-localized with fibrillarin in cell nucleoli, and co-associated as a complex in pull-down studies, while its nuclear import was unaffected in fibrillarin-depleted cells. Mutagenesis studies showed that the methyltransferase activity of fibrillarin was required for henipavirus infection, suggesting that this enzyme could be targeted therapeutically to combat henipavirus infections. C1 [Deffrasnes, Celine; Marsh, Glenn A.; Foo, Chwan Hong; Rootes, Christina L.; Monaghan, Paul; Lowenthal, John W.; Stewart, Cameron R.; Bean, Andrew G. D.; Wang, Lin-Fa] CSIRO Hlth & Biosecur, Australian Anim Hlth Lab, Geelong, Vic, Australia. [Gould, Cathryn M.; Simpson, Kaylene J.] Peter MacCallum Canc Ctr, Victorian Ctr Funct Genom, East Melbourne, Vic, Australia. [Grusovin, Julian; Adams, Timothy E.] CSIRO Mfg, Parkville, Vic, Australia. [Lo, Michael K.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA USA. [Tompkins, S. Mark; Lowenthal, John W.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA. [Tompkins, S. Mark; Lowenthal, John W.] Deakin Univ, Sch Med, Waurn Ponds, Vic, Australia. [Simpson, Kaylene J.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia. [Wang, Lin-Fa] Duke NUS Grad Med Sch, Program Emerging Infect Dis, Singapore, Singapore. RP Stewart, CR (reprint author), CSIRO Hlth & Biosecur, Australian Anim Hlth Lab, Geelong, Vic, Australia. EM cameron.stewart@csiro.au RI Adams, Timothy/I-6231-2012; Stewart, Cameron/E-6823-2011; OI Simpson, Kaylene/0000-0001-9136-1781; Lo, Michael/0000-0002-0409-7896 FU Commonwealth Scientific and Industrial Research Organisation; Australian National Health and Medical Research Council [1042452]; Victorian Centre for Functional Genomics - Australian Cancer Research Foundation (ACRF); Victorian Department of Industry, Innovation and Regional Development (DIIRD); Australian Phenomics Network (APN); Australian Government's Education Investment Fund through the Super Science Initiative; Australasian Genomics Technologies Association (AMATA); Brockhoff Foundation; Peter MacCallum Cancer Centre Foundation FX This work was supported by The Commonwealth Scientific and Industrial Research Organisation and the Australian National Health and Medical Research Council (grant 1042452 to CRS). The Victorian Centre for Functional Genomics is funded by the Australian Cancer Research Foundation (ACRF), the Victorian Department of Industry, Innovation and Regional Development (DIIRD), the Australian Phenomics Network (APN) and supported by funding from the Australian Government's Education Investment Fund through the Super Science Initiative, the Australasian Genomics Technologies Association (AMATA), the Brockhoff Foundation and the Peter MacCallum Cancer Centre Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 3 Z9 3 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD MAR PY 2016 VL 12 IS 3 AR e1005478 DI 10.1371/journal.ppat.1005478 PG 24 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA DP0CH UT WOS:000378154800019 PM 27010548 ER PT J AU Engelthaler, DM Roe, CC Hepp, CM Teixeira, M Driebe, EM Schupp, JM Gade, L Waddell, V Komatsu, K Arathoon, E Logemann, H Thompson, GR Chiller, T Barker, B Keim, P Litvintseva, AP AF Engelthaler, David M. Roe, Chandler C. Hepp, Crystal M. Teixeira, Marcus Driebe, Elizabeth M. Schupp, James M. Gade, Lalitha Waddell, Victor Komatsu, Kenneth Arathoon, Eduardo Logemann, Heidi Thompson, George R., III Chiller, Tom Barker, Bridget Keim, Paul Litvintseva, Anastasia P. TI Local Population Structure and Patterns of Western Hemisphere Dispersal for Coccidioides spp., the Fungal Cause of Valley Fever SO MBIO LA English DT Article ID MOLECULAR-IDENTIFICATION; PHYLOGENETIC NETWORKS; MODEL SELECTION; IMMITIS; POSADASII; EVOLUTIONARY; INFECTIONS; SOFTWARE; BRAZIL; STATE AB Coccidioidomycosis (or valley fever) is a fungal disease with high morbidity and mortality that affects tens of thousands of people each year. This infection is caused by two sibling species, Coccidioides immitis and C. posadasii, which are endemic to specific arid locales throughout the Western Hemisphere, particularly the desert southwest of the United States. Recent epidemiological and population genetic data suggest that the geographic range of coccidioidomycosis is expanding, as new endemic clusters have been identified in the state of Washington, well outside the established endemic range. The genetic mechanisms and epidemiological consequences of this expansion are unknown and require better understanding of the population structure and evolutionary history of these pathogens. Here we performed multiple phylogenetic inference and population genomics analyses of 68 new and 18 previously published genomes. The results provide evidence of substantial population structure in C. posadasii and demonstrate the presence of distinct geographic clades in central and southern Arizona as well as dispersed populations in Texas, Mexico, South America, and Central America. Although a smaller number of C. immitis strains were included in the analyses, some evidence of phylogeographic structure was also detected in this species, which has been historically limited to California and Baja, Mexico. Bayesian analyses indicated that C. posadasii is the more ancient of the two species and that Arizona contains the most diverse subpopulations. We propose a southern Arizona-northern Mexico origin for C posadasii and describe a pathway for dispersal and distribution out of this region. IMPORTANCE Coccidioidomycosis, or valley fever, is caused by the pathogenic fungi Coccidioides posadasii and C. immitis. The fungal species and disease are primarily found in the American desert southwest, with spotted distribution throughout the Western Hemisphere. Initial molecular studies suggested a likely anthropogenic movement of C. posadasii from North America to South America. Here we comparatively analyze eighty-six genomes of the two Coccidioides species and establish local and species-wide population structures to not only clarify the earlier dispersal hypothesis but also provide evidence of likely ancestral populations and patterns of dispersal for the known subpopulations of C. posadasii. C1 [Engelthaler, David M.; Roe, Chandler C.; Teixeira, Marcus; Driebe, Elizabeth M.; Schupp, James M.; Barker, Bridget; Keim, Paul] TGen North, Translat Genom Res Inst, Flagstaff, AZ 86001 USA. [Hepp, Crystal M.] No Arizona Univ, Informat & Comp Ctr, Flagstaff, AZ 86011 USA. [Gade, Lalitha; Chiller, Tom; Litvintseva, Anastasia P.] Ctr Dis Control & Prevent, Mycot Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Waddell, Victor; Komatsu, Kenneth] Arizona Dept Hlth Serv, Div Publ Hlth Serv, Phoenix, AZ 85007 USA. [Arathoon, Eduardo] Asociac Salud Integral, Guatemala City, Guatemala. [Logemann, Heidi] Univ San Carlos, Ciudad Univ, Guatemala City, Guatemala. [Thompson, George R., III] Univ Calif Davis, Dept Med, Div Infect Dis, Davis, CA 95616 USA. [Keim, Paul] No Arizona Univ, Microbial Genet & Genom Ctr, Flagstaff, AZ 86011 USA. RP Engelthaler, DM (reprint author), TGen North, Translat Genom Res Inst, Flagstaff, AZ 86001 USA. EM dengelthaler@tgen.org OI Barker, Bridget/0000-0002-3439-4517 FU HHS \ NIH National institute of Allergy and Infectious Diseases (NIAID) [R21AA076773]; HHS \ Centers for Disease Control and Prevention (CDC) [200201461029]; ADHS \ Arizona Biomedical Research Commission (ABRC) [20080816] FX This work, including the efforts of Paul Keim, was funded by HHS vertical bar NIH National institute of Allergy and Infectious Diseases (NIAID) (R21AA076773). This work, including the efforts of David M. Engelthaler was funded by HHS vertical bar Centers for Disease Control and Prevention (CDC) (200201461029). This work, including the efforts of Paul Keim, was funded by ADHS vertical bar Arizona Biomedical Research Commission (ABRC) (20080816). NR 67 TC 4 Z9 4 U1 4 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 2150-7511 J9 MBIO JI mBio PD MAR-APR PY 2016 VL 7 IS 2 AR 00550-16 DI 10.1128/mBio.00550-16 PG 15 WC Microbiology SC Microbiology GA DO4QT UT WOS:000377768700030 ER PT J AU Pereira, LE Mesquita, PMM Ham, A Singletary, T Deyounks, F Martin, A McNicholl, J Buckheit, KW Buckheit, RW Smith, JM AF Pereira, Lara E. Mesquita, Pedro M. M. Ham, Anthony Singletary, Tyana Deyounks, Frank Martin, Amy McNicholl, Janet Buckheit, Karen W. Buckheit, Robert W., Jr. Smith, James M. TI Pharmacokinetic and Pharmacodynamic Evaluation following Vaginal Application of IQB3002, a Dual-Chamber Microbicide Gel Containing the Nonnucleoside Reverse Transcriptase Inhibitor IQP-0528 in Rhesus Macaques SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID HETEROSEXUAL ANAL INTERCOURSE; TENOFOVIR DISOPROXIL FUMARATE; IMMUNODEFICIENCY-VIRUS TYPE-1; HIV TRANSMISSION RISK; COMPARTMENT MICROBICIDE; PIGTAILED MACAQUES; INTRAVAGINAL RING; UNITED-STATES; SOUTH-AFRICA; IN-VITRO AB We evaluated the in vivo pharmacokinetics and used a complementary ex vivo coculture assay to determine the pharmacodynamics of IQB3002 gel containing 1% IQP-0528, a nonnucleoside reverse transcriptase inhibitor (NNRTI), in rhesus macaques (RM). The gel (1.5 ml) was applied vaginally to 6 simian-human immunodeficiency (SHIV)-positive female RM. Blood, vaginal fluids, and rectal fluids were collected at 0, 1, 2, and 4 h. RM were euthanized at 4 h, and vaginal, cervical, rectal, and regional lymph node tissues were harvested. Anti-human immunodeficiency virus (HIV) activity was evaluated ex vivo by coculturing fresh or frozen vaginal tissues with activated human peripheral blood mononuclear cells (PBMCs) and measuring the p24 levels for 10 days after an HIV-1(Ba-L) challenge. The median levels of IQP-0528, determined using liquid chromatography-tandem mass spectroscopy (LC-MS/MS) methods, were between 104 and 105 ng/g in vaginal and cervical tissue, between 103 and 104 ng/g in rectal tissues, and between 105 and 107 ng/ml in vaginal fluids over the 4-h period. The vaginal tissues protected the cocultured PBMCs from HIV-1 infection ex vivo, with a viral inhibition range of 81 to 100% in fresh and frozen tissues that were proximal, medial, and distal relative to the cervix. No viral inhibition was detected in untreated baseline tissues. Collectively, the median drug levels observed were 5 to 7 logs higher than the in vitro 50% effective concentration (EC50) range (0.21 ng/ml to 1.29 ng/ml), suggesting that 1.5 ml of the gel delivers IQP-0528 throughout the RM vaginal compartment at levels that are highly inhibitory to HIV-1. Importantly, antiviral activity was observed in both fresh and frozen vaginal tissues, broadening the scope of the ex vivo coculture model for future NNRTI efficacy studies. C1 [Pereira, Lara E.] LifeSource Biomed LLC, Moffett Field, CA USA. [Mesquita, Pedro M. M.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Ham, Anthony; Buckheit, Karen W.; Buckheit, Robert W., Jr.] ImQuest BioSci, Frederick, MD USA. [Singletary, Tyana] Anyar Inc, Ft Walton Beach, FL USA. [Deyounks, Frank] Total Solut Inc, Madison, AL USA. [Martin, Amy; McNicholl, Janet; Smith, James M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Smith, JM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM ajo9@cdc.gov RI karanki, Archana/E-7014-2016; OI Mesquita, Pedro/0000-0002-6591-4896 FU HHS \ National Institutes of Health (NIH) [5U19AI101961-03] FX HHS vertical bar National Institutes of Health (NIH) provided funding to Anthony Ham, Karen W. Buckheit, and Robert W. Buckheit, Jr. under grant number 5U19AI101961-03. NR 46 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAR PY 2016 VL 60 IS 3 BP 1393 EP 1400 DI 10.1128/AAC.02201-15 PG 8 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DM6VM UT WOS:000376490800027 ER PT J AU Anderson-Carpenter, KD Watson-Thompson, J Chaney, L Jones, M AF Anderson-Carpenter, Kaston D. Watson-Thompson, Jomella Chaney, Lisa Jones, Marvia TI Reducing Binge Drinking in Adolescents through Implementation of the Strategic Prevention Framework SO AMERICAN JOURNAL OF COMMUNITY PSYCHOLOGY LA English DT Article DE Strategic prevention framework; Binge drinking; Enforcement; Youth and adolescents; Risk and protective factors; Community intervention ID EXCESSIVE ALCOHOL-CONSUMPTION; DRUG-USE; RISK; YOUTH; ENFORCEMENT; BEHAVIORS; STATES; HARMS; INFRASTRUCTURE; INTERVENTIONS AB The Strategic Prevention Framework (SPF) is a conceptual model that supports coalition-driven efforts to address underage drinking and related consequences. Although the SPF has been promoted by the U.S. Substance Abuse and Mental Health Services Administration's Center for Substance Abuse Prevention and implemented in multiple U.S. states and territories, there is limited research on the SPF's effectiveness on improving targeted outcomes and associated influencing factors. The present quasi-experimental study examines the effects of SPF implementation on binge drinking and enforcement of existing underage drinking laws as an influencing factor. The intervention group encompassed 11 school districts that were implementing the SPF with local prevention coalitions across eight Kansas communities. The comparison group consisted of 14 school districts that were matched based on demographic variables. The intervention districts collectively facilitated 137 community-level changes, including new or modified programs, policies, and practices. SPF implementation supported significant improvements in binge drinking and enforcement outcomes over time (p<.001), although there were no significant differences in improvements between the intervention and matched comparison groups (p>.05). Overall, the findings provide a basis for guiding future research and community-based prevention practice in implementing and evaluating the SPF. C1 [Anderson-Carpenter, Kaston D.] Univ Calif Los Angeles, Integrated Subst Abuse Programs, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Anderson-Carpenter, Kaston D.; Watson-Thompson, Jomella; Jones, Marvia] Univ Kansas, Work Grp Community Hlth & Dev, Lawrence, KS 66045 USA. [Watson-Thompson, Jomella] Univ Kansas, Dept Appl Behav Sci, Lawrence, KS 66045 USA. [Chaney, Lisa] Southeast Kansas Educ Serv Ctr Greenbush, Girard, KS USA. [Jones, Marvia] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Anderson-Carpenter, KD (reprint author), Univ Calif Los Angeles, Integrated Subst Abuse Programs, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.; Anderson-Carpenter, KD (reprint author), Univ Kansas, Work Grp Community Hlth & Dev, Lawrence, KS 66045 USA. EM kacarpenter@ucla.edu OI Anderson-Carpenter, Kaston/0000-0001-7438-958X FU Kansas SPF-SIG - Substance Abuse and Mental Health Services Administration; National Institute on Drug Abuse of the National Institutes of Health [5T32DA007272-23] FX This research was supported in part by funding from the Kansas SPF-SIG, awarded by the Substance Abuse and Mental Health Services Administration to the Kansas Department of Social and Rehabilitation Services. Research reported in this publication was also supported by the National Institute on Drug Abuse of the National Institutes of Health under award number 5T32DA007272-23. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or any other participating organization. NR 28 TC 1 Z9 1 U1 5 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0091-0562 EI 1573-2770 J9 AM J COMMUN PSYCHOL JI Am. J. Community Psychol. PD MAR PY 2016 VL 57 IS 1-2 BP 36 EP 46 DI 10.1002/ajcp.12029 PG 11 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Social Work SC Public, Environmental & Occupational Health; Psychology; Social Work GA DK1WA UT WOS:000374704500004 PM 27217310 ER PT J AU Koenig, LJ Hoyer, D Purcell, DW Zaza, S Mermin, J AF Koenig, Linda J. Hoyer, Deborah Purcell, David W. Zaza, Stephanie Mermin, Jonathan TI Young People and HIV: A Call to Action SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED-CONTROLLED-TRIAL; COMPREHENSIVE RISK-REDUCTION; SCHOOL-HEALTH SERVICES; GAY-STRAIGHT ALLIANCES; UNITED-STATES; PREVENTION INTERVENTION; ADOLESCENT PREGNANCY; ABSTINENCE EDUCATION; YOUTH AB HIV is having a significant impact on young people, among whom the rate of new diagnoses is high and health disparities are more pronounced. Incidence is increasing among young gay and bisexual men, and, among Black males, the largest percentage of new infections occur among those aged between 13 and 24 years. Youths are least likely to experience the health and prevention benefits of treatment. Nearly half of young people with HIV are not diagnosed; among those diagnosed, nearly a quarter are not linked to care, and three quarters are not virally suppressed. Addressing this burden will require renewed efforts to implement effective prevention strategies across multiple sectors, including educational, social, policy, and health care systems that influence prevention knowledge, service use, and treatment options for youths. C1 [Koenig, Linda J.; Purcell, David W.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Hoyer, Deborah] US Dept Hlth & Human Serv, Off Dis Prevent & Hlth Promot, Rockville, MD USA. [Zaza, Stephanie] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. [Mermin, Jonathan] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. RP Koenig, LJ (reprint author), US Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E37, Atlanta, GA USA. EM lkoenig@cdc.gov NR 49 TC 3 Z9 3 U1 5 U2 6 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2016 VL 106 IS 3 BP 402 EP 405 DI 10.2105/AJPH.2015.302979 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DL2EA UT WOS:000375444800007 PM 26794156 ER PT J AU Cooper, HLF West, B Linton, S Hunter-Jones, J Zlotorzynska, M Stall, R Wolfe, ME Williams, L Hall, HI Cleland, C Tempalski, B Friedman, SR AF Cooper, Hannah L. F. West, Brooke Linton, Sabriya Hunter-Jones, Josalin Zlotorzynska, Maria Stall, Ron Wolfe, Mary E. Williams, Leslie Hall, H. Irene Cleland, Charles Tempalski, Barbara Friedman, Samuel R. TI Contextual Predictors of Injection Drug Use Among Black Adolescents and Adults in US Metropolitan Areas, 1993-2007 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SYRINGE EXCHANGE PROGRAMS; RESIDENTIAL SEGREGATION; POLITICAL ECOLOGY; NEIGHBORHOOD DISADVANTAGE; RACIAL-DISCRIMINATION; SOCIOECONOMIC-STATUS; AFRICAN-AMERICANS; SUBSTANCE-ABUSE; SPATIAL ACCESS; UNITED-STATES AB Objectives. We sought to determine whether contextual factors shape injection drug use among Black adolescents and adults. Methods. For this longitudinal study of 95 US metropolitan statistical areas (MSAs), we drew annual MSA-specific estimates of the prevalence of injection drug use (IDU) among Black adolescents and adults in 1993 through 2007 from 3 surveillance databases. We used existing administrative data to measure MSA-level socioeconomic status; criminal justice activities; expenditures on social welfare, health, and policing; and histories of Black uprisings (1960-1969) and urban renewal funding (1949-1974). We regressed Black IDU prevalence on these predictors by using hierarchical linear models. Results. Black IDU prevalence was lower in MSAs with declining Black high-school dropout rates, a history of Black uprisings, higher percentages of Black residents, and, in MSAs where 1992 White income was high, higher 1992 Black income. Incarceration rates were unrelated. Conclusions. Contextual factors shape patterns of drug use among Black individuals. Structural interventions, especially those that improve Black socioeconomic security and political strength, may help reduce IDU among Black adolescents and adults. C1 [Cooper, Hannah L. F.; Linton, Sabriya; Hunter-Jones, Josalin; Zlotorzynska, Maria; Wolfe, Mary E.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. [West, Brooke] Univ Calif San Diego, Div Global Publ Hlth, La Jolla, CA 92093 USA. [Williams, Leslie; Tempalski, Barbara; Friedman, Samuel R.] Natl Dev & Res Inst Inc, New York, NY USA. [Stall, Ron] Univ Pittsburgh, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Stall, Ron] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA. [Hall, H. Irene] Ctr Dis Control & Prevent, HIV Incidence & Case Surveillance Branch, Atlanta, GA USA. [Cleland, Charles] NYU, Sch Nursing, New York, NY USA. RP Cooper, HLF (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM hcoope3@emory.edu FU Community Vulnerability and Responses to Drug-User Related HIV/AIDS [DA013336]; Metropolitan Trajectories of HIV Epidemics, Drug Use, and Responses in US Key Populations [DA037568]; Public Housing Relocations: Impact on HIV Risk and Drug Use [DA029513]; Place Characteristics and Disparities in HIV in IDUs: A Multilevel Analysis of NHBS (National HIV Behavior Surveillance) [DA035101]; Center for AIDS Research at Emory University [P30AI050409] FX Several grants supported this project: Community Vulnerability and Responses to Drug-User Related HIV/AIDS (DA013336; PIs: Friedman and Cooper); Metropolitan Trajectories of HIV Epidemics, Drug Use, and Responses in US Key Populations (DA037568; PIs: Cooper, Friedman, and Stall); Public Housing Relocations: Impact on HIV Risk and Drug Use (DA029513; PI: Cooper); Place Characteristics and Disparities in HIV in IDUs: A Multilevel Analysis of NHBS (National HIV Behavior Surveillance; DA035101; PI: Cooper); Center for AIDS Research at Emory University (P30AI050409; PI: Curran). NR 99 TC 2 Z9 2 U1 3 U2 5 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2016 VL 106 IS 3 BP 517 EP 526 DI 10.2105/AJPH.2015.302911 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DL2EA UT WOS:000375444800029 PM 26691126 ER PT J AU Whitfield, GP AF Whitfield, Geoffrey P. TI Active Transportation Surveillance-United States, 1999-2012 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material C1 [Whitfield, Geoffrey P.] CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Whitfield, GP (reprint author), CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM xdh5@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2016 VL 106 IS 3 BP E1 EP E4 DI 10.2105/AJPH.2016.303102 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DL2EA UT WOS:000375444800001 ER PT J AU Spradling, PR Bulkow, LR Negus, SE Homan, C Bruce, MG McMahon, BJ AF Spradling, Philip R. Bulkow, Lisa R. Negus, Susan E. Homan, Chriss Bruce, Michael G. McMahon, Brian J. TI Persistence of Seropositivity Among Persons Vaccinated for Hepatitis A During Infancy by Maternal Antibody Status: 15-Year Follow-up SO HEPATOLOGY LA English DT Article ID LONG-TERM PERSISTENCE; YOUNG-CHILDREN; UNITED-STATES; IMMUNOGENICITY; IMMUNIZATION; ADULTS; EPIDEMIOLOGY; RESPONSES; OUTBREAK AB The effect of passively transferred maternal antibody to hepatitis A virus (anti-HAV) on the duration of seropositivity after hepatitis A vaccination during infancy and early childhood is unclear. We obtained levels of anti-HAV at intervals through age 15-16 years among three groups of Alaskan Native children who initiated a two-dose inactivated hepatitis A vaccination series at ages 6 months (group 1), 12 months (group 2), and 15 months (group 3), each group randomized according to maternal anti-HAV status. Seropositivity (anti-HAV >= 20 mIU/mL) 30 years after the second vaccine dose among the three groups was predicted using a random effects model. One hundred eighty-three children participated in the study; follow-up did not differ significantly by vaccine group or maternal anti-HAV status. Although the frequency of seropositivity among all participants through age 10 years was high (100% among groups 2 and 3 and >90% among group 1), there was a decrease thereafter through age 15-16 years among group 1 children, who initiated vaccination at age 6 months (50%-75%), and among maternal anti-HAV-positive children in groups 2 and 3 (67%-87%), who initiated vaccination at ages 12 months and 15 months, respectively. Nonetheless, the model indicated that anti-HAV seropositivity should persist for >= 30 years after vaccination in 64% of all participants; among those seropositive at age 15-16 years, 84% were predicted to remain so for >= 30 years. Conclusion: Most children vaccinated during early childhood available for sampling maintained seropositivity through age 15-16 years; however, seropositivity was less frequent among those starting vaccination at age 6 months and among maternal antibody-positive participants who started vaccination at age 12 months or 15 months; overall, our findings support current vaccine recommendations and continued follow-up of this cohort. C1 [Spradling, Philip R.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Bulkow, Lisa R.; Bruce, Michael G.; McMahon, Brian J.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect Dis, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Negus, Susan E.; Homan, Chriss; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. RP Spradling, PR (reprint author), Mailstop G37,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM pspradling@cdc.gov FU Centers for Disease Control and Prevention FX Supported by the Centers for Disease Control and Prevention. NR 30 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD MAR PY 2016 VL 63 IS 3 BP 703 EP 711 DI 10.1002/hep.28375 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DJ8WF UT WOS:000374493200008 PM 26637987 ER PT J AU Militello, LG Saleem, JJ Borders, MR Sushereba, CE Haverkamp, D Wolf, SP Doebbeling, BN AF Militello, Laura G. Saleem, Jason J. Borders, Morgan R. Sushereba, Christen E. Haverkamp, Donald Wolf, Steven P. Doebbeling, Bradley N. TI Designing Colorectal Cancer Screening Decision Support: A Cognitive Engineering Enterprise SO JOURNAL OF COGNITIVE ENGINEERING AND DECISION MAKING LA English DT Article DE ethnographic observation; cognitive task analysis; agile software development; cancer prevention; health promotion ID HEALTH-CARE; TASK-FORCE; SYSTEMS; PREVENTION; LESSONS AB Adoption of clinical decision support has been limited. Important barriers include an emphasis on algorithmic approaches to decision support that do not align well with clinical work flow and human decision strategies, and the expense and challenge of developing, implementing, and refining decision support features in existing electronic health records (EHRs). We applied decision-centered design to create a modular software application to support physicians in managing and tracking colorectal cancer screening. Using decision-centered design facilitates a thorough understanding of cognitive support requirements from an end user perspective as a foundation for design. In this project, we used an iterative design process, including ethnographic observation and cognitive task analysis, to move from an initial design concept to a working modular software application called the Screening & Surveillance App. The beta version is tailored to work with the Veterans Health Administration's EHR Computerized Patient Record System (CPRS). Primary care providers using the beta version Screening & Surveillance App more accurately answered questions about patients and found relevant information more quickly compared to those using CPRS alone. Primary care providers also reported reduced mental effort and rated the Screening & Surveillance App positively for usability. C1 [Militello, Laura G.; Borders, Morgan R.; Sushereba, Christen E.] Appl Decis Sci LLC, 117 Chatham Dr, Dayton, OH 45429 USA. [Saleem, Jason J.] Univ Louisville, Louisville, KY 40292 USA. [Haverkamp, Donald] Ctr Dis Control & Prevent, Albuquerque, NM USA. [Wolf, Steven P.] Appl Decis Sci, Cincinnati, OH USA. [Doebbeling, Bradley N.] Arizona State Univ, Coll Hlth Solut, Sch Sci Healthcare Delivery, Phoenix, AZ USA. RP Militello, LG (reprint author), Appl Decis Sci LLC, 117 Chatham Dr, Dayton, OH 45429 USA. EM l.militello@applieddecisionscience.com FU Intramural CDC HHS [CC999999] NR 49 TC 1 Z9 1 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1555-3434 EI 2169-5032 J9 J Cogn Eng Decis Mak JI J. Cogn. Eng. Decis. Mak. PD MAR PY 2016 VL 10 IS 1 BP 74 EP 90 DI 10.1177/1555343416630875 PG 17 WC Psychology, Experimental SC Psychology GA DK1GT UT WOS:000374661200005 PM 26973441 ER PT J AU King, DK Allen, P Jones, DL Marquez, DX Brown, DR Rosenberg, D Janicek, S Allen, L Belza, B AF King, Diane K. Allen, Peg Jones, Dina L. Marquez, David X. Brown, David R. Rosenberg, Dori Janicek, Sarah Allen, Laila Belza, Basia TI Safe, Affordable, Convenient: Environmental Features of Malls and Other Public Spaces Used by Older Adults for Walking SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE environment; behavior; physical activity; observation; aging ID PHYSICAL-ACTIVITY; RETIREMENT COMMUNITIES; MOBILITY DISABILITIES; NEIGHBORHOOD; FACILITATORS; RESOURCES; BARRIERS; BEHAVIOR; DESIGN; HEALTH AB Background: Midlife and older adults use shopping malls for walking, but little research has examined mall characteristics that contribute to their walkability. Methods: We used modified versions of the Centers for Disease Control and Prevention (CDC)-Healthy Aging Research Network (HAN) Environmental Audit and the System for Observing Play and Recreation in Communities (SOPARC) tool to systematically observe 443 walkers in 10 shopping malls. We also observed 87 walkers in 6 community-based nonmall/nongym venues where older adults routinely walked for physical activity. Results: All venues had public transit stops and accessible parking. All malls and 67% of nonmalls had wayfinding aids, and most venues (81%) had an established circuitous walking route and clean, well-maintained public restrooms (94%). All venues had level floor surfaces, and one-half had benches along the walking route. Venues varied in hours of access, programming, tripping hazards, traffic control near entrances, and lighting. Conclusions: Despite diversity in location, size, and purpose, the mall and nonmall venues audited shared numerous environmental features known to promote walking in older adults and few barriers to walking. Future research should consider programmatic features and outreach strategies to expand the use of malls and other suitable public spaces for walking. C1 [King, Diane K.; Allen, Laila] Univ Alaska Anchorage, Ctr Behav Hlth Res & Serv, Anchorage, AK USA. [Allen, Peg] Washington Univ, George Warren Brown Sch Social Work, St Louis, MO 63130 USA. [Jones, Dina L.] W Virginia Univ, Dept Orthopaed, Morgantown, WV 26506 USA. [Jones, Dina L.] W Virginia Univ, Div Phys Therapy, Morgantown, WV 26506 USA. [Marquez, David X.; Janicek, Sarah] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA. [Brown, David R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rosenberg, Dori] Grp Hlth Res Inst, Dept Phys Act Res, Seattle, WA USA. [Belza, Basia] Univ Washington, Hlth Promot Res Ctr, Seattle, WA 98195 USA. RP King, DK (reprint author), Univ Alaska Anchorage, Ctr Behav Hlth Res & Serv, Anchorage, AK USA. EM dkking@uaa.alaska.edu FU Special Interest Project (SIP) from CDC [13-070]; [U48-DP001911] FX The authors acknowledge Rebecca Hunter and Thom McKenzie for guidance with the audit; Michael Kelly, Jeremy Thurston, Rebecca Tiffany, and Marc Cormier for assistance with data collection; Laura Farren and Christina E. Miyawaki for administrative support; and study participants. This publication is a product of the University of Washington Health Promotion Research Center, a Centers for Disease Control and Prevention (CDC) Prevention Research Center, and was supported by Cooperative Agreement Number U48-DP001911 and Special Interest Project (SIP) 13-070 from the CDC. The findings and conclusions in this publication are those of the author(s) and do not necessarily represent CDC's official position. NR 29 TC 1 Z9 1 U1 4 U2 11 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 EI 1543-5474 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD MAR PY 2016 VL 13 IS 3 BP 289 EP 295 DI 10.1123/jpah.2015-0118 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DK2DD UT WOS:000374723900007 PM 26181907 ER PT J AU Petrosky, E Neblett Fanfair, R Toevs, K DeSilva, M Schafer, S Hedberg, K Braxton, J Walters, J Markowitz, L Hariri, S AF Petrosky, Emiko Neblett Fanfair, Robyn Toevs, Kim DeSilva, Malini Schafer, Sean Hedberg, Katrina Braxton, Jim Walters, Jaime Markowitz, Lauri Hariri, Susan TI Early Syphilis Among Men Who Have Sex with Men in the US Pacific Northwest, 2008-2013: Clinical Management and Implications for Prevention SO AIDS PATIENT CARE AND STDS LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; GENITAL ULCER DISEASE; UNITED-STATES; ASYMPTOMATIC SYPHILIS; SECONDARY SYPHILIS; HOMOSEXUAL-MEN; HIV-INFECTION; HEALTH; TRANSMISSION; ASSOCIATION AB Substantial increases in syphilis during 2008-2013 were reported in the US Pacific Northwest state of Oregon, especially among men who have sex with men (MSM). The authors aimed to characterize the ongoing epidemic and identify possible gaps in clinical management of early syphilis (primary, secondary, and latent syphilis 1 year) among MSM in Multnomah County, Oregon to inform public health efforts. Administrative databases were used to examine trends in case characteristics during 2008-2013. Medical records were abstracted for cases occurring in 2013 to assess diagnosis, treatment, and screening practices. Early syphilis among MSM increased from 21 cases in 2008 to 229 in 2013. The majority of cases occurred in HIV-infected patients (range: 55.6%-69.2%) diagnosed with secondary syphilis (range: 36.2%-52.4%). In 2013, 119 (51.9%) cases were diagnosed in public sector medical settings and 110 (48.0%) in private sector settings. Over 80% of HIV-infected patients with syphilis were in HIV care. Although treatment was adequate and timely among all providers, management differed by provider type. Among HIV-infected patients, a larger proportion diagnosed by public HIV providers than private providers were tested for syphilis at least once in the previous 12 months (89.6% vs. 40.0%; p<0.001). The characteristics of MSM diagnosed with early syphilis in Multnomah County remained largely unchanged during 2008-2013. Syphilis control measures were well established, but early syphilis among MSM continued to increase. The results suggest a need to improve syphilis screening among private clinics, but few gaps in clinical management were identified. C1 [Petrosky, Emiko; DeSilva, Malini] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Petrosky, Emiko; Neblett Fanfair, Robyn; Braxton, Jim; Markowitz, Lauri; Hariri, Susan] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS, Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Toevs, Kim; Walters, Jaime] Multnomah Cty Publ Hlth Dept, Adolescent Hlth Promot & STD HIV HCV Programs, Portland, OR USA. [DeSilva, Malini; Schafer, Sean; Hedberg, Katrina] Ctr Publ Hlth Practice, Oregon Publ Hlth Div, HIV STD TB Program, Portland, OR USA. RP Petrosky, E (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Hwy NE,MS F-63, Atlanta, GA 30341 USA. EM xfq7@cdc.gov FU Intramural CDC HHS [CC999999] NR 33 TC 1 Z9 1 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD MAR PY 2016 VL 30 IS 3 BP 134 EP 140 DI 10.1089/apc.2015.0306 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DL1RO UT WOS:000375409900006 PM 27308806 ER PT J AU Fernandes, EG Leshem, E Patel, M Flannery, B Pellini, ACG Veras, MA Sato, HK AF Fernandes, Eder Gatti Leshem, Eyal Patel, Manish Flannery, Brendan Guedes Pellini, Alessandra Cristina Veras, Maria Amelia Sato, Helena Keico TI Hospital-based surveillance of intussusception among infants SO JORNAL DE PEDIATRIA LA English DT Article DE Rotavirus vaccines; Intussusception; Surveillance; Brazil ID ROTAVIRUS VACCINATION PROGRAM; US INFANTS; POSTMARKETING SURVEILLANCE; CHILDREN; SAFETY; MEXICO; RISK; BENEFITS; EFFICACY; VACCINES AB Objective: Intussusception surveillance was initiated after the nationwide introduction of live attenuated monovalent rotavirus vaccine (RV1). The objective is to assess the epidemiology of intussusception and compare the number of cases before and after the introduction of rotavirus vaccine. Methods: Cases of intussusception occurring between March 2006 and January 2008 were identified through a prospective enhanced passive surveillance system established in sentinel state hospitals. Retrospective review of medical records was used to identify cases, which occurred in sentinel hospitals between January 2001 and February 2006. Results: From 2001 to 2008, 331 intussusception cases were identified, 59.5% were male, with peak incidence among those 18-24 weeks of age. Overall <10% of cases were among infants 6-14 weeks of age (when the first dose of RV1 is administered). The most frequently observed signs or symptoms of intussusception included vomiting (89.4%), bloody stool (75.5%), and abdominal distention (71.8%). A majority (92.1%) of the case-patients required surgery for treatment; 31.8% of those who underwent surgery required bowel resection, and 13 (3.9%) died. Among the 21 hospitals that reported cases throughout the entire surveillance period (2001-2008), the number of intussusception events during 2007 (n = 26) and 2008 (n = 19) was not greater than the average annual number (n = 31, range 24-42) during baseline years 2001-2005. Conclusions: Although this analysis did not identify an increase in intussusception cases during the two years after RV1 introduction, these results support the need for special epidemiologic methods to assess the potential link between rotavirus vaccine and this very rare adverse event. (c) 2016 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved. C1 [Fernandes, Eder Gatti] Secretaria Estado Saude Sao Paulo, Field Epidemiol Training Program Sao Paulo State, Sao Paulo, SP, Brazil. [Leshem, Eyal] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA USA. [Patel, Manish] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Flannery, Brendan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Guedes Pellini, Alessandra Cristina] Secretaria Estado Saude Sao Paulo, Emergency Div Publ Hlth, Sao Paulo, SP, Brazil. [Veras, Maria Amelia] Fac Ciencias Med Santa Casa Sao Paulo, Dept Social Med, Sao Paulo, SP, Brazil. [Sato, Helena Keico] Secretaria Estado Saude Sao Paulo, Div Immunizat, Sao Paulo, SP, Brazil. RP Fernandes, EG (reprint author), Secretaria Estado Saude Sao Paulo, Field Epidemiol Training Program Sao Paulo State, Sao Paulo, SP, Brazil. EM egatti@saude.sp.gov.br RI Alessandra, Pellini/K-5156-2013; OI Leshem, Eyal/0000-0003-1267-6131 NR 22 TC 0 Z9 0 U1 1 U2 2 PU SOC BRASIL PEDIATRIA PI RIO DE JANEIRO, RJ PA RUA SANTA CLARA 292, RIO DE JANEIRO, RJ, CEP 22401-01, BRAZIL SN 0021-7557 EI 1678-4782 J9 J PEDIAT-BRAZIL JI J. Pediatr. PD MAR-APR PY 2016 VL 92 IS 2 BP 181 EP 187 DI 10.1016/j.jped.2015.06.008 PG 7 WC Pediatrics SC Pediatrics GA DK3QR UT WOS:000374833000014 PM 26804014 ER PT J AU He, YL Shimizu, I Schappert, S Xu, JM Beresovsky, V Khan, D Valverde, R Schenker, N AF He, Yulei Shimizu, Iris Schappert, Susan Xu, Jianmin Beresovsky, Vladislav Khan, Diba Valverde, Roberto Schenker, Nathaniel TI A Note on the Effect of Data Clustering on the Multiple-Imputation Variance Estimator: A Theoretical Addendum to the Lewis et al. article in JOS 2014 SO JOURNAL OF OFFICIAL STATISTICS LA English DT Article DE Bayesian; complex survey design; data release; exploratory data analysis; fraction of missing information; missing data AB Multiple imputation is a popular approach to handling missing data. Although it was originally motivated by survey nonresponse problems, it has been readily applied to other data settings. However, its general behavior still remains unclear when applied to survey data with complex sample designs, including clustering. Recently, Lewis et al. (2014) compared single-and multiple-imputation analyses for certain incomplete variables in the 2008 National Ambulatory Medicare Care Survey, which has a nationally representative, multistage, and clustered sampling design. Their study results suggested that the increase of the variance estimate due to multiple imputation compared with single imputation largely disappears for estimates with large design effects. We complement their empirical research by providing some theoretical reasoning. We consider data sampled from an equally weighted, single-stage cluster design and characterize the process using a balanced, one-way normal random-effects model. Assuming that the missingness is completely at random, we derive analytic expressions for the within-and between-multiple-imputation variance estimators for the mean estimator, and thus conveniently reveal the impact of design effects on these variance estimators. We propose approximations for the fraction of missing information in clustered samples, extending previous results for simple random samples. We discuss some generalizations of this research and its practical implications for data release by statistical agencies. C1 [He, Yulei; Shimizu, Iris; Schappert, Susan; Xu, Jianmin; Beresovsky, Vladislav; Khan, Diba; Valverde, Roberto; Schenker, Nathaniel] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP He, YL; Shimizu, I; Schappert, S; Xu, JM; Beresovsky, V; Khan, D; Valverde, R; Schenker, N (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM wdq7@cdc.gov; ims1@cdc.gov; sds0@cdc.gov; ewl4@cdc.gov; hvy4@cdc.gov; ild1@cdc.gov; rcv4@cdc.gov; nhs1@cdc.gov NR 25 TC 0 Z9 0 U1 2 U2 2 PU DE GRUYTER OPEN LTD PI WARSAW PA BOGUMILA ZUGA 32A ST, 01-811 WARSAW, POLAND SN 0282-423X J9 J OFF STAT JI J. Off. Stat. PD MAR PY 2016 VL 32 IS 1 BP 147 EP 164 DI 10.1515/JOS-2016-0007 PG 18 WC Social Sciences, Mathematical Methods; Statistics & Probability SC Mathematical Methods In Social Sciences; Mathematics GA DK6CN UT WOS:000375008900007 ER PT J AU Beer, L Mattson, CL Bradley, H Skarbinski, J AF Beer, Linda Mattson, Christine L. Bradley, Heather Skarbinski, Jacek CA Med Monitoring Project TI Understanding Cross-Sectional Racial, Ethnic, and Gender Disparities in Antiretroviral Use and Viral Suppression Among HIV Patients in the United States SO MEDICINE LA English DT Article ID TREATMENT ADHERENCE; INFECTED ADULTS; MEDICAL-CARE; THERAPY; STRESS; OUTPATIENT; LITERACY; BELIEFS; RECEIPT; HEALTH AB To examine racial/ethnic and gender disparities in antiretroviral (ART) use and viral suppression among HIV-infected persons in care and identify factors that might account for observed disparities. The Medical Monitoring Project (MMP) is a complex sample survey of HIV-infected adults receiving medical care in the United States. We used weighted interview and medical record data collected 06/2009 to 05/2012 to estimate the prevalence of ART use and viral suppression among gender-stratified racial/ethnic groups. We used (2) tests to identify significant differences in outcomes between white men versus other groups, and logistic regression models to identify the most parsimonious set of factors that could account for each observed difference. We found no significant disparity in ART use between white and Hispanic men, and no disparities between white men and white and Hispanic women after adjustment for disease stage, age, and poverty. Disparities in ART use between white men and black persons persisted after adjusting for other factors, but the observed differences were relatively small. Differences in ART use and adherence, demographic characteristics, and social determinants of health such as poverty, education, and insurance accounted for the observed disparities in viral suppression between white men and all groups except black men. In our model, accounting for these factors reduced the prevalence difference in viral suppression between white and black men by almost half. We found that factors associated with disparities differed among men and women of the same race/ethnicity, lending support to the assertion that gender affects access to care and health status among HIV-infected patients. In addition to supporting efforts to increase ART use and adherence among persons living with HIV, our analysis provides evidence for the importance of social determinants of health in understanding racial/ethnic and gender differences in ART use and viral suppression. C1 [Beer, Linda; Mattson, Christine L.; Bradley, Heather; Skarbinski, Jacek; Med Monitoring Project] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E46, Atlanta, GA 30329 USA. RP Beer, L (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E46, Atlanta, GA 30329 USA. EM LBeer@cdc.gov FU Centers for Disease Control and Prevention FX The authors thank participating MMP patients, facilities, project areas, and Provider and Community Advisory Board members. The authors also thank the Clinical Outcomes Team and Behavioral and Clinical Surveillance Branch at CDC and the MMP 2009 Study Group Members (http://www.cdc.gov/hiv/statistics/systems/mmp/resources.html#StudyGroup Members); Funding for the Medical Monitoring Project is provided by the Centers for Disease Control and Prevention. NR 35 TC 3 Z9 3 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD MAR PY 2016 VL 95 IS 13 AR e3171 DI 10.1097/MD.0000000000003171 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA DK9NE UT WOS:000375256500013 PM 27043679 ER PT J AU Liu, MB Ou, JM Zhang, LJ Shen, XN Hong, RT Ma, HL Zhu, BP Fontaine, RE AF Liu, Mingbin Ou, Jianming Zhang, Lijie Shen, Xiaona Hong, Rongtao Ma, Huilai Zhu, Bao-Ping Fontaine, Robert E. TI Protective Effect of Hand-Washing and Good Hygienic Habits Against Seasonal Influenza A Case-Control Study SO MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; NONPHARMACEUTICAL INTERVENTIONS; ANTIGENIC MATCH; TRANSMISSION; VIRUS; HOUSEHOLDS; SANITIZER; SURVIVAL; THAILAND; SURFACES AB Previous observational studies have reported protective effects of hand-washing in reducing upper respiratory infections, little is known about the associations between hand-washing and good hygienic habits and seasonal influenza infection. We conducted a case-control study to test whether the risk of influenza transmission associated with self-reported hand-washing and unhealthy hygienic habits among residents in Fujian Province, southeastern China. Laboratory confirmed seasonal influenza cases were consecutively included in the study as case-patients (n = 100). For each case, we selected 1 control person matched for age and city of residence. Telephone interview was used to collect information on hand-washing and hygienic habits. The associations were analyzed using conditional logistic regression. Compared with the poorest hand-washing score of 0 to 3, odds ratios of influenza infection decreased progressively from 0.26 to 0.029 as hand-washing score increased from 4 to the maximum of 9 (P< 0.001). Compared with the poorest hygienic habit score of 0 to 2, odds ratios of influenza infection decreased from 0.10 to 0.015 with improving score of hygienic habits (P< 0.001). Independent protective factors against influenza infection included good hygienic habits, higher hand-washing score, providing soap or hand cleaner beside the hand-washing basin, and receiving influenza vaccine. Regular hand-washing and good hygienic habits were associated with a reduced risk of influenza infection. These findings support the general recommendation for nonpharmaceutical interventions against influenza. C1 [Liu, Mingbin] Nanchang Ctr Dis Control & Prevent, Dept Infect Dis, Nanchang, Peoples R China. [Liu, Mingbin; Zhang, Lijie; Ma, Huilai] Chinese Ctr Dis Control & Prevent, Chinese Field Epidemiol Training Program, Beijing, Peoples R China. [Ou, Jianming; Shen, Xiaona; Hong, Rongtao] Fujian Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Fuzhou, Peoples R China. [Zhu, Bao-Ping; Fontaine, Robert E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Zhang, LJ (reprint author), Chinese Ctr Dis Control & Prevent, Chinese Field Epidemiol Training Program, Beijing, Peoples R China. EM cfetpzlj@126.com NR 24 TC 0 Z9 0 U1 5 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD MAR PY 2016 VL 95 IS 11 AR e3046 DI 10.1097/MD.0000000000003046 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DK8XG UT WOS:000375211900059 PM 26986125 ER PT J AU Myers, TR Lin, X Skarbinski, J AF Myers, Tanya R. Lin, Xia Skarbinski, Jacek TI Antiretroviral Therapy and Viral Suppression Among Foreign-Born HIV-Infected Persons Receiving Medical Care in the United States SO MEDICINE LA English DT Article ID IMMIGRANTS; HIV/AIDS; ACCESS AB Immigrants to the United States are more likely to be diagnosed with human immunodeficiency virus (HIV) infection compared with native-born persons. Navigating access to healthcare in the United States can be challenging for foreign-born persons, and HIV treatment outcomes may be suboptimal for these persons. We compared characteristics of and assessed disparities in clinical outcomes of foreign-born persons in care for HIV in the United States. The Medical Monitoring Project is a complex sample, cross-sectional survey designed to be nationally representative of HIV-infected adults receiving medical care in the United States. Using data from 2009, 2010, and 2011, we conducted descriptive analyses and multivariable logistic regression to assess associations between foreign-born status and antiretroviral therapy (ART) prescription, and between foreign-born status and viral suppression. In all, 13.4% of HIV-infected persons were self-identified as foreign-born; the most common regions of birth were Central America and Mexico (45.4%) and the Caribbean (16.0%). Nearly 90% of foreign-born persons were diagnosed with HIV after entry into the United States. Compared with US-born persons, foreign-born persons were more likely to be younger, Hispanic, less educated, and uninsured. The prevalence of ART prescription (prevalence ratio 1.00; 95% confidence interval 0.98-1.02) was not significantly different between foreign-born and US-born persons. A higher percentage of foreign-born persons achieved viral suppression compared with US-born persons (prevalence ratio 1.05; 95% confidence interval 1.00-1.09). No major disparities in ART prescription and viral suppression were found between foreign-born and US-born HIV-infected persons receiving medical care, despite higher percentages being uninsured. C1 [Myers, Tanya R.] Ctr Dis Control & Prevent, Div Healthcare Qual & Promot, Atlanta, GA USA. [Lin, Xia; Skarbinski, Jacek] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Lin, Xia] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Myers, TR (reprint author), Immunizat Safety Off, Mailstop D26,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM vje9@cdc.gov FU Centers for Disease Control and Prevention [PS09-937] FX Funding for the Medical Monitoring Project provided by a cooperative agreement (PS09-937) from the Centers for Disease Control and Prevention. The Centers for Disease Control and Prevention reviewed and approved the final submission but had no role in design or conduct of the study; in collection, analysis, and interpretation of data; or in preparation of the manuscript. NR 23 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD MAR PY 2016 VL 95 IS 11 AR UNSP e3051 DI 10.1097/MD.0000000000003051 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA DK8XG UT WOS:000375211900008 PM 26986128 ER PT J AU Neff, LJ Patel, D Davis, K Ridgeway, W Shafer, P Cox, S AF Neff, Linda J. Patel, Deesha Davis, Kevin Ridgeway, William Shafer, Paul Cox, Shanna TI Evaluation of the National Tips From Former Smokers Campaign: the 2014 Longitudinal Cohort SO PREVENTING CHRONIC DISEASE LA English DT Article ID MEDIA CAMPAIGN; INTERNET AB Introduction Since 2012, the Centers for Disease Control and Prevention has aired a national tobacco education campaign to encourage quitting, Tips From Former Smokers (Tips), which consists of graphic anti-smoking advertisements that feature former cigarette smokers. We evaluated phase 2 of the 2014 campaign by using a nationally representative longitudinal cohort. Methods Cigarette smokers who participated in a baseline survey were re-contacted for follow-up (n = 4,248) approximately 4 months later, immediately after the campaign's conclusion. The primary outcomes were incidence of a quit attempt in the previous 3 months, intention to quit within 30 days, and intention to quit within 6 months during the postcampaign period. We used multivariate logistic regression models to estimate the odds of each outcome. We also stratified models by race/ethnicity, education, and mental health status. Postcampaign rates of quit attempts, intentions to quit, and sustained quits were also estimated. Results Exposure to the campaign was associated with increased odds of a quit attempt in the previous 3 months (OR, 1.17; P = .03) among baseline smokers and intentions to quit within the next 6 months (OR, 1.28; P = .01) among current smokers at follow-up. The Tips campaign was associated with an estimated 1.83 million additional quit attempts, 1.73 million additional smokers intending to quit within 6 months, and 104,000 sustained quits of at least 6 months. Conclusion The Tips campaign continued to have a significant impact on cessation-related behaviors, providing further justification for the continued use of tobacco education campaigns to accelerate progress toward the goal of reducing adult smoking in the United States. C1 [Neff, Linda J.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F-79, Atlanta, GA 30341 USA. [Patel, Deesha; Cox, Shanna] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Davis, Kevin; Ridgeway, William; Shafer, Paul] RTI Int, Res Triangle Pk, NC USA. RP Neff, LJ (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F-79, Atlanta, GA 30341 USA. EM Len2@cdc.gov FU CDC, US Department of Health and Human Services FX We thank the 16 advertisement participants who shared their personal stories with the public in the 2014 Tips campaigns, especially recognizing the contributions of Rosemary (Rose) Hernandez, Nathan Moose, Bill Busse, and Terrie Hall, who passed away from their smoking-related illnesses after participating in the campaign. We thank Diane Beistle and Jane Mitchko, who oversaw the Tips campaign, and Robert Rodes, who guided the execution of the media buy. We also thank Tim McAfee, Rebecca Bunnell, Terry F. Pechacek, Xin Xu, Ralph Caraballo, Jami Fraze, Robert Alexander, Ann Malarcher, Steve Babb, Gabbi Promoff, and Brian King for scientific, programmatic, and technical support; staff of CDC's Office on Smoking and Health; Ursula Bauer and Thomas Frieden for mobilizing CDC support and providing scientific support; the Plowshare Group for undertaking the media campaign; and Jonathan Blitstein, Jennifer Duke, and Burton Levine of RTI International for data analysis and technical support. Funding was provided by CDC, US Department of Health and Human Services. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC or RTI International. NR 11 TC 0 Z9 0 U1 2 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAR PY 2016 VL 13 AR 150556 DI 10.5888/pcd13.150556 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DK8UG UT WOS:000375203200013 ER PT J AU Voetsch, K Sequeira, S Chavez, AH AF Voetsch, Karen Sequeira, Sonia Chavez, Amy Holmes TI A Customizable Model for Chronic Disease Coordination: Lessons Learned From the Coordinated Chronic Disease Program SO PREVENTING CHRONIC DISEASE LA English DT Article ID PUBLIC-HEALTH AB In 2012, the Centers for Disease Control and Prevention provided funding and technical assistance to all states and territories to implement the Coordinated Chronic Disease Program, marking the first time that all state health departments had federal resources to coordinate chronic disease prevention and control programs. This article describes lessons learned from this initiative and identifies key elements of a coordinated approach. We analyzed 80 programmatic documents from 21 states and conducted semistructured interviews with 7 chronic disease directors. Six overarching themes emerged: 1) focused agenda, 2) identification of functions, 3) comprehensive planning, 4) collaborative leadership and expertise, 5) managed resources, and 6) relationship building. These elements supported 4 essential activities: 1) evidence-based interventions, 2) strategic use of staff, 3) consistent communication, and 4) strong program infrastructure. On the basis of these elements and activities, we propose a conceptual model that frames overarching concepts, skills, and strategies needed to coordinate state chronic disease prevention and control programs. C1 [Voetsch, Karen] Ctr Dis Control & Prevent, 4770 Buford Hwy, Atlanta, GA 30341 USA. [Sequeira, Sonia; Chavez, Amy Holmes] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Sequeira, Sonia; Chavez, Amy Holmes] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP Voetsch, K (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy, Atlanta, GA 30341 USA. EM kmp9@cdc.gov FU NCCDPHP, CDC FX We thank Fran Butterfoss, Renee Lavinghouze, and Debra Wigand for input on the conceptual framework, Patrick Brady for graphic design, Natasha Underwood and Jeanne Alongi for technical assistance, and the Connecticut, Montana, and Ohio state health departments for the use of graphics. This project was supported in part by an appointment to the Research Participation Program at the NCCDPHP, CDC, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.. NR 12 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAR PY 2016 VL 13 AR 150509 DI 10.5888/pcd13.150509 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DK8UG UT WOS:000375203200014 ER PT J AU Johnston, DI Chang, A Viray, M Chatham-Stephens, K He, H Taylor, E Wong, LL Schier, J Martin, C Fabricant, D Salter, M Lewis, L Park, SY AF Johnston, David I. Chang, Arthur Viray, Melissa Chatham-Stephens, Kevin He, Hua Taylor, Ethel Wong, Linda L. Schier, Joshua Martin, Colleen Fabricant, Daniel Salter, Monique Lewis, Lauren Park, Sarah Y. TI Hepatotoxicity associated with the dietary supplement OxyELITE Pro (TM) Hawaii, 2013 SO DRUG TESTING AND ANALYSIS LA English DT Article DE toxic hepatitis; dietary supplements ID ACUTE LIVER-FAILURE; HERBAL HEPATOTOXICITY; WEIGHT-LOSS; CAUSALITY ASSESSMENT; INJURY; HEPATITIS AB Dietary supplements are increasingly marketed to and consumed by the American public for a variety of purported health benefits. On 9 September 2013, the Hawaii Department of Health (HDOH) was notified of a cluster of acute hepatitis and fulminant hepatic failure among individuals with exposure to the dietary supplement OxyELITE Pro (OEP). HDOH conducted an outbreak investigation in collaboration with federal partners. Physicians were asked to report cases, defined as individuals with acute onset hepatitis of unknown etiology on or after 1 April 2013, a history of weight-loss/muscle-building dietary supplement use during the 60 days before illness onset, and residence in Hawaii during the period of exposure. Reported cases' medical records were reviewed, questionnaires were administered, and a product investigation, including chemical analyses and traceback, was conducted. Of 76 reports, 44 (58%) met case definition; of these, 36 (82%) reported OEP exposure during the two months before illness. No other common supplements or exposures were observed. Within the OEP-exposed subset, two patients required liver transplantation, and a third patient died. Excessive product dosing was not reported. No unique lot numbers were identified; there were multiple mainland distribution points, and lot numbers common to cases in Hawaii were also identified in continental states. Product analysis found consumed products were consistent with labeled ingredients; the mechanism of hepatotoxicity was not identified. We report one of the largest statewide outbreaks of dietary supplement-associated hepatotoxicity. The implicated product was OEP. The increasing popularity of dietary supplements raises the potential for additional clusters of dietary supplement-related adverse events. Copyright (c) 2015 John Wiley & Sons, Ltd. C1 [Johnston, David I.; Viray, Melissa; He, Hua; Park, Sarah Y.] Hawaii Dept Hlth, Dis Outbreak Control Div, Honolulu, HI USA. [Chang, Arthur; Chatham-Stephens, Kevin; Taylor, Ethel; Schier, Joshua; Martin, Colleen; Lewis, Lauren] Ctr Dis Control & Prevent, Hlth Studies Branch, Natl Ctr Environm Hlth, Atlanta, GA USA. [Wong, Linda L.] Queens Med Ctr, Honolulu, HI USA. [Fabricant, Daniel] Nat Prod Assoc, Washington, DC USA. [Salter, Monique] US FDA, Off Foods & Vet Med, Coordinated Outbreak Response & Evaluat Network, Rockville, MD 20857 USA. RP Johnston, DI (reprint author), 1250 Punchbowl St, Honolulu, HI 96813 USA. EM david.johnston@doh.hawaii.gov FU Intramural CDC HHS [CC999999]; NIH HHS [T35 OD010991] NR 36 TC 9 Z9 9 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1942-7603 EI 1942-7611 J9 DRUG TEST ANAL JI Drug Test. Anal. PD MAR-APR PY 2016 VL 8 IS 3-4 SI SI BP 319 EP 327 DI 10.1002/dta.1894 PG 9 WC Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy GA DJ5NP UT WOS:000374255900009 PM 26538199 ER PT J AU Margos, G Lane, RS Fedorova, N Koloczek, J Piesman, J Hojgaard, A Sing, A Fingerle, V AF Margos, Gabriele Lane, Robert S. Fedorova, Natalia Koloczek, Johannes Piesman, Joseph Hojgaard, Andrias Sing, Andreas Fingerle, Volker TI Borrelia bissettiae sp nov and Borrelia californiensis sp nov prevail in diverse enzootic transmission cycles SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY LA English DT Article ID BURGDORFERI SENSU-LATO; MULTILOCUS SEQUENCE-ANALYSIS; LYME-DISEASE; MOLECULAR CHARACTERIZATION; PHENOTYPIC SIMILARITIES; NORTHERN COLORADO; IXODES-PACIFICUS; UNITED-STATES; REVEALS; TICKS AB Two species of the genus Borrelia, Borrelia bissettiae sp. nov. and Borrelia californiensis sp. nov., were first described by Postic and co-workers on the basis of genetic analyses of several loci. Multilocus sequence analysis of eight housekeeping loci confirmed that these two Borrelia genomospecies are distinct members of the Borrelia burgdorferi sensu lato complex. B. bissettiae sp. nov. was initially described in transmission cycles involving Neotoma fuscipes wood rats and Ixodes pacificus ticks in California, and Neotoma mexicana and Ixodes spinipalpis in Colorado. The preferred host of B. californiensis sp. nov. appears to be the California kangaroo rat, Dipodomys californicus; Ixodes jellisoni, I. spinipalipis and I. pacificus ticks are naturally infected with it. Thus, the ecological associations of the two genomospecies and their genetic distance from all other known Borrelia genomospecies species justify their description as separate genomospecies: B. bissettiae sp. nov. (type strain DN127(T) =DSM 17990(T) = CIP 109136(T)) and B. californiensis (type strain CA446(T) 5DSM 17989(T) 5ATCC BAA-2689(T)). C1 [Margos, Gabriele; Koloczek, Johannes; Sing, Andreas; Fingerle, Volker] German Natl Reference Ctr Borrelia, Bavarian Hlth & Food Safety Author, Vet Str 2, Oberschleissheim, Germany. [Lane, Robert S.; Fedorova, Natalia] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA. [Piesman, Joseph; Hojgaard, Andrias] Ctr Dis Control & Prevent, Vector Borne Dis Branch, Ft Collins, CO USA. RP Margos, G (reprint author), German Natl Reference Ctr Borrelia, Bavarian Hlth & Food Safety Author, Vet Str 2, Oberschleissheim, Germany. EM gabriele.margos@lgl.bayern.de FU US National Institutes of Health [AI22501]; Centers for Disease Control and Prevention [U50/CCU906594] FX The authors gratefully acknowledge Richard N. Brown, Kerry A. Padgett and Joyce E. Kleinjan who conducted ecologic studies at the University of California Hopland Research and Extension Center (formerly the Hopland Field Station) in Mendocino County that resulted in the detection and isolation of both spirochaetes at that facility. Those studies were supported in large part by funding to R.S.L. from the US National Institutes of Health (grant AI22501) and the Centers for Disease Control and Prevention (cooperative agreement U50/CCU906594). NR 30 TC 2 Z9 2 U1 1 U2 2 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1466-5026 EI 1466-5034 J9 INT J SYST EVOL MICR JI Int. J. Syst. Evol. Microbiol. PD MAR PY 2016 VL 66 BP 1447 EP 1452 DI 10.1099/ijsem.0.000897 PN 3 PG 6 WC Microbiology SC Microbiology GA DJ3JX UT WOS:000374102200054 ER PT J AU Minguez-Alarcon, L Chiu, YH Messerlian, C Williams, PL Sabatini, ME Toth, TL Ford, JB Calafat, AM Hauser, R AF Minguez-Alarcon, Lidia Chiu, Yu-Han Messerlian, Carmen Williams, Paige L. Sabatini, Mary E. Toth, Thomas L. Ford, Jennifer B. Calafat, Antonia M. Hauser, Russ CA EARTH Study Team TI Urinary paraben concentrations and in vitro fertilization outcomes among women from a fertility clinic SO FERTILITY AND STERILITY LA English DT Article DE Epidemiology; IVF outcomes; paraben; reproductive health ID ESTROGENIC ACTIVITY; SEMEN QUALITY; BISPHENOL-A; PHENOLS; STEROIDOGENESIS; POPULATION; EXCRETION; PHTHALATE; CELLS; MODEL AB Objective: To explore the relationship between urinary paraben concentrations and IVF outcomes among women attending an academic fertility center. Design: Prospective cohort study. Setting: Fertility clinic in a hospital setting. Patient(s): A total of 245 women contributing 356 IVF cycles. Intervention(s): None. Quantification of urinary concentrations of parabens by isotope-dilution tandem mass spectrometry, and assessment of clinical endpoints of IVF treatments abstracted from electronic medical records at the academic fertility center. Main Outcome Measure(s): Total and mature oocyte counts, proportion of high-quality embryos, fertilization rates, and rates of implantation, clinical pregnancy, and live births. Result(s): The geometric means of the urinary concentrations of methylparaben, propylparaben, and butylparaben in our study population were 133, 24, and 1.5 mu g/L, respectively. In models adjusted for age, body mass index, race/ethnicity, smoking status, and primary infertility diagnosis, urinary methylparaben, propylparaben, and butylparaben concentrations were not associated with IVF outcomes, specifically total and mature oocyte counts, proportion of high embryo quality, and fertilization rates. Moreover, no significant associations were found between urinary paraben concentrations and rates of implantation, clinical pregnancy, and live births. Conclusion(s): Urinary paraben concentrations were not associated with IVF outcomes among women undergoing infertility treatments. (C) 2016 by American Society for Reproductive Medicine. C1 [Minguez-Alarcon, Lidia; Messerlian, Carmen; Ford, Jennifer B.; Hauser, Russ] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA. [Chiu, Yu-Han] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Williams, Paige L.; Hauser, Russ] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Williams, Paige L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Sabatini, Mary E.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Toth, Thomas L.; Hauser, Russ] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA. [Toth, Thomas L.; Hauser, Russ] Harvard Univ, Sch Med, Boston, MA USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Minguez-Alarcon, L (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA. EM lminguez@hsph.harvard.edu OI Chiu, Yu-Han/0000-0002-0904-7855 FU National Institutes of Health from the National Institute of Environmental Health Sciences [R01ES022955, R01ES009718, R01ES000002]; National Institute of Child Health and Human Development [T32DK00770316] FX Study funding was provided by National Institutes of Health grants R01ES022955, R01ES009718, and R01ES000002 from the National Institute of Environmental Health Sciences; and grant T32DK00770316 from the National Institute of Child Health and Human Development. NR 32 TC 0 Z9 0 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD MAR PY 2016 VL 105 IS 3 BP 714 EP 721 DI 10.1016/j.fertnstert.2015.11.021 PG 8 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DI3NV UT WOS:000373406300027 PM 26654974 ER PT J AU Birhane, MG Miranda, MEG Dyer, JL Blanton, JD Recuenco, S AF Birhane, Meseret G. Miranda, Mary Elizabeth G. Dyer, Jessie L. Blanton, Jesse D. Recuenco, Sergio TI Willingness to Pay for Dog Rabies Vaccine and Registration in Ilocos Norte, Philippines (2012) SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID CONTINGENT VALUATION; CANINE RABIES; HEALTH-CARE; ELIMINATION; AFRICA; CAMPAIGNS; ECONOMICS; PROGRAM; BOHOL; CHAD AB Background The Philippines is one of the developing countries highly affected by rabies. Dog vaccination campaigns implemented through collaborative effort between the government and NGOs have played an important role in successfully reducing the burden of disease within the country. Nevertheless, rabies vaccination of the domestic animal population requires continuous commitment not only from governments and NGOs, but also from local communities that are directly affected by such efforts. To create such long-term sustained programs, the introduction of affordable dog vaccination and registration fees is essential and has been shown to be an important strategy in Bohol, Philippines. The aim of this study, therefore, was to estimate the average amount of money that individuals were willing to pay for dog vaccination and registration in Ilocos Norte, Philippines. This study also investigated some of the determinants of individuals' willingness to pay (WTP). Methods A cross-sectional questionnaire was administered to 300 households in 17 municipalities (out of a total of 21) selected through a multi-stage cluster survey technique. At the time of the survey, Ilocos Norte had a population of approximately 568,017 and was predominantly rural. The Contingent Valuation Method was used to elicit WTP for dog rabies vaccination and registration. A 'bidding game' elicitation strategy that aims to find the maximum amount of money individuals were willing to pay was also employed. Data were collected using paper-based questionnaires. Linear regression was used to examine factors influencing participants' WTP for dog rabies vaccination and registration. Key Results On average, Ilocos Norte residents were willing to pay 69.65 Philippine Pesos (PHP) (equivalent to 1.67 USD in 2012) for dog vaccination and 29.13PHP (0.70 USD) for dog registration. Eighty-six per cent of respondents were willing to pay the stated amount to vaccinate each of their dogs, annually. This study also found that WTP was influenced by demographic and knowledge factors. Among these, we found that age, income, participants' willingness to commit to pay each year, municipality of residency, knowledge of the signs of rabies in dogs, and number of dogs owed significantly predicted WTP. C1 [Birhane, Meseret G.; Dyer, Jessie L.; Blanton, Jesse D.; Recuenco, Sergio] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Highconsequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA USA. [Miranda, Mary Elizabeth G.] Global Alliance Rabies Control, Manhattan, KS USA. RP Birhane, MG (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Highconsequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA USA. EM vkl2@cdc.gov OI Recuenco-Cabrera, Sergio/0000-0002-8446-7411 FU Global Alliance for Rabies Control (GARC); UBS Optimus Foundation FX Funding to support this study was secured from the Global Alliance for Rabies Control (GARC) and UBS Optimus Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript NR 35 TC 1 Z9 1 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAR PY 2016 VL 10 IS 3 AR e0004486 DI 10.1371/journal.pntd.0004486 PG 19 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DI1RF UT WOS:000373272500024 PM 26999021 ER PT J AU Paz-Soldan, VA Bauer, K Morrison, AC Lopez, JJC Izumi, K Scott, TW Elder, JP Alexander, N Halsey, ES McCall, PJ Lenhart, A AF Paz-Soldan, Valerie A. Bauer, Karin Morrison, Amy C. Cordova Lopez, Jhonny J. Izumi, Kiyohiko Scott, Thomas W. Elder, John P. Alexander, Neal Halsey, Eric S. McCall, Philip J. Lenhart, Audrey TI Factors Associated with Correct and Consistent Insecticide Treated Curtain Use in Iquitos, Peru SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID AEDES-AEGYPTI DIPTERA; DENGUE VECTOR CONTROL; MALARIA; TRIAL; NETS; DETERMINANTS; ACCEPTABILITY; INTERVENTIONS; TRANSMISSION; COVERAGE AB Dengue is an arthropod-borne virus of great public health importance, and control of its mosquito vectors is currently the only available method for prevention. Previous research has suggested that insecticide treated curtains (ITCs) can lower dengue vector infestations in houses. This observational study investigated individual and household-level socio-demographic factors associated with correct and consistent use of ITCs in Iquitos, Peru. A baseline knowledge, attitudes, and practices (KAP) survey was administered to 1,333 study participants, and ITCs were then distributed to 593 households as part of a cluster-randomized trial. Follow up KAP surveys and ITC-monitoring checklists were conducted at 9, 18, and 27 months post-ITC distribution. At 9 months post-distribution, almost 70% of ITCs were hanging properly (e.g. hanging fully extended or tied up), particularly those hung on walls compared to other locations. Proper ITC hanging dropped at 18 months to 45.7%. The odds of hanging ITCs correctly and consistently were significantly greater among those participants who were housewives, knew three or more correct symptoms of dengue and at least one correct treatment for dengue, knew a relative or close friend who had had dengue, had children sleeping under a mosquito net, or perceived a change in the amount of mosquitoes in the home. Additionally, the odds of recommending ITCs in the future were significantly greater among those who perceived a change in the amount of mosquitoes in the home (e.g. perceived the ITCs to be effective). Despite various challenges associated with the sustained effectiveness of the selected ITCs, almost half of the ITCs were still hanging at 18 months, suggesting a feasible vector control strategy for sustained community use. C1 [Paz-Soldan, Valerie A.; Bauer, Karin; Izumi, Kiyohiko] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Global Hlth Syst & Dev, New Orleans, LA USA. [Morrison, Amy C.; Cordova Lopez, Jhonny J.] US Naval Med Res Unit 6 NAMRU 6, Iquitos Lab, Iquitos, Peru. [Morrison, Amy C.; Scott, Thomas W.] Univ Calif Davis, Dept Entomol & Nematol, Davis, CA 95616 USA. [Elder, John P.] San Diego State Univ, Div Hlth Promot & Behav Sci, Grad Sch Publ Hlth, San Diego, CA 92182 USA. [Alexander, Neal] London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London WC1, England. [Alexander, Neal] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England. [Halsey, Eric S.] US Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [McCall, Philip J.] London Sch Hyg & Trop Med, Dept Vector Biol, London WC1, England. [Lenhart, Audrey] US Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Entomol Branch, Atlanta, GA USA. RP Paz-Soldan, VA (reprint author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Global Hlth Syst & Dev, New Orleans, LA USA. EM vpazsold@tulane.edu FU Wellcome Trust [WT085714MA]; U.S. National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIH/NIAID) [R01 AI069341-01]; Armed Forces Health Surveillance Center Global Emerging Infections Systems Research Program [847705.82000.25GB.B0016]; Military Infectious Disease Research Program [S0263_10_LI, S0216_09_LI]; Fogarty International Center [K01 TW008414-01A1]; Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate, U.S. Department of Homeland Security; Fogarty International Center, National Institutes of Health FX This research was supported by funding from the Wellcome Trust (WT085714MA), the U.S. National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIH/NIAID) award number R01 AI069341-01, the Armed Forces Health Surveillance Center Global Emerging Infections Systems Research Program (847705.82000.25GB. B0016), and the Military Infectious Disease Research Program (S0263_10_LI and S0216_09_LI). VPS received supported from the Fogarty International Center, award number K01 TW008414-01A1. TWS received support from the Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate, U.S. Department of Homeland Security, and the Fogarty International Center, National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 42 TC 1 Z9 1 U1 3 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAR PY 2016 VL 10 IS 3 AR e0004409 DI 10.1371/journal.pntd.0004409 PG 18 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DI1RF UT WOS:000373272500010 PM 26967157 ER PT J AU Vig, J Miller, KS Chirwa-Motswere, C Winskell, K Stallcup, E AF Vig, Jessica Miller, Kim S. Chirwa-Motswere, Catherine Winskell, Kate Stallcup, Elizabeth TI Involving parents from the start: formative evaluation for a large randomised controlled trial with Botswana Junior Secondary School students SO AJAR-AFRICAN JOURNAL OF AIDS RESEARCH LA English DT Article DE adolescents; caregivers; HIV; prevention; sub-Saharan Africa ID SUB-SAHARAN AFRICA; SEXUAL HEALTH; HIV; ADOLESCENTS; PREVENTION AB While HIV prevention research conducted among adolescent populations may encounter parental resistance, the active engagement of parents from inception to trial completion may alleviate opposition. In preparation for implementing a large randomised controlled trial (RCT) examining the efficacy of a behavioural intervention targeting adolescent sexual risk behaviours, a formative evaluation was undertaken to assess parental reactions to the proposed trial. Six focus groups were conducted with parents of adolescents (aged 13-17) from rural, peri-urban and urban junior secondary schools in Botswana. Focus groups explored comprehension and acceptability among parents of the forthcoming trial including HSV-2 testing, the return of results to the adolescent (not the parent), trial information materials and the parental consent process. Parents welcomed the study and understood and accepted its moral and ethical considerations. Their reactions regarding return of HSV-2 results only to adolescents (not the parent) were mixed. Parents understood the consent process and most agreed to consent, while indicating their desire to remain informed and involved throughout the RCT. The focus group discussions (FGDs) provided valuable information and insights that helped strengthen the study. As a result of parents' feedback, counselling procedures were strengthened and direct linkages to local services and care were made. Informational materials were revised to increase clarity, and materials and procedures were developed to encourage and support parental involvement and parent-child dialogue. Ultimately, parental feedback led to a decision by the Government of Botswana to allow parents to access their child's HSV-2 test results. C1 [Vig, Jessica] Assoc Sch & Programs Publ Hlth, Washington, DC USA. [Miller, Kim S.; Stallcup, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA. [Chirwa-Motswere, Catherine] Ctr Dis Control & Prevent, Gaborone, Botswana. [Winskell, Kate] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Vig, J (reprint author), Assoc Sch & Programs Publ Hlth, Washington, DC USA. EM jessicavig@gmail.com FU Centers for Disease Control and Prevention FX We thank Sarah M. Lasswell for her contributions to the Project AIM formative evaluation. This research was supported by the President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 13 TC 1 Z9 1 U1 0 U2 0 PU NATL INQUIRY SERVICES CENTRE PTY LTD PI GRAHAMSTOWN PA 19 WORCESTER STREET, PO BOX 377, GRAHAMSTOWN 6140, SOUTH AFRICA SN 1608-5906 EI 1727-9445 J9 AJAR-AFR J AIDS RES JI AJAR-Afr. J. Aids Res. PD MAR PY 2016 VL 15 IS 1 BP 9 EP 15 DI 10.2989/16085906.2015.1135295 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH9YF UT WOS:000373151200002 PM 27002354 ER PT J AU Maenner, MJ Blumberg, SJ Kogan, MD Christensen, D Yeargin-Allsopp, M Schieve, LA AF Maenner, Matthew J. Blumberg, Stephen J. Kogan, Michael D. Christensen, Deborah Yeargin-Allsopp, Marshalyn Schieve, Laura A. TI Prevalence of cerebral palsy and intellectual disability among children identified in two US National Surveys, 2011-2013 SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Intellectual disability; Cerebral palsy; Developmental disabilities; Prevalence ID DEVELOPMENTAL-DISABILITIES; MONITORING NETWORK; UNITED-STATES; TRENDS; POPULATION; AUTISM AB Purpose: Cerebral palsy (CP) and intellectual disability (ID) are developmental disabilities that result in considerable functional limitations. There are few recent and nationally representative prevalence estimates of CP and ID in the United States. Methods: We used two U.S. nationally representative surveys, the 2011-2012 National Survey of Children's Health (NSCH) and the 2011-2013 National Health Interview Survey (NHIS), to determine the prevalence of CP and ID based on parent report among children aged 2-17 years. Results: CP prevalence was 2.6 (95% confidence interval [CI]: 2.1-3.2) per 1000 in the NSCH and 2.9 (95% CI: 23-3.7) in the NHIS. ID prevalence was 12.2 (95% CI: 10.7-13.9) and 12.1 (95% CI: 10.8-13.7) in NSCH and NHIS, respectively. For both conditions, the NSCH and NHIS prevalence estimates were similar to each other for nearly all sociodemographic subgroups examined. Conclusions: Despite using different modes of data collection, the two surveys produced similar and plausible estimates of CP and ID and offer opportunities to better understand the needs and situations of children with these conditions. Published by Elsevier Inc. C1 [Maenner, Matthew J.; Christensen, Deborah; Yeargin-Allsopp, Marshalyn; Schieve, Laura A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mail Stop E-86, Atlanta, GA 30329 USA. [Maenner, Matthew J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Blumberg, Stephen J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Kogan, Michael D.] Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, Rockville, MD USA. RP Maenner, MJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mail Stop E-86, Atlanta, GA 30329 USA. EM xde8@cdc.gov FU Intramural CDC HHS [CC999999] NR 25 TC 1 Z9 1 U1 4 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD MAR PY 2016 VL 26 IS 3 BP 222 EP 226 DI 10.1016/j.annepidem.2016.01.001 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH6ZO UT WOS:000372940800010 PM 26851824 ER PT J AU Moffitt, KB Case, AP Farag, NH Canfield, MA AF Moffitt, Karen B. Case, Amy P. Farag, Noha H. Canfield, Mark A. TI Hospitalization charges for children with birth defects in Texas, 2001 to 2010 SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE hospitalization; congenital abnormalities; hospital charges; length of stay ID LEFT-HEART SYNDROME; INTESTINAL ATRESIAS; SEPTAL-DEFECT; INFANTS BORN; COSTS; SURGERY; CLOSURE; DISEASE; MORTALITY; OUTCOMES AB BackgroundState-specific information about hospitalizations of children with birth defects can improve understanding of changes in occurrence, treatment practices, and health care financing policies. This study analyzed aggregated data on hospital charges and length of stay for a large, diverse population. MethodsWe extracted hospitalization data for children diagnosed with birth defects from the Texas Hospital Inpatient Discharge Public Use Data File (2001-2010). Analyses compared total charges and length of stay for children with and without a diagnosis code of any birth defect among 45 standard categories. We also examined trends for total charges by expected payer type. ResultsIn Texas, 431,296 hospital stays were reported for children with birth defects, with total charges of $24.8 billion. Mean hospital stay for children with birth defects was more than twice that of those without, whereas mean of hospital total charges was approximately six times greater. Pyloric stenosis accounted for the largest number of hospitalizations, followed by certain cardiac defects. Pediatric hospitalizations for birth defects increased 273.7%, compared with a 214.7% increase overall. The percentage of charges with Medicaid as expected payer (2004-2010) ranged from 56.5 to 62.0%. ConclusionCharges associated with these conditions are far greater than those associated with pediatric hospitalizations for other causes, whether in the newborn period or beyond. However, these charges vary depending on specific diagnoses, expected payer source, and year of treatment. Birth Defects Research (Part A) 106:155-163, 2016. (c) 2015 Wiley Periodicals, Inc. C1 [Moffitt, Karen B.; Case, Amy P.; Canfield, Mark A.] Birth Defects Epidemiol & Surveillance Branch, Texas Dept State Hlth Serv, Austin, TX USA. [Farag, Noha H.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Case, AP (reprint author), Consortium Independent Res, 512 E 27th St, Vancouver, WA 98663 USA. EM acase@research-commons.com FU Centers for Disease Control and Prevention [5U01DD000494-04]; Texas Department of State Health Services (DSHS); Title V Maternal Child Health block grant at Texas DSHS FX Contract grant sponsor: Centers for Disease Control and Prevention; contract grant number: #5U01DD000494-04.; Contract grant sponsor: The Texas Department of State Health Services (DSHS).; Contract grant sponsor: the Title V Maternal Child Health block grant at Texas DSHS. NR 39 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAR PY 2016 VL 106 IS 3 BP 155 EP 163 DI 10.1002/bdra.23470 PG 9 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA DH6NY UT WOS:000372908700001 PM 26690723 ER PT J AU Carmichael, SL Yang, W Gilboa, S Ailes, E Correa, A Botto, LD Feldkamp, ML Shaw, GM AF Carmichael, Suzan L. Yang, Wei Gilboa, Suzanne Ailes, Elizabeth Correa, Adolfo Botto, Lorenzo D. Feldkamp, Marcia L. Shaw, Gary M. CA Natl Birth Defects Prevention TI Elevated body mass index and decreased diet quality among women and risk of birth defects in their offspring SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE nutrition; obesity; congenital anomalies; diet; neural tube defects ID NEURAL-TUBE DEFECTS; PREPREGNANCY OBESITY; PREVENTION; PREGNANCY AB BackgroundWe examined whether risks of 32 birth defects were higher than expected in the presence of overweight or obese body mass index (BMI) and low diet quality, based on estimating individual and joint effects of these factors and calculating relative excess risk due to interaction. MethodsAnalyses included mothers of 20,250 cases with birth defects and 8617 population-based controls without birth defects born from 1997 to 2009 and interviewed for the National Birth Defects Prevention Study. We used logistic regression to generate adjusted odds ratios (AORs) reflecting the combined effects of BMI and diet quality. We focused analyses on 16 birth defects (n = 11,868 cases, 8617 controls) for which initial results suggested an association with BMI or diet quality. ResultsRelative to the reference group (normal weight women with not low diet quality, i.e., >lowest quartile), AORs for low diet quality among normal weight women tended to be >1, and AORs for overweight and obese women tended to be stronger among women who had low diet quality than not low diet quality. For 9/16 birth defects, AORs for obese women who had low diet qualitythe group we hypothesized to have highest riskwere higher than other stratum-specific AORs. Most relative excess risk due to interactions were positive but small (<0.5), with confidence intervals that included zero. ConclusionThese findings provide evidence for the hypothesis of highest birth defect risks among offspring to women who are obese and have low diet quality but insufficient evidence for an interaction of these factors in their contribution to risk. Birth Defects Research (Part A) 106:164-171, 2016. (c) 2015 Wiley Periodicals, Inc. C1 [Carmichael, Suzan L.; Yang, Wei; Shaw, Gary M.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA. [Gilboa, Suzanne; Ailes, Elizabeth] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA. [Botto, Lorenzo D.; Feldkamp, Marcia L.] Univ Utah, Sch Med, Dept Pediat, Div Med Genet, Salt Lake City, UT USA. RP Carmichael, SL (reprint author), Stanford Univ, Dept Pediat, Div Neonatal & Dev Med, 1265 Welch Rd,Room X111, Stanford, CA 94305 USA. EM scarmichael@stanford.edu FU University of North Carolina Epidemiology Core [DK56350]; CDC [U01 DD001033] FX We thank the California Department of Public Health Maternal Child and Adolescent Health Division for providing data and the University of North Carolina Epidemiology Core for help with the nutrient database (Grant #DK56350). This project was partially supported by CDC U01 DD001033. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the California Department of Public Health or the Centers for Disease Control and Prevention. NR 19 TC 0 Z9 0 U1 6 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAR PY 2016 VL 106 IS 3 BP 164 EP 171 DI 10.1002/bdra.23471 PG 8 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA DH6NY UT WOS:000372908700002 PM 26663631 ER PT J AU Vallabhaneni, S Mody, RK Walker, T Chiller, T AF Vallabhaneni, Snigdha Mody, Rajal K. Walker, Tiffany Chiller, Tom TI The Global Burden of Fungal Diseases SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Global burden; Epidemiology; Fungal diseases; Candida; Cryptococcus; Aspergillus; Mold; Endemic mycoses ID PENICILLIUM-MARNEFFEI INFECTION; SURVEILLANCE NETWORK TRANSNET; CELL TRANSPLANT RECIPIENTS; UNITED-STATES; CRYPTOCOCCAL MENINGITIS; HIV-INFECTION; EPIDEMIOLOGY; CANDIDEMIA; PNEUMONIA; MYCETOMA AB Fungal diseases require greater attention today than ever before, given the expanding population of immunosuppressed patients who are at higher risk for these diseases. This article reports on distribution, incidence, and prevalence of various fungal diseases and points out gaps in knowledge where such data are not available. Fungal diseases that contribute substantially to global morbidity and mortality are highlighted. Longterm, sustainable surveillance programs for fungal diseases and better noninvasive and reliable diagnostic tools are needed to estimate the burden of these diseases more accurately. C1 [Vallabhaneni, Snigdha; Mody, Rajal K.; Walker, Tiffany; Chiller, Tom] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. RP Vallabhaneni, S (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd Northeast,Mailstop C-09, Atlanta, GA 30329 USA. EM fco6@cdc.gov NR 62 TC 4 Z9 4 U1 2 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 EI 1557-9824 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD MAR PY 2016 VL 30 IS 1 BP 1 EP + DI 10.1016/j.idc.2015.10.004 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DH5UJ UT WOS:000372857200002 PM 26739604 ER PT J AU Butcher, MT Thomas, DR Riskin, DK Mitchell, RM Hermanson, JW AF Butcher, M. T. Thomas, D. R. Riskin, D. K. Mitchell, R. M. Hermanson, J. W. TI Myosin fiber types in moles: Fast muscles make the slow burrower SO INTEGRATIVE AND COMPARATIVE BIOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Integrative-and-Comparative-Biology (SICB) CY JAN 03-07, 2016 CL Portland, OR SP Soc Integrat & Comparat Biol C1 Youngstown State Univ, Youngstown, OH USA. Univ Toronto, Mississauga, ON L5L 1C6, Canada. Ctr Dis Control, Atlanta, GA 30333 USA. Cornell Univ, Ithaca, NY 14853 USA. EM mtbutcher@ysu.edu NR 0 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1540-7063 EI 1557-7023 J9 INTEGR COMP BIOL JI Integr. Comp. Biol. PD MAR PY 2016 VL 56 SU 1 MA 97-4 BP E29 EP E29 PG 1 WC Zoology SC Zoology GA DH0FJ UT WOS:000372457600114 ER PT J AU Hemans-Henry, C Blake, J Parton, H Koppaka, R Greene, CM AF Hemans-Henry, Calaine Blake, Janice Parton, Hilary Koppaka, Ram Greene, Carolyn M. TI Preparing Master of Public Health Graduates to Work in Local Health Departments SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE master of public health; workforce development; public health workforce; MPH; public health competencies ID WORKFORCE; COMPETENCES; PROFESSIONALS AB Objective: To identify key competencies and skills that all master of public health (MPH) graduates should have to be prepared to work in a local health department. Methods: In 2011-2012, the New York City Department of Health and Mental Hygiene administered electronic surveys to 2 categories of staff: current staff with an MPH as their highest degree, and current hiring managers. Results: In all, 312 (77%) staff members with an MPH as their highest degree and 170 (57%) hiring managers responded to the survey. Of the respondents with an MPH as their highest degree, 85% stated that their MPH program prepared them for work at the New York City Health Department. Skills for which MPH graduates most often stated they were underprepared included facility in using SAS (R) statistical software, quantitative data analysis/statistics, personnel management/leadership, and data collection/database management/data cleaning. Among the skills hiring managers identified as required of MPH graduates, the following were most often cited as those for which newly hired MPH graduates were inadequately prepared: quantitative data analysis, researching/conducting literature reviews, scientific writing and publication, management skills, and working with contracts/requests for proposals. Conclusion: These findings suggest that MPH graduates could be better prepared to work in a local health department upon graduation. To be successful, new MPH graduate hires should possess fundamental skills and knowledge related to analysis, communication, management, and leadership. Local health departments and schools of public health must each contribute to the development of the current and future public health workforce through both formal learning opportunities and supplementary employment-based training to reinforce prior coursework and facilitate practical skill development. C1 [Hemans-Henry, Calaine; Blake, Janice] New York City Dept Hlth & Mental Hyg, Bur Publ Hlth Training, New York, NY USA. [Parton, Hilary] New York City Dept Hlth & Mental Hyg, Bur Epidemiol Serv, New York, NY USA. [Koppaka, Ram] New York City Dept Hlth & Mental Hyg, Provider Educ Program, New York, NY USA. [Greene, Carolyn M.] New York City Dept Hlth & Mental Hyg, Div Epidemiol, New York, NY USA. [Koppaka, Ram] Ctr Dis Control & Prevent, Epidemiol & Anal Program, New York, NY USA. RP Hemans-Henry, C (reprint author), New York City Dept Hlth & Mental Hyg, Bur Publ Hlth Training, Div Epidemiol, 42-09 28th St,CN 65, Queens, NY 11101 USA. EM chemans@health.nyc.gov NR 15 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2016 VL 22 IS 2 SI SI BP 194 EP 199 DI 10.1097/PHH.0000000000000232 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH7NT UT WOS:000372981600013 PM 25734653 ER PT J AU Healey, KR Zhao, YA Perez, WB Lockhart, SR Sobel, JD Farmakiotis, D Kontoyiannis, DP Sanglard, D Taj-Aldeen, SJ Alexander, BD Jimenez-Ortigosa, C Shor, E Perlin, DS AF Healey, Kelley R. Zhao, Yanan Perez, Winder B. Lockhart, Shawn R. Sobel, Jack D. Farmakiotis, Dimitrios Kontoyiannis, Dimitrios P. Sanglard, Dominique Taj-Aldeen, Saad J. Alexander, Barbara D. Jimenez-Ortigosa, Cristina Shor, Erika Perlin, David S. TI Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance SO NATURE COMMUNICATIONS LA English DT Article ID ANTIFUNGAL DRUG-RESISTANCE; ECHINOCANDIN RESISTANCE; REDUCED SUSCEPTIBILITY; CLINICAL ISOLATE; AMPHOTERICIN-B; FKS MUTATIONS; ERG6 GENE; EPIDEMIOLOGY; MICAFUNGIN; PROPHYLAXIS AB The fungal pathogen Candida glabrata has emerged as a major health threat since it readily acquires resistance to multiple drug classes, including triazoles and/or echinocandins. Thus far, cellular mechanisms promoting the emergence of resistance to multiple drug classes have not been described in this organism. Here we demonstrate that a mutator phenotype caused by a mismatch repair defect is prevalent in C. glabrata clinical isolates. Strains carrying alterations in mismatch repair gene MSH2 exhibit a higher propensity to breakthrough antifungal treatment in vitro and in mouse models of colonization, and are recovered at a high rate (55% of all C. glabrata recovered) from patients. This genetic mechanism promotes the acquisition of resistance to multiple antifungals, at least partially explaining the elevated rates of triazole and multi-drug resistance associated with C. glabrata. We anticipate that identifying MSH2 defects in infecting strains may influence the management of patients on antifungal drug therapy. C1 [Healey, Kelley R.; Zhao, Yanan; Perez, Winder B.; Jimenez-Ortigosa, Cristina; Shor, Erika; Perlin, David S.] Rutgers Biomed & Hlth Sci, Publ Hlth Res Inst, New Jersey Med Sch, 225 Warren St, Newark, NJ 07103 USA. [Lockhart, Shawn R.] Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop G-11, Atlanta, GA 30333 USA. [Sobel, Jack D.] Wayne State Univ, Sch Med, 540 E Canfield Ave,1241 Scott Hall, Detroit, MI 48201 USA. [Farmakiotis, Dimitrios; Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, 1400 Pressler St,FCT12-5046,Unit 1463, Houston, TX 77030 USA. [Farmakiotis, Dimitrios] Brown Univ, Warren Alpert Med Sch, 593 Eddy St,Gerry House 113, Providence, RI 02903 USA. [Sanglard, Dominique] Univ Lausanne Hosp, Inst Microbiol, Rue Bugnon 48, CH-1011 Lausanne, Switzerland. [Taj-Aldeen, Saad J.] Hamad Med Corp, Dept Lab Med & Pathol, POB 3050, Doha, Qatar. [Alexander, Barbara D.] Duke Univ, 315 Trent Dr,Hanes House,Room 163A, Durham, NC 27710 USA. RP Perlin, DS (reprint author), Rutgers Biomed & Hlth Sci, Publ Hlth Res Inst, New Jersey Med Sch, 225 Warren St, Newark, NJ 07103 USA. EM perlinds@njms.rutgers.edu FU NIH [AI109025]; Arnold and Mabel Beckman Foundation; Swiss National Research Foundation [31003A_146936]; Qatar National Research Fund [NPRP 5-298-3-086] FX We thank the PHRI animal staff, especially Steven Park, Min Lee, Marizel Mina, Irina Kolesnikova and Guillaume Delmas, for their assistance. We note the assistance of Sujung Choi and Natan Haramati with sequencing efforts. This research was supported by the NIH grant AI109025 to D.S.P. and by an Arnold O. Beckman postdoctoral fellowship from the Arnold and Mabel Beckman Foundation to K.R.H. D.S. is funded by the Swiss National Research Foundation grant 31003A_146936. S.J.T.-A. is supported by grant NPRP 5-298-3-086 from the Qatar National Research Fund (a member of Qatar Foundation). NR 36 TC 14 Z9 14 U1 9 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD MAR PY 2016 VL 7 AR 11128 DI 10.1038/ncomms11128 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH9MK UT WOS:000373120000001 PM 27020939 ER PT J AU Fasula, AM Oraka, E Jeffries, WL Carry, M Ocfemia, MCB Balaji, AB Rose, CE Jayne, PE AF Fasula, Amy M. Oraka, Emeka Jeffries, William L. Carry, Monique Ocfemia, M. Cheryl Banez Balaji, Alexandra B. Rose, Charles E. Jayne, Paula E. CA Workgrp Adolescent Sexual TI Young Sexual Minority Males in the United States: Sociodemographic Characteristics And Sexual Attraction, Identity and Behavior SO PERSPECTIVES ON SEXUAL AND REPRODUCTIVE HEALTH LA English DT Article ID BISEXUAL YOUTHS; PROBABILITY SAMPLE; DIFFERENT PATTERNS; MEN; GAY; HIV; ORIENTATION; ADULTS; RISK; NUMBER AB CONTEXT: HIV incidence is increasing among 13-24-year-old U.S. men who have sex with men, yet limited research is available to guide HIV prevention efforts for this population. METHODS: National Survey of Family Growth data collected in 2002, in 2006-2010 and in 2011-2013 from 8,068 males aged 15-24 were analyzed to describe the population of U.S. young sexual minority males (i.e., males reporting same-sex attraction, identity or behavior). Correlates of sexual minority classification were assessed in logistic regression models. RESULTS: An estimated 10% of young males, representing a population of 2.1 million, were sexual minorities. Males had an elevated likelihood of being sexual minorities if they were aged 18-19 or 20-24, rather than 15-17 (prevalence ratio, 1.7 for each); belonged to nonblack, non-Hispanic racial or ethnic minority groups (1.6); had no religious affiliation, rather than considering religion very important (1.9); or lived below the federal poverty level (1.3). They had a reduced likelihood of being sexual minorities if they lived in metropolitan areas outside of central cities (0.7). Among young sexual minority males, 44% were 15-19 years old, 29% were poor and 59% resided outside central cities. Forty-seven percent had engaged in same-sex behavior. Of those with data on all measured dimensions of sexuality, 24% reported same-sex attraction, identity and behavior; 22% considered themselves heterosexual, yet had had a male sex partner. CONCLUSION: Future investigations can further explore subpopulations of young sexual minority males and assess sexual trajectories, resilience and HIV risk. C1 [Fasula, Amy M.; Jeffries, William L.; Carry, Monique; Ocfemia, M. Cheryl Banez; Balaji, Alexandra B.; Rose, Charles E.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Jayne, Paula E.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Oraka, Emeka] ICF Int, Atlanta, GA USA. RP Fasula, AM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. EM afasula@cdc.gov NR 37 TC 1 Z9 1 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-6341 EI 1931-2393 J9 PERSPECT SEX REPRO H JI Perspect. Sex Reprod. Health PD MAR PY 2016 VL 48 IS 1 BP 3 EP 8 DI 10.1363/48e7016 PG 6 WC Demography; Family Studies SC Demography; Family Studies GA DI0EG UT WOS:000373167300001 PM 26742996 ER PT J AU Lafond, KE Nair, H Rasooly, MH Valente, F Booy, R Rahman, M Kitsutani, P Yu, HJ Guzman, G Coulibaly, D Armero, J Jima, D Howie, SRC Ampofo, W Mena, R Chadha, M Sampurno, OD Emukule, GO Nurmatov, Z Corwin, A Heraud, JM Noyola, DE Cojocaru, R Nymadawa, P Barakat, A Adedeji, A von Horoch, M Olveda, R Nyatanyi, T Venter, M Mmbaga, V Chittaganpitch, M Nguyen, TH Theo, A Whaley, M Azziz-Baumgartner, E Bresee, J Campbell, H Widdowson, MA AF Lafond, Kathryn E. Nair, Harish Rasooly, Mohammad Hafiz Valente, Fatima Booy, Robert Rahman, Mahmudur Kitsutani, Paul Yu, Hongjie Guzman, Guiselle Coulibaly, Daouda Armero, Julio Jima, Daddi Howie, Stephen R. C. Ampofo, William Mena, Ricardo Chadha, Mandeep Sampurno, Ondri Dwi Emukule, Gideon O. Nurmatov, Zuridin Corwin, Andrew Heraud, Jean Michel Noyola, Daniel E. Cojocaru, Radu Nymadawa, Pagbajabyn Barakat, Amal Adedeji, Adebayo von Horoch, Marta Olveda, Remigio Nyatanyi, Thierry Venter, Marietjie Mmbaga, Vida Chittaganpitch, Malinee Tran Hien Nguyen Theo, Andros Whaley, Melissa Azziz-Baumgartner, Eduardo Bresee, Joseph Campbell, Harry Widdowson, Marc-Alain CA Global Resp Hospitalizations Influ TI Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982-2012: A Systematic Analysis SO PLOS MEDICINE LA English DT Article ID LABORATORY-CONFIRMED INFLUENZA; SEASONAL INFLUENZA; YOUNG-CHILDREN; UNITED-STATES; VIRUS; INFECTIONS; PNEUMONIA; MORTALITY; COUNTRIES; AFRICA C1 [Lafond, Kathryn E.; Kitsutani, Paul; Corwin, Andrew; Whaley, Melissa; Azziz-Baumgartner, Eduardo; Bresee, Joseph; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Lafond, Kathryn E.] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland. [Nair, Harish; Campbell, Harry] Univ Edinburgh, Ctr Global Hlth Res, Edinburgh, Midlothian, Scotland. [Nair, Harish] Publ Hlth Fdn India, New Delhi, India. [Rasooly, Mohammad Hafiz] Minist Publ Hlth, Afghanistan Natl Publ Hlth Inst, Kabul, Afghanistan. [Valente, Fatima] Minist Hlth, Natl Directorate Publ Hlth, Luanda, Angola. [Booy, Robert] Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia. [Rahman, Mahmudur] Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh. [Yu, Hongjie] Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing, Peoples R China. [Guzman, Guiselle] Caja Costarricense Seguro Social, San Jose, Costa Rica. [Coulibaly, Daouda] Pasteur Inst Cote Ivoire, Abidjan, Cote Ivoire. [Armero, Julio] Minist Salud El Salvador, San Salvador, El Salvador. [Jima, Daddi] Ethiopian Publ Hlth Inst, Addis Ababa, Ethiopia. [Howie, Stephen R. C.] MRC Unit, Fajara, Gambia. [Howie, Stephen R. C.] Univ Auckland, Dept Paediat, Auckland, New Zealand. [Howie, Stephen R. C.] Univ Otago, Ctr Int Hlth, Dunedin, New Zealand. [Ampofo, William] Univ Ghana, Noguchi Mem Inst Med Res, Accra, Ghana. [Mena, Ricardo] Minist Salud Publ & Asistencia Social, Guatemala City, Guatemala. [Chadha, Mandeep] Natl Inst Virol, Pune, Maharashtra, India. [Sampurno, Ondri Dwi] Natl Inst Hlth Res & Dev, Jakarta, Indonesia. [Emukule, Gideon O.] Ctr Dis Control & Prevent, Nairobi, Kenya. [Nurmatov, Zuridin] Minist Hlth, Bishkek, Kyrgyzstan. [Heraud, Jean Michel] Inst Pasteur Madagascar, Natl Influenza Ctr, Virol Unit, Antananarivo, Madagascar. [Noyola, Daniel E.] Univ Autonoma San Luis Potosi, San Luis Potosi, Mexico. [Cojocaru, Radu] Natl Ctr Publ Hlth, Kishinev, Moldova. [Nymadawa, Pagbajabyn] Natl Influenza Ctr, Ulaanbaatar, Mongol Peo Rep. [Barakat, Amal] Minist Sante, Natl Inst Hyg, Rabat, Morocco. [Adedeji, Adebayo] Fed Minist Hlth, Abuja, Nigeria. [von Horoch, Marta] Minist Salud Publ & Bienestar Social, Asuncion, Paraguay. [Olveda, Remigio] Res Inst Trop Med, Manila, Philippines. [Nyatanyi, Thierry] Minist Hlth, Kigali, Rwanda. [Venter, Marietjie] Natl Inst Communicable Dis, Johannesburg, South Africa. [Venter, Marietjie] Univ Pretoria, Dept Med Virol, Zoonoses Res Unit, ZA-0001 Pretoria, South Africa. [Venter, Marietjie] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA. [Mmbaga, Vida] Minist Hlth, Dar Es Salaam, Tanzania. [Chittaganpitch, Malinee] Minist Publ Hlth, Natl Inst Hlth, Nonthaburi, Thailand. [Tran Hien Nguyen] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam. [Theo, Andros] Univ Teaching Hosp, Virol Lab, Lusaka, Zambia. RP Lafond, KE; Widdowson, MA (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.; Lafond, KE (reprint author), Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland. EM gmj3@cdc.gov; zux5@cdc.gov RI Nair, Harish/E-7431-2010; Venter, Marietjie/P-9604-2016; OI Nair, Harish/0000-0002-9432-9100; Venter, Marietjie/0000-0003-2696-824X; HERAUD, Jean-Michel/0000-0003-1107-0859 FU U.S. Centers for Disease Control and Prevention (CDC) FX Funding for this study was provided entirely by the U.S. Centers for Disease Control and Prevention (CDC). The study was designed by the authors, and the results and conclusions do not necessarily reflect the official position of the CDC. NR 33 TC 4 Z9 5 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD MAR PY 2016 VL 13 IS 3 AR e1001977 DI 10.1371/journal.pmed.1001977 PG 19 WC Medicine, General & Internal SC General & Internal Medicine GA DH8JN UT WOS:000373039400010 PM 27011229 ER PT J AU Suchdev, PS Namaste, SML Aaron, GJ Raiten, DJ Brown, KH Flores-Ayala, R AF Suchdev, Parminder S. Namaste, Sorrel M. L. Aaron, Grant J. Raiten, Daniel J. Brown, Kenneth H. Flores-Ayala, Rafael CA BRINDA Working Grp TI Overview of the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) Project SO ADVANCES IN NUTRITION LA English DT Article DE anemia; biomarkers; inflammation; iron; public health ID TRANSFERRIN RECEPTOR CONCENTRATIONS; ACUTE-PHASE RESPONSE; PRESCHOOL-CHILDREN; IRON-DEFICIENCY; SYSTEMATIC ANALYSIS; NONPREGNANT WOMEN; PLASMA FERRITIN; RISK-FACTORS; VITAMIN-A; BODY IRON AB Anemia remains a widespread public health problem. Although iron deficiency is considered the leading cause of anemia globally, the cause of anemia varies considerably by country. To achieve global targets to reduce anemia, reliable estimates of the contribution of nutritional and non nutritional causes of anemia are needed to guide interventions. Inflammation is known to affect many biomarkers used to assess micronutrient status and can thus lead to incorrect diagnosis of individuals and to overestimation or underestimation of the prevalence of deficiency in a population. Reliable assessment of iron status is particularly needed in settings with high infectious disease burden, given the call to screen for iron deficiency to mitigate potential adverse effects of iron supplementation. To address these information gaps, in 2012 the CDC, National Institute for Child Health and Human Development, and Global Alliance for Improved Nutrition formed a collaborative research group called Biomarkers Reflecting Inflammation and Nutrition Determinants of Anemia (BRINDA). Data from nationally and regionally representative nutrition surveys conducted in the past 10 y that included preschool children and/or women of childbearing age were pooled. Of 25 data sets considered for inclusion, 17 were included, representing 30,000 preschool children, 26,000 women of reproductive age, and 21,000 school-aged children from all 6 WHO geographic regions. This article provides an overview of the BRINDA project and describes key research questions and programmatic and research implications. Findings from this project will inform global guidelines on the assessment of anemia and micronutrient status and will guide the development of a research agenda for future longitudinal studies. C1 [Suchdev, Parminder S.; Flores-Ayala, Rafael] Ctr Dis Control & Prevent, Nutr Branch, Atlanta, GA USA. [Suchdev, Parminder S.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Namaste, Sorrel M. L.] Helen Keller Int, New York, NY USA. [Namaste, Sorrel M. L.; Raiten, Daniel J.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. [Aaron, Grant J.] Global Alliance Improved Nutr, Geneva, Switzerland. [Brown, Kenneth H.] Bill & Melinda Gates Fdn, Seattle, WA USA. RP Suchdev, PS (reprint author), Ctr Dis Control & Prevent, Nutr Branch, Atlanta, GA USA.; Suchdev, PS (reprint author), Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. EM psuchde@emory.edu FU American Society for Nutrition (ASN); ASN Global Nutrition Council; ASN Nutritional Epidemiology Research Interest Section (RIS); Bill & Melinda Gates Foundation; NIH Office of Dietary Supplements; National Institute of Child Health and Human Development; CDC; Global Alliance for Improved Nutrition FX This article is a review from the symposium "Interpreting Epidemiological Data in Nutritional Literature An Historical Perspective" held 30 March 2015, at the ASN Scientific Sessions and Annual Meeting at Experimental Biology in Boston, MA. The symposium was sponsored by the American Society for Nutrition (ASN), the ASN Global Nutrition Council, and the ASN Nutritional Epidemiology Research Interest Section (RIS); The BRINDA project is supported by the Bill & Melinda Gates Foundation, NIH Office of Dietary Supplements, National Institute of Child Health and Human Development, CDC, and Global Alliance for Improved Nutrition NR 34 TC 6 Z9 6 U1 1 U2 4 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 2161-8313 EI 2156-5376 J9 ADV NUTR JI Adv. Nutr. PD MAR PY 2016 VL 7 IS 2 BP 349 EP 356 DI 10.3945/an.115.010215 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DH3FG UT WOS:000372672300009 PM 26980818 ER PT J AU Blackley, DJ Halldin, CN Cummings, KJ Laney, AS AF Blackley, David J. Halldin, Cara N. Cummings, Kristin J. Laney, A. Scott TI Lung Transplantation Is Increasingly Common Among Patients With Coal Workers' Pneumoconiosis SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE coal workers' pneumoconiosis; lung transplantation; occupational lung disease; coal mining ID UNITED-STATES; MINE DUST; DISEASE; EXPOSURE AB Background The prevalence of coal workers' pneumoconiosis (CWP) in U.S. coal miners has increased, and severe presentations are increasingly common. Methods We describe trends in lung transplantation during 1996-2014 for recipients with a primary diagnosis of CWP or pneumoconiosis unspecified, and we summarize recipient characteristics and estimate survival. Results A total of 47 transplants were included; nearly three-quarters were performed during 2008-2014. All recipients were male, 96% were white, and the mean age was 56 years. Mean FEV1% was 35%; mean FVC% was 53%. Mean time on a waitlist was 155 days, and 60% of transplants were bilateral. Median survival was 3.7 years. Conclusions These transplants reflect the use of a scarce resource for an entirely preventable disease, and highlight the need for enhanced efforts to reduce coal mine dust exposures. This article is a U.S. Government work and is in the public domain in the USA. C1 [Blackley, David J.; Halldin, Cara N.; Laney, A. Scott] NIOSH, Resp Hlth Div, Surveillance Branch, 1095 Willowdale Rd,Mailstop HG900-2, Morgantown, WV 26505 USA. [Cummings, Kristin J.] NIOSH, Resp Hlth Div, Field Studies Branch, 1095 Willowdale Rd,Mailstop HG900-2, Morgantown, WV 26505 USA. [Laney, A. Scott] NIOSH, Ctr Dis Control & Prevent, Resp Hlth Div, 1095 Willowdale Rd,Mailstop HG900-2, Morgantown, WV 26505 USA. RP Blackley, DJ (reprint author), NIOSH, Resp Hlth Div, Surveillance Branch, 1095 Willowdale Rd,Mailstop HG900-2, Morgantown, WV 26505 USA. EM dblackley@cdc.gov FU Health Resources and Services Administration [234-2005-370011C] FX This work was supported in part by Health Resources and Services Administration contract 234-2005-370011C. The content is the responsibility of the authors alone and does not necessarily reflect the views of the Department of Health and Human Services. This paper was prepared and written by NIOSH employees as part of their employment. NR 13 TC 0 Z9 1 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD MAR PY 2016 VL 59 IS 3 BP 175 EP 177 DI 10.1002/ajim.22551 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG7UW UT WOS:000372290200001 PM 26725917 ER PT J AU Konda, S Tiesman, HM Reichard, AA AF Konda, Srinivas Tiesman, Hope M. Reichard, Audrey A. TI Fatal Traumatic Brain Injuries in the Construction Industry, 2003-2010 SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE brain injuries; TBI; falls; roofers; occupational; older workers ID WORK; FALLS; US; SYSTEM; EPIDEMIOLOGY; COMMUNITY; IMPACT AB Background Research on fatal work-related traumatic brain injuries (TBIs) is limited. This study describes fatal TBIs in the US construction industry. Methods Fatal TBIs were extracted from the Bureau of Labor Statistics Census of Fatal Occupational Injuries. Results From 2003 to 2010, 2,210 fatal TBIs occurred in construction at a rate of 2.6 per 100,000 full-time equivalent (FTE) workers. Workers aged 65 years and older had the highest fatal TBI rates among all workers (7.9 per 100,000 FTE workers). Falls were the most frequent injury event (n = 1,269, 57%). Structural iron and steel workers and roofers had the highest fatal TBI rate per 100,000 FTE workers (13.7 and 11.2, respectively). Fall-related TBIs were the leading cause of death in these occupations. Conclusions A large percentage of TBIs in the construction industry were due to falls. Emphasis on safety interventions is needed to reduce these fall-related TBIs, especially among vulnerable workers. Published 2016. This article is a U.S. Government work and is in the public domain in the USA. C1 [Konda, Srinivas; Tiesman, Hope M.; Reichard, Audrey A.] NIOSH, Div Safety Res, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS 1811, Morgantown, WV 26506 USA. RP Konda, S (reprint author), NIOSH, Div Safety Res, 1095 Willowdale Rd,MS 1811, Morgantown, WV 26506 USA. EM skonda@cdc.gov NR 47 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD MAR PY 2016 VL 59 IS 3 BP 212 EP 220 DI 10.1002/ajim.22557 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG7UW UT WOS:000372290200006 PM 26765167 ER PT J AU Guy, GP Watson, M Richardson, LC Lushniak, BD AF Guy, Gery P., Jr. Watson, Meg Richardson, Lisa C. Lushniak, Boris D. TI Reducing Indoor Tanning-An Opportunity for Melanoma Prevention SO JAMA DERMATOLOGY LA English DT Editorial Material ID PREVALENCE; STATES; WOMEN C1 [Guy, Gery P., Jr.; Watson, Meg; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,Mail Stop F76, Atlanta, GA 30341 USA. [Lushniak, Boris D.] US PHS, Off Surgeon Gen, Washington, DC USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,Mail Stop F76, Atlanta, GA 30341 USA. EM irm2@cdc.gov NR 17 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD MAR PY 2016 VL 152 IS 3 BP 257 EP 259 DI 10.1001/jamadermatol.2015.3007 PG 3 WC Dermatology SC Dermatology GA DH0GH UT WOS:000372460300003 PM 26817798 ER PT J AU Wozniak, G Khan, T Gillespie, C Sifuentes, L Hasan, O Ritchey, M Kmetik, K Wynia, M AF Wozniak, Gregory Khan, Tamkeen Gillespie, Cathleen Sifuentes, Lori Hasan, Omar Ritchey, Matthew Kmetik, Karen Wynia, Matthew TI Hypertension Control Cascade: A Framework to Improve Hypertension Awareness, Treatment, and Control SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID AMERICAN-HEART-ASSOCIATION; BLOOD-PRESSURE CONTROL; UNITED-STATES; UNCONTROLLED HYPERTENSION; PRIMARY-CARE; RESISTANT HYPERTENSION; CARDIOVASCULAR HEALTH; SCIENTIFIC STATEMENT; ADHERENCE; UPDATE AB Evidence-based interventions differ for increasing hypertension awareness, treatment, and control and should betargeted for specific patient panels. This study developed a hypertension control cascade to identify patients with a usual source of care represented at each level of the cascade using the 2007-2012 National Health and Nutrition Examination Survey. Overall, 10.7 million adults in the United States were unaware of their condition, 3.8 million were aware but untreated, and 15.8 million were treated but uncontrolled. The results also suggest that failure to attain hypertension control because of lack of awareness or lack of treatment despite awareness occurs mainly among younger individuals and those with no annual healthcare visits, while the elderly and minorities are more likely to remain uncontrolled when aware and treated. Opportunitiesto leverage population health management functions in electronic health information systems to align the specificpatient subgroups facing barriers to hypertension control at each level of the cascade with targeted hypertensionmanagement interventions are discussed. C1 [Wozniak, Gregory; Khan, Tamkeen; Hasan, Omar; Kmetik, Karen] Amer Med Assoc, 330 North Wabash Ave,Suite 39300, Chicago, IL 60611 USA. [Gillespie, Cathleen; Ritchey, Matthew] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sifuentes, Lori] Valence Hlth, Chicago, IL USA. [Wynia, Matthew] Univ Colorado, Aurora, CO USA. RP Wozniak, G (reprint author), Amer Med Assoc, 330 North Wabash Ave,Suite 39300, Chicago, IL 60611 USA. EM Greg.Wozniak@ama-assn.org NR 49 TC 1 Z9 1 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD MAR PY 2016 VL 18 IS 3 BP 232 EP 239 DI 10.1111/jch.12654 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DH1AP UT WOS:000372517100013 PM 26337797 ER PT J AU Bird, BH Spengler, JR Chakrabarti, AK Khristova, ML Sealy, TK Coleman-McCray, JD Martin, BE Dodd, KA Goldsmith, CS Sanders, J Zaki, SR Nichol, ST Spiropoulou, CF AF Bird, Brian H. Spengler, Jessica R. Chakrabarti, Ayan K. Khristova, Marina L. Sealy, Tara K. Coleman-McCray, JoAnn D. Martin, Brock E. Dodd, Kimberly A. Goldsmith, Cynthia S. Sanders, Jeanine Zaki, Sherif R. Nichol, Stuart T. Spiropoulou, Christina F. TI Humanized Mouse Model of Ebola Virus Disease Mimics the Immune Responses in Human Disease SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Ebola virus disease; animal model; viral hemorrhagic fever; humanized mice; cytokine profile; virus pathogenesis ID HEMATOPOIETIC STEM-CELLS; VIRAL HEMORRHAGIC FEVERS; SIERRA-LEONE; ANIMAL RULE; MICE; INFECTION; ZAIRE AB Animal models recapitulating human Ebola virus disease (EVD) are critical for insights into virus pathogenesis. Ebola virus (EBOV) isolates derived directly from human specimens do not, without adaptation, cause disease in immunocompetent adult rodents. Here, we describe EVD in mice engrafted with human immune cells (hu-BLT). hu-BLT mice developed EVD following wild-type EBOV infection. Infection with high-dose EBOV resulted in rapid, lethal EVD with high viral loads, alterations in key human antiviral immune cytokines and chemokines, and severe histopathologic findings similar to those shown in the limited human postmortem data available. A dose-and donor-dependent clinical course was observed in hu-BLT mice infected with lower doses of either Mayinga (1976) or Makona (2014) isolates derived from human EBOV cases. Engraftment of the human cellular immune system appeared to be essential for the observed virulence, as nonengrafted mice did not support productive EBOV replication or develop lethal disease. hu-BLT mice offer a unique model for investigating the human immune response in EVD and an alternative animal model for EVD pathogenesis studies and therapeutic screening. C1 [Bird, Brian H.; Spengler, Jessica R.; Chakrabarti, Ayan K.; Sealy, Tara K.; Coleman-McCray, JoAnn D.; Martin, Brock E.; Dodd, Kimberly A.; Nichol, Stuart T.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd,MS G-14, Atlanta, GA 30333 USA. [Khristova, Marina L.] Ctr Dis Control & Prevent, Biotechnol Core Facil, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Goldsmith, Cynthia S.; Sanders, Jeanine; Zaki, Sherif R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Infect Dis Pathol Branch, Atlanta, GA USA. RP Spiropoulou, CF (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd,MS G-14, Atlanta, GA 30333 USA. EM ccs8@cdc.gov OI Spengler, Jessica R./0000-0002-5383-0513 FU Centers for Disease Control and Prevention (CDC); CDC Research Participation Program; National Institutes of Health Loan Repayment Program FX This work was supported by the Centers for Disease Control and Prevention (CDC; emerging infectious disease research core funds); the CDC Research Participation Program (to J. R. S., administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC); and the National Institutes of Health Loan Repayment Program (award to J. R. S.). NR 41 TC 7 Z9 7 U1 4 U2 14 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 1 PY 2016 VL 213 IS 5 BP 703 EP 711 DI 10.1093/infdis/jiv538 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DG9XY UT WOS:000372438300004 PM 26582961 ER PT J AU Wejnert, C Hess, KL Rose, CE Balaji, A Smith, JC Paz-Bailey, G AF Wejnert, Cyprian Hess, Kristen L. Rose, Charles E. Balaji, Alexandra Smith, Justin C. Paz-Bailey, Gabriela CA NHBS Study Grp TI Age-Specific Race and Ethnicity Disparities in HIV Infection and Awareness Among Men Who Have Sex With Men-20 US Cities, 2008-2014 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV; MSM; health disparities; black MSM ID BEHAVIORAL SURVEILLANCE SYSTEM; YOUNG BLACK-MEN; WHITE MEN; UNITED-STATES; RISK; PREVENTION; ATLANTA; METAANALYSIS; PREVALENCE; GA AB Background. Over half of human immunodeficiency virus (HIV) infections in the United States occur among men who have sex with men (MSM). Among MSM, 16% of estimated new infections in 2010 occurred among black MSM <25 years old. Methodology. We analyzed National HIV Behavioral Surveillance data on MSM from 20 cities. Poisson models were used to test racial disparities, by age, in HIV prevalence, HIV awareness, and sex behaviors among MSM in 2014. Data from 2008, 2011, and 2014 were used to examine how racial/ethnic disparities changed across time. Results. While black MSM did not report greater sexual risk than other MSM, they were most likely to be infected with HIV and least likely to know it. Among black MSM aged 18-24 years tested in 2014, 26% were HIV positive. Among white MSM aged 18-24 years tested in 2014, 3% were HIV positive. The disparity in HIV prevalence between black and white MSM increased from 2008 to 2014, especially among young MSM. Conclusions. Disparities in HIV prevalence between black and white MSM continue to increase. Black MSM may be infected with HIV at younger ages than other MSM and may benefit from prevention efforts that address the needs of younger men. C1 [Wejnert, Cyprian; Rose, Charles E.; Balaji, Alexandra; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Hess, Kristen L.; Smith, Justin C.] Oak Ridge Inst Sci & Educ, Atlanta, GA USA. RP Wejnert, C (reprint author), 1600 Clifton Rd NE,MS E 46, Atlanta, GA 30329 USA. EM cwejnert@cdc.gov NR 28 TC 2 Z9 2 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 1 PY 2016 VL 213 IS 5 BP 776 EP 783 DI 10.1093/infdis/jiv500 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DG9XY UT WOS:000372438300014 PM 26486637 ER PT J AU Fang, J Moore, L Loustalot, F Yang, QH Ayala, C AF Fang, Jing Moore, Latetia Loustalot, Fleetwood Yang, Quanhe Ayala, Carma TI Reporting of adherence to healthy lifestyle behaviors among hypertensive adults in the 50 states and the District of Columbia, 2013 SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article DE Hypertension; lifestyle intervention; states; surveillance ID FACTOR SURVEILLANCE SYSTEM; CORONARY-HEART-DISEASE; UNITED-STATES; BLOOD-PRESSURE; RANDOMIZED-TRIAL; PHYSICAL-ACTIVITY; RISK-FACTORS; INTERVENTION; PATTERNS; DISPARITIES AB Achieving and maintaining a healthy lifestyle is an important part of hypertension management. The purpose of this study was to assess US state-level prevalence of adherence to healthy lifestyle behaviors among those with self-reported hypertension. Using 2013 data from the Behavioral Risk Factor Surveillance System, a state-based telephone survey, we examined the adherence to five healthy lifestyle behaviors related to hypertension management: having a "normal" weight, not smoking, avoiding or limiting alcohol intake, consuming the recommended amount of fruits and vegetables, and engaging in the recommended amount of physical activity. We estimated age-standardized percentages of each healthy lifestyle behavior overall and by state, as well as prevalence of all five healthy lifestyle behaviors. Overall, the prevalence of healthy lifestyle behaviors varied widely among those with self-reported hypertension: 20.5% had a normal weight, 82.3% did not smoke, 94.1% reported no or limited alcohol intake, 14.1% consumed the recommended amounts of fruits or vegetables, and 46.6% engaged in the recommended amount of physical activity. Overall, only 1.7% of adults with self-reported hypertension reported all five healthy lifestyle behaviors, with significant variation by state. Age-standardized prevalence of individuals reporting all five healthy lifestyle behaviors ranged from 0.3% in Louisiana to 3.8% in the District of Columbia. In conclusion, adherence to healthy lifestyle behaviors varied among those with hypertension; fewer than 2% reported meeting current recommendations and standards when assessed collectively. Disparities were observed by demographic and descriptive characteristics, including geography. Published by Elsevier Inc. on behalf of American Society of Hypertension. C1 [Fang, Jing; Loustalot, Fleetwood; Yang, Quanhe; Ayala, Carma] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Moore, Latetia] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Fang, J (reprint author), 4770 Buford Hwy NE,MS F-72, Atlanta, GA 30341 USA. EM jfang@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 1 Z9 1 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD MAR PY 2016 VL 10 IS 3 BP 252 EP 262 DI 10.1016/j.jash.2016.01.008 PG 11 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DH3FQ UT WOS:000372673300013 PM 26851000 ER PT J AU Stewart, SL Townsend, JS Puckett, MC Rim, SH AF Stewart, Sherri L. Townsend, Julie S. Puckett, Mary C. Rim, Sun Hee TI Adherence of Primary Care Physicians to Evidence-Based Recommendations to Reduce Ovarian Cancer Mortality SO JOURNAL OF WOMENS HEALTH LA English DT Article ID GYNECOLOGIC ONCOLOGISTS; PATIENT PREFERENCES; CONTROL PROGRAM; RISK; WOMEN; METAANALYSIS; OUTCOMES; MASS AB Ovarian cancer is the deadliest gynecologic cancer. Receipt of treatment from a gynecologic oncologist is an evidence-based recommendation to reduce mortality from the disease. We examined knowledge and application of this evidence-based recommendation in primary care physicians as part of CDC gynecologic cancer awareness campaign efforts and discussed results in the context of CDC National Comprehensive Cancer Control Program (NCCCP). We analyzed primary care physician responses to questions about how often they refer patients diagnosed with ovarian cancer to gynecologic oncologists, and reasons for lack of referral. We also analyzed these physicians' knowledge of tests to help determine whether a gynecologic oncologist is needed for a planned surgery. The survey response rate was 52.2%. A total of 84% of primary care physicians (87% of family/general practitioners, 81% of internists and obstetrician/gynecologists) said they always referred patients to gynecologic oncologists for treatment. Common reasons for not always referring were patient preference or lack of gynecologic oncologists in the practice area. A total of 23% of primary care physicians had heard of the OVA1 test, which helps to determine whether gynecologic oncologist referral is needed. Although referral rates reported here are high, it is not clear whether ovarian cancer patients are actually seeing gynecologic oncologists for care. The NCCCP is undertaking several efforts to assist with this, including education of the recommendation among women and providers and assistance with treatment summaries and patient navigation toward appropriate treatment. Expansion of these efforts to all populations may help improve adherence to recommendations and reduce ovarian cancer mortality. C1 [Stewart, Sherri L.; Townsend, Julie S.; Puckett, Mary C.; Rim, Sun Hee] Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway,F-76, Atlanta, GA 30341 USA. RP Stewart, SL (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway,F-76, Atlanta, GA 30341 USA. EM sstewart2@cdc.gov FU Intramural CDC HHS [CC999999] NR 32 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD MAR 1 PY 2016 VL 25 IS 3 BP 235 EP 241 DI 10.1089/jwh.2015.5735 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA DG6DU UT WOS:000372173200006 PM 26978124 ER PT J AU Norris, KL Beckles, GL Chou, CF Zhang, XZ Saaddine, J AF Norris, Keri L. Beckles, Gloria L. Chou, Chiu-Fang Zhang, Xinzhi Saaddine, Jinan TI Association of Socioeconomic Status with Eye Health Among Women With and Without Diabetes SO JOURNAL OF WOMENS HEALTH LA English DT Article ID VISUAL IMPAIRMENT; UNITED-STATES; CARE UTILIZATION; GENDER-DIFFERENCES; INTERVIEW SURVEY; VISION HEALTH; US ADULTS; DISPARITIES; VALIDITY; DISEASES AB Objective: To investigate the association between socioeconomic position (SEP) and poor eye health among women. Materials and Methods: We included the 7,708 women aged >= 40 years who participated in the 2008 National Health Interview Survey. We defined poor eye health as self-reported age-related eye diseases (AREDs; cataract, glaucoma, macular degeneration, or diabetic retinopathy) or visual impairment (VI). We identified diagnosed diabetes by self-report. We measured SEP by education attained and annual household income. We conducted logistic regression analyses while controlling for demographic, clinical, behavioral, and healthcare access variables. Results: The age-standardized prevalence of VI and ARED was significantly higher among women with diagnosed diabetes than among those without diagnosed diabetes, 29.8% versus 14.4% and 34.1% versus 20.8%, respectively (p < 0.05 for both). The prevalence of VI and ARED increased with decreasing SEP, but the trends were only significant among women without diabetes. After multivariable adjustment, education and income were significantly associated with VI but not with ARED. We found no interaction with diagnosed diabetes. Conclusions: SEP was inversely associated with VI but not with ARED. We found no interaction with diagnosed diabetes. C1 [Norris, Keri L.; Beckles, Gloria L.; Chou, Chiu-Fang; Saaddine, Jinan] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, 4770 Buford Hwy NE,Mailstop F-73, Atlanta, GA 30341 USA. [Zhang, Xinzhi] Univ Alabama Birmingham, Dept Hlth Serv Adm, Birmingham, AL USA. RP Beckles, GL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, 4770 Buford Hwy NE,Mailstop F-73, Atlanta, GA 30341 USA. EM glb4@cdc.gov NR 35 TC 0 Z9 0 U1 4 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD MAR 1 PY 2016 VL 25 IS 3 BP 321 EP 326 DI 10.1089/jwh.2015.5255 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA DG6DU UT WOS:000372173200017 PM 26666895 ER PT J AU Schwartz, SR Kumwenda, N Kumwenda, J Chen, S Mofenson, LM Taylor, AW Fowler, MG Taha, TE AF Schwartz, Sheree R. Kumwenda, Newton Kumwenda, Johnstone Chen, Shu Mofenson, Lynne M. Taylor, Allan W. Fowler, Mary Glenn Taha, Taha E. TI Maternal Highly Active Antiretroviral Therapy and Child HIV-Free Survival in Malawi, 2004-2009 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE HIV-1; Prevention of mother-to-child transmission; Highly active antiretroviral therapy; Child survival; Breastfeeding ID DAR-ES-SALAAM; TRANSMISSION; WOMEN; MORTALITY; PROPHYLAXIS; PREVENTION; TANZANIA; TRIAL; DRUGS; PREGNANCY AB Objectives Highly active antiretroviral therapy (HAART) provision to eligible HIV-infected pregnant and post-partum women is critical for optimizing maternal health. We assessed the impact of maternal HAART on HIV-free survival of breastfed infants in Malawi. Methods The post-exposure prophylaxis of infants-Malawi trial (2004-2009) enrolled mothers/infants during labor or immediately postpartum to evaluate 14-week extended infant antiretroviral prophylaxis for preventing HIV transmission through breastfeeding. Mothers meeting national HAART guidelines were referred for therapy. Child HIV-free survival-survival without HIV infection-was compared by maternal HAART status. Results Overall, 3022 mother-infant pairs contributed 4214 infant/person-years (PY) at-risk for HIV infection or death, with 532 events (incidence 12.6/100 PY, 95 % confidence interval [CI] 11.6-13.7). During follow-up, 349 mothers were HAART initiated; 581 remained HAART naive with CD4 cell counts <250 cells/mm(3), and 2092 were never HAART-eligible. By 3 months, 11 % of infants with HAART naive mothers (CD4 < 250) were infected with HIV or died versus 7 % of infants of HAART-initiated mothers and 4 % of infants of HAART-ineligible mothers. Maternal HAART was associated with a 46 % reduction in infant HIV infection or death as compared to infants with HAART naive mothers (CD4 < 250) (adjusted hazards ratio 0.54, 95 % CI 0.36-0.81). Among HIV-exposed, uninfected infants, breastfeeding, but not HAART, was significantly associated with decreased child mortality. Conclusions HIV infection and mortality are high during the first 3 months post-partum in infants of mothers with advanced HIV, and rapid maternal HAART initiation can significantly improve HIV-related infant outcomes. C1 [Schwartz, Sheree R.; Kumwenda, Newton; Chen, Shu; Taha, Taha E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 North Wolfe St,E7139, Baltimore, MD 21205 USA. [Kumwenda, Johnstone] Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi. [Mofenson, Lynne M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Rockville, MD USA. [Taylor, Allan W.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Epidemiol Branch, Atlanta, GA USA. [Fowler, Mary Glenn] Johns Hopkins Med Sch, Dept Pathol, Baltimore, MD USA. RP Schwartz, SR (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 North Wolfe St,E7139, Baltimore, MD 21205 USA. EM sschwartz@jhu.edu; ttaha1@jhu.edu FU Centers for Disease Control and Prevention [5 U50 PS022061-05, U50/CC0222061]; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health FX This work was supported by a Cooperative Agreement (Grant number 5 U50 PS022061-05 and award # U50/CC0222061) from the Centers for Disease Control and Prevention and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. NR 24 TC 0 Z9 0 U1 2 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD MAR PY 2016 VL 20 IS 3 BP 542 EP 549 DI 10.1007/s10995-015-1852-5 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG6BW UT WOS:000372168200006 PM 26525557 ER PT J AU Goldenberg, AJ Comeau, AM Grosse, SD Tanksley, S Prosser, LA Ojodu, J Botkin, JR Kemper, AR Green, NS AF Goldenberg, Aaron J. Comeau, Anne Marie Grosse, Scott D. Tanksley, Susan Prosser, Lisa A. Ojodu, Jelili Botkin, Jeffrey R. Kemper, Alex R. Green, Nancy S. TI Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Review DE Harms; Burdens; Newborn screening; Net benefit; False positive ID IMMUNIZATION PRACTICES ACIP; SERVICES TASK-FORCE; ADVISORY-COMMITTEE; KRABBE-DISEASE; HEALTH-CARE; CHILDREN; CANCER; CHALLENGES; DISORDERS; PARENTS AB Background The Department of Health and Human Services (HHS) Advisory Committee on Heritable Disorders in Newborns and Children ("Advisory Committee'') makes recommendations to the HHS Secretary regarding addition of new conditions to the national Recommended Uniform Screening Panel for newborns. The Advisory Committee's decision-making process includes assessing the net benefit of screening for nominated conditions, informed by systematic evidence reviews generated by an independent Condition Review Workgroup. The evidence base regarding harms associated with screening for specific conditions is often more limited than that for benefits. Procedures The process for defining potential harms from newborn screening reviewed the frameworks from other public health evidence-based review processes, adapted to newborn screening by experts in systematic review, newborn screening programs and bioethics, with input from and approval by the Advisory Committee. Main findings To support the Advisory Committee's review of nominated conditions, the Workgroup has developed a standardized approach to evaluation of harms and relevant gaps in the evidence. Types of harms include the physical burden to infants; psychosocial and logistic burdens to families from screening or diagnostic evaluation; increased risk of medical treatment for infants diagnosed earlier than children with clinical presentation; delayed diagnosis from false negative results; psychosocial harm from false positive results; uncertainty of clinical diagnosis, age of onset or clinical spectrum; and disparities in access to diagnosis or therapy. Conclusions Estimating the numbers of children at risk, the magnitude, timing and likelihood of harms will be integrated into Workgroup reports to the Advisory Committee. C1 [Goldenberg, Aaron J.] Case Western Reserve Univ, Sch Med, Dept Bioeth, 10900 Euclid Ave, Cleveland, OH 44106 USA. [Comeau, Anne Marie] Univ Massachusetts, Sch Med, New England Newborn Screening Program, 305 South St, Jamaica Plain, MA 02130 USA. [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 4770 Buford Highway, Atlanta, GA 30341 USA. [Tanksley, Susan] State Hlth Serv, Texas Dept, Newborn Screening Lab, Lab Serv Sect, POB 149347,MC 1947, Austin, TX 78714 USA. [Prosser, Lisa A.] Univ Michigan, Sch Med, Dept Pediat, CHEAR Unit, Ann Arbor, MI 48109 USA. [Prosser, Lisa A.] Univ Michigan Hlth Syst, SPH CHEAR Unit, Pediat, Hlth Management & Policy, 300 N Ingalls St,Rm 6E14,SPC 5456, Ann Arbor, MI 48109 USA. [Ojodu, Jelili] Assoc Publ Hlth Labs, 8515 Georgia Ave,Suite 700, Silver Spring, MD 20910 USA. [Botkin, Jeffrey R.] Univ Utah, Dept Pediat, 75 South 2000 East 108, Salt Lake City, UT 84112 USA. [Kemper, Alex R.] Duke Univ, Duke Clin Res Inst, Dept Pediat, 2400 Pratt St Rm 0311,Terrace Level,NP, Durham, NC 27705 USA. [Green, Nancy S.] Columbia Univ, Med Ctr, Dept Pediat, 630 West 168 St,Black Bldg 2-241,Box 168, New York, NY 10032 USA. RP Green, NS (reprint author), Columbia Univ, Med Ctr, Dept Pediat, 630 West 168 St,Black Bldg 2-241,Box 168, New York, NY 10032 USA. EM nsg11@columbia.edu OI Green, Nancy/0000-0002-9877-1561 FU Maternal Child Health Bureau FX This work was funded a contract from the Maternal Child Health Bureau. NR 44 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD MAR PY 2016 VL 20 IS 3 BP 693 EP 700 DI 10.1007/s10995-015-1869-9 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG6BW UT WOS:000372168200023 PM 26833040 ER PT J AU Adesanya, MR Bailey, W Belcher, DC Beltran, M Branch, T Brand, MK Craft, EM Donahue, AH Dye, BA Thornton-Evans, G Garcia, I Hyman, F Joskow, R Lester, AM Makrides, NS Manski, RJ Mehegan, M Mouden, LD Nelson, D Norris, L O'Hara, J Cherry-Peppers, G Ricks, TL Rollins, R AF Adesanya, Margo R. Bailey, William Belcher, Donald C. Beltran, Marco Branch, Tracy Brand, Marcia K. Craft, Edwin M. Donahue, Agnes H. Dye, Bruce A. Thornton-Evans, Gina Garcia, Isabel Hyman, Frederick Joskow, Renee Lester, Arlene M. Makrides, Nicholas S. Manski, Richard J. Mehegan, Marian Mouden, Lynn Douglas Nelson, Danielle Norris, Laurie O'Hara, Jessica Cherry-Peppers, Gail Ricks, Timothy L. Rollins, Rochelle CA US Dept Hlth Human Serv TI US Department of Health and Human Services Oral Health Strategic Framework, 2014-2017 SO PUBLIC HEALTH REPORTS LA English DT Editorial Material ID DENTAL-CARE; CARIES C1 [Adesanya, Margo R.] Natl Inst Dent & Craniofacial Res, NIH, Off Sci Policy & Anal, Rockville, MD USA. [Bailey, William] Ctr Dis Control & Prevent, Atlanta, GA USA. [Belcher, Donald C.] US Coast Guard, Qual & Performance Improvement, Washington, DC USA. [Beltran, Marco; Rollins, Rochelle] Adm Children & Families, Washington, DC USA. [Branch, Tracy; Lester, Arlene M.] OS Off Minor Hlth, Washington, DC USA. [Brand, Marcia K.; Joskow, Renee] Hlth Resources & Serv Adm, Rockville, MD USA. [Craft, Edwin M.] Subst Abuse & Mental Hlth Serv Adm, Rockville, MD USA. [Donahue, Agnes H.] OS Off Assistant Secretary Hlth, OASH Intergovt Affairs RHA, Washington, DC USA. [Dye, Bruce A.] Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Thornton-Evans, Gina] Ctr Dis Control & Prevent, Div Oral Hlth, Atlanta, GA USA. [Garcia, Isabel] Natl Inst Dent & Craniofacial Res, NIH, Rockville, MD USA. [Hyman, Frederick] US FDA, Ctr Drug Evaluat & Res, Div Dermatol & Dent Prod, Silver Spring, MD USA. [Makrides, Nicholas S.] Fed Bur Prisons, Washington, DC USA. [Manski, Richard J.] Agcy Healthcare Res & Qual, Rockville, MD USA. [Mehegan, Marian] Off Assistant Secretary Hlth, Off Womens Hlth, Washington, DC USA. [Mouden, Lynn Douglas] Ctr Medicare & Medicaid Serv, Div Qual Evaluat & Hlth Outcomes, Children & Adults Hlth Programs Grp, Washington, DC USA. [Nelson, Danielle] Adm Community Living, Washington, DC USA. [Norris, Laurie] Ctr Medicare & Medicaid Serv, Oral Hlth Initiat, Div Qual Evaluat & Hlth Outcomes, Washington, DC USA. [O'Hara, Jessica] Off Secretary, Off Assistant Secretary Planning & Evaluat, Washington, DC USA. [Cherry-Peppers, Gail] US FDA, Ctr Tobacco Prod, Off Sci, Silver Spring, MD USA. [Ricks, Timothy L.] Indian Hlth Serv, Nashville Area Off Publ Hlth, Nashville, TN USA. RP Adesanya, MR (reprint author), Natl Inst Dent & Craniofacial Res, NIH, Off Sci Policy & Anal, Rockville, MD USA. NR 56 TC 0 Z9 0 U1 2 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2016 VL 131 IS 2 BP 242 EP 257 PG 16 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG9HH UT WOS:000372392900007 ER PT J AU Kwan, CK Rose, CE Brooks, JT Marks, G Sionean, C AF Kwan, Candice K. Rose, Charles E. Brooks, John T. Marks, Gary Sionean, Catlainn TI HIV Testing Among Men at Risk for Acquiring HIV Infection Before and After the 2006 CDC Recommendations SO PUBLIC HEALTH REPORTS LA English DT Article ID US HOUSEHOLD POPULATION; UNITED-STATES; EMERGENCY-DEPARTMENTS; NATIONAL-HEALTH; CARE; SEX; PREVENTION; RESIDENCE AB Objectives. Testing for human immunodeficiency virus (HIV) is the key first step in HIV treatment and prevention. In 2006, the Centers for Disease Control and Prevention (CDC) recommended annual HIV testing for people at high risk for HIV infection. We evaluated HIV testing among men with high-risk heterosexual (HRH) contact and sexually active men who have sex with men (MSM) before and after the CDC recommendations. Methods. We used data from the National Survey of Family Growth, 2002 and 2006-2010, to assess proportions of HRH respondents and MSM reporting HIV testing in the prior 12 months, compare rates of testing before and after release of the 2006 CDC HIV testing guidelines, and examine demographic variables and receipt of health-care services as correlates of HIV testing. Results. Among MSM, the proportion tested was 37.2% (95% confidence interval [CI] 28.2, 47.2) in 2002, 38.2% (95% CI 25.9, 52.2) in 2006-2008, and 41.7% (95% CI 29.2, 55.3) in 2008-2010; among HRH respondents, the proportion was 23.7% (95% CI 20.5, 27.3) in 2002, 24.5% (95% CI 20.9, 28.7) in 2006-2008, and 23.9% (95% CI 20.2, 28.1) in 2008-2010. HIV testing was more likely among MSM and HRH respondents who received testing or treatment for sexually transmitted disease in the prior 12 months, received a physical examination in the prior 12 months (MSM only), or were incarcerated in the prior 12 months. Conclusions. The rate of annual HIV testing was low for men with sexual risk for HIV infection, and little improvement took place from 2002 to 2006-2010. Interventions aimed at men at risk, especially MSM, in both nonmedical and health-care settings, likely could increase HIV testing. C1 [Kwan, Candice K.] Epidem Intelligence Serv, Atlanta, GA USA. [Kwan, Candice K.] NYU, Sch Med, 550 First Ave,NBV 16S 5-12, New York, NY 10016 USA. [Rose, Charles E.; Brooks, John T.; Marks, Gary; Sionean, Catlainn] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Kwan, CK (reprint author), NYU, Sch Med, 550 First Ave,NBV 16S 5-12, New York, NY 10016 USA. EM candicekwan@post.harvard.edu NR 34 TC 3 Z9 3 U1 0 U2 0 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2016 VL 131 IS 2 BP 311 EP 319 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG9HH UT WOS:000372392900014 PM 26957666 ER PT J AU Hurley, LP Bridges, CB Harpaz, R Allison, MA O' Leary, ST Crane, LA Brtnikova, M Stokley, S Beaty, BL Jimenez-Zambrano, A Kempe, A AF Hurley, Laura P. Bridges, Carolyn B. Harpaz, Rafael Allison, Mandy A. O' Leary, Sean T. Crane, Lori A. Brtnikova, Michaela Stokley, Shannon Beaty, Brenda L. Jimenez-Zambrano, Andrea Kempe, Allison TI Physician Attitudes Toward Adult Vaccines and Other Preventive Practices, United States, 2012 SO PUBLIC HEALTH REPORTS LA English DT Article ID IMMUNIZATION PRACTICES ACIP; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; AFFORDABLE CARE ACT; ADVISORY-COMMITTEE; CONJUGATE VACCINE; SERVICES; HEALTH; RECOMMENDATIONS; TIME; BARRIERS AB Objectives. We described the following among U.S. primary care physicians: (1) perceived importance of vaccines recommended by the Advisory Committee on Immunization Practices relative to U.S. Preventive Services Task Force (USPSTF) preventive services, (2) attitudes toward the U.S. adult immunization schedule, and (3) awareness and use of Medicare preventive service visits. Methods. We conducted an Internet and mail survey from March to June 2012 among national networks of general internists and family physicians. Results. We received responses from 352 of 445 (79%) general internists and 255 of 409 (62%) family physicians. For a 67-year-old hypothetical patient, 540/606 (89%, 95% confidence interval [CI] 87, 92) of physicians ranked seasonal influenza vaccine and 487/607 (80%, 95% CI 77, 83) ranked pneumococcal vaccine as very important, whereas 381/604 (63%, 95% CI 59, 67) ranked Tdap/Td vaccine and 288/607 (47%, 95% CI 43, 51) ranked herpes zoster vaccine as very important (p<0.001). All Grade A USPSTF recommendations were considered more important than Tdap/Td and herpes zoster vaccines. For the hypothetical patient aged 30 years, the number and percentage of physicians who reported that the Tdap/Td vaccine (377/604; 62%, 95% CI 59, 66) is very important was greater than the number and percentage who reported that the seasonal influenza vaccine (263/605; 43%, 95% CI 40, 47) is very important (p<0.001), and all Grade A and Grade B USPSTF recommendations were more often reported as very important than was any vaccine. A total of 172 of 587 physicians (29%) found aspects of the adult immunization schedule confusing. Among physicians aware of "Welcome to Medicare" and annual wellness visits, 492/514 (96%, 95% CI 94, 97) and 329/496 (66%, 95% CI 62, 70), respectively, reported having conducted fewer than 10 such visits in the previous month. Conclusions. Despite lack of prioritization of vaccines by ACIP, physicians are prioritizing some vaccines over others and ranking some vaccines below other preventive services. These attitudes and confusion about the immunization schedule may result in missed opportunities for vaccination. Medicare preventive visits are not being used widely despite offering a venue for delivery of preventive services, including vaccinations. C1 [Hurley, Laura P.] Denver Hlth, Div Gen Internal Med, Denver, CO 80204 USA. [Hurley, Laura P.; Allison, Mandy A.; O' Leary, Sean T.; Crane, Lori A.; Brtnikova, Michaela; Beaty, Brenda L.; Jimenez-Zambrano, Andrea; Kempe, Allison] Univ Colorado, Adult & Child Ctr Outcomes Res & Delivery Sci, Anschutz Med Campus, Aurora, CO USA. [Hurley, Laura P.; Allison, Mandy A.; O' Leary, Sean T.; Crane, Lori A.; Brtnikova, Michaela; Beaty, Brenda L.; Jimenez-Zambrano, Andrea; Kempe, Allison] Childrens Hosp Colorado, Aurora, CO USA. [Bridges, Carolyn B.; Harpaz, Rafael; Stokley, Shannon] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Allison, Mandy A.; O' Leary, Sean T.; Brtnikova, Michaela; Kempe, Allison] Univ Colorado, Sch Med, Dept Pediat, Anschutz Med Campus, Aurora, CO USA. [Crane, Lori A.] Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Aurora, CO USA. RP Hurley, LP (reprint author), Denver Hlth, 301 W 6th Ave,MC3251, Denver, CO 80204 USA. EM laura.hurley@dhha.org FU Centers for Disease Control and Prevention (CDC) [5U48DP001938] FX The human subjects review board at the University of Colorado Denver approved this study as exempt research not requiring written informed consent. This research was funded by Centers for Disease Control and Prevention (CDC) grant #5U48DP001938. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of CDC. NR 42 TC 2 Z9 2 U1 1 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2016 VL 131 IS 2 BP 320 EP 330 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG9HH UT WOS:000372392900015 PM 26957667 ER PT J AU Goldberg, H Stupp, P Okoroh, E Besera, G Goodman, D Danel, I AF Goldberg, Howard Stupp, Paul Okoroh, Ekwutosi Besera, Ghenet Goodman, David Danel, Isabella TI Female Genital Mutilation/Cutting in the United States: Updated Estimates of Women and Girls at Risk, 2012 SO PUBLIC HEALTH REPORTS LA English DT Article AB Objectives. In 1996, the U.S. Congress passed legislation making female genital mutilation/cutting (FGM/C) illegal in the United States. CDC published the first estimates of the number of women and girls at risk for FGM/C in 1997. Since 2012, various constituencies have again raised concerns about the practice in the United States. We updated an earlier estimate of the number of women and girls in the United States who were at risk for FGM/C or its consequences. Methods. We estimated the number of women and girls who were at risk for undergoing FGM/C or its consequences in 2012 by applying country-specific prevalence of FGM/C to the estimated number of women and girls living in the United States who were born in that country or who lived with a parent born in that country. Results. Approximately 513,000 women and girls in the United States were at risk for FGM/C or its consequences in 2012, which was more than three times higher than the earlier estimate, based on 1990 data. The increase in the number of women and girls younger than 18 years of age at risk for FGM/C was more than four times that of previous estimates. Conclusion. The estimated increase was wholly a result of rapid growth in the number of immigrants from FGM/C-practicing countries living in the United States and not from increases in FGM/C prevalence in those countries. Scientifically valid information regarding whether women or their daughters have actually undergone FGM/C and related information that can contribute to efforts to prevent the practice in the United States and provide needed health services to women who have undergone FGM/C are needed. C1 [Goldberg, Howard; Stupp, Paul; Okoroh, Ekwutosi; Besera, Ghenet; Goodman, David; Danel, Isabella] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, MS-F74,4770 Buford Hwy NE, Atlanta, GA 30341 USA. RP Goldberg, H (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, MS-F74,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM hgoldberg@cdc.gov NR 29 TC 2 Z9 2 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2016 VL 131 IS 2 BP 340 EP 347 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG9HH UT WOS:000372392900017 PM 26957669 ER PT J AU Paulukonis, ST Eckman, JR Snyder, AB Hagar, W Feuchtbaum, LB Zhou, M Grant, AM Hulihan, MM AF Paulukonis, Susan T. Eckman, James R. Snyder, Angela B. Hagar, Ward Feuchtbaum, Lisa B. Zhou, Mei Grant, Althea M. Hulihan, Mary M. TI Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008 SO PUBLIC HEALTH REPORTS LA English DT Article ID HEMOGLOBINOPATHIES; CHILDREN; SURVIVAL; JAMAICA; COHORT; DEATH; US AB Objective. Population-based surveillance data from California and Georgia for years 2004 through 2008 were linked to state death record files to determine the all-cause death rate among 12,143 patients identified with sickle cell disease (SCD). Methods. All-cause death rates, by age, among these SCD patients were compared with all-cause death rates among both African Americans and the total population in the two states. All-cause death rates were also compared with death rates for SCD derived from publicly available death records: the compressed mortality files and multiple cause of death files. Results. Of 12,143 patients identified with SCD, 615 patients died. The all-cause mortality rate for the SCD population was lower than the all-cause mortality rate among African Americans and similar to the total population all-cause mortality rates from birth through age 4 years, but the rate was higher among those with SCD than both the African American and total population rates from ages 5 through 74 years. The count of deceased patients identified by using population-based surveillance data (n=615) was more than twice as high as the count identified in compressed mortality files using SCD as the underlying cause of death alone (n=297). Conclusion. Accurate assessment of all-cause mortality and age at death requires long-term surveillance via population-based registries of patients with accurately diagnosed SCD. C1 [Paulukonis, Susan T.] Inst Publ Hlth, Oakland, CA USA. [Eckman, James R.] Emory Univ, Atlanta, GA 30322 USA. [Snyder, Angela B.; Hagar, Ward] Georgia State Univ, Dept Publ Management & Policy, Atlanta, GA 30303 USA. [Snyder, Angela B.; Zhou, Mei] Georgia State Univ, Georgia Hlth Policy Ctr, Atlanta, GA 30303 USA. [Hagar, Ward] Univ Calif San Francisco, Benioff Childrens Hosp Oakland, Oakland, CA USA. [Feuchtbaum, Lisa B.] Calif Dept Publ Hlth, Genet Dis Screening Program, Richmond, CA USA. [Grant, Althea M.; Hulihan, Mary M.] Ctr Dis Control & Prevent, Div Blood Disorders, 4770 Buford Hwy,MS E-64, Atlanta, GA 30333 USA. RP Hulihan, MM (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, 4770 Buford Hwy,MS E-64, Atlanta, GA 30333 USA. EM ibx5@cdc.gov FU Centers for Disease Control and Prevention (CDC) [DD12-1206] FX This work was supported by the Centers for Disease Control and Prevention (CDC) (DD12-1206). The authors thank Brendan Noggle, Maternal and Child Health Epidemiologist for the Georgia Department of Health, now with the Virginia Department of Health, for his initial work securing the Georgia death files and matching them with the surveillance data; and the entire California and Georgia Public Health Research Epidemiology and Surveillance for Hemoglobinopathies teams for their research support, especially Peter Lane, MD, Todd Griffin, MPH, and Tiffany Fowles, DrPH, who provided feedback on early versions of the study. NR 25 TC 2 Z9 2 U1 0 U2 0 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2016 VL 131 IS 2 BP 367 EP 375 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG9HH UT WOS:000372392900020 PM 26957672 ER PT J AU Sia, TY Taimur, S Blau, DM Lambe, J Ackelsberg, J Yacisin, K Bhatnagar, J Ritter, J Shieh, WJ Muehlenbachs, A Shulman, K Fong, D Kung, E Zaki, SR AF Sia, Tiffany Y. Taimur, Sarah Blau, Dianna M. Lambe, Jennifer Ackelsberg, Joel Yacisin, Kari Bhatnagar, Julu Ritter, Jana Shieh, Wun-Ju Muehlenbachs, Atis Shulman, Kenneth Fong, Danny Kung, Elaine Zaki, Sherif R. TI Clinical and Pathological Evaluation of Mycobacterium marinum Group Skin Infections Associated With Fish Markets in New York City SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Mycobacterium marinum; skin infection; fish; outbreak; diagnosis ID DISEASES AB Background. From December 2013 through May 2014, physicians, dermatopathologists, and public health authorities collaborated to characterize an outbreak of Mycobacterium marinum and other nontuberculous mycobacterial skin and soft tissue infections (SSTIs) associated with handling fish in New York City's Chinatown. Clinicopathologic and laboratory investigations were performed on a series of patients. Methods. Medical records were reviewed for 29 patients. Culture results were available for 27 patients and 24 biopsy specimens were evaluated by histopathology, immunohistochemistry (IHC) staining for acid-fast bacilli (AFB), and mycobacterial polymerase chain reaction (PCR) assays. Results. All patients received antibiotics. The most commonly prescribed antibiotic regimen was clarithromycin and ethambutol. Of the 29 patients in this case series, 16 (55%) received surgical treatment involving incision and drainage, mass excision, and synovectomy. Of these, 7 (44%) had deep tissue involvement. All patients showed improvement. For those with culture results, 11 of 27 (41%) were positive for M. marinum; the remainder showed no growth. Poorly formed granulomas (96%), neutrophils (75%), and necrosis (79%) were found in 24 biopsies. Of 15 cases that were culture-negative and analyzed by other methods, 9 were PCR positive for M. marinum group species, 8 were IHC positive, and 3 were positive by AFB stains. Conclusions. A multidisciplinary approach was used to identify cases in an outbreak of M. marinum infections. The use of histopathology, culture, and IHC plus PCR from full thickness skin biopsy can lead to improved diagnosis of M. marinum SSTIs compared to relying solely on mycobacterial culture, the current gold standard. C1 [Sia, Tiffany Y.] Icahn Sch Med Mt Sinai, Columbia Coll Phys & Surg, New York, NY 10029 USA. [Taimur, Sarah] Icahn Sch Med Mt Sinai, Div Infect Dis, New York, NY 10029 USA. [Blau, Dianna M.; Bhatnagar, Julu; Ritter, Jana; Shieh, Wun-Ju; Muehlenbachs, Atis; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, 1600 Clifton Rd, Atlanta, GA 30333 USA. [Lambe, Jennifer] StrataDx, Div Pathol, Lexington, MA USA. [Ackelsberg, Joel; Yacisin, Kari] NYC Dept Hlth & Mental Hyg, Port Chester, NY USA. [Shulman, Kenneth] Dermpath Diagnost, Port Chester, NY USA. [Fong, Danny] Mt Sinai Beth Israel Med Ctr, Div Plast Surg, New York, NY USA. [Kung, Elaine] Weill Cornell Med Coll, Div Dermatol, New York, NY USA. RP Zaki, SR (reprint author), Ctr Dis Control & Prevent, Infect Dis Pathol Branch, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM sxz1@cdc.gov FU Infectious Diseases Pathology Branch of the CDC FX This work was supported by the Infectious Diseases Pathology Branch of the CDC. NR 16 TC 1 Z9 1 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2016 VL 62 IS 5 BP 590 EP 595 DI 10.1093/cid/civ937 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DF9XK UT WOS:000371715600016 PM 26673347 ER PT J AU Guo, M Mishra, A Buchanan, RL Dubey, JP Hill, DE Gamble, HR Jones, JL Pradhan, AK AF Guo, Miao Mishra, Abhinav Buchanan, Robert L. Dubey, Jitender P. Hill, Dolores E. Gamble, H. Ray Jones, Jeffrey L. Pradhan, Abani K. TI A Systematic Meta-Analysis of Toxoplasma gondii Prevalence in Food Animals in the United States SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID QUANTITATIVE RISK-ASSESSMENT; HUMAN CONSUMPTION; DAIRY GOATS; SWINE FARMS; TRICHINELLA-SPIRALIS; DOMESTIC-ANIMALS; INFECTION; PIGS; ANTIBODIES; SHEEP AB Toxoplasma gondii is a widely distributed protozoan parasite. The Centers for Disease Control and Prevention reported that T. gondii is one of three pathogens (along with Salmonella and Listeria), that together account for >70% of all deaths due to foodborne illness in the United States. Food animals are reservoirs for T. gondii and act as one of the sources for parasite transmission to humans. Based on limited population-based data, the Food and Agriculture Organization/World Health Organization estimated that approximately 22% of human T. gondii infections are meatborne. The objective of the current study was to conduct a systematic meta-analysis to provide a precise estimation of T. gondii infection prevalence in food animals produced in the United States. Four databases were searched to collect eligible studies. Prevalence was estimated in six animal categories (confinement-raised market pigs, confinement-raised sows, non-confinement-raised pigs, lamb, goats, and non-confinement-raised chickens) by a quality-effects model. A wide variation in prevalence was observed in each animal category. Animals raised outdoors or that have outdoor access had a higher prevalence as compared with animals raised indoors. T. gondii prevalence in non-confinement-raised pigs ranked the highest (31.0%) followed by goats (30.7%), non-confinement-raised chickens (24.1%), lambs (22.0%), confinement-raised sows (16.7%), and confinement-raised market pigs (5.6%). These results indicate that T. gondii-infected animals are a food safety concern. The computed prevalence can be used as an important input in quantitative microbial risk assessment models to further predict public health burden. C1 [Guo, Miao; Mishra, Abhinav; Buchanan, Robert L.; Pradhan, Abani K.] Univ Maryland, Dept Nutr & Food Sci, Skinner Bldg Room 0112, College Pk, MD 20742 USA. [Buchanan, Robert L.; Pradhan, Abani K.] Univ Maryland, Ctr Food Safety & Secur Syst, College Pk, MD 20742 USA. [Dubey, Jitender P.; Hill, Dolores E.] USDA, Anim Parasit Dis Lab, Agr Res Serv, Beltsville Agr Res Ctr, Beltsville, MD 20705 USA. [Gamble, H. Ray] Natl Acad Sci, 2101 Constitut Ave Nw, Washington, DC 20418 USA. [Jones, Jeffrey L.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Pradhan, AK (reprint author), Univ Maryland, Dept Nutr & Food Sci, Skinner Bldg Room 0112, College Pk, MD 20742 USA. EM akp@umd.edu OI Mishra, Abhinav/0000-0001-9214-0745 FU USDA National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative [2012-67005-19611] FX This work was supported through a grant from the USDA National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (award 2012-67005-19611). NR 74 TC 3 Z9 3 U1 3 U2 13 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 EI 1556-7125 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD MAR 1 PY 2016 VL 13 IS 3 BP 109 EP 118 DI 10.1089/fpd.2015.2070 PG 10 WC Food Science & Technology SC Food Science & Technology GA DG2FN UT WOS:000371882100001 PM 26854596 ER PT J AU Santesso, N Mustafa, RA Schunemann, HJ Arbyn, M Blumenthal, PD Cain, J Chirenje, M Denny, L De Vuyst, H Eckert, LO Forhan, SE Franco, EL Gage, JC Garcia, F Herrero, R Jeronimo, J Lu, ER Luciani, S Quek, SC Sankaranarayanan, R Tsu, V Broutet, N AF Santesso, Nancy Mustafa, Reem A. Schuenemann, Holger J. Arbyn, Marc Blumenthal, Paul D. Cain, Joanna Chirenje, Michael Denny, Lynette De Vuyst, Hugo Eckert, Linda O'Neal Forhan, Sara E. Franco, Eduardo L. Gage, Julia C. Garcia, Francisco Herrero, Rolando Jeronimo, Jose Lu, Enriquito R. Luciani, Silvana Quek, Swee Chong Sankaranarayanan, Rengaswamy Tsu, Vivien Broutet, Nathalie CA Guideline Support Grp TI World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS LA English DT Editorial Material DE Cervical cancer; Cervical intraepithelial neoplasia; Guidelines; Recommendations; Screen; Treat ID HUMAN-PAPILLOMAVIRUS INFECTION; WOMENS PREFERENCES; GRADE; MANAGEMENT; INDIA AB Background: It is estimated that 1%-2% of women develop cervical intraepithelial neoplasia grade 2-3 (CIN 2-3) annually worldwide. The prevalence among women living with HIV is higher, at 10%. If left untreated, CIN 2-3 can progress to cervical cancer. WHO has previously published guidelines for strategies to screen and treat pre-cancerous cervical lesions and for treatment of histologically confirmed CIN 2-3. Methods: Guidelines were developed using the WHO Handbook for Guideline Development and the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. A multidisciplinary guideline panel was created. Systematic reviews of randomized controlled trials and observational studies were conducted. Evidence tables and Evidence to Recommendations Tables were prepared and presented to the panel. Results: There are nine recommendations for screen-and-treat strategies to prevent cervical cancer, including the HPV test, cytology, and visual inspection with acetic acid. There are seven for treatment of CIN with cryotherapy, loop electrosurgical excision procedure, and cold knife conization. Conclusion: Recommendations have been produced on the basis of the best available evidence. However, high-quality evidence was not available. Such evidence is needed, in particular for screen-and-treat strategies that are relevant to low- and middle-income countries. (C) 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology and Obstetrics. C1 [Santesso, Nancy; Mustafa, Reem A.; Schuenemann, Holger J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Room 2C16,1280 Main St West, Hamilton, ON L8S 4K1, Canada. [Mustafa, Reem A.] Univ Missouri, Dept Internal Med, Kansas City, MO 64110 USA. [Mustafa, Reem A.] Univ Missouri, Dept Nephrol, Kansas City, MO 64110 USA. [Mustafa, Reem A.] Univ Missouri, Dept Biomed & Hlth Informat, Kansas City, MO 64110 USA. [Arbyn, Marc] Sci Inst Publ Hlth, Canc Epidemiol Unit, Brussels, Belgium. [Blumenthal, Paul D.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Cain, Joanna] Univ Massachusetts, Sch Med, Worcester, MA USA. [Chirenje, Michael] Univ Zimbabwe, Harare, Zimbabwe. [Denny, Lynette] Univ Cape Town, ZA-7925 Cape Town, South Africa. [Denny, Lynette] Groote Schuur Hosp, ZA-7925 Cape Town, South Africa. [De Vuyst, Hugo; Herrero, Rolando; Sankaranarayanan, Rengaswamy] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France. [Eckert, Linda O'Neal] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Forhan, Sara E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Franco, Eduardo L.] McGill Univ, Montreal, PQ, Canada. [Gage, Julia C.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Garcia, Francisco] Amer Canc Soc, Tucson, AZ USA. [Jeronimo, Jose; Tsu, Vivien] PATH, Seattle, WA USA. [Lu, Enriquito R.] Jhpiego, Baltimore, MD USA. [Luciani, Silvana] Canc Prevent & Control PAHO, Washington, DC USA. [Quek, Swee Chong] KK Womens & Childrens Hosp, Singapore, Singapore. [Broutet, Nathalie] WHO, Reprod Hlth & Res, CH-1211 Geneva, Switzerland. RP Schunemann, HJ (reprint author), McMaster Univ, Dept Clin Epidemiol & Biostat, Room 2C16,1280 Main St West, Hamilton, ON L8S 4K1, Canada. OI Franco, Eduardo/0000-0002-4409-8084 FU World Health Organization [001] NR 22 TC 7 Z9 8 U1 1 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0020-7292 EI 1879-3479 J9 INT J GYNECOL OBSTET JI Int. J. Gynecol. Obstet. PD MAR PY 2016 VL 132 IS 3 BP 252 EP 258 DI 10.1016/j.ijgo.2015.07.038 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DG3AO UT WOS:000371942100002 PM 26868062 ER PT J AU McNeil, MM Weintraub, ES Duffy, J Sukumaran, L Jacobsen, SJ Klein, NP Hambidge, SJ Lee, GM Jackson, LA Irving, SA King, JP Kharbanda, EO Bednarczyk, RA DeStefano, F AF McNeil, Michael M. Weintraub, Eric S. Duffy, Jonathan Sukumaran, Lakshmi Jacobsen, Steven J. Klein, Nicola P. Hambidge, Simon J. Lee, Grace M. Jackson, Lisa A. Irving, Stephanie A. King, Jennifer P. Kharbanda, Elyse O. Bednarczyk, Robert A. DeStefano, Frank TI Risk of anaphylaxis after vaccination in children and adults SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Anaphylaxis; vaccine safety; immunization ID UNITED-STATES; IMMUNIZATION SAFETY; HUMAN VACCINES; SEX-HORMONES; FOLLOW-UP; INFLUENZA; DEFINITION; DATALINK; SYSTEM; HEALTH AB Background: Anaphylaxis is a potentially life-threatening allergic reaction. The risk of anaphylaxis after vaccination has not been well described in adults or with newer vaccines in children. Objective: We sought to estimate the incidence of anaphylaxis after vaccines and describe the demographic and clinical characteristics of confirmed cases of anaphylaxis. Methods: Using health care data from the Vaccine Safety Datalink, we determined rates of anaphylaxis after vaccination in children and adults. We first identified all patients with a vaccination record from January 2009 through December 2011 and used diagnostic and procedure codes to identify potential anaphylaxis cases. Medical records of potential cases were reviewed. Confirmed cases met the Brighton Collaboration definition for anaphylaxis and had to be determined to be vaccine triggered. We calculated the incidence of anaphylaxis after all vaccines combined and for selected individual vaccines. Results: We identified 33 confirmed vaccine-triggered anaphylaxis cases that occurred after 25,173,965 vaccine doses. The rate of anaphylaxis was 1.31 (95% CI, 0.90-1.84) per million vaccine doses. The incidence did not vary significantly by age, and there was a nonsignificant female predominance. Vaccine-specific rates included 1.35 (95% CI, 0.65-2.47) per million doses for inactivated trivalent influenza vaccine (10 cases, 7,434,628 doses given alone) and 1.83 (95% CI, 0.22-6.63) per million doses for inactivated monovalent influenza vaccine (2 cases, 1,090,279 doses given alone). The onset of symptoms among cases was within 30 minutes (8 cases), 30 to less than 120 minutes (8 cases), 2 to less than 4 hours (10 cases), 4 to 8 hours (2 cases), the next day (1 case), and not documented (4 cases). Conclusion: Anaphylaxis after vaccination is rare in all age groups. Despite its rarity, anaphylaxis is a potentially life-threatening medical emergency that vaccine providers need to be prepared to treat. C1 [McNeil, Michael M.; Weintraub, Eric S.; Duffy, Jonathan; Sukumaran, Lakshmi; DeStefano, Frank] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Jacobsen, Steven J.] Kaiser Permanente So Calif, Pasadena, CA 91101 USA. [Klein, Nicola P.] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. [Hambidge, Simon J.] Kaiser Permanente, Inst Hlth Res, Denver, CO USA. [Lee, Grace M.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA. [Irving, Stephanie A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [King, Jennifer P.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Kharbanda, Elyse O.] HealthPartners Inst Educ & Res, Minneapolis, MN USA. [Bednarczyk, Robert A.] Kaiser Permanente Ctr Hlth Res, Atlanta, GA USA. [Bednarczyk, Robert A.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP McNeil, MM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA. EM mmm2@cdc.gov FU CDC FX The findings and conclusions of this report are those of the authors and do not necessarily represent the official policy or position of the Centers for Disease Control and Prevention (CDC). Use of trade names and commercial sources is for identification only and does not imply endorsement by the CDC. The Vaccine Safety Datalink Project is funded by the CDC. This study was supported by the CDC, and no external funding was secured. NR 49 TC 11 Z9 12 U1 2 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD MAR PY 2016 VL 137 IS 3 BP 868 EP 878 DI 10.1016/j.jaci.2015.07.048 PG 11 WC Allergy; Immunology SC Allergy; Immunology GA DG2LB UT WOS:000371897500031 PM 26452420 ER PT J AU Ndzi, ES Asonganyi, T Nkinin, MB Xiao, LH Didier, ES Bowers, LC Nkinin, SW Kaneshiro, ES AF Ndzi, Edward S. Asonganyi, Tazoacha Nkinin, Mary Bello Xiao, Lihua Didier, Elizabeth S. Bowers, Lisa C. Nkinin, Stephenson W. Kaneshiro, Edna S. TI Fast Technology Analysis Enables Identification of Species and Genotypes of Latent Microsporidia Infections in Healthy Native Cameroonians SO JOURNAL OF EUKARYOTIC MICROBIOLOGY LA English DT Article DE Encephalitozoon cuniculi; Encephalitozoon intestinalis; enteric parasites; Enterocytozoon bieneusi; epidemiology; fecal samples; microsporidial DNA; opportunistic pathogens; PCR analysis ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTS SOLENOPSIS-INVICTA; ENTEROCYTOZOON-BIENEUSI; PCR DETECTION; TEMPLATE PREPARATION; EMERGING PATHOGENS; STOOL SPECIMENS; PUBLIC-HEALTH; PREVALENCE; CHILDREN AB Several enteric microsporidia species have been detected in humans and other vertebrates and their identifications at the genotype level are currently being elucidated. As advanced methods, reagents, and disposal kits for detecting and identifying pathogens become commercially available, it is important to test them in settings other than in laboratories with state-of-the-art equipment and well-trained staff members. In the present study, we sought to detect microsporidia DNA preserved and extracted from FTA (fast technology analysis) cards spotted with human fecal suspensions obtained from Cameroonian volunteers living in the capital city of Yaounde to preclude the need for employing spore-concentrating protocols. Further, we tested whether amplicon nucleotide sequencing approaches could be used on small aliquots taken from the cards to elucidate the diversity of microsporidia species and strains infecting native residents. Of 196 samples analyzed, 12 (6.1%) were positive for microsporidia DNA; Enterocytozoon bieneusi (Type IV and KIN-1), Encephalitozoon cuniculi, and Encephalitozoon intestinalis were identified. These data demonstrate the utility of the FTA cards in identifying genotypes of microsporidia DNA in human fecal samples that may be applied to field testing for prevalence studies. C1 [Ndzi, Edward S.] Inst Med Res & Med Plants Studies IMPM, Yaounde, Cameroon. [Ndzi, Edward S.] Univ Buea, Buea, Cameroon. [Asonganyi, Tazoacha] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon. [Nkinin, Mary Bello] Cent Hosp Yaounde, Neurol & Phys Med Serv, Electroencephalog Lab, Yaounde, Cameroon. [Xiao, Lihua] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Didier, Elizabeth S.; Bowers, Lisa C.] Tulane Natl Primate Res Ctr, Covington, LA USA. [Nkinin, Stephenson W.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Nkinin, Stephenson W.; Kaneshiro, Edna S.] Univ Cincinnati, Dept Biol Sci, Cincinnati, OH 45221 USA. RP Kaneshiro, ES (reprint author), Univ Cincinnati, Dept Biol Sci, Cincinnati, OH 45221 USA. EM edna.kaneshiro@uc.edu RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU National Institutes of Health [OD011104] FX This study was supported in part by a grant from the National Institutes of Health, OD011104, to the Tulane National Primate Research Center. NR 44 TC 0 Z9 0 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5234 EI 1550-7408 J9 J EUKARYOT MICROBIOL JI J. Eukaryot. Microbiol. PD MAR-APR PY 2016 VL 63 IS 2 BP 146 EP 152 DI 10.1111/jeu.12262 PG 7 WC Microbiology SC Microbiology GA DG6IJ UT WOS:000372187300001 PM 26303263 ER PT J AU Smith, DB Simmonds, P Izopet, J Oliveira, EF Ulrich, RG Johne, R Koenig, M Jameel, S Harrison, TJ Meng, XJ Okamoto, H Van der Poel, WHM Purdy, MA AF Smith, Donald B. Simmonds, Peter Izopet, Jacques Oliveira-Filho, Edmilson F. Ulrich, Rainer G. Johne, Reimar Koenig, Matthias Jameel, Shahid Harrison, Tim J. Meng, Xiang-Jin Okamoto, Hiroaki Van der Poel, Wim H. M. Purdy, Michael A. TI Proposed reference sequences for hepatitis E virus subtypes SO JOURNAL OF GENERAL VIROLOGY LA English DT Review ID PHYLOGENETIC ANALYSIS; GENETIC-VARIABILITY; CLASSIFICATION; DIVERSITY; HUMANS; TRANSMISSION; ENGLAND; FRANCE AB The nomenclature of hepatitis E virus (HEV) subtypes is inconsistent and makes comparison of different studies problematic. We have provided a table of proposed complete genome reference sequences for each subtype. The criteria for subtype assignment vary between different genotypes and methodologies, and so a conservative pragmatic approach has been favoured. Updates to this table will be posted on the International Committee on Taxonomy of Viruses website (http://talk.ictvonline.org/r.ashx?C). The use of common reference sequences will facilitate communication between researchers and help clarify the epidemiology of this important human pathogen. This subtyping procedure might be adopted for other taxa of the genus Orthohepevirus. C1 [Smith, Donald B.; Simmonds, Peter] Univ Edinburgh, Ctr Immun Infect & Evolut, Edinburgh, Midlothian, Scotland. [Izopet, Jacques] INSERM, UMR1043, F-31300 Toulouse, France. [Oliveira-Filho, Edmilson F.] Univ Liege, Vet Virol & Anim Viral Dis, Dept Infect & Parasit Dis, Fundamental & Appl Res Anim Hlth Ctr,Fac Vet Med, Liege, Belgium. [Ulrich, Rainer G.] Friedrich Loeffler Inst, Fed Res Inst Anim Hlth, Inst Novel & Emerging Infect Dis, Greifswald, Germany. [Ulrich, Rainer G.] German Ctr Infect Res DZIF, Partner Site Hamburg Luebeck Borstel Insel Riems, Hamburg, Germany. [Johne, Reimar] Fed Inst Risk Assessment, Berlin, Germany. [Koenig, Matthias] Univ Giessen, D-35390 Giessen, Germany. [Jameel, Shahid] Wellcome Trust DBT India Alliance, Hyderabad, Andhra Pradesh, India. [Harrison, Tim J.] UCL, London, England. [Meng, Xiang-Jin] Virginia Polytech Inst & State Univ, Coll Vet Med, Blacksburg, VA 24061 USA. [Okamoto, Hiroaki] Jichi Med Univ, Div Virol, Dept Infect & Immun, Sch Med, Shimotsuke, Tochigi, Japan. [Van der Poel, Wim H. M.] Univ Wageningen & Res Ctr, Cent Vet Inst, Lelystad, Netherlands. [Purdy, Michael A.] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD TB Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Smith, DB (reprint author), Univ Edinburgh, Ctr Immun Infect & Evolut, Edinburgh, Midlothian, Scotland. EM d.b.smith@ed.ac.uk RI Okamoto, Hiroaki/H-4371-2011 OI Okamoto, Hiroaki/0000-0003-0827-0964 FU Wellcome Trust [095831/Z/11/Z] FX This work was supported by The Wellcome Trust (grant 095831/Z/11/Z) to the Centre for Immunity, Infection and Evolution at the University of Edinburgh, UK. NR 16 TC 21 Z9 21 U1 4 U2 8 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 EI 1465-2099 J9 J GEN VIROL JI J. Gen. Virol. PD MAR PY 2016 VL 97 BP 537 EP 542 DI 10.1099/jgv.0.000393 PN 3 PG 6 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA DG8KP UT WOS:000372333000001 PM 26743685 ER PT J AU Eisen, RJ Eisen, L Ogden, NH Beard, CB AF Eisen, Rebecca J. Eisen, Lars Ogden, Nicholas H. Beard, Charles B. TI Linkages of Weather and Climate With Ixodes scapularis and Ixodes pacificus (Acari: Ixodidae), Enzootic Transmission of Borrelia burgdorferi, and Lyme Disease in North America SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE Lyme disease; climate change; Ixodes pacificus; Ixodes scapularis; Borrelia burgdorferi ID NORTHEASTERN UNITED-STATES; LIZARD SCELOPORUS-OCCIDENTALIS; BLACKLEGGED TICK ACARI; DAMMINI ACARI; SEASONAL ACTIVITY; NEW-JERSEY; RESERVOIR COMPETENCE; HUMAN BABESIOSIS; LONG POINT; TRANSOVARIAL TRANSMISSION AB Lyme disease has increased both in incidence and geographic extent in the United States and Canada over the past two decades. One of the underlying causes is changes during the same time period in the distribution and abundance of the primary vectors: Ixodes scapularis Say and Ixodes pacificus Cooley and Kohls in eastern and western North America, respectively. Aside from short periods of time when they are feeding on hosts, these ticks exist in the environment where temperature and relative humidity directly affect their development, survival, and host-seeking behavior. Other important factors that strongly influence tick abundance as well as the proportion of ticks infected with the Lyme disease spirochete, Borrelia burgdorferi, include the abundance of hosts for the ticks and the capacity of tick hosts to serve as B. burgdorferi reservoirs. Here, we explore the linkages between climate variation and: 1) duration of the seasonal period and the timing of peak activity; 2) geographic tick distributions and local abundance; 3) enzootic B. burgdorferi transmission cycles; and 4) Lyme disease cases. We conclude that meteorological variables are most influential in determining host-seeking phenology and development, but, while remaining important cofactors, additional variables become critical when exploring geographic distribution and local abundance of ticks, enzootic transmission of B. burgdorferi, and Lyme disease case occurrence. Finally, we review climate change-driven projections for future impact on vector ticks and Lyme disease and discuss knowledge gaps and research needs. C1 [Eisen, Rebecca J.; Eisen, Lars; Beard, Charles B.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vectorborne Dis, Natl Ctr Emerging Zoonot Infect Dis, Ft Collins, CO USA. [Ogden, Nicholas H.] Publ Hlth Agcy Canada, Ctr Food Borne Environm & Zoonot Infect Dis, Zoonoses Div, St Hyacinthe, PQ, Canada. RP Eisen, RJ (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vectorborne Dis, Natl Ctr Emerging Zoonot Infect Dis, Ft Collins, CO USA. EM dyn2@cdc.gov; evp4@cdc.gov; nicholas.ogden@phac-aspc.gc.ca; cbb0@cdc.gov FU Intramural CDC HHS [CC999999] NR 148 TC 9 Z9 9 U1 30 U2 66 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD MAR PY 2016 VL 53 IS 2 BP 250 EP 261 DI 10.1093/jme/tjv199 PG 12 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA DG2PA UT WOS:000371908500002 PM 26681789 ER PT J AU Eisen, RJ Eisen, L Beard, CB AF Eisen, Rebecca J. Eisen, Lars Beard, Charles B. TI County-Scale Distribution of Ixodes scapularis and Ixodes pacificus (Acari: Ixodidae) in the Continental United States SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE Ixodes scapularis; Ixodes pacificus; distribution; Lyme disease ID LYME-DISEASE VECTOR; WHITE-TAILED DEER; BURGDORFERI SPIROCHAETALES-SPIROCHAETACEAE; TICK-BORNE PATHOGENS; CLIMATE-BASED MODEL; BORRELIA-BURGDORFERI; ANAPLASMA-PHAGOCYTOPHILUM; GEOGRAPHIC-DISTRIBUTION; BLACKLEGGED TICK; DAMMINI ACARI AB The blacklegged tick, Ixodes scapularis Say, is the primary vector to humans in the eastern United States of the Lyme disease spirochete Borrelia burgdorferi, as well as causative agents of anaplasmosis and babesiosis. Its close relative in the far western United States, the western blacklegged tick Ixodes pacificus Cooley and Kohls, is the primary vector to humans in that region of the Lyme disease and anaplasmosis agents. Since 1991, when standardized surveillance and reporting began, Lyme disease case counts have increased steadily in number and in geographical distribution in the eastern United States. Similar trends have been observed for anaplasmosis and babesiosis. To better understand the changing landscape of risk of human exposure to disease agents transmitted by I. scapularis and I. pacificus, and to document changes in their recorded distribution over the past two decades, we updated the distribution of these species from a map published in 1998. The presence of I. scapularis has now been documented from 1,420 (45.7%) of the 3,110 continental United States counties, as compared with 111 (3.6%) counties for I. pacificus. Combined, these vectors of B. burgdorferi and other disease agents now have been identified in a total of 1,531 (49.2%) counties spread across 43 states. This marks a 44.7% increase in the number of counties that have recorded the presence of these ticks since the previous map was presented in 1998, when 1,058 counties in 41 states reported the ticks to be present. Notably, the number of counties in which I. scapularis is considered established (six or more individuals or one or more life stages identified in a single year) has more than doubled since the previous national distribution map was published nearly two decades ago. The majority of county status changes occurred in the North-Central and Northeastern states, whereas the distribution in the South remained fairly stable. Two previously distinct foci for I. scapularis in the Northeast and North-Central states appear to be merging in the Ohio River Valley to form a single contiguous focus. Here we document a shifting landscape of risk for human exposure to medically important ticks and point to areas of re-emergence where enhanced vector surveillance and control may be warranted. C1 [Eisen, Rebecca J.; Eisen, Lars; Beard, Charles B.] CDC, Div Vector Borne Dis, NCEZID, 3156 Rampart Rd, Ft Collins, CO 80522 USA. RP Eisen, RJ (reprint author), CDC, Div Vector Borne Dis, NCEZID, 3156 Rampart Rd, Ft Collins, CO 80522 USA. EM dyn2@cdc.gov; evp4@cdc.gov; cbb0@cdc.gov FU Intramural CDC HHS [CC999999] NR 95 TC 14 Z9 14 U1 6 U2 21 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD MAR PY 2016 VL 53 IS 2 BP 349 EP 386 DI 10.1093/jme/tjv237 PG 38 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA DG2PA UT WOS:000371908500013 PM 26783367 ER PT J AU Fauver, JR Pecher, L Schurich, JA Bolling, BG Calhoon, M Grubaugh, ND Burkhalter, KL Eisen, L Andre, BG Nasci, RS LeBailly, A Ebel, GD Moore, CG AF Fauver, Joseph R. Pecher, Lauren Schurich, Jessica A. Bolling, Bethany G. Calhoon, Mike Grubaugh, Nathan D. Burkhalter, Kristen L. Eisen, Lars Andre, Barbara G. Nasci, Roger S. LeBailly, Adrienne Ebel, Gregory D. Moore, Chester G. TI Temporal and Spatial Variability of Entomological Risk Indices for West Nile Virus Infection in Northern Colorado: 2006-2013 SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE West Nile virus; Culex tarsalis; Culex pipiens; surveillance; vector index ID NORTHEASTERN UNITED-STATES; CULEX-TARSALIS ABUNDANCE; DIPTERA-CULICIDAE; NEW-YORK; HUMAN-DISEASE; ENCEPHALITIS EPIDEMIC; VERTICAL TRANSMISSION; FRONT RANGE; NEW-JERSEY; MOSQUITOS AB West Nile virus (WNV) is enzootic in northern Colorado. Annual surveillance activities in Fort Collins, CO, include collecting female Culex mosquitoes and testing them for the presence of WNV RNA in order to calculate 1) Culex female abundance, 2) WNV infection rate, and 3) the vector index (VI). These entomological risk indices inform public policy regarding the need for emergency adulticiding. Currently, these are calculated on a city-wide basis. In this study, we present descriptive data from historical surveillance records spanning 2006-2013 to discern seasonal and yearly patterns of entomological risk for WNV infection. Also, we retrospectively test the hypothesis that entomological risk is correlated with human transmission risk and is heterogeneous within the City of Fort Collins. Four logistically relevant zones within the city were established and used to test this hypothesis. Zones in the eastern portion of the city consistently had significantly higher Culex abundance and VI compared with zones in the west, leading to higher entomological risk indicators for human WNV infection in the east. Moreover, the relative risk of a reported human case of WNV infection was significantly higher in the eastern zones of the city. Our results suggest that a more spatially targeted WNV management program may better mitigate human risk for WNV infection in Fort Collins, and possibly other cities where transmission is enzootic, while at the same time reducing pesticide use. C1 [Fauver, Joseph R.; Bolling, Bethany G.; Grubaugh, Nathan D.; Eisen, Lars; Ebel, Gregory D.; Moore, Chester G.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Arthropod Borne & Infect Dis Lab, 1690 Campus Delivery, Ft Collins, CO 80521 USA. [Pecher, Lauren; LeBailly, Adrienne] Larimer Cty Dept Hlth & Environm, 1525 Blue Spruce Dr, Ft Collins, CO 80524 USA. [Pecher, Lauren] 106 Med Detachment Vet Serv Support, Unit 15252, APO, AP 96205 USA. [Schurich, Jessica A.] Colorado Mosquito Control Inc, Loveland, CO 80537 USA. [Bolling, Bethany G.] Texas Dept State Hlth Serv, Austin, TX 78714 USA. [Calhoon, Mike] City Ft Collins, Pk Deptartment, 413 S Bryan Ave, Ft Collins, CO 80521 USA. [Burkhalter, Kristen L.; Eisen, Lars; Nasci, Roger S.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Andre, Barbara G.] Colorado State Univ, Deptartment Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. RP Moore, CG (reprint author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Arthropod Borne & Infect Dis Lab, 1690 Campus Delivery, Ft Collins, CO 80521 USA. EM Joseph.Fauver@colostate.edu; lauren.pecher@gmail.com; jessicaschurich@yahoo.com; Bethany.Bolling@dshs.state.tx.us; mcalhoon@fcgov.com; nathan.grubaugh@yahoo.com; ktb3@cdc.gov; evp4@cdc.gov; Barb.Andre@colostate.edu; rnasci@n-smad.com; lebailae@co.lari-mer.co.us; Gregory.Ebel@colostate.edu; Culex.tarsalis@comcast.net RI Ebel, Gregory/D-8324-2017 FU City of Fort Collins West Nile virus Surveillance grant FX We would like to thank Kamaria Price, Kacy Cobble, Amanda Hardison, Stacey Elmore, Scott Sieke, Abhishek Prasad, and Benjamin Dodd for their assistance in the Laboratory at AIDL; we would also like to thank Erin McCool, Sarah Yoder, Stacy Marshall, Casey Funderburk, Monica Heersink, and Dominic Rose for their support at CMC. We would like to thank Claudia Ruckert and Kristen Davenport for their assistance in reviewing the manuscript. This work was supported, in part, by the annual City of Fort Collins West Nile virus Surveillance grant. We thank the editor and an anonymous reviewer for insightful comments that improved an earlier draft of the manuscript. NR 45 TC 1 Z9 1 U1 3 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD MAR PY 2016 VL 53 IS 2 BP 425 EP 434 DI 10.1093/jme/tjv234 PG 10 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA DG2PA UT WOS:000371908500019 PM 26718715 ER PT J AU Graham, CB Eisen, RJ Belthoff, JR AF Graham, Christine B. Eisen, Rebecca J. Belthoff, James R. TI Detecting Burrowing Owl Bloodmeals in Pulex irritans (Siphonaptera: Pulicidae) SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE Pulex irritans; burrowing owl; Athene cunicularia; bloodmeal identification; flea ID EARLY-PHASE TRANSMISSION; YERSINIA-PESTIS; PLAGUE EPIZOOTICS; ATHENE-CUNICULARIA; SOUTHWESTERN IDAHO; UNBLOCKED FLEAS; PRAIRIE DOGS; GREAT TITS; CERATOPHYLLIDAE; IDENTIFICATION AB Pulex irritans L. is a cosmopolitan flea species that infests a wide variety of hosts. In North America it generally parasitizes large wild mammals, but in the Pacific Northwest an association has emerged between P. irritans and the western burrowing owl (Athene cunicularia hypugaea). While investigators have recognized this association for decades, it has not been clear if P. irritans feeds on burrowing owls, or if the owls serve exclusively as phoretic hosts. Here we describe using a real-time assay that was originally developed to identify bloodmeals in Ugandan cat fleas (Ctenocephalides felis Bouche') to detect burrowing owl DNA in P. irritans collected from burrowing owls in southern Idaho. Of 50 fleas tested, 12 had no detectable vertebrate bloodmeal. The remaining 38 (76%) contained burrowing owl DNA. The assay did not detect vertebrate DNA in unfed fleas exposed to owl or mouse pelts and is therefore unlikely to detect DNA in fleas from vertebrates that have served exclusively as phoretic hosts. We conclude that P. irritans feeds on burrowing owls. We discuss the potential implications of this finding for burrowing owl conservation and enzootic plague dynamics. C1 [Graham, Christine B.; Eisen, Rebecca J.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. [Belthoff, James R.] Boise State Univ, Dept Biol Sci, 1910 Univ Dr, Boise, ID 83725 USA. [Belthoff, James R.] Boise State Univ, Raptor Res Ctr, 1910 Univ Dr, Boise, ID 83725 USA. RP Graham, CB (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM hyb4@cdc.gov; dyn2@cdc.gov; jbeltho@boisestate.edu NR 39 TC 0 Z9 0 U1 3 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD MAR PY 2016 VL 53 IS 2 BP 446 EP 450 DI 10.1093/jme/tjv177 PG 5 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA DG2PA UT WOS:000371908500022 PM 26545716 ER PT J AU Perna, FM Coa, K Troiano, RP Lawman, HG Wang, CY Li, Y Moser, RP Ciccolo, JT Comstock, BA Kraemer, WJ AF Perna, Frank M. Coa, Kisha Troiano, Richard P. Lawman, Hannah G. Wang, Chia-Yih Li, Yan Moser, Richard P. Ciccolo, Joseph T. Comstock, Brett A. Kraemer, William J. TI MUSCULAR GRIP STRENGTH ESTIMATES OF THE US POPULATION FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2011-2012 SO JOURNAL OF STRENGTH AND CONDITIONING RESEARCH LA English DT Article DE NHANES; fitness; youth; adults ID BODY-COMPOSITION; OLDER-ADULTS; MUSCLE MASS; MUSCULOSKELETAL FITNESS; HANDGRIP STRENGTH; MORTALITY; CHILDREN; ADOLESCENTS; RESISTANCE; WEIGHT AB Perna, FM, Coa, K, Troiano, RP, Lawman, HG, Wang, C-Y, Li, Y, Moser, RP, Ciccolo, JT, Comstock, BA, and Kraemer, WJ. Muscular grip strength estimates of the U.S. population from the National Health and Nutrition Examination Survey 2011-12. J Strength Cond Res 30(3): 867-874, 2016The purposes of this study were to use the National Health and Nutrition Examination Study (2011-12) data to determine nationally representative combined handgrip strength ranges and percentile information by sex and age group, examine trends in strength across age by sex, and to determine the relative proportion of children and adults falling into established health benefit zones (HBZ). Results indicate that mean strength was greater among men than women and increased linearly for children and in a quadratic fashion among adults for both sexes. Grip strength peaked in the 30- to 39-year age group for both men (216.4 lbs) and women (136.5 lbs) with subsequent age groups showing gradual decline, p < 0.0001. Relative and absolute increases in grip strength were greater for men than for women, but relative decrease from peak strength was less among women than men. Although absolute strength was greater among men than women, HBZ data indicated that a higher percentage of men than women overall and at each age group fell into the needs improvement zone, with differences particularly pronounced during adolescence and older adulthood. These data provide the first nationally representative population estimates of combined handgrip strength and percentile information from childhood through senescence and suggest consideration of HBZ information in conjunction with grip strength to improve surveillance data interpretation and intervention planning. C1 [Perna, Frank M.; Coa, Kisha; Troiano, Richard P.; Moser, Richard P.] NCI, Bethesda, MD 20892 USA. [Lawman, Hannah G.; Wang, Chia-Yih] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Li, Yan] Univ Maryland, Silver Spring, MD USA. [Ciccolo, Joseph T.] Columbia Univ, Teachers Coll, Dept Biobehav Sci, New York, NY 10027 USA. [Comstock, Brett A.] Univ S Dakota, Dept Kinesiol & Sport Sci, Vermillion, SD 57069 USA. [Kraemer, William J.] Ohio State Univ, Dept Human Sci, Columbus, OH 43210 USA. RP Perna, FM (reprint author), NCI, Bethesda, MD 20892 USA. EM pernafm@mail.nih.gov NR 35 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1064-8011 EI 1533-4287 J9 J STRENGTH COND RES JI J. Strength Cond. Res. PD MAR PY 2016 VL 30 IS 3 BP 867 EP 874 DI 10.1519/JSC.0000000000001104 PG 8 WC Sport Sciences SC Sport Sciences GA DG1MF UT WOS:000371831500034 PM 26196662 ER PT J AU Vallabhaneni, S Purfield, AE Benedict, K Luvsansharav, U Lockhart, SR Pham, CD Pascoe, N Heseltine, G Chung, W Hall, E Brust, KB Wheeler, CF Halpin, AL Park, BJ AF Vallabhaneni, Snigdha Purfield, Anne E. Benedict, Kaitlin Luvsansharav, Ulzii Lockhart, Shawn R. Pham, Cau D. Pascoe, Neil Heseltine, Gary Chung, Wendy Hall, Emily Brust, Karen B. Wheeler, Charlotte F. Halpin, Alison Laufer Park, Benjamin J. TI Cardiothoracic surgical site phaeohyphomycosis caused by Bipolaris mould, multiple US states, 2008-2013: a clinical description SO MEDICAL MYCOLOGY LA English DT Article DE Bipolaris; mould; fungal; surgical site infections; cardiothoracic surgery; phaeohyphomycosis ID DELAYED STERNAL CLOSURE; ASPERGILLOSIS; INFECTION AB Bipolaris mould surgical site infections (SSIs) are exceedingly rare. We describe 21 cases of Bipolaris SSIs in pediatric and adult cardiothoracic surgery patients at ten hospitals in Texas, Arkansas, and Florida during 2008-2013. Median case-patient age was 55 years (range: 3 days-82 years), and 19 (90%) weremale. Ten (48%) had coronary artery bypass or valve surgery, and seven (33%) had heart transplantation. Fifteen (71%) had more than one cardiothoracic procedure (median: 3, range: 1-11). Thirteen (62%) case-patients (all 5 pediatric patients, and 8 (50%) of 16 adult patients) had delayed sternal closure (chest closed > 1 day [median = 8 days; range: 2-22] following the initial cardiothoracic procedure). Thirteen (62%) had mediastinitis. Median time from initial surgery to positive Bipolaris culture was 20 days (range: 6-497). Sixteen (76%) case-patients died. C1 [Vallabhaneni, Snigdha; Purfield, Anne E.; Luvsansharav, Ulzii] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Vallabhaneni, Snigdha; Purfield, Anne E.; Benedict, Kaitlin; Luvsansharav, Ulzii; Lockhart, Shawn R.; Pham, Cau D.; Park, Benjamin J.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. [Pascoe, Neil; Heseltine, Gary] Texas Dept State Hlth Serv, Austin, TX USA. [Chung, Wendy; Hall, Emily] Dallas Cty Hlth & Human Serv, Dallas, TX USA. [Brust, Karen B.; Wheeler, Charlotte F.] Scott & White Mem Hosp & Clin, Temple, TX 76508 USA. [Halpin, Alison Laufer] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. RP Vallabhaneni, S (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C-09, Atlanta, GA 30329 USA. EM fco6@cdc.gov NR 14 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1369-3786 EI 1460-2709 J9 MED MYCOL JI Med. Mycol. PD MAR PY 2016 VL 54 IS 3 BP 318 EP 321 DI 10.1093/mmy/myv101 PG 4 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA DG5GO UT WOS:000372105200013 PM 26705838 ER PT J AU Suchdev, PS Addo, OY Martorell, R Grant, FKE Ruth, LJ Patel, MK Juliao, PC Quick, R Flores-Ayala, R AF Suchdev, Parminder S. Addo, O. Yaw Martorell, Reynaldo Grant, Frederick K. E. Ruth, Laird J. Patel, Minal K. Juliao, Patricia C. Quick, Rob Flores-Ayala, Rafael TI Effects of community-based sales of micronutrient powders on morbidity episodes in preschool children in Western Kenya SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE anemia; malaria; micronutrient powders; morbidity; Kenya; hospitalizations ID RANDOMIZED CONTROLLED-TRIAL; YOUNG-CHILDREN; ZINC SUPPLEMENTATION; IRON FORTIFICATION; VITAMIN-A; SPRINKLES; DIARRHEA; INFANTS; INFLAMMATION; DEFICIENCY AB Background: Although the use of micronutrient powders (MNPs) is considered the preferred approach for childhood anemia control, concerns about iron-related morbidity from clinical trials have challenged programmatic scale-up. Objective: We aimed to measure the effects of community-based sales of MNPs on diarrhea-, fever-, cough-, and malaria-morbidity episodes in children 6-35 mo of age. Design: We conducted a cluster-randomized trial in rural Western Kenya where 60 villages were randomly assigned to either intervention or control groups. MNPs (containing iron, vitamin A, zinc, and 11 other micronutrients) and other health products (e.g., insecticide treated bednets, soap, and water disinfectant) were marketed in 30 intervention villages from June 2007 to March 2008. Household visits every 2 wk were used to monitor self-reported MNP use and morbidity (illness episodes in the previous 24 h and hospitalizations in the previous 2 wk) in both groups. Iron, vitamin A, anemia, malaria, and anthropometric measures were assessed at baseline and at 12 mo of follow-up. Data were analyzed by intent-to treat analyses. Results: Of 1062 children enrolled in the study, 1038 children (97.7%) were followed (a total of 14,204 surveillance visits). Mean MNP intake in intervention villages was 0.9 sachets/wk. Children in intervention villages, compared with children in control villages, had similar to 60% fewer hospitalizations for diarrhea (0.9% compared with 2.4%, respectively; P = 0.03) and 70% fewer hospitalizations for fever (1.8% compared with 5.3%, respectively; P = 0.003) but no significant differences in hospitalizations for respiratory illness (1.1% compared with 2.2%, respectively; P = 0.11) or malaria (3.1% compared with 2.9%, respectively; P = 0.82). There were no differences between groups in the numbers of episodes of diarrhea, cough, or fever. Conclusions: MNP use in Western Kenya through market-based community sales was not associated with increased infectious morbidity in young children and was associated with decreased hospitalizations for diarrhea and fever. An integrated distribution of MNPs with other health interventions should be explored further in settings with a high child malnutrition and infection burden. This trial was registered at clinicaltrials.gov as NCT01088958. C1 [Suchdev, Parminder S.; Ruth, Laird J.; Flores-Ayala, Rafael] CDC, Nutr Branch, Atlanta, GA 30333 USA. [Patel, Minal K.; Juliao, Patricia C.; Quick, Rob] CDC, Waterborne Dis Prevent Branch, Atlanta, GA 30333 USA. [Suchdev, Parminder S.; Addo, O. Yaw; Martorell, Reynaldo; Grant, Frederick K. E.; Flores-Ayala, Rafael] Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. RP Suchdev, PS (reprint author), CDC, Nutr Branch, Atlanta, GA 30333 USA.; Suchdev, PS (reprint author), Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. EM psuchde@emory.edu OI Addo, O.Yaw/0000-0003-1269-759X FU CDC; Global Alliance for Improved Nutrition FX Supported by the CDC and the Global Alliance for Improved Nutrition. NR 38 TC 0 Z9 0 U1 4 U2 8 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD MAR PY 2016 VL 103 IS 3 BP 934 EP 941 DI 10.3945/ajcn.115.118000 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DF8ZO UT WOS:000371650200032 PM 26864367 ER PT J AU Lee, BY Bartsch, SM Wong, KF McKinnell, JA Slayton, RB Miller, LG Cao, CH Kim, DS Kallen, AJ Jernigan, JA Huang, SS AF Lee, Bruce Y. Bartsch, Sarah M. Wong, Kim F. McKinnell, James A. Slayton, Rachel B. Miller, Loren G. Cao, Chenghua Kim, Diane S. Kallen, Alexander J. Jernigan, John A. Huang, Susan S. TI The Potential Trajectory of Carbapenem-Resistant Enterobacteriaceae, an Emerging Threat to Health-Care Facilities, and the Impact of the Centers for Disease Control and Prevention Toolkit SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE carbapenem-resistant Enterobacteriaceae; control measures; coordinated responses; regional spread; surveillance ID TERM ACUTE-CARE; SURVEILLANCE RECTAL SWABS; KLEBSIELLA-PNEUMONIAE; UNITED-STATES; HOSPITAL DISCHARGE; RISK-FACTORS; EPIDEMIOLOGY; COLONIZATION; INFECTION; CARRIAGE AB Carbapenem-resistant Enterobacteriaceae (CRE), a group of pathogens resistant to most antibiotics and associated with high mortality, are a rising emerging public health threat. Current approaches to infection control and prevention have not been adequate to prevent spread. An important but unproven approach is to have hospitals in a region coordinate surveillance and infection control measures. Using our Regional Healthcare Ecosystem Analyst (RHEA) simulation model and detailed Orange County, California, patient-level data on adult inpatient hospital and nursing home admissions (2011-2012), we simulated the spread of CRE throughout Orange County health-care facilities under 3 scenarios: no specific control measures, facility-level infection control efforts (uncoordinated control measures), and a coordinated regional effort. Aggressive uncoordinated and coordinated approaches were highly similar, averting 2,976 and 2,789 CRE transmission events, respectively (72.2% and 77.0% of transmission events), by year 5. With moderate control measures, coordinated regional control resulted in 21.3% more averted cases (n = 408) than did uncoordinated control at year 5. Our model suggests that without increased infection control approaches, CRE would become endemic in nearly all Orange County health-care facilities within 10 years. While implementing the interventions in the Centers for Disease Control and Prevention's CRE toolkit would not completely stop the spread of CRE, it would cut its spread substantially, by half. C1 [Lee, Bruce Y.; Bartsch, Sarah M.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Publ Hlth Computat & Operat Res, Baltimore, MD USA. [Wong, Kim F.] Univ Pittsburgh, Ctr Simulat & Modeling, Pittsburgh, PA USA. [McKinnell, James A.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Infect Dis Clin Outcomes Res Unit, Torrance, CA 90509 USA. [McKinnell, James A.; Miller, Loren G.] Torrance Mem Med Ctr, Torrance, CA USA. [Slayton, Rachel B.; Kallen, Alexander J.; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Cao, Chenghua; Kim, Diane S.; Huang, Susan S.] UC Irvine Hlth, Sch Med, Div Infect Dis, Irvine, CA USA. [Cao, Chenghua; Kim, Diane S.; Huang, Susan S.] UC Irvine Hlth, Sch Med, Hlth Policy Res Inst, Irvine, CA USA. RP Lee, BY (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Publ Hlth Computat & Operat Res, 615 N Wolfe St, Baltimore, MD 21205 USA. EM blee106@jhu.edu FU Agency for Healthcare Research and Quality [R01HS023317]; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Office of Behavioral and Social Sciences Research of the National Institutes of Health; Global Obesity Prevention Center at Johns Hopkins [U54HD070725, 1 U01 HD086861]; University of Pittsburgh Center for Simulation and Modeling FX This work was supported by the Agency for Healthcare Research and Quality ( grant R01HS023317), the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the Office of Behavioral and Social Sciences Research of the National Institutes of Health, and the Global Obesity Prevention Center at Johns Hopkins ( grants U54HD070725 and 1 U01 HD086861). Personnel time was supported in part by an intergovernmental personnel act agreement with the Centers for Disease Control and Prevention. The research was also supported in part by the University of Pittsburgh Center for Simulation and Modeling through the supercomputing resources provided. NR 37 TC 5 Z9 5 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAR 1 PY 2016 VL 183 IS 5 BP 471 EP 479 DI 10.1093/aje/kwv299 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF9NU UT WOS:000371688800023 PM 26861238 ER PT J AU Rosinger, A Ogden, C AF Rosinger, Asher Ogden, Cynthia TI The role of obesity on water intake and hydration status in US adults: 2009-2012 SO AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY LA English DT Meeting Abstract CT 85th Annual Meeting of the American-Association-of-Physical-Anthropologists CY APR 13-16, 2016 CL Atlanta, GA SP Amer Assoc Phys Anthropologists C1 [Rosinger, Asher] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Rosinger, Asher; Ogden, Cynthia] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-9483 EI 1096-8644 J9 AM J PHYS ANTHROPOL JI Am. J. Phys. Anthropol. PD MAR PY 2016 VL 159 SU 62 BP 273 EP 273 PG 1 WC Anthropology; Evolutionary Biology SC Anthropology; Evolutionary Biology GA DF3OW UT WOS:000371255202153 ER PT J AU Schneider-Crease, IA Noh, JC Bergman, TJ Beehner, JC AF Schneider-Crease, India A. Noh, John C. Bergman, Thore J. Beehner, Jacinta C. TI Cease and De-Cyst: Female geladas are more likely than males to fight off cyst-inducing tapeworms SO AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY LA English DT Meeting Abstract CT 85th Annual Meeting of the American-Association-of-Physical-Anthropologists CY APR 13-16, 2016 CL Atlanta, GA SP Amer Assoc Phys Anthropologists C1 [Schneider-Crease, India A.] Duke Univ, Evolutionary Anthropol, Durham, NC 27706 USA. [Noh, John C.] Ctr Dis Control & Prevent CDC, Div Parasit Dis & Malaria, Atlanta, GA USA. [Bergman, Thore J.; Beehner, Jacinta C.] Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA. [Bergman, Thore J.] Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA. [Beehner, Jacinta C.] Univ Michigan, Dept Anthropol, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-9483 EI 1096-8644 J9 AM J PHYS ANTHROPOL JI Am. J. Phys. Anthropol. PD MAR PY 2016 VL 159 SU 62 BP 282 EP 282 PG 1 WC Anthropology; Evolutionary Biology SC Anthropology; Evolutionary Biology GA DF3OW UT WOS:000371255202191 ER PT J AU Biggs, HM Turabelidze, G Pratt, D Todd, SR Jacobs-Slifka, K Drexler, NA McCurdy, G Lloyd, J Evavold, CL Fitzpatrick, KA Priestley, RA Singleton, J Sun, D Tang, M Kato, C Kersh, GJ Anderson, A AF Biggs, Holly M. Turabelidze, George Pratt, Drew Todd, Suzanne R. Jacobs-Slifka, Kara Drexler, Naomi A. McCurdy, Gail Lloyd, Jennifer Evavold, Charles L. Fitzpatrick, Kelly A. Priestley, Rachael A. Singleton, Joseph Sun, David Minh Tang Kato, Cecilia Kersh, Gilbert J. Anderson, Alicia TI Coxiella burnetii Infection in a Community Operating a Large-Scale Cow and Goat Dairy, Missouri, 2013 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID Q-FEVER OUTBREAK; INJECTION-DRUG USERS; UNITED-STATES; ENDOCARDITIS; NETHERLANDS; PNEUMONIA; FEATURES; SHEEP; WIND; AREA AB Coxiella burnetii is a zoonotic pathogen that causes Q fever in humans and is transmitted primarily from infected goats, sheep, or cows. Q fever typically presents as an acute febrile illness; however, individuals with certain predisposing conditions, including cardiac valvulopathy, are at risk for chronic Q fever, a serious manifestation that may present as endocarditis. In response to a cluster of Q fever cases detected by public health surveillance, we evaluated C. burnetii infection in a community that operates a large-scale cow and goat dairy. A case was defined as an individual linked to the community with a C. burnetii phase II IgG titer >= 128. Of 135 participants, 47 (35%) cases were identified. Contact with or close proximity to cows, goats, and their excreta was associated with being a case (relative risk 2.7, 95% confidence interval 1.3-5.3). Cases were also identified among individuals without cow or goat contact and could be related to windborne spread or tracking of C. burnetii on fomites within the community. A history of injection drug use was reported by 26/130 (20%) participants; follow-up for the presence of valvulopathy and monitoring for development of chronic Q fever may be especially important among this population. C1 [Biggs, Holly M.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Rickettsial Zoonoses Branch, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Turabelidze, George; Pratt, Drew; McCurdy, Gail; Lloyd, Jennifer] Missouri Dept Hlth & Senior Serv, Jefferson City, MO USA. [Biggs, Holly M.; Todd, Suzanne R.; Jacobs-Slifka, Kara; Drexler, Naomi A.; Evavold, Charles L.; Fitzpatrick, Kelly A.; Priestley, Rachael A.; Singleton, Joseph; Sun, David; Minh Tang; Kato, Cecilia; Kersh, Gilbert J.; Anderson, Alicia] CDC, Atlanta, GA 30333 USA. RP Biggs, HM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Rickettsial Zoonoses Branch, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM hbiggs@cdc.gov; george.turabelidze@health.mo.gov; drew.pratt@health.mo.gov; fww8@cdc.gov; ipf8@cdc.gov; isj3@cdc.gov; mccurg@lpha.mopublic.org; jennifer.lloyd@health.mo.gov; xka7@cdc.gov; hwm8@cdc.gov; rnp9@cdc.gov; jys7@cdc.gov; wnk3@cdc.gov; mltang@cdc.gov; hex0@cdc.gov; hws7@cdc.gov; aha5@cdc.gov NR 36 TC 1 Z9 1 U1 0 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAR PY 2016 VL 94 IS 3 BP 525 EP 531 DI 10.4269/ajtmh.15-0726 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA DF5DS UT WOS:000371372600011 PM 26811433 ER PT J AU Vila, J Bowman, JD Richardson, L Kincl, L Conover, DL McLean, D Mann, S Vecchia, P van Tongeren, M Cardis, E AF Vila, Javier Bowman, Joseph D. Richardson, Lesley Kincl, Laurel Conover, Dave L. McLean, Dave Mann, Simon Vecchia, Paolo van Tongeren, Martie Cardis, Elisabeth CA INTEROCC Study Grp TI A Source-based Measurement Database for Occupational Exposure Assessment of Electromagnetic Fields in the INTEROCC Study: A Literature Review Approach SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE electromagnetic fields; EMF sources; exposure database; literature review ID FREQUENCY MAGNETIC-FIELDS; HAZARD SURVEILLANCE; DIELECTRIC HEATERS; OPERATOR EXPOSURE; INDUCTION HEATERS; PLASTIC SEALERS; ELECTRIC-FIELDS; BRAIN-TUMORS; RADIOFREQUENCY; WORKERS AB To date, occupational exposure assessment of electromagnetic fields (EMF) has relied on occupation-based measurements and exposure estimates. However, misclassification due to between-worker variability remains an unsolved challenge. A source-based approach, supported by detailed subject data on determinants of exposure, may allow for a more individualized exposure assessment. Detailed information on the use of occupational sources of exposure to EMF was collected as part of the INTERPHONE-INTEROCC study. To support a source-based exposure assessment effort within this study, this work aimed to construct a measurement database for the occupational sources of EMF exposure identified, assembling available measurements from the scientific literature. First, a comprehensive literature search was performed for published and unpublished documents containing exposure measurements for the EMF sources identified, a priori as well as from answers of study subjects. Then, the measurements identified were assessed for quality and relevance to the study objectives. Finally, the measurements selected and complementary information were compiled into an Occupational Exposure Measurement Database (OEMD). Currently, the OEMD contains 1624 sets of measurements (> 3000 entries) for 285 sources of EMF exposure, organized by frequency band (0 Hz to 300 GHz) and dosimetry type. Ninety-five documents were selected from the literature (almost 35% of them are unpublished technical reports), containing measurements which were considered informative and valid for our purpose. Measurement data and complementary information collected from these documents came from 16 different countries and cover the time period between 1974 and 2013. We have constructed a database with measurements and complementary information for the most common sources of exposure to EMF in the workplace, based on the responses to the INTERPHONE-INTEROCC study questionnaire. This database covers the entire EMF frequency range and represents the most comprehensive resource of information on occupational EMF exposure. It is available at . C1 [Vila, Javier; Cardis, Elisabeth] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain. [Vila, Javier; Cardis, Elisabeth] Univ Pompeu Fabra, Barcelona, Spain. [Vila, Javier; Cardis, Elisabeth] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain. [Bowman, Joseph D.; Conover, Dave L.] NIOSH, Cincinnati, OH 45226 USA. [Richardson, Lesley] Univ Montreal, Hosp Res Ctr CRCHUM, Montreal, PQ, Canada. [Kincl, Laurel] Oregon State Univ, Corvallis, OR 97331 USA. [McLean, Dave] Massey Univ, Wellington, New Zealand. [Mann, Simon] Publ Hlth England, Chilton, England. [Vecchia, Paolo] Natl Inst Hlth ISS, Rome, Italy. [van Tongeren, Martie] Inst Occupat Med, Edinburgh EH8 9SV, Midlothian, Scotland. RP Vila, J (reprint author), Ctr Res Environm Epidemiol CREAL, Barcelona, Spain.; Vila, J (reprint author), Univ Pompeu Fabra, Barcelona, Spain.; Vila, J (reprint author), CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain. EM jvila@creal.cat RI Cardis, Elisabeth/C-3904-2017 FU National Institutes for Health (NIH) [1R01CA124759-01]; AFSSET [ST-2005-004]; European Fifth Framework Program, 'Quality of Life and Management of Living Resources' [100 QLK4-CT-1999901563]; International Union against Cancer (UICC); Mobile Manufacturers' Forum; GSM Association; Australian National Health and Medical Research 5 Council (EME) [219129]; University of Sydney Medical Foundation Program; Cancer Council NSW; Cancer Council Victoria; Canadian Institutes of Health Research [MOP-42525]; Canada Research Chair programme; Guzzo-CRS Chair in Environment and Cancer; Fonds de la recherche en sante du Quebec; Ottawa, Canada, from the Canadian Institutes of Health Research (CIHR); Vancouver, Canada, from the Canadian Institutes of Health Research (CIHR); Canadian Wireless Telecommunications Association; NSERC/SSHRC/McLaughlin Chair in Population Health Risk Assessment at the University of Ottawa; l'Association pour la Recherche sur le Cancer (ARC) [N85142]; German Mobile Phone Research Program (Deutsches Mobilfunkforschungsprogramm) of the German Federal Ministry for the Environment, Nuclear 45 Safety, and Nature Protection; Ministry for the Environment and Traffic of the state of Baden Wurttemberg; Ministry for the Environment of the State of North Rhine-Westphalia; MAIFOR Program (Mainzer Forschungsforderungsprogramm) of the University of Mainz; Health Research Council; Hawkes Bay Medical Research Foundation; Wellington Medical Research Foundation; Waikato Medical Research Foundation; Cancer Society of New Zealand; Mobile Telecommunications, Health and Research (MTHR) program; Health and Safety Executive; Department of Health; UK Network Operator (O2); UK Network Operator (Orange); UK Network Operator (T-Mobile); UK Network Operator (Vodafone); UK Network Operator ('3'); Scottish Executive FX This work was funded by the National Institutes for Health (NIH) Grant No. 1R01CA124759-01. Coding of the French occupational data was in part funded by AFSSET (Convention No ST-2005-004). The INTERPHONE study was supported by funding from the European Fifth Framework Program, 'Quality of Life and Management of Living Resources' (contract 100 QLK4-CT-1999901563) and the International Union against Cancer (UICC). The UICC received funds for this purpose from the Mobile Manufacturers' Forum and GSM Association. Provision of funds to the INTERPHONE study investigators via the UICC was governed by agreements that guaranteed INTERPHONE's complete scientific independence (http://interphone.iarc.fr/interphone_funding.php). In Australia, funding was received from the Australian National Health and Medical Research 5 Council (EME Grant 219129) with funds originally derived from mobile phone service license fees; a University of Sydney Medical Foundation Program; the Cancer Council NSW; and The Cancer Council Victoria. In Montreal, Canada, funding was received from the Canadian Institutes of Health Research (project MOP-42525); the Canada Research Chair programme; the Guzzo-CRS Chair in Environment and Cancer; the Fonds de la recherche en sante du Quebec; in Ottawa and Vancouver, Canada, from the Canadian Institutes of Health Research (CIHR), the latter including partial support from the Canadian Wireless Telecommunications Association; the NSERC/SSHRC/McLaughlin Chair in Population Health Risk Assessment at the University of Ottawa. In France, funding was received by l'Association pour la Recherche sur le Cancer (ARC) (Contrat N85142) and three network operators (Orange, SFR, Bouygues Telecom). In Germany, funding was received from the German Mobile Phone Research Program (Deutsches Mobilfunkforschungsprogramm) of the German Federal Ministry for the Environment, Nuclear 45 Safety, and Nature Protection; the Ministry for the Environment and Traffic of the state of Baden Wurttemberg; the Ministry for the Environment of the State of North Rhine-Westphalia; the MAIFOR Program (Mainzer Forschungsforderungsprogramm) of the University of Mainz. In New Zealand, funding was provided by the Health Research Council, Hawkes Bay Medical Research Foundation, the Wellington Medical Research Foundation, the Waikato Medical Research Foundation and the Cancer Society of New Zealand. Additional funding for the UK study was received from the Mobile Telecommunications, Health and Research (MTHR) program, funding from the Health and Safety Executive, the Department of Health, the UK Network Operators (O2, Orange, T-Mobile, Vodafone, '3') and the Scottish Executive. All industry funding was governed by contracts guaranteeing the complete scientific independence of the investigators. NR 106 TC 1 Z9 1 U1 6 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 EI 1475-3162 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD MAR PY 2016 VL 60 IS 2 BP 184 EP 204 DI 10.1093/annhyg/mev076 PG 21 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA DF9OM UT WOS:000371690700005 PM 26493616 ER PT J AU Qi, CL Echt, A Gressel, MG AF Qi, Chaolong Echt, Alan Gressel, Michael G. TI On the Characterization of the Generation Rate and Size-Dependent Crystalline Silica Content of the Dust from Cutting Fiber Cement Siding SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE crystalline silica; dust generation; fiber cement; MOUDI ID EXPOSURE AB A laboratory testing system was developed to systematically characterize the dust generation rate and size-dependent crystalline silica content when cutting or shaping silica containing materials. The tests of cutting fiber cement siding in this system verify that it provides high test repeatability, making it suitable for the targeted characterizations. The mass-based size distributions obtained from a gravimetric-based instrument and a direct reading instrument both show bimodal lognormal distributions with a larger mode similar to 13 A mu m and another mode < 5 A mu m for the dusts from cutting four different brands of fiber cement siding. The generation rates of respirable dust obtained from the two instruments are comparable, and the results from each instrument are similar for the four brands. The silica content in the airborne dusts, however, strongly depends on the amount of silica used in the respective product. It is also observed that the silica content in the airborne dust from cutting the four brands of fiber cement siding showed the same trend of an increase with the aerodynamic diameter of the dust, approaching the silica content levels found in their respective bulk samples. Combining the results for both the dust size distribution and size-dependent silica content, it is found that most of the respirable crystalline silica (RCS) resides in the dust similar to 2.5 A mu m in aerodynamic diameter. These results would help guide the development of specific engineering control measures targeted at lowering workers' exposure to RCS while cutting fiber cement siding. With the high repeatability using the laboratory testing system, the dust generation rate could then be characterized under different operating conditions, and with the deployment of various engineering control measures. This would greatly facilitate the systematic evaluation of the control effectiveness and the selection of the optimal control solutions for field trials. C1 [Qi, Chaolong; Echt, Alan; Gressel, Michael G.] Natl Inst Occupat Safety & Hlth, Ctr Dis Control & Prevent, 1090 Tusculum Ave,MS R5, Cincinnati, OH 45226 USA. RP Qi, CL (reprint author), Natl Inst Occupat Safety & Hlth, Ctr Dis Control & Prevent, 1090 Tusculum Ave,MS R5, Cincinnati, OH 45226 USA. EM hif1@cdc.gov FU National Institute for Occupational Safety and Health project [Partnering to Control Dust from Fiber-Cement Siding (CAN)] [0927ZJSB] FX National Institute for Occupational Safety and Health project [Partnering to Control Dust from Fiber-Cement Siding (CAN# 0927ZJSB)]. NR 23 TC 2 Z9 2 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 EI 1475-3162 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD MAR PY 2016 VL 60 IS 2 BP 220 EP 230 DI 10.1093/annhyg/mev066 PG 11 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA DF9OM UT WOS:000371690700007 PM 26391971 ER PT J AU Schauer, GL Wheaton, AG Malarcher, AM Croft, JB AF Schauer, Gillian L. Wheaton, Anne G. Malarcher, Ann M. Croft, Janet B. TI Health-care Provider Screening and Advice for Smoking Cessation Among Smokers With and Without COPD 2009-2010 National Adult Tobacco Survey SO CHEST LA English DT Article DE COPD; epidemiology; smoking; tobacco ID OBSTRUCTIVE PULMONARY-DISEASE; UNITED-STATES; LUNG-FUNCTION; PATIENT; INTERVENTION; PREVALENCE; MORTALITY; CAMPAIGN; HMOS AB BACKGROUND: Cigarette smoking is the predominant cause of COPD. Quitting can prevent development of and complications from COPD. The gold standard in clinician delivery of smoking cessation treatments is the 5As (ask, advise, assess, assist, arrange). This study assessed prevalence and correlates of self-reported receipt of the 5A strategies among adult smokers with and without COPD. METHODS: Data were analyzed from 20,021 adult past-year cigarette smokers in the 2009-2010 National Adult Tobacco Survey, a nationally representative telephone survey of US adults 18 years of age and older. Past-year receipt of the 5As was self-reported by participants who saw a clinician in the past year. Logistic regression was used to estimate the likelihood of receipt of each of the 5As by COPD status, adjusted for sociodemographic and smoking characteristics. RESULTS: Among smokers, those with COPD were more likely than those without COPD to report being asked about tobacco use (95.4% vs 85.8%), advised to quit (87.5% vs 59.4%), assessed for readiness to quit (63.8% vs 37.9%), offered any assistance to quit (58.6% vs 34.0%), and offered follow-up (14.9% vs 5.2%). In adjusted logistic regression models, those with COPD were significantly more likely than those without COPD to receive each of the 5As. CONCLUSIONS: Health professionals should continue to prioritize tobacco cessation counseling and treatment to smokers with COPD. Increased system-level changes and insurance coverage for cessation treatments could be used to improve the delivery of brief tobacco cessation counseling to all smokers, regardless of COPD status. C1 [Schauer, Gillian L.] Ctr Dis Control & Prevent, Carter Consulting Inc, Off Smoking & Hlth, 4770 Buford Hwy NE,Mailstop F 79, Atlanta, GA 30341 USA. [Wheaton, Anne G.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30341 USA. [Malarcher, Ann M.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Schauer, GL (reprint author), Ctr Dis Control & Prevent, Carter Consulting Inc, Off Smoking & Hlth, 4770 Buford Hwy NE,Mailstop F 79, Atlanta, GA 30341 USA. EM gschauer@cdc.gov NR 28 TC 2 Z9 2 U1 3 U2 7 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD MAR PY 2016 VL 149 IS 3 BP 676 EP 684 DI 10.1378/chest.14-2965 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DF6OD UT WOS:000371474200021 PM 26291388 ER PT J AU Hutchinson, AB Farnham, PG Sansom, SL Yaylali, E Mermin, JH AF Hutchinson, Angela B. Farnham, Paul G. Sansom, Stephanie L. Yaylali, Emine Mermin, Jonathan H. TI Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE injection drug users; HIV testing; test frequency; men who have sex with men; cost-effectiveness ID ANTIRETROVIRAL THERAPY; HEALTH-CARE; DRUG-USERS; INFECTION; DIAGNOSIS; SEX; MEN; TRANSMISSION; CITIES; SEROCONVERSION AB Purpose: Data showing a high incidence of HIV infection among men who have sex with men (MSM) who had annual testing suggest that more frequent HIV testing may be warranted. Testing technology is also a consideration given the availability of sensitive testing modalities and the increased use of less-sensitive rapid, point-of-care antibody tests. We assessed the cost-effectiveness of HIV testing of MSM and injection drug users (IDUs) at 3- and 6-month intervals using fourth-generation and rapid tests. Methods: We used a published mathematical model of HIV transmission to evaluate testing intervals for each population using cohorts of 10,000 MSM and IDU. We incorporated HIV transmissions averted due to serostatus awareness and viral suppression. We included costs for HIV testing and treatment initiation, and also treatment costs saved from averted transmissions. Results: For MSM, HIV testing was cost saving or cost effective over a 1-year period for both 6-month compared with annual testing and quarterly compared with 6-month testing using either test. Testing IDU every 6 months compared with annually was moderately cost effective over a 1-year period with a fourth-generation test, while testing with rapid, point-of-care tests or quarterly was not cost effective. MSM results remained robust in sensitivity analysis, whereas IDU results were sensitive to changes in HIV incidence and continuum-of-care parameters. Threshold analyses on costs suggested that additional implementation costs could be incurred for more frequent testing for MSM while remaining cost effective. Conclusions: HIV testing of MSM as frequently as quarterly is cost effective compared with annual testing, but testing IDU more frequently than annually is generally not cost effective. C1 [Hutchinson, Angela B.; Farnham, Paul G.; Sansom, Stephanie L.; Yaylali, Emine; Mermin, Jonathan H.] CDC, Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent NCH, Div HIV AIDS Prevent, Atlanta, GA 30306 USA. RP Hutchinson, AB (reprint author), CDC, Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent NCH, Div HIV AIDS Prevent, Atlanta, GA 30306 USA. EM ash2@cdc.gov NR 50 TC 3 Z9 4 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAR 1 PY 2016 VL 71 IS 3 BP 323 EP 330 DI 10.1097/QAI.0000000000000838 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DF7FB UT WOS:000371522100012 PM 26361172 ER PT J AU Bock, NN Emerson, RC Reed, JB Nkambule, R Donnell, DJ Bicego, GT Okello, V Philip, NM Ehrenkranz, PD Duong, YT Moore, JS Justman, JE AF Bock, Naomi N. Emerson, Ruth C. Reed, Jason B. Nkambule, Rejoice Donnell, Deborah J. Bicego, George T. Okello, Velephi Philip, Neena M. Ehrenkranz, Peter D. Duong, Yen T. Moore, Janet S. Justman, Jessica E. TI Changing Antiretroviral Eligibility Criteria: Impact on the Number and Proportion of Adults Requiring Treatment in Swaziland SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE CD4(+) count; HIV treatment eligibility; Swaziland; viral load; HIV; antiretroviral treatment ID HIV-1 INFECTION; RURAL UGANDA; THERAPY; PREVENTION; AFRICA; CARE AB Objective: Early initiation of antiretroviral treatment (ART) at CD4(+) cell count >= 500 cells per microliter reduces morbidity and mortality in HIV-infected adults. We determined the proportion of HIV-infected people with high viral load (VL) for whom transmission prevention would be an additional benefit of early treatment. Design: A randomly selected subset of a nationally representative sample of HIV-infected adults in Swaziland in 2012. Methods: Eight to 12 months after a national survey to determine adult HIV prevalence, 1067 of 5802 individuals identified as HIV-infected were asked to participate in a follow-up cross-sectional assessment. CD4(+) cell enumeration, VL measurements, and ART status were obtained to estimate the proportion of currently untreated adults and of the entire HIV-infected population with high VL (>= 1000 copies/mL) whose treatment under a test-and-treat or VL threshold eligibility strategy would reduce HIV transmission. Results: Of the 927 (87% of 1067) participants enrolled, 466 (50%) reported no ART use. Among them, 424 (91%) had VL >= 1000 copies per milliliter; of these, 148 (35%) were eligible for ART at the then existing CD4(+) count threshold of <350 cells per microliter; an additional 107 (25%) were eligible with expanded CD4(+) criterion of <500 cells per microliter; and 169 (40%) remained ART ineligible. Thus, 36% of the 466 currently untreated and 18% of the total 927 had high VL yet remained ART ineligible under a CD4(+) criterion of Conclusions: A test-and-treat or VL threshold for treatment eligibility is necessary to maximize the HIV transmission prevention benefits of ART. C1 [Bock, Naomi N.; Reed, Jason B.; Bicego, George T.; Duong, Yen T.; Moore, Janet S.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div HIV AIDS, Atlanta, GA 30033 USA. [Emerson, Ruth C.; Donnell, Deborah J.] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, 1124 Columbia St, Seattle, WA 98104 USA. [Emerson, Ruth C.; Donnell, Deborah J.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Inst, 1124 Columbia St, Seattle, WA 98104 USA. [Nkambule, Rejoice; Okello, Velephi] Minist Hlth Swaziland, Mbabane, Swaziland. [Justman, Jessica E.] Columbia Univ, Mailman Sch Publ Hlth, ICAP Columbia, New York, NY USA. [Ehrenkranz, Peter D.] Ctr Dis Control & Prevent, Mbabane, Swaziland. RP Bock, NN (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, HIV Prevent Branch, 1600 Clifton Rd,Mail Stop E-04, Atlanta, GA 30033 USA. EM neb2@cdc.gov OI Donnell, Deborah/0000-0002-0587-7480 FU U.S. Centers for Disease Control and Prevention [5U2GPS002005] FX Supported by Cooperative Agreement #5U2GPS002005 from the U.S. Centers for Disease Control and Prevention. NR 28 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAR 1 PY 2016 VL 71 IS 3 BP 338 EP 344 DI 10.1097/QAI.0000000000000846 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DF7FB UT WOS:000371522100014 PM 26361174 ER PT J AU Tohme, RA Andre-Alboth, J Tejada-Strop, A Shi, R Boncy, J Francois, J Domercant, JW Griswold, M Hyppolite, E Adrien, P Kamili, S AF Tohme, Rania A. Andre-Alboth, Jocelyne Tejada-Strop, Alexandra Shi, Ran Boncy, Jacques Francois, Jeannot Domercant, Jean Wysler Griswold, Mark Hyppolite, Erlantz Adrien, Paul Kamili, Saleem TI Hepatitis B virus infection among pregnant women in Haiti: A cross-sectional serosurvey SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Hepatitis B; Pregnant women; Haiti; Hepatitis B vaccines; Serosurvey ID BIRTH DOSE COVERAGE; PERINATAL TRANSMISSION; COST-EFFECTIVENESS; HIV PREVALENCE; VACCINATION; INFANTS; COHORT; IMMUNIZATION; MORTALITY; COUNTRIES AB Background: Hepatitis B vaccine administered shortly after birth is highly effective in preventing mother to child transmission (MTCT) of infection. While hepatitis B vaccine was introduced in Haiti as part of a combined pentavalent vaccine in 2012, a birth dose is not yet included in the immunization schedule. Objectives: Determine the seroprevalence of hepatitis B virus (HBV) infection among pregnant women to evaluate the risk of MTCT. Study design: We selected 1364 residual serum specimens collected during a 2012 human immunodeficiency virus (HIV) sentinel serosurvey among pregnant women attending antenatal care clinics. Haiti was stratified into two regions: West, which includes metropolitan Port-au-Prince, and non-West, which includes all other departments. We evaluated the association between demographic and socioeconomic characteristics and HIV infection with HBV infection. Results: Of 1364 selected specimens, 1307 (96%) were available for testing. A total of 422 specimens (32.7%) tested positive for total anti-HBc (38.2% in West vs. 27% in non-West, p < 0.001), and 33 specimens (2.5%) were HBsAg positive (2.1% in West vs. 3% in non-West, p=0.4). Of HBsAg positive specimens, 79% had detectable HBV DNA. Women aged 30 and older had more than double the odds of positive total anti-HBc than women aged 15-19 years (p < 0.001). Women with secondary (adjusted odds ratio (aOR) = 0.54; 95% CI: 0.36-0.81) and post-secondary education (aOR = 0.40, 95% CI: 0.19-0.79) had lower odds of total anti-HBc positivity compared with women with no education. HIV-status was not associated with HBV infection. Conclusions: Haiti has an intermediate endemicity of chronic HBV infection with high prevalence of positive HBV DNA among chronically infected women. Introduction of a universal birth dose of hepatitis B vaccine might help prevent perinatal HBV transmission. Published by Elsevier B.V. C1 [Tohme, Rania A.; Tejada-Strop, Alexandra; Kamili, Saleem] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Andre-Alboth, Jocelyne; Boncy, Jacques] Minist Publ Hlth & Populat, Natl Publ Hlth Lab, Port Au Prince, Haiti. [Shi, Ran] Emory Univ, Atlanta, GA 30322 USA. [Francois, Jeannot] Minist Publ Hlth & Populat, Expanded Program Immunizat, Port Au Prince, Haiti. [Domercant, Jean Wysler] Ctr Dis Control & Prevent, Haiti Country Off, Port Au Prince, Haiti. [Griswold, Mark] Natl Alliance State & Terr AIDS Directors, Global Program, Washington, DC USA. [Hyppolite, Erlantz] Natl Alliance State & Terr AIDS Directors, Port Au Prince, Haiti. [Adrien, Paul] Minist Publ Hlth & Populat, Directorate Epidemiol Lab & Res, Port Au Prince, Haiti. RP Tohme, RA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E-98, Atlanta, GA 30329 USA. EM rtohme@cdc.gov FU Centers for Disease Control and Prevention FX Testing of the specimens was supported by the Centers for Disease Control and Prevention. NR 37 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD MAR PY 2016 VL 76 BP 66 EP 71 DI 10.1016/j.jcv.2016.01.012 PG 6 WC Virology SC Virology GA DG0WF UT WOS:000371785900014 PM 26851543 ER PT J AU Thompson, MG Clippard, J Petrie, JG Jackson, ML McLean, HQ Gaglani, M Reis, EC Flannery, B Monto, AS Jackson, L Belongia, EA Murthy, K Zimmerman, RK Thaker, S Fry, AM AF Thompson, Mark G. Clippard, Jessie Petrie, Joshua G. Jackson, Michael L. McLean, Huong Q. Gaglani, Manjusha Reis, Evelyn C. Flannery, Brendan Monto, Arnold S. Jackson, Lisa Belongia, Edward A. Murthy, Kempapura Zimmerman, Richard K. Thaker, Swathi Fry, Alicia M. TI Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013 The Importance of Two Priming Doses SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article ID IMMUNIZATION PRACTICES ACIP; LABORATORY-CONFIRMED INFLUENZA; 6-TO 23-MONTH-OLD CHILDREN; TEST-NEGATIVE DESIGN; THAN 5 YEARS; UNITED-STATES; ADVISORY-COMMITTEE; YOUNG-CHILDREN; SEASONAL INFLUENZA; 2009-JANUARY 2010 AB Background: Few studies have examined the effectiveness of full versus partial vaccination with inactivated trivalent influenza vaccines (IIV3) as defined by the US CDC Advisory Committee on Immunization Practices. Methods: Respiratory swabs were collected from outpatients aged 6 months to 8 years with acute cough for <= 7 days in clinics in 5 states during the 2011-2012 and 2012-2013 influenza seasons. Influenza was confirmed by real-time reverse transcription polymerase chain reaction assay. Receipt of current season IIV3 and up to 4 prior vaccinations was documented from medical records and immunization registries. Using a test-negative design, vaccine effectiveness (VE) was estimated adjusting for age, race/ethnicity, medical conditions, study site and month of enrollment. Results: We did not observe higher VE for children fully versus partially vaccinated with IIV3, as defined by US Advisory Committee on Immunization Practice, although our sample of partially vaccinated children was relatively small. However, among children aged 2-8 years in both seasons and against A(H3N2) and B influenza illness separately, VE point estimates were consistently higher for children who had received 2 doses in the same prior season compared with those without (VE range of 58%-80% vs. 33%-44%, respectively). Across seasons, the odds of A(H3N2) illness despite IIV3 vaccination were 2.4-fold (95% confidence interval: 1.4-4.3) higher among children who had not received 2 doses in the same prior season. We also noted residual protection among unvaccinated children who were vaccinated the previous season (VE range = 36%-40% across outcomes). Conclusion: Vaccination with IIV3 may provide preventive benefit in subsequent seasons, including possible residual protection if vaccination is missed. Two vaccine doses in the same season may be more effective than alternative priming strategies. C1 [Thompson, Mark G.; Clippard, Jessie; Flannery, Brendan; Thaker, Swathi; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA. [Petrie, Joshua G.; Monto, Arnold S.] Univ Michigan, Ann Arbor, MI 48109 USA. [Jackson, Michael L.; Jackson, Lisa] Grp Hlth Cooperat Puget Sound, Seattle, WA USA. [McLean, Huong Q.; Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Gaglani, Manjusha; Murthy, Kempapura] Baylor Scott & White Hlth, Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA. [Zimmerman, Richard K.] Univ Pittsburgh, Pittsburgh, PA USA. RP Thompson, MG (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA. EM isq8@cdc.gov OI Zimmerman, Richard/0000-0001-5941-6092 FU Centers for Disease Control and Prevention through University of Michigan [U01 IP000474]; Group Health Research Institute [U01 IP000466]; Marshfield Clinic Research Foundation [U01 IP000471]; University of Pittsburgh [U01 IP000467]; Baylor Scott and White Health [U01 IP000473]; National Institutes of Health [UL1 RR024153, UL1TR000005] FX This work was supported by the Centers for Disease Control and Prevention through cooperative agreements with the University of Michigan (U01 IP000474), Group Health Research Institute (U01 IP000466), Marshfield Clinic Research Foundation (U01 IP000471), University of Pittsburgh (U01 IP000467) and Baylor Scott and White Health (U01 IP000473). At the University of Pittsburgh, the project was also supported by the National Institutes of Health through Grant Numbers UL1 RR024153 and UL1TR000005. NR 53 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAR PY 2016 VL 35 IS 3 BP 299 EP 308 DI 10.1097/INF.0000000000001006 PG 10 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA DF6WY UT WOS:000371499900014 PM 26658375 ER PT J AU Hillis, S Mercy, J Amobi, A Kress, H AF Hillis, Susan Mercy, James Amobi, Adaugo Kress, Howard TI Global Prevalence of Past-year Violence Against Children: A Systematic Review and Minimum Estimates SO PEDIATRICS LA English DT Review ID ADVERSE CHILDHOOD EXPERIENCES; SECONDARY-SCHOOL STUDENTS; INTIMATE PARTNER VIOLENCE; SEXUAL VIOLENCE; BULLYING VICTIMIZATION; CORPORAL PUNISHMENT; INCOME COUNTRIES; CONTROLLED-TRIAL; NATIONAL SAMPLE; UNITED-STATES AB CONTEXT: Evidence confirms associations between childhood violence and major causes of mortality in adulthood. A synthesis of data on past-year prevalence of violence against children will help advance the United Nations' call to end all violence against children. OBJECTIVES: Investigators systematically reviewed population-based surveys on the prevalence of past-year violence against children and synthesized the best available evidence to generate minimum regional and global estimates. DATA SOURCES: We searched Medline, PubMed, Global Health, NBASE, CINAHL, and the World Wide Web for reports of representative surveys estimating prevalences of violence against children. STUDY SELECTION: Two investigators independently assessed surveys against inclusion criteria and rated those included on indicators of quality. DATA EXTRACTION: Investigators extracted data on past-year prevalences of violent victimization by country, age group, and type (physical, sexual, emotional, or multiple types). We used a triangulation approach which synthesized data to generate minimum regional prevalences, derived from population-weighted averages of the country-specific prevalences. RESULTS: Thirty-eight reports provided quality data for 96 countries on past-year prevalences of violence against children. Base case estimates showed a minimum of 50% or more of children in Asia, Africa, and Northern America experienced past-year violence, and that globally over half of all children-1 billion children, ages 2-17 years-experienced such violence. LIMITATIONS: Due to variations in timing and types of violence reported, triangulation could only be used to generate minimum prevalence estimates. CONCLUSIONS: Expanded population-based surveillance of violence against children is essential to target prevention and drive the urgent investment in action endorsed in the United Nations 2030 Sustainable Development Agenda. C1 [Hillis, Susan] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30333 USA. [Mercy, James; Kress, Howard] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Amobi, Adaugo] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA. RP Hillis, S (reprint author), Ctr Dis Control & Prevent, US Publ Hlth Serv, Natl Ctr Injury Prevent & Control, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM shillis@cdc.gov RI Figueroa Ossa, Ulda Omar/N-5821-2016 NR 92 TC 10 Z9 11 U1 6 U2 14 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2016 VL 137 IS 3 AR e20154079 DI 10.1542/peds.2015-4079 PG 13 WC Pediatrics SC Pediatrics GA DF5MK UT WOS:000371395800062 PM 26810785 ER PT J AU Kempe, A O'Leary, ST Shoup, JA Stokley, S Lockhart, S Furniss, A Dickinson, LM Barnard, J Daley, MF AF Kempe, Allison O'Leary, Sean T. Shoup, Jo Ann Stokley, Shannon Lockhart, Steven Furniss, Anna Dickinson, L. Miriam Barnard, Juliana Daley, Matthew F. TI Parental Choice of Recall Method for HPV Vaccination: A Pragmatic Trial SO PEDIATRICS LA English DT Article ID HUMAN-PAPILLOMAVIRUS VACCINATION; IMMUNIZATION PRACTICES ACIP; CLUSTER RANDOMIZED-TRIALS; PREVENTIVE CARE VISITS; CENTRALIZED REMINDER/RECALL; CONSTRAINED RANDOMIZATION; ADOLESCENT IMMUNIZATIONS; ADVISORY-COMMITTEE; UNITED-STATES; HEALTH AB OBJECTIVES: Completion rates for the human papillomavirus vaccine (HPV) series among adolescents remain low. Effectiveness of recall with parents choosing the method (preference-based recall) for increasing HPV series completion is unstudied. Within a cluster-randomized trial, we examined effectiveness of preference-based recall compared with usual care for increasing series completion and the association of recall choices with completion. METHODS: All Kaiser Permanente Colorado pediatric practices (n = 7) were randomized to intervention (n = 4) or control (n = 3) by using covariate-constrained randomization. From January to June 2013, parents at intervention practices whose adolescents received HPV 1 were asked the recall method they preferred for subsequent doses and if they also wanted their child reminded. Completion rates were assessed 1 year after HPV 1. RESULTS: At intervention practices, 374 (43%) of 867 patients were enrolled; 39% preferred text, 18% e-mail, 9% auto-dialer, and 34% 2-methods; 19% chose to have adolescent also recalled. Intervention adolescents were more likely to complete (63% vs 38%) than were controls (adjusted risk ratio 1.47 [1.38-1.57]) and less likely to be late in completing the series (45% vs 57%, P=.02). Rates of completion were similar between different recall methods, but significantly higher for those preferring e-mail and phone compared withother methods (90% vs 60%. P=.008). Completion rates were similar for adolescents who also received recalls (62%) versus those who did not (63%). CONCLUSIONS: Preference-based recall was effective in increasing HPV series completion rates, with point estimates substantially higher than for most published studies of reminder/recall. C1 [Kempe, Allison; O'Leary, Sean T.; Lockhart, Steven; Furniss, Anna; Dickinson, L. Miriam; Barnard, Juliana] Univ Colorado, ACCORDS, Anschutz Med Campus,13199 Montview Blvd,Suite 300, Aurora, CO 80045 USA. [Kempe, Allison; O'Leary, Sean T.; Lockhart, Steven; Furniss, Anna; Dickinson, L. Miriam; Barnard, Juliana] Childrens Hosp Colorado, Aurora, CO USA. [Kempe, Allison; O'Leary, Sean T.; Daley, Matthew F.] Univ Colorado, Dept Pediat, Aurora, CO 80045 USA. [Dickinson, L. Miriam] Univ Colorado, Dept Family Med, Aurora, CO 80045 USA. [Shoup, Jo Ann; Daley, Matthew F.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Stokley, Shannon] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Kempe, A (reprint author), Univ Colorado, ACCORDS, Anschutz Med Campus,13199 Montview Blvd,Suite 300, Aurora, CO 80045 USA. EM allison.kempe@childrenscolorado.org FU Centers for Disease Control and Prevention [5U01IP000310-02] FX This investigation was supported by the Centers for Disease Control and Prevention (grant 5U01IP000310-02). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 62 TC 0 Z9 0 U1 1 U2 6 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2016 VL 137 IS 3 AR e20152857 DI 10.1542/peds.2015-2857 PG 10 WC Pediatrics SC Pediatrics GA DF5MK UT WOS:000371395800034 PM 26921286 ER PT J AU Marin, M Marti, M Kambhampati, A Jeram, SM Seward, JF AF Marin, Mona Marti, Melanie Kambhampati, Anita Jeram, Stanley M. Seward, Jane F. TI Global Varicella Vaccine Effectiveness: A Meta-analysis SO PEDIATRICS LA English DT Review ID DAY-CARE-CENTERS; HERPES-ZOSTER; HEALTHY-CHILDREN; UNITED-STATES; ELEMENTARY-SCHOOL; CLINICAL CHARACTERISTICS; OUTBREAK; IMMUNIZATION; IMPACT; HOSPITALIZATIONS AB CONTEXT: Several varicella vaccines are available worldwide. Countries with a varicella vaccination program use 1-or 2-dose schedules. OBJECTIVE: We examined postlicensure estimates of varicella vaccine effectiveness (VE) among healthy children. DATA SOURCES: Systematic review and descriptive and meta-analysis of Medline, Embase, Cochrane libraries, and CINAHL databases for reports published during 1995-2014. STUDY SELECTION: Publications that reported original data on dose-specific varicella VE among immunocompetent children. DATA EXTRACTION: We used random effects meta-analysis models to obtain pooled one dose VE estimates by disease severity (all varicella and moderate/severe varicella). Within each severity category, we assessed pooled VE by vaccine and by study design. We used descriptive statistics to summarize 1-dose VE against severe disease. For 2-dose VE, we calculated pooled estimates against all varicella and by study design. RESULTS: The pooled 1-dose VE was 81% (95% confidence interval [CI]: 78%-84%) against all varicella and 98% (95% CI: 97%-99%) against moderate/severe varicella with no significant association between VE and vaccine type or study design (P>.1). For 1 dose, median VE for prevention of severe disease was 100% (mean = 99.4%). The pooled 2-dose VE against all varicella was 92% (95% CI: 88%-95%), with similar estimates by study design. LIMITATIONS: VE was assessed primarily during outbreak investigations and using clinically diagnosed varicella. CONCLUSIONS: One dose of varicella vaccine was moderately effective in preventing all varicella and highly effective in preventing moderate/severe varicella, with no differences by vaccine. The second dose adds improved protection against all varicella. C1 [Marin, Mona; Kambhampati, Anita; Seward, Jane F.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Marti, Melanie; Jeram, Stanley M.] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. RP Marin, M (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,NE MS A-47, Atlanta, GA 30333 USA. EM mmarin@cdc.gov FU World Health Organization [001] NR 62 TC 4 Z9 4 U1 3 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2016 VL 137 IS 3 AR e20153741 DI 10.1542/peds.2015-3741 PG 10 WC Pediatrics SC Pediatrics GA DF5MK UT WOS:000371395800058 PM 26908671 ER PT J AU Markowitz, LE Liu, G Hariri, S Steinau, M Dunne, EF Unger, ER AF Markowitz, Lauri E. Liu, Gui Hariri, Susan Steinau, Martin Dunne, Eileen F. Unger, Elizabeth R. TI Prevalence of HPV After Introduction of the Vaccination Program in the United States SO PEDIATRICS LA English DT Article ID HUMAN-PAPILLOMAVIRUS VACCINATION; AGED 16-26 YEARS; YOUNG-WOMEN; PARTICLE VACCINE; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; NATIONAL-HEALTH; GENITAL WARTS; DOUBLE-BLIND; INFECTION AB BACKGROUND: Since mid-2006, human papillomavirus (HPV) vaccination has been recommended for females aged 11 to 12 years and through 26 years if not previously vaccinated. METHODS: HPV DNA prevalence was analyzed in cervicovaginal specimens from females aged 14 to 34 years in NHANES in the prevaccine era (2003-2006) and 4 years of the vaccine era (2009-2012) according to age group. Prevalence of quadrivalent HPV vaccine (4vHPV) types (HPV-6, -11, -16, and -18) and other HPV type categories were compared between eras. Prevalence among sexually active females aged 14 to 24 years was also analyzed according to vaccination history. RESULTS: Between the prevacccine and vaccine eras, 4vHPV type prevalence declined from 11.5% to 4.3% (adjusted prevalence ratio [aPR]: 0.36 [95% confidence interval (CI): 0.21-0.61]) among females aged 14 to 19 years and from 18.5% to 12.1% (aPR: 0.66 [95% CI: 0.47-0.93]) among females aged 20 to 24 years. There was no decrease in 4vHPV type prevalence in older age groups. Within the vaccine era, among sexually active females aged 14 to 24 years, 4vHPV type prevalence was lower in vaccinated (>= 1 dose) compared with unvaccinated females: 2.1% vs 16.9% (aPR: 0.11 [95% CI: 0.05-0.24]). There were no statistically significant changes in other HPV type categories that indicate cross-protection. CONCLUSIONS: Within 6 years of vaccine introduction, there was a 64% decrease in 4vHPV type prevalence among females aged 14 to 19 years and a 34% decrease among those aged 20 to 24 years. This finding extends previous observations of population impact in the United States and demonstrates the first national evidence of impact among females in their 20s. C1 [Markowitz, Lauri E.; Liu, Gui; Hariri, Susan; Dunne, Eileen F.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Steinau, Martin; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. RP Markowitz, LE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30329 USA. EM lem2@cdc.gov FU Centers for Disease Control and Prevention FX Supported by the Centers for Disease Control and Prevention. NR 32 TC 24 Z9 24 U1 1 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2016 VL 137 IS 3 AR e20151968 DI 10.1542/peds.2015-1968 PG 9 WC Pediatrics SC Pediatrics GA DF5MK UT WOS:000371395800016 PM 26908697 ER PT J AU McCarthy, NL Gee, J Sukumaran, L Weintraub, E Duffy, J Kharbanda, EO Baxter, R Irving, S King, J Daley, MF Hechter, R McNeil, MM AF McCarthy, Natalie L. Gee, Julianne Sukumaran, Lakshmi Weintraub, Eric Duffy, Jonathan Kharbanda, Elyse O. Baxter, Roger Irving, Stephanie King, Jennifer Daley, Matthew F. Hechter, Rulin McNeil, Michael M. TI Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adults SO PEDIATRICS LA English DT Article ID IMMUNIZATION PRACTICES ACIP; EVENT REPORTING SYSTEM; INFANT-DEATH-SYNDROME; ADVISORY-COMMITTEE; INFLUENZA VACCINATION; SEASONAL INFLUENZA; SAFETY DATALINK; UNITED-STATES; SUDDEN-DEATH; VACCINES AB OBJECTIVE: This study evaluates the potential association of vaccination and death in the Vaccine Safety Datalink (VSD). METHODS: The study cohort included individuals ages 9 to 26 years with deaths between January 1, 2005, and December 31, 2011. We implemented a case-centered method to estimate a relative risk (RR) for death in days 0 to 30 after vaccination. Deaths due to external causes (accidents, homicides, and suicides) were excluded from the primary analysis. In a secondary analysis, we included all deaths regardless of cause. A team of physicians reviewed available medical records and coroner's reports to confirm cause of death and assess the causal relationship between death and vaccination. RESULTS: Of the 1100 deaths identified during the study period, 76 (7%) occurred 0 to 30 days after vaccination. The relative risks for deaths after any vaccination and influenza vaccination were significantly lower for deaths due to nonexternal causes (RR 0.57, 95% confidence interval [CI] 0.38-0.83, and RR 0.44, 95% CI 0.24-0.80, respectively) and deaths due to all causes (RR 0.72, 95% CI 0.56-0.91, and RR 0.44, 95% CI 0.28-0.65). No other individual vaccines were significantly associated with death. Among deaths reviewed, 1 cause of death was unknown, 25 deaths were due to nonexternal causes, and 34 deaths were due to external causes. The causality assessment found no evidence of a causal association between vaccination and death. CONCLUSIONS: Risk of death was not increased during the 30 days after vaccination, and no deaths were found to be causally associated with vaccination. C1 [McCarthy, Natalie L.; Gee, Julianne; Sukumaran, Lakshmi; Weintraub, Eric; Duffy, Jonathan; McNeil, Michael M.] Ctr Dis Control & Prevent, 1600 Clifton Rd,MS-D26, Atlanta, GA 30333 USA. [Sukumaran, Lakshmi] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Kharbanda, Elyse O.] HealthPartners Inst Educ & Res, Minneapolis, MN USA. [Baxter, Roger] Kaiser Permanente No Calif, Oakland, CA USA. [Irving, Stephanie] Kaiser Permanente Northwest, Portland, OR USA. [King, Jennifer] Marshfield Clin Res Fdn, Marshfield, WI USA. [Daley, Matthew F.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Hechter, Rulin] Kaiser Permanente So Calif, Pasadena, CA 91101 USA. RP McCarthy, NL (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS-D26, Atlanta, GA 30333 USA. EM nmccarthy@cdc.gov FU Centers for Disease Control and Prevention [200-2012-53580]; National Institute of Allergy and Infectious Diseases [T32AI074492] FX This study was supported by the Centers for Disease Control and Prevention, contract 200-2012-53580. Dr Sukumaran was supported by award number T32AI074492 from the National Institute of Allergy and Infectious Diseases. NR 44 TC 0 Z9 0 U1 0 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2016 VL 137 IS 3 AR e20152970 DI 10.1542/peds.2015-2970 PG 8 WC Pediatrics SC Pediatrics GA DF5MK UT WOS:000371395800039 PM 26908690 ER PT J AU Santibanez, TA Grohskopf, LA Zhai, YS Kahn, KE AF Santibanez, Tammy A. Grohskopf, Lisa A. Zhai, Yusheng Kahn, Katherine E. TI Complete Influenza Vaccination Trends for Children Six to Twenty-Three Months SO PEDIATRICS LA English DT Article ID IMMUNIZATION PRACTICES ACIP; ADVISORY-COMMITTEE; VACCINES RECOMMENDATIONS; UNITED-STATES; SEASONAL INFLUENZA; PREVENTION; COVERAGE AB OBJECTIVE: Prevention of influenza among infants and young children is a public health priority because of their high risk for influenza-related complications. Depending on a child's age and previous influenza vaccination history, they are recommended to receive either 1 dose or 2 doses of influenza vaccine to be considered fully vaccinated against influenza for the season. We compared estimates of full (complete) influenza vaccination coverage of children 6 to 23 months across 10 consecutive influenza seasons (2002-2012), by race/ethnicity, age group, and by number of doses required to be fully vaccinated given child's vaccination history. METHODS: National Immunization Survey data were used to estimate full influenza vaccination status among children 6 to 23 months on the basis of provider report. Estimates were computed by using Kaplan-Meier survival analysis methods. RESULTS: Full influenza vaccination coverage among children 6 to 23 months increased from 4.8% in the 2002-2003 influenza season to 44.7% in the 2011-2012 season. In all 10 influenza seasons studied, non-Hispanic black children and Hispanic children had lower full influenza vaccination coverage than non-Hispanic white children. For all 10 influenza seasons, full influenza vaccination coverage was higher among children requiring only 1 dose compared with those requiring 2 doses. CONCLUSIONS: Less than half of children 6 to 23 months in the United States, and an even a smaller percentage of Hispanic and non-Hispanic black children, are fully vaccinated against influenza. More implementation of evidence-based strategies that increase the percentage of children who are fully vaccinated is needed. C1 [Santibanez, Tammy A.; Grohskopf, Lisa A.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Zhai, Yusheng; Kahn, Katherine E.] Leidos Inc, Atlanta, GA USA. RP Santibanez, TA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop A-19, Atlanta, GA 30329 USA. EM afz5@cdc.gov NR 31 TC 2 Z9 2 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2016 VL 137 IS 3 AR e20153280 DI 10.1542/peds.2015-3280 PG 10 WC Pediatrics SC Pediatrics GA DF5MK UT WOS:000371395800046 PM 26908692 ER PT J AU Shvedova, AA Yanamala, N Kisin, ER Khailullin, TO Birch, ME Fatkhutdinova, LM AF Shvedova, Anna A. Yanamala, Naveena Kisin, Elena R. Khailullin, Timur O. Birch, M. Eileen Fatkhutdinova, Liliya M. TI Integrated Analysis of Dysregulated ncRNA and mRNA Expression Profiles in Humans Exposed to Carbon Nanotubes SO PLOS ONE LA English DT Article ID DAVID BIOINFORMATICS RESOURCES; LUNG EPITHELIAL-CELLS; OVARIAN-CANCER CELLS; LONG NONCODING RNAS; LARGE GENE LISTS; PULMONARY TOXICITY; ANTISENSE RNA; HUMAN-DISEASE; CLIP-SEQ; MICE AB Background As the application of carbon nanotubes (CNT) in consumer products continues to rise, studies have expanded to determine the associated risks of exposure on human and environmental health. In particular, several lines of evidence indicate that exposure to multi-walled carbon nanotubes (MWCNT) could pose a carcinogenic risk similar to asbestos fibers. However, to date the potential markers of MWCNT exposure are not yet explored in humans. Methods In the present study, global mRNA and ncRNA expression profiles in the blood of exposed workers, having direct contact with MWCNT aerosol for at least 6 months (n = 8), were compared with expression profiles of non-exposed (n = 7) workers (e.g., professional and/or technical staff) from the same manufacturing facility. Results Significant changes in the ncRNA and mRNA expression profiles were observed between exposed and non-exposed worker groups. An integrative analysis of ncRNA-mRNA correlations was performed to identify target genes, functional relationships, and regulatory networks in MWCNT-exposed workers. The coordinated changes in ncRNA and mRNA expression profiles revealed a set of miRNAs and their target genes with roles in cell cycle regulation/progression/control, apoptosis and proliferation. Further, the identified pathways and signaling networks also revealed MWCNT potential to trigger pulmonary and cardiovascular effects as well as carcinogenic outcomes in humans, similar to those previously described in rodents exposed to MWCNTs. Conclusion This study is the first to investigate aberrant changes in mRNA and ncRNA expression profiles in the blood of humans exposed to MWCNT. The significant changes in several miRNAs and mRNAs expression as well as their regulatory networks are important for getting molecular insights into the MWCNT-induced toxicity and pathogenesis in humans. Further large-scale prospective studies are necessary to validate the potential applicability of such changes in mRNAs and miRNAs as prognostic markers of MWCNT exposures in humans. C1 [Shvedova, Anna A.; Yanamala, Naveena; Kisin, Elena R.] NIOSH, Exposure Assessment Branch, HELD, CDC, Morgantown, WV 26505 USA. [Shvedova, Anna A.; Khailullin, Timur O.] W Virginia Univ, Dept Physiol & Pharmacol, Morgantown, WV 26505 USA. [Birch, M. Eileen] NIOSH, CDC, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. [Khailullin, Timur O.; Fatkhutdinova, Liliya M.] Kazan State Med Univ, Dept Hyg & Occupat Hlth, Ul Butlerova 49, Kazan 420012, Russia. RP Shvedova, AA (reprint author), NIOSH, Exposure Assessment Branch, HELD, CDC, Morgantown, WV 26505 USA.; Shvedova, AA (reprint author), W Virginia Univ, Dept Physiol & Pharmacol, Morgantown, WV 26505 USA. EM ats1@cdc.gov FU Government of Tatarstan Republic; EC-FP-7-NANOSOLUTIONS; NORA [939051G]; NTRC [939011K] FX Grant of the Government of Tatarstan Republic "Algarysh" for prospective area "Nanotechnology" (2008-2009), LF; EC-FP-7-NANOSOLUTIONS, AS; NORA 939051G, AS and NTRC 939011K, AS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 120 TC 2 Z9 2 U1 4 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 1 PY 2016 VL 11 IS 3 AR e0150628 DI 10.1371/journal.pone.0150628 PG 32 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF5ZW UT WOS:000371434500177 PM 26930275 ER PT J AU Anderson, JL Apostoaei, AI Yiin, JH Fleming, DA Tseng, CY Chen, PH AF Anderson, Jeri L. Apostoaei, A. Iulian Yiin, James H. Fleming, Donald A. Tseng, Chih-Yu Chen, Pi-Hsueh TI Internal exposure to uranium in a pooled cohort of gaseous diffusion plant workers SO RADIATION PROTECTION DOSIMETRY LA English DT Article AB Intakes and absorbed organ doses were estimated for 29 303 workers employed at three former US gaseous diffusion plants as part of a study of cause-specific mortality and cancer incidence in uranium enrichment workers. Uranium urinalysis data (> 600 000 urine samples) were available for 58 % of the pooled cohort. Facility records provided uranium gravimetric and radioactivity concentration data and allowed estimation of enrichment levels of uranium to which workers may have been exposed. Urine data were generally recorded with facility department numbers, which were also available in study subjects' work histories. Bioassay data were imputed for study subjects with no recorded sample results (33 % of pooled cohort) by assigning department average urine uranium concentration. Gravimetric data were converted to 24-h uranium activity excretion using department average specific activities. Intakes and organ doses were calculated assuming chronic exposure by inhalation to a 5-A mu m activity median aerodynamic diameter aerosol of soluble uranium. Median intakes varied between 0.31 and 0.74 Bq d(-1) for the three facilities. Median organ doses for the three facilities varied between 0.019 and 0.051, 0.68 and 1.8, 0.078 and 0.22, 0.28 and 0.74, and 0.094 and 0.25 mGy for lung, bone surface, red bone marrow, kidneys, and liver, respectively. Estimated intakes and organ doses for study subjects with imputed bioassay data were similar in magnitude. C1 [Anderson, Jeri L.; Yiin, James H.; Fleming, Donald A.; Tseng, Chih-Yu; Chen, Pi-Hsueh] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 1090 Tusculum Ave,MS R-14, Cincinnati, OH 45226 USA. [Apostoaei, A. Iulian] Oak Ridge Ctr Risk Anal Inc, Oak Ridge, TN 37830 USA. RP Anderson, JL (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 1090 Tusculum Ave,MS R-14, Cincinnati, OH 45226 USA. EM jlanderson@cdc.gov FU U.S. Department of Energy (DOE); U.S. Department of Health and Human Services (DHHS) FX This work was supported through an agreement between the U.S. Department of Energy (DOE) and the U.S. Department of Health and Human Services (DHHS). NR 16 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0144-8420 EI 1742-3406 J9 RADIAT PROT DOSIM JI Radiat. Prot. Dosim. PD MAR PY 2016 VL 168 IS 4 BP 471 EP 477 DI 10.1093/rpd/ncv357 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA DF8LE UT WOS:000371608500006 PM 26113578 ER PT J AU Karpathy, SE Allerdice, ME Sheth, M Dasch, GA Levin, ML AF Karpathy, Sandor E. Allerdice, Michelle E. J. Sheth, Mili Dasch, Gregory A. Levin, Michael L. TI Co-Feeding Transmission of the Ehrlichia muris-Like Agent to Mice (Mus musculus) SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Transmission; Ehrlichia muris-like agent (EMLA); Co-feeding; Peromyscus leucopus; Ixodes scapularis ID EXPERIMENTAL-INFECTION; PEROMYSCUS-LEUCOPUS; ANIMAL-MODEL; TICKS; IDENTIFICATION; CHAFFEENSIS; COMPETENCE; PATHOGENS; RUSSIA; MOUSE AB The Ehrlichia muris-like agent (EMLA) is a newly recognized human pathogen found in Wisconsin and Minnesota. Ecological investigations have implicated both the blacklegged tick, Ixodes scapularis, and the white-footed mouse, Peromyscus leucopus, as playing roles in the maintenance of EMLA in nature. The work presented here shows that I. scapularis is an efficient vector of EMLA in a laboratory mouse model, but that Dermacentor variabilis, another frequent human biting tick found in EMLA endemic areas, is not. Additionally, I. scapularis larvae are able to acquire EMLA through co-feeding with infected nymphs. As EMLA only persists in mouse blood for a relatively short period of time, co-feeding transmission may play an important role in the maintenance of EMLA in ticks, and subsequently may play a role in limiting the geographic distribution of this pathogen in areas where co-feeding of larvae and nymphs is less common. C1 [Karpathy, Sandor E.; Allerdice, Michelle E. J.; Sheth, Mili; Dasch, Gregory A.; Levin, Michael L.] US Dept HHS, Ctr Dis Control & Prevent, Div Vector Borne Dis, Rickettsial Zoonoses Branch, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. [Sheth, Mili] US Dept HHS, Ctr Dis Control & Prevent, Div Sci Resources, Biotechnol Core Facil Branch, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. RP Karpathy, SE (reprint author), US Dept HHS, Ctr Dis Control & Prevent, Div Vector Borne Dis, Rickettsial Zoonoses Branch, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM skarpathy@cdc.gov FU Intramural CDC HHS [CC999999] NR 29 TC 3 Z9 3 U1 3 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD MAR 1 PY 2016 VL 16 IS 3 BP 145 EP 150 DI 10.1089/vbz.2015.1878 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DG0BT UT WOS:000371727700001 PM 26824725 ER PT J AU Kosoy, O Rabe, I Geissler, A Adjemian, J Panella, A Laven, J Basile, AJ Velez, J Griffith, K Wong, D Fischer, M Lanciotti, RS AF Kosoy, Olga Rabe, Ingrid Geissler, Aimee Adjemian, Jennifer Panella, Amanda Laven, Janeen Basile, Alison J. Velez, Jason Griffith, Kevin Wong, David Fischer, Marc Lanciotti, Robert S. TI Serological Survey for Antibodies to Mosquito-Borne Bunyaviruses Among US National Park Service and US Forest Service Employees SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Arbovirus(es); Antibodies; Bunyaviruses; Mosquito(es); Vector borne ID CACHE VALLEY VIRUS; BUNYAMWERA SEROGROUP VIRUSES; JAMESTOWN-CANYON-VIRUS; LINKED IMMUNOSORBENT ASSAYS; LA-CROSSE ENCEPHALITIS; SNOWSHOE HARE VIRUSES; CALIFORNIA SEROGROUP; UNITED-STATES; LEPUS-AMERICANUS; INFECTIONS AB Serum samples from 295 employees of Great Smoky Mountains National Park (GRSM), Rocky Mountain National Park (ROMO), and Grand Teton National Park with adjacent Bridger-Teton National Forest (GRTE-BTNF) were subjected to serological analysis for mosquito-borne bunyaviruses. The sera were analyzed for neutralizing antibodies against six orthobunyaviruses: La Crosse virus (LACV), Jamestown Canyon virus (JCV), snowshoe hare virus (SSHV), California encephalitis virus, and Trivittatus virus (TVTV) belonging to the California serogroup and Cache Valley virus (CVV) belonging to the Bunyamwera serogroup. Sera were also tested for immunoglobulin (Ig) G antibodies against LACV and JCV by enzyme-linked immunosorbent assay (ELISA). The proportion of employees with neutralizing antibodies to any California serogroup bunyavirus was similar in all three sites, with the prevalence ranging from 28% to 36%. The study demonstrated a seroprevalence of 3% to CVV across the three parks. However, proportions of persons with antibodies to specific viruses differed between parks. Participants residing in the eastern regions had a higher seroprevalence to LACV, with 24% (18/75) GRSM employees being seropositive. In contrast, SSHV seroprevalence was limited to employees from the western sites, with 1.7% (1/60) ROMO and 3.8% (6/160) GRTE-BTNF employees being positive. Seroprevalence to JCV was noted in employees from all sites at rates of 6.7% in GRSM, 21.7% in ROMO, and 15.6% in GRTE-BTNF. One employee each from ROMO (1.7%) and GRTE-BTNF (1.9%) were positive for TVTV. This study also has illustrated the greater sensitivity and specificity of plaque reduction neutralization test compared to IgG ELISA in conducting serosurveys for LACV and JCV. C1 [Kosoy, Olga; Rabe, Ingrid; Panella, Amanda; Laven, Janeen; Basile, Alison J.; Velez, Jason; Griffith, Kevin; Fischer, Marc; Lanciotti, Robert S.] Ctr Dis Control & Prevent, 3156 Rampart Rd Mail Stop P-02, Ft Collins, CO 80521 USA. [Geissler, Aimee; Adjemian, Jennifer] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wong, David] Natl Pk Serv, Off Publ Hlth, Washington, DC USA. RP Kosoy, O (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd Mail Stop P-02, Ft Collins, CO 80521 USA. EM oak3@cdc.gov NR 49 TC 0 Z9 0 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD MAR 1 PY 2016 VL 16 IS 3 BP 191 EP 198 DI 10.1089/vbz.2015.1865 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DG0BT UT WOS:000371727700008 PM 26855300 ER PT J AU Dunn, AC Walker, TA Redd, J Sugerman, D McFadden, J Singh, T Jasperse, J Kamara, BO Sesay, T McAuley, J Kilmarx, PH AF Dunn, Angela C. Walker, Tiffany A. Redd, John Sugerman, David McFadden, Jevon Singh, Tushar Jasperse, Joseph Kamara, Brima Osaio Sesay, Tom McAuley, James Kilmarx, Peter H. TI Nosocomial transmission of Ebola virus disease on pediatric and maternity wards: Bombali and Tonkolili, Sierra Leone, 2014 SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE West Africa; Hospital-acquired infection; Infection control; Epidemiology; Outbreak ID HEMORRHAGIC-FEVER AB Background: In the largest Ebola virus disease (EVD) outbreak in history, nosocomial transmission of EVD increased spread of the disease. We report on 2 instances in Sierra Leone where patients unknowingly infected with EVD were admitted to a general hospital ward (1 pediatric ward and 1 maternity ward), exposing health care workers, caregivers, and other patients to EVD. Both patients died on the general wards, and were later confirmed as being infected with EVD. We initiated contact tracing and assessed risk factors for secondary infections to guide containment recommendations. Methods: We reviewed medical records to establish the index patients' symptom onset. Health care workers, patients, and caregivers were interviewed to determine exposures and personal protective equipment (PPE) use. Contacts were monitored daily for EVD symptoms. Those who experienced EVD symptoms were isolated and tested. Results: Eighty-two contacts were identified: 64 health care workers, 7 caregivers, 4 patients, 4 newborns, and 3 children of patients. Seven contacts became symptomatic and tested positive for EVD: 2 health care workers (1 nurse and 1 hospital cleaner), 2 caregivers, 2 newborns, and 1 patient. The infected nurse placed an intravenous catheter in the pediatric index patient with only short gloves PPE and the hospital cleaner cleaned the operating room of the maternity ward index patient wearing short gloves PPE. The maternity ward index patient's caregiver and newborn were exposed to her body fluids. The infected patient and her newborn shared the ward and latrine with the maternity ward index patient. Hospital staff members did not use adequate PPE. Caregivers were not offered PPE. Conclusions: Delayed recognition of EVD and inadequate PPE likely led to exposures and secondary infections. Earlier recognition of EVD and adequate PPE might have reduced direct contact with body fluids. Limiting nonhealth-care worker contact, improving access to PPE, and enhancing screening methods for pregnant women, children, and inpatients may help decrease EVD transmission in general health care settings. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Dunn, Angela C.; Walker, Tiffany A.; Singh, Tushar] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Dunn, Angela C.; Walker, Tiffany A.; Redd, John; Sugerman, David; McFadden, Jevon; Singh, Tushar; McAuley, James; Kilmarx, Peter H.] CDC Sierra Leone Ebola Response Team, Freetown, Sierra Leone. [Jasperse, Joseph] Concern Worldwide, Tonkolili Dist, Sierra Leone. [Kamara, Brima Osaio] Sierra Leone Minist Hlth & Sanitat, Tonkolili Dist, Sierra Leone. [Sesay, Tom] Sierra Leone Minist Hlth & Sanitat, Bombali Dist, Sierra Leone. RP Dunn, AC (reprint author), Utah Dept Hlth, Bur Epidemiol, POB 142104, Salt Lake City, UT 84114 USA. EM ydg8@cdc.gov OI Dunn, Angela/0000-0002-7862-6818 NR 9 TC 7 Z9 7 U1 2 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAR 1 PY 2016 VL 44 IS 3 BP 269 EP 272 DI 10.1016/j.ajic.2015.09.016 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DF4CS UT WOS:000371295500008 PM 26521701 ER PT J AU Halpin, AL Sinkowitz-Cochran, R Allen-Bridson, K Edwards, JR Pollock, D McDonald, LC Gould, CV AF Halpin, Alison Laufer Sinkowitz-Cochran, Ronda Allen-Bridson, Katherine Edwards, Jonathan R. Pollock, Daniel McDonald, L. Clifford Gould, Carolyn V. TI Letter in Response to "Questionable validity of the catheter-associated urinary tract infection metric used for value-based purchasing" SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Letter C1 [Halpin, Alison Laufer; Sinkowitz-Cochran, Ronda; Allen-Bridson, Katherine; Edwards, Jonathan R.; Pollock, Daniel; McDonald, L. Clifford; Gould, Carolyn V.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-31, Atlanta, GA 30329 USA. RP Halpin, AL (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-31, Atlanta, GA 30329 USA. EM ALaufer@cdc.gov RI Laufer Halpin, Alison/E-5453-2015 OI Laufer Halpin, Alison/0000-0003-1643-1617 NR 5 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAR 1 PY 2016 VL 44 IS 3 BP 369 EP 370 DI 10.1016/j.ajic.2015.11.035 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DF4CS UT WOS:000371295500031 PM 26940597 ER PT J AU Hennessey, M Fischer, M Staples, JE AF Hennessey, M. Fischer, M. Staples, J. E. TI Zika Virus Spreads to New Areas - Region of the Americas, May 2015-January 2016 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Reprint ID MICRONESIA C1 [Hennessey, M.; Fischer, M.; Staples, J. E.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Atlanta, GA 30333 USA. RP Fischer, M (reprint author), CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Atlanta, GA 30333 USA. EM mfischer@cdc.gov NR 13 TC 8 Z9 8 U1 1 U2 26 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAR PY 2016 VL 16 IS 3 BP 1031 EP 1034 DI 10.1111/ajt.13743 PG 4 WC Surgery; Transplantation SC Surgery; Transplantation GA DF3JQ UT WOS:000371240500036 PM 26914735 ER PT J AU Chace, DH Hannon, WH AF Chace, Donald H. Hannon, William H. TI Filter Paper as a Blood Sample Collection Device for Newborn Screening SO CLINICAL CHEMISTRY LA English DT Editorial Material ID DRIED BLOOD C1 [Chace, Donald H.] Ctr Res Educ & Qual, Pediatrix Analyt, Sunrise, FL USA. [Hannon, William H.] CDC Fdn, Atlanta, GA USA. [Hannon, William H.] CDC, Newborn Screening Branch, Atlanta, GA 30333 USA. RP Chace, DH (reprint author), Pediatrix Med Grp, 1301 Concord Terrace, Sunrise, FL 33323 USA. EM donald_chace@pediatrix.com NR 11 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 EI 1530-8561 J9 CLIN CHEM JI Clin. Chem. PD MAR PY 2016 VL 62 IS 3 BP 423 EP 425 DI 10.1373/clinchem.2015.252007 PG 3 WC Medical Laboratory Technology SC Medical Laboratory Technology GA DF3DX UT WOS:000371225200002 PM 26797689 ER PT J AU Rifai, N Young, IS Nordestgaard, BG Wierzbicki, AS Vesper, H Mora, S Stone, NJ Genest, J Miller, G AF Rifai, Nader Young, Ian S. Nordestgaard, Borge G. Wierzbicki, Anthony S. Vesper, Hubert Mora, Samia Stone, Neil J. Genest, Jacques Miller, Greg TI Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come? SO CLINICAL CHEMISTRY LA English DT Editorial Material C1 [Rifai, Nader] Boston Childrens Hosp, Dept Lab Med, 300 Longwood Ave, Boston, MA 02115 USA. [Rifai, Nader] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [Rifai, Nader] Harvard Univ, Sch Med, Boston, MA USA. [Young, Ian S.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland. [Nordestgaard, Borge G.] European Atherosclerosis Soc, European Federat Clin Chem & Lab Med Expert Panel, Copenhagen, Denmark. [Nordestgaard, Borge G.] Copenhagen Univ Hosp, Clin Chem, Copenhagen, Denmark. [Nordestgaard, Borge G.] Univ Copenhagen, DK-1168 Copenhagen, Denmark. [Wierzbicki, Anthony S.] Natl Inst Hlth & Clin Excellence, Lipids & Cardiovasc Risk Assessment Guideline Grp, London, England. [Wierzbicki, Anthony S.] Guys Hosp, Lipid Unit, London SE1 9RT, England. [Wierzbicki, Anthony S.] St Thomas Hosp, Lipid Unit, London, England. [Vesper, Hubert] Ctr Dis Control & Prevent, Prot Biomarker Lab, Atlanta, GA USA. [Mora, Samia] Brigham & Womens Hosp, Cardiovasc & Prevent Med, 75 Francis St, Boston, MA 02115 USA. [Mora, Samia] Harvard Univ, Sch Med, Med, Boston, MA USA. [Stone, Neil J.] 2013 Amer Coll Cardiol, Amer Heart Assoc Task Force Practice Guidelines, Chicago, IL USA. [Stone, Neil J.] Northwestern Univ, Med Prevent Cardiol, Feinberg Sch Med, Chicago, IL 60611 USA. [Genest, Jacques] McGill Univ, Fac Med, Montreal, PQ, Canada. [Miller, Greg] Virginia Commonwealth Univ Hlth Syst, Pathol, Richmond, VA USA. [Miller, Greg] Virginia Commonwealth Univ Hlth Syst, Clin Chem Lab, Richmond, VA USA. RP Rifai, N (reprint author), Boston Childrens Hosp, Dept Lab Med, 300 Longwood Ave, Boston, MA 02115 USA. EM nader.rifai@childrens.harvard.edu FU Medical Research Council [G0901530, MR/J000388/1] NR 0 TC 2 Z9 3 U1 2 U2 3 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 EI 1530-8561 J9 CLIN CHEM JI Clin. Chem. PD MAR PY 2016 VL 62 IS 3 BP 428 EP 435 DI 10.1373/clinchem.2015.247866 PG 8 WC Medical Laboratory Technology SC Medical Laboratory Technology GA DF3DX UT WOS:000371225200004 PM 26787760 ER PT J AU Benedict, K Mody, RK AF Benedict, Kaitlin Mody, Rajal K. TI Epidemiology of Histoplasmosis Outbreaks, United States, 1938-2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID STARLING ROOST; INDIANAPOLIS; DIAGNOSIS; ARKANSAS; UPDATE; CAVE C1 [Benedict, Kaitlin; Mody, Rajal K.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30329 USA. RP Benedict, K (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30329 USA. EM jsy8@cdc.gov NR 40 TC 3 Z9 3 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2016 VL 22 IS 3 BP 370 EP 378 DI 10.3201/eid2203.151117 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DF2RS UT WOS:000371192100002 PM 26890817 ER PT J AU Sharma, A Bloss, E Heilig, CM Click, ES AF Sharma, Aditya Bloss, Emily Heilig, Charles M. Click, Eleanor S. TI Tuberculosis Caused by Mycobacterium africanum, United States, 2004 2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID WEST-AFRICA; SUBTYPE-II; TRANSMISSION; COMPLEX; CATTLE; PULMONARY; GENOTYPES; STRAINS; LINEAGE; NIGERIA C1 [Sharma, Aditya; Bloss, Emily; Heilig, Charles M.; Click, Eleanor S.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E10, Atlanta, GA 30329 USA. RP Sharma, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E10, Atlanta, GA 30329 USA. EM asharma4@cdc.gov OI Heilig, Charles/0000-0003-1075-1310 FU Centers for Disease Control and Prevention FX This study was supported by the Centers for Disease Control and Prevention. NR 38 TC 2 Z9 2 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2016 VL 22 IS 3 BP 396 EP 403 DI 10.3201/eid2203.151505 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DF2RS UT WOS:000371192100005 PM 26886258 ER PT J AU Cassiday, PK Skoff, TH Jawahir, S Tondella, ML AF Cassiday, Pamela K. Skoff, Tami H. Jawahir, Selina Tondella, M. Lucia TI Changes in Predominance of Pulsed-Field Gel Electrophoresis Profiles of Bordetella pertussis Isolates, United States, 2000-2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID DIFFERENT VACCINATION PROGRAMS; MOLECULAR EPIDEMIOLOGY; EUROPEAN COUNTRIES; TYPING METHODS; PERTACTIN; DIVERSITY; STRAINS; SWEDEN; ASSOCIATION; POPULATIONS AB To clarify the characteristics of circulating Bordetella pertussis isolates, we used pulsed-field gel electrophoresis (PFGE) to analyze 5,262 isolates collected in the United States during 2000-2012. We found 199 PFGE profiles; 5 profiles accounted for 72% of isolates. The most common profile, CDC013, accounted for 35%-46% of isolates tested from 2000-2009; however, the proportion of isolates of this profile rapidly decreased in 2010. Profile CDC237, first seen in 2009, increased rapidly and accounted for 29% of 2012 isolates. No location bias was observed among profiles during 2000-2010, but differences were observed among isolates from different states during 2012. Predominant profiles match those observed in recent European PFGE studies. PFGE profile changes are concurrent with other recent molecular changes in B. pertussis and may be contributing to the reemergence of pertussis in the United States. Continued PFGE monitoring is critical for understanding the changing epidemiology of pertussis. C1 [Cassiday, Pamela K.; Skoff, Tami H.; Tondella, M. Lucia] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D11, Atlanta, GA 30249 USA. [Jawahir, Selina] Minnesota Dept Hlth, St Paul, MN USA. RP Cassiday, PK (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D11, Atlanta, GA 30249 USA. EM PCassiday@cdc.gov NR 37 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2016 VL 22 IS 3 BP 442 EP 448 DI 10.3201/eid2203.151136 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DF2RS UT WOS:000371192100011 PM 26886905 ER PT J AU Etienne, KA Roe, CC Smith, RM Vallabhaneni, S Duarte, C Escandon, P Castaneda, E Gomez, BL de Bedout, C Lopez, LF Salas, V Hederra, LM Fernandez, J Pidal, P Hormazabel, JC Otaiza-O'Ryan, F Vannberg, FO Gillece, J Lemmer, D Driebe, EM Engelthaler, DM Litvintseva, AP AF Etienne, Kizee A. Roe, Chandler C. Smith, Rachel M. Vallabhaneni, Snigdha Duarte, Carolina Escandon, Patricia Castaneda, Elizabeth Gomez, Beatriz L. de Bedout, Catalina Lopez, Luisa F. Salas, Valentina Maria Hederra, Luz Fernandez, Jorge Pidal, Paola Carlos Hormazabel, Juan Otaiza-O'Ryan, Fernando Vannberg, Fredrik O. Gillece, John Lemmer, Darrin Driebe, Elizabeth M. Engelthaler, David M. Litvintseva, Anastasia P. TI Whole-Genome Sequencing to Determine Origin of Multinational Outbreak of Sarocladium kiliense Bloodstream Infections SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MULTISTATE OUTBREAK; ENDOPHTHALMITIS; BIPOLARIS AB We used whole-genome sequence typing (WGST) to investigate an outbreak of Sarocladium kiliense bloodstream infections (BSI) associated with receipt of contaminated antinausea medication among oncology patients in Colombia and Chile during 2013-2014. Twenty-five outbreak isolates (18 from patients and 7 from medication vials) and 11 control isolates unrelated to this outbreak were subjected to WGST to elucidate a source of infection. All outbreak isolates were nearly indistinguishable (<= 5 single-nucleotide polymorphisms), and >21,000 single-nucleotide polymorphisms were identified from unrelated control isolates, suggesting a point source for this outbreak. S. kiliense has been previously implicated in healthcare-related infections; however, the lack of available typing methods has precluded the ability to substantiate point sources. WGST for outbreak investigation caused by eukaryotic pathogens without reference genomes or existing genotyping methods enables accurate source identification to guide implementation of appropriate control and prevention measures. C1 [Etienne, Kizee A.; Smith, Rachel M.; Vallabhaneni, Snigdha; Litvintseva, Anastasia P.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G11, Atlanta, GA 30329 USA. [Etienne, Kizee A.; Vannberg, Fredrik O.] Georgia Inst Technol, Atlanta, GA 30332 USA. [Roe, Chandler C.; Gillece, John; Lemmer, Darrin; Driebe, Elizabeth M.; Engelthaler, David M.] Translat Genom Res Inst, Flagstaff, AZ USA. [Duarte, Carolina; Escandon, Patricia; Castaneda, Elizabeth] Inst Nacl Salud, Bogota, Colombia. Univ Rosario, Bogota, Colombia. [Gomez, Beatriz L.; de Bedout, Catalina; Lopez, Luisa F.] Corp Invest Biol, Medellin, Colombia. [Salas, Valentina; Maria Hederra, Luz; Fernandez, Jorge; Pidal, Paola; Carlos Hormazabel, Juan] Inst Salud Publ Chile, Santiago, Chile. Minist Hlth Santiago, Santiago, Chile. RP Etienne, KA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G11, Atlanta, GA 30329 USA. EM gufl@cdc.gov OI Castaneda, Elizabeth/0000-0001-5970-1598 NR 26 TC 1 Z9 1 U1 2 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2016 VL 22 IS 3 BP 476 EP 481 DI 10.3202/eid2203.151193 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DF2RS UT WOS:000371192100016 PM 26891230 ER PT J AU Tupasi, TE Garfin, AMCG Kurbatova, EV Mangan, JM Orillaza-Chi, R Naval, LC Balane, GI Basilio, R Golubkov, A Joson, ES Lew, WJ Lofranco, V Mantala, M Pancho, S Sarol, JN AF Tupasi, Thelma E. Garfin, Anna Marie Celina G. Kurbatova, Ekaterina V. Mangan, Joan M. Orillaza-Chi, Ruth Naval, Leilani C. Balane, Glenn I. Basilio, Ramon Golubkov, Alexander Joson, Evelyn S. Lew, Woo-jin Lofranco, Vivian Mantala, Mariquita Pancho, Stuart Sarol, Jesus N., Jr. TI Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012-2014 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID TREATMENT DEFAULT; SELF-EFFICACY; DOTS-PLUS; PREDICTORS; OUTCOMES; INTERVENTIONS; METAANALYSIS; PHYSICIANS; TRUST; TOMSK AB To identify factors associated with loss to follow-up during treatment for multidrug-resistant (MDR) tuberculosis (TB) in the Philippines, we conducted a case control study of adult patients who began receiving treatment for rifampin-resistant TB during July 1 December 31, 2012. Among 91 case-patients (those lost to follow-up) and 182 control-patients (those who adhered to treatment), independent factors associated with loss to follow-up included patients' higher self-rating of the severity of vomiting as an adverse drug reaction and alcohol abuse. Protective factors included receiving any type of assistance from the TB program, better. TB knowledge, and higher levels of trust in and support from physicians and nurses. These results provide insights for designing interventions aimed at reducing patient loss to follow-up during treatment for MDR TB. C1 [Tupasi, Thelma E.; Naval, Leilani C.; Balane, Glenn I.; Joson, Evelyn S.; Sarol, Jesus N., Jr.] Trop Dis Fdn Inc, Amorsolo St & Urban Ave, Makati 1230, Philippines. [Garfin, Anna Marie Celina G.; Basilio, Ramon] Dept Hlth, Manila, Philippines. [Kurbatova, Ekaterina V.; Mangan, Joan M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Orillaza-Chi, Ruth] Philippine Business Social Progress Innovat & Mul, Manila, Philippines. [Golubkov, Alexander] US Agcy Int Dev, Washington, DC 20523 USA. [Lew, Woo-jin] WHO, Manila, Philippines. [Lofranco, Vivian; Pancho, Stuart] Lung Ctr Philippines, Manila, Philippines. [Mantala, Mariquita] Tech Assistance Countries USAID Funded Act, Manila, Philippines. RP Tupasi, TE (reprint author), Trop Dis Fdn Inc, Amorsolo St & Urban Ave, Makati 1230, Philippines. EM tetupasi@yahoo.com FU USAID Philippines with Philippine Business for Social Progress for the Innovations and Multisectoral Partnership FX Funding for this study was provided by USAID Philippines through cooperative agreement with Philippine Business for Social Progress for the Innovations and Multisectoral Partnership to Achieve Control of Tuberculosis project. NR 34 TC 5 Z9 5 U1 3 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2016 VL 22 IS 3 BP 491 EP 502 DI 10.3201/eid2203.151788 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DF2RS UT WOS:000371192100018 PM 26889786 ER PT J AU Nelson, CA Starr, JA Kugeler, KJ Mead, PS AF Nelson, Christina A. Starr, J. Andrew Kugeler, Kiersten J. Mead, Paul S. TI Lyme Disease in Hispanics, United States, 2000-2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID RISK-FACTORS AB Hispanics comprise a growing portion of the US population and might have distinct risk factors for tickborne diseases. During 2000-2013, a total of 5,473 Lyme disease cases were reported among Hispanics through national surveillance. Hispanics were more likely than non-Hispanics to have signs of disseminated infection and onset during fall months. C1 [Nelson, Christina A.; Kugeler, Kiersten J.; Mead, Paul S.] Ctr Dis Control & Prevent, 3156 Rampart Rd,Mailstop P02, Ft Collins, CO 80521 USA. [Starr, J. Andrew] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. RP Nelson, CA (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd,Mailstop P02, Ft Collins, CO 80521 USA. EM wje1@cdc.gov NR 14 TC 0 Z9 0 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2016 VL 22 IS 3 BP 522 EP 525 DI 10.3203/eid2203.151273 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DF2RS UT WOS:000371192100024 PM 26889721 ER PT J AU Kandelaki, G Malania, L Bai, Y Chakvetadze, N Katsitadze, G Imnadze, P Nelson, C Harrus, S Kosoy, M AF Kandelaki, George Malania, Lile Bai, Ying Chakvetadze, Neli Katsitadze, Guram Imnadze, Paata Nelson, Christina Harrus, Shimon Kosoy, Michael TI Human Lymphadenopathy Caused by Ratborne Bartonella, Tbilisi, Georgia SO EMERGING INFECTIOUS DISEASES LA English DT Article ID GENUS RATTUS; RATS; ELIZABETHAE; HOSTS AB Lymphadenopathy and fever that developed in a woman in Tbilisi, Georgia, most likely were caused by a ratborne Bartonella strain related B. tribocorum and B. elizabethae. The finding suggests that this Bartonella strain could be spread by infected rats and represents a potential human risk. C1 [Kandelaki, George] Cent Univ Hosp, Tbilisi, Rep of Georgia. [Kandelaki, George; Malania, Lile; Chakvetadze, Neli; Katsitadze, Guram; Imnadze, Paata] Natl Ctr Dis Control & Publ Hlth, Tbilisi, Rep of Georgia. [Bai, Ying; Nelson, Christina; Kosoy, Michael] Ctr Dis Control & Prevent, 3156 Rampart Rd,Mailstop P02, Ft Collins, CO 80521 USA. [Harrus, Shimon] Hebrew Univ Jerusalem, IL-76100 Rehovot, Israel. RP Kosoy, M (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd,Mailstop P02, Ft Collins, CO 80521 USA. EM mck3@cdc.gov RI Harrus, Shimon/H-5175-2016 OI Harrus, Shimon/0000-0003-0542-207X FU International Science and Technology Center; Centers for Disease Control and Prevention's Global Diseases Detection Program FX The International Science and Technology Center and the Centers for Disease Control and Prevention's Global Diseases Detection Program provided financial support. NR 13 TC 2 Z9 2 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2016 VL 22 IS 3 BP 544 EP 546 DI 10.3203/eid2203.151823 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DF2RS UT WOS:000371192100031 PM 26889959 ER PT J AU Chorba, T Breedlove, B AF Chorba, Terence Breedlove, Byron TI Depictions of Heroism in Battle and Anguish from Tuberculosis SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Chorba, Terence; Breedlove, Byron] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C19, Atlanta, GA 30329 USA. RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C19, Atlanta, GA 30329 USA. EM wbbl@cdc.gov OI Breedlove, Byron/0000-0002-1026-1963 NR 7 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2016 VL 22 IS 3 BP 573 EP 574 DI 10.3201/eid2203.AC2203 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DF2RS UT WOS:000371192100045 PM 27326438 ER PT J AU Wei, BN Aiwis, KU Li, Z Wang, LQ Valentin-Blasini, L Sosnoff, CS Xia, Y Conway, KP Blount, BC AF Wei, Binnian Aiwis, K. Udeni Li, Zheng Wang, Lanqing Valentin-Blasini, Liza Sosnoff, Connie S. Xia, Yang Conway, Kevin P. Blount, Benjamin C. TI Urinary concentrations of PAH and VOC metabolites in marijuana users SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Cannabis smoke; Biomonitoring; PAHs; VOCs; Secondhand smoke; Environmental tobacco smoke (ETS) ID TANDEM MASS-SPECTROMETRY; POLYCYCLIC AROMATIC-HYDROCARBONS; PRENATAL CANNABIS EXPOSURE; TOBACCO-SMOKE; US POPULATION; SIDESTREAM MARIJUANA; ION CHROMATOGRAPHY; SECONDHAND SMOKE; CIGARETTE-SMOKE; LUNG-CANCER AB Background: Marijuana is seeing increased therapeutic use, and is the world's third most-popular recreational drug following alcohol and tobacco. This widening use poses increased exposure to potentially toxic combustion by-products from marijuana smoke and the potential for public health concerns. Objectives: To compare urinary metabolites of polycyclic aromatic hydrocarbons (PAHs) and volatile organic compounds (VOCs) among self-reported recent marijuana users and nonusers, while accounting for tobacco smoke exposure. Methods: Measurements of PAH and VOC metabolites in urine samples were combined with questionnaire data collected from participants in the National Health and Nutrition Examination Surveys (NHANES) from 2005 to 2012 in order to categorize participants (>= 18 years) into exclusive recent marijuana users and nonusers. Adjusted geometric means (GMs) of urinary concentrations were computed for these groups using multiple regression analyses to adjust for potential confounders. Results: Adjusted GMs of many individual monohydroxy PAHs (OH-PAHs) were significantly higher in recent marijuana users than in nonusers (p < 0.05). Urinary thiocyanate (p < 0.001) and urinary concentrations of many VOC metabolites, including metabolites of acrylonitrile (p < 0.001) and acrylamide (p < 0.001), were significantly higher in recent marijuana users than in nonusers. Conclusions: We found elevated levels of biomarkers for potentially harmful chemicals among self-identified, recent marijuana users compared with nonusers. These findings suggest that further studies are needed to evaluate the potential health risks to humans from the exposure to these agents when smoking marijuana. Published by Elsevier Ltd. C1 [Wei, Binnian; Aiwis, K. Udeni; Li, Zheng; Wang, Lanqing; Valentin-Blasini, Liza; Sosnoff, Connie S.; Xia, Yang; Blount, Benjamin C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Conway, Kevin P.] NIH, Div Epidemiol Serv & Prevent Res, Bethesda, MD USA. RP Wei, BN (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, 4770 Buford Hwy,NE Rd,Mail Stop F44, Atlanta, GA 30341 USA. EM bwei@cdc.gov OI Conway, Kevin/0000-0002-7638-339X; Wei, Binnian/0000-0003-0465-9964 FU Intramural CDC HHS [CC999999] NR 53 TC 2 Z9 2 U1 9 U2 43 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD MAR PY 2016 VL 88 BP 1 EP 8 DI 10.1016/j.envint.2015.12.003 PG 8 WC Environmental Sciences SC Environmental Sciences & Ecology GA DF4YU UT WOS:000371359300001 PM 26690539 ER PT J AU Thai, PK Heffernan, AL Toms, LML Li, Z Calafat, AM Hobson, P Broomhall, S Mueller, JF AF Thai, Phong K. Heffernan, Amy L. Toms, Leisa-Maree L. Li, Zheng Calafat, Antonia M. Hobson, Peter Broomhall, Sara Mueller, Jochen F. TI Monitoring exposure to polycyclic aromatic hydrocarbons in an Australian population using pooled urine samples SO ENVIRONMENT INTERNATIONAL LA English DT Article DE OH-PAHs; Urinary metabolite; Biomonitoring; Infant; Exposure monitoring ID ENVIRONMENTAL CHEMICALS; GENERAL-POPULATION; BISPHENOL-A; METABOLITES; 1-HYDROXYPYRENE; 2-NAPHTHOL; EXCRETION; CHILDREN; PAHS; PROFILES AB Integrated exposure to polycyclic aromatic hydrocarbons (PAHs) can be assessed through monitoring of urinary mono-hydroxylated PAHs (OH-PAHs). The aim of this study was to provide the first assessment of exposure to PAHs in a large sample of the population in Queensland, Australia including exposure to infant (0-4 years). De-identified urine specimens, obtained from a pathology laboratory, were stratified by age and sex, and pooled (n = 24 pools of 100) and OH-PAHs were measured by gas chromatography-isotope dilution-tandem mass spectrometry. Geometric mean (GM) concentrations ranged from 30 ng/L (4-hydroxyphenanthrene) to 9221 ng/L (1-naphthol). GM of 1-hydroxypyrene, the most commonly used PAH exposure biomarker, was 142 ng/L. The concentrations of OH-PAHs found in this study are consistent with those in developed countries and lower than those in developing countries. We observed no association between sex and OH-PAH concentrations. However, we observed lower urinary concentrations of all OH-PAHs in samples from infants (0-4 years), children (5-14 years) and the elderly (>60 year old) compared with samples from other age groups (15-29, 30-44 and 45-59 years) which may be attributed to age-dependent behaviour-specific exposure sources. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Thai, Phong K.] Queensland Univ Technol, Int Lab Air Qual & Hlth, Brisbane, Qld 4001, Australia. [Thai, Phong K.; Heffernan, Amy L.; Mueller, Jochen F.] Univ Queensland, Natl Res Ctr Environm Toxicol, Brisbane, Qld, Australia. [Toms, Leisa-Maree L.] Queensland Univ Technol, Sch Publ Hlth & Social Work, Brisbane, Qld 4001, Australia. [Toms, Leisa-Maree L.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia. [Li, Zheng; Calafat, Antonia M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hobson, Peter] Sullivan Nicolaides Pathol, Taringa, Qld, Australia. [Broomhall, Sara] Dept Environm, Canberra, ACT, Australia. RP Thai, PK (reprint author), Queensland Univ Technol, Brisbane, Qld 4001, Australia. EM phong.thai@qut.edu.au RI Mueller, Jochen/C-6241-2008; Thai, Phong/A-3998-2011; Heffernan, Amy/F-8490-2014; OI Thai, Phong/0000-0003-0042-3057; Heffernan, Amy/0000-0003-3338-8542; Mueller, Jochen/0000-0002-0000-1973 FU UQ Postdoctoral Fellowship; QUT VC Research Fellowship; ARC DECRA [DE120100161]; ARC Future Fellowship; Australian Government Department of the Environment FX The authors wish to thank Soumini Vijayasarathy, Andrew Banks, Beatrix Fletcher, Nhung Dang and the staff at Sullivan Nicolaides Pathology Taringa for assistance with sample collection and pooling. We also gratefully acknowledge US CDC staff for technical assistance in chemical analysis and statistical analysis. PT is partly funded by a UQ Postdoctoral Fellowship and a QUT VC Research Fellowship. LMLT is partly funded by an ARC DECRA (DE120100161). JFM is funded by an ARC Future Fellowship. The authors would like to thank the Australian Government Department of the Environment for their financial support. The authors declare no conflict of interest. Entox is a joint venture of the University of Queensland and the Queensland Department of Health. NR 40 TC 5 Z9 5 U1 5 U2 25 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD MAR PY 2016 VL 88 BP 30 EP 35 DI 10.1016/j.envint.2015.11.019 PG 6 WC Environmental Sciences SC Environmental Sciences & Ecology GA DF4YU UT WOS:000371359300005 PM 26700419 ER PT J AU Buser, MC Scinicariello, F AF Buser, Melanie C. Scinicariello, Franco TI Perfluoroalkyl substances and food allergies in adolescents SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Adolescents; Food allergies; NHANES; Perfluoroalkyl compounds ID PERFLUOROOCTANE SULFONATE; PRENATAL EXPOSURE; EARLY-CHILDHOOD; CHILDREN; ASTHMA; MICE; IMMUNOTOXICITY; PERSPECTIVES; CHEMICALS; DISEASES AB Perfluoroalkyl and polyfluoroalkyl substances (PFASs) are a class of organic compounds that are persistent in the environment due to their stable carbon-fluorine backbone, which is not susceptible to degradation. Research suggests these chemicals may exert an immunotoxic effect. The aim of this study is to investigate the associations between four PFASs - perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), and perfluorohexane sulfonic acid (PFHxS) - with food sensitization and food allergies in adolescent participants (ages 12-19 years) in the National Health and Nutrition Examination Survey (NHANES) 2005-2006 and 2007-2010, respectively. We performed multivariate logistic regression to analyze the association between individual PFASs with food sensitization (defined as having at least 1 food-specific IgE level >= 0.35 kU/L) in NHANES 2005-2006 and food allergies (self-reported) in NHANES 2007-2010. Serum PFOA, PFOS, and PFHxS were statistically significantly associated with higher odds to have self-reported food allergies in NHANES 2007-2010. When using IgE levels as a marker of food sensitization, we found that serum PFNA was inversely associated with food sensitization (NHANES 2005-2006). In conclusion, we found that serum levels of PFASs were associated with higher odds to have self-reported food allergies. Conversely, adolescents with higher serum PFNA were less likely to be sensitized to food allergens. These results, along with previous studies, warrant further investigation, such as well-designed longitudinal studies. Published by Elsevier Ltd. C1 [Buser, Melanie C.; Scinicariello, Franco] Agcy Tox Subst & Dis Registry ATSDR, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA. RP Scinicariello, F (reprint author), Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, 4770 Buford Hwy,MS F57, Atlanta, GA 30341 USA. EM fes6@cdc.gov NR 24 TC 1 Z9 1 U1 2 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD MAR PY 2016 VL 88 BP 74 EP 79 DI 10.1016/j.envint.2015.12.020 PG 6 WC Environmental Sciences SC Environmental Sciences & Ecology GA DF4YU UT WOS:000371359300011 PM 26722671 ER PT J AU Ramos, MJG Heffernan, AL Toms, LML Calafat, AM Ye, X Hobson, P Broomhall, S Mueller, JF AF Ramos, M. J. Gomez Heffernan, A. L. Toms, L. M. L. Calafat, A. M. Ye, X. Hobson, P. Broomhall, S. Mueller, J. F. TI Concentrations of phthalates and DINCH metabolites in pooled urine from Queensland, Australia SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Biomonitoring; Urine; Phthalates; DINCH; Plasticizers; Population monitoring; Children; Australia ID 1,2-CYCLOHEXANE DICARBOXYLIC-ACID; NUTRITION EXAMINATION SURVEY; MOTHER-CHILD-PAIRS; OXIDATIVE METABOLITES; NATIONAL-HEALTH; PREGNANT-WOMEN; HUMAN EXPOSURE; ESTER DINCH; PLASTICIZER; POPULATION AB Dialkyl phthalate esters (phthalates) are ubiquitous chemicals used extensively as plasticizers, solvents and adhesives in a range of industrial and consumer products. 1,2-Cyclohexane dicarboxylic acid, diisononyl ester (DINCH) is a phthalate alternative introduced due to a more favourable toxicological profile, but exposure is largely uncharacterised. The aim of this study was to provide the first assessment of exposure to phthalates and DINCH in the general Australian population. De-identified urine specimens stratified by age and sex were obtained from a community-based pathology laboratory and pooled (n = 24 pools of 100). Concentrations of free and total species were measured using online solid phase extraction isotope dilution high performance liquid chromatography tandem mass spectrometry. Concentrations ranged from 2.4 to 71.9 ng/mL for metabolites of di(2-ethylhexyl)phthalate, and from <0.5 to 775 ng/mL for all other metabolites. Our data suggest that phthalate metabolites concentrations in Australia were at least two times higher than in the United States and Germany; and may be related to legislative differences among countries. DINCH metabolite concentrations were comparatively low and consistent with the limited data available. Ongoing biomonitoring among the general Australian population may help assess temporal trends in exposure and assess the effectiveness of actions aimed at reducing exposures. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Ramos, M. J. Gomez; Heffernan, A. L.; Mueller, J. F.] Univ Queensland, Natl Res Ctr Environm Toxicol, Brisbane, Qld, Australia. [Toms, L. M. L.] Queensland Univ Technol, Sch Publ Hlth & Social Work, Brisbane, Qld 4001, Australia. [Toms, L. M. L.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia. [Calafat, A. M.; Ye, X.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hobson, P.] Sullivan Nicolaides Pathol, Taringa, Qld, Australia. [Broomhall, S.] Australian Govt, Dept Environm, Canberra, ACT, Australia. RP Heffernan, AL (reprint author), Natl Res Ctr Environm Toxicol, 39 Kessels Rd, Coopers Plains, Qld 4108, Australia. EM m.gomezramos@uq.edu.au; amy.heffernan@uqconnect.edu.au; leisamaree.toms@qut.edu.au; aic7@cdc.gov; xay5@cdc.gov; Peter_Hobson@snp.com.au; Sara.Broomhall@environment.gov.au; j.mueller@uq.edu.au RI Mueller, Jochen/C-6241-2008; Heffernan, Amy/F-8490-2014; OI Heffernan, Amy/0000-0003-3338-8542; Mueller, Jochen/0000-0002-0000-1973 FU ARC DECRA [DE120100161]; ARC Future Fellowship [FF120100546]; Australian Government Department of the Environment FX The authors wish to thank Soumini Vijayasarathy, Andrew Banks, Beatrix Fletcher, Nhung Dang and the staff at Sullivan Nicolaides Pathology Taringa for assistance with sample collection and pooling. We also gratefully acknowledge Manori Silva, Ella Samandar, Jim Preau, and Tao Jia for technical assistance in measuring the urinary concentrations of the phthalate and DINCH metabolites. LMLT is funded by an ARC DECRA (DE120100161). JFM is funded by an ARC Future Fellowship (FF120100546). The authors would like to thank the Australian Government Department of the Environment for their financial support, and for allowing access to the submitted report entitled "Chemical Monitoring Initiative: Australian human blood sample collection and chemical testing". The authors declare no conflict of interest. Entox is a joint venture of the University of Queensland and the Queensland Department of Health. NR 56 TC 3 Z9 3 U1 8 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD MAR PY 2016 VL 88 BP 179 EP 186 DI 10.1016/j.envint.2015.12.016 PG 8 WC Environmental Sciences SC Environmental Sciences & Ecology GA DF4YU UT WOS:000371359300024 ER PT J AU Jukic, AM Calafat, AM McConnaughey, DR Longnecker, MP Hoppin, JA Weinberg, CR Wilcox, AJ Baird, DD AF Jukic, Anne Marie Calafat, Antonia M. McConnaughey, D. Robert Longnecker, Matthew P. Hoppin, Jane A. Weinberg, Clarice R. Wilcox, Allen J. Baird, Donna D. TI Urinary Concentrations of Phthalate Metabolites and Bisphenol A and Associations with Follicular-Phase Length, Luteal-Phase Length, Fecundability, and Early Pregnancy Loss SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID OXIDATIVE STRESS; INTRAUTERINE IMPLANTATION; PRENATAL EXPOSURE; FERTILIZED OVA; IN-VITRO; WOMEN; CONCEPTION; PROGESTERONE; PROBABILITY; VARIABILITY AB BACKGROUND: Certain phthalates and bisphenol A (BPA) show reproductive effects in animal studies and potentially affect human ovulation, conception, and pregnancy loss. OBJECTIVES: We investigated these chemicals in relation to follicular-and luteal-phase lengths, time to pregnancy, and early pregnancy loss (within 6 weeks of the last menstrual period) among women attempting pregnancy. METHODS: Women discontinuing contraception provided daily first-morning urine specimens and recorded days with vaginal bleeding for up to 6 months. Specimens had previously been analyzed for estrogen and progesterone metabolites and human chorionic gonadotropin. A total of 221 participants contributed 706 menstrual cycles. We measured 11 phthalate metabolites and BPA in pooled urine from three specimens spaced throughout each menstrual cycle. We analyzed associations between chemical concentrations and outcomes using linear mixed models for follicular-and luteal-phase lengths, discrete-time fecundability models for time to pregnancy, and logistic regression for early pregnancy loss. RESULTS: Higher concentrations of monocarboxyoctyl phthalate (MCOP) were associated with shorter luteal phase [2nd tertile vs. 1st tertile: -0.5 days (95% CI: -0.9, -0.1), 3rd vs. 1st: -0.4 days (95% CI: -0.8, 0.01), p = 0.04]. BPA was also associated with shorter luteal phase [2nd vs. 1st: -0.8 days (95% CI: -1.2, -0.4), 3rd vs. 1st: -0.4 days (95% CI: -0.8, 0.02), p = 0.001]. CONCLUSIONS: BPA and MCOP (or its precursors) were associated with shorter luteal phase. Menstrual cycle-specific estimates of urinary BPA and phthalate metabolites were not associated with detrimental alterations in follicular-phase length, time to pregnancy, or early pregnancy loss, and in fact, DEHP [di(2-ethylhexyl) phthalate] metabolites {MEOHP [mono(2-ethyl-5oxohexyl) phthalate] and SDEHP} were associated with reduced early loss. These findings should be confirmed in future human studies. C1 [Jukic, Anne Marie; Longnecker, Matthew P.; Hoppin, Jane A.; Wilcox, Allen J.; Baird, Donna D.] NIEHS, Epidemiol Branch, NIH, DHHS, POB 12233, Durham, NC 27709 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. [McConnaughey, D. Robert] Westat Corp, Durham, NC USA. [Hoppin, Jane A.] N Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA. [Weinberg, Clarice R.] NIEHS, Biostat Branch, NIH, DHHS, POB 12233, Durham, NC 27709 USA. [Jukic, Anne Marie] Yale Ctr Perinatal Pediat & Environm Epidemiol, One Church St,6th Floor, New Haven, CT 06510 USA. RP Jukic, AM (reprint author), NIEHS, Epidemiol Branch, POB 12233, Durham, NC 27709 USA. EM jukica@niehs.nih.gov RI Baird, Donna/D-5214-2017; OI Baird, Donna/0000-0002-5544-2653; Longnecker, Matthew/0000-0001-6073-5322; Wilcox, Allen/0000-0002-3376-1311 FU Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences [Z01ES049003-23] FX This research was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (grant Z01ES049003-23). NR 53 TC 8 Z9 8 U1 6 U2 25 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAR PY 2016 VL 124 IS 3 BP 321 EP 328 DI 10.1289/ehp.1408164 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA DF6CJ UT WOS:000371442500018 PM 26161573 ER PT J AU Wells, EM Herbstman, JB Lin, YH Jarrett, J Verdon, CP Ward, C Caldwell, KL Hibbeln, JR Witter, FR Halden, RU Goldman, LR AF Wells, Ellen M. Herbstman, Julie B. Lin, Yu Hong Jarrett, Jeffery Verdon, Carl P. Ward, Cynthia Caldwell, Kathleen L. Hibbeln, Joseph R. Witter, Frank R. Halden, Rolf U. Goldman, Lynn R. TI Cord Blood Methylmercury and Fetal Growth Outcomes in Baltimore Newborns: Potential Confounding and Effect Modification by Omega-3 Fatty Acids, Selenium, and Sex SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID MERCURY EXPOSURE; BIRTH-WEIGHT; POLYCHLORINATED-BIPHENYLS; PROSPECTIVE COHORT; FISHING COMMUNITY; INORGANIC MERCURY; GESTATIONAL-AGE; MATERNAL BLOOD; FATTY-ACIDS; RISK-FACTOR AB BACKGROUND: Methylmercury (MeHg) may affect fetal growth; however, prior research often lacked assessment of mercury speciation, confounders, and interactions. OBJECTIVE: Our objective was to assess the relationship between MeHg and fetal growth as well as the potential for confounding or interaction of this relationship from speciated mercury, fatty acids, selenium, and sex. METHODS: This cross-sectional study includes 271 singletons born in Baltimore, Maryland, 2004-2005. Umbilical cord blood was analyzed for speciated mercury, serum omega-3 highly unsaturated fatty acids (n-3 HUFAs), and selenium. Multivariable linear regression models controlled for gestational age, birth weight, maternal age, parity, prepregnancy body mass index, smoking, hypertension, diabetes, selenium, n-3 HUFAs, and inorganic mercury (IHg). RESULTS: Geometric mean cord blood MeHg was 0.94 mu g/L (95% CI: 0.84, 1.07). In adjusted models for ponderal index, beta ln(MeHg) = -0.045 (g/cm(3)) x 100 (95% CI: -0.084, -0.005). There was no evidence of a MeHg x sex interaction with ponderal index. Contrastingly, there was evidence of a MeHg x n-3 HUFAs interaction with birth length [among low n-3 HUFAs, beta ln(MeHg) = 0.40 cm, 95% CI: -0.02, 0.81; among high n-3 HUFAs, beta ln(MeHg) = -0.15, 95% CI: -0.54, 0.25; p-interaction = 0.048] and head circumference [among low n-3 HUFAs, beta ln(MeHg) = 0.01 cm, 95% CI: -0.27, 0.29; among high n-3 HUFAs, beta ln(MeHg) = -0.37, 95% CI: -0.63, -0.10; p-interaction = 0.042]. The association of MeHg with birth weight and ponderal index was affected by n-3 HUFAs, selenium, and IHg. For birth weight, beta ln(MeHg) without these variables was -16.8 g (95% CI: -75.0, 41.3) versus -29.7 (95% CI: -93.9, 34.6) with all covariates. Corresponding values for ponderal index were -0.030 (g/cm(3)) x 100 (95% CI: -0.065, 0.005) and -0.045 (95% CI: -0.084, -0005). CONCLUSION: We observed an association of increased MeHg with decreased ponderal index. There is evidence for interaction between MeHg and n-3 HUFAs; infants with higher MeHg and n-3 HUFAs had lower birth length and head circumference. These results should be verified with additional studies. C1 [Wells, Ellen M.] Purdue Univ, Sch Hlth Sci, Hampton Hall Civil Engn 1269,550 Stadium Mall Dr, W Lafayette, IN 47907 USA. [Herbstman, Julie B.] Columbia Univ, Columbia Ctr Childrens Environm Hlth, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA. [Lin, Yu Hong; Hibbeln, Joseph R.] NIAAA, Lab Membrane Biochem & Biophys, Dept Hlth & Human Serv, NIH, Rockville, MD 20852 USA. [Jarrett, Jeffery; Verdon, Carl P.; Ward, Cynthia; Caldwell, Kathleen L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. [Witter, Frank R.] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA. [Halden, Rolf U.] Arizona State Univ, Ctr Environm Secur, Biodesign Inst, Global Secur Initiat, Tempe, AZ USA. [Goldman, Lynn R.] George Washington Univ, Milken Inst Sch Publ Hlth, Dept Environm & Occupat Hlth, Washington, DC USA. RP Wells, EM (reprint author), Purdue Univ, Sch Hlth Sci, Hampton Hall Civil Engn 1269,550 Stadium Mall Dr, W Lafayette, IN 47907 USA. EM wells54@purdue.edu OI Jarrett, Jeffery/0000-0001-5755-3552; Wells, Ellen/0000-0002-7293-1395 FU Maryland Department of Health and Mental Hygiene Cigarette Restitution Program (Baltimore, MD); National Institute of Environmental Health Sciences/National Institutes of Health (NIH) (Bethesda, MD) [1R01ES015445]; U.S. Environmental Protection Agency (EPA) STAR Fellowship Program (Washington, DC) FX This study was funded by the Maryland Department of Health and Mental Hygiene Cigarette Restitution Program (Baltimore, MD), the National Institute of Environmental Health Sciences/National Institutes of Health (NIH) grant 1R01ES015445 (Bethesda, MD) (R.U.H.), and the U.S. Environmental Protection Agency (EPA) STAR Fellowship Program (Washington, DC) (E.M.W.). NR 55 TC 2 Z9 2 U1 8 U2 19 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAR PY 2016 VL 124 IS 3 BP 373 EP 379 DI 10.1289/ehp.1408596 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA DF6CJ UT WOS:000371442500025 PM 26115160 ER PT J AU Pratt, LA Druss, BG Manderscheid, RW Walker, ER AF Pratt, Laura A. Druss, Benjamin G. Manderscheid, Ronald W. Walker, Elizabeth Reisinger TI Excess mortality due to depression and anxiety in the United States: results from a nationally representative survey SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE NHIS; Mental health; Depression; Anxiety; Mortality ID EPIDEMIOLOGIC CATCHMENT-AREA; ALL-CAUSE MORTALITY; MAJOR DEPRESSION; MENTAL-DISORDERS; EDUCATIONAL-ATTAINMENT; PSYCHIATRIC-DISORDERS; FOLLOW-UP; ILLNESS; SCHIZOPHRENIA; POPULATION AB Objectives: We compared the mortality of persons with and without anxiety and depression in a nationally representative survey and examined the role of socioeconomic factors, chronic diseases and health behaviors in explaining excess mortality. Methods: The 1999 National Health Interview Survey was linked with mortality data through 2011. We calculated the hazard ratio (HR) for mortality by presence or absence of anxiety/depression and evaluated potential mediators. We calculated the population attributable risk of mortality for anxiety/depression. Results: Persons with anxiety/depression died 7.9 years earlier than other persons. At a population level, 3.5% of deaths were attributable to anxiety/depression. Adjusting for demographic factors, anxiety/depression was associated with an elevated risk of mortality [HR=1.61, 95% confidence interval (CI)= 1.40, 1.84]. Chronic diseases and health behaviors explained much of the elevated risk. Adjusting for demographic factors, people with past-year contact with a mental health professional did not demonstrate excess mortality associated with anxiety/depression while those without contact did. Conclusions: Anxiety/depression presents a mortality burden at both individual and population levels. Our findings are consistent with targeting health behaviors and physical illnesses as strategies for reducing this excess mortality among people with anxiety/depression. Published by Elsevier Inc. C1 [Pratt, Laura A.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 6333, Hyattsville, MD 20782 USA. [Druss, Benjamin G.; Walker, Elizabeth Reisinger] Rollins Sch Publ Hlth, Ctr Behav Hlth Policy Studies, Dept Hlth Policy & Management, 1518 Clifton Rd NE,Room 638, Atlanta, GA 30322 USA. [Manderscheid, Ronald W.] Natl Assoc Cty Behav Hlth & Dev Disabil Directors, 25 Massachusetts Ave NW,Suite 500, Washington, DC 20001 USA. RP Pratt, LA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 6333, Hyattsville, MD 20782 USA. EM lpratt@cdc.gov; bdrus@emory.edu; rmanderscheid@nacbhd.org; ereisin@emory.edu FU National Institute of Mental Health Award [K24 MH075867]; National Institutes of Health/National Institute of General Medical Sciences Institutional Research and Academic Career Development Award [K12 GM00680-05]; Academic Career Development Award [K12 GM00680-05] FX This research was supported by a National Institute of Mental Health Award (K24 MH075867) and by a National Institutes of Health/National Institute of General Medical Sciences Institutional Research and Academic Career Development Award (K12 GM00680-05). NR 46 TC 3 Z9 3 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 EI 1873-7714 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD MAR-APR PY 2016 VL 39 BP 39 EP 45 DI 10.1016/j.genhosppsych.2015.12.003 PG 7 WC Psychiatry SC Psychiatry GA DF3KY UT WOS:000371244000006 PM 26791259 ER PT J AU Baker, MW Atkins, AE Cordovado, SK Hendrix, M Earley, MC Farrell, PM AF Baker, Mei W. Atkins, Anne E. Cordovado, Suzanne K. Hendrix, Miyono Earley, Marie C. Farrell, Philip M. TI Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study SO GENETICS IN MEDICINE LA English DT Article DE cystic fibrosis; cystic fibrosis transmembrane conductance regulator; immunoreactive trypsinogen; newborn screening; next-generation sequencing ID TRANSMEMBRANE CONDUCTANCE REGULATOR; IMMUNOREACTIVE TRYPSINOGEN; METABOLIC SYNDROME; GENETIC-ANALYSIS; CFTR GENE; MUTATION; POPULATION; INFANTS; IDENTIFICATION; EXPERIENCE AB Purpose: Many regions have implemented newborn screening (NBS) for cystic fibrosis (CF) using a limited panel of cystic fibrosis transmembrane regulator (CFTR) mutations after immunoreactive trypsinogen (IRT) analysis. We sought to assess the feasibility of further improving the screening using next-generation sequencing (NGS) technology. Methods: An NGS assay was used to detect 162 CFTR mutations/ variants characterized by the CFTR2 project. We used 67 dried blood spots (DBSs) containing 48 distinct CFTR mutations to validate the assay. NGS assay was retrospectively performed on 165 CF screen-positive samples with one CFTR mutation. Results: The NGS assay was successfully performed using DNA isolated from DBSs, and it correctly detected all CFTR mutations in the validation. Among 165 screen-positive infants with one CFTR muta-tion, no additional disease-causing mutation was identified in 151 samples consistent with normal sweat tests. Five infants had a CF-causing mutation that was not included in this panel, and nine with two CF-causing mutations were identified. Conclusion: The NGS assay was 100% concordant with traditional methods. Retrospective analysis results indicate an IRT/NGS screening algorithm would enable high sensitivity, better specificity and positive predictive value (PPV). This study lays the foundation for prospective studies and for introducing NGS in NBS laboratories. C1 [Baker, Mei W.; Farrell, Philip M.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA. [Baker, Mei W.; Atkins, Anne E.] Univ Wisconsin, Wisconsin State Lab Hyg, Newborn Screening Lab, Madison, WI 53706 USA. [Cordovado, Suzanne K.; Hendrix, Miyono; Earley, Marie C.] Ctr Dis Control & Prevent, Newborn Screening & Mol Biol Branch, Atlanta, GA USA. [Farrell, Philip M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. RP Baker, MW (reprint author), Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA.; Baker, MW (reprint author), Univ Wisconsin, Wisconsin State Lab Hyg, Newborn Screening Lab, Madison, WI 53706 USA. EM mwbaker@wisc.edu FU Legacy of Angels Foundation FX This study was funded by the Legacy of Angels Foundation. The authors thank Laurence Lee for his assistance with the figure. Mention of any company or product does not constitute endorsement by the Centers for Disease Control and Prevention. NR 30 TC 10 Z9 10 U1 4 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD MAR PY 2016 VL 18 IS 3 BP 231 EP 238 DI 10.1038/gim.2014.209 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA DF4IX UT WOS:000371312300004 PM 25674778 ER PT J AU Piel, FB Adamkiewicz, TV Amendah, D Williams, TN Gupta, S Grosse, SD AF Piel, Frederic B. Adamkiewicz, Thomas V. Amendah, Djesika Williams, Thomas N. Gupta, Sunetra Grosse, Scott D. TI Observed and expected frequencies of structural hemoglobin variants in newborn screening surveys in Africa and the Middle East: deviations from Hardy-Weinberg equilibrium SO GENETICS IN MEDICINE LA English DT Article DE deviation; Hardy-Weinberg equilibrium; hemoglobin C; newborn screening; sickle hemoglobin ID SICKLE-CELL-DISEASE; GLOBAL EPIDEMIOLOGY; CONSANGUINITY; DIVERSITY; ADMIXTURE; CHILDREN; MALARIA; ANEMIA; MODEL AB Purpose: Our objective was to compare observed and expected genotype proportions from newborn screening surveys of structural hemoglobin variants. Methods: We conducted a systematic review of newborn screening surveys of hemoglobins S and C in Africa and the Middle East. We compared observed frequencies to those expected assuming Hardy-Weinberg equilibrium (HWE). Significant deviations were identified by an exact test. The fixation index F-IS was calculated to assess excess homozygosity. We compared newborn estimates corrected and uncorrected for HWE deviations using demographic data. Results: Sixty samples reported genotype counts for hemoglobin variants in Africa and the Middle East. Observed and expected counts matched in 27%. The observed number of sickle cell anemia (SCA) individuals was higher than expected in 42 samples, reaching significance (P < 0.05) in 24. High F-IS values were common across the study regions. The estimated total number of newborns with SCA, corrected based on F-IS, was 33,261 annual births instead of 24,958 for the 38 samples across sub-Saharan Africa and 1,109 annual births instead of 578 for 12 samples from the Middle East. Conclusion: Differences between observed and expected genotype frequencies are common in surveys of hemoglobin variants in the study regions. Further research is required to identify and quantify factors responsible for such deviations. Estimates based on HWE might substantially underestimate the annual number of SCA-affected newborns (up to one-third in sub-Saharan Africa and one-half in the Middle East). C1 [Piel, Frederic B.; Gupta, Sunetra] Univ Oxford, Dept Zool, S Parks Rd, Oxford, England. [Adamkiewicz, Thomas V.] Morehouse Sch Med, Dept Family Med, Atlanta, GA 30310 USA. [Amendah, Djesika] African Populat & Hlth Res Ctr, Nairobi, Kenya. [Williams, Thomas N.] Kilifi Dist Hosp, Ctr Geog Med Res Coast, Wellcome Trust Programme, Kenya Med Res Inst, Kilifi, Kenya. [Williams, Thomas N.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Med, London, England. [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Piel, FB (reprint author), Univ Oxford, Dept Zool, S Parks Rd, Oxford, England. EM fred.piel@zoo.ox.ac.uk OI Williams, Thomas/0000-0003-4456-2382; Piel, Frederic B./0000-0001-8131-7728; Grosse, Scott/0000-0003-1078-6855 FU European Research Council; Wellcome Trust [091758] FX The authors thank Krista Crider for comments on an early version of the manuscript, and Danielle Lena from the Association Mediterranee Hemoglobine (Med-Hem) for sharing additional data about the surveys described in Diallo, 2008. F.B.P. has been partly supported by an advanced grant (Diversity) from the European Research Council. TNW is funded by a senior clinical fellowship from the Wellcome Trust (091758). This report was submitted with permission of the Director of the Kenya Medical Research Institute. NR 41 TC 3 Z9 3 U1 3 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD MAR PY 2016 VL 18 IS 3 BP 265 EP 274 DI 10.1038/gim.2015.143 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA DF4IX UT WOS:000371312300008 PM 26633548 ER PT J AU Limbago, BM AF Limbago, Brandi M. TI What's in a Name? The Impact of Accurate Staphylococcus pseudintermedius Identification on Appropriate Antimicrobial Susceptibility Testing SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Editorial Material ID INTERMEDIUS; STRAINS; AUREUS AB Bacteria in the Staphylococcus intermedius group, including Staphylococcus pseudintermedius, often encode mecA-mediated methicillin resistance. Reliable detection of this phenotype for proper treatment and infection control decisions requires that these coagulase-positive staphylococci are accurately identified and specifically that they are not misidentified as S. aureus. As correct species level bacterial identification becomes more commonplace in clinical laboratories, one can expect to see changes in guidance for antimicrobial susceptibility testing and interpretation. The study by Wu et al. in this issue (M. T. Wu, C.-A. D. Burnham, L. F. Westblade, J. Dien Bard, S. D. Lawhon, M. A. Wallace, T. Stanley, E. Burd, J. Hindler, R. M. Humphries, J Clin Microbiol 54:535-542, 2016, http://dx.doi.org/10.1128/JCM.02864-15) highlights the impact of robust identification of S. intermedius group organisms on the selection of appropriate antimicrobial susceptibility testing methods and interpretation. C1 [Limbago, Brandi M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Limbago, BM (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. EM BBL7@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2016 VL 54 IS 3 BP 516 EP 517 DI 10.1128/JCM.03091-15 PG 2 WC Microbiology SC Microbiology GA DF2EC UT WOS:000371152200004 PM 26763965 ER PT J AU Lutgring, JD Limbago, BM AF Lutgring, Joseph D. Limbago, Brandi M. TI The Problem of Carbapenemase-Producing-Carbapenem-Resistant-Enterobacteriaceae Detection SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Review ID MODIFIED HODGE TEST; KLEBSIELLA-PNEUMONIAE CARBAPENEMASE; GRAM-NEGATIVE BACTERIA; DESORPTION IONIZATION-TIME; FLIGHT MASS-SPECTROMETRY; RAPID DETECTION; UNITED-STATES; NP TEST; PSEUDOMONAS-AERUGINOSA; BETA-LACTAMASES AB The emergence and spread of carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) are a significant clinical and public health concern. Reliable detection of CP-CRE is the first step in combating this problem. There are both phenotypic and molecular methods available for CP-CRE detection. There is no single detection method that is ideal for all situations. C1 [Lutgring, Joseph D.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Limbago, Brandi M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Clin & Environm Microbiol Branch, Atlanta, GA USA. RP Limbago, BM (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Clin & Environm Microbiol Branch, Atlanta, GA USA. EM blimbago@cdc.gov NR 45 TC 12 Z9 13 U1 6 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2016 VL 54 IS 3 BP 529 EP 534 DI 10.1128/JCM.02771-15 PG 6 WC Microbiology SC Microbiology GA DF2EC UT WOS:000371152200007 PM 26739152 ER PT J AU Shewmaker, PL Whitney, AM Humrighouse, BW AF Shewmaker, P. L. Whitney, A. M. Humrighouse, B. W. TI Phenotypic, Genotypic, and Antimicrobial Characteristics of Streptococcus halichoeri Isolates from Humans, Proposal To Rename Streptococcus halichoeri as Streptococcus halichoeri subsp halichoeri, and Description of Streptococcus halichoeri subsp hominis subsp nov., a Bacterium Associated with Human Clinical Infections SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID NEIGHBOR-JOINING METHOD; GENUS STREPTOCOCCUS; IDENTIFICATION; PHYLOGENIES AB Phenotypic, genotypic, and antimicrobial characteristics of six phenotypically distinct human clinical isolates that most closely resembled the type strain of Streptococcus halichoeri isolated from a seal are presented. Sequencing of the 16S rRNA, rpoB, sodA, and recN genes; comparative whole-genome analysis; conventional biochemical and Rapid ID 32 Strep identification methods; and antimicrobial susceptibility testing were performed on the human isolates, the type strain of S. halichoeri, and type strains of closely related species. The six human clinical isolates were biochemically indistinguishable from each other and showed 100% 16S rRNA, rpoB, sodA, and recN gene sequence similarity. Comparative 16S rRNA gene sequencing analysis revealed 98.6% similarity to S. halichoeri CCUG 48324(T), 97.9% similarity to S. canis ATCC 43496(T), and 97.8% similarity to S. ictaluri ATCC BAA-1300(T). A 3,530-bp fragment of the rpoB gene was 98.8% similar to the S. halichoeri type strain, 84.6% to the S. canis type strain, and 83.8% to the S. ictaluri type strain. The S. halichoeri type strain and the human clinical isolates were susceptible to the antimicrobials tested based on CLSI guidelines for Streptococcus species viridans group with the exception of tetracycline and erythromycin. The human isolates were phenotypically distinct from the type strain isolated from a seal; comparative whole-genome sequence analysis confirmed that the human isolates were S. halichoeri. On the basis of these results, a novel subspecies, Streptococcus halichoeri subsp. hominis, is proposed for the human isolates and Streptococcus halichoeri subsp. halichoeri is proposed for the gray seal isolates. The type strain of the novel subspecies is SS1844(T) = CCUG 67100(T) = LMG 28801(T). C1 [Shewmaker, P. L.] Ctr Dis Control & Prevent, Div Resp Dis, Atlanta, GA USA. [Whitney, A. M.; Humrighouse, B. W.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Shewmaker, PL (reprint author), Ctr Dis Control & Prevent, Div Resp Dis, Atlanta, GA USA. EM PShewmaker@cdc.gov NR 20 TC 2 Z9 2 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2016 VL 54 IS 3 BP 739 EP 744 DI 10.1128/JCM.03214-15 PG 6 WC Microbiology SC Microbiology GA DF2EC UT WOS:000371152200034 PM 26763962 ER PT J AU Arnold, AR Burnham, CAD Ford, BA Lawhon, SD McAllister, SK Lonsway, D Albrecht, V Jerris, RC Rasheed, JK Limbago, B Burd, EM Westblade, LF AF Arnold, A. R. Burnham, C. -A. D. Ford, B. A. Lawhon, S. D. McAllister, S. K. Lonsway, D. Albrecht, V. Jerris, R. C. Rasheed, J. K. Limbago, B. Burd, E. M. Westblade, L. F. TI Evaluation of an Immunochromatographic Assay for Rapid Detection of Penicillin-Binding Protein 2a in Human and Animal Staphylococcus intermedius Group, Staphylococcus lugdunensis, and Staphylococcus schleiferi Clinical Isolates SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID COAGULASE-NEGATIVE STAPHYLOCOCCI; METHICILLIN RESISTANCE; AUREUS; PSEUDINTERMEDIUS; PATHOGENESIS; INFECTION; IDENTIFICATION; EPIDEMIOLOGY; DIAGNOSTICS; EMERGENCE AB The performance of a rapid penicillin-binding protein 2a (PBP2a) detection assay, the Alere PBP2a culture colony test, was evaluated for identification of PBP2a-mediated beta-lactam resistance in human and animal clinical isolates of Staphylococcus intermedius group, Staphylococcus lugdunensis, and Staphylococcus schleiferi. The assay was sensitive and specific, with all PBP2a-negative and PBP2a-positive strains testing negative and positive, respectively. C1 [Arnold, A. R.; Jerris, R. C.; Burd, E. M.] Emory Univ, Sch Med, Atlanta, GA USA. [Burnham, C. -A. D.] Washington Univ, Sch Med, St Louis, MO USA. [Ford, B. A.] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA. [Lawhon, S. D.] Texas A&M Univ, Coll Vet Med & Biomed Sci, College Stn, TX USA. [McAllister, S. K.; Lonsway, D.; Albrecht, V.; Rasheed, J. K.; Limbago, B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jerris, R. C.] Childrens Healthcare Atlanta, Atlanta, GA USA. [Burd, E. M.] Emory Antibiot Resistance Ctr, Atlanta, GA USA. [Westblade, L. F.] Weill Cornell Med Coll, New York, NY USA. RP Burd, EM (reprint author), Emory Univ, Sch Med, Atlanta, GA USA.; Burd, EM (reprint author), Emory Antibiot Resistance Ctr, Atlanta, GA USA.; Westblade, LF (reprint author), Weill Cornell Med Coll, New York, NY USA. EM eburd@emory.edu; law9067@med.cornell.edu RI Lawhon, Sara/G-5147-2011 OI Lawhon, Sara/0000-0001-9154-8909 NR 22 TC 2 Z9 2 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2016 VL 54 IS 3 BP 745 EP 748 DI 10.1128/JCM.02869-15 PG 4 WC Microbiology SC Microbiology GA DF2EC UT WOS:000371152200035 PM 26677248 ER PT J AU Matanock, A Katz, LS Jackson, KA Kucerova, Z Conrad, AR Glover, WA Nguyen, V Mohr, MC Marsden-Haug, N Thompson, D Dunn, JR Stroika, S Melius, B Tarr, C Dietrich, SE Kao, AS Kornstein, L Li, Z Maroufi, A Marder, EP Meyer, R Perez-Osorio, AC Reddy, V Reporter, R Carleton, H Tweeten, S Waechter, H Yee, LM Wise, ME Davis, K Jackson, BR AF Matanock, Almea Katz, Lee S. Jackson, Kelly A. Kucerova, Zuzana Conrad, Amanda R. Glover, William A. Von Nguyen Mohr, Marika C. Marsden-Haug, Nicola Thompson, Deborah Dunn, John R. Stroika, Steven Melius, Beth Tarr, Cheryl Dietrich, Stephen E. Kao, Annie S. Kornstein, Laura Li, Zhen Maroufi, Azarnoush Marder, Ellyn P. Meyer, Rebecca Perez-Osorio, Ailyn C. Reddy, Vasudha Reporter, Roshan Carleton, Heather Tweeten, Samantha Waechter, HaeNa Yee, Lisa M. Wise, Matthew E. Davis, Kim Jackson, Brendan R. TI Two Listeria monocytogenes Pseudo-outbreaks Caused by Contaminated Laboratory Culture Media SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article AB Listeriosis is a serious foodborne infection that disproportionately affects elderly adults, pregnant women, newborns, and immunocompromised individuals. Diagnosis is made by culturing Listeria monocytogenes from sterile body fluids or from products of conception. This report describes the investigations of two listeriosis pseudo-outbreaks caused by contaminated laboratory media made from sheep blood. C1 [Matanock, Almea; Katz, Lee S.; Jackson, Kelly A.; Kucerova, Zuzana; Conrad, Amanda R.; Von Nguyen; Stroika, Steven; Tarr, Cheryl; Carleton, Heather; Jackson, Brendan R.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Matanock, Almea] Epidem Intelligence Serv, Atlanta, GA USA. [Conrad, Amanda R.] Atlanta Res & Educ Fdn, Decatur, GA USA. [Glover, William A.; Marsden-Haug, Nicola; Melius, Beth; Li, Zhen; Perez-Osorio, Ailyn C.] Washington State Dept Hlth, Shoreline, WA USA. [Mohr, Marika C.] Ohio Dept Hlth, Columbus, OH 43266 USA. [Thompson, Deborah] New Mexico Dept Hlth, Santa Fe, NM USA. [Dunn, John R.; Marder, Ellyn P.] Tennessee Dept Hlth, Nashville, TN USA. [Dietrich, Stephen E.] Michigan Dept Hlth & Human Serv, Lansing, MI USA. [Kao, Annie S.] Cty San Diego Hlth & Human Serv Agcy, San Diego, CA USA. [Kornstein, Laura; Reddy, Vasudha; Waechter, HaeNa] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Meyer, Rebecca] Georgia Dept Publ Hlth, Atlanta, GA USA. [Maroufi, Azarnoush; Reporter, Roshan; Tweeten, Samantha; Yee, Lisa M.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Davis, Kim] US FDA, Silver Spring, MD USA. RP Matanock, A (reprint author), US Ctr Dis Control & Prevent, Atlanta, GA USA. EM xdf2@cdc.gov NR 5 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2016 VL 54 IS 3 BP 768 EP 770 DI 10.1128/JCM.02035-15 PG 3 WC Microbiology SC Microbiology GA DF2EC UT WOS:000371152200040 PM 26699704 ER PT J AU Gallo, MF Legardy-Williams, J Hylton-Kong, T Rattray, C Kourtis, AP Jamieson, DJ Steiner, MJ AF Gallo, Maria F. Legardy-Williams, Jennifer Hylton-Kong, Tina Rattray, Carole Kourtis, Athena P. Jamieson, Denise J. Steiner, Markus J. TI Association of Progestin Contraceptive Implant and Weight Gain SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID BODY-MASS INDEX; UNITED-STATES; CONTINUATION; PATTERNS; TRIALS; SAFETY; ADULTS; WOMEN AB OBJECTIVE: To evaluate initiation of a two-rod, 150-mg levonorgestrel contraceptive implant on women's perceived and observed body weight. METHODS: We conducted a secondary analysis of data from an open, randomized controlled trial of adult, nonpregnant, human immunodeficiency virus-negative women attending a public clinic in Kingston, Jamaica, who were assigned to initiate implant use either immediately or after a 3-month delay. The primary objective of the parent study was to assess the effect of initiation of the implant on the frequency of condom use. We compared study arms during follow-up using one-sided chi(2) tests for differences in perceived weight gain and loss, one-sided Wilcoxon-Mann-Whitney tests for median gain in measured weight, and logistic regression with generalized estimating equations for risk of gaining greater than 2 kg. RESULTS: From 2012 to 2014, women were assigned to the implant (n=208) or delay arm (n=206). At 3 months, more women in the implant arm (15.3%) reported perceived weight gain than in the control arm (4.3%) (P=.01). Despite differences in perception, the implant and control arms did not differ significantly in median weight gain at 1-month (0.0 kg and 0.0 kg, respectively; P=.44) and 3-month visits (0.5 kg and 0.0 kg, respectively; P=.27). Study arms did not differ in risk of gaining greater than 2 kg (odds ratio 0.9, 95% confidence interval 0.6-1.3). CONCLUSION: We found no evidence of weight gain from short-term implant use. Through the power of the nocebo effect, the practice of counseling women to expect possible weight gain from initiating implant use could lead them to perceive weight gain even in its absence and contribute to the early discontinuation of this highly effective contraceptive method. C1 [Gallo, Maria F.] Ohio State Univ, Div Epidemiol, Coll Publ Hlth, 324 Cunz Hall,1841 Neil Ave, Columbus, OH 43210 USA. Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. Comprehens Hlth Ctr, Epidemiol Res & Training Unit, Kingston, Jamaica. Univ Hosp West Indies, Minist Hlth, Kingston, Jamaica. Contracept Technol Innovat Div, FHI 360, Durham, NC USA. RP Gallo, MF (reprint author), Ohio State Univ, Div Epidemiol, Coll Publ Hlth, 324 Cunz Hall,1841 Neil Ave, Columbus, OH 43210 USA. EM mgallo@cph.osu.edu FU Centers for Disease Control and Prevention, U.S. Agency for International Development, Family Health International [FHI 360, CA/GPO-A-00-05-00022] FX Supported by the Centers for Disease Control and Prevention, U.S. Agency for International Development, Family Health International (FHI 360) cooperative agreement, CA/GPO-A-00-05-00022. NR 20 TC 2 Z9 2 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD MAR PY 2016 VL 127 IS 3 BP 573 EP 576 DI 10.1097/AOG.0000000000001289 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DE6DJ UT WOS:000370723600002 PM 26855107 ER PT J AU Benacer, D Zain, SNM Sim, SZ Khalid, MKNM Galloway, RL Souris, M Thong, KL AF Benacer, Douadi Zain, Siti Nursheena Mohd Sim, Shin Zhu Khalid, Mohd Khairul Nizam Mohd Galloway, Renee L. Souris, Marc Thong, Kwai Lin TI Determination of Leptospira borgpetersenii serovar Javanica and Leptospira interrogans serovar Bataviae as the persistent Leptospira serovars circulating in the urban rat populations in Peninsular Malaysia SO PARASITES & VECTORS LA English DT Article DE Leptospira; Leptospirosis; Rodents; Outbreaks ID BACTERIOLOGICAL CULTURE; PATHOGENIC LEPTOSPIRES; INFECTION; RISK; RODENTS; PCR; ENVIRONMENT; PREVALENCE; DYNAMICS; CENTERS AB Background: Leptospirosis is an emerging infectious disease of global significance, and is endemic in tropical countries, including Malaysia. Over the last decade, a dramatic increase of human cases was reported; however, information on the primary vector, the rat, and the Leptospira serovars circulating among the rat population is limited. Therefore, the present study was undertaken to isolate Leptospira and characterise the serovars circulating in the urban rat populations from selected main cities in Peninsular Malaysia. Methods: Rat trappings were carried out between October 2011 to February 2014 in five urban cities which were chosen as study sites to represent different geographical locations in Peninsular Malaysia. Microscopic agglutination test (MAT) and PCR were carried out to identify the Leptospiral serogroup and determine the pathogenic status of the isolates, respectively while pulsed-field gel electrophoresis (PFGE) and random amplified polymorphic DNA (RAPD)-PCR were used to characterize the isolates. Results: Three rat species were identified from the three hundred and fifty seven rats captured with Rattus rattus, being the dominant rat species (285, 80 %) followed by Rattus norgevicus (53, 15 %) and Rattus exulans (19, 5 %). Only 39 samples (11.0 %) were positive by culture and further confirmed as pathogenic Leptospira by PCR. Significant associations were shown between host infection with locality, season, host-age and species. Based on MAT, two serogroups were identified in the population namely; L. borgpetersenii serogroup Javanica (n = 16) and L. interrogans serogroup Bataviae (n = 23). Pulsed-field gel electrophoresis (PFGE) distinguished the two serovars in the urban rat populations: L. borgpetersenii serovar Javanica (41 %), and L. interrogans serovar Bataviae (59 %). RAPD-PCR yielded 14 distinct patterns and was found to be more discriminative than PFGE. Conclusions: This study confirms two Leptospira serovars circulating among the urban rats population in Peninsular Malaysia namely; L. borgpetersenii serovar Javanica and L. interrogans serovars Bataviae. Despite the low number of isolates obtained from the rat population, this study suggests that rodent control programs and disease surveillance may help to reduce the possible risk of disease transmission. C1 [Benacer, Douadi; Zain, Siti Nursheena Mohd; Thong, Kwai Lin] Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur, Malaysia. [Sim, Shin Zhu] Univ Malaya, Fac Sci, Inst Math Sci, Kuala Lumpur, Malaysia. [Sim, Shin Zhu] Univ Tunku Abdul Rahman, Lee Kong Chian Fac Engn & Sci, Kuala Lumpur, Malaysia. [Khalid, Mohd Khairul Nizam Mohd] Minist Hlth, Inst Med Res, Bacteriol Unit, Kuala Lumpur, Malaysia. [Galloway, Renee L.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Atlanta, GA USA. [Souris, Marc] Aix Marseille Univ, IRD, EHESP, UMR Emergence Pathol Virales 190, Marseille, France. RP Thong, KL (reprint author), Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur, Malaysia. EM thongkl@um.edu.my RI Mohd Khalid, Mohd Khairul Nizam/F-3821-2016; Thong, Kwai Lin/B-3946-2009; SOURIS, Marc/K-2506-2016 OI Mohd Khalid, Mohd Khairul Nizam/0000-0001-7200-3102; SOURIS, Marc/0000-0002-2933-3488 FU University of Malaya, Kuala Lumpur, Malaysia [RG053/11BIO RP016B-14AFR, UM.C/625/1HIR/MOHE/CHAN/11/2] FX This study was funded by research grant (RG053/11BIO & RP016B-14AFR) and Malaya High Impact Research Grant [reference UM.C/625/1HIR/MOHE/CHAN/11/2] from the University of Malaya, Kuala Lumpur, Malaysia. We would like to thank Ms Nur Adilah BB and Mr Cheong ZY for help in rat trappings. Sincere thanks are extended to the following agencies for their invaluable assistance in sampling the wild rats, namely, Vector and Rodent Unit of Kuantan Municipal Council (MPK), Public Health Unit, Municipal Council of Penang Island (MPPP) and Vector Control Unit of Melaka Historic City Council (MBMB). Ampang Jaya Municipal Council and Kuala Selangor District Council. Grateful thanks are also extended to staff members from University of Science Malaysia (USM), International Islamic University Malaysia (IIUM) Kuantan and Kolej Antarabangsa Sains dan Teknologi Melaka (MiCoST) for their support and assistance. NR 48 TC 3 Z9 3 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD MAR 1 PY 2016 VL 9 AR 117 DI 10.1186/s13071-016-1400-1 PG 11 WC Parasitology SC Parasitology GA DF6GW UT WOS:000371454900001 PM 26927873 ER PT J AU Xu, HL Jin, Y Wu, WX Li, P Wang, L Li, N Feng, YY Xiao, LH AF Xu, Hailing Jin, Yue Wu, Wenxian Li, Pei Wang, Lin Li, Na Feng, Yaoyu Xiao, Lihua TI Genotypes of Cryptosporidium spp., Enterocytozoon bieneusi and Giardia duodenalis in dogs and cats in Shanghai, China SO PARASITES & VECTORS LA English DT Article DE Cryptosporidium spp.; Enterocytozoon bieneusi; Giardia duodenalis; Genotype ID MOLECULAR CHARACTERIZATION; ZOONOTIC TRANSMISSION; SOUTHERN CHINA; ASSEMBLAGE B; PET DOGS; IDENTIFICATION; PREVALENCE; ANIMALS; EPIDEMIOLOGY; DIVERSITY AB Background: Controversies exist on the potential role of companion animals in the transmission of enteric pathogens in humans. This study was conducted to examine the genotype distribution of Cryptosporidium spp., Enterocytozoon bieneusi, and Giardia duodenalis in companion animals in Shanghai, China, and to assess their zoonotic potential. Methods: Fecal specimens from 485 dogs and 160 cats were examined for the occurrence and genotype distribution of the three pathogens by PCR. PCR products were sequenced to determine the species and genotypes. The chi(2) test was used to compare differences in infection rates between living conditions or age groups. Results: Cryptosporidium spp., E. bieneusi and G. duodenalis were found in 39 (8.0 %), 29 (6.0 %) and 127 (26.2 %) of dogs, and 6 (3.8 %), 9 (5.6 %) and 21 (13.1 %) of cats, respectively. Infection rates of the pathogens in dogs from pet shops and a clinic were higher than those in household dogs, and higher in cats from one animal shelter than from pet shops. No significant differences in infection rates were detected among age groups. Cryptosporidium canis and C. felis were the only Cryptosporidium species found in dogs and cats, respectively. Enterocytozoon bieneusi genotype PtEb IX was the dominant genotype in dogs, whereas Type IV and D were the most common ones in cats. Multi-locus sequence typing at the glutamate dehydrogenase, beta-giardin, and triosephosphate isomerase loci revealed the presence of G. duodenalis assemblages A (n = 23), B (n = 1), C (n = 26), and D (n = 58) in dogs (only A in household dogs) and assemblages A (n = 2), B (n = 6), C (n = 2), D (n = 1), and F (n = 7) in cats. Co-infection was detected in 24 dogs and 5 cats, especially those living in crowded conditions. Conclusions: Living condition is a major risk factor affecting the occurrence of enteric protists in companion animals in China, and although dogs and cats can be potential sources of human infections, the different distribution of pathogen species and genotypes between dogs and cats suggests that inter-species transmission of these pathogens is probably rare in the study area. C1 [Xu, Hailing; Jin, Yue; Wu, Wenxian; Li, Pei; Wang, Lin; Li, Na; Feng, Yaoyu] E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. [Xiao, Lihua] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Li, N; Feng, YY (reprint author), E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. EM nli@ecust.edu.cn; yyfeng@ecust.edu.cn RI Feng, Yaoyu/B-3076-2014; Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU National Natural Science Foundation of China [31425025, 31229005, 31302078, 31502055]; Open Funding Project of the State Key Laboratory of Veterinary Etiological Biology, Lanzhou, China [SKLVEB2014KFKT008]; Fundamental Research Funds for the Central Universities, China FX This work was supported by the National Natural Science Foundation of China (31425025, 31229005, 31302078, and 31502055), the Open Funding Project of the State Key Laboratory of Veterinary Etiological Biology, Lanzhou, China (SKLVEB2014KFKT008), and the Fundamental Research Funds for the Central Universities, China. The findings and conclusions in this study are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 38 TC 3 Z9 3 U1 4 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD MAR 1 PY 2016 VL 9 AR 121 DI 10.1186/s13071-016-1409-5 PG 9 WC Parasitology SC Parasitology GA DF6HB UT WOS:000371455400001 PM 26932267 ER PT J AU Odhiambo, C Zeh, C Angira, F Opollo, V Akinyi, B Masaba, R Williamson, JM Otieno, J Mills, LA Lecher, SL Thomas, TK AF Odhiambo, Collins Zeh, Clement Angira, Frank Opollo, Valarie Akinyi, Brenda Masaba, Rose Williamson, John M. Otieno, Juliana Mills, Lisa A. Lecher, Shirley Lee Thomas, Timothy K. TI Anaemia in HIV-infected pregnant women receiving triple antiretroviral combination therapy for prevention of mother-to-child transmission: a secondary analysis of the Kisumu breastfeeding study (KiBS) SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE anaemia; prevention of mother-to-child transmission; HIV; antiretroviral therapy ID HUMAN-IMMUNODEFICIENCY-VIRUS; COTRIMOXAZOLE PROPHYLAXIS; POSTPARTUM HEMORRHAGE; WESTERN KENYA; SOUTH-AFRICA; IRON STATUS; MALARIA; DISEASE; SUPPLEMENTATION; NELFINAVIR AB ObjectiveThe prevalence of anaemia during pregnancy is estimated to be 35-75% in sub-Saharan Africa and is associated with an increased risk of maternal mortality. We evaluated the frequency and factors associated with anaemia in HIV-infected women undergoing antiretroviral (ARV) therapy for prevention of mother-to-child transmission (PMTCT) enrolled in The Kisumu Breastfeeding Study 2003-2009. MethodsMaternal haematological parameters were monitored from 32 to 34 weeks of gestation to 2 years post-delivery among 522 enrolled women. Clinical and laboratory assessments for causes of anaemia were performed, and appropriate management was initiated. Anaemia was graded using the National Institutes of Health Division of AIDS 1994 Adult Toxicity Tables. Data were analysed using SAS software, v 9.2. The Wilcoxon two-sample rank test was used to compare groups. A logistic regression model was fitted to describe the trend in anaemia over time. ResultsAt enrolment, the prevalence of any grade anaemia (Hb < 9.4 g/dl) was 61.8%, but fell during ARV therapy, reaching a nadir (7.4%) by 6 months post-partum. A total of 41 women (8%) developed severe anaemia (Hb < 7 g/dl) during follow-up; 2 (4.9%) were hospitalised for blood transfusion, whereas 3 (7.3%) were transfused while hospitalised (for delivery). The greatest proportion of severe anaemia events occurred around delivery (48.8%; n = 20). Anaemia (Hb 7 and < 9.4 g/dl) at enrolment was associated with severe anaemia at delivery (OR 5.87; 95% CI: 4.48, 7.68, P < 0.01). Few cases of severe anaemia coincided with clinical malaria (24.4%; n = 10) and helminth (7.3%; n = 3) infections. ConclusionResolution of anaemia among most participants during study follow-up was likely related to receipt of ARV therapy. Efforts should be geared towards addressing common causes of anaemia in HIV-infected pregnant women, prioritising initiation of ARV therapy and management of peripartum blood loss. C1 [Odhiambo, Collins; Angira, Frank; Opollo, Valarie; Akinyi, Brenda; Masaba, Rose] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu Busia Highway,POB 1578-40100, Kisumu, Kenya. [Zeh, Clement; Williamson, John M.; Mills, Lisa A.; Lecher, Shirley Lee; Thomas, Timothy K.] Ctr Dis Control & Prevent, Kisumu, Kenya. [Zeh, Clement; Lecher, Shirley Lee] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Otieno, Juliana] Jaramogi Oginga Odinga Teaching & Referral Hosp, Kisumu, Kenya. RP Odhiambo, C (reprint author), Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu Busia Highway,POB 1578-40100, Kisumu, Kenya. EM odhiamboc@hotmail.com FU Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA FX We are grateful to the study participants, the KiBS team, the HIV Research Laboratory, Kenya Medical Research Institute and Kenya Ministry of Health whose participation made this study possible. We also thank Glaxo SmithKline and Boehringer Ingelheim for providing the study medications, the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA, for funding. CDC staff participated in the design, data collection, analysis and interpretation of the data; writing the report; and the decision to submit the manuscript for publication. This manuscript is published with the permission of the Director of KEMRI. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the U.S. Centers for Disease Control and Prevention. Use of trade names is for identification purposes only and does not constitute endorsement by the U.S. Centers for Disease Control and Prevention or the Department of Health and Human Services. NR 43 TC 0 Z9 0 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD MAR PY 2016 VL 21 IS 3 BP 373 EP 384 DI 10.1111/tmi.12662 PG 12 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA DF7AH UT WOS:000371509400008 PM 26799167 ER PT J AU Omarov, RT Ciomperlik, J Scholthof, HB AF Omarov, Rustem T. Ciomperlik, Jessica Scholthof, Herman B. TI An in vitro reprogrammable antiviral RISC with size-preferential ribonuclease activity SO VIROLOGY LA English DT Article DE RNA silencing; Plant; Virus; RISC ID BUSHY-STUNT-VIRUS; DEFECTIVE INTERFERING RNAS; TOMBUSVIRUS-ENCODED P19; DOUBLE-STRANDED-RNA; NICOTIANA-BENTHAMIANA; VIRAL SUPPRESSORS; MOLECULAR-BIOLOGY; GENE-FUNCTION; TOMATO; PLANTS AB Infection of Nicotiana benthamiana plants with Tomato bushy stunt virus (TBSV) mutants compromised for silencing suppression induces formation of an antiviral RISC (vRISC) that can be isolated using chromatography procedures. The isolated vRISC sequence-specifically degrades TBSV RNA in vitro, its activity can be down-regulated by removing siRNAs, and re-stimulated by exogenous supply of siRNAs. vRISC is most effective at hydrolyzing the similar to 4.8 kb genomic RNA, but less so for a similar to 2.2 kb TBSV subgenomic mRNA (sgRNA1), while the 3' co-terminal sgRNA2 of similar to 0.9 kb appears insensitive to vRISC cleavage. Moreover, experiments with in vitro generated 5' co-terminal viral transcripts show that RNAs of similar to 2.7 kb are efficiently cleaved while those of similar to 1.1 kb or shorter are unaffected. The isolated antiviral ribonuclease complex fails to degrade similar to 0.4 kb defective interfering RNAs (DIs) in vitro, agreeing with findings that in plants DIs are not targeted by silencing. (C) 2016 Published by Elsevier Inc. C1 [Omarov, Rustem T.; Ciomperlik, Jessica; Scholthof, Herman B.] Texas A&M Univ, Dept Plant Pathol & Microbiol, 2132 TAMU, College Stn, TX 77843 USA. [Omarov, Rustem T.] LN Gumilyov Eurasian Natl Univ, Astana, Kazakhstan. [Ciomperlik, Jessica] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Scholthof, HB (reprint author), Texas A&M Univ, Dept Plant Pathol & Microbiol, 2132 TAMU, College Stn, TX 77843 USA. EM herscho@tamu.edu RI Omarov, Rustem/P-4520-2014 OI Omarov, Rustem/0000-0003-1672-4700 FU Texas AgriLife Research [TEX08387]; National Institutes of Allergy and Infectious Diseases [RO3-AI067384]; United States Department of Agriculture (USDA) National Research Initiative [2006-35319-17211]; Agriculture and Food Research Initiative of the USDA National Institute of Food and Agriculture [2015-67013-22916] FX We are grateful for the helpful comments by Karen-Beth G. Scholthof and her research group, and Yi-Cheng Hsieh, at various stages of this study. Funding was provided by Texas AgriLife Research (TEX08387), the National Institutes of Allergy and Infectious Diseases RO3-AI067384, the United States Department of Agriculture (USDA) National Research Initiative (2006-35319-17211), and the Agriculture and Food Research Initiative of the USDA National Institute of Food and Agriculture (2015-67013-22916). NR 64 TC 0 Z9 0 U1 4 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD MAR PY 2016 VL 490 BP 41 EP 48 DI 10.1016/j.virol.2015.12.017 PG 8 WC Virology SC Virology GA DF6DF UT WOS:000371445400005 PM 26812224 ER PT J AU Tryggvason, G Jonasson, F Cotch, MF Li, CM Hoffman, HJ Themann, CL Eiriksdottir, G Sverrisdottir, JE Harris, TB Launer, LJ Gudnason, V Petersen, H AF Tryggvason, Geir Jonasson, Fridbert Cotch, Mary Frances Li, Chuan-Ming Hoffman, Howard J. Themann, Christa L. Eiriksdottir, Gudny Sverrisdottir, Johanna Eyrun Harris, Tamara B. Launer, Lenore J. Gudnason, Vilmundur Petersen, Hannes TI Hearing in older adults with exfoliation syndrome/exfoliation glaucoma or primary open-angle glaucoma SO ACTA OPHTHALMOLOGICA LA English DT Article DE adjustment for age and sex; exfoliation glaucoma; hearing; primary open-angle glaucoma ID PSEUDOEXFOLIATION SYNDROME; REYKJAVIK EYE; POPULATION; PREVALENCE; SUSCEPTIBILITY; ASSOCIATION; VARIANTS; RISK AB Purpose: To determine whether adults, aged 66-96 years, with exfoliation syndrome (XFS)/exfoliation glaucoma (XFG), or primary open-angle glaucoma (POAG) have poorer hearing than controls of similar age. Methods: Case (XFS/XFG and POAG) and control status was diagnosed in the Reykjavik Glaucoma Studies (RGS) using slit-lamp examination, visual field testing and optic disc photographs; the RGS data were merged with the Age, Gene/Environment Susceptibility-Reykjavik Study that collected hearing data using air-conduction, pure-tone thresholds obtained at 0.5, 1, 2, 3, 4, 6 and 8 kHz categorized by better ear and worse ear, based on pure-tone averages (PTAs) calculated separately for low and middle frequencies (PTA(512) - mean of thresholds at 0.5, 1 and 2 kHz) and high frequencies (PTA(3468) - mean of thresholds at 3, 4, 6 and 8 kHz). Multivariable linear regression was used to test for differences in PTAs between cases and controls. Results: Themeanage for 158XFS/XFGcases (30.4% male) was 77.4 years, 95POAG cases (35.8% male) was 77.9 years, and 123 controls (46.3% male) was 76.8 years. Using multivariable linear regression analysis, there were no consistent, statistically significant differences in PTAs between the two case groups and controls in either the low-or high-frequency range, evenwhenstratifiedbyagegroup. Conclusion: Among the older individuals examined in this study hearing loss is highly prevalent and strongly associated with male gender and increasing age. As we did not find consistent statistically significant difference in hearing between cases and controls the diagnosis of XFS/XFGorPOAG does not as such routinely call for audiological evaluation. C1 [Tryggvason, Geir] Oslo Univ Hosp, Dept Otolaryngol Head & Neck Surg, Oslo, Norway. [Jonasson, Fridbert] Landspitali Univ Hosp, Dept Ophthalmol, Reykjavik, Iceland. [Jonasson, Fridbert; Gudnason, Vilmundur; Petersen, Hannes] Univ Iceland, Fac Med, Reykjavik, Iceland. [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA. [Li, Chuan-Ming; Hoffman, Howard J.] NIDCD, Epidemiol & Stat Program, NIH, Bethesda, MD USA. [Themann, Christa L.] NIOSH, Hearing Loss Prevent Team, Ctr Dis Control & Prevent CDC, Cincinnati, OH 45226 USA. [Eiriksdottir, Gudny; Sverrisdottir, Johanna Eyrun; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland. [Harris, Tamara B.; Launer, Lenore J.] NIA, Lab Populat Sci, NIH, Bethesda, MD 20892 USA. [Petersen, Hannes] Landspitali Univ Hosp, Dept Otolaryngol Head & Neck Surg, Reykjavik, Iceland. RP Jonasson, F (reprint author), Landspitali Univ Hosp, Dept Ophthalmol, Reykjavik, Iceland.; Petersen, H (reprint author), Landspitali Univ Hosp, Dept Otolaryngol, Reykjavik, Iceland. EM fridbert@landspitali.is; hpet@hi.is FU National Institutes of Health NIA Intramural Research Program [N01-AG-1-2100]; National Eye Institute [ZIAEY000401]; National Institute on Deafness and Other Communication Disorders (NIDCD), Division of Scientific Programs [IAA Y2-DC1004-02]; Hjartavernd (the Icelandic Heart Association); Althingi (the Icelandic Parliament); University of Iceland Research Fund; Helga Jonsdottir and Sigurlidi Kristjansson Research Fund FX This study has been funded by contract N01-AG-1-2100 from the National Institutes of Health NIA Intramural Research Program, an Intramural Research Program Award (ZIAEY000401) from the National Eye Institute, an award from the National Institute on Deafness and Other Communication Disorders (NIDCD), Division of Scientific Programs (IAA Y2-DC1004-02), Hjartavernd (the Icelandic Heart Association), the Althingi (the Icelandic Parliament), the University of Iceland Research Fund, and the Helga Jonsdottir and Sigurlidi Kristjansson Research Fund. We thank Ms. May Chiu, NIDCD, NIH, for classifying the AGES-R tympanograms based on the Liden-Jerger method. The researchers are indebted to the participants for their willingness to participate in the studies. NR 34 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1755-375X EI 1755-3768 J9 ACTA OPHTHALMOL JI Acta Ophthalmol. PD MAR PY 2016 VL 94 IS 2 BP 140 EP 146 DI 10.1111/aos.12914 PG 7 WC Ophthalmology SC Ophthalmology GA DE9KR UT WOS:000370956800024 PM 26547142 ER PT J AU Su, JR Brooks, LC Davis, DW Torrone, EA Weinstock, HS Kamb, ML AF Su, John R. Brooks, Lesley C. Davis, Darlene W. Torrone, Elizabeth A. Weinstock, Hillard S. Kamb, Mary L. TI Congenital syphilis: trends in mortality and morbidity in the United States, 1999 through 2013 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE congenital syphilis; infant mortality; prenatal care; sexually transmitted disease surveillance; stillbirth ID SEXUALLY-TRANSMITTED-DISEASES; SOCIAL DETERMINANTS; PREGNANCY AB BACKGROUND: Congenital syphilis (CS) results when an infected pregnant mother transmits syphilis to her unborn child prior to or at delivery. The severity of infection can range from a delivery at term without signs of infection to stillbirth or death after delivery. OBJECTIVE: We sought to describe CS morbidity and mortality during 1999 through 2013. STUDY DESIGN: National CS case data reported to Centers for Disease Control and Prevention during 1999 through 2013 were analyzed. Cases were classified as dead (stillbirths and deaths up to 12 months after delivery), morbid (cases with strong [physical, radiographic, and/or nonserologic laboratory] evidence of CS), and nonmorbid (cases with a normal physical examination reported, without strong evidence of infection). Annual rates of these cases were calculated. Cases were compared using selected maternal and infant criteria. RESULTS: During 1999 through 2013, 6383 cases of CS were reported: 6.5% dead, 33.6% morbid, 53.9% nonmorbid, and 5.9% unknown morbidity; 81.8% of dead cases were stillbirths. Rates of dead, morbid, and nonmorbid cases all decreased over this time period, but the overall proportions that were dead ormorbid cases did not significantly change. The overall case fatality ratio during 1999 through 2013 was 6.5%. Among cases of CS, maternal race/ethnicity was not associated with increased morbidity or death, although most cases (83%) occurred among black or Hispanic mothers. No or inadequate treatment for maternal syphilis, <10 prenatal visits, and maternal nontreponemal titer >= 1:8 increased the likelihood of a dead case; risk of a dead case increased with maternal nontreponemal titer (chi(2) for trend P<.001). Infants with CS born alive at <28 weeks' gestation (relative risk, 107.4; P<.001) or born weighing <1500 g (relative risk, 43.9; P<.001) were at greatly increased risk of death. CONCLUSION: CS remains an important preventable cause of perinatal morbidity and mortality, with comparable case fatality ratios during 1999 through 2013 (6.5%) and 1992 through 1998 (6.4%). Detection and treatment of syphilis early during pregnancy remain crucial to reducing CS morbidity and mortality. C1 [Su, John R.; Davis, Darlene W.; Torrone, Elizabeth A.; Weinstock, Hillard S.; Kamb, Mary L.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, 1600 Clifton Rd MS E-63, Atlanta, GA 30333 USA. [Brooks, Lesley C.] Sunrise Monfort Community Hlth Ctr, Greeley, CO USA. [Brooks, Lesley C.] North Colorado Hlth Alliance, Greeley, CO USA. RP Su, JR (reprint author), Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, 1600 Clifton Rd MS E-63, Atlanta, GA 30333 USA. EM ezu2@cdc.gov FU Centers for Disease Control and Prevention (CDC) Experience Fellowship FX Dr Brooks was supported by the Centers for Disease Control and Prevention (CDC) Experience Fellowship, which had no involvement in this analysis. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 27 TC 2 Z9 2 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD MAR PY 2016 VL 214 IS 3 AR 381.e1-e9 DI 10.1016/j.ajog.2015.10.007 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DF0JC UT WOS:000371024100031 PM 26470826 ER PT J AU Ng, DL Al Hosani, F Keating, MK Gerber, SI Jones, TL Metcalfe, MG Tong, SX Tao, Y Alami, NN Haynes, LM Mutei, MA Abdel-Wareth, L Uyeki, TM Swerdlow, DL Barakat, M Zaki, SR AF Ng, Dianna L. Al Hosani, Farida Keating, M. Kelly Gerber, Susan I. Jones, Tara L. Metcalfe, Maureen G. Tong, Suxiang Tao, Ying Alami, Negar N. Haynes, Lia M. Mutei, Mowafaq Ali Abdel-Wareth, Laila Uyeki, Timothy M. Swerdlow, David L. Barakat, Maha Zaki, Sherif R. TI Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014 SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID FUNCTIONAL RECEPTOR; SAUDI-ARABIA; SARS CORONAVIRUS; DROMEDARY CAMELS; PATHOGENESIS; LOCALIZATION; OUTBREAK; OUTCOMES; LUNGS AB Middle East respiratory syndrome coronavirus (MERS-CoV) infection causes an acute respiratory illness and is associated with a high case fatality rate; however, the pathogenesis of severe and fatal MERS-CoV infection is unknown. We describe the histopathologic, immunohistochemical, and ultrastructural findings from the first autopsy performed on a fatal case of MERS-CoV in the world, which was related to a hospital outbreak in the United Arab Emirates in April 2014. The main histopathologic finding in the lungs was diffuse alveolar damage. Evidence of chronic disease, including severe peripheral vascular disease, patchy cardiac fibrosis, and hepatic steatosis, was noted in the other organs. Double staining immunoassays that used anti MERS-CoV antibodies paired with immunohistochemistry for cytokeratin and surfactant identified pneumocytes and epithelial syncytial cells as important targets of MERS-CoV antigen; double immunostaining with dipeptidyl peptidase 4 showed colocalization in scattered pneumocytes and syncytial cells. No evidence of extrapulmonary MERS-CoV antigens were detected, including the kidney. These results provide critical insights into the pathogenesis of MERS-CoV in humans. C1 [Ng, Dianna L.; Keating, M. Kelly; Jones, Tara L.; Metcalfe, Maureen G.; Zaki, Sherif R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Infect Dis Pathol Branch, Atlanta, GA 30329 USA. [Gerber, Susan I.] Ctr Dis Control & Prevent, Epidemiol Branch, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Tong, Suxiang; Tao, Ying] Ctr Dis Control & Prevent, Gastroenteritis & Resp Virus Lab Branch, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Alami, Negar N.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Haynes, Lia M.] Ctr Dis Control & Prevent, Off Director, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Swerdlow, David L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Alami, Negar N.] Ctr Dis Control & Prevent, Int Res & Programs Branch, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Al Hosani, Farida] Communicable Dis Dept, Abu Dhabi, U Arab Emirates. [Mutei, Mowafaq Ali] Emergency & Disaster Dept, Abu Dhabi, U Arab Emirates. [Barakat, Maha] Hlth Author Abu Dhabi, Abu Dhabi, U Arab Emirates. [Abdel-Wareth, Laila] Cleveland Clin, Pathol & Lab Med Inst, Abu Dhabi, U Arab Emirates. RP Zaki, SR (reprint author), Ctr Dis Control & Prevent, Infect Dis Pathol Branch, 1600 Clifton Rd NE,Bldg 18-SB-130,Mail Stop G-32, Atlanta, GA 30329 USA. EM szaki@cdc.gov FU CDC FX Supported by CDC operational funds. NR 30 TC 16 Z9 16 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD MAR PY 2016 VL 186 IS 3 BP 652 EP 658 DI 10.1016/j.ajpath.2015.10.024 PG 7 WC Pathology SC Pathology GA DE9WY UT WOS:000370991800019 PM 26857507 ER PT J AU Plantinga, L Lim, SS Patzer, R McClellan, W Kramer, M Klein, M Pastan, S Gordon, C Helmick, C Drenkard, C AF Plantinga, Laura Lim, S. Sam Patzer, Rachel McClellan, William Kramer, Michael Klein, Mitchel Pastan, Stephen Gordon, Caroline Helmick, Charles Drenkard, Cristina TI Incidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry SO ARTHRITIS CARE & RESEARCH LA English DT Article ID UNITED-STATES; MEDICAID BENEFICIARIES; SOCIOECONOMIC-STATUS; AFRICAN-AMERICANS; KIDNEY-DISEASE; NEPHRITIS; US; CLASSIFICATION; OUTCOMES; COHORT AB ObjectiveTo estimate and identify factors associated with the incidence of all-cause end-stage renal disease (ESRD) among newly diagnosed systemic lupus erythematosus (SLE) patients. MethodsData from a national registry of treated ESRD were linked to data from a lupus registry of SLE patients who were newly diagnosed and living in Atlanta, Georgia, 2002-2004 (median followup 7.8 years). Cumulative incidence and incidence rates (ESRD treatment initiations per 1,000 patient-years) were calculated, and age- and race-adjusted Poisson models were used to calculate incidence rate ratios (IRRs). ResultsAmong 344 newly diagnosed SLE patients, 29 initiated ESRD treatment over 2,603.8 years of followup. Incidence rates were 13.8 (95% confidence interval [95% CI] 9.4-20.3) among black patients and 3.3 (95% CI 0.8-13.0) among white patients, per 1,000 patient-years; corresponding 5-year cumulative incidence was 6.4% and 2.5% among black and white patients, respectively. Lupus nephritis documented prior to 2005, which occurred in 80% of those who progressed to ESRD, was the strongest risk factor for incident ESRD (IRR 6.7 [95% CI 2.7-16.8]; incidence rate 27.6 per 1,000 patient-years). Results suggested that patients who were black versus white (IRR 3.9 [95% CI 0.9-16.4]) or <18 years old (versus 30 years old) at diagnosis (IRR 2.1 [95% CI 0.9-5.3]) may be more likely to progress to ESRD, but incidence did not differ by sex or other characteristics. ConclusionThe incidence of all-cause ESRD among patients with a recent diagnosis of SLE is high in Georgia. Interventions to decrease ESRD incidence among newly diagnosed SLE patients should target young and black patients, as well as patients with lupus nephritis. C1 [Plantinga, Laura; Lim, S. Sam; Patzer, Rachel; McClellan, William; Kramer, Michael; Klein, Mitchel; Pastan, Stephen; Drenkard, Cristina] Emory Univ, Atlanta, GA 30322 USA. [Pastan, Stephen] Emory Healthcare, Emory Transplant Ctr, Atlanta, GA USA. [Gordon, Caroline] Univ Birmingham, Coll Med & Dent Sci, Birmingham, W Midlands, England. [Helmick, Charles] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Plantinga, L (reprint author), Emory Univ, Div Renal Med, Dept Med, 101 Woodruff Circle,5105 Woodruff Mem Bldg, Atlanta, GA 30322 USA. EM laura.plantinga@emory.edu FU Lupus Foundation of America; Centers for Disease Control and Prevention (CDC) [PA03022, U01-DP-005119]; Laney Graduate School at Emory University; NIH [R01-AR-065493]; National Center for Advancing Translational Sciences, a division of the NIH [UL1-TR000454, KL2-TR-000455]; National Institute on Minority Health and Health Disparities [1R24MD008077-01]; [CDC-RFA-DP08-806] FX Supported by the Lupus Foundation of America. The Georgia Lupus Registry was supported in part by the Centers for Disease Control and Prevention (CDC) and by cooperative agreement CDC-RFA-DP08-806 and, earlier, by cooperative agreement PA03022 from the CDC. NR 48 TC 2 Z9 2 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAR PY 2016 VL 68 IS 3 BP 357 EP 365 DI 10.1002/acr.22685 PG 9 WC Rheumatology SC Rheumatology GA DF0VG UT WOS:000371056700011 PM 26239749 ER PT J AU Weir, HK Johnson, CJ Ward, KC Coleman, MP AF Weir, Hannah K. Johnson, Christopher J. Ward, Kevin C. Coleman, Michel P. TI The effect of multiple primary rules on cancer incidence rates and trends SO CANCER CAUSES & CONTROL LA English DT Article DE Incidence rates; Trends; Multiple primary cancers; Population-based cancer registry; SEER; IARC; IACR ID PROSTATE-SPECIFIC ANTIGEN; SURVIVAL; SURVEILLANCE; NATION; IMPACT; EPIDEMIOLOGY; REGISTRIES; MORTALITY; BLADDER; INDEX AB Purpose An examination of multiple primary cancers can provide insight into the etiologic role of genes, the environment, and prior cancer treatment on a cancer patient's risk of developing a subsequent cancer. Different rules for registering multiple primary cancers (MP) are used by cancer registries throughout the world making data comparisons difficult. Methods We evaluated the effect of SEER and IARC/IACR rules on cancer incidence rates and trends using data from the SEER Program. We estimated age-standardized incidence rate (ASIR) and trends (1975-2011) for the top 26 cancer categories using joinpoint regression analysis. Results ASIRs were higher using SEER compared to IARC/IACR rules for all cancers combined (3 %) and, in rank order, melanoma (9 %), female breast (7 %), urinary bladder (6 %), colon (4 %), kidney and renal pelvis (4 %), oral cavity and pharynx (3 %), lung and bronchus (2 %), and non-Hodgkin lymphoma (2 %). ASIR differences were largest for patients aged 65+ years. Trends were similar using both MP rules with the exception of cancers of the urinary bladder, and kidney and renal pelvis. Conclusions The choice of multiple primary coding rules effects incidence rates and trends. Compared to SEER MP coding rules, IARC/IACR rules are less complex, have not changed over time, and report fewer multiple primary cancers, particularly cancers that occur in paired organs, at the same anatomic site and with the same or related histologic type. Cancer registries collecting incidence data using SEER rules may want to consider including incidence rates and trends using IARC/IACR rules to facilitate international data comparisons. C1 [Weir, Hannah K.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy MS-F76, Atlanta, GA 30341 USA. [Johnson, Christopher J.] Canc Data Registry Idaho, Boise, ID USA. [Ward, Kevin C.] Emory Univ, Georgia Ctr Canc Stat, Atlanta, GA 30322 USA. [Coleman, Michel P.] London Sch Hyg & Trop Med, London WC1, England. RP Weir, HK (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy MS-F76, Atlanta, GA 30341 USA. EM hweir@cdc.gov FU Cancer Research UK [11700] NR 39 TC 2 Z9 2 U1 3 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAR PY 2016 VL 27 IS 3 BP 377 EP 390 DI 10.1007/s10552-016-0714-9 PG 14 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DE9JW UT WOS:000370953900009 PM 26809509 ER PT J AU Shoemaker, ML White, MC AF Shoemaker, Meredith L. White, Mary C. TI Breast and cervical cancer screening among Hispanic subgroups in the USA: estimates from the National Health Interview Survey 2008, 2010, and 2013 SO CANCER CAUSES & CONTROL LA English DT Article DE Hispanics; Mammography; Pap test; Healthcare disparities; Cancer screening ID RISK-FACTORS AB This study examined patterns in mammography and Pap test use across and within subpopulations of Hispanic women. Based on data from the National Health Interview Survey (2008, 2010, and 2013), we estimated the proportion of Hispanic women reporting testing for breast and cervical cancer for specific subgroups. We examined test use by demographic characteristics using Chi-square tests. Overall, the proportion of women aged 50-74 years who reported a mammogram within the past 2 years did not differ significantly across Hispanic subgroups. Among publically and uninsured women, however, proportions of mammography utilization varied significantly across Hispanic subgroups. The proportion of women aged 21-65 years who received a Pap test within the past 3 years differed significantly across Hispanic subgroups. Among subgroups of Hispanic women, patterns in mammography and Pap test use vary by insurance status, length of US residency, and type of screening. Certain subgroups of Hispanic women may benefit from culturally tailored efforts to promote breast and cervical cancer screening. C1 [Shoemaker, Meredith L.; White, Mary C.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, 4770 Buford Highway NE,Mailstop F-76, Atlanta, GA 30341 USA. RP Shoemaker, ML (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, 4770 Buford Highway NE,Mailstop F-76, Atlanta, GA 30341 USA. EM Xhr1@cdc.gov NR 8 TC 0 Z9 0 U1 2 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAR PY 2016 VL 27 IS 3 BP 453 EP 457 DI 10.1007/s10552-016-0718-5 PG 5 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DE9JW UT WOS:000370953900016 PM 26809510 ER PT J AU Fakih, MG Gould, CV Trautner, BW Meddings, J Olmsted, RN Krein, SL Saint, S AF Fakih, Mohamad G. Gould, Carolyn V. Trautner, Barbara W. Meddings, Jennifer Olmsted, Russell N. Krein, Sarah L. Saint, Sanjay TI Beyond Infection: Device Utilization Ratio as a Performance Measure for Urinary Catheter Harm SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Review ID CARE-ASSOCIATED INFECTIONS; SAFETY NETWORK REPORT; TRACT-INFECTION; ASYMPTOMATIC BACTERIURIA; SURVEILLANCE; OVERTREATMENT; IMPROVEMENT; OUTCOMES; MODULE AB Catheter-associated urinary tract infection (CAUTI) is considered a reasonably preventable event in the hospital setting, and it has been included in the US Department of Health and Human Services National Action Plan to Prevent Healthcare-Associated Infections. While multiple. definitions for measuring CAUTI exist, each has important limitations, and understanding these limitations is important to both clinical practice and policy decisions. The National Healthcare Safety Network (NHSN) surveillance definition, the most frequently used outcome measure for CAUTI prevention efforts, has limited clinical correlation and does not necessarily reflect noninfectious harms related to the catheter. We advocate use of the device utilization ratio (DUR) as an additional performance measure for potential urinary catheter harm. The DUR is patient-centered and objective and is currently captured as part of NHSN reporting. Furthermore, these data are readily obtainable from electronic medical records. The DUR also provides a more direct reflection of improvement efforts focused on reducing inappropriate urinary catheter use. C1 [Fakih, Mohamad G.] St John Hosp & Med Ctr, Detroit, MI USA. [Fakih, Mohamad G.] Wayne State Univ, Sch Med, Detroit, MI USA. [Gould, Carolyn V.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Trautner, Barbara W.] Michael E DeBakey VA Med Ctr, Houston VA Ctr Innovat Qual Effectiveness & Safet, Houston, TX USA. [Trautner, Barbara W.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA. [Trautner, Barbara W.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA. [Meddings, Jennifer] Univ Michigan, Sch Med, Dept Internal Med, Div Gen Med, Ann Arbor, MI USA. [Olmsted, Russell N.] Trinity Hlth, Unified Clin Org, Infect Prevent & Control, Livonia, MI USA. [Krein, Sarah L.; Saint, Sanjay] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Saint, Sanjay] Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA. RP Fakih, MG (reprint author), St John Hosp & Med Ctr, Infect Prevent & Control, 19251 Mack Ave,Suite 190, Grosse Pointe Woods, MI 48236 USA. EM Mohamad.Fakih@stjohn.org FU Agency for Healthcare Research and Quality [HHSA290201000025I/HHSA29032001T] FX This project was supported by a contract from the Agency for Healthcare Research and Quality (grant no. HHSA290201000025I/HHSA29032001T). NR 40 TC 4 Z9 4 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAR PY 2016 VL 37 IS 3 BP 327 EP 333 DI 10.1017/ice.2015.287 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DE9ZG UT WOS:000370997800012 PM 26894622 ER PT J AU Havers, F Fry, AM Chen, JF Christensen, D Moore, C Peacock, G Finelli, L Reed, C AF Havers, Fiona Fry, Alicia M. Chen, Jufu Christensen, Deborah Moore, Cynthia Peacock, Georgina Finelli, Lyn Reed, Carrie TI Hospitalizations Attributable to Respiratory Infections among Children with Neurologic Disorders SO JOURNAL OF PEDIATRICS LA English DT Article ID 2009 PANDEMIC INFLUENZA; UNITED-STATES; DEVELOPMENTAL-DISABILITIES; PEDIATRIC DEATHS; TRACT INFECTIONS; US CHILDREN; PREVALENCE; RISK; RECOMMENDATIONS; COMPLICATIONS AB Objectives To characterize respiratory infection hospitalizations in children with neurologic disorders and to compare them with those of the general pediatric population. Study design We analyzed claims data from commercial insurance and Medicaid enrollees <19 years of age from July 2006 to June 2011 who had >= 1 visit with an International Classification of Diseases, Ninth Revision, diagnosis code for a neurologic disorder. We identified hospitalizations with primary diagnosis codes indicating a respiratory infection and compared hospitalization rates with random samples of children from the commercial and Medicaid databases (comparison groups). Results Among 33 651 923 children, 255 046 (0.76%) had >= 1 neurologic condition. Among children with neurologic conditions, 8249 of 68 717 hospitalizations (12%) were attributed to a respiratory infection (rate: 21/ 1000 person-years), although rates varied by disorder. Children with neurologic disorders had greater rates than children in comparison groups (relative rate: Commercial Claims 7.4 [95% CI 7.1-7.7]; Medicaid 5.0 [95% CI 4.8-5.2]). Children < 2 years were most likely to be hospitalized, although those 10-18 years were 14.5 (95% CI 13.3-16.7) times more likely to be hospitalized than age-matched comparison groups. Co-occurring deafness, blindness, and scoliosis were associated with increased respiratory hospitalization rates. Conclusions Children with neurologic disorders are at 5- to 7-fold greater risk for hospitalization from respiratory infections compared with all children, although rates vary widely by disorder type, age, and comorbidities. Children with specific neurologic disorders and those who had co-occurring conditions have the highest rates. C1 [Havers, Fiona; Fry, Alicia M.; Chen, Jufu; Finelli, Lyn; Reed, Carrie] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Christensen, Deborah; Moore, Cynthia] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Peacock, Georgina] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Havers, F (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A 32, Atlanta, GA 30333 USA. EM fhavers@cdc.gov OI Havers, Fiona/0000-0001-9873-6195 FU Centers for Disease Control and Prevention FX Funded by the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. The authors declare no conflicts of interest. NR 23 TC 1 Z9 1 U1 2 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD MAR PY 2016 VL 170 BP 135 EP + DI 10.1016/j.jpeds.2015.11.030 PG 12 WC Pediatrics SC Pediatrics GA DE7MH UT WOS:000370820500031 PM 26687576 ER PT J AU Eissa, MA Mihalopoulos, NL Holubkov, R Dai, SF Labarthe, DR AF Eissa, Mona A. Mihalopoulos, Nicole L. Holubkov, Richard Dai, Shifan Labarthe, Darwin R. TI Changes in Fasting Lipids during Puberty SO JOURNAL OF PEDIATRICS LA English DT Article ID DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR RISK-FACTORS; SEXUAL-MATURATION; PROJECT HEARTBEAT; YOUNG-ADULTS; SERUM-LIPOPROTEINS; BLOOD-PRESSURE; CHILDREN; AGE; HEALTH AB Objective To describe longitudinal changes in plasma lipid levels and pubertal stage in youths from age 818 years, in Project HeartBeat! Study design Fasting blood samples and pubertal stage, using physical assessment of secondary sex characteristics, were obtained every 4 months for up to 4 years in a mixed longitudinal study of 633 children (49.1% female, 20.1% black), initially aged 8, 11, and 14 years. Total cholesterol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, triglycerides (TG), and nonhigh density lipoprotein-cholesterol measurements were obtained. Data were collected from 1991-1995. Results Pubertal stage correlations with age varied among all race-sex groups (range, r = 0.61-0.70), and a given pubertal stage could represent a range of 5 years or more of chronological age. Throughout puberty, levels of total cholesterol, low density lipoprotein-cholesterol, and nonhigh density lipoprotein-cholesterol decreased, TG in males increased, and high density lipoprotein-cholesterol and TG in females showed no changes. Within a given pubertal stage, plasma lipid levels tended to differ by race, sex, or both. Conclusions Lipid levels change markedly by pubertal stage, and patterns differ by sex and race. Chronological age ranges widely within a given pubertal stage and is an insensitive indicator of pubertal stage and the related changes in lipid levels. Pubertal development should be considered when determining screening criteria to identify youths with adverse blood lipid levels. C1 [Eissa, Mona A.] Univ Texas Houston, Sch Med, Dept Pediat, 6431 Fannin St, Houston, TX 77030 USA. [Mihalopoulos, Nicole L.; Holubkov, Richard] Univ Utah, Dept Pediat, Salt Lake City, UT USA. [Dai, Shifan] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Labarthe, Darwin R.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. RP Eissa, MA (reprint author), Univ Texas Houston, Sch Med, Dept Pediat, 6431 Fannin St, Houston, TX 77030 USA. EM mona.a.eissa@uth.tmc.edu FU National Heart, Lung, and Blood Institute [U01-HL-41166]; Centers for Disease Control and Prevention through the Southwest Center for prevention Research [U48/CCU609653]; National Heart, Lung, and Blood Institute (HL) [092069] FX Supported by the National Heart, Lung, and Blood Institute (through Cooperative Agreement U01-HL-41166) and the Centers for Disease Control and Prevention through the Southwest Center for prevention Research (U48/CCU609653). N.M. was supported by the National Heart, Lung, and Blood Institute (HL#092069). The authors declare no conflicts of interest. NR 41 TC 1 Z9 1 U1 2 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD MAR PY 2016 VL 170 BP 199 EP 205 DI 10.1016/j.jpeds.2015.11.018 PG 7 WC Pediatrics SC Pediatrics GA DE7MH UT WOS:000370820500042 PM 26706233 ER PT J AU Coker, AL Bush, HM Fisher, BS Swan, SC Williams, CM Clear, ER DeGue, S AF Coker, Ann L. Bush, Heather M. Fisher, Bonnie S. Swan, Suzanne C. Williams, Corrine M. Clear, Emily R. DeGue, Sarah TI Multi-College Bystander Intervention Evaluation for Violence Prevention SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID HIGH-SCHOOL-STUDENTS; SEXUAL VIOLENCE; DATING VIOLENCE; EDUCATION; PROGRAM; VICTIMIZATION; PERPETRATION; PERSPECTIVE; HARASSMENT; MILITARY AB Introduction: The 2013 Campus Sexual Violence Elimination Act requires U.S. colleges to provide bystander-based training to reduce sexual violence, but little is known about the efficacy of such programs for preventing violent behavior. This study provides the first multiyear evaluation of a bystander intervention's campus-level impact on reducing interpersonal violence victimization and perpetration behavior on college campuses. Methods: First-year students attending three similarly sized public university campuses were randomly selected and invited to complete online surveys in the spring terms of 2010 - 2013. On one campus, the Green Dot bystander intervention was implemented in 2008 (Intervention, n = 2,979) and two comparison campuses had no bystander programming at baseline (Comparison, n = 4,132). Data analyses conducted in 2014 - 2015 compared violence rates by condition over the four survey periods. Multivariable logistic regression was used to estimate violence risk on Intervention relative to Comparison campuses, adjusting for demographic factors and time (2010 - 2013). Results: Interpersonal violence victimization rates (measured in the past academic year) were 17% lower among students attending the Intervention (46.4%) relative to Comparison (55.7%) campuses (adjusted rate ratio = 0.83; 95% CI = 0.79, 0.88); a similar pattern held for interpersonal violence perpetration (25.5% in Intervention; 32.2% in Comparison; adjusted rate ratio = 0.79; 95% CI = 0.71, 0.86). Violence rates were lower on Intervention versus Comparison campuses for unwanted sexual victimization, sexual harassment, stalking, and psychological dating violence victimization and perpetration (p<0.01). Conclusions: Green Dot may be an efficacious intervention to reduce violence at the community level and meet Campus Sexual Violence Elimination Act bystander training requirements. (C) 2016 American Journal of Preventive Medicine. All rights reserved. C1 [Coker, Ann L.; Clear, Emily R.] Univ Kentucky, Coll Med, Dept Obstet & Gynecol, Lexington, KY USA. [Bush, Heather M.] Univ Kentucky, Coll Publ Hlth, Dept Biostat, Lexington, KY USA. [Fisher, Bonnie S.] Univ Cincinnati, Coll Educ Criminal Justice & Human Serv, Sch Criminal Justice, Cincinnati, OH USA. [Swan, Suzanne C.] Univ S Carolina, Dept Psychol, Columbia, SC 29208 USA. [Swan, Suzanne C.] Univ S Carolina, Coll Arts & Sci, Womens & Gender Studies Program, Columbia, SC 29208 USA. [Williams, Corrine M.] Univ Kentucky, Coll Publ Hlth, Dept Hlth Behav, Lexington, KY USA. [DeGue, Sarah] CDC, Res & Evaluat Branch, Div Violence Prevent, Atlanta, GA 30333 USA. RP Coker, AL (reprint author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Obstet & Gynecol, C361,Pavil H, Lexington, KY 40536 USA. EM ann.coker@uky.edu FU University of Kentucky; NIH [5R21HD069897] FX Research was supported by the University of Kentucky and NIH (5R21HD069897). NR 20 TC 3 Z9 3 U1 7 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2016 VL 50 IS 3 BP 295 EP 302 DI 10.1016/j.amepre.2015.08.034 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DD9QI UT WOS:000370260300004 PM 26541099 ER PT J AU Mitra, M Mouradian, VE Fox, MH Pratt, C AF Mitra, Monika Mouradian, Vera E. Fox, Michael H. Pratt, Carter TI Self-Reported Prevalence of Alcohol Screening Among US Adults SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SEXUAL VIOLENCE VICTIMIZATION; INTIMATE PARTNER VIOLENCE; UNITED-STATES; DISABILITIES; WOMEN; MEN; EXPERIENCES; ABUSE; RISK AB Introduction: The U.S. Preventive Services Task Force recommends for adults alcohol screening and brief behavioral counseling interventions in primary care settings. However, there is a paucity of population-based data on the prevalence of alcohol screening. This study examines adherence to this U.S. Preventive Services Task Force recommendation by estimating the prevalence of alcohol screening by demographic characteristics and binge drinking. Methods: A cross-sectional analysis was conducted in 2013 and 2014 on data from the 2013 fall wave of the ConsumerStyles survey. ConsumerStyles is drawn from an Internet panel randomly recruited by probability-based sampling to be representative of the U.S. population. Data from 2,592 adult respondents who visited primary care physicians in the last year were analyzed to determine the prevalence of alcohol screening. Results: Only 24.7% of respondents reported receiving alcohol screening. The prevalence of screening was similar among women (24.9%) and men (24.5%). Black non-Hispanics reported a significantly lower prevalence of screening than white non-Hispanics (16.2% vs 26.9%, prevalence ratio = 0.60, 95% CI = 0.40, 0.90). College graduates reported a significantly higher prevalence of screening than respondents with a high school degree or less (28.1% vs 20.8%, prevalence ratio = 1.35, 95% CI = 1.08, 1.69). Conclusions: Only about one in four respondents who visited a primary care physician in the last year reported being screened for alcohol misuse. Therefore, many men and women who misuse alcohol are unlikely to be identified. Increased screening may help reduce alcohol misuse and related negative health outcomes. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Mitra, Monika; Pratt, Carter] Univ Massachusetts, Sch Med, Ctr Hlth Policy & Res, 333 South St, Shrewsbury, MA 01545 USA. [Mouradian, Vera E.] Massachusetts Dept Publ Hlth, Boston, MA USA. [Fox, Michael H.] CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Mitra, M (reprint author), Univ Massachusetts, Sch Med, Ctr Hlth Policy & Res, 333 South St, Shrewsbury, MA 01545 USA. EM monika.mitra@umassmed.edu FU Intramural CDC HHS [CC999999] NR 23 TC 0 Z9 0 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2016 VL 50 IS 3 BP 311 EP 317 DI 10.1016/j.amepre.2015.09.016 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DD9QI UT WOS:000370260300006 PM 26474667 ER PT J AU Denny, CH Hungerford, DW McKnight-Eily, LR Green, PP Dang, EP Cannon, MJ Cheal, NE Sniezek, JE AF Denny, Clark H. Hungerford, Daniel W. McKnight-Eily, Lela R. Green, Patricia P. Dang, Elizabeth P. Cannon, Michael J. Cheal, Nancy E. Sniezek, Joseph E. TI Self-Reported Prevalence of Alcohol Screening Among US Adults SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID DRINKING; CONSUMPTION; PREGNANCY; CARE AB Introduction: The U.S. Preventive Services Task Force recommends for adults alcohol screening and brief behavioral counseling interventions in primary care settings. However, there is a paucity of population-based data on the prevalence of alcohol screening. This study examines adherence to this U.S. Preventive Services Task Force recommendation by estimating the prevalence of alcohol screening by demographic characteristics and binge drinking. Methods: A cross-sectional analysis was conducted in 2013 and 2014 on data from the 2013 fall wave of the ConsumerStyles survey. ConsumerStyles is drawn from an Internet panel randomly recruited by probability-based sampling to be representative of the U.S. population. Data from 2,592 adult respondents who visited primary care physicians in the last year were analyzed to determine the prevalence of alcohol screening. Results: Only 24.7% of respondents reported receiving alcohol screening. The prevalence of screening was similar among women (24.9%) and men (24.5%). Black non-Hispanics reported a significantly lower prevalence of screening than white non-Hispanics (16.2% vs 26.9%, prevalence ratio = 0.60, 95% CI = 0.40, 0.90). College graduates reported a significantly higher prevalence of screening than respondents with a high school degree or less (28.1% vs 20.8%, prevalence ratio = 1.35, 95% CI = 1.08, 1.69). Conclusions: Only about one in four respondents who visited a primary care physician in the last year reported being screened for alcohol misuse. Therefore, many men and women who misuse alcohol are unlikely to be identified. Increased screening may help reduce alcohol misuse and related negative health outcomes. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Denny, Clark H.; Hungerford, Daniel W.; McKnight-Eily, Lela R.; Green, Patricia P.; Dang, Elizabeth P.; Cannon, Michael J.; Cheal, Nancy E.; Sniezek, Joseph E.] CDC, Prevent Res Branch, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Denny, CH (reprint author), CDC, Chamblee Campus,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM cfd3@cdc.gov FU Intramural CDC HHS [CC999999] NR 16 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2016 VL 50 IS 3 BP 380 EP 383 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DD9QI UT WOS:000370260300014 PM 26520573 ER PT J AU Khoury, MJ Iademarco, MF Riley, WT AF Khoury, Muin J. Iademarco, Michael F. Riley, William T. TI Precision Public Health for the Era of Precision Medicine SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article C1 [Khoury, Muin J.; Iademarco, Michael F.] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Khoury, Muin J.; Riley, William T.] NCI, Div Canc Control & Populat Sci, Rockville, MD USA. [Iademarco, Michael F.] US PHS, Commissioned Corps, Washington, DC 20201 USA. RP Khoury, MJ (reprint author), CDC, Off Publ Hlth Genom, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM muk1@cdc.gov FU Intramural CDC HHS [CC999999]; Intramural NIH HHS [Z99 CA999999] NR 12 TC 11 Z9 13 U1 3 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2016 VL 50 IS 3 BP 398 EP 401 DI 10.1016/j.amepre.2015.08.031 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DD9QI UT WOS:000370260300017 PM 26547538 ER PT J AU Buchanan, LR Rooks-Peck, CR Finnie, RKC Wethington, HR Jacob, V Fulton, JE Johnson, DB Kahwati, LC Pratt, CA Ramirez, G Glanz, K AF Buchanan, Leigh Ramsey Rooks-Peck, Cherie R. Finnie, Ramona K. C. Wethington, Holly R. Jacob, Verughese Fulton, Janet E. Johnson, Donna B. Kahwati, Leila C. Pratt, Charlotte A. Ramirez, Gilbert Glanz, Karen CA Community Preventive Serv Task TI Reducing Recreational Sedentary Screen Time A Community Guide Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID RANDOMIZED-CONTROLLED-TRIAL; BODY-MASS INDEX; OBESITY PREVENTION PROGRAM; PROMOTE PHYSICAL-ACTIVITY; PRIMARY-SCHOOL CHILDREN; OPEN-LOOP FEEDBACK; PRESCHOOL-CHILDREN; PRIMARY-CARE; INTERDISCIPLINARY INTERVENTION; DECISION-MAKING AB Context: Sedentary time spent with screen media is associated with obesity among children and adults. Obesity has potentially serious health consequences, such as heart disease and diabetes. This Community Guide systematic review examined the effectiveness and economic efficiency of behavioral interventions aimed at reducing recreational (i.e., neither school-nor work-related) sedentary screen time, as measured by screen time, physical activity, diet, and weight-related outcomes. Evidence acquisition: For this review, an earlier ("original") review (search period, 1966 through July 2007) was combined with updated evidence (search period, April 2007 through June 2013) to assess effectiveness of behavioral interventions aimed at reducing recreational sedentary screen time. Existing Community Guide systematic review methods were used. Analyses were conducted in 2013-2014. Evidence synthesis: The review included 49 studies. Two types of behavioral interventions were evaluated that either (1) focus on reducing recreational sedentary screen time only (12 studies); or (2) focus equally on reducing recreational sedentary screen time and improving physical activity or diet (37 studies). Most studies targeted children aged <= 13 years. Children's composite screen time (TV viewing plus other forms of recreational sedentary screen time) decreased 26.4 (interquartile interval = -74.4, -12.0) minutes/day and obesity prevalence decreased 2.3 (interquartile interval = -4.5, -1.2) percentage points versus a comparison group. Improvements in physical activity and diet were reported. Three study arms among adults found composite screen time decreased by 130.2 minutes/day. Conclusions: Among children, these interventions demonstrated reduced screen time, increased physical activity, and improved diet- and weight-related outcomes. More research is needed among adolescents and adults. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Buchanan, Leigh Ramsey; Rooks-Peck, Cherie R.; Finnie, Ramona K. C.; Wethington, Holly R.; Jacob, Verughese] CDC, Community Guide Branch, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Fulton, Janet E.] CDC, Phys Act & Hlth Branch, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Pratt, Charlotte A.] NHLBI, Clin Applicat & Prevent Branch, Prevent & Populat Sci Program, Div Cardiovasc Sci,NIH, Bldg 10, Bethesda, MD 20892 USA. [Johnson, Donna B.] Univ Washington, Ctr Publ Hlth Nutr, Seattle, WA 98195 USA. [Kahwati, Leila C.] RTI Int, Res Triangle Pk, NC USA. [Ramirez, Gilbert] Texas A&M, Sch Publ Hlth, College Stn, TX USA. [Glanz, Karen] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Glanz, Karen] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. RP Wethington, HR (reprint author), CDC, Community Guide Branch, 1600 Clifton Rd,Mailstop E69, Atlanta, GA 30329 USA. EM hwethington@cdc.gov FU Oak Ridge Institute for Science and Education FX The work of Cherie R. Rooks-Peck and Ramona K. C. Finnie was supported with funds from the Oak Ridge Institute for Science and Education. NR 89 TC 4 Z9 4 U1 3 U2 24 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2016 VL 50 IS 3 BP 402 EP 415 DI 10.1016/j.amepre.2015.09.030 PG 14 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DD9QI UT WOS:000370260300018 ER PT J AU Wethington, HR AF Wethington, Holly R. CA Community Preventive Serv Task TI Reducing Children's Recreational Sedentary Screen Time Recommendation of the Community Preventive Services Task Force Community Preventive Services Task Force SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article C1 [Wethington, Holly R.] CDC, Community Guide Branch, 1600 Clifton Rd,Mailstop E69, Atlanta, GA 30329 USA. RP Wethington, HR (reprint author), CDC, Community Guide Branch, 1600 Clifton Rd,Mailstop E69, Atlanta, GA 30329 USA. EM hwethington@cdc.gov NR 3 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2016 VL 50 IS 3 BP 416 EP 418 DI 10.1016/j.amepre.2015.09.014 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DD9QI UT WOS:000370260300019 ER PT J AU Scinicariello, F Portier, C AF Scinicariello, Franco Portier, Christopher TI A simple procedure for estimating pseudo risk ratios from exposure to non-carcinogenic chemical mixtures SO ARCHIVES OF TOXICOLOGY LA English DT Article DE Toxicological mixtures; Risk assessment; Minimal Risk Levels; Acceptable risk; Benchmark dose; Lowest-observed-adverse effect; Point of departure ID TOXIC EQUIVALENCY FACTORS; DIOXIN-LIKE COMPOUNDS; CYP1A2 ENZYME-ACTIVITY; DERIVATION AB Non-cancer risk assessment traditionally assumes a threshold of effect, below which there is a negligible risk of an adverse effect. The Agency for Toxic Substances and Disease Registry derives health-based guidance values known as Minimal Risk Levels (MRLs) as estimates of the toxicity threshold for non-carcinogens. Although the definition of an MRL, as well as EPA reference dose values (RfD and RfC), is a level that corresponds to "negligible risk," they represent daily exposure doses or concentrations, not risks. We present a new approach to calculate the risk at exposure to specific doses for chemical mixtures, the assumption in this approach is to assign de minimis risk at the MRL. The assigned risk enables the estimation of parameters in an exponential model, providing a complete dose-response curve for each compound from the chosen point of departure to zero. We estimated parameters for 27 chemicals. The value of k, which determines the shape of the dose-response curve, was moderately insensitive to the choice of the risk at the MRL. The approach presented here allows for the calculation of a risk from a single substance or the combined risk from multiple chemical exposures in a community. The methodology is applicable from point of departure data derived from quantal data, such as data from benchmark dose analyses or from data that can be transformed into probabilities, such as lowest-observed-adverse-effect level. The individual risks are used to calculate risk ratios that can facilitate comparison and cost-benefit analyses of environmental contamination control strategies. C1 [Scinicariello, Franco; Portier, Christopher] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Agcy Tox Subst & Dis Registry, 4770 Buford Hwy,MS F57, Atlanta, GA 30341 USA. RP Portier, C (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Agcy Tox Subst & Dis Registry, 4770 Buford Hwy,MS F57, Atlanta, GA 30341 USA. EM fes6@cdc.gov; cportier@mac.com NR 27 TC 0 Z9 0 U1 3 U2 9 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0340-5761 EI 1432-0738 J9 ARCH TOXICOL JI Arch. Toxicol. PD MAR PY 2016 VL 90 IS 3 BP 513 EP 523 DI 10.1007/s00204-015-1467-z PG 11 WC Toxicology SC Toxicology GA DE0VJ UT WOS:000370343000002 PM 25667015 ER PT J AU Silva, MJ Hilton, D Furr, J Gray, LE Preau, JL Calafat, AM Ye, XY AF Silva, Manori J. Hilton, Donald Furr, Johnathan Gray, L. Earl Preau, James L. Calafat, Antonia M. Ye, Xiaoyun TI Quantification of tetrabromo benzoic acid and tetrabromo phthalic acid in rats exposed to the flame retardant Uniplex FPR-45 SO ARCHIVES OF TOXICOLOGY LA English DT Article DE Flame retardant; EH-TBB; BEH-TEBP; Bis-(2-ethylhexyl)-2,3,4,5-tetrabromophthalate; 2-Ethylhexyl-2,3,4,5-tetrabromobenzoate; Tetrabromo benzoic acid; Tetrabromo phthalic acid ID FIREMASTER(R) 550; INDOOR DUST; METABOLITES; URINARY AB The first withdrawal of certain polybrominated diphenyl ethers flame retardants from the US market occurred in 2004. Since then, use of brominated non-PBDE compounds such as bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate (BEH-TEBP) and 2-ethylhexyl-2,3,4,5-tetrabromobenzoate (EH-TBB) in commercial formulations has increased. Assessing human exposure to these chemicals requires identifying metabolites that can potentially serve as their biomarkers of exposure. We administered by gavage a dose of 500 mg/Kg bw of Uniplex FRP-45 (> 95 % BEH-TEBP) to nine adult female Sprague-Dawley rats. Using authentic standards and mass spectrometry, we positively identified and quantified 2,3,4,5-tetrabromo benzoic acid (TBBA) and 2,3,4,5-tetrabromo phthalic acid (TBPA) in 24-h urine samples collected 1 day after dosing the rats and in serum at necropsy, 2 days post-exposure. Interestingly, TBBA and TBPA concentrations correlated well (R (2) = 0.92). The levels of TBBA, a known metabolite of EH-TBB, were much higher than the levels of TBPA both in urine and serum. Because Uniplex FRP-45 was technical grade and EH-TBB was present in the formulation, TBBA likely resulted from the metabolism of EH-TBB. Taken together, our data suggest that TBBA and TBPA may serve as biomarkers of exposure to non-PBDE brominated flame retardant mixtures. Additional research can provide useful information to better understand the composition and in vivo toxicokinetics of these commercial mixtures. C1 [Silva, Manori J.; Hilton, Donald; Preau, James L.; Calafat, Antonia M.; Ye, Xiaoyun] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Furr, Johnathan; Gray, L. Earl] US EPA, Reprod Toxicol Branch, Tox Assessment Div, Natl Hlth & Environm Effects Res Lab,Off Res & De, Res Triangle Pk, NC 27709 USA. RP Silva, MJ (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM zca2@cdc.gov FU Intramural CDC HHS [CC999999] NR 17 TC 4 Z9 4 U1 6 U2 13 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0340-5761 EI 1432-0738 J9 ARCH TOXICOL JI Arch. Toxicol. PD MAR PY 2016 VL 90 IS 3 BP 551 EP 557 DI 10.1007/s00204-015-1489-6 PG 7 WC Toxicology SC Toxicology GA DE0VJ UT WOS:000370343000005 PM 25804200 ER PT J AU Rossen, LM Simon, AE Herrick, KA AF Rossen, Lauren M. Simon, Alan E. Herrick, Kirsten A. TI Types of Infant Formulas Consumed in the United States SO CLINICAL PEDIATRICS LA English DT Article DE nutrition; survey; diet; children ID FED BREAST-MILK; COWS MILK; SOY FORMULA AB We examined consumption of different types of infant formula (eg, cow's milk, soy, gentle/lactose-reduced, and specialty) and regular milk among a nationally representative sample of 1864 infants, 0 to 12 months old, from the National Health and Nutrition Examination Survey, 2003-2010. Among the 81% of infants who were fed formula or regular milk, 69% consumed cow's milk formula, 12% consumed soy formula, 5% consumed gentle/ lactose-reduced formulas, 6% consumed specialty formulas, and 13% consumed regular milk products. There were differences by household education and income in the percentage of infants consuming cow's milk formula and regular milk products. The majority of infants in the United States who were fed formula or regular milk consumed cow's milk formula (69%), with lower percentages receiving soy, specialty, gentle/sensitive, or lactose-free/reduced formulas. Contrary to national recommendations, 13% of infants younger than 1 year consumed regular milk, and the percentage varied by household education and income levels. C1 [Rossen, Lauren M.; Simon, Alan E.; Herrick, Kirsten A.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Rossen, LM (reprint author), Ctr Dis Control & Prevent, Infant Child & Womens Hlth Stat Branch, Off Anal & Epidemiol, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 6121, Hyattsville, MD 20782 USA. EM lrossen@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 2 Z9 2 U1 5 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 EI 1938-2707 J9 CLIN PEDIATR JI Clin. Pediatr. PD MAR PY 2016 VL 55 IS 3 BP 278 EP 285 DI 10.1177/0009922815591881 PG 8 WC Pediatrics SC Pediatrics GA DE1VN UT WOS:000370414700011 PM 26149849 ER PT J AU Pool, LR Wagner, RM Scott, LL RoyChowdhury, D Berhane, R Wu, C Pearson, K Sutton, JA Schaffer, WT AF Pool, Lindsay R. Wagner, Robin M. Scott, Lindsey L. RoyChowdhury, Deepshikha Berhane, Rediet Wu, Charles Pearson, Katrina Sutton, Jennifer A. Schaffer, Walter T. TI Size and characteristics of the biomedical research workforce associated with US National Institutes of Health extramural grants SO FASEB JOURNAL LA English DT Article DE researcher census; occupation; career stage; educational attainment; personnel age distribution AB The U.S. National Institutes of Health (NIH) annually invests approximately $22 billion in biomedical research through its extramural grant programs. Since fiscal year (FY) 2010, all persons involved in research during the previous project year have been required to be listed on the annual grant progress report. These new data have enabled the production of the first-ever census of the NIH-funded extramural research workforce. Data were extracted from All Personnel Reports submitted for NIH grants funded in FY 2009, including position title, months of effort, academic degrees obtained, and personal identifiers. Data were de-duplicated to determine a unique person count. Person-years of effort (PYE) on NIH grants were computed. In FY 2009, NIH funded 50,885 grant projects, which created 313,049 full- and part-time positions spanning all job functions involved in biomedical research. These positions were staffed by 247,457 people at 2,604 institutions. These persons devoted 121,465 PYE to NIH grant-supported research. Research project grants each supported 6 full- or part-time positions, on average. Over 20% of positions were occupied by postdoctoral researchers and graduate and undergraduate students. These baseline data were used to project workforce estimates for FYs 2010-2014 and will serve as a foundation for future research. C1 [Pool, Lindsay R.; Wagner, Robin M.; Pearson, Katrina; Sutton, Jennifer A.; Schaffer, Walter T.] NIH, Off Extramural Res, Off Director, Dept Hlth & Human Serv, Bethesda, MD USA. [Wagner, Robin M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Wagner, RM (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Sci Serv, 2500 Century Ctr Blvd NE,Room 5202,Mailstop E33, Atlanta, GA 30345 USA. EM riw8@cdc.gov FU NIH Evaluation Set-Aside Program [11-6002 OD-OER] FX The authors thank Drs. D. Hann, R. Ikeda, J. Onken, S. Rockey, R. Ulane, and D. Zuk for the insights and comments on drafts of this manuscript, provided by the U.S. National Institutes of Health (NIH) senior staff, and NIH financial specialist, S. Schiaffino, who provided able assistance in securing contract support for the study. This study was partially supported by a project, Reference Number 11-6002 OD-OER, funded by the NIH Evaluation Set-Aside Program, administered by the Office of Program Evaluation and Performance, Division of Program, Coordination, Planning, and Strategic Initiatives, Office of the Director, NIH. The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The coauthors who were federal employees (L.R.P., R.M.W., J.A.S., K.P., and W.T.S.) conducted this research as part of their salaried duties. The work by L.L.S., D.R., R.B., and C.W. was contracted by the NIH. L.R.P., R.M.W., J.A.S., and W.T.S. conceived of and designed the study; L.R.P, L.L.S., D.R., R.B., C.W., K.P. and R.M.W. analyzed the data; L.R.P., R.M.W., K.P., J.A.S., and W.T.S. made significant contributions to interpretation of the results; and L.R.P. and R.M.W. wrote the manuscript. The OCR extraction of data was performed by Discovery Logic (Rockville, MD, USA), a Thomson Reuters business. Drs. L. Haak and J. Schnell served as the OCR project managers, and K. Barden, M. Cissel, and M. Probus performed the analyses. The authors declare no conflicts of interest. NR 23 TC 1 Z9 1 U1 4 U2 10 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD MAR PY 2016 VL 30 IS 3 BP 1023 EP 1036 DI 10.1096/fj.14-264358 PG 14 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA DE1LF UT WOS:000370387800003 PM 26625903 ER PT J AU Lewis, S AF Lewis, Sarah TI Responsive Leadership in Social Services: A Practical Approach for Optimizing Engagement and Performance SO HEALTH PROMOTION PRACTICE LA English DT Article DE lead; workforce development: worksite safety and health AB Responsive Leadership in Social Services: A Practical Approach for Optimizing Engagement and Performance emphasizes the importance of effective supervision as a key component of quality leadership. The Responsive Leadership Approach considers employee needs, values, goals, and strengths to optimize worker performance. It is posited that when leaders integrate and operationalize the meaning embedded in the "employee story," they improve employee engagement and work performance as well as advance their own leadership ability. Discovery tools such as the Key Performance Motivators Scale, Preferred Leadership Profile, and Strengths Index are provided. The impact of operationalizing important values and using a strengths-based approach on organizational climate and employee morale is explored. Active listening and empathic response are discussed as practical methods to discover employee meaning. Techniques for dealing with " difficult" employees and undesirable attitudes and behaviors are described. This book is a valuable resource for developing the leadership capacities of first-time and experienced health and social services supervisors. C1 [Lewis, Sarah] Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30329 USA. RP Lewis, S (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30329 USA. EM irr6@cdc.gov NR 4 TC 0 Z9 0 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1524-8399 EI 1552-6372 J9 HEALTH PROMOT PRACT JI Health Promot. Pract. PD MAR PY 2016 VL 17 IS 2 BP 169 EP 171 DI 10.1177/1524839915623763 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DE6WF UT WOS:000370774400002 PM 26724310 ER PT J AU Su, S Fry, AM Kirley, PD Aragon, D Yousey-Hindes, K Meek, J Openo, K Oni, O Sharangpani, R Morin, C Hollick, G Lung, K Laidler, M Lindegren, ML Schaffner, W Atkinson, A Chaves, SS AF Su, Su Fry, Alicia M. Kirley, Pam Daily Aragon, Deborah Yousey-Hindes, Kimberly Meek, James Openo, Kyle Oni, Oluwakemi Sharangpani, Ruta Morin, Craig Hollick, Gary Lung, Krista Laidler, Matt Lindegren, Mary Lou Schaffner, William Atkinson, Annette Chaves, Sandra S. TI Survey of influenza and other respiratory viruses diagnostic testing in US hospitals, 2012-2013 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE EIP; FluSurv-NET; influenza; laboratory capacity; respiratory viruses ID RAPID INFLUENZA; UNITED-STATES; HOSPITALIZATIONS; MANAGEMENT; INFECTION AB BackgroundLittle is known about laboratory capacity to routinely diagnose influenza and other respiratory viruses at clinical laboratories and hospitals. AimsWe sought to assess diagnostic practices for influenza and other respiratory virus in a survey of hospitals and laboratories participating in the US Influenza Hospitalization Surveillance Network in 2012-2013. Materials and MethodsAll hospitals and their associated laboratories participating in the Influenza Hospitalization Surveillance Network (FluSurv-NET) were included in this evaluation. The network covers more than 80 counties in 15 states, CA, CO, CT, GA, MD, MN, NM, NY, OR, TN, IA, MI, OH, RI, and UT, with a catchment population of similar to 28 million people. We administered a standardized questionnaire to key personnel, including infection control practitioners and laboratory departments, at each hospital through telephone interviews. ResultsOf the 240 participating laboratories, 67% relied only on commercially available rapid influenza diagnostic tests to diagnose influenza. Few reported the availability of molecular diagnostic assays for detection of influenza (26%) and other viral pathogens (20%) in hospitals and commercial laboratories. ConclusionReliance on insensitive assays to detect influenza may detract from optimal clinical management of influenza infections in hospitals. C1 [Su, Su; Fry, Alicia M.; Chaves, Sandra S.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Su, Su; Openo, Kyle] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Kirley, Pam Daily] Calif Emerging Infect Program, Oakland, CA USA. [Aragon, Deborah] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Yousey-Hindes, Kimberly; Meek, James] Yale Univ, Connecticut Emerging Infect Program, Sch Publ Hlth, New Haven, CT USA. [Openo, Kyle] Georgia Emerging Infect Program, Atlanta, GA USA. [Oni, Oluwakemi] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA. [Sharangpani, Ruta] Michigan Dept Hlth & Human Serv, Lansing, MI USA. [Morin, Craig] Minnesota Dept Hlth, St Paul, MN USA. [Hollick, Gary] Univ Rochester, Ctr Community Hlth, Minneapolis, MN USA. [Lung, Krista] Ohio Dept Hlth, Columbus, OH 43266 USA. [Laidler, Matt] Oregon Publ Hlth Div, Portland, OR USA. [Lindegren, Mary Lou; Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Atkinson, Annette] Utah Dept Hlth, Salt Lake City, UT 84116 USA. RP Fry, AM (reprint author), 1600 Clifton Rd NE,Mailstop A32, Atlanta, GA 30333 USA. EM afry@cdc.gov FU Centers for Disease Control and Prevention (CDC) [CDC-RFA-CK12-1202, 5U38HM000414] FX The Influenza Hospitalization Surveillance Network (FluSurv-NET) is a collaboration of state health departments, academic institutions and local partners and is funded by the Centers for Disease Control and Prevention (CDC). This publication was supported in part by Cooperative Agreement number CDC-RFA-CK12-1202 and 5U38HM000414 from CDC. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention, US Department of Health and Human Services. NR 15 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAR PY 2016 VL 10 IS 2 BP 86 EP 90 DI 10.1111/irv.12355 PG 5 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA DD9CA UT WOS:000370222100003 PM 26505742 ER PT J AU Peddecord, KM Wang, W Wang, L Ralston, K Ly, E Friedman, L Curtis, CR Sawyer, MH AF Peddecord, K. Michael Wang, Wendy Wang, Lawrence Ralston, Kimberly Ly, Evelyn Friedman, Lawrence Curtis, C. Robinette Sawyer, Mark H. TI Adolescents' Self-Reported Recall of Anticipatory Guidance Provided During Well-Visits at Nine Medical Clinics in San Diego, California, 2009-2011 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Adolescents; Clinical preventive services; Anticipatory guidance; Well visits; Patient privacy; Vaccine; Clinic characteristics; Evidence-based practices; Primary medical care; Community health centers; Electronic medical record ID PREVENTIVE SERVICES; CARE; BEHAVIOR; QUALITY; INTERVENTIONS; ASSOCIATION; GUIDELINES AB Purpose: Anticipatory guidance (AG) is recommended for adolescent well care. AG recall is important in the event sequence that might lead to behavioral change, reduced health risk, and improved health. We assessed factors influencing adolescents' self-reported recall of specific AG topics. Methods: Through convenience sampling of nine clinics in San Diego, California, 872 adolescents (429 aged 11-13 years; 443 aged 14-17 years) who had received well visits completed standardized surveys between 2009 and 2011. Adolescents were asked to report recall of either 17 or 23 age-appropriate AG topics that were analyzed in five categories (health maintenance; social/emotional, safety/violence; smoking/substance abuse, and puberty/sexual health); a summary score for all categories was developed. Summary scores' associations with demographic variables, visit characteristics (including having time without parents present [private time]), clinic procedures, and lead physician attitudes were assessed. Results: AG recall was independently associated with adolescents having private time with clinicians, completing previsit questionnaires, reporting the well visit was helpful, and the well visit lasting at least 10 minutes. Higher summary recall scores were observed among adolescents who received care in clinics providing AG at both sick and well visits and having policies encouraging private time. Clinic electronic medical record use for AG prompts was associated with recall of fewer topics. Conclusions: To increase adolescents' AG recall and potentially foster behavior change, our results suggest medical providers should adopt procedures advocated by professional societies, including assuring adolescents receive private time during visits, increasing visit time during well visits, using patient-completed questionnaires, and providing AG during all visits. (C) 2016 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved. C1 [Peddecord, K. Michael] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. [Wang, Wendy; Wang, Lawrence; Ralston, Kimberly; Ly, Evelyn; Friedman, Lawrence; Sawyer, Mark H.] Univ Calif San Diego, Sch Med, Dept Pediat, Div Infect Dis, La Jolla, CA 92093 USA. [Wang, Wendy; Wang, Lawrence; Ralston, Kimberly; Ly, Evelyn; Friedman, Lawrence; Sawyer, Mark H.] Univ Calif San Diego, Sch Med, Dept Pediat, Div Adolescent Med, La Jolla, CA 92093 USA. [Curtis, C. Robinette] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Peddecord, KM (reprint author), Immunizat Branch, POB 85222,MS P511B, San Diego, CA 92186 USA. EM mpeddeco@mail.sdsu.edu OI Ly, Evelyn/0000-0001-8420-2360 FU Centers for Disease Control and Prevention USCD [1U01IP000136-01, 5U01IP000136] FX The study was funded by Centers for Disease Control and Prevention USCD Grant # 1U01IP000136-01 (COOP agreement number 5U01IP000136). NR 23 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAR PY 2016 VL 58 IS 3 BP 267 EP 275 DI 10.1016/j.jadohealth.2015.10.007 PG 9 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DE4QU UT WOS:000370615500005 PM 26699230 ER PT J AU Hallum-Montes, R Middleton, D Schlanger, K Romero, L AF Hallum-Montes, Rachel Middleton, Dawn Schlanger, Karen Romero, Lisa TI Barriers and Facilitators to Health Center Implementation of Evidence-Based Clinical Practices in Adolescent Reproductive Health Services SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Reproductive health; Implementation science; Contraception; Long-acting reversible contraception; Teen pregnancy ID POSITION PAPER; UNITED-STATES; MISSED OPPORTUNITIES; CARE SERVICES; YOUNG-WOMEN; MEDICINE; SOCIETY; DISPARITIES AB Purpose: Despite the substantial evidence supporting the guidelines for the provision of reproductive health services for adolescents, research points to a persistent gap in their translation into health care practice. This study examines barriers and facilitators that health centers experience when implementing evidence-based clinical practices for adolescent reproductive health services and discusses strategies to address identified barriers. Methods: Semistructured interviews were conducted with 85 leaders and staff of 30 health centers in Alabama, Georgia, Massachusetts, North Carolina, South Carolina, Pennsylvania, and Texas. Interview data were analyzed for emergent themes following a grounded theory approach. Results: Data analysis revealed that certain factors at health system and community levels influenced health centers' efforts to implement evidence-based clinical practices for adolescent reproductive health care. In particular, support from health center leadership, communication between leadership and staff, and staff attitudes and beliefs were reported as factors that facilitated the implementation of new practices. Conclusions: Health center efforts to implement new practice guidelines should include efforts to build the capacity of health center leadership to mobilize staff and resources to ensure that new practices are implemented consistently and with quality. (C) 2016 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved. C1 [Hallum-Montes, Rachel; Middleton, Dawn; Schlanger, Karen] CAI, New York, NY USA. [Romero, Lisa] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hallum-Montes, Rachel] ZS Associates, Evanston, IL USA. RP Hallum-Montes, R (reprint author), 2500-22 Carlmont Dr, Belmont, CA 94002 USA. EM rhallum.montes@gmail.com FU Centers for Disease Control and Prevention [5U58DP002942-02] FX This publication was made possible by Grant/Cooperative Agreement Number 5U58DP002942-02 from the Centers for Disease Control and Prevention. NR 26 TC 0 Z9 0 U1 5 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAR PY 2016 VL 58 IS 3 BP 276 EP 283 DI 10.1016/j.jadohealth.2015.11.002 PG 8 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DE4QU UT WOS:000370615500006 PM 26903427 ER PT J AU Cai, B McDermott, S Wang, YD Royer, JA Mann, JR Hardin, JW Ozturk, O Ouyang, LJ AF Cai, Bo McDermott, Suzanne Wang, Yinding Royer, Julie A. Mann, Joshua R. Hardin, James W. Ozturk, Orgul Ouyang, Lijing TI Skin Ulcers and Mortality Among Adolescents and Young Adults With Spina Bifida in South Carolina During 2000-2010 SO JOURNAL OF CHILD NEUROLOGY LA English DT Article DE Adolescent; young adult; health; skin ulcer; spina bifida; survival analysis ID NEW-YORK-STATE; BIRTH-DEFECTS; HEALTH-CARE; TRANSITION; PRESSURE; HYDROCEPHALUS; SURVIVAL; OUTCOMES; CHILDREN; ISSUES AB The authors investigated 48 deaths (7% death rate) among 690 adolescents and young adults with spina bifida in South Carolina during 2000-2010. The authors used Medicaid and other administrative data and a retrospective cohort design that included people with spina bifida identified using ICD-9 codes. Cox regression models with time-dependent and time-invariant covariates, and Kaplan-Meier survival curves were constructed. The authors found that 21.4% of the study group had a skin ulcer during the study period and individuals with skin ulcers had significantly higher mortality than those without ulcers (P < .0001). People who had their first skin ulcer during adolescence had higher mortality than those who had the first skin ulcer during young adulthood (P = .0002; hazard ratio = 10.70, 95% confidence interval for hazard ratio: 3.01, 38.00) and those without skin ulcers, controlling for other covariates. This study showed that age at which individuals first had a skin ulcer was associated with mortality. C1 [Cai, Bo; McDermott, Suzanne; Wang, Yinding; Hardin, James W.] Univ S Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, 915 Greene St,Ste 460, Columbia, SC 29208 USA. [Royer, Julie A.] South Carolina Revenue & Fiscal Affairs, Div Res & Stat, Columbia, SC USA. [Mann, Joshua R.] Univ S Carolina, Dept Family & Prevent Med, Sch Med, Columbia, SC 29208 USA. [Ozturk, Orgul] Univ S Carolina, Moore Sch Business, Dept Econ, Columbia, SC 29208 USA. [Ouyang, Lijing] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Cai, B (reprint author), Univ S Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, 915 Greene St,Ste 460, Columbia, SC 29208 USA. EM BOCAI@mailbox.sc.edu RI Hardin, James/Q-7617-2016 OI Hardin, James/0000-0003-0506-5500 FU US Department of Health and Human Services, Centers for Disease Control and Prevention [5U01DD000776-03 (CFDA 93.283)] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Grant 5U01DD000776-03 (CFDA 93.283) from the US Department of Health and Human Services, Centers for Disease Control and Prevention. NR 28 TC 0 Z9 0 U1 1 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0883-0738 EI 1708-8283 J9 J CHILD NEUROL JI J. Child Neurol. PD MAR PY 2016 VL 31 IS 3 BP 370 EP 377 DI 10.1177/0883073815596611 PG 8 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA DE2AX UT WOS:000370429700016 PM 26239488 ER PT J AU Sutter, RW Kew, OM AF Sutter, Roland W. Kew, Olen M. TI Renaissance of an "old" vaccine SO LANCET INFECTIOUS DISEASES LA English DT Editorial Material ID INACTIVATED POLIOVIRUS VACCINE; CONTROLLED-TRIAL C1 [Sutter, Roland W.] World Hlth Org, Polio Eradicat Dept, Geneva, Switzerland. Ctr Dis Control & Prevent CDC, Natl Ctr Infect Dis, Atlanta, GA USA. RP Sutter, RW (reprint author), World Hlth Org, Polio Eradicat Dept, Geneva, Switzerland. EM sutterr@who.int NR 12 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAR PY 2016 VL 16 IS 3 BP 268 EP 270 DI 10.1016/S1473-3099(15)00526-5 PG 3 WC Infectious Diseases SC Infectious Diseases GA DE4FQ UT WOS:000370585000004 PM 26719059 ER PT J AU Pathmanathan, I Pevzner, ES Marston, BJ Hader, SL Dokubo, EK AF Pathmanathan, Ishani Pevzner, Eric S. Marston, Barbara J. Hader, Shannon L. Dokubo, E. Kainne TI Insights from the Ebola response to address HIV and tuberculosis SO LANCET INFECTIOUS DISEASES LA English DT Editorial Material ID CRISIS C1 [Pathmanathan, Ishani; Pevzner, Eric S.; Hader, Shannon L.; Dokubo, E. Kainne] US Ctr Dis Control & Prevent, Div Global HIV & TB, Ctr Global Hlth, Atlanta, GA 30329 USA. [Marston, Barbara J.] US Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30329 USA. RP Pathmanathan, I (reprint author), US Ctr Dis Control & Prevent, Div Global HIV & TB, Ctr Global Hlth, Atlanta, GA 30329 USA. EM ydi6@cdc.gov FU Intramural CDC HHS [CC999999]; PEPFAR NR 10 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAR PY 2016 VL 16 IS 3 BP 276 EP 278 PG 3 WC Infectious Diseases SC Infectious Diseases GA DE4FQ UT WOS:000370585000010 PM 26973303 ER PT J AU Saez-Llorens, X Clemens, R Leroux-Roels, G Jimeno, J Clemens, SAC Weldon, WC Oberste, MS Molina, N Bandyopadhyay, AS AF Saez-Llorens, Xavier Clemens, Ralf Leroux-Roels, Geert Jimeno, Jose Clemens, Sue Ann Costa Weldon, William C. Oberste, M. Steven Molina, Natanael Bandyopadhyay, Ananda S. TI Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial SO LANCET INFECTIOUS DISEASES LA English DT Article ID OPEN-LABEL; POLIOMYELITIS; SCHEDULE AB Background Following the proposed worldwide switch from trivalent oral poliovirus vaccine (tOPV) to bivalent types 1 and 3 OPV (bOPV) in 2016, inactivated poliovirus vaccine (IPV) will be the only source of protection against poliovirus type 2. With most countries opting for one dose of IPV in routine immunisation schedules during this transition because of cost and manufacturing constraints, optimisation of protection against all poliovirus types will be a priority of the global eradication programme. We assessed the immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine (mIPV2HD) in infants. Methods This observer-blind, comparative, randomised controlled trial was done in a single centre in Panama. We enrolled healthy infants who had not received any previous vaccination against poliovirus. Infants were randomly assigned (1:1) by computer-generated randomisation sequence to receive a single dose of either mIPV2HD or standard trivalent IPV given concurrently with a third dose of bOPV at 14 weeks of age. At 18 weeks, all infants were challenged with one dose of monovalent type 2 OPV (mOPV2). Primary endpoints were seroconversion and median antibody titres to type 2 poliovirus 4 weeks after vaccination with mIPV2HD or IPV; and safety (as determined by the proportion and nature of serious adverse events and important medical events for 8 weeks after vaccination). The primary immunogenicity analyses included all participants for whom a post-vaccination blood sample was available. All randomised participants were included in the safety analyses. This trial is registered with ClinicalTrials.gov, number NCT02111135. Findings Between April 14 and May 9,2014,233 children were enrolled and randomly assigned to receive mIPV2HD (117 infants) or IPV (116 infants). 4 weeks after vaccination with mIPV2HD or IPV, seroconversion to poliovirus type 2 was recorded in 107 (93.0%, 95% CI 86.8-96.9) of 115 infants in the mIPV2HD group compared with 86 (74.8%, 65.8-82.4) of 115 infants in the IPV group (difference between groups 18.3%, 95% CI 5.0-31.1; p<0.0001), and median antibody titres against poliovirus type 2 were 181 (95% CI 72.0-362.0) in the mIPV2HD group and 36 (18.0-113-8) in the IPV group (difference between groups 98.8, 95% CI 60.7-136.9; p<0.0001). Serious adverse events were reported for six (5%) of 117 infants in the mIPV2HD group and seven (6%) of 116 infants in the IPV group during the 8-week period after vaccination; none were related to vaccination. No important medical events were reported. Interpretation Our findings lend support to the use of mIPV2HD as an option for stockpiling for outbreak response or primary protection in selected areas at risk for emergence of poliovirus type 2 during the next phase of the polio eradication plan. C1 [Saez-Llorens, Xavier] Hosp Nino, Panama City, Panama. [Clemens, Ralf] Global Res Infect Dis, Rio De Janeiro, Brazil. [Leroux-Roels, Geert] Ctr Vaccinol CEVAC, Ghent, Belgium. [Jimeno, Jose; Molina, Natanael] VaxTrials, Panama City, Panama. [Clemens, Sue Ann Costa] Inst Pos Grad Carlos Chagas, Rio De Janeiro, Brazil. [Weldon, William C.; Oberste, M. Steven] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bandyopadhyay, Ananda S.] Bill & Melinda Gates Fdn, Seattle, WA USA. RP Bandyopadhyay, AS (reprint author), Bill & Melinda Gates Fdn, Global Dev, 1432 Elliott Ave W, Seattle, WA 98119 USA. EM Ananda.Bandyopadhyay@gatesfoundation.org OI Bandyopadhyay, Ananda/0000-0002-8395-2001 FU Bill & Melinda Gates Foundation FX The study was funded by the Bill & Melinda Gates Foundation. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the US Centers for Disease Control and Prevention (CDC) and other contributing agencies. The use of trade names is for identification purposes only and does not constitute an endorsement by the CDC or the US Government. Important contributors were Ana Cecilia Villarreal who was the site coordinator for the study; Steve Self, Bhavesh R Borate, and Chris Gast of the Fred Hutchinson Cancer Research Center, who provided input into study design and data analysis, respectively; Chris Wilson of the Bill & Melinda Gates Foundation who provided input into study design; and Mohamed Amakrane, Marie-Cecile Bozonnat, and Anne Hepburn of 4Clinics, who performed the statistical analysis and assisted in the preparation of the study'report and manuscript. We thank Victor' Sales and Johnny Escobar of VaxTrials for their support in the study conduct; Mark Pallansch, CDC, for his expert advice during the development of the study design; Maria Luisa Avila, Maria Teresa Valenzuela, Claudio Strunchiner, Luiza Helena Falleiros, and Carolina Danovaro for study supervision within the data safety monitoring board; Gerrit Van Roekel and Kim Bush of the Bill & Melinda Gates Foundation for coordinating vaccine supply; Jay Wenger and John Modlin of the Bill & Melinda Gates Foundation who provided input into study design and data analysis; and the laboratory staff at the CDC (Deborah Moore, Yiting Zhang, Sharla McDonald, Latin McDuffie, William Hendley, Patricia Mitchell, Mario Nicolas, Demetrius Mathis, Brittani Brown, and Jessica Wielgus) for performing poliovirus titration and seroneutralisation assays. We also thank Bilthoven Biologicals, GlaxoSmithICline, and Sanofi Pasteur for kindly donating vaccines for the study. We are grateful to the Panama site members Juan Carlos Batista, Luis Casal, Evelyn Castillo, Rita Tello, Maria Guadalupe de Fletcher, John Solano, Onix Saldaria, and Stephany Alvarez for their participation. NR 27 TC 2 Z9 2 U1 5 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAR PY 2016 VL 16 IS 3 BP 321 EP 330 DI 10.1016/S1473-3099(15)00488-0 PG 10 WC Infectious Diseases SC Infectious Diseases GA DE4FQ UT WOS:000370585000037 PM 26719058 ER PT J AU Patel, CG Chesson, HW Tao, GY AF Patel, Chirag G. Chesson, Harrell W. Tao, Guoyu TI Racial Differences in Receipt of Chlamydia Testing Among Medicaid-Insured Women in 2013 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; DISEASES TREATMENT GUIDELINES; PELVIC-INFLAMMATORY-DISEASE; UNITED-STATES; HEALTH-CARE; DISPARITIES; TRACHOMATIS; GONORRHEA AB Objective To estimate the percentage of young, sexually active Medicaid-insured women who were tested for chlamydia by age, race/ethnicity, and history of sexually transmitted disease (STD) diagnosis. Methods We used the medical diagnostic and procedural codes from Truven Health MarketScan Medicaid claims data from 10 states in 2012 and 2013 to estimate the rates of chlamydia testing in 2013 and previous STD diagnosis (diagnosed in 2012) among Medicaid-insured women aged 15-25 years who were sexually active in 2013. We also used a logit model to assess the association between chlamydia testing and women's age, race/ethnicity, and previous STD diagnosis. Results Overall, among approximately 261,000 Medicaid-insured women aged 15-25 years in 2013 who were classified as sexually active, 50.2% were tested for chlamydia in 2013. The chlamydia testing rate was 45.6% for white women and 57.5% for black women. The chlamydia testing rate was 63.5% for women diagnosed as having an STD in 2012 and 46.8% for women not diagnosed as having an STD in 2012. The chlamydia testing rate was significantly (P < 0.05) associated with previous STD diagnosis, age, and race/ethnicity in our logit model. Conclusions Higher chlamydia testing rates among black women can be explained in part by higher rates of previous STD diagnoses. Our finding that black women have the highest chlamydia testing rates is encouraging, as improved access to STD prevention services among racial/ethnic minorities can help to reduce racial/ethnic disparities in STDs. However, chlamydia screening remains an underused preventive health service for young women of all racial and ethnic groups. C1 [Patel, Chirag G.; Chesson, Harrell W.; Tao, Guoyu] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA USA. [Patel, Chirag G.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP Patel, CG (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS-E80, Atlanta, GA 30316 USA. EM wyp3@cdc.gov NR 29 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2016 VL 43 IS 3 BP 147 EP 151 DI 10.1097/OLQ.0000000000000405 PG 5 WC Infectious Diseases SC Infectious Diseases GA DE2WO UT WOS:000370488100002 PM 26859801 ER PT J AU Turner, AN Reese, PC Snead, MC Fields, K Ervin, M Kourtis, AP Klebanoff, MA Gallo, MF AF Turner, Abigail Norris Reese, Patricia Carr Snead, Margaret Christine Fields, Karen Ervin, Melissa Kourtis, Athena P. Klebanoff, Mark A. Gallo, Maria F. TI Recent Biomarker-Confirmed Unprotected Vaginal Sex, But Not Self-reported Unprotected Sex, Is Associated With Recurrent Bacterial Vaginosis SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID PROSTATE-SPECIFIC ANTIGEN; RISK-FACTORS; CONDOM USE; WOMEN; SEMEN; CANDIDIASIS; RELIABILITY; EXPOSURE; VALIDITY; FAILURE AB Background Self-reported unprotected vaginal sex seems to increase risk of bacterial vaginosis (BV). However, the validity of self-reports is questionable, given their inconsistency with more objective measures of recent semen exposure such as detection of prostate-specific antigen (PSA). We examined whether recent unprotected sex, as measured both by PSA detection on vaginal swabs and by self-report, was associated with increased BV recurrence. Methods We analyzed randomized trial data from nonpregnant, BV-positive adult women recruited from a sexually transmitted disease clinic. Participants received BV therapy at enrollment and were scheduled to return after 4, 12, and 24 weeks. Bacterial vaginosis (by Nugent score) and PSA were measured at each visit. We used Cox proportional hazards models to examine the association between PSA positivity and recurrent BV. We also evaluated associations between self-reported unprotected sex (ever/never since the last visit and in the last 48 hours, analyzed separately) and recurrent BV. Results Prostate-specific antigen and BV results were available for 96 women who contributed 226 follow-up visits. Prostate-specific antigen positivity was associated with increased BV recurrence (adjusted hazard ratio [aHR], 2.32; 95% confidence interval [CI], 1.28-4.21). In contrast, we observed no significant increase in BV recurrence among women self-reporting unprotected sex since the last visit (aHR, 1.63; 95% CI, 0.77-3.43) or in the last 48 hours (aHR, 1.28; 95% CI, 0.70-2.36). Conclusions Estimates from earlier studies linking self-reported unprotected sex and BV may be biased by misclassification. Biomarkers can improve measurement of unprotected sex, a critical exposure variable in sexual health research. C1 [Turner, Abigail Norris] Ohio State Univ, Coll Med, Div Infect Dis, Columbus, OH 43210 USA. [Reese, Patricia Carr] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. [Snead, Margaret Christine; Kourtis, Athena P.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Fields, Karen; Ervin, Melissa] Columbus Publ Hlth, Sexual Hlth Clin, Columbus, OH USA. [Klebanoff, Mark A.] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA. [Klebanoff, Mark A.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA. [Gallo, Maria F.] Ohio State Univ, Div Epidemiol, Coll Publ Hlth, Columbus, OH 43210 USA. RP Turner, AN (reprint author), Ohio State Univ, Dept Internal Med, Div Infect Dis, Columbus, OH 43210 USA. EM ant@osumc.edu FU Ohio State University Center for Clinical Translational Science [KL2RR025754]; National Center for Advancing Translational Sciences [8UL1TR000090-05]; National Institute for Allergy Infectious Diseases [R21AI095987] FX This work was supported by KL2RR025754 through the Ohio State University Center for Clinical Translational Science. The Ohio State University Center for Clinical Translational Science is supported by the National Center for Advancing Translational Sciences (8UL1TR000090-05). A.N.T was also supported by R21AI095987 from the National Institute for Allergy Infectious Diseases. The US CDC, Division of Reproductive Health, and the Division of Scientific Resources quantified prostate-specific antigen for this project. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the National Institutes of Health, National Center for Advancing Translational Sciences, National Institute for Allergy Infectious Diseases, or CDC. Use of trade names is for identification only and does not imply endorsement by the US Department of Health Human Services. NR 31 TC 1 Z9 2 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2016 VL 43 IS 3 BP 172 EP 176 DI 10.1097/OLQ.0000000000000414 PG 5 WC Infectious Diseases SC Infectious Diseases GA DE2WO UT WOS:000370488100005 ER PT J AU Peterman, TA Fakile, YF AF Peterman, Thomas A. Fakile, Yetunde F. TI What Is the Use of Rapid Syphilis Tests in the United States? SO SEXUALLY TRANSMITTED DISEASES LA English DT Editorial Material AB Syphilis testing is complicated. Rapid syphilis tests may change screening practices in the United States, but first, more studies are needed to demonstrate the advantages and disadvantages in the field. C1 [Peterman, Thomas A.; Fakile, Yetunde F.] CDC, Div STD Prevent, NCHHSTP, Atlanta, GA 30333 USA. RP Peterman, TA (reprint author), CDC, Mailstop E02,1600 Clifton Rd, Atlanta, GA 30333 USA. EM tap1@cdc.gov NR 14 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2016 VL 43 IS 3 BP 201 EP 203 DI 10.1097/OLQ.0000000000000413 PG 3 WC Infectious Diseases SC Infectious Diseases GA DE2WO UT WOS:000370488100010 PM 26859809 ER PT J AU Bertke, SJ Meyers, AR Wurzelbacher, SJ Measure, A Lampl, MP Robins, D AF Bertke, S. J. Meyers, A. R. Wurzelbacher, S. J. Measure, A. Lampl, M. P. Robins, D. TI Comparison of methods for auto-coding causation of injury narratives SO ACCIDENT ANALYSIS AND PREVENTION LA English DT Article DE Auto-coding; Naive Bayes; Regularized logistic regression; Injury narratives; Workers' compensation ID TOOL AB Manually reading free-text narratives in large databases to identify the cause of an injury can be very time consuming and recently, there has been much work in automating this process. In particular, the variations of the naive Bayes model have been used to successfully auto-code free text narratives describing the event/exposure leading to the injury of a workers' compensation claim. This paper compares the naive Bayes model with an alternative logistic model and found that this new model outperformed the naive Bayesian model. Further modest improvements were found through the addition of sequences of keywords in the models as opposed to consideration of only single keywords. The programs and weights used in this paper are available upon request to researchers without a training set wishing to automatically assign event codes to large data-sets of text narratives. The utility of sharing this program was tested on an outside set of injury narratives provided by the Bureau of Labor Statistics with promising results. Published by Elsevier Ltd. C1 [Bertke, S. J.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Industrywide Studies Branch, 1090 Tusculum Ave, Cincinnati, OH 45226 USA. [Meyers, A. R.; Wurzelbacher, S. J.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Industrywide Studies Branch, Ctr Workers Compensat Studies, 1090 Tusculum Ave, Cincinnati, OH 45226 USA. [Measure, A.] US Bur Labor Stat, Occupat Safety & Hlth Stat, 2 Massachusetts Ave, Washington, DC 20212 USA. [Lampl, M. P.; Robins, D.] Ohio Bur Workers Compensat, Div Safety & Hyg, 13430 Yarmouth Dr, Pickerington, OH 43147 USA. RP Bertke, SJ (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Industrywide Studies Branch, 1090 Tusculum Ave, Cincinnati, OH 45226 USA. EM inh4@cdc.gov OI Meyers, Alysha/0000-0002-6402-0145 FU Intramural CDC HHS [CC999999] NR 14 TC 4 Z9 4 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0001-4575 EI 1879-2057 J9 ACCIDENT ANAL PREV JI Accid. Anal. Prev. PD MAR PY 2016 VL 88 BP 117 EP 123 DI 10.1016/j.aap.2015.12.006 PG 7 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA DD7LH UT WOS:000370105500013 PM 26745274 ER PT J AU Riley, HEM Berry-Bibee, E England, LJ Jamieson, DJ Marchbanks, PA Curtis, KM AF Riley, Halley E. M. Berry-Bibee, Erin England, Lucinda J. Jamieson, Denise J. Marchbanks, Polly A. Curtis, Kathryn M. TI Hormonal contraception among electronic cigarette users and cardiovascular risk: a systematic review SO CONTRACEPTION LA English DT Review DE Electronic cigarettes; Hormonal contraceptives; Nicotine; Propylene glycol; Glycerol; Cardiovascular disease ID SMOKELESS TOBACCO USE; ALASKA NATIVE WOMEN; ORAL-CONTRACEPTIVES; NICOTINE-DELIVERY; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; PREGNANCY OUTCOMES; SMOKING-HABITS; UNITED-STATES; PRODUCT USE AB Background: Women who use combined hormonal contraceptives and cigarettes have an increased risk for cardiovascular (CV) events. We reviewed the literature to determine whether women who use hormonal contraceptives (HC) and electronic cigarettes (e-cigarettes) also have an increased risk. Study Design: Systematic review. Methods: We searched for articles reporting myocardial infarction (MI), stroke, venous thromboembolism, peripheral arterial disease or changes to CV markers in women using e-cigarettes and HC. We also searched for indirect evidence, such as CV outcomes among e-cigarette users in the general population and among HC users exposed to nicotine, propylene glycol or glycerol. Results: No articles reported on outcomes among e-cigarette users using HC. Among the general population, 13 articles reported on heart rate or blood pressure after e-cigarette use. These markers generally remained normal, even when significant changes were observed. In three studies, changes were less pronounced after e-cigarette use than cigarette use. One MI was reported among 1012 people exposed to e-cigarettes in these studies. One article on nicotine and HC exposure found both exposures to be significantly associated with acute changes to heart rate, though mean heart rate remained normal. No articles on propylene glycol or glycerol and HC exposure were identified. Conclusion: We identified no evidence on CV outcomes among e-cigarette users using HC. Limited data reporting mostly acute outcomes suggested that CV events are rare among e-cigarette users in the general population and that e-cigarettes may affect heart rate and blood pressure less than conventional cigarettes. There is a need for research assessing joint HC and e-cigarette exposure on clinical CV outcomes. (C) 2016 Elsevier Inc. All rights reserved. C1 [Riley, Halley E. M.; Berry-Bibee, Erin; Jamieson, Denise J.; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [England, Lucinda J.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. RP Riley, HEM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.; Riley, HEM (reprint author), Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM heriley@emory.edu NR 73 TC 2 Z9 2 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD MAR PY 2016 VL 93 IS 3 BP 190 EP 208 DI 10.1016/j.contraception.2015.11.003 PG 19 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DD7PR UT WOS:000370117100002 PM 26546021 ER PT J AU Jacobson, L Garbers, S Helmy, H Roobol, H Kohn, JE Kavanaugh, ML AF Jacobson, Laura Garbers, Samantha Helmy, Hannah Roobol, Hope Kohn, Julia E. Kavanaugh, Megan L. TI IUD services among primary care practices in New York City SO CONTRACEPTION LA English DT Article DE Intrauterine device; IUD; Primary care; LARC; Long-acting reversible contraception ID ACTING REVERSIBLE CONTRACEPTIVES; QUALIFIED HEALTH CENTERS; UNITED-STATES; LARCS; YOUNG; WOMEN AB Objective: Intrauterine devices (IUDs) are one of the most effective forms of reversible contraception and can reduce unintended pregnancy rates. We explored practice characteristics associated with IUD services across a network of primary care practices in New York City during 2010-2013. Study Design: Data were extracted from electronic health records (EHRs) for 253 primary care practices participating in an EHR quality improvement program in New York City. We used diagnostic and procedure codes to count IUD insertions and removals among females aged 10-49 years during 2010-2013. Logistic regression models predicted the likelihood of IUD insertion, removal or no activity for 2013, based on practice characteristics. We stratified trends in IUD services over time by practice type and specialty. Results: From 2010 to 2013, the proportion of practices that inserted IUDs increased slightly from 4.7% to 6.3% (p=0.17), and the proportion removing IUDs increased from 8.3% to 12.3% (p<0.01). More than 60% of obstetricians/gynecologists and midwives performed insertions or removals each year; fewer than 10% of internal medicine and pediatric providers did so. Community health centers had higher odds of performing removals than independent practices (adjusted odds ratio=10.24, 95% confidence interval: 3.37-31.17). Practices seeing >66% female patients had higher odds of performing both insertions and removals. Conclusions: From 2010 to 2013, IUD services increased but remained low among primary care practices in this network. Provider training and system readiness programs should include independent primary care practices, which rarely provide IUDs, to ensure that women can receive IUDs or IUD service referrals in the primary care setting. (C) 2016 Elsevier Inc. All rights reserved. C1 [Jacobson, Laura] NYC Dept Hlth & Mental Hyg, Primary Care Informat Project, 42-09 28th St,CN 52, Queens, NY 11101 USA. [Garbers, Samantha] Columbia Univ, Mailman Sch Publ Hlth, Heilbrunn Dept Populat & Family Hlth, 60 Haven Ave,Room 2D, New York, NY 10032 USA. [Helmy, Hannah] Montefiore Med Ctr, 3544 Jerome Ave, Bronx, NY 10467 USA. [Roobol, Hope] Ctr Dis Control & Prevent, Off State Tribal Local & Terr Support, 4770 Buford Highway,Mailstop E70, Atlanta, GA 30341 USA. [Kohn, Julia E.] Planned Parenthood Federat Amer, Res Dept, 434 West 33 St, New York, NY USA. [Kavanaugh, Megan L.] Alan Guttmacher Inst, Div Res, 125 Maiden Lane, New York, NY 10038 USA. RP Jacobson, L (reprint author), NYC Dept Hlth & Mental Hyg, Primary Care Informat Project, 42-09 28th St,CN 52, Queens, NY 11101 USA. EM ljacobson1@health.nyc.gov; svg2108@cumc.columbia.edu; hhelmy@montefiore.org; vtt2@cdc.gov; julia.kohn@ppfa.org; mkavanaugh@guttmacher.org FU Centers for Disease Control and Prevention Community Transformation [5U58DP003689-02] FX The authors would like to acknowledge Remle Newton-Dame and the Hub team at the PCIP, eClinicalWorks, the Bureau of Maternal, Infant, and Reproductive Health of the New York City Department of Health and Mental Hygiene and the New York City IUD Taskforce, now the New York City LARC Access Taskforce. The Hub was partially supported by a Centers for Disease Control and Prevention Community Transformation Grant (no. 5U58DP003689-02). NR 28 TC 0 Z9 0 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD MAR PY 2016 VL 93 IS 3 BP 257 EP 262 DI 10.1016/j.contraception.2015.11.002 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DD7PR UT WOS:000370117100011 PM 26569447 ER PT J AU Wright, AP Richardson, L Mahon, BE Rothenberg, R Cole, DJ AF Wright, A. P. Richardson, L. Mahon, B. E. Rothenberg, R. Cole, D. J. TI The rise and decline in Salmonella enterica serovar Enteritidis outbreaks attributed to egg-containing foods in the United States, 1973-2009 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Eggs; foodborne outbreaks; Salmonella enterica serovar Enteritidis ID FOODBORNE DISEASE OUTBREAKS; SEROTYPE ENTERITIDIS; INFECTIONS; SURVEILLANCE; SITES; PROGRAMS; ILLNESS AB Salmonella enterica causes an estimated 1 million domestically acquired foodborne illnesses annually. Salmonella enterica serovar Enteritidis (SE) is among the top three serovars of reported cases of Salmonella. We examined trends in SE foodborne outbreaks from 1973 to 2009 using Joinpoint and Poisson regression. The annual number of SE outbreaks increased sharply in the 1970s and 1980s but declined significantly after 1990. Over the study period, SE outbreaks were most frequently attributed to foods containing eggs. The average rate of SE outbreaks attributed to egg-containing foods reported by states began to decline significantly after 1990, and the proportion of SE outbreaks attributed to egg-containing foods began declining after 1997. Our results suggest that interventions initiated in the 1990s to decrease SE contamination of shell eggs may have been integral to preventing SE outbreaks. C1 [Wright, A. P.; Richardson, L.; Mahon, B. E.; Cole, D. J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wright, A. P.] Lexington Fayette Urban Cty Govt, Lexington, KY USA. [Rothenberg, R.] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30303 USA. RP Wright, AP (reprint author), 723 Cramer Ave, Lexington, KY 40502 USA. EM ashtonpotterwright@gmail.com NR 38 TC 1 Z9 1 U1 4 U2 9 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAR PY 2016 VL 144 IS 4 BP 810 EP 819 DI 10.1017/S0950268815001867 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DD1VY UT WOS:000369712100018 PM 26289100 ER PT J AU Pattanasin, S Wimonsate, W Chonwattana, W Tongtoyai, J Chaikummao, S Sriporn, A Sukwicha, W Mock, PA Holtz, TH AF Pattanasin, Sarika Wimonsate, Wipas Chonwattana, Wannee Tongtoyai, Jaray Chaikummao, Supaporn Sriporn, Anuwat Sukwicha, Wichuda Mock, Philip A. Holtz, Timothy H. TI Loss to follow-up and bias assessment among a cohort of Thai men who have sex with men in Bangkok, Thailand SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE HIV; AIDS; men; Epidemiology; homosexual; men who have sex with men; MSM; Asia; high-risk behaviour; prospective studies; loss to follow-up ID HIV-INFECTION; ANTIRETROVIRAL THERAPY; BISEXUAL MEN; METHAMPHETAMINE; PREDICTORS; PREVALENCE; GUIDELINES; ADULTS; GAY AB Minimising loss to follow-up is essential to obtain unbiased results. This study aimed to assess factors associated with loss to follow-up and effects on biasing exposure-outcome associations in a cohort of men who have sex with men in Bangkok. We enrolled sexually-active Thai men who have sex with men, at least 18 years old, in a study with four-monthly follow-up visits. At each visit, men answered HIV risk behaviour questions using audio computer-assisted self-interview. Logistic regression was used to evaluate factors associated with loss to follow-up and bias between exposures and prevalent HIV infection were estimated using adjusted relative odds ratios. From 2006 to 2010, we enrolled 1744 men who have sex with men; as of April, 2014, 1256 (72%) had completed at least the month-36 visit; loss to follow-up was 9.6%. Factors independently associated with loss to follow-up were age (18-21 years), education (primary level or less, secondary or vocational education), living outside Bangkok and vicinity, sexual orientation (bisexual, heterosexual), previous HIV testing, HIV infection, and behaviour in the past 4 months (recreational drug use, reporting group sex). An effect of loss to follow-up on factors of prevalent HIV infection was found by sexual orientation (transgender) and unprotected anal intercourse (receptive/insertive). These findings highlight the need to strengthen post-HIV test counselling. Directed counselling for HIV care should be given to young men who have sex with men and recreational drug users. C1 [Pattanasin, Sarika; Wimonsate, Wipas; Chonwattana, Wannee; Tongtoyai, Jaray; Chaikummao, Supaporn; Sriporn, Anuwat; Sukwicha, Wichuda; Mock, Philip A.; Holtz, Timothy H.] Thailand Minist Publ Hlth, US Ctr Dis Control & Prevent Collaborat, Mail POB 139, Nonthaburi 11000, Thailand. [Holtz, Timothy H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Pattanasin, S (reprint author), Thailand Minist Publ Hlth, US Ctr Dis Control & Prevent Collaborat, Mail POB 139, Nonthaburi 11000, Thailand.; Pattanasin, S (reprint author), Thailand MOPH, US CDC Collaborat, Mail POB 139, Nonthaburi 11000, Thailand. EM vpv6@cdc.gov FU US Centers for Disease Control and Prevention FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The US Centers for Disease Control and Prevention sponsored this study. NR 22 TC 1 Z9 1 U1 1 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD MAR PY 2016 VL 27 IS 3 BP 196 EP 206 DI 10.1177/0956462415578954 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DD5UJ UT WOS:000369989700005 PM 25792548 ER PT J AU Lucas, IR Kowalski, P Callahan, DB Noonan, GP Moffett, DB Olson, DR Malilay, J AF Lucas, Isabela Ribeiro Kowalski, Peter Callahan, David B. Noonan, Gary P. Moffett, Daphne B. Olson, David R. Malilay, Josephine TI Formaldehyde Levels in Traditional and Portable Classrooms: A Pilot Investigation SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article ID LOS-ANGELES-COUNTY; MOBILE HOMES; PERFORMANCE; EXPOSURE; HEALTH AB The pilot study discussed in this article assessed formaldehyde levels in portable classrooms (PCs) and traditional classrooms (TCs) and explored factors influencing indoor air quality (e.g., carbon dioxide, temperature, and relative humidity). In a cross-sectional design, the authors evaluated formaldehyde levels in day and overnight indoor air samples from nine PCs renovated within three years previously and three TCs in a school district in metropolitan Atlanta, Georgia. Formaldehyde levels ranged from 0.0068 to 0.038 parts per million (ppm). In both types of classroom, overnight formaldehyde median levels (PCs = 0.018 ppm; TCs = 0.019 ppm) were higher than day formaldehyde median levels (PCs = 0.011 ppm; TCs = 0.016 ppm). Carbon dioxide levels measured 470-790 ppm at 7:00 a.m. and 470-1800 ppm at 4:00 p.m. Afternoon medians were higher in TCs (1,400 ppm) than in PCs (780 ppm). Consistent with previous studies, formaldehyde levels were similar among PCs and TCs. Reducing carbon dioxide levels by improving ventilation is recommended for classrooms. C1 [Lucas, Isabela Ribeiro] ICF Int, Publ Hlth & Survey Res Div, 3 Corp Sq NE,Suite 370, Atlanta, GA 30329 USA. [Kowalski, Peter] Agcy Tox Subst & Dis Registry, Div Community Hlth Invest, Atlanta, GA USA. [Callahan, David B.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Noonan, Gary P.; Olson, David R.; Malilay, Josephine] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Moffett, Daphne B.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. RP Lucas, IR (reprint author), ICF Int, 3 Corp Sq NE,Suite 370, Atlanta, GA 30329 USA. EM Isabela.Lucas@icfi.com FU Intramural CDC HHS [CC999999] NR 28 TC 0 Z9 0 U1 5 U2 7 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAR PY 2016 VL 78 IS 7 BP 8 EP 14 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DD7JS UT WOS:000370101100002 PM 27197349 ER PT J AU Burkel, V AF Burkel, Veronica TI Environmental Health Tracking Rides the Open Data Wave SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 [Burkel, Veronica] CDC, Environm Hlth Tracking Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway,NE,MS F-60, Atlanta, GA 30341 USA. RP Burkel, V (reprint author), CDC, Environm Hlth Tracking Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway,NE,MS F-60, Atlanta, GA 30341 USA. EM xee5@cdc.gov NR 6 TC 0 Z9 0 U1 3 U2 5 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAR PY 2016 VL 78 IS 7 BP 36 EP 38 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DD7JS UT WOS:000370101100008 PM 27197355 ER PT J AU Nuss, HJ Hester, LL Perry, MA Stewart-Briley, C Reagon, VM Collins, P AF Nuss, Henry J. Hester, Laura L. Perry, Mark A. Stewart-Briley, Collette Reagon, Valamar M. Collins, Pamela TI Applying the Social Ecological Model to Creating Asthma-Friendly Schools in Louisiana SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE asthma; social ecological model; schools ID HEALTH-PROMOTION; CHILDHOOD ASTHMA; PROGRAMS; CHILDREN AB BACKGROUNDIn 2010, the Louisiana Asthma Management and Prevention Program (LAMP) implemented the Asthma-Friendly Schools Initiative in high-risk Louisiana populations. The social ecological model (SEM) was used as a framework for an asthma program implemented in 70 state K-12 public schools over 2 years. METHODSActivities included a needs assessment, identification of students with asthma, individualized asthma action plans (AAP), staff trainings, environmental quality improvement, and school system policy changes to address the asthma burden. RESULTSThere were 522 new or existing asthma cases recognized. Asthma knowledge/awareness was measurably improved among school personnel. School indoor air quality was improved across all locations. School-level polices were adopted that improved AAP collection, compliance to bus-idling restrictions, and asthma medication self-carry. CONCLUSIONSThe SEM framework can be used for school-based programs to address successfully and improve asthma-related issues from the individual through policy levels. C1 [Nuss, Henry J.] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, 2020 Grader St,Ste 216, New Orleans, LA 70112 USA. [Hester, Laura L.] Ctr Dis Control & Prevent, ORISE CDC Res Program, Ait Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, 4770 Buford Hwy, Atlanta, GA 30341 USA. [Perry, Mark A.] Univ Phoenix, Coll Hlth Sci & Nursing, Baton Rouge, LA USA. [Stewart-Briley, Collette] Off Publ Hlth, Sect Environm Epidemiol & Toxicol, Dept Hlth & Hosp, 628 N,4th St, Baton Rouge, LA 70812 USA. [Reagon, Valamar M.] Georgia So Univ, Jiann Ping Hsu Coll Publ Hlth, 501 Forest Dr, Statesboro, GA 30458 USA. [Collins, Pamela] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Nuss, HJ (reprint author), Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, 2020 Grader St,Ste 216, New Orleans, LA 70112 USA. EM hnussj@lsuhsc.edu; Ilhester@live.unc.edu; mark.perry@la.gov; Collette.Stewart-Briley@LA.GOV; jphcoph@georgiasouthern.edu; ing4@cdc.gov FU Centers for Disease Control and Prevention (CDC) [CDC-RFA-EH09-90105CONT13] FX Funding for the Louisiana Asthma Management and Prevention Program is provided by the Centers for Disease Control and Prevention (CDC) grant # CDC-RFA-EH09-90105CONT13. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the CDC. NR 18 TC 0 Z9 0 U1 9 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD MAR PY 2016 VL 86 IS 3 BP 225 EP 232 DI 10.1111/josh.12369 PG 8 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA DD2IR UT WOS:000369746400009 PM 26830509 ER PT J AU Tian, Y Holzman, C Siega-Riz, AM Williams, MA Dole, N Enquobahrie, DA Ferre, CD AF Tian, Yan Holzman, Claudia Siega-Riz, Anna M. Williams, Michelle A. Dole, Nancy Enquobahrie, Daniel A. Ferre, Cynthia D. TI Maternal Serum 25-Hydroxyvitamin D Concentrations during Pregnancy and Infant Birthweight for Gestational Age: a Three-Cohort Study SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE birthweight for gestational age; race; ethnicity; pregnancy; sex difference; 25-hydroxyvitamin D ID VITAMIN-D STATUS; D SUPPLEMENTATION; PRETERM DELIVERY; FETAL-GROWTH; OUTCOMES; METAANALYSIS; WOMEN; CALCIUM; ASSOCIATION; NEWBORN AB BackgroundIn response to inconsistent findings, we investigated associations between maternal serum 25-hydroxyvitamin D [25(OH)D] concentrations and infant birthweight for gestational age (BW/GA), including potential effect modification by maternal race/ethnicity and infant sex. MethodsData from 2558 pregnant women were combined in a nested case-control study (preterm and term) sampled from three cohorts: the Omega study, the Pregnancy, Infection and Nutrition study, and the Pregnancy Outcomes and Community Health study. Maternal 25(OH)D concentrations were sampled at 4 to 29 weeks gestation (80% 14-26 weeks). BW/GA was modelled as sex and gestational age-specific birthweight z-scores. General linear regression models (adjusting for age, education, parity, pre-pregnancy body mass index, season at blood draw, and smoking) assessed 25(OH)D concentrations in relation to BW/GA. ResultsAmong non-Hispanic Black women, the positive association between 25(OH)D concentrations and BW/GA was of similar magnitude in pregnancies with female or male infants [beta ()=0.015, standard error (SE)=0.007, P=0.025; =0.018, SE=0.006, P=0.003, respectively]. Among non-Hispanic White women, 25(OH)D-BW/GA association was observed only with male infants, and the effect size was lower (=0.008, SE=0.003, P=0.02). ConclusionsMaternal serum concentrations of 25(OH)D in early and mid-pregnancy were positively associated with BW/GA among non-Hispanic Black male and female infants and non-Hispanic White male infants. Effect modification by race/ethnicity may be due, in part, to overall lower concentrations of 25(OH)D in non-Hispanic Blacks. Reasons for effect modification by infant sex remain unclear. C1 [Tian, Yan; Holzman, Claudia] Michigan State Univ, Coll Human Med, Dept Epidemiol & Biostat, E Lansing, MI 48823 USA. [Siega-Riz, Anna M.; Dole, Nancy] Univ N Carolina, Carolina Populat Ctr, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. [Williams, Michelle A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Enquobahrie, Daniel A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Ferre, Cynthia D.] Ctr Dis Control & Prevent, Maternal & Infant Hlth Branch, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Holzman, C (reprint author), Michigan State Univ, 909 Fee Rd,West Fee Hall,Room B601, E Lansing, MI 48823 USA. EM holzman@msu.edu FU CDC [200-2008-27956-12, U01 DP000143-01]; Omega: NICHD [R01 HD32562]; PIN: NICHD [RO1 HD28684, HD28684A, HD37584, HD39373, NIH RR0046, R24 HD050924]; POUCH: NIH [R01 HD034543, R01 HD34543]; March of Dimes Foundation [20-FY98-0697, 20-FY04-37]; Thrasher Research Foundation [02816-7] FX CDC 200-2008-27956-12; Omega: NICHD R01 HD32562; PIN: NICHD RO1 HD28684, HD28684A, HD37584, HD39373, NIH RR0046, R24 HD050924; POUCH: NIH R01 HD034543, R01 HD34543, March of Dimes Foundation 20-FY98-0697 through 20-FY04-37, Thrasher Research Foundation grant 02816-7, CDC U01 DP000143-01. NR 37 TC 0 Z9 0 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 EI 1365-3016 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD MAR PY 2016 VL 30 IS 2 BP 124 EP 133 DI 10.1111/ppe.12262 PG 10 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA DD9ME UT WOS:000370249000004 PM 26575943 ER PT J AU Kit, BK Simon, AE Tilert, T Okelo, S Akinbami, LJ AF Kit, Brian K. Simon, Alan E. Tilert, Timothy Okelo, Sande Akinbami, Lara J. TI Differences in spirometry values between US children 6-11 years and adolescents 12-19 years with current asthma, 2007-2010 SO PEDIATRIC PULMONOLOGY LA English DT Article DE asthma; spirometry; child; adolescent; NHANES ID FORCED EXPIRATORY VOLUME; PRIMARY-CARE PHYSICIANS; EXHALED NITRIC-OXIDE; PULMONARY-FUNCTION; LUNG-FUNCTION; MEDICATION USE; SEVERITY; CLASSIFICATION; STANDARDIZATION; MANAGEMENT AB BackgroundNational Asthma Education and Prevention Program (NAEPP) guidelines recommend that periodic spirometry be performed in youth with asthma. NAEPP uses different spirometry criteria to define uncontrolled asthma for children (6-11 years) and adolescents (12+ years). ObjectiveTo describe differences in spirometry between US children and adolescents with current asthma. MethodsWe examined cross-sectional spirometry data from 453 US youth with current asthma age 6-19 years from the 2007-2010 National Health and Nutrition Examination Surveys. The main outcomes were percentage predicted forced expiratory volume at 1sec (FEV1%) 80 and the ratio of FEV1 to forced vital capacity (FEV1/FVC) 0.80. We also examined the prevalence of youth with spirometry values consistent with uncontrolled asthma, using NAEPP age-specific criteria, defined for children aged 6-11 years as FEV1% 80 or FEV1/FVC 0.80, and for adolescents aged 12-19 years as FEV1% 80. ResultsChildren 6-11 years and adolescents 12-19 years did not differ in prevalence of FEV1% 80 (10.1% vs. 9.0%) or FEV1/FVC 0.80 (30.6% vs. 29.8%). However, based on the NAEPP age-specific criteria, 33.0% of children 6-11 years and 9.0% of adolescents 12-19 years had spirometry values consistent with uncontrolled asthma (P<0.001). ConclusionChildren 6-11 years and adolescents 12-19 years with current asthma did not differ in the percentage with FEV1% 80 or FEV1/FVC 0.80. However, the percent of children and adolescents with spirometry values consistent with uncontrolled asthma did differ. The difference appears to stem mainly from the different spirometry criteria for the two age groups. Pediatr Pulmonol. 2016;51:272-279. (c) 2015 Wiley Periodicals, Inc. C1 [Kit, Brian K.; Tilert, Timothy] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4419, Hyattsville, MD 20782 USA. [Kit, Brian K.; Akinbami, Lara J.] US PHS, Rockville, MD USA. [Simon, Alan E.; Akinbami, Lara J.] Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Okelo, Sande] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Pediat Pulmonol,Mattel Childrens Hosp UCLA, Los Angeles, CA 90095 USA. RP Kit, BK (reprint author), Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4419, Hyattsville, MD 20782 USA. EM bkit@cdc.gov NR 31 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD MAR PY 2016 VL 51 IS 3 BP 272 EP 279 DI 10.1002/ppul.23238 PG 8 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA DD8EP UT WOS:000370158400007 PM 26152859 ER PT J AU Obon-Santacana, M Freisling, H Peeters, PH Lujan-Barroso, L Ferrari, P Boutron-Ruault, MC Mesrine, S Baglietto, L Turzanski-Fortner, R Katzke, VA Boeing, H Quiros, JR Molina-Portillo, E Larranaga, N Chirlaque, MD Barricarte, A Khaw, KT Wareham, N Travis, RC Merritt, MA Gunter, MJ Trichopoulou, A Lagiou, P Naska, A Palli, D Sieri, S Tumino, R Fiano, V Galassom, R Bueno-de-Mesquita, HB Onland-Moret, NC Idahl, A Lundin, E Weiderpass, E Vesper, H Riboli, E Duell, EJ AF Obon-Santacana, Mireia Freisling, Heinz Peeters, Petra H. Lujan-Barroso, Leila Ferrari, Pietro Boutron-Ruault, Marie-Christine Mesrine, Sylvie Baglietto, Laura Turzanski-Fortner, Renee Katzke, Verena A. Boeing, Heiner Quiros, J. Ramon Molina-Portillo, Elena Larranaga, Nerea Chirlaque, Maria-Dolores Barricarte, Aurelio Khaw, Kay-Tee Wareham, Nick Travis, Ruth C. Merritt, Melissa A. Gunter, Marc J. Trichopoulou, Antonia Lagiou, Pagona Naska, Androniki Palli, Domenico Sieri, Sabina Tumino, Rosario Fiano, Valentina Galassom, Rocco Bueno-de-Mesquita, H. B(as) Onland-Moret, N. Charlotte Idahl, Annika Lundin, Eva Weiderpass, Elisabete Vesper, Hubert Riboli, Elio Duell, Eric J. TI Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: A nested case-control study in nonsmoking postmenopausal women from the EPIC cohort SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE hemoglobin adduct; acrylamide; glycidamide; endometrial cancer; EPIC ID DIETARY ACRYLAMIDE; EXPOSURE; ASSOCIATIONS; BIOMARKERS; OVARIAN; BREAST; MODEL; FOOD AB Acrylamide, classified in 1994 by IARC as "probably carcinogenic to humans," was discovered in 2002 in some heat-treated, carbohydrate-rich foods. Four prospective studies have evaluated the association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent results. The purpose of this nested case-control study, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, was to evaluate, for the first time, the association between hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA) and the risk of developing EC in non-smoking postmenopausal women. Hemoglobin adducts were measured in red blood cells by HPLC/MS/MS. Four exposure variables were evaluated: HbAA, HbGA, their sum (HbAA1HbGA), and their ratio (HbGA/HbAA). The association between hemoglobin adducts and EC was evaluated using unconditional multivariable logistic regression models, and included 383 EC cases (171 were type-I EC), and 385 controls. Exposure variables were analyzed in quintiles based on control distributions. None of the biomarker variables had an effect on overall EC (HRHbAA;Q5vsQ1: 0.84, 95% CI: 0.49-1.48; HRHbGA;Q5vsQ1: 0.94, 95% CI: 0.54-1.63) or type-I EC risk. Additionally, none of the subgroups investigated (BMI < 25 vs. >= 25 kg m 22, alcohol drinkers vs. never drinkers, oral contraceptive users vs. non-users) demonstrated effect measure modification. Hemoglobin adducts of acrylamide or glycidamide were not associated with EC or type-I EC risk in 768 nonsmoking postmenopausal women from the EPIC cohort. C1 [Obon-Santacana, Mireia; Lujan-Barroso, Leila; Duell, Eric J.] Catalan Inst Oncol, IDIBELL, Unit Nutr & Canc, Canc Epidemiol Res Program, Avda Gran Via 199-203, Barcelona 08907, Spain. [Freisling, Heinz; Ferrari, Pietro] Int Agcy Res Canc, Dietary Exposure Assessment Grp, 150 Cours Albert Thomas, F-69372 Lyon, France. [Peeters, Petra H.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Dept Epidemiol, Utrecht, Netherlands. [Peeters, Petra H.; Merritt, Melissa A.; Gunter, Marc J.; Bueno-de-Mesquita, H. B(as); Riboli, Elio] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England. [Boutron-Ruault, Marie-Christine; Mesrine, Sylvie] INSERM, CESP Ctr Res Epidemiol & Populat Hlth Lifestyle G, Villejuif, France. [Boutron-Ruault, Marie-Christine; Mesrine, Sylvie] Univ Paris 11, Villejuif, France. [Boutron-Ruault, Marie-Christine; Mesrine, Sylvie] Inst Gustave Roussy, Villejuif, France. [Baglietto, Laura] Canc Epidemiol Ctr, Canc Council Victoria, Melbourne, Vic, Australia. [Baglietto, Laura] Univ Melbourne, Ctr Biostat & Epidemiol, Sch Populat & Global Hlth, Melbourne, Vic, Australia. [Turzanski-Fortner, Renee; Katzke, Verena A.] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany. [Boeing, Heiner] German Inst Human Nutr, Dept Epidemiol, Potsdam Rehbruecke, Nuthetal, Germany. [Quiros, J. Ramon] Publ Hlth Directorate, Asturias, Spain. [Molina-Portillo, Elena] Univ Granada, Hosp Univ Granada, GRANADA, Escuela Andaluza Salud Publ,Inst Invest Biosanita, Granada, Spain. [Molina-Portillo, Elena; Larranaga, Nerea; Chirlaque, Maria-Dolores; Barricarte, Aurelio] CIBER, Epidemiol & Publ Hlth CIBERESP, Madrid, Spain. [Larranaga, Nerea] Reg Govt Basque Country, Publ Hlth Div Gipuzkoa, Gipuzkoa, Spain. [Chirlaque, Maria-Dolores] Reg Hlth Council, Dept Epidemiol, Murcia, Spain. [Chirlaque, Maria-Dolores] Univ Murcia, Dept Hlth & Social Sci, Murcia, Spain. [Barricarte, Aurelio] Navarra Publ Hlth Inst, Pamplona, Spain. [Barricarte, Aurelio] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain. [Khaw, Kay-Tee] Univ Cambridge, Sch Clin Med, Cambridge, England. [Wareham, Nick; Travis, Ruth C.] Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Oxford, England. [Trichopoulou, Antonia; Lagiou, Pagona; Naska, Androniki] Hellen Hlth Fdn, Athens, Greece. [Lagiou, Pagona; Naska, Androniki] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, GR-11527 Athens, Greece. [Palli, Domenico] Canc Res & Prevent Inst ISPO, Mol & Nutr Epidemiol Unit, Florence, Italy. [Sieri, Sabina] Fdn IRCCS Ist Nazl Tumori, Dept Prevent & Predict Med, Epidemiol & Prevent Unit, Milan, Italy. [Tumino, Rosario] Civ MP Arezzo Hosp, ASP Ragusa, Canc Registry & Histopathol Unit, Ragusa, Italy. [Fiano, Valentina] Univ Turin, CERMS, Dept Med Sci, Canc Epidemiol Unit, Turin, Italy. [Galassom, Rocco] IRCCS Ctr Riferimento Oncol Basilicata, Clin Epidemiol Unit, Biostat & Canc Registry, Potenza, Italy. [Bueno-de-Mesquita, H. B(as)] Natl Inst Publ Hlth & Environm RIVM, Dept Determinants Chron Dis DCD, Bilthoven, Netherlands. [Bueno-de-Mesquita, H. B(as)] Univ Med Ctr, Dept Gastroenterol & Hepatol, Utrecht, Netherlands. [Bueno-de-Mesquita, H. B(as)] Univ Malaya, Fac Med, Dept Social & Prevent Med, Kuala Lumpur, Malaysia. [Onland-Moret, N. Charlotte] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands. [Idahl, Annika] Umea Univ, Dept Clin Sci Obstet & Gynecol, Nutr Res, Umea, Sweden. [Idahl, Annika] Umea Univ, Dept Publ Hlth & Clin Med, Nutr Res, Umea, Sweden. [Lundin, Eva] Umea Univ, Dept Med Biosci, Pathol, Umea, Sweden. [Weiderpass, Elisabete] Univ Tromso, Arctic Univ Norway, Fac Hlth Sci, Dept Community Med, Tromso, Norway. [Weiderpass, Elisabete] Canc Registry Norway, Dept Res, Oslo, Norway. [Weiderpass, Elisabete] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Weiderpass, Elisabete] Folkhalsan Res Ctr, Genet Epidemiol Grp, Helsinki, Finland. [Vesper, Hubert] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Duell, EJ (reprint author), Catalan Inst Oncol, IDIBELL, Unit Nutr & Canc, Canc Epidemiol Res Program, Avda Gran Via 199-203, Barcelona 08907, Spain. EM eduell@iconcologia.net RI Sieri, Sabina/K-4667-2016; Onland-Moret, N. Charlotte/G-9185-2011; Weiderpass, Elisabete/M-4029-2016; Molina, Pedro/B-7739-2017; Tagliabue, Giovanna /D-4194-2017; OI Fortner, Renee/0000-0002-1426-8505; Sieri, Sabina/0000-0001-5201-172X; Weiderpass, Elisabete/0000-0003-2237-0128; Molina, Pedro/0000-0001-8568-9449; Tagliabue, Giovanna /0000-0001-8165-5524; Lujan-Barroso, Leila/0000-0001-6224-1764; PALLI, Domenico/0000-0002-5558-2437; FIANO, VALENTINA/0000-0001-7978-372X; Sacerdote, Carlotta/0000-0002-8008-5096 FU Wereld Kanker Onderzoek Fonds (WCRF NL) [WCRF 2011/442]; Health Research Fund (FIS) of the Spanish Ministry of Health [PI11/01473]; Navarra and the Catalan Institute of Oncology, La Caixa [BM 06-130]; Red Tematica de Investigacion Cooperativa en Cancer (Spain) [RD12/0036/0018, RD06/0020/0091]; European Commission (DG-SANCO); International Agency for Research on Cancer; Danish Cancer Society (Denmark); Ligue contre le Cancer; Institut Gustave Roussy; Mutuelle Generale de l'Education Nationale; Institut National de la Sante et de la Recherche Medicale (INSERM) (France); Deutsche Krebshilfe; Deutsches Krebsforschungszentrum (DKFZ); Federal Ministry of Education and Research (Germany); Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro (AIRC); National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS); Netherlands Cancer Registry (NKR); LK Research Funds; Dutch Prevention Funds; Dutch ZON (Zorg Onderzoek Nederland); World Cancer Research Fund (WCRF); Statistics Netherlands (The Netherlands); Nordic Center of Excellence in Food, Nutrition and Health Helga (Norway); Swedish Cancer Society; Swedish Scientific Council and Regional Government of Skane and Vasterbotten (Sweden); Cancer Research UK; Medical Research Council (United Kingdom); Health Research Fund (FIS) of the Spanish Ministry of Health, Regional Government of Andalucia [6236]; Health Research Fund (FIS) of the Spanish Ministry of Health, Regional Government of Asturias [6236]; Health Research Fund (FIS) of the Spanish Ministry of Health, Regional Government of Basque Country [6236]; Health Research Fund (FIS) of the Spanish Ministry of Health, Regional Government of Murcia [6236] FX Grant sponsor: Wereld Kanker Onderzoek Fonds (WCRF NL); Grant number: WCRF 2011/442; Grant sponsor: Health Research Fund (FIS) of the Spanish Ministry of Health; Grant number: Exp PI11/01473; Grant sponsor: Health Research Fund (FIS) of the Spanish Ministry of Health, Regional Governments of Andalucia, Asturias, Basque Country, Murcia; Grant number: 6236; Grant sponsor: Navarra and the Catalan Institute of Oncology, La Caixa; Grant number: BM 06-130; Grant sponsor: Red Tematica de Investigacion Cooperativa en Cancer (Spain); Grant numbers: RD12/0036/0018; RD06/0020/0091; Grant sponsors: European Commission (DG-SANCO); International Agency for Research on Cancer; Danish Cancer Society (Denmark); Ligue contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum (DKFZ); Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro (AIRC); National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF); Statistics Netherlands (The Netherlands); Nordic Center of Excellence in Food, Nutrition and Health Helga (Norway); Swedish Cancer Society, Swedish Scientific Council and Regional Government of Skane and Vasterbotten (Sweden); Cancer Research UK, Medical Research Council (United Kingdom) NR 28 TC 0 Z9 0 U1 7 U2 27 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 EI 1097-0215 J9 INT J CANCER JI Int. J. Cancer PD MAR 1 PY 2016 VL 138 IS 5 BP 1129 EP 1138 DI 10.1002/ijc.29853 PG 10 WC Oncology SC Oncology GA DC4BL UT WOS:000369164700010 PM 26376083 ER PT J AU Schmidt, MR Lisco, CG Parrott, DJ Tharp, AT AF Schmidt, Megan R. Lisco, Claire G. Parrott, Dominic J. Tharp, Andra T. TI Moderating Effect of Negative Peer Group Climate on the Relation Between Men's Locus of Control and Aggression Toward Intimate Partners SO JOURNAL OF INTERPERSONAL VIOLENCE LA English DT Article DE intimate partner aggression; external locus of control; negative peer group climate ID GENDER-DIFFERENCES; SOCIAL NETWORKS; SELF-CONTROL; VIOLENCE; PERCEPTION; PREVENTION; BEHAVIOR; SUPPORT AB The present study sought to examine the interactive effects of an external locus of control and interaction in a negative peer group climate on men's perpetration of physical aggression and infliction of injury toward their female intimate partners. Participants were 206 heterosexual males recruited from the metro-Atlanta community who completed self-report measures of external locus of control, involvement in a negative peer group climate, and physical aggression and infliction of injury against intimate partners during the past 12 months. Negative peer group climate was conceptualized as a peer group that displays behavior which may instigate aggressive norms, attitudes, and behaviors. Results indicated that men with an external locus of control were more likely to perpetrate physical aggression toward and inflict injury on their intimate partners if they reported high, but not low, involvement in a negative peer group climate. These results extend current research suggesting external locus of control as a risk factor for intimate partner aggression by highlighting the impact of negative peer groups. Implications and future intervention research are discussed. C1 [Schmidt, Megan R.; Parrott, Dominic J.] Georgia State Univ, Dept Psychol, POB 5010, Atlanta, GA 30302 USA. [Lisco, Claire G.; Parrott, Dominic J.] Georgia State Univ, Clin Psychol, Atlanta, GA 30303 USA. [Tharp, Andra T.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Parrott, DJ (reprint author), Georgia State Univ, Dept Psychol, POB 5010, Atlanta, GA 30302 USA. EM parrott@gsu.edu FU Centers for Disease Control; Georgia State University FX The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This research was supported by a joint grant by the Centers for Disease Control and Georgia State University to Dominic J. Parrott and Andra T. Tharp. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 39 TC 2 Z9 2 U1 1 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0886-2605 EI 1552-6518 J9 J INTERPERS VIOLENCE JI J. Interpers. Violence PD MAR PY 2016 VL 31 IS 5 BP 755 EP 773 DI 10.1177/0886260514556761 PG 19 WC Criminology & Penology; Family Studies; Psychology, Applied SC Criminology & Penology; Family Studies; Psychology GA DB9HO UT WOS:000368827200001 PM 25389191 ER PT J AU Sneed, CD Willis, LA AF Sneed, Carl D. Willis, Leigh A. TI Differences between residential and non-residential fathers on sexual socialisation of African American youth SO SEX EDUCATION-SEXUALITY SOCIETY AND LEARNING LA English DT Article DE Sexual socialisation; parent-child communication; fathers; African American; youth ID RISK BEHAVIORS; PARENTAL COMMUNICATION; ADOLESCENTS; PREVENTION; INTERVENTION; CHILDREN; ALCOHOL; BIRDS; MODEL; BEES AB This study investigated differences between residential and non-residential fathers on topics discussed during father-child sex communication and factors associated with child sexual socialisation. Young people (N=159, 53% female) provided self-reports using computer surveys on the role of their fathers on father-child sex communication, general communication, parental monitoring, father social support and topics discussed during father-child sex communication. The analysis revealed differences in topics discussed between young people with residential vs. non-residential fathers. Independent group t-tests revealed significant differences between young people with residential vs. non-residential fathers on social support and parental monitoring for sons and parental monitoring for daughters. Sons and daughters with residential fathers had higher scores on these variables. Discriminant function analyses, chi-square tests and hierarchical linear regression analyses were carried out to determine whether there were meaningful distinctions between young people with residential vs. non-residential fathers. The analysis revealed social support and parental monitoring provided the most meaningful distinction between young people with residential vs. non-residential fathers. These results highlight the importance of non-residential fathers in the sexual socialisation of their young people through parent-child sex communication. Discussion focuses on the need for development of interventions to promote the inclusion of non-residential fathers in the sexual socialisation of African American youth. C1 [Sneed, Carl D.] Calif State Univ, Dept Psychol, Carson, CA 90747 USA. [Willis, Leigh A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Sneed, CD (reprint author), Calif State Univ, Dept Psychol, Carson, CA 90747 USA. EM csneed@csudh.edu FU Centers for Disease Control and Prevention, Minority HIV/AIDS Research Initiative [PS07-003] FX This work was supported by the Centers for Disease Control and Prevention, Minority HIV/AIDS Research Initiative [grant number #PS07-003]. NR 40 TC 0 Z9 0 U1 1 U2 10 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1468-1811 EI 1472-0825 J9 SEX EDUC-SEX SOC LEA JI Sex Educ.-Sex. Soc. Learn. PD MAR PY 2016 VL 16 IS 2 BP 199 EP 212 DI 10.1080/14681811.2015.1089226 PG 14 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA DA5MR UT WOS:000367847700007 ER PT J AU Feng, ZL Han, Q Qiu, ZP Hill, AN Glasser, JW AF Feng, Zhilan Han, Qing Qiu, Zhipeng Hill, Andrew N. Glasser, John W. TI COMPUTATION OF R IN AGE-STRUCTURED EPIDEMIOLOGICAL MODELS WITH MATERNAL AND TEMPORARY IMMUNITY SO DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS-SERIES B LA English DT Article DE Age-structured epidemiological model; reproduction numbers; partial immunity; multiple infections ID INFECTIOUS-DISEASES; TRANSMISSION; PERTUSSIS; PATTERNS AB For infectious diseases such as pertussis, susceptibility is determined by immunity, which is chronological age-dependent. We consider an age-structured epidemiological model that accounts for both passively acquired maternal antibodies that decay and active immunity that wanes, permitting reinfection. The model is a 6-dimensional system of partial differential equations (PDE). By assuming constant rates within each age-group, the PDE system can be reduced to an ordinary differential equation (ODE) system with aging from one age-group to the next. We derive formulae for the effective reproduction number R and provide their biological interpretation in some special cases. We show that the disease-free equilibrium is stable when R < 1 and unstable if R > 1. C1 [Feng, Zhilan; Han, Qing] Purdue Univ, Dept Math, W Lafayette, IN 47907 USA. [Qiu, Zhipeng] Nanjing Univ Sci & Technol, Dept Appl Math, Nanjing 210094, Jiangsu, Peoples R China. [Hill, Andrew N.] Natl Ctr HIV AIDS Viral Hepatits STD & TB Prevent, Atlanta, GA 30333 USA. [Glasser, John W.] Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Feng, ZL (reprint author), Purdue Univ, Dept Math, 150 N Univ St, W Lafayette, IN 47907 USA. EM fengz@purdue.edu; han85@purdue.edu; nustqzp@njust.edu.cn; ahill2@cdc.gov; jglasser@cdc.gov FU NSF [DMS-1022758]; NSFC [11271190] FX The research is supported in part by the NSF Grant DMS-1022758, and Zhipeng Qiu is supported by the NSFC Grant 11271190. We thank the Reviewers for helpful comments which improved the presentation. NR 13 TC 0 Z9 0 U1 2 U2 13 PU AMER INST MATHEMATICAL SCIENCES PI SPRINGFIELD PA PO BOX 2604, SPRINGFIELD, MO 65801-2604 USA SN 1531-3492 EI 1553-524X J9 DISCRETE CONT DYN-B JI Discrete Contin. Dyn. Syst.-Ser. B PD MAR PY 2016 VL 21 IS 2 SI SI BP 399 EP 415 DI 10.3934/dcdsb.2016.21.399 PG 17 WC Mathematics, Applied SC Mathematics GA CX3RS UT WOS:000365617500004 ER PT J AU Gonese, E Mushavi, A Mungati, M Mhangara, M Dzangare, J Mugurungi, O Dee, J Kilmarx, PH Shambira, G Tshimanga, MT Hargrove, J AF Gonese, E. Mushavi, A. Mungati, M. Mhangara, M. Dzangare, J. Mugurungi, O. Dee, J. Kilmarx, P. H. Shambira, G. Tshimanga, M. T. Hargrove, J. TI Is Zimbabwe ready to transition from anonymous unlinked sero-surveillance to using prevention of mother to child transmission of HIV (PMTCT) program data for HIV surveillance?: results of PMTCT utility study, 2012 SO BMC INFECTIOUS DISEASES LA English DT Article AB Background: Prevention of mother-to-child transmission of HIV (PMTCT) programs collect socio-demographic and HIV testing information similar to that collected by unlinked anonymous testing sero-surveillance (UAT) in antenatal settings. Zimbabwe evaluated the utility of PMTCT data in replacing UAT. Methods: A UAT dataset was created by capturing socio-demographic, testing practices from the woman's booking-card and testing remnant blood at a laboratory from 1 June to 30 September 2012. PMTCT data were collected retrospectively from ANC registers. UAT and PMTCT data were linked by bar-code labels that were temporarily affixed to the ANC register. A questionnaire was used to obtain facility-level data at 53 sites. Results: Pooled HIV prevalence was 15.8 % (95 % CI 15.3-16.4) among 17,349 women sampled by UAT, and 16.3 % (95 % CI 15.8 %-16.9 %) among 17,150 women in PMTCT datasets for 53 sites. Pooled national percent-positive agreement (PPA) was 91.2 %, and percent-negative agreement (PNA) was 98.7 % for 16,782 women with matched UAT and PMTCT data. Based on UAT methods, overall median prevalence was 12.9 % (Range 4.0 %-19.4 %) among acceptors and refusers of HIV test in PMTCT compared to 12.5 % ((Range 3.4 %-19.5 %) among acceptors in ANC registers. There were variations in prevalence by site. Conclusion: Although, there is no statistical difference between pooled HIV prevalence in UAT compared to PMTCT program, the overall PPA of 91.2 % and PNA of 98.7 % fall below World Health Organisation (WHO) benchmarks of 97.6 % and 99.6 % respectively. Zimbabwe will need to strengthen quality assurance (QA) of rapid HIV testing and data collection practices. Sites with good performance should be prioritised for transitioning. C1 [Gonese, E.] Ctr Dis Control & Prevent, 38 Nelson Mandela Rd,Box 3088, Harare, Zimbabwe. [Mushavi, A.; Mungati, M.; Mhangara, M.; Dzangare, J.; Mugurungi, O.] Ministry Hlth & Child Care Zimbabwe, Mukwati Bldg,Corner Livingstone Fifth St, Harare, Zimbabwe. [Dee, J.] Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30329 USA. [Kilmarx, P. H.] NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Shambira, G.; Tshimanga, M. T.] Univ Zimbabwe, Parirenyatwa Hosp, Dept Community Med, Mazoe St, Harare, Zimbabwe. [Hargrove, J.] Univ Stellenbosch, South Africa Ctr Epidemiol Modelling & Anal, 19 Jonkershoek Rd, ZA-7602 Stellenbosch, South Africa. RP Gonese, E (reprint author), Ctr Dis Control & Prevent, 38 Nelson Mandela Rd,Box 3088, Harare, Zimbabwe. EM egonese@cdc.gov FU Ministry of Health Child Care; AIDS & TB Unit, Zimbabwe; U.S. Centers for Disease Control and Prevention (CDC) [1U2GGH000315-01]; Department of Community Medicine [1U2GGH000315-01] FX We would like to thank the Ministry of Health & Child Care and the AIDS & TB Unit, Zimbabwe for their support and granting us permission to conduct the study. The survey was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through a cooperative agreement between the U.S. Centers for Disease Control and Prevention (CDC) and the Department of Community Medicine (#1U2GGH000315-01). We acknowledge technical support in data collection and analysis from CDC Zimbabwe and CDC Atlanta. NR 19 TC 1 Z9 1 U1 2 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD FEB 29 PY 2016 VL 16 AR 97 DI 10.1186/s12879-016-1425-2 PG 13 WC Infectious Diseases SC Infectious Diseases GA DF5GS UT WOS:000371380400001 PM 26923185 ER PT J AU Wang, LL Mei, ZG Li, HT Zhang, YL Liu, JM Serdula, MK AF Wang, Linlin Mei, Zuguo Li, Hongtian Zhang, Yali Liu, Jianmeng Serdula, Mary K. TI Modifying effects of maternal Hb concentration on infant birth weight in women receiving prenatal iron-containing supplements: a randomised controlled trial SO BRITISH JOURNAL OF NUTRITION LA English DT Article DE Iron-containing supplements; Birth weight; High maternal Hb ID PREGNANT-WOMEN; HEMOGLOBIN CONCENTRATION; PROPHYLACTIC IRON; PRETERM BIRTH; RISK; OUTCOMES; ANEMIA; CHINA AB Concerns have been raised about the benefits of Fe-containing supplements on infant birth weight among women with normal/high Hb levels at baseline. Thus far, no clinical trials have examined whether the effects of prenatal Fe-containing supplements on birth weight vary by maternal Hb levels. We compared the effects of Fe-folic acid (IFA) or multiple micronutrients (MMN) with folic acid (FA) supplements on birth weight among pregnant women with mild/no anaemia or high Hb levels. A double-blind randomised controlled trial was conducted in 2006-2009. In total, 18 775 pregnant women with mild/no anaemia (<100 g/l) were enrolled from five counties in north China. During the period from before 20 weeks of gestation to delivery, the women randomly received a daily supplement containing the following: (1) FA (400 g); (2) IFA (FA, 400 g; Fe, 30 mg); or (3) MMN (FA, Fe and thirteen additional vitamins and minerals). Birth weight was measured within the 1st hour of birth. Maternal Hb concentration was determined at enrolment. Among women with normal (132 g/l) or high (133-145 g/l) baseline Hb levels, IFA or MMN supplementation had no effect on birth weight. Among women with very high (>145 g/l) baseline Hb levels, IFA and MMN supplements increased birth weight by 9144 (95 % CI 337, 17951) g and 10763 (95 % CI 2198, 19328) g (P<005), respectively, compared with the FA group. No differences were found between the IFA and the MMN group, regardless of maternal Hb concentration. In conclusion, the effects of Fe-containing supplements on birth weight depended on baseline Hb concentrations. The Fe-containing supplements improved birth weight in women with very high Hb levels before 20 weeks of gestation. C1 [Wang, Linlin; Li, Hongtian; Zhang, Yali; Liu, Jianmeng] Peking Univ, Inst Reprod & Child Hlth, Key Lab Reprod Hlth, Minist Hlth,Hlth Sci Ctr, Beijing 100191, Peoples R China. [Mei, Zuguo; Serdula, Mary K.] Ctr Dis Control & Prevent CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30329 USA. RP Liu, JM (reprint author), Peking Univ, Inst Reprod & Child Hlth, Key Lab Reprod Hlth, Minist Hlth,Hlth Sci Ctr, Beijing 100191, Peoples R China. EM liujm@pku.edu.cn FU Peking University Health Science Center; Centers for Disease Control and Prevention FX This study was supported by a cooperative agreement between Peking University Health Science Center and the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The sponsor had a role in the study design, data collection, data analysis and interpretation and writing of the report. NR 28 TC 0 Z9 0 U1 5 U2 7 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0007-1145 EI 1475-2662 J9 BRIT J NUTR JI Br. J. Nutr. PD FEB 28 PY 2016 VL 115 IS 4 BP 644 EP 649 DI 10.1017/S0007114515004870 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DE5GT UT WOS:000370660100009 PM 26824731 ER PT J AU Park, S Xu, F Town, M Blanck, HM AF Park, Sohyun Xu, Fang Town, Machell Blanck, Heidi M. TI Prevalence of Sugar-Sweetened Beverage Intake Among Adults-23 States and the District of Columbia, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID US ADULTS; CONSUMPTION C1 [Park, Sohyun; Blanck, Heidi M.] CDC, Div Nutr Phys Act & Obes, NCCDPHP, Atlanta, GA 30333 USA. [Xu, Fang; Town, Machell] CDC, Div Populat Hlth, NCCDPHP, Atlanta, GA 30333 USA. RP Park, S (reprint author), CDC, Div Nutr Phys Act & Obes, NCCDPHP, Atlanta, GA 30333 USA. EM spark3@cdc.gov NR 9 TC 5 Z9 5 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 26 PY 2016 VL 65 IS 7 BP 169 EP 174 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4UB UT WOS:000371345300001 PM 26914018 ER PT J AU Burke, P Needham, M Jackson, BR Bokanyi, R St Germain, E Englender, SJ AF Burke, Patrick Needham, Michael Jackson, Brendan R. Bokanyi, Rick St Germain, Eric Englender, Steven J. TI Outbreak of Foodborne Botulism Associated with Improperly Jarred Pesto - Ohio and California, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Burke, Patrick; Englender, Steven J.] Cincinnati Hlth Dept, Cincinnati, OH USA. [Needham, Michael] Food & Drug Branch, Calif Dept Publ Hlth, San Diego, CA USA. [Jackson, Brendan R.] CDC, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Bokanyi, Rick; St Germain, Eric] Ohio Dept Hlth Laboratory, Columbus, OH USA. RP Burke, P (reprint author), Cincinnati Hlth Dept, Cincinnati, OH USA. EM Burke@cincinnati-oh.gov NR 6 TC 1 Z9 1 U1 2 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 26 PY 2016 VL 65 IS 7 BP 175 EP 177 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4UB UT WOS:000371345300002 PM 26914208 ER PT J AU Lucas, KD Eckert, V Behrends, CN Wheeler, C MacGowan, RJ Mohle-Boetani, JC AF Lucas, Kimberley D. Eckert, Valorie Behrends, Czarina N. Wheeler, Charlotte MacGowan, Robin J. Mohle-Boetani, Janet C. TI Evaluation of Routine HIV Opt-Out Screening and Continuum of Care Services Following Entry into Eight Prison Reception Centers - California, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID INTAKE MEDICAL EVALUATION; ANTIRETROVIRAL THERAPY; RHODE-ISLAND; JAIL; INFECTION; RELEASE C1 [Lucas, Kimberley D.; Wheeler, Charlotte; Mohle-Boetani, Janet C.] Calif Correct Hlth Care Serv, Publ Hlth Branch, Sacramento, CA 95814 USA. [Eckert, Valorie; Behrends, Czarina N.] Calif Dept Publ Hlth, Ctr Infect Dis, Off AIDS, Sacramento, CA USA. [MacGowan, Robin J.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV, Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Lucas, KD (reprint author), Calif Correct Hlth Care Serv, Publ Hlth Branch, Sacramento, CA 95814 USA. EM Kimberley.Lucas@cdcr.ca.gov NR 10 TC 0 Z9 0 U1 3 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 26 PY 2016 VL 65 IS 7 BP 178 EP 181 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4UB UT WOS:000371345300003 PM 26914322 ER PT J AU Fleming-Dutra, KE Nelson, JM Fischer, M Staples, JE Karwowski, MP Mead, P Villanueva, J Renquist, CM Minta, AA Jamieson, DJ Honein, MA Moore, CA Rasmussen, SA AF Fleming-Dutra, Katherine E. Nelson, Jennifer M. Fischer, Marc Staples, J. Erin Karwowski, Mateusz P. Mead, Paul Villanueva, Julie Renquist, Christina M. Minta, Anna A. Jamieson, Denise J. Honein, Margaret A. Moore, Cynthia A. Rasmussen, Sonja A. TI Update: Interim Guidelines for Health Care Providers Caring for Infants and Children with Possible Zika Virus Infection - United States, February 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID TRANSMISSION; INDONESIA; OUTCOMES; DENGUE; FEVER C1 [Fleming-Dutra, Katherine E.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Nelson, Jennifer M.; Karwowski, Mateusz P.; Minta, Anna A.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Nelson, Jennifer M.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis & Hlth Promot, Atlanta, GA 30333 USA. [Fischer, Marc; Staples, J. Erin; Mead, Paul] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Karwowski, Mateusz P.] CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Villanueva, Julie] CDC, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Renquist, Christina M.; Honein, Margaret A.; Moore, Cynthia A.] CDC, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Minta, Anna A.] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Jamieson, Denise J.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Rasmussen, Sonja A.] CDC, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Fleming-Dutra, KE (reprint author), CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM eocbirthdef@cdc.gov NR 29 TC 20 Z9 21 U1 3 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 26 PY 2016 VL 65 IS 7 BP 182 EP 187 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4UB UT WOS:000371345300004 PM 26914500 ER PT J AU Ratto, J Ivy, W Purfield, A Bangura, J Omoko, A Boateng, I Duffy, N Sims, G Beamer, B Pi-Sunyer, T Kamara, S Conteh, S Redd, J AF Ratto, Jeffrey Ivy, Wade Purfield, Anne Bangura, James Omoko, Anthony Boateng, Isaac Duffy, Nadia Sims, George Beamer, Bryan Pi-Sunyer, Teresa Kamara, Sarian Conteh, Sulaiman Redd, John TI Ebola Virus Disease Response Activities During a Mass Displacement Event After Flooding - Freetown, Sierra Leone, September-November, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Ratto, Jeffrey; Redd, John] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. [Ivy, Wade; Purfield, Anne] CDC, Natl Ctr HIV AIDS, Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Bangura, James; Kamara, Sarian; Conteh, Sulaiman] Sierra Leone Minist Hlth & Sanitat, Siegen, Germany. [Omoko, Anthony; Boateng, Isaac; Pi-Sunyer, Teresa] World Hlth Org, Washington, DC USA. [Duffy, Nadia] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Sims, George; Beamer, Bryan] CDC, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. RP Ratto, J (reprint author), CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. EM JRatto@cdc.gov NR 7 TC 0 Z9 0 U1 5 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 26 PY 2016 VL 65 IS 7 BP 188 EP 189 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4UB UT WOS:000371345300005 PM 26914633 ER PT J AU Yaffee, AQ Roser, L Daniels, K Humbaugh, K Brawley, R Thoroughman, D Flinchum, A AF Yaffee, Anna Q. Roser, Lynn Daniels, Kimberly Humbaugh, Kraig Brawley, Robert Thoroughman, Douglas Flinchum, Andrea TI Verona Integron-Encoded Metallo-Beta-Lactamase-Producing Carbapenem-Resistant Enterobacteriaceae in a Neonatal and Adult Intensive Care Unit - Kentucky, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Yaffee, Anna Q.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Yaffee, Anna Q.; Roser, Lynn; Daniels, Kimberly; Humbaugh, Kraig; Brawley, Robert; Thoroughman, Douglas; Flinchum, Andrea] Kentucky Dept Publ Hlh, Sacramento, CA USA. [Thoroughman, Douglas] CDC, Atlanta, GA 30333 USA. RP Yaffee, AQ (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Yaffee, AQ (reprint author), Kentucky Dept Publ Hlh, Sacramento, CA USA. EM vmv7@cdc.gov NR 8 TC 4 Z9 4 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 26 PY 2016 VL 65 IS 7 BP 190 EP 190 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4UB UT WOS:000371345300006 PM 26914726 ER PT J AU Lane, J Verani, A Hijazi, M Hurley, E Hagopian, A Judice, N MacInnis, R Sanford, S Zelek, S Katz, A AF Lane, Jeffrey Verani, Andre Hijazi, Mai Hurley, Erin Hagopian, Amy Judice, Nicole MacInnis, Ron Sanford, Sallie Zelek, Sarah Katz, Aaron TI Monitoring HIV and AIDS Related Policy Reforms: A Road Map to Strengthen Policy Monitoring and Implementation in PEPFAR Partner Countries SO PLOS ONE LA English DT Article ID SOUTH-AFRICA; PROGRAMS; HIV/AIDS; IMPACT AB Achieving an AIDS-free generation will require the adoption and implementation of critical health policy reforms. However, countries with high HIV burden often have low policy development, advocacy, and monitoring capacity. This lack of capacity may be a significant barrier to achieving the AIDS-free generation goals. This manuscript describes the increased focus on policy development and implementation by the United States President's Emergency Plan for AIDS Relief (PEPFAR). It evaluates the curriculum and learning modalities used for two regional policy capacity building workshops organized around the PEPFAR Partnership Framework agreements and the Road Map for Monitoring and Implementing Policy Reforms. A total of 64 participants representing the U.S. Government, partner country governments, and civil society organizations attended the workshops. On average, participants responded that their policy monitoring skills improved and that they felt they were better prepared to monitor policy reforms three months after the workshop. When followed-up regarding utilization of the Road Map action plan, responses were mixed. Reasons cited for not making progress included an inability to meet or a lack of time, personnel, or governmental support. This lack of progress may point to a need for building policy monitoring systems in high HIV burden countries. Because the success of policy reforms cannot be measured by the mere adoption of written policy documents, monitoring the implementation of policy reforms and evaluating their public health impact is essential. In many high HIV burden countries, policy development and monitoring capacity remains weak. This lack of capacity could hinder efforts to achieve the ambitious AIDS-free generation treatment, care and prevention goals. The Road Map appears to be a useful tool for strengthening these critical capacities. C1 [Lane, Jeffrey; Hagopian, Amy; Zelek, Sarah; Katz, Aaron] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Lane, Jeffrey; Sanford, Sallie] Univ Washington, Sch Law, Seattle, WA 98195 USA. [Lane, Jeffrey] Foster Pepper PLLC, Seattle, WA USA. [Verani, Andre; Hurley, Erin] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Hijazi, Mai] US Agcy Int Dev, Washington, DC 20523 USA. [Judice, Nicole; MacInnis, Ron] Hlth Policy Project, Futures Grp, Washington, DC USA. RP Lane, J (reprint author), Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. EM lanej3@u.washington.edu FU Centers for Disease Control and Prevention (CDC.) [U48-DP001911]; Health Policy Project - U.S. Agency for International Development; U.S. President's Emergency Plan for AIDS Relief (PEPFAR) [AID-OAA-A-10-00067]; United States President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention; United States Agency for International Development; Foster Pepper, PLLC FX This research is a product of the University of Washington Health Promotion Research Center and was supported by Cooperative Agreement Number U48-DP001911 from the Centers for Disease Control and Prevention (CDC.) Support for the study was also provided through the Health Policy Project, which is funded by the U.S. Agency for International Development and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) under Agreement No. AID-OAA-A-10-00067, beginning 30th September 2010. This work was supported by the United States President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention and the United States Agency for International Development. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention or of the U.S. Agency for International Development. Foster Pepper, PLLC, provided support in the form of salary for author Jeffrey Lane, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of Jeffrey Lane are articulated in the 'author contributions' section. NR 32 TC 0 Z9 0 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 25 PY 2016 VL 11 IS 2 AR e0146720 DI 10.1371/journal.pone.0146720 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF2LW UT WOS:000371175700003 PM 26914708 ER PT J AU Muller, DA Pearson, FE Fernando, GJP Agyei-Yeboah, C Owens, NS Corrie, SR Crichton, ML Wei, JCJ Weldon, WC Oberste, MS Young, PR Kendall, MAF AF Muller, David A. Pearson, Frances E. Fernando, Germain J. P. Agyei-Yeboah, Christiana Owens, Nick S. Corrie, Simon R. Crichton, Michael L. Wei, Jonathan C. J. Weldon, William C. Oberste, M. Steven Young, Paul R. Kendall, Mark A. F. TI Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses SO SCIENTIFIC REPORTS LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; JET INJECTOR; IMMUNOGENICITY; ANTIGEN; NEEDLE; VIRUS; POLIOMYELITIS; ERADICATION; EXTRACTION; STRATEGIES AB Polio eradication is progressing rapidly, and the live attenuated Sabin strains in the oral poliovirus vaccine (OPV) are being removed sequentially, starting with type 2 in April 2016. For risk mitigation, countries are introducing inactivated poliovirus vaccine (IPV) into routine vaccination programs. After April 2016, monovalent type 2 OPV will be available for type 2 outbreak control. Because the current IPV is not suitable for house-to-house vaccination campaigns (the intramuscular injections require health professionals), we developed a high-density microprojection array, the Nanopatch, delivered monovalent type 2 IPV (IPV2) vaccine to the skin. To assess the immunogenicity of the Nanopatch, we performed a dose-matched study in rats, comparing the immunogenicity of IPV2 delivered by intramuscular injection or Nanopatch immunisation. A single dose of 0.2 D-antigen units of IPV2 elicited protective levels of poliovirus antibodies in 100% of animals. However, animals receiving IPV2 by IM required at least 3 immunisations to reach the same neutralising antibody titres. This level of dose reduction (1/40th of a full dose) is unprecedented for poliovirus vaccine delivery. The ease of administration coupled with the dose reduction observed in this study points to the Nanopatch as a potential tool for facilitating inexpensive IPV for mass vaccination campaigns. C1 [Muller, David A.; Pearson, Frances E.; Fernando, Germain J. P.; Agyei-Yeboah, Christiana; Owens, Nick S.; Corrie, Simon R.; Crichton, Michael L.; Wei, Jonathan C. J.; Kendall, Mark A. F.] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Delivery Drugs & Genes Grp D2G2, Brisbane, Qld, Australia. [Muller, David A.; Fernando, Germain J. P.; Corrie, Simon R.; Young, Paul R.; Kendall, Mark A. F.] Univ Queensland, Australian Infect Dis Res Ctr, Brisbane, Qld, Australia. [Weldon, William C.; Oberste, M. Steven] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA. [Young, Paul R.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia. RP Muller, DA; Kendall, MAF (reprint author), Univ Queensland, Australian Inst Bioengn & Nanotechnol, Delivery Drugs & Genes Grp D2G2, Brisbane, Qld, Australia.; Muller, DA; Kendall, MAF (reprint author), Univ Queensland, Australian Infect Dis Res Ctr, Brisbane, Qld, Australia. EM d.muller4@uq.edu.au; m.kendall@uq.edu.au RI Muller, David/B-3413-2012; Fernando, Germain/C-3733-2009; Corrie, Simon/D-1596-2009; OI Fernando, Germain/0000-0003-3260-0548; Corrie, Simon/0000-0001-8029-1896; Crichton, Michael/0000-0002-3683-802X FU World health Organisation; Vaxxas Inc; Rotary Club of Jindalee; Rotary Club of Ipswich City; Rotary Foundation FX The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of CDC and other contributing agencies. The use of trade names is for identification purposes only and does not constitute an endorsement by the Centers for Disease Control and Prevention or the US Government. We would like to thank the World Health Organisation (Hiromasa Okayasu and Roland Sutter); Vaxxas (Angus Forster, Paul Fahey) for strategic guidance of the project, Sasikaran Kandasamy and Stephen Ben Baker for Nanopatch fabrication; Julian Hickling (Working in Tandem Ltd) for critical reading of the manuscript. We also acknowledge the technical assistance of Jin Zhang, Chelsea Stewart and the staff of the University of Queensland Biological Resources. We would like to thank the members of the CDC polio serology team, Sharla McDonald, Deborah Moore, Will Hendley, and Yiting Zhang, for their assistance in performing the poliovirus neutralisation assays. We thank Naomi Dybdahl-Sissoko for sharing the D-antigen ELISA. We thank Bilthoven Biologicals for providing the IPV vaccine. Finally, we wish to acknowledge the funding organisations, the World health Organisation, Vaxxas Inc, the Rotary Club of Jindalee, the Rotary Club of Ipswich City and the Rotary Foundation through District 9630 for supporting this work. NR 43 TC 2 Z9 3 U1 3 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD FEB 25 PY 2016 VL 6 AR 22094 DI 10.1038/srep22094 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DE7FQ UT WOS:000370801400001 PM 26911254 ER PT J AU Saadatian-Elahi, M Horstick, O Breiman, RF Gessner, BD Gubler, DJ Louis, J Parashar, UD Tapia, R Picot, V Zinsou, JA Nelson, CB AF Saadatian-Elahi, Mitra Horstick, Olaf Breiman, Robert F. Gessner, Bradford D. Gubler, Duane J. Louis, Jacques Parashar, Umesh D. Tapia, Roberto Picot, Valentina Zinsou, Jean-Antoine Nelson, Christopher B. TI Beyond efficacy: The full public health impact of vaccines SO VACCINE LA English DT Article DE Vaccine efficacy; Vaccine preventable disease incidence; Vaccine effectiveness; Vaccine probe analysis; Beyond vaccine efficacy; Conference report ID PNEUMOCOCCAL CONJUGATE VACCINE; PENTAVALENT ROTAVIRUS VACCINE; CLUSTER-RANDOMIZED-TRIAL; RTS,S/AS01 MALARIA VACCINE; IMMUNIZATION PROGRAM; HERD PROTECTION; TYPHOID VACCINE; AFRICAN INFANTS; PHASE-3 TRIAL; DOUBLE-BLIND AB There is an active discussion in the public health community on how to assess and incorporate, in addition to safety and measures of protective efficacy, the full public health value of preventive vaccines into the evidence-based decision-making process of vaccine licensure and recommendations for public health use. The conference "Beyond efficacy: the full public health impact of vaccines in addition to efficacy measures in trials" held in Annecy, France (June 22-24, 2015) has addressed this issue and provided recommendations on how to better capture the whole public health impact of vaccines. Using key examples, the expert group stressed that we are in the midst of a new paradigm in vaccine evaluation, where all aspects of public health value of vaccines beyond efficacy should be evaluated. To yield a wider scope of vaccine benefits, additional measures such as vaccine preventable disease incidence, overall efficacy and other outcomes such as under-five mortality or non-etiologically confirmed clinical syndromes should be assessed in addition to traditional efficacy or effectiveness measurements. Dynamic modelling and the use of probe studies should also be considered to provide additional insight to the full public health value of a vaccine. The use of burden reduction and conditional licensure of vaccines based on collection of outcome results should be considered by regulatory agencies. C1 [Saadatian-Elahi, Mitra] Groupement Hosp Edouard Herriot, Hosp Civils Lyon, 5 Pl Arsonval, F-69437 Lyon 03, France. [Horstick, Olaf] Heidelberg Univ, Inst Publ Hlth, Bergheimer Str 58, D-69115 Heidelberg, Germany. [Breiman, Robert F.] Emory Univ, Emory Global Hlth Inst, Atlanta, GA 30322 USA. [Gessner, Bradford D.] Agence Med Prevent, Paris, France. [Gubler, Duane J.] Duke NUS Grad Med Sch, 8 Coll Rd, Singapore 169857, Singapore. [Louis, Jacques; Picot, Valentina] Fdn Merieux, 17 Rue Bourgelat, F-69002 Lyon, France. [Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Tapia, Roberto] Fdn Carlos Slim, Mexico City, DF, Mexico. [Zinsou, Jean-Antoine; Nelson, Christopher B.] Sanofi Pasteur, Vaccinat Policy Dept, 2 Ave Pont Pasteur, F-69367 Lyon 07, France. RP Saadatian-Elahi, M (reprint author), Groupement Hosp Edouard Herriot, Serv Hyg Epidemiol & Prevent, Batiment 1,5,Pl Arsonval, F-69437 Lyon 03, France. EM mitra.elahi@chu-lyon.fr FU Crucell; GSK; Hilleman Laboratories; Merck; Pfizer; Sanofi Pasteur FX CBN and JAZ are employee of Sanofi Pasteur. BDG works for AMP which receives grant support from Crucell, GSK, Hilleman Laboratories, Merck, Pfizer, and Sanofi Pasteur. Other authors declare that they have no conflicts of interest to report. NR 56 TC 3 Z9 3 U1 1 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD FEB 24 PY 2016 VL 34 IS 9 BP 1139 EP 1147 DI 10.1016/j.vaccine.2016.01.021 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA DF7OZ UT WOS:000371548600001 PM 26808648 ER PT J AU Hofstetter, AR De La Cruz, JA Cao, WP Patel, J Belser, JA McCoy, J Liepkalns, JS Amoah, S Cheng, GJ Ranjan, P Diebold, BA Shieh, WJ Zaki, S Katz, JM Sambhara, S Lambeth, JD Gangappa, S AF Hofstetter, Amelia R. De La Cruz, Juan A. Cao, Weiping Patel, Jenish Belser, Jessica A. McCoy, James Liepkalns, Justine S. Amoah, Samuel Cheng, Guangjie Ranjan, Priya Diebold, Becky A. Shieh, Wun-Ju Zaki, Sherif Katz, Jacqueline M. Sambhara, Suryaprakash Lambeth, J. David Gangappa, Shivaprakash TI NADPH Oxidase 1 Is Associated with Altered Host Survival and T Cell Phenotypes after Influenza A Virus Infection in Mice SO PLOS ONE LA English DT Article ID DENDRITIC CELLS; REACTIVE OXYGEN; ANTIBODY-RESPONSE; NOX ENZYMES; DIFFERENTIATION; PATHOGENESIS; MEMORY; EXPRESSION; EFFECTOR; CD4(+) AB The role of the reactive oxygen species-producing NADPH oxidase family of enzymes in the pathology of influenza A virus infection remains enigmatic. Previous reports implicated NADPH oxidase 2 in influenza A virus-induced inflammation. In contrast, NADPH oxidase 1 (Nox1) was reported to decrease inflammation in mice within 7 days post-influenza A virus infection. However, the effect of NADPH oxidase 1 on lethality and adaptive immunity after influenza A virus challenge has not been explored. Here we report improved survival and decreased morbidity in mice with catalytically inactive NADPH oxidase 1 (Nox1(*/Y)) compared with controls after challenge with A/PR/8/34 influenza A virus. While changes in lung inflammation were not obvious between Nox1(*/Y) and control mice, we observed alterations in the T cell response to influenza A virus by day 15 post-infection, including increased interleukin-7 receptor-expressing virus-specific CD8(+) T cells in lungs and draining lymph nodes of Nox1(*/Y), and increased cytokine-producing T cells in lungs and spleen. Furthermore, a greater percentage of conventional and interstitial dendritic cells from Nox1(*/Y) draining lymph nodes expressed the co-stimulatory ligand CD40 within 6 days post-infection. Results indicate that NADPH oxidase 1 modulates the innate and adaptive cellular immune response to influenza virus infection, while also playing a role in host survival. Results suggest that NADPH oxidase 1 inhibitors may be beneficial as adjunct therapeutics during acute influenza infection. C1 [Hofstetter, Amelia R.; De La Cruz, Juan A.; Cao, Weiping; Patel, Jenish; Belser, Jessica A.; Liepkalns, Justine S.; Amoah, Samuel; Ranjan, Priya; Katz, Jacqueline M.; Sambhara, Suryaprakash; Gangappa, Shivaprakash] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Hofstetter, Amelia R.; McCoy, James; Cheng, Guangjie; Diebold, Becky A.; Lambeth, J. David] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Shieh, Wun-Ju; Zaki, Sherif] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. [Cheng, Guangjie] UAB Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. RP Gangappa, S (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.; Lambeth, JD (reprint author), Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. EM noxdoc@mac.com; sgangappa@cdc.gov OI Hofstetter, Amelia/0000-0003-4113-5473 FU National Institutes of Health [AI102197-01, T32 DK00771]; Centers for Disease Control and Prevention FX This study was funded by National Institutes of Health Grants AI102197-01 (JDL) (http://report.nih.gov/quicklinks.aspx), T32 DK00771 (http://report.nih.gov/quicklinks.aspx), and Centers for Disease Control and Prevention intramural funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 68 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 24 PY 2016 VL 11 IS 2 AR e0149864 DI 10.1371/journal.pone.0149864 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF2IA UT WOS:000371164700051 PM 26910342 ER PT J AU MacKellar, DA Williams, D Storer, N Okello, V Azih, C Drummond, J Nuwagaba-Biribonwoha, H Preko, P Morgan, RL Dlamini, M Byrd, J Agolory, S Baughman, AL McNairy, ML Sahabo, R Ehrenkranz, P AF MacKellar, Duncan A. Williams, Daniel Storer, Nosipho Okello, Velephi Azih, Charles Drummond, Jennifer Nuwagaba-Biribonwoha, Harriet Preko, Peter Morgan, Rebecca L. Dlamini, Makhosazana Byrd, Johnita Agolory, Simon Baughman, Andrew L. McNairy, Margaret L. Sahabo, Ruben Ehrenkranz, Peter TI Enrollment in HIV Care Two Years after HIV Diagnosis in the Kingdom of Swaziland: An Evaluation of a National Program of New Linkage Procedures SO PLOS ONE LA English DT Article ID SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; WESTERN KENYA; SOUTH-AFRICA; RETENTION; INITIATION; INFECTION; PERCEPTIONS; COMMUNITY; BARRIERS AB To improve early enrollment in HIV care, the Swaziland Ministry of Health implemented new linkage procedures for persons HIV diagnosed during the Soka Uncobe male circumcision campaign (SOKA, 2011-2012) and the Swaziland HIV Incidence Measurement Survey (SHIMS, 2011). Abstraction of clinical records and telephone interviews of a retrospective cohort of HIV-diagnosed SOKA and SHIMS clients were conducted in 2013-2014 to evaluate compliance with new linkage procedures and enrollment in HIV care at 92 facilities throughout Swaziland. Of 1,105 clients evaluated, within 3, 12, and 24 months of diagnosis, an estimated 14.0%, 24.3%, and 37.0% enrolled in HIV care, respectively, after adjusting for lost to follow-up and non-response. Kaplan-Meier functions indicated lower enrollment probability among clients 14-24 (P = 0.0001) and 25-29 (P = 0.001) years of age compared with clients > 35 years of age. At 69 facilities to which clients were referred for HIV care, compliance with new linkage procedures was low: referral forms were located for less than half (46.8%) of the clients, and few (9.6%) were recorded in the appointment register or called either before (0.3%) or after (4.9%) their appointment. Of over one thousand clients newly HIV diagnosed in Swaziland in 2011 and 2012, few received linkage services in accordance with national procedures and most had not enrolled in HIV care two years after their diagnosis. Our findings are a call to action to improve linkage services and early enrollment in HIV care in Swaziland. C1 [MacKellar, Duncan A.; Williams, Daniel; Drummond, Jennifer; Agolory, Simon; Baughman, Andrew L.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Natl Ctr Global Hlth, Atlanta, GA USA. [Storer, Nosipho; Nuwagaba-Biribonwoha, Harriet; Sahabo, Ruben] Columbia Univ, ICAP, Columbia, Swaziland. [Okello, Velephi; Azih, Charles] Swaziland Minist Hlth, Swaziland Natl AIDS Programme, Mbabane, Swaziland. [Nuwagaba-Biribonwoha, Harriet; McNairy, Margaret L.] Columbia Univ, ICAP, New York, NY USA. [Preko, Peter] Ctr Dis Control & Prevent Country Off, CTS Global assigned, Mbabane, Swaziland. [Morgan, Rebecca L.] McMaster Univ, Hamilton, ON, Canada. [Dlamini, Makhosazana] Populat Serv Int Country Program, Mbabane, Swaziland. [Byrd, Johnita] ICF Int, Atlanta, GA USA. [Byrd, Johnita] Bill & Melinda Gates Fdn, Seattle, WA USA. RP MacKellar, DA (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Natl Ctr Global Hlth, Atlanta, GA USA. EM dym4@cdc.gov FU ICF International; Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention [U2GPS002005] FX This work was funded through the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (cooperative agreement U2GPS002005). ICF International was contracted by the U.S. Centers for Disease Control and Prevention to provide data-management services only. Author Johnita Byrd is employed by ICF International. ICF International provided support in the form of salary for author JB, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section. NR 35 TC 2 Z9 2 U1 2 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 24 PY 2016 VL 11 IS 2 AR e0150086 DI 10.1371/journal.pone.0150086 PG 21 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF2IA UT WOS:000371164700065 PM 26910847 ER PT J AU Voelker, R AF Voelker, Rebecca TI Petroleum Workers' Hydrocarbon Risk SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT News Item C1 [Voelker, Rebecca] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Voelker, R (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 23 PY 2016 VL 315 IS 8 BP 743 EP 743 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA EM0BB UT WOS:000394982700003 ER PT J AU Heymann, DL Hodgson, A Sall, AA Freedman, DO Staples, JE Althabe, F Baruah, K Mahmud, G Kandun, N Vasconcelos, PFC Bino, S Menon, KU AF Heymann, David L. Hodgson, Abraham Sall, Amadou Alpha Freedman, David O. Staples, J. Erin Althabe, Fernando Baruah, Kalpana Mahmud, Ghazala Kandun, Nyoman Vasconcelos, Pedro F. C. Bino, Silvia Menon, K. U. TI Zika virus and microcephaly: why is this situation a PHEIC? SO LANCET LA English DT Editorial Material C1 [Heymann, David L.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, London WC1, England. [Heymann, David L.] Royal Inst Int Affairs, Ctr Global Hlth Secur, Chatham House, London SW1Y 4LE, England. [Hodgson, Abraham] Ghana Hlth Serv, Div Res & Dev, Accra, Ghana. [Hodgson, Abraham] Senegal Inst Pasteur Dakar, WHO Collaborating Ctr Arboviruses & Viral Haemorr, Dakar, Senegal. [Freedman, David O.] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA. [Staples, J. Erin] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Althabe, Fernando] Inst Clin Effectiveness & Hlth Policy, Dept Maternal & Child Hlth Res, Buenos Aires, DF, Argentina. [Baruah, Kalpana] Govt India, Minist Hlth & Family Welf, Natl Vector Borne Dis Control Programme, New Delhi, India. [Mahmud, Ghazala] Quaid I Azam Univ, Quaid I Azam Post Grad Med Coll, Fac Med, Pakistan Inst Med Sci, Islamabad, Pakistan. [Kandun, Nyoman] Minist Hlth, Field Epidemiol Training Program, Jakarta, Indonesia. [Vasconcelos, Pedro F. C.] Evandro Chagas Inst, Dept Arbovirol & Hemorrhag Fevers, Ananindeua, Brazil. [Bino, Silvia] Inst Publ Hlth, Control Infect Dis Dept, Tirana, Albania. [Menon, K. U.] Minist Commun & Informat, Singapore, Singapore. RP Heymann, DL (reprint author), London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, London WC1, England.; Heymann, DL (reprint author), Royal Inst Int Affairs, Ctr Global Hlth Secur, Chatham House, London SW1Y 4LE, England. EM david.heymann@phe.gov.uk NR 17 TC 66 Z9 72 U1 5 U2 55 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD FEB 20 PY 2016 VL 387 IS 10020 BP 719 EP 721 DI 10.1016/S0140-6736(16)00320-2 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DE1WU UT WOS:000370418000004 PM 26876373 ER PT J AU Liu, Y Wheaton, AG Chapman, DP Cunningham, TJ Lu, H Croft, JB AF Liu, Yong Wheaton, Anne G. Chapman, Daniel P. Cunningham, Timothy J. Lu, Hua Croft, Janet B. TI Prevalence of Healthy Sleep Duration among Adults - United States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Liu, Yong; Wheaton, Anne G.; Chapman, Daniel P.; Cunningham, Timothy J.; Lu, Hua; Croft, Janet B.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Wheaton, AG (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM AWheaton@cdc.gov NR 10 TC 14 Z9 14 U1 4 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 19 PY 2016 VL 65 IS 6 BP 137 EP 141 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4TY UT WOS:000371345000001 PM 26890214 ER PT J AU Russell, K Blanton, L Kniss, K Mustaquim, D Smith, S Cohen, J Garg, S Flannery, B Fry, AM Grohskopf, LA Bresee, J Wallis, T Sessions, W Garten, R Xu, XY Elal, AIA Gubareva, L Barnes, J Wentworth, DE Burns, E Katz, J Jernigan, D Brammer, L AF Russell, Kate Blanton, Lenee Kniss, Krista Mustaquim, Desiree Smith, Sophie Cohen, Jessica Garg, Shikha Flannery, Brendan Fry, Alicia M. Grohskopf, Lisa A. Bresee, Joseph Wallis, Teresa Sessions, Wendy Garten, Rebecca Xu, Xiyan Elal, Anwar Isa Abd Gubareva, Larisa Barnes, John Wentworth, David E. Burns, Erin Katz, Jacqueline Jernigan, Daniel Brammer, Lynnette TI Update: Influenza Activity - United States, October 4, 2015-February 6, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID VIRUS C1 [Russell, Kate] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Russell, Kate; Blanton, Lenee; Kniss, Krista; Mustaquim, Desiree; Smith, Sophie; Cohen, Jessica; Garg, Shikha; Flannery, Brendan; Fry, Alicia M.; Grohskopf, Lisa A.; Bresee, Joseph; Wallis, Teresa; Sessions, Wendy; Garten, Rebecca; Xu, Xiyan; Elal, Anwar Isa Abd; Gubareva, Larisa; Barnes, John; Wentworth, David E.; Burns, Erin; Katz, Jacqueline; Jernigan, Daniel; Brammer, Lynnette] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Cohen, Jessica] Atlanta Res & Educ Fdn, Atlanta, GA USA. RP Russell, K (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Russell, K (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM KERussell@cdc.gov OI Russell, Kate/0000-0001-9343-3355; Wentworth, David/0000-0002-5190-980X NR 8 TC 4 Z9 4 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 19 PY 2016 VL 65 IS 6 BP 146 EP 153 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4TY UT WOS:000371345000003 PM 26891596 ER PT J AU Thomas, DL Sharp, TM Torres, J Armstrong, PA Munoz-Jordan, J Ryff, KR Martinez-Quinones, A Arias-Berrios, J Mayshack, M Garayalde, GJ Saavedra, S Luciano, CA Valencia-Prado, M Waterman, S Rivera-Garcia, B AF Thomas, Dana L. Sharp, Tyler M. Torres, Jomil Armstrong, Paige A. Munoz-Jordan, Jorge Ryff, Kyle R. Martinez-Quinones, Alma Arias-Berrios, Jose Mayshack, Marrielle Garayalde, Glenn J. Saavedra, Sonia Luciano, Carlos A. Valencia-Prado, Miguel Waterman, Steve Rivera-Garcia, Brenda TI Local Transmission of Zika Virus - Puerto Rico, November 23, 2015-January 28, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID STATES C1 [Thomas, Dana L.; Torres, Jomil; Ryff, Kyle R.; Mayshack, Marrielle; Rivera-Garcia, Brenda] Puerto Rico Dept Hlth, Off Epidemiol, San Juan, PR USA. [Thomas, Dana L.] CDC, Off Publ Hlth Preparedness & Response, Div State Lab Readiness, Atlanta, GA 30333 USA. [Sharp, Tyler M.; Munoz-Jordan, Jorge; Waterman, Steve] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Atlanta, GA 30333 USA. [Armstrong, Paige A.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Martinez-Quinones, Alma; Valencia-Prado, Miguel] Puerto Rico Dept Hlth, Puerto Rico Birth Defects Surveillance & Prevent, San Juan, PR USA. [Arias-Berrios, Jose; Luciano, Carlos A.] Univ Puerto Rico, Sch Med, Dept Neurol, San Juan, PR USA. [Mayshack, Marrielle] CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA. [Garayalde, Glenn J.; Saavedra, Sonia] Vet Affairs Caribbean Healthcare Syst, San Juan, PR USA. RP Thomas, DL (reprint author), Puerto Rico Dept Hlth, Off Epidemiol, San Juan, PR USA.; Thomas, DL (reprint author), CDC, Off Publ Hlth Preparedness & Response, Div State Lab Readiness, Atlanta, GA 30333 USA. EM Zika@salud.gov.pr NR 11 TC 35 Z9 39 U1 5 U2 16 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 19 PY 2016 VL 65 IS 6 BP 154 EP 158 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4TY UT WOS:000371345000004 PM 26890470 ER PT J AU Martines, RB Bhatnagar, J Keating, MK Silva-Flannery, L Muehlenbachs, A Gary, J Goldsmith, C Hale, G Ritter, J Rollin, D Shieh, WJ Luz, KG Ramos, AMDO Davi, HPF de Oliveria, WK Lanciotti, R Lambert, A Zaki, S AF Martines, Roosecelis Brasil Bhatnagar, Julu Keating, M. Kelly Silva-Flannery, Luciana Muehlenbachs, Atis Gary, Joy Goldsmith, Cynthia Hale, Gillian Ritter, Jana Rollin, Dominique Shieh, Wun-Ju Luz, Kleber G. de Oliveira Ramos, Ana Maria Freire Davi, Helaine Pompeia de Oliveria, Wanderson Kleber Lanciotti, Robert Lambert, Amy Zaki, Sherif TI Evidence of Zika Virus Infection in Brain and Placental Tissues from Two Congenitally Infected Newborns and Two Fetal Losses - Brazil, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Martines, Roosecelis Brasil; Bhatnagar, Julu; Keating, M. Kelly; Silva-Flannery, Luciana; Muehlenbachs, Atis; Gary, Joy; Goldsmith, Cynthia; Hale, Gillian; Ritter, Jana; Rollin, Dominique; Shieh, Wun-Ju; Zaki, Sherif] CDC, Infectious Dis Pathol Branch, Div High Consequence Pathogens & Pathol, NCEZID, Atlanta, GA 30333 USA. [Luz, Kleber G.] Univ Fed Rio Grande do Norte, Dept Infect Dis, BR-59072970 Natal, RN, Brazil. [de Oliveira Ramos, Ana Maria] Univ Fed Rio Grande do Norte, Dept Pathol, BR-59072970 Natal, RN, Brazil. [Freire Davi, Helaine Pompeia] Serv Ascertaining Death State Rio Grande do Nort, Natal, RN, Brazil. [de Oliveria, Wanderson Kleber] Minist Hlth, Sao Paulo, Brazil. [Lanciotti, Robert; Lambert, Amy] CDC, Arboviral Dis Branch, Div Vector Borne Dis, NCEZID, Atlanta, GA 30333 USA. RP Martines, RB (reprint author), CDC, Infectious Dis Pathol Branch, Div High Consequence Pathogens & Pathol, NCEZID, Atlanta, GA 30333 USA. EM RBrasilMartines@cdc.gov NR 5 TC 138 Z9 139 U1 13 U2 45 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 19 PY 2016 VL 65 IS 6 BP 159 EP 160 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4TY UT WOS:000371345000005 ER PT J AU Su, JR Miller, ER Duffy, J Baer, BM Cano, MV AF Su, John R. Miller, Elaine R. Duffy, Jonathan Baer, Bethany M. Cano, Maria V. TI Administration Error Involving a Meningococcal Conjugate Vaccine - United States, March 1, 2010-September 22, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Su, John R.; Miller, Elaine R.; Duffy, Jonathan; Cano, Maria V.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Baer, Bethany M.] Food & Drug Adm, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, San Diego, CA USA. RP Su, JR (reprint author), CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM ezu2@cdc.gov NR 5 TC 1 Z9 1 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 19 PY 2016 VL 65 IS 6 BP 161 EP 162 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4TY UT WOS:000371345000006 PM 26890604 ER PT J AU Tan, KR Coleman, J Smith, B Hamainza, B Katebe-Sakala, C Kean, C Kowal, A Vanden Eng, J Parris, TK Mapp, CT Smith, SC Wirtz, R Kamuliwo, M Craig, AS AF Tan, Kathrine R. Coleman, Jane Smith, Barbara Hamainza, Busiku Katebe-Sakala, Cecilia Kean, Casey Kowal, Ashley Vanden Eng, Jodi Parris, Tiffany K. Mapp, Carla T. Smith, Stephen C. Wirtz, Robert Kamuliwo, Mulakwa Craig, Allen S. TI A longitudinal study of the durability of long-lasting insecticidal nets in Zambia SO MALARIA JOURNAL LA English DT Article DE Long-lasting insecticidal nets; Durability; Attrition ID MOSQUITO NET; PHYSICAL CONDITION; LIFE; SENEGAL; REPAIR; UGANDA; KENYA; CARE AB Background: A key goal of malaria control is to achieve universal access to, and use of, long-lasting insecticidal nets (LLINs) among people at risk for malaria. Quantifying the number of LLINs needed to achieve and maintain universal coverage requires knowing when nets need replacement. Longitudinal studies have observed physical deterioration in LLINs well before the assumed net lifespan of 3 years. The objective of this study was to describe attrition, physical integrity and insecticide persistence of LLINs over time to assist with better quantification of nets needing replacement. Methods: 999 LLINs distributed in 2011 in two highly endemic provinces in Zambia were randomly selected, and were enrolled at 12 months old. LLINs were followed every 6 months up to 30 months of age. Holes were counted and measured (finger, fist, and head method) and a proportional hole index (pHI) was calculated. Households were surveyed about net care and repair and if applicable, reasons for attrition. Functional survival was defined as nets with a pHI <643 and present for follow-up. At 12 and 24 months of age, 74 LLINs were randomly selected for examination of insecticidal activity and content using bioassay and chemical analysis methods previously described by the World Health Organization (WHO). Results: A total of 999 LLINs were enrolled; 505 deltamethrin-treated polyester nets and 494 permethrin-treated polyethylene nets. With 74 used to examine insecticide activity, 925 were available for full follow-up. At 30 months, 325 (33 %) LLINs remained. Net attrition was primarily due to disposal (29 %). Presence of repairs and use over a reed mat were significantly associated with larger pHIs. By 30 months, only 56 % of remaining nets met criteria for functional survival. A shorter functional survival was associated with having been washed. At 24 months, nets had reduced insecticidal activity (57 % met WHO minimal criteria) and content (5 % met WHO target insecticide content). Conclusions: The median functional survival time for LLINs observed the study was 2.5-3 years and insecticide activity and content were markedly decreased by 2 years. A better measure of net survival incorporating insecticidal field effectiveness, net physical integrity, and attrition is needed. C1 [Tan, Kathrine R.] Ctr Dis Control & Prevent, Ctr Global Hlth, Malaria Branch, 1600 Clifton Rd MS A6, Atlanta, GA 30333 USA. [Coleman, Jane] Jhpiego, Washington, DC USA. [Smith, Barbara] Peace Corps, San Francisco, CA USA. [Hamainza, Busiku; Kamuliwo, Mulakwa] Zambia Natl Malaria Control Ctr, Lusaka, Zambia. [Katebe-Sakala, Cecilia] Bayer Pty Ltd, Isando, South Africa. [Kean, Casey] Success Acad Charter Sch, Brooklyn, NY USA. [Kowal, Ashley] Soc Family Hlth, Lusaka, Zambia. [Vanden Eng, Jodi] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Parris, Tiffany K.] Ctr Dis Control & Prevent, Natl Ctr Enter Zoonot & Infect Dis, Atlanta, GA 30333 USA. [Mapp, Carla T.; Smith, Stephen C.; Wirtz, Robert] Ctr Dis Control & Prevent, Ctr Global Hlth, Entomol Branch, Atlanta, GA 30333 USA. [Craig, Allen S.] Ctr Dis Control & Prevent, Ctr Global Hlth, Polio Eradicat Branch, Atlanta, GA 30333 USA. RP Tan, KR (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Malaria Branch, 1600 Clifton Rd MS A6, Atlanta, GA 30333 USA. EM ktan@cdc.gov FU President's Malaria Initiative, under the terms of an Interagency Agreement; Centers for Disease Control and Prevention FX The authors would like to gratefully acknowledge the United States Peace Corps Volunteers who helped to implement the study, Lucy Muzia who assisted with entomologic work, and Ryan E. Wiegand for his additional biostatistical support. This study was made possible through support provided by the President's Malaria Initiative, under the terms of an Interagency Agreement with the Centers for Disease Control and Prevention. The findings, results, and opinions expressed herein are those of the authors and do not necessarily reflect the views of the US Agency for International Development or the Centers for Disease Control and Prevention. NR 23 TC 1 Z9 1 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD FEB 19 PY 2016 VL 15 AR 106 DI 10.1186/s12936-016-1154-4 PG 12 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DE3WC UT WOS:000370560100005 PM 26891696 ER PT J AU Uyeki, TM Mehta, AK Davey, RT Liddell, AM Wolf, T Vetter, P Schmiedel, S Grunewald, T Jacobs, M Arribas, JR Evans, L Hewlett, AL Brantsaeter, AB Ippolito, G Rapp, C Hoepelman, AIM Rapp, C Hoepelman, AIM Gutman, J AF Uyeki, Timothy M. Mehta, Aneesh K. Davey, Richard T., Jr. Liddell, Allison M. Wolf, Timo Vetter, Pauline Schmiedel, Stefan Gruenewald, Thomas Jacobs, Michael Arribas, Jose R. Evans, Laura Hewlett, Angela L. Brantsaeter, Arne B. Ippolito, Giuseppe Rapp, Christophe Hoepelman, Andy I. M. Rapp, Christophe Hoepelman, Andy I. M. Gutman, Julie CA US-European Clinical Network TI Clinical Management of Ebola Virus Disease in the United States and Europe SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID CONVALESCENT PLASMA; SIERRA-LEONE; WEST-AFRICA; CRITICAL-CARE; PATIENT; EPIDEMIC; FEATURES AB BACKGROUND Available data on the characteristics of patients with Ebola virus disease (EVD) and clinical management of EVD in settings outside West Africa, as well as the complications observed in those patients, are limited. METHODS We reviewed available clinical, laboratory, and virologic data from all patients with laboratory-confirmed Ebola virus infection who received care in U.S. and European hospitals from August 2014 through December 2015. RESULTS A total of 27 patients (median age, 36 years [range, 25 to 75]) with EVD received care; 19 patients (70%) were male, 9 of 26 patients (35%) had coexisting conditions, and 22 (81%) were health care personnel. Of the 27 patients, 24 (89%) were medically evacuated from West Africa or were exposed to and infected with Ebola virus in West Africa and had onset of illness and laboratory confirmation of Ebola virus infection in Europe or the United States, and 3 (11%) acquired EVD in the United States or Europe. At the onset of illness, the most common signs and symptoms were fatigue (20 patients [80%]) and fever or feverishness (17 patients [68%]). During the clinical course, the predominant findings included diarrhea, hypoalbuminemia, hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia; 14 patients (52%) had hypoxemia, and 9 (33%) had oliguria, of whom 5 had anuria. Aminotransferase levels peaked at a median of 9 days after the onset of illness. Nearly all the patients received intravenous fluids and electrolyte supplementation; 9 (33%) received noninvasive or invasive mechanical ventilation; 5 (19%) received continuous renalreplacement therapy; 22 (81%) received empirical antibiotics; and 23 (85%) received investigational therapies (19 [70%] received at least two experimental interventions). Ebola viral RNA levels in blood peaked at a median of 7 days after the onset of illness, and the median time from the onset of symptoms to clearance of viremia was 17.5 days. A total of 5 patients died, including 3 who had respiratory and renal failure, for a mortality of 18.5%. CONCLUSIONS Among the patients with EVD who were cared for in the United States or Europe, close monitoring and aggressive supportive care that included intravenous fluid hydration, correction of electrolyte abnormalities, nutritional support, and critical care management for respiratory and renal failure were needed; 81.5% of these patients who received this care survived. C1 [Uyeki, Timothy M.; Gutman, Julie] Ctr Dis Control & Prevent, Mail Stop A-20,1600 Clifton Rd NE, Atlanta, GA 30329 USA. [Mehta, Aneesh K.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. [Davey, Richard T., Jr.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Liddell, Allison M.] Texas Hlth Presbyterian Hosp Dallas, Dallas, TX USA. [Wolf, Timo] Univ Hosp Frankfurt, Dept Infect Dis, Frankfurt, Germany. [Schmiedel, Stefan] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany. [Gruenewald, Thomas] Klinikum St Georg, Leipzig Treatment Ctr Highly Contagious Dis, Leipzig, Germany. [Vetter, Pauline] Univ Hosp Geneva, Div Infect Dis & Lab Virol, Geneva, Switzerland. [Jacobs, Michael] Royal Free London NHS Fdn Trust, Dept Infect, London, England. [Arribas, Jose R.] Hosp La Paz Carlos III IdiPAZ, Infect Dis Unit Madrid, Dept Internal Med, Madrid, Spain. [Evans, Laura] NYU, Bellevue Hosp Ctr, Sch Med, New York, NY 10016 USA. [Hewlett, Angela L.] Univ Nebraska Med Ctr, Omaha, NE USA. [Brantsaeter, Arne B.] Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway. [Brantsaeter, Arne B.] Oslo Univ Hosp, Dept Acute Med, Oslo, Norway. [Ippolito, Giuseppe] Lazzaro Spallanzani Natl Inst Infect Dis, Rome, Italy. [Rapp, Christophe] Begin Mil Hosp, Infect & Trop Dis Dept, St Mande, France. [Hoepelman, Andy I. M.] Univ Med Ctr Utrecht, Dept Internal Med & Infect Dis, Utrecht, Netherlands. RP Uyeki, TM (reprint author), Ctr Dis Control & Prevent, Mail Stop A-20,1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM tuyeki@cdc.gov RI Martin, Daniel/F-7997-2010; Castilletti, Concetta/B-6545-2016; OI Castilletti, Concetta/0000-0001-9819-236X; Di Caro, Antonino/0000-0001-6027-3009; Mora-Rillo, Marta/0000-0002-2735-5931 FU Intramural CDC HHS [CC999999] NR 26 TC 29 Z9 29 U1 2 U2 10 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 18 PY 2016 VL 374 IS 7 BP 636 EP 646 DI 10.1056/NEJMoa1504874 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA DD9ER UT WOS:000370229000009 PM 26886522 ER PT J AU Geller, AI Mozersky, RP Budnitz, DS AF Geller, Andrew I. Mozersky, Robert P. Budnitz, Daniel S. TI Emergency Department Visits Related to Dietary Supplements Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Geller, Andrew I.; Budnitz, Daniel S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mozersky, Robert P.] Food & Drug Adm, College Pk, MD USA. RP Geller, AI (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM ageller@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 18 PY 2016 VL 374 IS 7 BP 695 EP 695 DI 10.1056/NEJMc1514454 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DD9ER UT WOS:000370229000030 PM 26886539 ER PT J AU Usuf, E Mackenzie, G Sambou, S Atherly, D Suraratdecha, C AF Usuf, Effua Mackenzie, Grant Sambou, Sana Atherly, Deborah Suraratdecha, Chutima TI The economic burden of childhood pneumococcal diseases in The Gambia SO COST EFFECTIVENESS AND RESOURCE ALLOCATION LA English DT Article ID CONJUGATE VACCINATION; BACTERIAL-MENINGITIS; COST-EFFECTIVENESS; PNEUMONIA; COMMUNITY; MORTALITY; KENYA; RISK; CARE AB Background: Streptococcus pneumoniae is a common cause of child death. However, the economic burden of pneumococcal disease in low-income countries is poorly described. We aimed to estimate from a societal perspective, the costs incurred by health providers and families of children with pneumococcal diseases. Methods: We recruited children less than 5 years of age with outpatient pneumonia, inpatient pneumonia, pneumococcal sepsis and bacterial meningitis at facilities in rural and urban Gambia. We collected provider costs, out of pocket costs and productivity loss for the families of children. For each disease diagnostic category, costs were collected before, during, and for 1 week after discharge from hospital or outpatient visit. Results: A total of 340 children were enrolled; 100 outpatient pneumonia, 175 inpatient pneumonia 36 pneumococcal sepsis, and 29 bacterial meningitis cases. The mean provider costs per patient for treating outpatient pneumonia, inpatient pneumonia, pneumococcal sepsis and meningitis were US$ 8, US$ 64, US$ 87 and US$ 124 respectively and the mean out of pocket costs per patient were US$ 6, US$ 31, US$ 44 and US$ 34 respectively. The economic burden of outpatient pneumonia, inpatient pneumonia, pneumococcal sepsis and meningitis increased to US$ 15, US$ 109, US$ 144 and US$ 170 respectively when family members' time loss from work was taken into account. Conclusion: The economic burden of pneumococcal disease in The Gambia is substantial, costs to families was approximately one-third to a half of the provider costs, and accounted for up to 30 % of total societal costs. The introduction of pneumococcal conjugate vaccine has the potential to significantly reduce this economic burden in this society. C1 [Usuf, Effua; Mackenzie, Grant] MRC, Gambia Unit, POB 273, Banjul, Gambia. [Mackenzie, Grant] Murdoch Childrens Res Inst, Pneumococcal Grp, Parkville, Vic, Australia. [Mackenzie, Grant] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England. [Sambou, Sana] Minist Hlth, Banjul, Gambia. [Atherly, Deborah; Suraratdecha, Chutima] PATH, Seattle, WA USA. [Suraratdecha, Chutima] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Usuf, E (reprint author), MRC, Gambia Unit, POB 273, Banjul, Gambia. EM eusuf@mrc.gm FU Bill & Melinda Gates Foundation; PATH; MRC (UK) FX This study was funded by PATH, MRC (UK), and the Bill & Melinda Gates Foundation. NR 24 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-7547 J9 COST EFFECT RESOUR A JI Cost Effect. Resour Alloc. PD FEB 17 PY 2016 VL 14 AR 4 DI 10.1186/s12962-016-0053-4 PG 10 WC Health Policy & Services SC Health Care Sciences & Services GA EF0NW UT WOS:000390023600001 PM 26893592 ER PT J AU Hampel, D Shahab-Ferdows, S Adair, LS Bentley, ME Flax, VL Jamieson, DJ Ellington, SR Tegha, G Chasela, CS Kamwendo, D Allen, LH AF Hampel, Daniela Shahab-Ferdows, Setareh Adair, Linda S. Bentley, Margaret E. Flax, Valerie L. Jamieson, Denise J. Ellington, Sascha R. Tegha, Gerald Chasela, Charles S. Kamwendo, Debbie Allen, Lindsay H. TI Thiamin and Riboflavin in Human Milk: Effects of Lipid-Based Nutrient Supplementation and Stage of Lactation on Vitamer Secretion and Contributions to Total Vitamin Content SO PLOS ONE LA English DT Article ID CANCER RESISTANCE PROTEIN; BREAST-MILK; RANDOMIZED-TRIAL; MATERNAL STATUS; B VITAMINS; WOMEN; TRANSPORTER; TRANSMISSION; POSTPARTUM; DEFICIENCY AB While thiamin and riboflavin in breast milk have been analyzed for over 50 years, less attention has been given to the different forms of each vitamin. Thiamin-monophosphate (TMP) and free thiamin contribute to total thiamin content; flavin adenine-dinucleotide (FAD) and free riboflavin are the main contributors to total riboflavin. We analyzed milk collected at 2 (n = 258) or 6 (n = 104), and 24 weeks (n = 362) from HIV-infected Malawian mothers within the Breastfeeding, Antiretrovirals and Nutrition (BAN) study, randomly assigned at delivery to lipid-based nutrient supplements (LNS) or a control group, to investigate each vitamer's contribution to total milk vitamin content and the effects of supplementation on the different thiamin and riboflavin vitamers at early and later stages of lactation, and obtain insight into the transport and distribution of these vitamers in human milk. Thiamin vitamers were derivatized into thiochrome-esters and analyzed by high-performance liquid-chromatography-fluorescence-detection (HPLC-FLD). Riboflavin and FAD were analyzed by ultra-performance liquid-chromatography-tandem-mass-spectrometry (ULPC-MS/MS). Thiamin-pyrophosphate (TPP), identified here for the first time in breast milk, contributed 1.9-4.5% to total thiamin. Free thiamin increased significantly from 2/6 to 24 weeks regardless of treatment indicating an active transport of this vitamer in milk. LNS significantly increased TMP and free thiamin only at 2 weeks compared to the control: median 170 versus 151 mu g/L (TMP), 13.3 versus 10.5 mu g/L (free thiamin, p<0.05 for both, suggesting an up-regulated active mechanism for TMP and free thiamin accumulation at early stages of lactation. Free riboflavin was consistently and significantly increased with LNS (range: 14.8-19.6 mu g/L (LNS) versus 5.0-7.4 mu g/L (control), p<0.001), shifting FAD: riboflavin relative amounts from 92-94:6-8% to 85:15%, indicating a preferred secretion of the free form into breast milk. The continuous presence of FAD in breast milk suggests an active transport and secretion system for this vitamer or possibly formation of this co-enymatic form in the mammary gland. C1 [Hampel, Daniela; Shahab-Ferdows, Setareh; Allen, Lindsay H.] ARS, USDA, Western Human Nutr Res Ctr, Davis, CA USA. [Hampel, Daniela; Allen, Lindsay H.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA. [Adair, Linda S.; Bentley, Margaret E.; Flax, Valerie L.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Jamieson, Denise J.; Ellington, Sascha R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tegha, Gerald; Chasela, Charles S.; Kamwendo, Debbie] UNC Project, Lilongwe, Malawi. [Chasela, Charles S.] Univ Witwatersrand, Sch Publ Hlth, Div Epidemiol & Biostat, Johannesburg, South Africa. RP Hampel, D (reprint author), ARS, USDA, Western Human Nutr Res Ctr, Davis, CA USA.; Hampel, D (reprint author), Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA. EM dhampel@ucdavis.edu FU Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, SIP 22-09 U48-DP001944-01]; Bill & Melinda Gates Foundation [OPP53107, OPP1061055]; National Institute of Allergy and Infectious Diseases; University of North Carolina Center for AIDS Research [P30-AI50410]; Carolina Population Center [R24 HD050924]; NIH Fogarty AIDS International Training and Research Program [DHHS/NIH/FIC 2-D43 Tw01039-06, R24 Tw00798]; NIH Fogarty AIDS International Training and Research Program (American Recovery and Reinvestment Act); intramural USDA-ARS Project [5306-51000-003-00D]; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Program; Malawi Ministry of Health and Population; Johnson Johnson; U.S. Agency for International Development FX The Breastfeeding, Antiretrovirals, and Nutrition Study was supported by grants from the Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, and SIP 22-09 U48-DP001944-01), Bill & Melinda Gates Foundation (OPP53107 and OPP1061055), the National Institute of Allergy and Infectious Diseases, the University of North Carolina Center for AIDS Research (P30-AI50410), the Carolina Population Center (R24 HD050924), the NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC 2-D43 Tw01039-06 and R24 Tw00798; the American Recovery and Reinvestment Act), and intramural USDA-ARS Project (5306-51000-003-00D). The antiretrovirals used in the BAN study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. The Call to Action PMTCT program was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Program, the Malawi Ministry of Health and Population, Johnson & Johnson, and the U.S. Agency for International Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 45 TC 2 Z9 2 U1 3 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 17 PY 2016 VL 11 IS 2 AR e0149479 DI 10.1371/journal.pone.0149479 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF3BJ UT WOS:000371218400089 PM 26886782 ER PT J AU Arriola, CS Vasconez, N Thompson, M Mirza, S Moen, AC Bresee, J Talavera, I Ropero, AM AF Arriola, Carmen S. Vasconez, Nancy Thompson, Mark Mirza, Sara Moen, Ann C. Bresee, Joseph Talavera, Ivy Ropero, Alba Maria TI Factors associated with a successful expansion of influenza vaccination among pregnant women in Nicaragua SO VACCINE LA English DT Article DE Influenza vaccination; Pregnant women; Acceptability ID VIRUS INFECTION; COVERAGE; DETERMINANTS; INFANTS; ILLNESS; SEASON; RATES; ACCEPTANCE AB Background: Pregnant women are at risk of severe influenza disease and are a priority group for influenza vaccination programs. Nicaragua expanded recommendations to include influenza vaccination to all pregnant women in the municipality of Managua in 2013. Methods: We carried out a survey among 1,807 pregnant women who delivered at public hospitals in the municipality of Managua to evaluate the uptake of influenza vaccination and factors associated with vaccination. Results: We observed a high (71%) uptake of influenza vaccination among this population, with no differences observed by age, education or parity of the women. Having four antenatal visits and five or more visits were associated with receipt of influenza vaccination (AORs: 2.58; 95% CI: 1.15, 5.81, and 2.37; 95% CI: 1.12, 5.0, respectively). Also, receipt of influenza vaccination recommendation from a health care provider was positively associated with receipt of influenza vaccination (AOR: 14.22; 95% CI: 10.45, 19.33). Conclusions: The successful expansion of influenza vaccination among pregnant women in the municipality of Managua may be due to ready access to free medical care and health care providers' recommendation for vaccination at health care clinics that received influenza vaccine. Published by Elsevier Ltd. C1 [Arriola, Carmen S.] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Atlanta, GA 30333 USA. [Arriola, Carmen S.; Thompson, Mark; Mirza, Sara; Moen, Ann C.; Bresee, Joseph] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Vasconez, Nancy; Talavera, Ivy] Pan Amer Hlth Org, Managua, Nicaragua. [Ropero, Alba Maria] Pan Amer Hlth Org, Washington, DC USA. RP Arriola, CS (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, 1600 Clifton Rd MS A-32, Atlanta, GA 30333 USA. EM wus3@cdc.gov FU US Centers for Disease Control and Prevention [U51GH001191] FX This study was supported by the US Centers for Disease Control and Prevention (Grant number U51GH001191). The findings and conclusions in this publication are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention and the Pan American Health Organization. The content of this article has not been previously presented. NR 33 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD FEB 17 PY 2016 VL 34 IS 8 BP 1086 EP 1090 DI 10.1016/j.vaccine.2015.12.065 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA DF1LK UT WOS:000371101100014 PM 26782740 ER PT J AU Wagner, L Rechtman, L Jordan, H Ritsick, M Sanchez, M Sorenson, E Kaye, W AF Wagner, Laurie Rechtman, Lindsay Jordan, Heather Ritsick, Maggie Sanchez, Marchelle Sorenson, Eric Kaye, Wendy TI State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION LA English DT Article DE Amyotrophic lateral sclerosis (ALS); incidence; prevalence; epidemiology; ALS surveillance ID COGNITIVE IMPAIRMENT; CLINICAL-FEATURES; UNITED-STATES; EL-ESCORIAL; DIAGNOSIS; CRITERIA; REGISTRY; PREVALENCE; DISEASE; TIME AB Our objective was to develop state and metropolitan area-based surveillance projects to describe the characteristics of those with ALS and to assist with evaluating the completeness of the National ALS Registry. Because the literature suggested that ethnic/racial minorities have lower incidence of ALS, three state and eight metropolitan areas were selected to over-represent ethnic/racial minorities to have a sufficient number of minority patients. Project activities relied on reports from medical providers and medical records abstraction. The project areas represented approximately 27% of the U.S. population. The combined racial and ethnic distribution of these areas is 64.4% white, 16.0% African-American, 6.7% Asian, and 28.3% Hispanic. Most neurologists did not diagnose or provide care for ALS patients. The number of unique patients reported was close to expected (5883 vs. 6673). Age and gender distribution of patients was similar to the literature. The crude average annual incidence rate was 1.52 per 100,000 person-years, CI 1.44-1.61, and the 2009 prevalence rate was 3.84 per 100,000 population, CI 3.70-3.97. In conclusion, this study represents the largest number of clinically diagnosed ALS patients reported by neurologists in the U.S. Comparison of these data with those in the National ALS Registry will help evaluate the completeness of administrative databases. C1 [Wagner, Laurie; Rechtman, Lindsay; Jordan, Heather; Ritsick, Maggie; Kaye, Wendy] McKing Consulting Corp, 2900 Chamblee Tucker Rd,Bldg 10,Suite 100, Atlanta, GA 30341 USA. [Sanchez, Marchelle] Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [Sorenson, Eric] Mayo Clin, Rochester, MN USA. RP Wagner, L (reprint author), McKing Consulting Corp, 2900 Chamblee Tucker Rd,Bldg 10,Suite 100, Atlanta, GA 30341 USA. EM lwagner@secure.mcking.com FU Agency for Toxic Substances and Disease Registry FX This project was funded by the Agency for Toxic Substances and Disease Registry. NR 29 TC 2 Z9 2 U1 2 U2 4 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 2167-8421 EI 2167-9223 J9 AMYOTROPH LAT SCL FR JI Amyotroph. Lateral Scher. Frontotemp. Degenerat. PD FEB 17 PY 2016 VL 17 IS 1-2 BP 128 EP 134 DI 10.3109/21678421.2015.1074699 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DB8BZ UT WOS:000368742700016 PM 26399278 ER PT J AU McNairy, ML Gwynn, C Rabkin, M Antelman, G Wu, YF Alemayehu, B Lim, T Imtiaz, R Mosha, F Mwasekaga, M Othman, AA Justman, J AF McNairy, Margaret L. Gwynn, Charon Rabkin, Miriam Antelman, Gretchen Wu, Yingfeng Alemayehu, Bereket Lim, Travis Imtiaz, Rubina Mosha, Fausta Mwasekaga, Michael Othman, Asha A. Justman, Jessica TI Increased utilisation of PEPFAR-supported laboratory services by non-HIV patients in Tanzania SO AFRICAN JOURNAL OF LABORATORY MEDICINE LA English DT Article ID GLOBAL HEALTH INITIATIVES; SCALE-UP; SYSTEMS; SETTINGS; PROGRAMS AB Background: It is unknown to what extent the non-HIV population utilises laboratories supported by the President's Emergency Plan for AIDS Relief (PEPFAR). Objectives: We aimed to describe the number and proportion of laboratory tests performed in 2009 and 2011 for patients referred from HIV and non-HIV services (NHSs) in a convenience sample collected from 127 laboratories supported by PEPFAR in Tanzania. We then compared changes in the proportions of tests performed for patients referred from NHSs in 2009 vs 2011. Methods: Haematology, chemistry, tuberculosis and syphilis test data were collected from available laboratory registers. Referral sources, including HIV services, NHSs, or lack of a documented referral source, were recorded. A generalised linear mixed model reported the odds that a test was from a NHS. Results: A total of 94 132 tests from 94 laboratories in 2009 and 157 343 tests from 101 laboratories in 2011 were recorded. Half of all tests lacked a documented referral source. Tests from NHSs constituted 42% (66 084) of all tests in 2011, compared with 31% (29 181) in 2009. A test in 2011 was twice as likely to have been referred from a NHS as in 2009 (adjusted odds ratio: 2.0 [95% confidence interval: 2.0-2.1]). Conclusion: Between 2009 and 2011, the number and proportion of tests from NHSs increased across all types of test. This finding may reflect increased documentation of NHS referrals or that the laboratory scale-up originally intended to service the HIV-positive population in Tanzania may be associated with a 'spillover effect' amongst the general population. C1 [McNairy, Margaret L.; Gwynn, Charon; Rabkin, Miriam; Antelman, Gretchen; Wu, Yingfeng; Alemayehu, Bereket; Justman, Jessica] Columbia Univ, ICAP, New York, NY 10027 USA. [McNairy, Margaret L.] Weill Cornell Med Coll, New York, NY 10065 USA. [Lim, Travis; Imtiaz, Rubina] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mosha, Fausta] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania. [Mwasekaga, Michael] Ctr Dis Control & Prevent, Dar Es Salaam, Tanzania. [Othman, Asha A.] Minist Hlth, Zanzibar, Tanzania. RP McNairy, ML (reprint author), Columbia Univ, ICAP, New York, NY 10027 USA.; McNairy, ML (reprint author), Weill Cornell Med Coll, New York, NY 10065 USA. EM mollymcnairy@gmail.com NR 10 TC 0 Z9 0 U1 0 U2 0 PU AOSIS PI CAPE TOWN PA POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA SN 2225-2002 EI 2225-2010 J9 AFR J LAB MED JI Afr. J. Lab. Med. PD FEB 16 PY 2016 VL 5 IS 1 AR 318 DI 10.4102/ajlm.v5i1.318 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DX2ZE UT WOS:000384241600001 ER PT J AU Peters, PJ Westheimer, E Cohen, S Hightow-Weidman, LB Moss, N Tsoi, B Hall, L Fann, C Daskalakis, DC Beagle, S Patel, P Radix, A Foust, E Kohn, RP Marmorino, J Pandori, M Fu, J Samandari, T Gay, CL AF Peters, Philip J. Westheimer, Emily Cohen, Stephanie Hightow-Weidman, Lisa B. Moss, Nicholas Tsoi, Benjamin Hall, Laura Fann, Charles Daskalakis, Demetre C. Beagle, Steve Patel, Pragna Radix, Asa Foust, Evelyn Kohn, Robert P. Marmorino, Jenni Pandori, Mark Fu, Jie Samandari, Taraz Gay, Cynthia L. TI Screening Yield of HIV Antigen/Antibody Combination and Pooled HIV RNA Testing for Acute HIV Infection in a High-Prevalence Population SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID SEXUAL TRANSMISSION; RATES AB IMPORTANCE Although acute HIV infection contributes disproportionately to onward HIV transmission, HIV testing has not routinely included screening for acute HIV infection. OBJECTIVE To evaluate the performance of an HIV antigen/antibody (Ag/Ab) combination assay to detect acute HIV infection compared with pooled HIV RNA testing. DESIGN, SETTING, AND PARTICIPANTS Multisite, prospective, within-individual comparison study conducted between September 2011 and October 2013 in 7 sexually transmitted infection clinics and 5 community-based programs in New York, California, and North Carolina. Participants were 12 years or older and seeking HIV testing, without known HIV infection. EXPOSURES All participants with a negative rapid HIV test result were screened for acute HIV infection with an HIV Ag/Ab combination assay (index test) and pooled human immunodeficiency virus 1(HIV-1) RNA testing. HIV RNA testing was the reference standard, with positive reference standard result defined as detectable HIV-1 RNA on an individual RNA test. MAIN OUTCOMES AND MEASURES Number and proportion with acute HIV infections detected. RESULTS Among 86 836 participants with complete test results (median age, 29 years; 75.0% men; 51.8% men who have sex with men), established HIV infection was diagnosed in 1158 participants (1.33%) and acute HIV infection was diagnosed in 168 participants (0.19%). Acute HIV infection was detected in 134 participants with HIV Ag/Ab combination testing (0.15% [95% CI, 0]3%-0.18%]; sensitivity, 79.8% [95% CI, 72.9%-85.6%]; specificity, 99.9% [95% CI, 99.9%-99.9M; positive predictive value, 59.0% [95% CI, 52.3%-65.5%]) and in 164 participants with pooled HIV RNA testing (0.19% [95% CI, 0.16%-0.22%]; sensitivity, 97.6% [95% CI, 94.0%-99.4%]; specificity, 100% [95% CI, 100%-100%]; positive predictive value, 96.5% [95% CI, 92.5%-98.7%]; sensitivity comparison, P < .001). Overall HIV Ag/Ab combination testing detected 82% of acute HIV infections detectable by pooled HIV RNA testing. Compared with rapid HIV testing alone, HIV Ag/Ab combination testing increased the relative HIV diagnostic yield (both established and acute HIV infections) by 10.4% (95% CI, 8.8%-12.2%) and pooled HIV RNA testing increased the relative HIV diagnostic yield by 12.4% (95% CI, 10.7%-14.3%). CONCLUSIONS AND RELEVANCE In a high-prevalence population, HIV screening using an HIV Ag/Ab combination assay following a negative rapid test detected 82% of acute HIV infections detectable by pooled HIV RNA testing, with a positive predictive value of 59%. Further research is needed to evaluate this strategy in lower-prevalence populations and in persons using preexposure prophylaxis for HIV prevention. C1 [Peters, Philip J.; Patel, Pragna; Samandari, Taraz] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-45, Atlanta, GA 30329 USA. [Westheimer, Emily; Tsoi, Benjamin; Daskalakis, Demetre C.; Fu, Jie] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Cohen, Stephanie; Moss, Nicholas; Fann, Charles; Kohn, Robert P.; Pandori, Mark] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Hightow-Weidman, Lisa B.; Beagle, Steve; Marmorino, Jenni; Gay, Cynthia L.] Univ N Carolina, Chapel Hill, NC USA. [Moss, Nicholas; Pandori, Mark] Alameda Cty Dept Publ Hlth, Oakland, CA USA. [Hall, Laura] ICE Int, Atlanta, GA USA. [Daskalakis, Demetre C.] Mt Sinai Sch Med, New York, NY USA. [Radix, Asa] Callen Lorde Community Hlth Ctr, New York, NY USA. [Foust, Evelyn] North Carolina Dept Publ Hlth, Raleigh, NC USA. RP Peters, PJ (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-45, Atlanta, GA 30329 USA. EM pjpeters@cdc.gov OI Radix, Asa/0000-0001-9611-4181; Radix, Asa/0000-0001-8594-1077 FU Centers for Disease Control and Prevention (CDC) [5U01PS001564]; San Francisco Department of Public Health, [5U01PS001564]; New York City Department of Health and Mental Hygiene [5U01PS001561]; University of North Carolina at Chapel Hill [5U01PS001559] FX This research was supported by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the San Francisco Department of Public Health (5U01PS001564), New York City Department of Health and Mental Hygiene (5U01PS001561), and the University of North Carolina at Chapel Hill (5U01PS001559). NR 34 TC 2 Z9 2 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 16 PY 2016 VL 315 IS 7 BP 682 EP 690 DI 10.1001/jama.2016.0286 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA DD8JB UT WOS:000370171500014 PM 26881371 ER PT J AU Ng'etich, AI Rawago, FO Jura, WGZO Mwinzi, PN Won, KY Odiere, MR AF Ng'etich, Annette I. Rawago, Fredrick O. Jura, Walter G. Z. O. Mwinzi, Pauline N. Won, Kimberly Y. Odiere, Maurice R. TI A cross-sectional study on schistosomiasis and soil-transmitted helminths in Mbita district, western Kenya using different copromicroscopic techniques SO PARASITES & VECTORS LA English DT Article DE Diagnosis; Kato-Katz; Mini-Parasep; Modified Mini-FLOTAC; Sensitivity; Schistosomiasis ID LAKE VICTORIA; MINI-FLOTAC; PARASITIC INFECTIONS; KATO-KATZ; PREVALENCE; MANSONI; DIAGNOSIS; SHORE; RISK AB Background: Identification of populations to be targeted for individual treatment and broad-spectrum therapy in schistosomiasis-endemic areas, assessment of therapy efficacy, morbidity, and evaluation of control strategies need to be based on reliable diagnostic tools. Kato-Katz is routinely used and remains the standard diagnostic technique for schistosomiasis, despite its many challenges. This study was conducted in Nyamanga village, Mbita, western Kenya, and evaluated the diagnostic performance of Kato-Katz, Mini-Parasep and modified Mini-FLOTAC techniques in detection of Schistosoma mansoni and soil-transmitted helminths (Ascaris lumbricoides, Trichuris trichiura and hookworm) ova. Methods: Stool samples from 132 individuals were screened for eggs of S. mansoni by the 3 techniques. Mini-Parasep (R) faecal parasite concentrator (Apacor Ltd, England), a single-use diagnostic device with a built-in filter for faecal concentration of helminth eggs by sedimentation was employed on stool samples fixed in 10 % formalin. A modified Mini-FLOTAC (University of Naples, Italy) was based on floatation of helminths eggs with two different solutions (FS2 and FS7) using a closed system (Fill-FLOTAC) with 5 % formalin. Kato-Katz was performed following WHO recommendation. Prevalence of S. mansoni and STH, sensitivity and degree of agreement among the 3 techniques were determined. Results: Prevalence of S. mansoni was 47.0 %, 34.1 % and 20.5 % by Mini-Parasep, Kato-Katz and modified Mini-FLOTAC FS7 techniques, respectively. Prevalence of any STH infection was 6.1 %, 3.0 %, 6.1 % and 6.8 % by Mini-Parasep, Kato-Katz, modified Mini-FLOTAC FS2 and modified Mini-FLOTAC FS7 techniques, respectively. Considering the pooled results of the three methods (Mini-Parasep, Kato-Katz and modified Mini-FLOTAC FS7) as diagnostic 'gold' standard, the sensitivity of Mini-Parasep, Kato-Katz and modified Mini-FLOTAC FS7 for S. mansoni was 77.5 %, 6.1 %, and 33.8 %, respectively. Mini-Parasep and modified Mini-FLOTAC FS7 techniques had moderate (kappa = 0.46) and fairly good (kappa = 0.25) agreements with Kato-Katz for S. mansoni, respectively. Mini-Parasep detected a higher proportion of light intensity S. mansoni infections compared to Kato-Katz, which detected high proportions of heavy infections. Mini-Parasep detected a similar mean number of S. mansoni eggs per gram (EPG) of stool compared to the standard Kato-Katz (62.9 vs 97.3; t ((131)) = -0.49, P = 0.6265) and significantly higher EPG compared to the modified Mini-FLOTAC FS7 (62.9 vs 34.6; t ((131)) = 5.39, P < 0.0001). Conclusions: The high sensitivity of Mini-Parasep suggests its promising potential as an alternative tool in enhancing diagnosis and in monitoring schistosomiasis transmission and determining endpoint of intervention programs, especially in low endemicity areas. Mini-Parasep is also easy to operate, safe and also permits work with fresh stool. C1 [Ng'etich, Annette I.; Rawago, Fredrick O.; Mwinzi, Pauline N.; Odiere, Maurice R.] Kenya Govt Med Res Ctr, Neglected Trop Dis Branch, Ctr Global Hlth Res, POB 1578-40100, Kisumu, Kenya. [Ng'etich, Annette I.; Jura, Walter G. Z. O.] Maseno Univ, Dept Zool, Maseno, Kenya. [Won, Kimberly Y.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Odiere, MR (reprint author), Kenya Govt Med Res Ctr, Neglected Trop Dis Branch, Ctr Global Hlth Res, POB 1578-40100, Kisumu, Kenya. EM MOdiere@kemricdc.org FU Bill and Melinda Gates Foundation FX Funding support for this study was provided by The Bill and Melinda Gates Foundation. The authors acknowledge Prof. Giuseppe Cringoli's lab at the University of Naples, Italy for providing Mini-FLOTAC and Fill-FLOTAC kits, and Apacor Ltd, England for providing Mini-Parasep kits that were used in this study. We thank the participants who provided samples and participated in this study. We acknowledge the help of Division of Vector-Borne and Neglected Tropical Diseases (DVBNTD) personnel, Homa-bay, and KEMRI/CGHR NTD staff, Kisumu, for their assistance with stool collection and microscopy. Our appreciation also goes to Henry Bishop (CDC-DPDx) for his support and training on detection methods and identification of helminths and other intestinal parasites. This paper is published with the permission of the Director of the Kenya Medical Research Institute. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC. NR 28 TC 0 Z9 0 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD FEB 16 PY 2016 VL 9 AR 87 DI 10.1186/s13071-016-1368-x PG 9 WC Parasitology SC Parasitology GA DD9FJ UT WOS:000370230800002 PM 26883744 ER PT J AU Self, WH Williams, DJ Zhu, YW Ampoto, K Pavia, AT Chappell, JD Hymas, WC Stockmann, C Bramley, AM Schneider, E Erdman, D Finelli, L Jain, S Edwards, KM Grijalva, CG AF Self, Wesley H. Williams, Derek J. Zhu, Yuwei Ampoto, Krow Pavia, Andrew T. Chappell, James D. Hymas, Weston C. Stockmann, Chris Bramley, Anna M. Schneider, Eileen Erdman, Dean Finelli, Lyn Jain, Seema Edwards, Kathryn M. Grijalva, Carlos G. TI Respiratory Viral Detection in Children and Adults: Comparing Asymptomatic Controls and Patients With Community-Acquired Pneumonia SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE pneumonia; etiology; virus; asymptomatic infection; attributable fraction ID POLYMERASE-CHAIN-REACTION; HOSPITALIZED CHILDREN; HUMAN CORONAVIRUS; INFECTIONS; ETIOLOGY; VIRUSES; ILLNESS; IDENTIFICATION; RHINOVIRUSES; DIAGNOSTICS AB Background. The clinical significance of viruses detected in patients with community-acquired pneumonia (CAP) is often unclear. Methods. We conducted a prospective study to identify the prevalence of 13 viruses in the upper respiratory tract of patients with CAP and concurrently enrolled asymptomatic controls with real-time reverse-transcriptase polymerase chain reaction. We compared age-stratified prevalence of each virus between patients with CAP and controls and used multivariable logistic regression to calculate attributable fractions (AFs). Results. We enrolled 1024 patients with CAP and 759 controls. Detections of influenza, respiratory syncytial virus, and human metapneumovirus were substantially more common in patients with CAP of all ages than in controls (AFs near 1.0). Parainfluenza and coronaviruses were also more common among patients with CAP (AF, 0.5-0.75). Rhinovirus was associated with CAP among adults (AF, 0.93) but not children (AF, 0.02). Adenovirus was associated with CAP only among children <2 years old (AF, 0.77). Conclusions. The probability that a virus detected with real-time reverse-transcriptase polymerase chain reaction in patients with CAP contributed to symptomatic disease varied by age group and specific virus. Detections of influenza, respiratory syncytial virus, and human metapneumovirus among patients with CAP of all ages probably indicate an etiologic role, whereas detections of parainfluenza, coronaviruses, rhinovirus, and adenovirus, especially in children, require further scrutiny. C1 [Self, Wesley H.] Vanderbilt Univ, Sch Med, Dept Emergency Med, Nashville, TN 37212 USA. [Williams, Derek J.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. [Zhu, Yuwei] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA. [Chappell, James D.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA. [Grijalva, Carlos G.] Univ Utah Hlth Sci Ctr, Dept Pediat, Salt Lake City, UT USA. [Ampoto, Krow] Univ Utah Hlth Sci Ctr, Dept Pediat, Salt Lake City, UT USA. [Pavia, Andrew T.] Univ Utah Hlth Sci Ctr, Dept Internal Med, Salt Lake City, UT USA. [Hymas, Weston C.] Univ Utah Hlth Sci Ctr, ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA. [Stockmann, Chris] Univ Utah Hlth Sci Ctr, Dept Pediat, Salt Lake City, UT USA. [Bramley, Anna M.; Schneider, Eileen; Erdman, Dean; Finelli, Lyn; Jain, Seema] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Self, WH (reprint author), 1313 21st Ave S,703 Oxford House, Nashville, TN 37232 USA. EM wesley.self@vanderbilt.edu FU CDC [U18 IP000299]; Vanderbilt Institute for Clinical and Translational Research from the National Institute for Advancing Translational Sciences [UL1TR000445]; National Institute of General Medical Sciences [1K23GM110469]; National Institute for Advancing Translational Sciences [KL2TR000446]; National Institute of Allergy and Infectious Diseases [K23AI104779]; Agency for HealthCare Research and Quality [1R03HS022342] FX This work was supported by a cooperative agreement with the CDC (grant U18 IP000299) and a research grant through the Vanderbilt Institute for Clinical and Translational Research (grant UL1TR000445) from the National Institute for Advancing Translational Sciences. W. H. S. was supported in part by career development grants from the National Institute of General Medical Sciences (grant 1K23GM110469) and National Institute for Advancing Translational Sciences (grant KL2TR000446). D. J. W. was supported in part by a career development grant from the National Institute of Allergy and Infectious Diseases (grant K23AI104779). C. G. G. was supported in part by the Agency for HealthCare Research and Quality (grant 1R03HS022342). NR 41 TC 21 Z9 22 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 15 PY 2016 VL 213 IS 4 BP 584 EP 591 DI 10.1093/infdis/jiv323 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DG9XS UT WOS:000372437700014 PM 26180044 ER PT J AU Bischoff, WE McNall, RJ Blevins, MW Turner, J Lopareva, EN Rota, PA Stehle, JR AF Bischoff, Werner E. McNall, Rebecca J. Blevins, Maria W. Turner, JoLyn Lopareva, Elena N. Rota, Paul A. Stehle, John R., Jr. TI Detection of Measles Virus RNA in Air and Surface Specimens in a Hospital Setting SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE measles; aerosol; exposure; infectious period; transmission; infection prevention ID INFECTION; GENOTYPES AB Measles virus (MeV) is known to be highly contagious, with an infectious period lasting from 4 days before to 4 days after rash onset. An unvaccinated, young, female patient with measles confirmed by direct epidemiologic link was hospitalized on day 5 after rash onset. Environmental samples were collected over the 4-day period of hospitalization in a single room. MeV RNA was detectable in air specimens, on surface specimens, and on respirators on days 5-8 after rash onset. This is the first report of environmental surveillance for MeV, and the results suggest that MeV-infected fomites may be present in healthcare settings. C1 Wake Forest Baptist Hlth, Infect Dis, Winston Salem, NC USA. [McNall, Rebecca J.; Lopareva, Elena N.; Rota, Paul A.] Ctr Dis Control & Prevent, Div Viral Dis, Measles Mumps Rubella & Herpesviruses Lab Branch, Atlanta, GA USA. RP Bischoff, WE (reprint author), Wake Forest Univ, Sch Med, Dept Internal Med, Infect Dis Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM wbischof@wakehealth.edu NR 15 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 15 PY 2016 VL 213 IS 4 BP 600 EP 603 DI 10.1093/infdis/jiv465 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DG9XS UT WOS:000372437700016 PM 26386428 ER PT J AU Ly, KN Klevens, RM Jiles, RB AF Ly, Kathleen N. Klevens, R. Monina Jiles, Ruth B. TI Should Hepatitis A Vaccine Coverage be Expanded? Reply SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter ID NUTRITION EXAMINATION SURVEY; UNITED-STATES; NATIONAL-HEALTH; ADULTS C1 [Ly, Kathleen N.; Klevens, R. Monina; Jiles, Ruth B.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Ly, KN (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd,Mail Stop G-37, Atlanta, GA 30329 USA. EM kathleenly@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 15 PY 2016 VL 213 IS 4 BP 686 EP 687 DI 10.1093/infdis/jiv478 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DG9XS UT WOS:000372437700029 PM 26450420 ER PT J AU Cegielski, JP Kurbatova, E van der Walt, M Brand, J Ershova, J Tupasi, T Caoili, JC Dalton, T Contreras, C Yagui, M Bayona, J Kvasnovsky, C Leimane, V Kuksa, L Chen, MP Via, LE Hwang, SH Wolfgang, M Volchenkov, GV Somova, T Smith, SE Akksilp, S Wattanaamornkiet, W Kim, HJ Kim, CK Kazennyy, BY Khorosheva, T Kliiman, K Viiklepp, P Jou, R Huang, ASE Vasilyeva, IA Demikhova, OV AF Cegielski, J. Peter Kurbatova, Ekaterina van der Walt, Martie Brand, Jeannette Ershova, Julia Tupasi, Thelma Caoili, Janice Campos Dalton, Tracy Contreras, Carmen Yagui, Martin Bayona, Jaime Kvasnovsky, Charlotte Leimane, Vaira Kuksa, Liga Chen, Michael P. Via, Laura E. Hwang, Soo Hee Wolfgang, Melanie Volchenkov, Grigory V. Somova, Tatiana Smith, Sarah E. Akksilp, Somsak Wattanaamornkiet, Wanpen Kim, Hee Jin Kim, Chang-Ki Kazennyy, Boris Y. Khorosheva, Tatiana Kliiman, Kai Viiklepp, Piret Jou, Ruwen Huang, Angela Song-En Vasilyeva, Irina A. Demikhova, Olga V. CA Global PETTS Investigators TI Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE multidrug-resistant tuberculosis; extensively drug-resistant tuberculosis; second-line drugs; treatment outcome; acquired drug resistance ID MYCOBACTERIUM-TUBERCULOSIS; AGGRESSIVE REGIMENS; UNITED-STATES AB Background. Resistance to second-line drugs develops during treatment of multidrug-resistant (MDR) tuberculosis, but the impact on treatment outcome has not been determined. Methods. Patients with MDR tuberculosis starting second-line drug treatment were enrolled in a prospective cohort study. Sputum cultures were analyzed at a central reference laboratory. We compared subjects with successful and poor treatment outcomes in terms of (1) initial and acquired resistance to fluoroquinolones and second-line injectable drugs (SLIs) and (2) treatment regimens. Results. Of 1244 patients with MDR tuberculosis, 973 (78.2%) had known outcomes and 232 (18.6%) were lost to follow-up. Among those with known outcomes, treatment succeeded in 85.8% with plain MDR tuberculosis, 69.7% with initial resistance to either a fluoroquinolone or an SLI, 37.5% with acquired resistance to a fluoroquinolone or SLI, 29.3% with initial and 13.0% with acquired extensively drug-resistant tuberculosis (P<.001 for trend). In contrast, among those with known outcomes, treatment success increased stepwise from 41.6% to 92.3% as the number of drugs proven effective increased from <= 1 to >= 5 (P<.001 for trend), while acquired drug resistance decreased from 12% to 16% range, depending on the drug, down to 0%-2% (P<.001 for trend). In multivariable analysis, the adjusted odds of treatment success decreased 0.62-fold (95% confidence interval,.56-.69) for each increment in drug resistance and increased 2.1-fold (1.40-3.18) for each additional effective drug, controlling for differences between programs and patients. Specific treatment, patient, and program variables were also associated with treatment outcome. Conclusions. Increasing drug resistance was associated in a logical stepwise manner with poor treatment outcomes. Acquired resistance was worse than initial resistance to the same drugs. Increasing numbers of effective drugs, specific drugs, and specific program characteristics were associated with better outcomes and less acquired resistance. C1 [Cegielski, J. Peter; Kurbatova, Ekaterina; Ershova, Julia; Dalton, Tracy; Kvasnovsky, Charlotte; Chen, Michael P.; Wolfgang, Melanie] US Ctr Dis Control & Prevent, Atlanta, GA USA. [van der Walt, Martie; Via, Laura E.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [van der Walt, Martie; Brand, Jeannette] MRC, Pretoria, South Africa. [Tupasi, Thelma; Caoili, Janice Campos] Trop Dis Fdn, Manila, Philippines. [Contreras, Carmen; Bayona, Jaime] Socios Salud Sucursal, Lima, Peru. [Yagui, Martin] Natl Inst Hlth, Lima, Peru. [Leimane, Vaira; Kuksa, Liga] Riga East Univ Hosp, Ctr TB & Lung Dis, Riga, Latvia. [Hwang, Soo Hee] Natl Masan Hosp, Chang Won, South Korea. [Kim, Hee Jin; Kim, Chang-Ki] Korean Inst TB, Seoul, South Korea. [Volchenkov, Grigory V.; Somova, Tatiana] Vladimir Oblast TB Dispensary, Moscow, Russia. [Kazennyy, Boris Y.; Khorosheva, Tatiana] Orel Oblast TB Dispensary, Moscow, Russia. [Vasilyeva, Irina A.; Demikhova, Olga V.] Russian Acad Med Sci, Cent TB Res Inst, Moscow, Russia. [Akksilp, Somsak] Minist Hlth, Bangkok, Thailand. [Wattanaamornkiet, Wanpen] Office Dis Prevent & Control Reg 7, Ubon Ratchathani, Thailand. [Kliiman, Kai] Tartu Univ Hosp, Tallinn, Estonia. [Viiklepp, Piret] Natl Inst Hlth Dev, Natl TB Registry, Tallinn, Estonia. [Jou, Ruwen; Huang, Angela Song-En] Taiwan Ctr Dis Control, Taipei, Taiwan. RP Cegielski, JP (reprint author), Ctr Dis Control & Prevent, Global TB Branch, Div Global HIV & TB, Mail Stop E 04,1600 Clifton Rd,NE, Atlanta, GA 30329 USA. EM pcegielski@cdc.gov FU US Agency for International Development; CDC; US National Institute of Allergy and Infectious Diseases Division of Intramural Research FX This work was supported by the US Agency for International Development, the CDC, and, for one of the South Korean sites, by the US National Institute of Allergy and Infectious Diseases Division of Intramural Research. NR 23 TC 7 Z9 7 U1 3 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2016 VL 62 IS 4 BP 418 EP 430 DI 10.1093/cid/civ910 PG 13 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DD9VX UT WOS:000370274900007 PM 26508515 ER PT J AU Petrie, JG Cheng, C Malosh, RE VanWormer, JJ Flannery, B Zimmerman, RK Gaglani, M Jackson, ML King, JP Nowalk, MP Benoit, J Robertson, A Thaker, SN Monto, AS Ohmit, SE AF Petrie, Joshua G. Cheng, Caroline Malosh, Ryan E. VanWormer, Jeffrey J. Flannery, Brendan Zimmerman, Richard K. Gaglani, Manjusha Jackson, Michael L. King, Jennifer P. Nowalk, Mary Patricia Benoit, Joyce Robertson, Anne Thaker, Swathi N. Monto, Arnold S. Ohmit, Suzanne E. TI Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE medically attended acute respiratory illness; medically attended influenza; illness severity; work productivity; vaccine effectiveness ID LABORATORY-CONFIRMED INFLUENZA; TEST-NEGATIVE DESIGN; HEALTH-CARE WORKERS; UNITED-STATES; SEASONAL INFLUENZA; OUTPATIENT; CHILDREN; EFFICACY; VIRUSES; BURDEN AB Background. Influenza causes significant morbidity and mortality, with considerable economic costs, including lost work productivity. Influenza vaccines may reduce the economic burden through primary prevention of influenza and reduction in illness severity. Methods. We examined illness severity and work productivity loss among working adults with medically attended acute respiratory illnesses and compared outcomes for subjects with and without laboratory-confirmed influenza and by influenza vaccination status among subjects with influenza during the 2012-2013 influenza season. Results. Illnesses laboratory-confirmed as influenza (ie, cases) were subjectively assessed as more severe than illnesses not caused by influenza (ie, noncases) based on multiple measures, including current health status at study enrollment (<= 7 days from illness onset) and current activity and sleep quality status relative to usual. Influenza cases reported missing 45% more work hours (20.5 vs 15.0; P<.001) than noncases and subjectively assessed their work productivity as impeded to a greater degree (6.0 vs 5.4; P<.001). Current health status and current activity relative to usual were subjectively assessed as modestly but significantly better for vaccinated cases compared with unvaccinated cases; however, no significant modifications of sleep quality, missed work hours, or work productivity loss were noted for vaccinated subjects. Conclusions. Influenza illnesses were more severe and resulted in more missed work hours and productivity loss than illnesses not confirmed as influenza. Modest reductions in illness severity for vaccinated cases were observed. These findings highlight the burden of influenza illnesses and illustrate the importance of laboratory confirmation of influenza outcomes in evaluations of vaccine effectiveness. C1 [Petrie, Joshua G.; Cheng, Caroline; Malosh, Ryan E.; Monto, Arnold S.; Ohmit, Suzanne E.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [VanWormer, Jeffrey J.; King, Jennifer P.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Flannery, Brendan; Thaker, Swathi N.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Zimmerman, Richard K.; Nowalk, Mary Patricia] Univ Pittsburgh, Sch Hlth Sci, Pittsburgh, PA 15260 USA. [Zimmerman, Richard K.; Nowalk, Mary Patricia] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. [Gaglani, Manjusha; Robertson, Anne] Texas A&M Univ, Coll Med, Scott & White Hlth, Hlth Sci Ctr, Temple, TX 76508 USA. [Jackson, Michael L.; Benoit, Joyce] Grp Hlth Res Inst, Seattle, WA USA. RP Ohmit, SE (reprint author), Univ Michigan, Sch Publ Hlth, 1415 Washington Hts, Ann Arbor, MI 48109 USA. EM sohmit@umich.edu OI Zimmerman, Richard/0000-0001-5941-6092 FU CDC; University of Michigan [U01 IP000474]; Group Health Research Institute [U01 IP000466]; Marshfield Clinic Research Foundation [U01 IP000471]; University of Pittsburgh [U01 IP000467]; Scott and White Healthcare [U01 IP000473]; National Institutes of Health [UL1 RR024153, UL1TR000005] FX This work was supported by the CDC through cooperative agreements with the University of Michigan (grant number U01 IP000474), Group Health Research Institute (grant number U01 IP000466), Marshfield Clinic Research Foundation (grant number U01 IP000471), University of Pittsburgh (grant number U01 IP000467), and Scott and White Healthcare (grant number U01 IP000473). At the University of Pittsburgh, the project was also supported by the National Institutes of Health (grant numbers UL1 RR024153 and UL1TR000005). NR 32 TC 2 Z9 2 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2016 VL 62 IS 4 BP 448 EP 455 DI 10.1093/cid/civ952 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DD9VX UT WOS:000370274900011 PM 26565004 ER PT J AU Ridpath, A Taylor, E Greenstreet, C Martens, M Wicke, H Martin, C AF Ridpath, Alison Taylor, Ethel Greenstreet, Charlene Martens, Margaret Wicke, Heather Martin, Colleen TI Description of calls from private well owners to a national well water hotline, 2013 SO SCIENCE OF THE TOTAL ENVIRONMENT LA English DT Article DE Private well; Well stewardship; National hotline; Well water safety; United States ID DRINKING-WATER; SUPPLIES AB Water Systems Council (WSC) is a national, non-profit organization providing education and resources to private household well owners. Since 2003, WSC has provided wellcare (R), a toll-free telephone hotline to answer questions from the public regarding well stewardship. In order to identify knowledge gaps regarding well stewardship among private well owners, we obtained data from WSC and reviewed calls made during 2013 to wellcare. WSC records data from each wellcare (R) call-including caller information, primary reason for call, main use of well water, and if they were calling about a cistern, private well, shared well, or spring. We searched for calls with key words indicating specific contaminants of interest and reviewed primary reasons for calls. Calls classified as primarily testing-related were further categorized depending on whether the caller asked about how to test well water or how to interpret testing results. During 2013, wellcare (R) received 1100 calls from private well owners who were residents of 48 states. Among these calls, 87 (8%) mentioned radon, 83 (8%) coliforms, 51 (5%) chemicals related to fracking, 34 (3%) arsenic, and 32 (3%) nitrates key words. Only 38% of private well owners reported conducting any well maintenance activities, such as inspecting, cleaning, repairing the well, or testing well water, during the previous 12 months. The primary reason for calls were related to well water testing (n = 403), general information relating to wells (n = 249), contaminants (n = 229), and well water treatment (n = 97). Among calls related to testing, 319 had questions about how to test their well water, and 33 had questions about how to interpret testing results. Calls from private well owners to the wellcare (R) Hotline during 2013 identified key knowledge gaps regarding well stewardship; well owners are generally not testing or maintaining their wells, have questions about well water testing treatment, and concerns about well water contaminants. Published by Elsevier B.V. C1 [Ridpath, Alison; Taylor, Ethel; Martin, Colleen] Ctr Dis Control & Prevent, 4770 Buford Hwy,NE,MS-F-60, Chamblee, GA 30341 USA. [Greenstreet, Charlene; Martens, Margaret; Wicke, Heather] Water Syst Council, 1101 30th St NW, Washington, DC 20007 USA. RP Ridpath, A (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,NE,MS-F-60, Chamblee, GA 30341 USA. EM etf4@cdc.gov FU Centers for Disease Control and Prevention [200-2014M-59262] FX This work was supported by the Centers for Disease Control and Prevention (contract 200-2014M-59262). NR 13 TC 0 Z9 0 U1 3 U2 25 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0048-9697 EI 1879-1026 J9 SCI TOTAL ENVIRON JI Sci. Total Environ. PD FEB 15 PY 2016 VL 544 BP 601 EP 605 DI 10.1016/j.scitotenv.2015.11.141 PG 5 WC Environmental Sciences SC Environmental Sciences & Ecology GA DC8TB UT WOS:000369491500065 PM 26674689 ER PT J AU Smith, AE Lincoln, RA Paulu, C Simones, TL Caldwell, KL Jones, RL Backer, LC AF Smith, Andrew E. Lincoln, Rebecca A. Paulu, Chris Simones, Thomas L. Caldwell, Kathleen L. Jones, Robert L. Backer, Lorraine C. TI Assessing arsenic exposure in households using bottled water or point-of-use treatment systems to mitigate well water contamination SO SCIENCE OF THE TOTAL ENVIRONMENT LA English DT Article DE Arsenic; Well water; Bottled water; Point-of-use; Bathing; Children ID RICE CONSUMPTION; POPULATION; GROUNDWATER; REDUCTION; EXCRETION; BEHAVIOR; URINE AB There is little published literature on the efficacy of strategies to reduce exposure to residential well water arsenic. The objectives of our study were to: 1) determine if water arsenic remained a significant exposure source in households using bottled water or point-of-use treatment systems; and 2) evaluate the major sources and routes of any remaining arsenic exposure. We conducted a cross-sectional study of 167 households in Maine using one of these two strategies to prevent exposure to arsenic. Most households included one adult and at least one child. Untreated well water arsenic concentrations ranged from <10 mu g/L to 640 mu g/L. Urine samples, water samples, daily diet and bathing diaries, and household dietary and water use habit surveys were collected. Generalized estimating equations were used to model the relationship between urinary arsenic and untreated well water arsenic concentration, while accounting for documented consumption of untreated water and dietary sources. If mitigation strategies were fully effective, there should be no relationship between urinary arsenic and well water arsenic. To the contrary, we found that untreated arsenic water concentration remained a significant (p <= 0.001) predictor of urinary arsenic levels. When untreated water arsenic concentrations were <40 mu g/L, untreated water arsenic was no longer a significant predictor of urinary arsenic. Time spent bathing (alone or in combination with water arsenic concentration) was not associated with urinary arsenic. A predictive analysis of the average study participant suggested that when untreated water arsenic ranged from 100 to 500 mu g/L, elimination of any untreated water use would result in an 8%-32% reduction in urinary arsenic for young children, and a 14%-59% reduction for adults. These results demonstrate the importance of complying with a point-of-use or bottled water exposure reduction strategy. However, there remained unexplained, water-related routes of exposure. (C) 2015 Elsevier B.V. All rights reserved. C1 [Smith, Andrew E.; Lincoln, Rebecca A.; Paulu, Chris; Simones, Thomas L.] Maine Ctr Dis Control & Prevent, Maine Dept Hlth & Human Serv, 286 Water St, Augusta, ME 04333 USA. [Paulu, Chris] Univ So Maine, Muskie Sch Publ Serv, POB 9300, Portland, ME 04140 USA. [Caldwell, Kathleen L.; Jones, Robert L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Inorgan & Radiat Analyt Toxicol Branch, 4770 Buford Highway NE,MS F 18, Chamblee, GA 30341 USA. [Backer, Lorraine C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Hlth Studies Branch, 4770 Buford Highway NE,MS F 18, Chamblee, GA 30341 USA. RP Smith, AE (reprint author), Maine Ctr Dis Control & Prevent, Environm & Occupat Hlth Programs, 286 Water St,11 State House Stn, Augusta, ME 04333 USA. EM Andy.E.Smith@maine.gov FU Maine Department of Health and Human Services; CDC FX We would like to acknowledge the integral role of Deborah Moll in the study design and study logistics. We thank Tom Crosby and Cheryl Soucy for laboratory water analyses, Deborah Rice for helpful discussions on dietary data and associated exposure measures, Doug Thompson for assistance with statistical analyses, Erin Guay and Emily Gilbertson for field work, and Raquel Sabogal and Carlos Bell for assistance with the development of study materials and data entry. We also thank Carl Verdon, Mark Fresquez, Dana Henahan, Jeff Jarrett, Jennifer Buzzel and Pam Olive at the CDC for laboratory urine analyses. This work was jointly supported by funding from the Maine Department of Health and Human Services and the CDC. NR 37 TC 2 Z9 2 U1 4 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0048-9697 EI 1879-1026 J9 SCI TOTAL ENVIRON JI Sci. Total Environ. PD FEB 15 PY 2016 VL 544 BP 701 EP 710 DI 10.1016/j.scitotenv.2015.11.136 PG 10 WC Environmental Sciences SC Environmental Sciences & Ecology GA DC8TB UT WOS:000369491500076 PM 26674699 ER PT J AU Zeh, C Inzaule, SC Ondoa, P Nafisa, LG Kasembeli, A Otieno, F Vandenhoudt, H Amornkul, PN Mills, LA Nkengasong, JN AF Zeh, Clement Inzaule, Seth C. Ondoa, Pascale Nafisa, Lillian G. Kasembeli, Alex Otieno, Fredrick Vandenhoudt, Hilde Amornkul, Pauli N. Mills, Lisa A. Nkengasong, John N. TI Molecular Epidemiology and Transmission Dynamics of Recent and Long-Term HIV-1 Infections in Rural Western Kenya SO PLOS ONE LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; DISEASE PROGRESSION; GENETIC DIVERSITY; DRUG-RESISTANCE; GENITAL ULCERS; PREGNANT-WOMEN; NETWORKS; SUBTYPE AB Objective To identify unique characteristics of recent versus established HIV infections and describe sexual transmission networks, we characterized circulating HIV-1 strains from two randomly selected populations of ART-naive participants in rural western Kenya. Methods Recent HIV infections were identified by the HIV-1 subtype B, E and D, immunoglobulin G capture immunoassay (IgG BED-CEIA) and BioRad avidity assays. Genotypic and phylogenetic analyses were performed on the pol gene to identify transmitted drug resistance (TDR) mutations, characterize HIV subtypes and potential transmission clusters. Factors associated with recent infection and clustering were assessed by logistic regression. Results Of the 320 specimens, 40 (12.5%) were concordantly identified by the two assays as recent infections. Factors independently associated with being recently infected were age <= 19 years (P = 0.001) and history of sexually transmitted infections (STIs) in the past six months (P = 0.004). HIV subtype distribution differed in recently versus chronically infected participants, with subtype A observed among 53% recent vs. 68% chronic infections (p = 0.04) and subtype D among 26% recent vs. 12% chronic infections (p = 0.012). Overall, the prevalence of primary drug resistance was 1.16%. Of the 258 sequences, 11.2% were in monophyletic clusters of between 2-4 individuals. In multivariate analysis factors associated with clustering included having recent HIV infection P = 0.043 and being from Gem region P = 0.002. Conclusions Recent HIV-1 infection was more frequent among 13-19 year olds compared with older age groups, underscoring the ongoing risk and susceptibility of younger persons for acquiring HIV infection. Our findings also provide evidence of sexual networks. The association of recent infections with clustering suggests that early infections may be contributing significant proportions of onward transmission highlighting the need for early diagnosis and treatment as prevention for ongoing prevention. Larger studies are needed to better understand the structure of these networks and subsequently implement and evaluate targeted interventions. C1 [Zeh, Clement; Amornkul, Pauli N.; Mills, Lisa A.] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent CDC, Kisumu, Kenya. [Inzaule, Seth C.; Nafisa, Lillian G.; Kasembeli, Alex; Otieno, Fredrick; Mills, Lisa A.] Kenya Med Res Inst KEMRI CDC Res & Publ Hlth Coll, Kisumu Field Res Stn, Kisumu, Kenya. [Inzaule, Seth C.] Univ Amsterdam, Acad Med Ctr, AIGHD, Dept Global Hlth, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. [Vandenhoudt, Hilde] Inst Trop Med, B-2000 Antwerp, Belgium. [Nkengasong, John N.] CDC, Div Global HIV & TB, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Zeh, C (reprint author), US Ctr Dis Control & Prevent, Div HIV AIDS Prevent CDC, Kisumu, Kenya. EM cbz2@cdc.gov FU Kenya Medical Research Institute; U.S. Centers for Disease Control and Prevention (CDC), Division of HIV/AIDS Prevention-Surveillance and Epidemiology [5U19C1000323-04] FX This work was supported by the Kenya Medical Research Institute through a cooperative agreement with the U.S. Centers for Disease Control and Prevention (CDC), Division of HIV/AIDS Prevention-Surveillance and Epidemiology, grant award number-5U19C1000323-04. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 1 Z9 1 U1 2 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 12 PY 2016 VL 11 IS 2 AR e0147436 DI 10.1371/journal.pone.0147436 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DD6SI UT WOS:000370054100007 PM 26871567 ER PT J AU Hadler, JL Yousey-Hindes, K Perez, A Anderson, EJ Bargsten, M Bohm, SR Hill, M Hogan, B Laidler, M Lindegren, ML Lung, KL Mermel, E Miller, L Morin, C Parker, E Zansky, SM Chaves, SS AF Hadler, James L. Yousey-Hindes, Kimberly Perez, Alejandro Anderson, Evan J. Bargsten, Marisa Bohm, Susan R. Hill, Mary Hogan, Brenna Laidler, Matt Lindegren, Mary Lou Lung, Krista L. Mermel, Elizabeth Miller, Lisa Morin, Craig Parker, Erin Zansky, Shelley M. Chaves, Sandra S. TI Influenza-Related Hospitalizations and Poverty Levels - United States, 2010-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID NEW-HAVEN COUNTY; SOCIOECONOMIC-STATUS; HEALTH DISPARITIES; CONNECTICUT; PREVENTION C1 [Hadler, James L.; Yousey-Hindes, Kimberly] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA. [Perez, Alejandro; Chaves, Sandra S.] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Anderson, Evan J.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Anderson, Evan J.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Anderson, Evan J.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Bargsten, Marisa] New Mexico Dept Hlth, Santa Fe, NM 87505 USA. [Bohm, Susan R.] Michigan Dept Hlth & Human Serv, Div Communicable Dis, Highland Pk, MI 48203 USA. [Hill, Mary] Salt Lake Cty Hlth Dept, Salt Lake City, UT USA. [Hogan, Brenna] Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. [Laidler, Matt] Oregon Hlth Author, Oregon Publ Hlth Div, Portland, OR USA. [Lindegren, Mary Lou] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Dept Pediat, Nashville, TN 37212 USA. [Lung, Krista L.] Ohio Dept Hlth, Columbus, OH 43266 USA. [Mermel, Elizabeth] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Miller, Lisa] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Morin, Craig] Virginia Dept Hlth, Henrico, VA USA. [Parker, Erin] Calif Emerging Infect Program, Atlanta, GA USA. [Zansky, Shelley M.] New York State Dept Hlth, New York Emerging Infect Program, Albany, NY 12237 USA. RP Hadler, JL (reprint author), Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA. EM hadler-epi@att.net NR 11 TC 3 Z9 3 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 12 PY 2016 VL 65 IS 5 BP 101 EP 105 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DE2OO UT WOS:000370466800001 PM 26866729 ER PT J AU Kann, L Olsen, EO Kinchen, S Morris, E Wolitski, RJ AF Kann, Laura Olsen, Emily O'Malley Kinchen, Steve Morris, Elana Wolitski, Richard J. TI HIV-Related Risk Behaviors Among Male High School Students Who Had Sexual Contact with Males-17 Large Urban School Districts, United States, 2009-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID MEN; DISPARITIES; YOUTH; BLACK C1 [Kann, Laura; Olsen, Emily O'Malley; Kinchen, Steve] CDC, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Morris, Elana] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Wolitski, Richard J.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Kann, L (reprint author), CDC, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM lkkl@cdc.gov NR 8 TC 2 Z9 2 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 12 PY 2016 VL 65 IS 5 BP 106 EP 109 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DE2OO UT WOS:000370466800002 PM 26867146 ER PT J AU Wilken, JA Ried, C Rickett, P Arno, JN Mendez, Y Harrison, RJ Wohlfeiler, D Bauer, HM Joyce, MP Switzer, WM Heneine, W Shankar, A Mark, KE AF Wilken, Jason A. Ried, Christopher Rickett, Pristeen Arno, Janet N. Mendez, Yesenia Harrison, Robert J. Wohlfeiler, Dan Bauer, Heidi M. Joyce, M. Patricia Switzer, William M. Heneine, Walid Shankar, Anupama Mark, Karen E. TI Occupational HIV Transmission Among Male Adult Film Performers - Multiple States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Wilken, Jason A.; Harrison, Robert J.] Calif Dept Publ Hlth, Occupat Hlth Branch, Richmond, VA 94804 USA. [Wilken, Jason A.] CDC, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Ried, Christopher; Rickett, Pristeen] Orange Cty Hlth Care Agcy, HIV STD Program, Santa Ana, CA USA. [Arno, Janet N.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Mendez, Yesenia] Colorado Dept Publ Hlth & Environm, Grand Junction, CO 81501 USA. [Wohlfeiler, Dan; Bauer, Heidi M.] Calif Dept Publ Hlth, STD Control Branch, Richmond, CA USA. [Joyce, M. Patricia; Switzer, William M.; Heneine, Walid; Shankar, Anupama] CDC, Div HIV & AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Mark, Karen E.] Calif Dept Publ Hlth, Off AIDS, Richmond, CA USA. RP Wilken, JA (reprint author), Calif Dept Publ Hlth, Occupat Hlth Branch, Richmond, VA 94804 USA.; Wilken, JA (reprint author), CDC, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.; Ried, C (reprint author), Orange Cty Hlth Care Agcy, HIV STD Program, Santa Ana, CA USA. EM jwilken@cdc.gov; cried@ochca.com NR 5 TC 2 Z9 2 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 12 PY 2016 VL 65 IS 5 BP 110 EP 114 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DE2OO UT WOS:000370466800003 PM 26866344 ER PT J AU Chevalier, MS Kuehnert, M Basavaraju, SV Bjork, A Pitman, JP AF Chevalier, Michelle S. Kuehnert, Matthew Basavaraju, Sridhar V. Bjork, Adam Pitman, John P. TI Progress Toward Strengthening National Blood Transfusion Services-14 Countries, 2011-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID AFRICA; HIV C1 [Chevalier, Michelle S.; Bjork, Adam; Pitman, John P.] CDC, Ctr Global Hlth, Div Global HIV AIDS & TB, Atlanta, GA 30333 USA. [Kuehnert, Matthew; Basavaraju, Sridhar V.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Chevalier, MS (reprint author), CDC, Ctr Global Hlth, Div Global HIV AIDS & TB, Atlanta, GA 30333 USA. EM MChevalier@cdc.gov OI Pitman, John/0000-0001-5983-7241 FU HMBL budget code FX PEPFAR funding trends (https://data.pepfar.net/). Blood Safety programs are funded through the HMBL budget code. NR 10 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 12 PY 2016 VL 65 IS 5 BP 115 EP 119 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DE2OO UT WOS:000370466800004 PM 26866413 ER PT J AU Oster, AM Brooks, JT Stryker, JE Kachur, RE Mead, P Pesik, NT Petersen, LR AF Oster, Alexandra M. Brooks, John T. Stryker, Jo Ellen Kachur, Rachel E. Mead, Paul Pesik, Nicki T. Petersen, Lyle R. TI Interim Guidelines for Prevention of Sexual Transmission of Zika Virus - United States, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Oster, Alexandra M.; Brooks, John T.; Stryker, Jo Ellen] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Kachur, Rachel E.] CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Mead, Paul; Petersen, Lyle R.] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Pesik, Nicki T.] CDC, Off Director, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Brooks, JT (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM zud4@cdc.gov NR 8 TC 64 Z9 76 U1 5 U2 31 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 12 PY 2016 VL 65 IS 5 BP 120 EP 121 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DE2OO UT WOS:000370466800005 PM 26866485 ER PT J AU Oduyebo, T Petersen, EE Rasmussen, SA Mead, PS Meaney-Delman, D Renquist, CM Ellington, SR Fischer, M Staples, JE Powers, AM Villanueva, J Galang, RR Dieke, A Munoz, JL Honein, MA Jamieson, DJ AF Oduyebo, Titilope Petersen, Emily E. Rasmussen, Sonja A. Mead, Paul S. Meaney-Delman, Dana Renquist, Christina M. Ellington, Sascha R. Fischer, Marc Staples, J. Erin Powers, Ann M. Villanueva, Julie Galang, Romeo R. Dieke, Ada Munoz, Jorge L. Honein, Margaret A. Jamieson, Denise J. TI Update: Interim Guidelines for Health Care Providers Caring for Pregnant Women and Women of Reproductive Age with Possible Zika Virus Exposure - United States, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID INFECTION; ANTIBODY C1 [Oduyebo, Titilope; Galang, Romeo R.; Dieke, Ada] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Oduyebo, Titilope; Petersen, Emily E.; Ellington, Sascha R.; Dieke, Ada; Jamieson, Denise J.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Rasmussen, Sonja A.] CDC, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Mead, Paul S.; Fischer, Marc; Staples, J. Erin; Powers, Ann M.; Villanueva, Julie; Munoz, Jorge L.] CDC, Arboviral Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Meaney-Delman, Dana] CDC, Off Director, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Renquist, Christina M.; Honein, Margaret A.] CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Galang, Romeo R.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Jamieson, DJ (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM eocbirthdef@cdc.gov NR 25 TC 63 Z9 66 U1 0 U2 15 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 12 PY 2016 VL 65 IS 5 BP 122 EP 127 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DE2OO UT WOS:000370466800006 PM 26866840 ER PT J AU Morales, M Nnadi, CD Tangermann, RH Wassilak, SGF AF Morales, Michelle Nnadi, Chimeremma D. Tangermann, Rudolf H. Wassilak, Steven G. F. TI Circulating Vaccine-Derived Poliovirus Outbreaks - Five Countries, 2014-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID WORLDWIDE C1 [Morales, Michelle] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Morales, Michelle; Nnadi, Chimeremma D.; Wassilak, Steven G. F.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. [Tangermann, Rudolf H.] WHO, Polio Eradicat Dept, CH-1211 Geneva, Switzerland. RP Morales, M (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Morales, M (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. EM yxm5@cdc.gov NR 6 TC 6 Z9 6 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 12 PY 2016 VL 65 IS 5 BP 128 EP 129 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DE2OO UT WOS:000370466800007 PM 26866942 ER PT J AU Ren, ZP Wang, DQ Ma, AM Hwang, J Bennett, A Sturrock, HJW Fan, JF Zhang, WJ Yang, D Feng, XY Xia, ZG Zhou, XN Wang, JF AF Ren, Zhoupeng Wang, Duoquan Ma, Aimin Hwang, Jimee Bennett, Adam Sturrock, Hugh J. W. Fan, Junfu Zhang, Wenjie Yang, Dian Feng, Xinyu Xia, Zhigui Zhou, Xiao-Nong Wang, Jinfeng TI Predicting malaria vector distribution under climate change scenarios in China: Challenges for malaria elimination SO SCIENTIFIC REPORTS LA English DT Article ID PLASMODIUM-FALCIPARUM; SPECIES DISTRIBUTIONS; ANOPHELES-ARABIENSIS; NIGHT LIGHTS; TRANSMISSION; TEMPERATURE; MODELS; FUTURE; PROJECTIONS; CULICIDAE AB Projecting the distribution of malaria vectors under climate change is essential for planning integrated vector control activities for sustaining elimination and preventing reintroduction of malaria. In China, however, little knowledge exists on the possible effects of climate change on malaria vectors. Here we assess the potential impact of climate change on four dominant malaria vectors (An. dirus, An. minimus, An. lesteri and An. sinensis) using species distribution models for two future decades: the 2030 s and the 2050 s. Simulation-based estimates suggest that the environmentally suitable area (ESA) for An. dirus and An. minimus would increase by an average of 49% and 16%, respectively, under all three scenarios for the 2030 s, but decrease by 11% and 16%, respectively in the 2050 s. By contrast, an increase of 36% and 11%, respectively, in ESA of An. lesteri and An. sinensis, was estimated under medium stabilizing (RCP4.5) and very heavy (RCP8.5) emission scenarios. in the 2050 s. In total, we predict a substantial net increase in the population exposed to the four dominant malaria vectors in the decades of the 2030 s and 2050 s, considering land use changes and urbanization simultaneously. Strategies to achieve and sustain malaria elimination in China will need to account for these potential changes in vector distributions and receptivity. C1 [Ren, Zhoupeng; Ma, Aimin; Zhang, Wenjie; Yang, Dian; Wang, Jinfeng] Chinese Acad Sci, State Key Lab Resources & Environm Informat Syst, Inst Geog Sci & Nat Resource Res, Beijing 100101, Peoples R China. [Ren, Zhoupeng; Zhang, Wenjie] Univ Chinese Acad Sci, Beijing 100049, Peoples R China. [Ren, Zhoupeng; Wang, Jinfeng] Chinese Ctr Dis Control & Prevent, Key Lab Surveillance & Early Warning Infect Dis, Beijing 102206, Peoples R China. [Wang, Duoquan; Feng, Xinyu; Xia, Zhigui; Zhou, Xiao-Nong] Chinese Ctr Dis Control & Prevent, Natl Inst Parasit Dis, Shanghai, Peoples R China. [Wang, Duoquan; Feng, Xinyu; Xia, Zhigui; Zhou, Xiao-Nong] World Hlth Org Collaborating Ctr Trop Dis, Shanghai, Peoples R China. [Wang, Duoquan; Feng, Xinyu; Xia, Zhigui; Zhou, Xiao-Nong] Natl Ctr Int Res Trop Dis, Shanghai, Peoples R China. [Ma, Aimin] China Univ Min & Technol, Coll Geosci & Surveying Engn, Beijing 100083, Peoples R China. [Hwang, Jimee; Bennett, Adam; Sturrock, Hugh J. W.] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA. [Hwang, Jimee] Ctr Dis Control & Prevent, Presidents Malaria Initiat, Malaria Branch, Atlanta, GA USA. [Fan, Junfu] Shandong Univ Technol, Sch Civil & Architectural Engn, Zibo, Peoples R China. [Wang, Jinfeng] Jiangsu Ctr Collaborat Innovat Geog Informat Reso, Nanjing 210023, Jiangsu, Peoples R China. RP Wang, JF (reprint author), Chinese Acad Sci, State Key Lab Resources & Environm Informat Syst, Inst Geog Sci & Nat Resource Res, Beijing 100101, Peoples R China.; Wang, JF (reprint author), Chinese Ctr Dis Control & Prevent, Key Lab Surveillance & Early Warning Infect Dis, Beijing 102206, Peoples R China.; Wang, DQ (reprint author), Chinese Ctr Dis Control & Prevent, Natl Inst Parasit Dis, Shanghai, Peoples R China.; Wang, DQ (reprint author), World Hlth Org Collaborating Ctr Trop Dis, Shanghai, Peoples R China.; Wang, DQ (reprint author), Natl Ctr Int Res Trop Dis, Shanghai, Peoples R China.; Wang, JF (reprint author), Jiangsu Ctr Collaborat Innovat Geog Informat Reso, Nanjing 210023, Jiangsu, Peoples R China. EM wdq730609@126.com; wangjf@Lreis.ac.cn FU National S & T Major Program [2012CB955503, 2012ZX10004-220, 2012 ZX10004-201]; US President's Malaria Initiative; TDR [HQTDR1409931]; Asia Pacific Malaria Elimination Network fellowship; University of California San Francisco FX We would like to thank all the staff enrolled in this national surveillance program for their excellent cooperation. We also thank the technical advisory group of Anopheles experts for the malaria vector data search and confirmation. This study was supported by the National S & T Major Program (Grant No. 2012CB955503, 2012ZX10004-220, and 2012 ZX10004-201). J.H. receives salary support from the US President's Malaria Initiative. W.D.Q. receives support from TDR (HQTDR1409931) and 2014 Asia Pacific Malaria Elimination Network fellowship and the University of California San Francisco. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the US Centers for Disease Control and Prevention. NR 66 TC 3 Z9 3 U1 9 U2 31 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD FEB 12 PY 2016 VL 6 AR 20604 DI 10.1038/srep20604 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DD4ZI UT WOS:000369931300001 PM 26868185 ER PT J AU Kruger, J O'Halloran, A Rosenthal, AC Babb, SD Fiore, MC AF Kruger, Judy O'Halloran, Alissa Rosenthal, Abby C. Babb, Stephen D. Fiore, Michael C. TI Receipt of evidence-based brief cessation interventions by health professionals and use of cessation assisted treatments among current adult cigarette-only smokers: National Adult Tobacco Survey, 2009-2010 SO BMC PUBLIC HEALTH LA English DT Article DE Smoking cessation; USPHS clinical guideline; Tobacco; Health professionals; Clinicians ID SMOKING-CESSATION; UNITED-STATES; CLINICAL-PRACTICE; PATIENT; SERVICES; SYSTEM; IMPACT; HMOS; 5AS AB Background: Helping tobacco smokers to quit during a medical visit is a clinical and public health priority. Research suggests that most health professionals engage their patients in at least some of the '5 A's' of the brief cessation intervention recommended in the U.S. Public Health Service Clinical Practice Guideline, but information on the extent to which patients act on this intervention is uncertain. We assessed current cigarette-only smokers' self-reported receipt of the 5 A's to determine the odds of using optimal cessation assisted treatments (a combination of counseling and medication). Methods: Data came from the 2009-2010 National Adult Tobacco Survey (NATS), a nationally representative landline and mobile phone survey of adults aged >= 18 years. Among current cigarette-only smokers who visited a health professional in the past 12 months, we assessed patients' self-reported receipt of the 5 A's, use of the combination of counseling and medication for smoking cessation, and use of other cessation treatments. We used logistic regression to examine whether receipt of the 5 A's during a recent clinic visit was associated with use of cessation treatments (counseling, medication, or a combination of counseling and medication) among current cigarette-only smokers. Results: In this large sample (N = 10,801) of current cigarette-only smokers who visited a health professional in the past 12 months, 6.3 % reported use of both counseling and medication for smoking cessation within the past year. Other assisted cessation treatments used to quit were: medication (19.6 %); class or program (3.8 %); one-on-one counseling (3.7 %); and telephone quitline (2.6 %). Current cigarette-only smokers who reported receiving all 5 A's during a recent clinic visit were more likely to use counseling (odds ratio [OR]: 11.2, 95 % confidence interval [CI]: 7.1-17.5), medication (OR: 6.2, 95 % CI: 4.3-9.0), or a combination of counseling and medication (OR: 14.6, 95 % CI: 9.3-23.0), compared to smokers who received one or none of the 5 A's components. Conclusions: Receipt of the '5 A's' intervention was associated with a significant increase in patients' use of recommended counseling and medication for cessation. It is important for health professionals to deliver all 5 A's when conducting brief cessation interventions with patients who smoke. C1 [Kruger, Judy; Babb, Stephen D.] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. [Kruger, Judy] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. [O'Halloran, Alissa] Natl Ctr Chron Dis Prevent, Contractor NGIS Off Smoking & Hlth, Atlanta, GA 30341 USA. [Rosenthal, Abby C.] Hlth Syst Consulting, Atlanta, GA 30341 USA. [Fiore, Michael C.] Univ Wisconsin, Ctr Tobacco Res & Intervent, Sch Med & Publ Hlth, Madison, WI 53711 USA. RP Kruger, J (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. EM Ezk0@cdc.gov NR 34 TC 1 Z9 1 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD FEB 11 PY 2016 VL 16 AR 141 DI 10.1186/s12889-016-2798-2 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD6GP UT WOS:000370023000001 PM 26868930 ER PT J AU Baker, BJ Winston, CA Liu, YC France, AM Cain, KP AF Baker, Brian J. Winston, Carla A. Liu, Yecai France, Anne Marie Cain, Kevin P. TI Abrupt Decline in Tuberculosis among Foreign- Born Persons in the United States SO PLOS ONE LA English DT Article ID US-BOUND IMMIGRANTS; LATENT TUBERCULOSIS; INFECTION; RISK; IMPLEMENTATION; SURVEILLANCE; REFUGEES; TRENDS AB While the number of reported tuberculosis (TB) cases in the United States has declined over the past two decades, TB morbidity among foreign-born persons has remained persistently elevated. A recent unexpected decline in reported TB cases among foreign-born persons beginning in 2007 provided an opportunity to examine contributing factors and inform future TB control strategies. We investigated the relative influence of three factors on the decline: 1) changes in the size of the foreign-born population through immigration and emigration, 2) changes in distribution of country of origin among foreign-born persons, and 3) changes in the TB case rates among foreign-born subpopulations. Using data from the U.S. National Tuberculosis Surveillance System and the American Community Survey, we examined TB case counts, TB case rates, and population estimates, stratified by years since U.S. entry and country of origin. Regression modeling was used to assess statistically significant changes in trend. Among foreign-born recent entrants (<3 years since U.S. entry), we found a 39.5% decline (-1,013 cases) beginning in 2007 (P<0.05 compared to 2000-2007) and ending in 2011 (P<0.05 compared to 2011-2014). Among recent entrants from Mexico, 80.7% of the decline was attributable to a decrease in population, while the declines among recent entrants from the Philippines, India, Vietnam, and China were almost exclusively (95.5%-100%) the result of decreases in TB case rates. Among foreign-born non-recent entrants (>= 3 years since U.S. entry), we found an 8.9% decline (-443 cases) that resulted entirely (100%) from a decrease in the TB case rate. Both recent and non-recent entrants contributed to the decline in TB cases; factors contributing to the decline among recent entrants varied by country of origin. Strategies that impact both recent and non-recent entrants (e.g., investment in overseas TB control) as well as those that focus on non-recent entrants (e.g., expanded targeted testing of high-risk subgroups among non-recent entrants) will be necessary to achieve further declines in TB morbidity among foreign-born persons. C1 [Baker, Brian J.; Winston, Carla A.; France, Anne Marie] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Liu, Yecai] US Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Cain, Kevin P.] US Ctr Dis Control & Prevent, Div TB Eliminat, Kisumu, Kenya. RP Baker, BJ (reprint author), US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. EM bjbaker@cdc.gov NR 41 TC 1 Z9 1 U1 2 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 10 PY 2016 VL 11 IS 2 AR e0147353 DI 10.1371/journal.pone.0147353 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DD6PR UT WOS:000370046600027 PM 26863004 ER PT J AU Kharbanda, EO Vazquez-Benitez, G Lipkind, HS Klein, NP Cheetham, TC Naleway, AL Lee, GM Hambidge, S Jackson, ML Omeri, SB McCarthy, N Nordin, JD AF Kharbanda, Elyse Olshen Vazquez-Benitez, Gabriela Lipkind, Heather S. Klein, Nicola P. Cheetham, T. Craig Naleway, Allison L. Lee, Grace M. Hambidge, Simon Jackson, Michael L. Omeri, Saad B. McCarthy, Natalie Nordin, James D. TI Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013 SO VACCINE LA English DT Article DE Tdap; Vaccine coverage; Vaccine safety; Maternal vaccination ID ACELLULAR PERTUSSIS-VACCINE; INACTIVATED INFLUENZA VACCINE; CARE UTILIZATION INDEX; PREGNANT-WOMEN; TETANUS-DIPHTHERIA; ACUTE MYOPERICARDITIS; OBSTETRIC EVENTS; ADVERSE EVENTS; ADULT TETANUS; EPIDEMIC AB Introduction: Since October 2012, the combined tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine (Tdap) has been recommended in the United States during every pregnancy. Methods: In this observational study from the Vaccine Safety Datalink, we describe receipt of Tdap during pregnancy among insured women with live births across seven health systems. Using a retrospective matched cohort, we evaluated risks for selected medically attended adverse events in pregnant women, occurring within 42 days of vaccination. Using a generalized estimating equation, we calculated adjusted incident rate ratios (AIRR). Results: Our vaccine coverage cohort included 438,487 live births between January 1, 2007 and November 15, 2013. Across the coverage cohort, 14% received Tdap during pregnancy. By 2013, Tdap was administered during pregnancy in 41.7% of live births, primarily in the 3rd trimester. Our vaccine safety cohort included 53,885 vaccinated and 109,253 matched unvaccinated pregnant women. There was no increased risk for a composite outcome of medically attended acute adverse events within 3 days of vaccination. Similarly, across the safety cohort, over a 42 day window, incident neurologic events, thrombotic events, and new onset proteinuria did not differ by maternal receipt of Tdap. Among women receiving Tdap at 20 weeks gestation or later, as compared to their matched controls, there was no increased risk for gestational diabetes or cardiac events while venous thromboembolic events and thrombocytopenia were diagnosed within 42 days of vaccination at slightly decreased rates. Conclusion: Tdap coverage during pregnancy increased from 2007 through 2013, but was still below 50%. No acute maternal safety signals were detected in this large cohort. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Kharbanda, Elyse Olshen; Vazquez-Benitez, Gabriela; Nordin, James D.] HealthPartners Inst Educ & Res, Minneapolis, MN USA. [Lipkind, Heather S.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA. [Klein, Nicola P.] Kaiser Permanente No Calif, Oakland, CA USA. [Cheetham, T. Craig] Kaiser Permanente So Calif, Pasadena, CA 91101 USA. [Naleway, Allison L.] Kaiser Permanente Northwest, Portland, OR USA. [Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Lee, Grace M.] Harvard Univ, Sch Med, Boston, MA USA. [Hambidge, Simon] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Hambidge, Simon] Denver Hlth, Dept Ambulatory Care Serv, Denver, CO USA. [Jackson, Michael L.] Grp Hlth Cooperat Puget Sound, Seattle, WA USA. [Omeri, Saad B.] Kaiser Permanente Georgia, Atlanta, GA USA. [McCarthy, Natalie] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Kharbanda, EO (reprint author), HealthPartners Inst Educ & Res, Minneapolis, MN USA. EM Elyse.o.kharbanda@healthpartners.com FU Centers for Disease Control and Prevention [200-2012-53526] FX This study was funded by the Centers for Disease Control and Prevention, Contract 200-2012-53526. Findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 41 TC 11 Z9 11 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD FEB 10 PY 2016 VL 34 IS 7 BP 968 EP 973 DI 10.1016/j.vaccine.2015.12.046 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA DD7EW UT WOS:000370087500013 PM 26765288 ER PT J AU Thompson, MG Naleway, A Fry, AM Ball, S Spencer, SM Reynolds, S Bozeman, S Levine, M Katz, JM Gaglani, M AF Thompson, Mark G. Naleway, Allison Fry, Alicia M. Ball, Sarah Spencer, Sarah M. Reynolds, Sue Bozeman, Sam Levine, Min Katz, Jacqueline M. Gaglani, Manjusha TI Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11 SO VACCINE LA English DT Article DE influenza vaccination; hemagglutination inhibition antibody; healthcare personnel; immunogenicity ID ACUTE RESPIRATORY ILLNESS; IMMUNE-RESPONSE; SEASONAL INFLUENZA; UNITED-STATES; PROTECTION; IMMUNOGENICITY; POPULATION; KINETICS; EFFICACY; VACCINES AB Background: Recently, lower estimates of influenza vaccine effectiveness (VE) against A(H3N2) virus illness among those vaccinated during the previous season or multiple seasons have been reported; however, it is unclear whether these effects are due to differences in immunogenicity. Methods: We performed hemagglutination inhibition antibody (HI) assays on serum collected at preseason, similar to 30 days post-vaccination, and postseason from a prospective cohort of healthcare personnel (HCP). Eligible participants had medical and vaccination records for at least four years (since July, 2006), including 578 HCP who received 2010-11 trivalent inactivated influenza vaccine [IIV3, containing A/Perth/16/2009-like A(H3N2)] and 209 HCP who declined vaccination. Estimates of the percentage with high titers (>= 40 and >100) and geometric mean fold change ratios (GMRs) to A/Perth/16/2009-like virus by number of prior vaccinations were adjusted for age, sex, race, education, household size, hospital care responsibilities, and study site. Results: Post-vaccination GMRs were inversely associated with the number of prior vaccinations, increasing from 2.3 among those with 4 prior vaccinations to 6.2 among HCP with zero prior vaccinations (F[4,567] = 9.97, p < .0005). Thirty-two percent of HCP with 1 prior vaccination achieved titers >100 compared to only 11% of HCP with 4 prior vaccinations (adjusted odds ratio = 6.8, 95% CI = 3.1 - 15.3). Conclusion: Our findings point to an exposure-response association between repeated IIV3 vaccination and HI for A(H3N2) and are consistent with recent VE observations. Ultimately, better vaccines and vaccine strategies may be needed in order to optimize immunogenicity and VE for HCP and other repeated vaccinees. Published by Elsevier Ltd. C1 [Thompson, Mark G.; Fry, Alicia M.; Spencer, Sarah M.; Reynolds, Sue; Levine, Min; Katz, Jacqueline M.] CDC, Epidemiol & Prevent Branch, Influenza Div, NCIRD, Atlanta, GA 30333 USA. [Naleway, Allison; Bozeman, Sam] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR 97227 USA. [Ball, Sarah] Abt Associates Inc, Cambridge, MA 02138 USA. [Gaglani, Manjusha] Texas A&M HSC COM, Baylor Scott & White Hlth, Div Pediat Infect Dis, Temple, TX 76508 USA. RP Thompson, MG (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA. EM isq8@cdc.gov FU CDC [200-2010-F-33396]; US Department of Energy FX This work was supported by the CDC (contract 200-2010-F-33396 to Abt Associates Inc). This research was supported in part by an appointment to the Research Participation Program at the CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC. NR 37 TC 7 Z9 7 U1 1 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD FEB 10 PY 2016 VL 34 IS 7 BP 981 EP 988 DI 10.1016/j.vaccine.2015.10.119 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA DD7EW UT WOS:000370087500015 PM 26813801 ER PT J AU Shuford, K Were, F Awino, N Samuels, A Ouma, P Kariuki, S Desai, M Allen, DR AF Shuford, Kathryn Were, Florence Awino, Norbert Samuels, Aaron Ouma, Peter Kariuki, Simon Desai, Meghna Allen, Denise Roth TI Community perceptions of mass screening and treatment for malaria in Siaya County, western Kenya SO MALARIA JOURNAL LA English DT Article DE Mass screen and treat; Malaria elimination; Acceptability; Adherence; Perceptions; Community sensitization; Qualitative methods ID INTERMITTENT PREVENTIVE TREATMENT; RAPID DIAGNOSTIC-TESTS; SUB-SAHARAN AFRICA; INFANTS IPTI; HEALTH WORKERS; EXPANDED PROGRAM; INFORMED-CONSENT; SCHOOL-CHILDREN; ACCEPTABILITY; EXPERIENCES AB Background: Intermittent mass screening and treatment (iMSaT) is currently being evaluated as a possible additional tool for malaria control and prevention in western Kenya. The literature identifying success and/or barriers to drug trial compliance and acceptability on malaria treatment and control interventions is considerable, especially as it relates to specific target groups, such as school-aged children and pregnant women, but there is a lack of such studies for mass screening and treatment and mass drug administration in the general population. Methods: A qualitative study was conducted to explore community perceptions of the iMSaT intervention, and specifically of testing and treatment in the absence of symptoms, before and after implementation in order to identify aspects of iMSaT that should be improved in future rounds. Two rounds of qualitative data collection were completed in six randomly selected study communities: a total of 36 focus group discussions (FGDs) with men, women, and opinion leaders, and 12 individual or small group interviews with community health workers. All interviews were conducted in the local dialect Dholuo, digitally recorded, and transcribed into English. English transcripts were imported into the qualitative software programme NVivo8 for content analysis. Results: There were mixed opinions of the intervention. In the pre-implementation round, respondents were generally positive and willing to participate in the upcoming study. However, there were concerns about testing in the absence of symptoms including fear of covert HIV testing and issues around blood sampling. There were fewer concerns about treatment, mostly because of the simpler dosing regimen of the study drug (dihydroartemisinin-piperaquine) compared to the current first-line treatment (artemether-lumefantrine). After the first implementation round, there was a clear shift in perceptions with less common concerns overall, although some of the same issues around testing and general misconceptions about research remained. Conclusions: Although iMSaT was generally accepted throughout the community, proper sensitization activities-and arguably, a more long-term approach to community engagement-are necessary for dispelling fears, clarifying misconceptions, and educating communities on the consequences of asymptomatic malaria. C1 [Shuford, Kathryn; Samuels, Aaron; Desai, Meghna; Allen, Denise Roth] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Were, Florence; Awino, Norbert; Ouma, Peter; Kariuki, Simon] Kenya Med Res Inst KEMRI, Kisian, Kenya. RP Shuford, K (reprint author), Ctr Dis Control & Prevent CDC, Atlanta, GA USA. EM kvshuford@gmail.com FU President's Malaria Initiative; U.S. Agency for International Development; CDC FX The authors would like to thank the research and field team without whom this study would have not been possible. We are also grateful for all the community members who participated in this study and took the time to answer our questions and provide useful insight. This publication was made possible through support provided by the President's Malaria Initiative, U.S. Agency for International Development, under the terms of an Interagency Agreement with CDC. The opinions expressed herein are those of the author(s) and do not necessarily reflect the views of the U.S. Agency for International Development or of the Centers for Disease Control and Prevention. This paper is published with the permission of KEMRI Director. NR 30 TC 1 Z9 1 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD FEB 6 PY 2016 VL 15 AR 71 DI 10.1186/s12936-016-1123-y PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DC6VT UT WOS:000369358400005 PM 26852227 ER PT J AU Williams, WW Lu, PJ O'Halloran, A Kim, DK Grohskopf, LA Pilishvili, T Skoff, TH Nelson, NP Harpaz, R Markowitz, LE Rodriguez-Lainz, A Bridges, CB AF Williams, Walter W. Lu, Peng-Jun O'Halloran, Alissa Kim, David K. Grohskopf, Lisa A. Pilishvili, Tamara Skoff, Tami H. Nelson, Noele P. Harpaz, Rafael Markowitz, Lauri E. Rodriguez-Lainz, Alfonso Bridges, Carolyn B. TI Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID HEALTH-CARE PERSONNEL; HUMAN-PAPILLOMAVIRUS VACCINE; NUTRITION EXAMINATION SURVEY; IMMUNIZATION PRACTICES ACIP; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; ESTIMATED INFLUENZA ILLNESSES; AGED 13-17 YEARS; ADVISORY-COMMITTEE; NATIONAL-HEALTH; HERPES-ZOSTER AB Problem/Condition: Overall, the prevalence of illness attributable to vaccine-preventable diseases is greater among adults than among children. Adults are recommended to receive vaccinations based on their age, underlying medical conditions, lifestyle, prior vaccinations, and other considerations. Updated vaccination recommendations from CDC are published annually in the U.S. Adult Immunization Schedule. Despite longstanding recommendations for use of many vaccines, vaccination coverage among U.S. adults is low. Reporting Period: August 2013 June 2014 (for influenza vaccination) and January December 2014 (for pneumococcal, tetanus and diphtheria [Td] and tetanus and diphtheria with acellular pertussis [Tdap], hepatitis A, hepatitis B, herpes zoster, and human papillomavirus [HPV] vaccination). Description of System: The National Health Interview Survey (NHIS) is a continuous, cross-sectional national household survey of the noninstitutionalized U.S. civilian population. In-person interviews are conducted throughout the year in a probability sample of households, and NHIS data are compiled and released annually. The survey objective is to monitor the health of the U.S. population and provide estimates of health indicators, health care use and access, and health-related behaviors. Results: Compared with data from the 2013 NHIS, increases in vaccination coverage occurred for Tdap vaccine among adults aged >= 19 years (a 2.9 percentage point increase to 20.1%) and herpes zoster vaccine among adults aged >= 60 years (a 3.6 percentage point increase to 27.9%). Aside from these modest improvements, vaccination coverage among adults in 2014 was similar to estimates from 2013 (for influenza coverage, similar to the 2012-13 season). Influenza vaccination coverage among adults aged >= 19 years was 43.2%. Pneumococcal vaccination coverage among high-risk persons aged 19-64 years was 20.3% and among adults aged >= 65 years was 61.3%. Td vaccination coverage among adults >= 19 aged years was 62.2%. Hepatitis A vaccination coverage among adults aged >= 19 years was 9.0%. Hepatitis B vaccination coverage among adults >= 19 aged years was 24.5%. HPV vaccination coverage among adults aged 19-26 years was 40.2% for females and 8.2% for males. Racial/ethnic differences in coverage persisted for all seven vaccines, with higher coverage generally for whites compared with most other groups. Adults without health insurance were significantly less likely than those with health insurance to report receipt of influenza vaccine (aged >= 19 years), pneumococcal vaccine (aged 19-64 years with high-risk conditions and aged >= 65 years), Td vaccine (aged >= 19 years), Tdap vaccine (aged >= 19 years and 19-64 years), hepatitis A vaccine (aged >= 19 years overall and among travelers), hepatitis B vaccine (aged >= 19 years, 19-49 years, and 19-59 years with diabetes), herpes zoster vaccine (aged >= 60 years and 60-64 years), and HPV vaccine (females aged 19-26 years and males aged 19-26 years). Adults who reported having a usual place for health care generally were more likely to receive recommended vaccinations than those who did not have a usual place for health care, regardless of whether they had health insurance. Vaccination coverage was significantly higher among those reporting one or more physician contacts in the past year compared with those who had not visited a physician in the past year, regardless of whether they had health insurance. Even among adults who had health insurance and 10 physician contacts within the past year, 23.8%-88.8% reported not having received vaccinations that were recommended either for all persons or for those with some specific indication. Overall, vaccination coverage among U.S.-born respondents was significantly higher than that of foreign-born respondents with few exceptions (influenza vaccination [adults aged 19-49 years], hepatitis A vaccination [adults aged 19 years], hepatitis B vaccination [adults with diabetes aged >= 60 years], and HPV vaccination [males aged 19-26 years]). Interpretation: Overall, increases in adult vaccination coverage are needed. Although modest gains occurred in Tdap vaccination coverage among adults aged >= 19 years and herpes zoster vaccination coverage among adults aged >= 60 years, coverage for other vaccines and risk groups did not improve, and racial/ethnic disparities persisted for routinely recommended adult vaccines. Coverage for all vaccines for adults remained low, and missed opportunities to vaccinate adults continued. Although having health insurance coverage and a usual place for health care are associated with higher vaccination coverage, these factors alone do not assure optimal adult vaccination coverage. Public Health Actions: Assessing associations with vaccination is important for understanding factors that contribute to low coverage rates and to disparities in vaccination, and for implementing strategies to improve vaccination coverage. Practices that have been demonstrated to improve vaccination coverage should be used. These practices include assessment of patients' vaccination indications by health care providers and routine recommendation and offer of needed vaccines to adults, implementation of reminder-recall systems, use of standing-order programs for vaccination, and assessment of practice-level vaccination rates with feedback to staff members. For vaccination to be improved among those least likely to be up-to-date on recommended adult vaccines, efforts also are needed to identify adults who do not have a regular provider or insurance and who report fewer health care visits. C1 [Williams, Walter W.; Lu, Peng-Jun; O'Halloran, Alissa; Kim, David K.; Bridges, Carolyn B.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Grohskopf, Lisa A.] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Pilishvili, Tamara; Skoff, Tami H.] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Nelson, Noele P.] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Harpaz, Rafael] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Markowitz, Lauri E.] CDC, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Rodriguez-Lainz, Alfonso] CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Williams, WW (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM www1@cdc.gov NR 91 TC 24 Z9 24 U1 3 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD FEB 5 PY 2016 VL 65 IS 1 BP 1 EP 36 PG 36 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DL0PI UT WOS:000375334600001 PM 26844596 ER PT J AU Dasgupta, S Oster, AM Li, JM Hall, HI AF Dasgupta, Sharoda Oster, Alexandra M. Li, Jianmin Hall, H. Irene TI Disparities in Consistent Retention in HIV Care-11 States and the District of Columbia, 2011-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Dasgupta, Sharoda; Oster, Alexandra M.; Li, Jianmin; Hall, H. Irene] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Dasgupta, Sharoda] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. RP Dasgupta, S (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.; Dasgupta, S (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM sdasgupta@cdc.gov NR 10 TC 4 Z9 4 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 5 PY 2016 VL 65 IS 4 BP 77 EP 82 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4TT UT WOS:000371344500001 PM 26844978 ER PT J AU Stein, R Pierce, T Hollis, N Smith, J AF Stein, Renee Pierce, Taran Hollis, Natasha Smith, Jennifer TI HIV Testing and Service Delivery Among Black Females-61 Health Department Jurisdictions, United States, 2012-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID TRANSMISSION; VIRUS C1 [Stein, Renee; Pierce, Taran; Hollis, Natasha; Smith, Jennifer] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Stein, R (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM rstein1@cdc.gov FU CDC FX CDC-funded partners include health departments in the 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and eight directly funded city/county health departments (Baltimore, Maryland; Chicago, Illinois; Fulton County, Georgia; Houston, Texas; Los Angeles County, California; New York City, New York; Philadelphia, Pennsylvania; and San Francisco, California) and 151 community-based organizations. Community-based organizations report their National HIV Prevention Program Monitoring and Evaluation HIV testing data to their jurisdiction's health department who then submit them to CDC. NR 8 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 5 PY 2016 VL 65 IS 4 BP 83 EP 85 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4TT UT WOS:000371344500002 PM 26845101 ER PT J AU Robinson, CL AF Robinson, Candice L. CA ACIP ACIP Child Adolescent Immunization TI Advisory Committee on Immunization Practices Recommended Immunization Schedules for Persons Aged 0 Through 18 Years - United States, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Robinson, Candice L.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [ACIP; ACIP Child Adolescent Immunization] ACIP Child Adolescent Immunizat Work Grp, ACIP, Atlanta, GA USA. RP Robinson, CL (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM CRobinson4@cdc.gov NR 0 TC 7 Z9 7 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 5 PY 2016 VL 65 IS 4 BP 86 EP 87 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4TT UT WOS:000371344500003 PM 26845283 ER PT J AU Kim, DK Bridges, CB Harriman, KH AF Kim, David K. Bridges, Carolyn B. Harriman, Kathleen H. CA ACIP ACIP Adult Immunization Work Grp TI Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID B MENINGOCOCCAL VACCINES; PRACTICES ACIP C1 [Kim, David K.; Bridges, Carolyn B.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Harriman, Kathleen H.] California Dept Publ Hlth, San Jose, CA USA. [ACIP; ACIP Adult Immunization Work Grp] Adult Immunizat Work Grp, Advisory Committee Immunizat Practices, San Jose, CA USA. RP Kim, DK (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM dkim@cdc.gov NR 8 TC 5 Z9 5 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 5 PY 2016 VL 65 IS 4 BP 88 EP 90 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4TT UT WOS:000371344500004 PM 26845417 ER PT J AU Green, PP McKnight-Eily, LR Tan, CH Mejia, R Denny, CH AF Green, Patricia P. McKnight-Eily, Lela R. Tan, Cheryl H. Mejia, Roberto Denny, Clark H. TI Vital Signs: Alcohol-Exposed Pregnancies - United States, 2011-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SERVICES TASK-FORCE; PRIMARY-CARE; SPECTRUM DISORDERS; BRIEF INTERVENTION; CHILDBEARING AGE; WOMEN; TRIAL; METAANALYSIS; MISUSE AB Background: Alcohol is a teratogen.* Prenatal alcohol exposure is associated with a range of adverse reproductive outcomes and can cause fetal alcohol spectrum disorders (FASDs) characterized by lifelong physical, behavioral, and intellectual disabilities. FASDs are completely preventable if a woman does not drink alcohol while pregnant. Methods: CDC analyzed data from the 2011-2013 National Survey of Family Growth to generate U.S. prevalence estimates of risk for an alcohol-exposed pregnancy for 4,303 nonpregnant, nonsterile women aged 15-44 years, by selected demographic and behavioral factors. A woman was considered at risk for an alcohol-exposed pregnancy during the past month if she had sex with a male, drank any alcohol, and did not (and her partner did not with her) use contraception in the past month; was not sterile; and had a partner (or partners) not known to be sterile. Results: The weighted prevalence of alcohol-exposed pregnancy risk among U.S. women aged 15-44 years was 7.3%. During a 1-month period, approximately 3.3 million women in the United States were at risk for an alcohol-exposed pregnancy. Conclusions and Implications for Public Health Practice: Alcohol use in pregnancy is associated with low birthweight, preterm birth, birth defects, and developmental disabilities. Women of reproductive age should be informed of the risks of alcohol use during pregnancy, and contraception should be recommended, as appropriate, for women who do not want to become pregnant. Women wanting a pregnancy should be advised to stop drinking at the same time contraception is discontinued. Health care providers should advise women not to drink at all if they are pregnant or there is any chance they might be pregnant. Alcohol misuse screening and behavioral counseling (also known as alcohol screening and brief intervention) is recommended for all adults in primary care, including reproductive-aged and pregnant women, as an evidenced-based approach to reducing alcohol consumption among persons who consume alcohol in excess of the recommended guidelines. C1 [Green, Patricia P.; McKnight-Eily, Lela R.; Tan, Cheryl H.; Mejia, Roberto; Denny, Clark H.] CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Green, PP (reprint author), CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM PAP5@cdc.gov NR 27 TC 6 Z9 6 U1 4 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 5 PY 2016 VL 65 IS 4 BP 91 EP 97 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4TT UT WOS:000371344500005 PM 26845520 ER PT J AU Dave, PV Shah, AN Nimavat, PB Modi, BB Pujara, KR Patel, P Mehariya, K Rade, KV Shekar, S Sachdeva, KS Oeltmann, JE Kumar, AMV AF Dave, Paresh Vamanrao Shah, Amar Niranjan Nimavat, Pankaj B. Modi, Bhavesh B. Pujara, Kirit R. Patel, Pradip Mehariya, Keshabhai Rade, Kiran Vaman Shekar, Soma Sachdeva, Kuldeep S. Oeltmann, John E. Kumar, Ajay M. V. TI Direct Observation of Treatment Provided by a Family Member as Compared to Non-Family Member among Children with New Tuberculosis: A Pragmatic, Non-Inferiority, Cluster-Randomized Trial in Gujarat, India SO PLOS ONE LA English DT Article ID DIRECTLY OBSERVED THERAPY; COMMUNITY; METAANALYSIS; STRATEGIES; ADHERENCE; DOTS AB Background The World Health Organization recommends direct observation of treatment (DOT) to support patients with tuberculosis (TB) and to ensure treatment completion. As per national programme guidelines in India, a DOT provider can be anyone who is acceptable and accessible to the patient and accountable to the health system, except a family member. This poses challenges among children with TB who may be more comfortable receiving medicines from their parents or family members than from unfamiliar DOT providers. We conducted a non-inferiority trial to assess the effect of family DOT on treatment success rates among children with newly diagnosed TB registered for treatment during June-September 2012. Methods We randomly assigned all districts (n = 30) in Gujarat to the intervention (n = 15) or usual-practice group (n = 15). Adult family members in the intervention districts were given the choice to become their child's DOT provider. DOT was provided by a non-family member in the usual-practice districts. Using routinely collected clinic-based TB treatment cards, we compared treatment success rates (cured and treatment completed) between the two groups and the non-inferiority limit was kept at 5%. Results Of 624 children with newly diagnosed TB, 359 (58%) were from intervention districts and 265 (42%) were from usual-practice districts. The two groups were similar with respect to baseline characteristics including age, sex, type of TB, and initial body weight. The treatment success rates were 344 (95.8%) and 247 (93.2%) (p = 0.11) among the intervention and usual-practice groups respectively. Conclusion DOT provided by a family member is not inferior to DOT provided by a non-family member among new TB cases in children and can attain international targets for treatment success. C1 [Dave, Paresh Vamanrao; Nimavat, Pankaj B.; Modi, Bhavesh B.; Pujara, Kirit R.; Patel, Pradip; Mehariya, Keshabhai] Govt Gujarat, Dept Hlth & Family Welf, Gandhinagar, Gujarat, India. [Shah, Amar Niranjan; Rade, Kiran Vaman] WHO Country Off India, New Delhi, India. [Shekar, Soma] Govt India, Natl TB Inst, Bangalore, Karnataka, India. [Sachdeva, Kuldeep S.] Govt India, Minist Hlth & Family Welf, Cent TB Div, New Delhi, India. [Oeltmann, John E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kumar, Ajay M. V.] South East Asia Reg Off, Int Union TB & Lung Dis, New Delhi, India. RP Shah, AN (reprint author), WHO Country Off India, New Delhi, India. EM dr.amar.mph@gmail.com FU Government Revised National Tuberculosis Control Program, Gujarat, India FX Study cost regarding data collection, supervision & monitoring was borne by Government Revised National Tuberculosis Control Program, Gujarat, India. The study was conducted as a part of the 'TB Operations Research Training Project' aimed to build operational research capacity within the Government of India's RNTCP. This training project was conceived and implemented jointly by Central TB Division (Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India), The National TB Institute (Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, Bangalore, India), World Health Organization (India Country Office), The International Union Against Tuberculosis and Lung Diseases (The Union, South-East Asia Regional Office, New Delhi, India) and U.S. Centers for Disease Control and Prevention (Division of TB Elimination, Atlanta, USA). The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. NR 31 TC 0 Z9 0 U1 2 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 5 PY 2016 VL 11 IS 2 AR e0148488 DI 10.1371/journal.pone.0148488 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DC9PR UT WOS:000369554000106 PM 26849442 ER PT J AU Leung, NHL Zhou, J Chu, DKW Yu, H Lindsley, WG Beezhold, DH Yen, HL Li, YG Seto, WH Peiris, JSM Cowling, BJ AF Leung, Nancy H. L. Zhou, Jie Chu, Daniel K. W. Yu, Han Lindsley, William G. Beezhold, Donald H. Yen, Hui-Ling Li, Yuguo Seto, Wing-Hong Peiris, Joseph S. M. Cowling, Benjamin J. TI Quantification of Influenza Virus RNA in Aerosols in Patient Rooms SO PLOS ONE LA English DT Article ID TRANSMISSION; SEASONALITY; HUMIDITY AB Background The potential for human influenza viruses to spread through fine particle aerosols remains controversial. The objective of our study was to determine whether influenza viruses could be detected in fine particles in hospital rooms. Methods and Findings We sampled the air in 2-bed patient isolation rooms for four hours, placing cyclone samplers at heights of 1.5m and 1.0m. We collected ten air samples each in the presence of at least one patient with confirmed influenza A virus infection, and tested the samples by reverse transcription polymerase chain reaction. We recovered influenza A virus RNA from 5/10 collections (50%); 4/5 were from particles> 4 mu m, 1/5 from 1-4 mu m, and none in particles< 1 mu m. Conclusions Detection of influenza virus RNA in aerosols at low concentrations in patient rooms suggests that healthcare workers and visitors might have frequent exposure to airborne influenza virus in proximity to infected patients. A limitation of our study was the small sample size. Further studies should be done to quantify the concentration of viable influenza virus in healthcare settings, and factors affecting the detection of influenza viruses in fine particles in the air. C1 [Leung, Nancy H. L.; Yen, Hui-Ling; Seto, Wing-Hong; Peiris, Joseph S. M.; Cowling, Benjamin J.] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, WHO Collaborating Ctr Infect Dis Epidemiol & Cont, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China. [Zhou, Jie; Chu, Daniel K. W.; Yen, Hui-Ling; Peiris, Joseph S. M.] Univ Hong Kong, Li Ka Shing Fac Med, Influenza Res Ctr, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China. [Yu, Han; Li, Yuguo] Univ Hong Kong, Dept Mech Engn, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China. [Lindsley, William G.; Beezhold, Donald H.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. RP Cowling, BJ (reprint author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, WHO Collaborating Ctr Infect Dis Epidemiol & Cont, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China. EM bcowling@hku.hk RI Li, Yuguo/A-9469-2010; Yen, Hui-Ling/C-4501-2009; OI Li, Yuguo/0000-0002-2281-4529; Yen, Hui-Ling/0000-0003-2493-3609; Leung, Nancy Hiu Lan/0000-0001-7314-840X FU Research Grants Council of the Hong Kong Special Administrative Region, China [T11-705/14N]; Harvard Center for Communicable Disease Dynamics from the National Institute of General Medical Sciences [U54 GM088558]; Health and Medical Research Fund, Food and Health Bureau, Government of the Hong Kong Special Administrative Region FX This work was supported by the Theme-based Research Scheme from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. T11-705/14N), the Harvard Center for Communicable Disease Dynamics from the National Institute of General Medical Sciences (grant no. U54 GM088558), and a commissioned grant from the Health and Medical Research Fund, Food and Health Bureau, Government of the Hong Kong Special Administrative Region. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 15 TC 1 Z9 1 U1 7 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 5 PY 2016 VL 11 IS 2 AR e0148669 DI 10.1371/journal.pone.0148669 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DC9PR UT WOS:000369554000151 PM 26849130 ER PT J AU Deming, R Manrique-Saide, P Barreiro, AM Cardena, EUK Che-Mendoza, A Jones, B Liebman, K Vizcaino, L Vazquez-Prokopec, G Lenhart, A AF Deming, Regan Manrique-Saide, Pablo Medina Barreiro, Anuar Koyoc Cardena, Edgar Ulises Che-Mendoza, Azael Jones, Bryant Liebman, Kelly Vizcaino, Lucrecia Vazquez-Prokopec, Gonzalo Lenhart, Audrey TI Spatial variation of insecticide resistance in the dengue vector Aedes aegypti presents unique vector control challenges SO PARASITES & VECTORS LA English DT Article DE Aedes aegypti; Dengue; Insecticide resistance; kdr ID SODIUM-CHANNEL GENE; PRODUCTIVE BREEDING-SITES; TREATED HOUSE SCREENS; PYRETHROID RESISTANCE; DIPTERA-CULICIDAE; HEMORRHAGIC-FEVER; HEALTH PROBLEM; KDR MUTATIONS; YUCATAN STATE; MEXICO AB Background: Dengue is a major public health problem in Mexico, where the use of chemical insecticides to control the principal dengue vector, Aedes aegypti, is widespread. Resistance to insecticides has been reported in multiple sites, and the frequency of kdr mutations associated with pyrethroid resistance has increased rapidly in recent years. In the present study, we characterized patterns of insecticide resistance in Ae. aegypti populations in five small towns surrounding the city of Merida, Mexico. Methods: A cross-sectional, entomological survey was performed between June and August 2013 in 250 houses in each of the five towns. Indoor resting adult mosquitoes were collected in all houses and four ovitraps were placed in each study block. CDC bottle bioassays were conducted using F-0-F-2 individuals reared from the ovitraps and kdr allele (Ile1016 and Cys1534) frequencies were determined. Results: High, but varying, levels of resistance to chorpyrifos-ethyl was detected in all study towns, complete susceptibility to bendiocarb in all except one town, and variations in resistance to deltamethrin between towns, ranging from 63-88 % mortality. Significant associations were detected between deltamethrin resistance and the presence of both kdr alleles. Phenotypic resistance was highly predictive of the presence of both alleles, however, not all mosquitoes containing a mutant allele were phenotypically resistant. An analysis of genotypic differentiation (exact G test) between the five towns based on the adult female Ae. aegypti collected from inside houses showed highly significant differences (p < 0.0001) between genotypes for both loci. When this was further analyzed to look for fine scale differences at the block level within towns, genotypic differentiation was significant for both loci in San Lorenzo (Ile1016, p = 0.018 and Cys1534, p = 0.007) and for Ile1016 in Acanceh (p = 0.013) and Conkal (p = 0.031). Conclusions: The results from this study suggest that 3 years after switching chemical groups, deltamethrin resistance and a high frequency of kdr alleles persisted in Ae. aegypti populations. The spatial variation that was detected in both resistance phenotypes and genotypes has practical implications, both for vector control operations as well as insecticide resistance management strategies. C1 [Deming, Regan; Jones, Bryant; Vazquez-Prokopec, Gonzalo] Emory Univ, Dept Environm Sci, Atlanta, GA 30322 USA. [Manrique-Saide, Pablo; Medina Barreiro, Anuar; Koyoc Cardena, Edgar Ulises] Univ Autonoma Yucatan, Unidad Colaborat Bioensayos Entomol, Campus Ciencias Biol & Agr, Merida, Mexico. [Che-Mendoza, Azael] Gobierno Estado Yucatan, Serv Salud Yucatan, Merida, Mexico. [Liebman, Kelly; Vizcaino, Lucrecia; Lenhart, Audrey] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Entomol Branch, Ctr Global Hlth, Atlanta, GA USA. RP Lenhart, A (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Entomol Branch, Ctr Global Hlth, Atlanta, GA USA. EM AJL8@cdc.gov OI Lenhart, Audrey/0000-0002-9156-4228 FU Consejo Nacional de Ciencia y Tecnologia (CONACYT Mexico); Fondo Sectorial de Investigacion en Salud y Seguridad Social (SSA/IMSS/ISSSTE-CONACYT) [SALUD-2011-1-161551] FX We are grateful to the people of San Lorenzo, Progreso, Acanceh, Hunucma, and Conkal for allowing us to sample mosquitoes in their homes. Funding for this study was provided to PMS by the Consejo Nacional de Ciencia y Tecnologia (CONACYT Mexico), Fondo Sectorial de Investigacion en Salud y Seguridad Social (SSA/IMSS/ISSSTE-CONACYT) (SALUD-2011-1-161551). The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 63 TC 6 Z9 6 U1 5 U2 26 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD FEB 4 PY 2016 VL 9 AR 67 DI 10.1186/s13071-016-1346-3 PG 10 WC Parasitology SC Parasitology GA DC6ZA UT WOS:000369366900001 PM 26846468 ER PT J AU Homaira, N Luby, SP Hossain, K Islam, K Ahmed, M Rahman, M Rahman, Z Paul, RC Bhuiyan, MU Brooks, WA Sohel, BM Banik, KC Widdowson, MA Willby, M Rahman, M Bresee, J Ramirez, KS Azziz-Baumgartner, E AF Homaira, Nusrat Luby, Stephen P. Hossain, Kamal Islam, Kariul Ahmed, Makhdum Rahman, Mustafizur Rahman, Ziaur Paul, Repon C. Bhuiyan, Mejbah Uddin Brooks, W. Abdullah Sohel, Badrul Munir Banik, Kajal Chandra Widdowson, Marc-Alain Willby, Melisa Rahman, Mahmudur Bresee, Joseph Ramirez, Katharine-Sturm Azziz-Baumgartner, Eduardo TI Respiratory Viruses Associated Hospitalization among Children Aged < 5 Years in Bangladesh: 2010-2014 SO PLOS ONE LA English DT Article ID SYNCYTIAL VIRUS; DELTA METHOD; INFLUENZA; INFECTIONS; PNEUMONIA; INFANTS; COST; IMMUNIZATION; PROPHYLAXIS; RHINOVIRUS AB Background We combined hospital-based surveillance and health utilization survey data to estimate the incidence of respiratory viral infections associated hospitalization among children aged <5 years in Bangladesh. Methods Surveillance physicians collected respiratory specimens from children aged <5 years hospitalized with respiratory illness and residing in the primary hospital catchment areas. We tested respiratory specimens for respiratory syncytial virus, parainfluenza viruses, human metapneumovirus, influenza, adenovirus and rhinoviruses using rRT-PCR. During 2013, we conducted a health utilization survey in the primary catchment areas of the hospitals to determine the proportion of all hospitalizations for respiratory illness among children aged <5 years at the surveillance hospitals during the preceding 12 months. We estimated the respiratory virus-specific incidence of hospitalization by dividing the estimated number of hospitalized children with a laboratory confirmed infection with a respiratory virus by the population aged <5 years of the catchment areas and adjusted for the proportion of children who were hospitalized at the surveillance hospitals. Results We estimated that the annual incidence per 1000 children (95% CI) of all cause associated respiratory hospitalization was 11.5 (10-12). The incidences per 1000 children (95% CI) per year for respiratory syncytial virus, parainfluenza, adenovirus, human metapneumovirus and influenza infections were 3(2-3), 0.5(0.4-0.8), 0.4 (0.3-0.6), 0.4 (0.3-0.6), and 0.4 (0.3-0.6) respectively. The incidences per 1000 children (95%CI) of rhinovirus-associated infections among hospitalized children were 5 (3-7), 2 (1-3), 1 (0.6-2), and 3 (2-4) in 2010, 2011, 2012 and 2013, respectively. Conclusion Our data suggest that respiratory viruses are associated with a substantial burden of hospitalization in children aged <5 years in Bangladesh. C1 [Homaira, Nusrat; Luby, Stephen P.; Hossain, Kamal; Islam, Kariul; Ahmed, Makhdum; Rahman, Mustafizur; Rahman, Ziaur; Paul, Repon C.; Bhuiyan, Mejbah Uddin; Brooks, W. Abdullah; Sohel, Badrul Munir; Banik, Kajal Chandra; Ramirez, Katharine-Sturm; Azziz-Baumgartner, Eduardo] Icddr B, Dhaka, Bangladesh. [Luby, Stephen P.; Widdowson, Marc-Alain; Willby, Melisa; Bresee, Joseph; Ramirez, Katharine-Sturm; Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Brooks, W. Abdullah] Johns Hopkins Univ, Dept Int Hlth, Bloomberg Sch Publ, Baltimore, MD USA. [Rahman, Mahmudur] IEDCR, Dhaka, Bangladesh. RP Homaira, N (reprint author), Icddr B, Dhaka, Bangladesh. EM nhomaira@icddrb.org RI Ahmed, Makhdum/D-2615-2012; OI Ahmed, Makhdum/0000-0002-0772-8710; Luby, Stephen/0000-0001-5385-899X FU Influenza Division of Centers for Disease Control and Prevention (CDC), Atlanta [1U01CI000628-01, 1U01CI000628-04]; US CDC [1U01CI000628-04] FX This work was funded by the Influenza Division of Centers for Disease Control and Prevention (CDC), Atlanta under the co-operative agreement numbers 1U01CI000628-01 and 1U01CI000628-04. Co-authors SPL, MAW, MW, JB, KSR and EAB who work for the funding body were also involved in designing and analyzing of the study.; icddr,b is grateful for the commitment of CDC to its research efforts. US CDC gave financial support for this study (cooperative agreement 1U01CI000628-04). The authors would like to thank all the study participants and the surveillance hospitals for their contribution in the study. We gratefully acknowledge the relentless effort of the field staff involved in data collection and compilation. We also acknowledge the contribution of Dean D. Erdman for the design of the primers and probes for the laboratory testing of the study. We are also very grateful to Diana DiazGranados for her help with editing of the manuscript. NR 50 TC 1 Z9 1 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 3 PY 2016 VL 11 IS 2 AR e0147982 DI 10.1371/journal.pone.0147982 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DC9OF UT WOS:000369550200074 PM 26840782 ER PT J AU Munsakul, W Lolekha, R Kowadisaiburana, B Roongpisuthipong, A Jirajariyavej, S Asavapiriyanont, S Hancharoenkit, U Baipluthong, B Pattanasin, S Martin, M AF Munsakul, Warangkana Lolekha, Rangsima Kowadisaiburana, Boonchai Roongpisuthipong, Anuvat Jirajariyavej, Supannee Asavapiriyanont, Suvanna Hancharoenkit, Ubonsri Baipluthong, Benjamas Pattanasin, Sarika Martin, Michael TI Dual contraceptive method use and pregnancy intention among people living with HIV receiving HIV care at six hospitals in Thailand SO REPRODUCTIVE HEALTH LA English DT Article DE HIV infection; Pregnancy desire; Dual contraceptive use; Family planning; Thailand ID FERTILITY DESIRES; INFECTED WOMEN; POSITIVE WOMEN; UNITED-STATES; FAILURE; COHORT AB Background: Describe dual contraceptive method use and the intention to become pregnant of people living with HIV (PLHIV) and their partners in Thailand. Methods: From January 2008-March 2009, we systematically selected a cohort of PLHIV from PLHIV seeking care at five tertiary care hospitals and one community hospital to complete a questionnaire assessing sexual activity, intention to become pregnant, and contraceptive practices at baseline and 12 months after enrollment. Participants received short family planning messages every 2-3 months to promote the use of dual contraceptives and were offered family planning services. Results: A total of 1,388 PLHIV enrolled, their median age was 37 years (IQR 33-43), 898 (64.7 %) had a steady partner, and 737 (53.1 %) were male. Among those with a steady partner, 862 (96.0 %) did not intend to become pregnant; 709 (82.3 %) had sex during the previous 3 months, 683 (96.3 %) used at least one contraceptive method, and 202 (29.6 %) used dual contraceptive methods. Of the 317 PLHIV who used a single contraceptive method at baseline, 66 (20.8 %) reported using dual methods at 12 months. Participants at two tertiary care hospitals where coordinators facilitated PLHIV referral between HIV and OB/GYN clinics were more likely than participants at the other hospitals to change from single method to dual method (p <= 0.03). Conclusion: Few PLHIV in this study intended to become pregnant; however, only one-fourth used dual contraceptive methods. Integrating an assessment of the intention to become pregnant and strengthening the PLHIV referral systems in family planning services may contribute to higher rates of dual contraceptive use. C1 [Munsakul, Warangkana] Navamindharadhiraj Univ, Fac Med, Vajira Hosp, Bangkok, Thailand. [Lolekha, Rangsima; Baipluthong, Benjamas; Pattanasin, Sarika; Martin, Michael] Thailand Minist Publ Health US Ctr Dis Control &, POB 139, Nonthaburi 11000, Thailand. [Kowadisaiburana, Boonchai] Bamrasnaradura Infect Dis Inst, Nonthaburi, Thailand. [Roongpisuthipong, Anuvat] Mahidol Univ, Siriraj Hosp, Bangkok 10700, Thailand. [Jirajariyavej, Supannee] Taksin Hosp, Bangkok, Thailand. [Asavapiriyanont, Suvanna] Rajavithi Hosp, Bangkok, Thailand. [Hancharoenkit, Ubonsri] Wiang Pa Pao Hosp, Chiang Rai, Thailand. [Martin, Michael] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. RP Lolekha, R (reprint author), Thailand Minist Publ Health US Ctr Dis Control &, POB 139, Nonthaburi 11000, Thailand. EM hpu8@cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) through CDC [3U19GH000004-03] FX We acknowledge the staff of the HIV and OB/GYN clinics of the 6 participating hospitals for their contribution to this project. We thank the Thailand MOPH, Bureau of AIDS, TB, and STIs for the development of the Prevention with Positives services. This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through CDC under the terms of 3U19GH000004-03. NR 32 TC 1 Z9 1 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4755 J9 REPROD HEALTH JI Reprod. Health PD FEB 3 PY 2016 VL 13 AR 8 DI 10.1186/s12978-016-0123-2 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD6JS UT WOS:000370031100001 PM 26842976 ER PT J AU Cao, WP Liepkalns, JS Hassan, AO Kamal, RP Hofstetter, AR Amoah, S Kim, JH Reber, AJ Stevens, J Katz, JM Gangappa, S York, IA Mittal, SK Sambhara, S AF Cao, Weiping Liepkalns, Justine S. Hassan, Ahmed O. Kamal, Ram P. Hofstetter, Amelia R. Amoah, Samuel Kim, Jin Hyang Reber, Adrian J. Stevens, James Katz, Jacqueline M. Gangappa, Shivaprakash York, Ian A. Mittal, Suresh K. Sambhara, Suryaprakash TI A highly immunogenic vaccine against A/H7N9 influenza virus SO VACCINE LA English DT Article DE A/H7N9 influenza vaccine; Adenoviral vector vaccine; H7HA, cell-mediated immunity; Antibody responses; Protective immunity; Mouse model ID ADENOVIRAL VECTORS; ANTIBODY; STRAINS; MICE AB Since the first case of human infection in March 2013, continued reports of H7N9 cases highlight a potential pandemic threat. Highly immunogenic vaccines to this virus are urgently needed to protect vulnerable populations who lack protective immunity. In this study, an egg- and adjuvant-independent adenoviral vector-based, hemagglutinin H7 subtype influenza vaccine (HAd-H7HA) demonstrated enhanced cell mediated immunity as well as serum antibody responses in a mouse model. Most importantly, this vaccine provided complete protection against homologous A/H7N9 viral challenge suggesting its potential utility as a pandemic vaccine. Published by Elsevier Ltd. C1 [Cao, Weiping; Liepkalns, Justine S.; Kamal, Ram P.; Hofstetter, Amelia R.; Amoah, Samuel; Kim, Jin Hyang; Reber, Adrian J.; Katz, Jacqueline M.; Gangappa, Shivaprakash; York, Ian A.; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA USA. [Hassan, Ahmed O.; Mittal, Suresh K.] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA. [Kamal, Ram P.; Amoah, Samuel] Battelle Mem Inst, Atlanta, GA USA. [Hofstetter, Amelia R.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Stevens, James] Ctr Dis Control & Prevent, Virus, Surveillance & Diag Branch, Influenza Div,Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA USA. RP Sambhara, S (reprint author), Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA USA.; Mittal, SK (reprint author), Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA. EM mittal@purdue.edu; zao1@cdc.gov OI York, Ian/0000-0002-3478-3344; Hofstetter, Amelia/0000-0003-4113-5473 FU Influenza Division of Centers for Disease Control and Prevention; Public Health Service grant from the National Institute of Allergy and Infectious Diseases [AI059374]; Hatch fund at Purdue University; Juvaris Bio-Therapeutics; GlaxoSmithKline FX We thank members of the Immunology and Pathogenesis Branch in the Influenza Division, Centers for Disease Control and Prevention for providing reagents and constructive comments for this study. We also thank Sai Vemula and Omar Amen for their help in vector construction and Jane Kovach for secretarial assistance. This work was supported by the Influenza Division of Centers for Disease Control and Prevention, the Public Health Service grant AI059374 from the National Institute of Allergy and Infectious Diseases and the Hatch fund at Purdue University.; J. M. K. received funds from Juvaris Bio-Therapeutics and GlaxoSmithKline as cooperative research agreement. All other authors report no potential conflicts. NR 19 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD FEB 3 PY 2016 VL 34 IS 6 BP 744 EP 749 DI 10.1016/j.vaccine.2015.12.062 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA DD7ML UT WOS:000370108500005 PM 26765287 ER PT J AU Menezes, APD Azevedo, J Leite, MC Campos, LC Cunha, M Carvalho, MDS Reis, MG Ko, AI Weinberger, DM Ribeiro, G Reis, JN AF Menezes, Ana Paula de O. Azevedo, Jailton Leite, Mariela C. Campos, Leila C. Cunha, Marcelo Carvalho, Maria da Gloria S. Reis, Mitermayer G. Ko, Albert I. Weinberger, Daniel M. Ribeiro, Guilherme Reis, Joice N. TI Nasopharyngeal carriage of Streptococcus pneumoniae among children in an urban setting in Brazil prior to PCV10 introduction SO VACCINE LA English DT Article DE Children; Nasopharyngeal carriage; Streptococcus pneumoniae; Serotypes; PCV10-vaccine ID PNEUMOCOCCAL CONJUGATE VACCINE; COMMUNITY-LEVEL PREDICTORS; ATTENDING DAY-CARE; SEROTYPE DISTRIBUTION; INVASIVE DISEASE; COLONIZATION; REPLACEMENT; POPULATION; RESISTANCE; INFANTS AB Information on pneumococcal carriage in the pre-vaccine period is essential to predict and assess the impact of PCV in settings where disease surveillance is particularly difficult. Therefore, we present data on pneumococcal carriage before the introduction of the 10-valent-pneumococcal conjugate vaccine (PCV10) in Brazil. We conducted a prospective study on a cohort of 203 children aged <5 years old, randomly selected in an urban community located in the periphery of the city of Salvador, Brazil and followed them from January/2008 to January/2009. Nasopharyngeal swabs were collected from each child at four times. In total, 721 swabs were collected, yielding a pneumococcal carriage prevalence of 55% (n=398). In multivariate analyses, the variables associated with carriage were having contact with three or more children <2 years old (OR, 2.00; 95% CI 1.33-2.89) and living in a house with an average of 3 residents per room (OR, 1.77; 95% CI 1.05-3.10). Also, white participants were more likely to be protected from colonization (OR, 0.52; 95% CI 0.29-0.93), and prevalence of carriage varied over time, with lower prevalence occurring from February to June (OR, 0.53; 95% CI 0.37-0.78) compared to July to January. Contact with children under 2 years of age and living in crowded housing also were associated with colonization by highly invasive serotypes, although this relationship was not significant. The most prevalent vaccine serotypes were 6A/B (25.4%), 19F (10.1%) and 14 (9.0%), while the most prevalent non-vaccine serotypes were 16F (4.8%), 15B/C (4.5%) and 6C/D (3.5%). Overall, 38.4% (153/398) of the isolates were non-susceptible to penicillin, and of those, 73.8% (113/153) were non-susceptible to trimethoprim/sulfamethoxazole. Colonization rate by PCV10 serotypes was 52.2%. Routine PCV10 vaccination can lead to significant changes in pneumococcal serotypes found in NP colonization, indicating a need for continued monitoring, especially in crowded settings, as occurs in Brazil's slums. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Menezes, Ana Paula de O.; Azevedo, Jailton; Campos, Leila C.; Reis, Mitermayer G.; Ko, Albert I.; Ribeiro, Guilherme; Reis, Joice N.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil. [Leite, Mariela C.; Reis, Joice N.] Univ Fed Bahia, Fac Farm, Salvador, BA, Brazil. [Cunha, Marcelo] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, RJ, Brazil. [Carvalho, Maria da Gloria S.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. [Ko, Albert I.; Weinberger, Daniel M.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA. [Ribeiro, Guilherme] Univ Fed Bahia, Inst Saude Colet, Salvador, BA, Brazil. RP Reis, JN (reprint author), Univ Fed Bahia, Fac Farm, Dept Anal Clin & Toxicol, BR-40170115 Salvador, BA, Brazil. EM joice@ufba.br RI Reis, Joice/H-9227-2013; Ko, Albert/P-2343-2015; OI Azevedo, Jailton /0000-0002-0801-8673; Weinberger, Daniel/0000-0003-1178-8086 FU Brazilian National Research Council [482755/2010-5]; Research Support Foundation of the State of Bahia (FAPESB) [1431040054051]; National Institutes of Health [TW007303]; Global Health Equity Scholars training program [TW009338]; Bill and Melinda Gates Foundation [OPP1114733]; Yale Program on Aging [P30AG021342]; NIH/NIAID [R56 AI110449] FX This work was supported by grants from the Brazilian National Research Council (482755/2010-5), the Research Support Foundation of the State of Bahia (FAPESB: 1431040054051) and the National Institutes of Health (TW007303). DMW is supported by the Global Health Equity Scholars training program (TW009338), the Bill and Melinda Gates Foundation (OPP1114733), the Yale Program on Aging (P30AG021342), and NIH/NIAID (R56 AI110449). NR 39 TC 2 Z9 2 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD FEB 3 PY 2016 VL 34 IS 6 BP 791 EP 797 DI 10.1016/j.vaccine.2015.12.042 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA DD7ML UT WOS:000370108500012 PM 26742946 ER PT J AU Karaceper, MD Chakraborty, P Coyle, D Wilson, K Kronick, JB Hawken, S Davies, C Brownell, M Dodds, L Feigenbaum, A Fell, DB Grosse, SD Guttmann, A Laberge, AM Mhanni, A Miller, FA Mitchell, JJ Nakhla, M Prasad, C Rockman-Greenberg, C Sparkes, R Wilson, BJ Potter, BK AF Karaceper, Maria D. Chakraborty, Pranesh Coyle, Doug Wilson, Kumanan Kronick, Jonathan B. Hawken, Steven Davies, Christine Brownell, Marni Dodds, Linda Feigenbaum, Annette Fell, Deshayne B. Grosse, Scott D. Guttmann, Astrid Laberge, Anne-Marie Mhanni, Aizeddin Miller, Fiona A. Mitchell, John J. Nakhla, Meranda Prasad, Chitra Rockman-Greenberg, Cheryl Sparkes, Rebecca Wilson, Brenda J. Potter, Beth K. CA Canadian Inherited Metab Dis Res N TI The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study SO ORPHANET JOURNAL OF RARE DISEASES LA English DT Article DE Neonatal screening; Metabolic diseases; Health services utilization ID COST-EFFECTIVENESS; MCAD DEFICIENCY; EPIDEMIOLOGY; DISORDERS; MUTATION; OUTCOMES; INFANTS AB Background: There is no consensus in the literature regarding the impact of false positive newborn screening results on early health care utilization patterns. We evaluated the impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency (MCADD) in a cohort of Ontario infants. Methods: The cohort included all children who received newborn screening in Ontario between April 1, 2006 and March 31, 2010. Newborn screening and diagnostic confirmation results were linked to province-wide health care administrative datasets covering physician visits, emergency department visits, and inpatient hospitalizations, to determine health service utilization from April 1, 2006 through March 31, 2012. Incidence rate ratios (IRRs) were used to compare those with false positive results for MCADD to those with negative newborn screening results, stratified by age at service use. Results: We identified 43 infants with a false positive newborn screening result for MCADD during the study period. These infants experienced significantly higher rates of physician visits (IRR: 1.42) and hospitalizations (IRR: 2.32) in the first year of life relative to a screen negative cohort in adjusted analyses. Differences in health services use were not observed after the first year of life. Conclusions: The higher use of some health services among false positive infants during the first year of life may be explained by a psychosocial impact of false positive results on parental perceptions of infant health, and/or by differences in underlying health status. Understanding the impact of false positive newborn screening results can help to inform newborn screening programs in designing support and education for families. This is particularly important as additional disorders are added to expanded screening panels, yielding important clinical benefits for affected children but also a higher frequency of false positive findings. C1 [Karaceper, Maria D.; Coyle, Doug; Wilson, Brenda J.; Potter, Beth K.] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada. [Chakraborty, Pranesh; Davies, Christine] Childrens Hosp Eastern Ontario, Newborn Screening Ontario, Ottawa, ON K1H 8L1, Canada. [Wilson, Kumanan; Hawken, Steven] Ottawa Hosp Res Inst, Ottawa, ON, Canada. [Kronick, Jonathan B.; Feigenbaum, Annette] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada. [Brownell, Marni] Univ Manitoba, Coll Med, Fac Hlth Sci, Manitoba Ctr Hlth Policy,Dept Community Hlth Sci, Winnipeg, MB, Canada. [Dodds, Linda] Dalhousie Univ, Dept Obstet & Gynecol, Halifax, NS, Canada. [Dodds, Linda] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada. [Fell, Deshayne B.] BORN Ontario, Ottawa, ON, Canada. [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Guttmann, Astrid] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Guttmann, Astrid] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Paediat Med, Toronto, ON M5G 1X8, Canada. [Laberge, Anne-Marie] Univ Montreal, CHU St Justine, Med Genet, Montreal, PQ, Canada. [Laberge, Anne-Marie] Univ Montreal, Dept Pediat, Montreal, PQ H3C 3J7, Canada. [Mhanni, Aizeddin; Rockman-Greenberg, Cheryl] Univ Manitoba, Coll Med, Fac Hlth Sci, Dept Paediat & Child Hlth, Winnipeg, MB, Canada. [Miller, Fiona A.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Mitchell, John J.; Nakhla, Meranda] McGill Univ, Montreal Childrens Hosp, Montreal, PQ, Canada. [Prasad, Chitra] Univ Western Ontario, London Hlth Sci Ctr, Genet Metab & Pediat, London, ON, Canada. [Sparkes, Rebecca] Alberta Childrens Prov Gen Hosp, Clin Genet Sect, Dept Pediat, Calgary, AB, Canada. [Wilson, Kumanan] Univ Ottawa, Dept Med, Ottawa, ON, Canada. RP Potter, BK (reprint author), Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada. EM bpotter@uottawa.ca FU Canadian Institutes of Health Research (CIHR) Emerging Team Grant [TR3-119195]; Ontario Ministry of Health and Long-Term Care (MOHLTC) FX We gratefully acknowledge Robin Ducharme for her assistance in preparing the datasets for this study. This study was Funded through a Canadian Institutes of Health Research (CIHR) Emerging Team Grant (TR3-119195). Maria Karaceper received a graduate scholarship through a charitable donation to the Children's Hospital of Eastern Ontario. This study was performed at the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed herein are those of the author, and not necessarily those of CIHI. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The opinions, results and conclusions reported in this paper are those of the authors and are independent from all funding sources. Study sponsors had no role in the following: (1) study design; (2) the collection, analysis, and interpretation of data; (3) the writing of the report; and (4) the decision to submit the paper for publication. NR 36 TC 1 Z9 2 U1 3 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-1172 J9 ORPHANET J RARE DIS JI Orphanet J. Rare Dis. PD FEB 3 PY 2016 VL 11 AR 12 DI 10.1186/s13023-016-0391-5 PG 9 WC Genetics & Heredity; Medicine, Research & Experimental SC Genetics & Heredity; Research & Experimental Medicine GA DC5BL UT WOS:000369235300001 PM 26841949 ER PT J AU Martin, E Chirivella, M Co, JKG Santiago, GA Gubler, DJ Munoz-Jordan, JL Bennett, SN AF Martin, Estelle Chirivella, Maritza Co, Juliene K. G. Santiago, Gilberto A. Gubler, Duane J. Munoz-Jordan, Jorge L. Bennett, Shannon N. TI Insights into the molecular evolution of Dengue virus type 4 in Puerto Rico over two decades of emergence SO VIRUS RESEARCH LA English DT Article DE Dengue virus; Evolution; Lineage turnover; Emergence; Natural selection ID ORIGINAL ANTIGENIC SIN; HEMORRHAGIC-FEVER; CRYSTAL-STRUCTURE; DISEASE SEVERITY; STRAINS; PATHOGENESIS; INFECTION; SELECTION; EPIDEMIOLOGY; ASSOCIATION AB Dengue has emerged globally as a major human health problem since the 1950s and is now the most important arboviral disease of humans, infecting nearly 400 million people annually. While some cases are asymptomatic, others can develop a febrile illness (dengue fever) or even progress to severe and fatal dengue. Dengue is caused by any of 4 closely related but distinct viruses, known as Dengue virus serotype 1 to 4 (DENV-1 to DENV-4) which are maintained in endemic transmission to humans in large urban centers of the tropics by Aedes mosquitoes. Since the early 1960s, Puerto Rico, a major metropolitan center in the Caribbean, has experienced increasingly larger and clinically more severe epidemics following the introduction of all four dengue serotypes. The first dengue hemorrhagic fever epidemic in 1986, and a particularly severe outbreak in 1998 were dominated by novel DENV-4 strains that evolved in Puerto Rico, replacing earlier strains and spreading throughout the region. Sequence characterization of 54 complete DENV-4 genomes and their comparative evolution against 74 previously published viral sequences from the region over several decades shows that DENV-4 strains from these periods were genetically distinct based on unique changes in the envelope and non-structural genes. Their replacement of earlier strains in Puerto Rico progressed rapidly, suggesting that strong natural selection played a role in their fixation. This study confirms that DENVs evolve through rapid lineage turnover driven in part by natural selection and genetic drift. (C) 2015 Elsevier B.V. All rights reserved. C1 [Martin, Estelle; Bennett, Shannon N.] Univ Hawaii Manoa, John A Burns Sch Med, Dept Trop Med Med Microbiol & Pharmacol, Honolulu, HI 96822 USA. [Chirivella, Maritza; Santiago, Gilberto A.; Munoz-Jordan, Jorge L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Dengue Branch, San Juan, PR USA. [Co, Juliene K. G.] De La Salle Univ, Dept Biol, Manila, Philippines. [Gubler, Duane J.] Duke Nat Univ Singapore Grad Med Sch, Program Emerging Infect Dis, Singapore, Singapore. [Bennett, Shannon N.] Calif Acad Sci, Dept Microbiol, 55 Mus Concourse Dr, San Francisco, CA 94118 USA. RP Bennett, SN (reprint author), Calif Acad Sci, Dept Microbiol, 55 Mus Concourse Dr, San Francisco, CA 94118 USA. EM sbennett@calacademy.org FU NIH/NIAID Pacific Southwest Regional Center of Excellence (PSWRCE) [U54A1065359]; NIH/NCRR COBRE [P20RR018727]; RCMI programs [G12RR003061]; US Department of Defense [DOD06187000]; Hawaii Community Foundation [13ADVC-60318] FX We gratefully acknowledge the work of Vance Vorndam and other members of the CDC San Juan Dengue Branch for their contributions to this study and the curation of an extensive archival DENV collection; Ric Yanagihara for editorial comments; and financial support from NIH/NIAID Pacific Southwest Regional Center of Excellence (PSWRCE U54A1065359), NIH/NCRR COBRE (P20RR018727) and RCMI (G12RR003061) programs, the US Department of Defense (DOD06187000) and the Hawaii Community Foundation (13ADVC-60318). NR 69 TC 1 Z9 1 U1 3 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1702 EI 1872-7492 J9 VIRUS RES JI Virus Res. PD FEB 2 PY 2016 VL 213 BP 23 EP 31 DI 10.1016/j.virusres.2015.11.009 PG 9 WC Virology SC Virology GA DG1PS UT WOS:000371840600004 PM 26569594 ER PT J AU Kruger, J Patel, R Kegler, M Babb, SD King, BA AF Kruger, Judy Patel, Roshni Kegler, Michelle Babb, Steven D. King, Brian A. TI Perceptions of harm from secondhand smoke exposure among US adults, 2009-2010 SO TOBACCO INDUCED DISEASES LA English DT Article DE Tobacco; Smoking; Policy; Secondhand smoke ID ENVIRONMENTAL TOBACCO-SMOKE; CLEAN INDOOR AIR; 4 COUNTRY SURVEY; FREE BAR LAW; RISK PERCEPTIONS; CHILD EXPOSURE; UNITED-STATES; ATTITUDES; BELIEFS; LEGISLATION AB Background: Exposure to secondhand smoke (SHS) causes significant disease and death. We assessed the prevalence and correlates of perceptions about the health harm of SHS among U.S. adults at the national and state level. Methods: Data came from the 2009-2010 National Adult Tobacco Survey, a national landline and cellular telephone survey. Perceptions about the health harms of SHS were assessed as follows: 'not at all harmful', 'somewhat harmful', and 'very harmful'. Descriptive statistics were used to assess the prevalence of SHS harm perceptions by tobacco use and sociodemographic factors, including sex, age, race/ethnicity, education, marital status, annual household income, region, sexual orientation, children in the household, and smoke-free law coverage. Logistic regression was used to assess odds of perceiving SHS to be "very harmful" (vs. "not at all harmful" or "somewhat harmful"), adjusting for the aforementioned factors. Results: Nationally, 64.5 % of adults perceived SHS as 'very harmful' (state range: 73.5 % [Utah] to 53.7 % [Kentucky]). By tobacco use, the perception that SHS is 'very harmful' was: 76.5 % among nonusers of tobacco; 62.1 % among noncombustible only users; 47.9 % among combustible only users; and 40.8 % among dual combustible and noncombustible users. Following adjustment, the perception that SHS was 'very harmful' was higher among females, non-Hispanic minorities and Hispanics, respondents living with children, and states with 100 % smoke-free law coverage. Among current tobacco users the odds of perceiving SHS to be 'very harmful' was lower in the Midwest than the West. Conclusions: Almost two-thirds of American adults perceive SHS as 'very harmful'; however, currently only half of all Americans are protected by comprehensive state or local smoke-free laws. These findings underscore the importance of public education campaigns to increase awareness of SHS exposure harm and the benefits of smoke-free environments. Expanding comprehensive smoke-free laws could protect all Americans from SHS. C1 [Kruger, Judy] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA USA. [Patel, Roshni] Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA USA. [Kegler, Michelle] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Kruger, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA USA. EM ezk0@cdc.gov FU National Cancer Institute under the State and Community Tobacco Control Initiative [UO1-CA154282] FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Funding for Dr. Michelle Kegler's contribution to this work was provided by the National Cancer Institute under the State and Community Tobacco Control Initiative, Grant Number UO1-CA154282. There were no sources of funding, direct or indirect, for other authors in regards to the reported research. NR 48 TC 1 Z9 1 U1 4 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1617-9625 J9 TOB INDUC DIS JI Tob. Induc. Dis. PD FEB 2 PY 2016 VL 14 AR 3 DI 10.1186/s12971-016-0069-8 PG 13 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA DD4PE UT WOS:000369904200001 PM 26839528 ER PT J AU Kim, DK Bridges, CB Harriman, KH AF Kim, David K. Bridges, Carolyn B. Harriman, Kathleen H. CA Advisory Comm Immunization Practic TI Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2016 SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID MENINGOCOCCAL DISEASE RECOMMENDATIONS; PERTUSSIS-VACCINE TDAP; PRACTICES ACIP; INFLUENZA VACCINATION; PREVENTION; METAANALYSIS; DIPHTHERIA; TETANUS; RISK C1 [Kim, David K.; Bridges, Carolyn B.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop A-19, Atlanta, GA 30333 USA. [Harriman, Kathleen H.] Calif Dept Publ Hlth, 850 Marina Bay Pkwy,Bldg P,Second Floor, Richmond, CA 94804 USA. RP Kim, DK (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop A-19, Atlanta, GA 30333 USA. EM dkim@cdc.gov NR 20 TC 9 Z9 10 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 2 PY 2016 VL 164 IS 3 BP 184 EP U174 DI 10.7326/M15-3005 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA DC4DD UT WOS:000369169400007 PM 26829913 ER PT J AU Geyer, H Bauer, M Neumann, J Ludde, A Rennert, P Friedrich, N Claus, C Perelygina, L Mankertz, A AF Geyer, Henriette Bauer, Michael Neumann, Jennifer Luedde, Amy Rennert, Paul Friedrich, Nicole Claus, Claudia Perelygina, Ludmilla Mankertz, Annette TI Gene expression profiling of rubella virus infected primary endothelial cells of fetal and adult origin SO VIROLOGY JOURNAL LA English DT Article DE Rubella virus; Congenital rubella syndrome; Gene expression; Sensory organ development; Teratogenicity; Endothelial cells ID CONGENITAL-RUBELLA; INNER-EAR; USHER-SYNDROME; VERO CELLS; PATHWAY; NOGGIN; REPLICATION; MECHANISMS; CHEMOKINES; PATHOLOGY AB Background: Rubella virus (RV) infection is usually a mild illness in children and adults. However, maternal infection during the first trimester of pregnancy can lead to congenital rubella syndrome (CRS) in the infant. Fetuses with CRS show damage to the endothelium of the heart and blood vessels; thus, it has been speculated that the clinical manifestations associated with CRS may be a result of endothelial cells persistently infected with RV. Here, we compared the effects of RV infection on gene expression in primary endothelial cells of fetal (HUVEC) and of adult (HSaVEC) origin by transcriptional profiling. Results: More than 75 % of the genes differentially regulated following RV infection were identical in both cell types. Gene Ontology (GO) analysis of these commonly regulated genes showed an enrichment of terms involved in cytokine production and cytokine regulation. Increased accumulation of inflammatory cytokines following RV infection was verified by protein microarray. Interestingly, the chemokine CCL14, which is implicated in supporting embryo implantation at the fetal-maternal interface, was down-regulated following RV infection only in HUVEC. Most noticeably, when analyzing the uniquely regulated transcripts for each cell type, GO term-based cluster analysis of the down-regulated genes of HUVEC revealed an enrichment of the GO terms "sensory organ development", "ear development" and "eye development". Conclusion: Since impairment in vision and hearing are the most prominent clinical manifestations observed in CRS patients, the here detected down-regulated genes involved in the development of sensory organs sheds light on the molecular mechanisms that may contribute to the teratogenic effect of RV. C1 [Geyer, Henriette; Luedde, Amy; Rennert, Paul; Friedrich, Nicole; Mankertz, Annette] Robert Koch Inst, Div Measles Mumps Rubella & Viruses Affecting Imm, D-13353 Berlin, Germany. [Bauer, Michael] Univ Zurich, Inst Mol Life Sci, CH-8057 Zurich, Switzerland. [Neumann, Jennifer] Bundesinst Risikobewertung, Unit Diagnost & Pathogen Characterisat, D-12277 Berlin, Germany. [Claus, Claudia] Univ Leipzig, Inst Virol, Johannisallee 30, D-04103 Leipzig, Germany. [Perelygina, Ludmilla] Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA. RP Geyer, H (reprint author), Robert Koch Inst, Div Measles Mumps Rubella & Viruses Affecting Imm, D-13353 Berlin, Germany. EM geyerh@rki.de FU Robert Koch Institute FX We would like to thank Dr. Benedikt Weissbrich for providing the Wb-12 strain used in this work. This research was supported by the Robert Koch Institute. NR 40 TC 0 Z9 0 U1 4 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-422X J9 VIROL J JI Virol. J. PD FEB 2 PY 2016 VL 13 AR 21 DI 10.1186/s12985-016-0475-9 PG 17 WC Virology SC Virology GA DC6WJ UT WOS:000369360000002 PM 26837541 ER PT J AU Kesteman, T Rafalimanantsoa, SA Razafimandimby, H Rasamimanana, HH Raharimanga, V Ramarosandratana, B Ratsimbasoa, A Ratovonjato, J Elissa, N Randrianasolo, L Finlay, A Rogier, C Randrianarivelojosia, M AF Kesteman, Thomas Rafalimanantsoa, Solofoniaina A. Razafimandimby, Harimahefa Rasamimanana, Heriniaina H. Raharimanga, Vaomalala Ramarosandratana, Benjamin Ratsimbasoa, Arsene Ratovonjato, Jocelyn Elissa, Nohal Randrianasolo, Laurence Finlay, Alyssa Rogier, Christophe Randrianarivelojosia, Milijaona TI Multiple causes of an unexpected malaria outbreak in a high-transmission area in Madagascar SO MALARIA JOURNAL LA English DT Article DE Malaria; Madagascar; Infectious disease outbreaks; Epidemiology ID SUB-SAHARAN AFRICA AB Background: The malaria burden in Madagascar dropped down last decade, largely due to scale-up of control measures. Nevertheless, a significant rise of malaria cases occurred in 2011-2012 in two regions of the rainy South-Eastern Madagascar, where malaria is considered as mesoendemic and the population is supposed to be protected by its acquired immunity against Plasmodium. A multidisciplinary investigation was conducted in order to identify the causes of the outbreak. Methods: In March 2012, a cross-sectional study was conducted in 20 randomly selected clusters, involving the rapid diagnostic testing of all >= 6 month-old members of households and a questionnaire about socio-demographic data and exposure to malaria control interventions. Changes in environmental conditions were evaluated by qualitative interview of local authorities, climatic conditions were evaluated by remote-sensing, and stock outs of malaria supplies in health facilities were evaluated by quantitative means. Two long-lasting insecticidal nets (LLINs) were sampled in each cluster in order to evaluate their condition and the remanence of their insecticidal activity. The entomological investigation also encompassed the collection Anopheles vectors in two sites, and the measure of their sensitivity to deltamethrin. Results: The cross-sectional survey included 1615 members of 440 households. The mean Plasmodium infection rate was 25.6 % and the mean bed net use on the day before survey was 71.1 %. The prevalence of Plasmodium infections was higher in 6-14 year-old children (odds ratio (OR) 7.73 [95 % CI 3.58-16.68]), in rural areas (OR 6.25 [4.46-8.76]), in poorest socio-economic tercile (OR 1.54 [1.13-2.08]), and it was lower in individuals sleeping regularly under the bed net (OR 0.51 [0.32-0.82]). Stock outs of anti-malarial drugs in the last 6 months have been reported in two third of health facilities. Rainfalls were increased as compared with the three previous rainy seasons. Vectors collected were sensitive to pyrethroids. Two years after distribution, nearly all LLINs collected showed a loss of physical integrity and insecticide activity, Conclusions: Increased rainfall, decreasing use and reduced insecticide activity of long-lasting insecticide-treated nets, and drug shortages may have been responsible for, or contributed to, the outbreak observed in South-Eastern Madagascar in 2011-2012. Control interventions for malaria elimination must be sustained at the risk of triggering harmful epidemics, even in zones of high transmission. C1 [Kesteman, Thomas; Rafalimanantsoa, Solofoniaina A.; Razafimandimby, Harimahefa; Raharimanga, Vaomalala; Ratovonjato, Jocelyn; Elissa, Nohal; Randrianasolo, Laurence; Rogier, Christophe; Randrianarivelojosia, Milijaona] Inst Pasteur Madagascar, BP 1274, Antananarivo 101, Madagascar. [Kesteman, Thomas; Rogier, Christophe] UMR 6236, URMITE, 27 Blvd Jean Moulin, F-13385 Marseille 05, France. [Kesteman, Thomas] Fdn Merieux, 17 Rue Bourgelat, F-69002 Lyon, France. [Rafalimanantsoa, Solofoniaina A.; Razafimandimby, Harimahefa] Minist Sante, Direct Veille Sanit & Surveillance Epidemiol, Antananarivo, Madagascar. [Rasamimanana, Heriniaina H.; Ramarosandratana, Benjamin; Ratsimbasoa, Arsene] Minist Sante Publ, Direct Lutte Paludisme, Antananarivo, Madagascar. [Finlay, Alyssa] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Rogier, Christophe] Inst Biomed Res French Armed Forces IRBA, BP 73, F-91223 Bretigny Sur Orge, France. RP Kesteman, T (reprint author), Inst Pasteur Madagascar, BP 1274, Antananarivo 101, Madagascar.; Kesteman, T (reprint author), UMR 6236, URMITE, 27 Blvd Jean Moulin, F-13385 Marseille 05, France.; Kesteman, T (reprint author), Fdn Merieux, 17 Rue Bourgelat, F-69002 Lyon, France. EM thomask@pasteur.mg OI Kesteman, Thomas/0000-0002-7951-8261 FU Institut Pasteur de Madagascar FX This research was supported by the Institut Pasteur de Madagascar. We especially thank the population of Vatovavy Fitovinany and Atsimo Atsinanana regions who participated the study. We thank those who facilitated the survey, i.e. the fokonolona, chiefs of fokontany, local administration authorities and health authorities from Ministry of Health and National Malaria Control Program. We thank also the survey teams and partners, especially Leonora M. W. T. Ravolanjarasoa, Jemima A. Ravelonarivo, Rogelin Raherinjafy, Tianasoa W. A. Andriamiandranoro, Harinah Zafiarison, Michel A. Marolahy, Rado Randriamiarana, Lovasoa Rasoanandrasana, Daudet Randrianasolo, Solo H. Rajaobary, Marie-Clemence Rakotoarivony, Louise Ranaivo, Mirasoa Randrianomanana, Suzanantsoa A. Zilera, and Florian Girond. Michael Casey deserves special thanks for his English proof reading. NR 15 TC 4 Z9 4 U1 4 U2 14 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD FEB 2 PY 2016 VL 15 AR 57 DI 10.1186/s12936-016-1113-0 PG 6 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DC3SJ UT WOS:000369138800002 PM 26838369 ER PT J AU Shafer, PR Davis, KC Patel, D Rodes, R Beistle, D AF Shafer, Paul R. Davis, Kevin C. Patel, Deesha Rodes, Robert Beistle, Diane TI Association Between Media Dose, Ad Tagging, and Changes in Web Traffic for a National Tobacco Education Campaign: A Market-Level Longitudinal Study SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE Internet; advertising; health communication; smoking cessation; public health; tobacco control AB Background: In 2012, the US Centers for Disease Control and Prevention (CDC) launched Tips From Former Smokers (Tips), the first federally funded national tobacco education campaign. In 2013, a follow-up Tips campaign aired on national cable television networks, radio, and other channels, with supporting digital advertising to drive traffic to the Tips campaign website. Objective: The objective of this study was to use geographic and temporal variability in 2013 Tips campaign television media doses and ad tagging to evaluate changes in traffic to the campaign website in response to specific doses of campaign media. Methods: Linear regression models were used to estimate the dose-response relationship between weekly market-level television gross rating points (GRPs) and weekly Web traffic to the Tips campaign website. This relationship was measured using unique visitors, total visits, and page views as outcomes. Ad GRP effects were estimated separately for ads tagged with the Tips campaign website URL and 1-800-QUIT-NOW. Results: In the average media market, an increase of 100 television GRPs per week for ads tagged with the Tips campaign website URL was associated with an increase of 650 unique visitors (P<.001), 769 total visits (P<.001), and 1255 total page views (P<.001) per week. The associations between GRPs for ads tagged with 1-800-QUIT-NOW and each Web traffic measure were also statistically significant (P<.001), but smaller in magnitude. Conclusions: Based on these findings, we estimate that the 16-week 2013 Tips television campaign generated approximately 660,000 unique visitors, 900,000 total visits, and 1,390,000 page views for the Tips campaign website. These findings can help campaign planners forecast the likely impact of targeted advertising efforts on consumers' use of campaign-specific websites. C1 [Shafer, Paul R.; Davis, Kevin C.] RTI Int, Ctr Hlth Policy Sci & Tobacco Res, 3040 East Cornwallis Rd, Res Triangle Pk, NC 27709 USA. [Shafer, Paul R.] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC USA. [Patel, Deesha; Rodes, Robert; Beistle, Diane] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. RP Shafer, PR (reprint author), RTI Int, Ctr Hlth Policy Sci & Tobacco Res, 3040 East Cornwallis Rd, Res Triangle Pk, NC 27709 USA. EM pshafer@rti.org OI Shafer, Paul/0000-0003-0654-5821 FU Centers for Disease Control and Prevention FX This work was funded by the Centers for Disease Control and Prevention. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or RTI International. The authors would like to acknowledge Caryn Coln and Amy Rowland for providing the data and answering follow-up questions needed for the analysis. NR 7 TC 1 Z9 1 U1 3 U2 3 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD FEB PY 2016 VL 18 IS 2 AR e39 DI 10.2196/jmir.5343 PG 5 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA DS4TP UT WOS:000380774800010 PM 26887959 ER PT J AU Rader, EP Layner, KN Triscuit, AM Chetlin, RD Ensey, J Baker, BA AF Rader, Erik P. Layner, Kayla N. Triscuit, Alyssa M. Chetlin, Robert D. Ensey, James Baker, Brent A. TI Age-dependent Muscle Adaptation after Chronic Stretch-shortening Contractions in Rats SO AGING AND DISEASE LA English DT Article DE dorsiflexor muscles; dynamometer; Fisher 344XBrown Norway rats; repetitive exposure ID SKELETAL-MUSCLE; RESISTANCE EXERCISE; ADOLESCENT BOYS; YOUNG-RATS; OLD RATS; RESPONSES; RECOVERY; FATIGUE; PERFORMANCE; STRENGTH AB Age-related differences in contraction-induced adaptation have been well characterized especially for young and old rodent models but much less so at intermediate ages. Therefore, additional research is warranted to determine to what extent alterations in adaptation are due to maturation versus aging per se. The purpose of our study was to evaluate muscles of Fisher 344XBrown Norway rats of various ages following one month of exposure to stretch-shortening contractions (SSCs). With exposure, muscles mass increased by similar to 10% for 27 and 30 month old rats vs. similar to 20% for 3 and 6 month old rats (P < 0.05). For 3 month old rats, maximum isometric force and dynamic peak force increased by 22 +/- 8% and 27 +/- 10%, respectively (P < 0.05). For 6 month old rats, these forces were unaltered by exposure and positive work capacity diminished by 27 +/- 2% (P = 0.006). By 30 months of age, age-related deficits in maximum isometric force, peak force, negative work, and positive work were apparent and SSC exposure was ineffective at counteracting such deficits. Recovery from fatigue was also tested and exposure-induced improvements in fatigue recovery were indicated for 6 month old rats and to a lesser extent for 3 month old rats whereas no such effect was observed for older rats. Alterations in fatigue recovery were accompanied by evidence of substantial type IIb to IIx fiber type shifting. These results highlight the exceptional adaptive capacity for strength at a young age, the inclination for adaptation in fatigue recovery at early adulthood, and diminished adaptation for muscle performance in general beginning at late adulthood. Such findings motivate careful investigation to determine appropriate SSC exposures at all stages of life. C1 [Rader, Erik P.; Layner, Kayla N.; Triscuit, Alyssa M.; Chetlin, Robert D.; Ensey, James; Baker, Brent A.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Chetlin, Robert D.] Mercyhurst Univ, Dept Sports Med, Erie, PA 16546 USA. RP Rader, EP (reprint author), MS L3014,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM WLZ4@cdc.gov FU National Institute for Occupational Safety and Health FX This study was supported by internal funds at the National Institute for Occupational Safety and Health. NR 30 TC 1 Z9 1 U1 0 U2 3 PU INT SOC AGING & DISEASE PI FORT WORTH PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA SN 2152-5250 J9 AGING DIS JI Aging Dis. PD FEB PY 2016 VL 7 IS 1 DI 10.14336/AD.2015.0920 PG 13 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA DO5AV UT WOS:000377796900001 ER PT J AU Sohler, N Matti-Orozco, B Young, E Li, X Gregg, EW Ali, MK Bullard, KM Albu, JB AF Sohler, Nancy Matti-Orozco, Brenda Young, Edwin Li, Xuan Gregg, Edward W. Ali, Mohammed K. Bullard, Kai McKeever Albu, Jeanine B. TI OPPORTUNISTIC SCREENING FOR DIABETES AND PREDIABETES USING HEMOGLOBIN A1C IN AN URBAN PRIMARY CARE SETTING SO ENDOCRINE PRACTICE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; FASTING GLUCOSE; NATIONAL-HEALTH; SECULAR CHANGES; PLASMA-GLUCOSE; LIFE-STYLE; US ADULTS; FOLLOW-UP; HIGH-RISK; PREVALENCE AB Objective: In 2010, the American Diabetes Association (ADA) endorsed hemoglobin A1c (HbA1c) as 1 of 3 tests for diabetes and prediabetes screening. We describe the use of HbA1c testing for screening during routine visits in primary care clinics of an urban health care system in the U.S. Methods: In 2013 to 2014, retrospective analyses of deidentified electronic health records over a 2-year period, January 2010 to December 2011, for academic private practices (clinic group 1) and federally-qualified Community Health Centers (clinic group 2) identified 11,885 adults without prior diabetes or recent HbA1c testing. We estimated the proportion of patients eligible for screening according to ADA and U.S. Preventative Services Task Force (USPSTF) guidelines and calculated the potential yield of previously undiagnosed diabetes or prediabetes among those who received at least 1 HbA1c test. Results: Overall, 3,316 and 5,613 patients of clinic groups 1 and 2 (75.2% of each) were eligible for screening by ADA guidelines, while only 1,764 (39.9%) of clinic group 1 and 3,799 (50.9%) of clinic group 2 were eligible by USPSTF guidelines. In those eligible by either guideline, 731 (21.4%) patients of clinic group 1 and 1,293 (21.5%) of clinic group 2 received HbA1c testing; among these, in 71 (9.7%) and 121 (9.4%) patients from clinic groups 1 and 2, respectively, HbA1c results were in the diabetes range, and in 330 (45.2%) and 733 (56.7%), results were in the prediabetes range. Conclusion: In urban primary care settings, appropriate HbA1c testing could result in the detection of a substantial number of previously undiagnosed diabetes and prediabetes cases needing treatment. C1 [Sohler, Nancy] CUNY City Coll, CUNY Med Sch, Sophie Davis Sch Biomed Educ, New York, NY 10031 USA. [Matti-Orozco, Brenda; Young, Edwin; Albu, Jeanine B.] Icahn Sch Med Mt Sinai, Mt Sinai St Lukes Hosp, Dept Med, Div Endocrinol, New York, NY 10029 USA. [Matti-Orozco, Brenda; Young, Edwin; Albu, Jeanine B.] Icahn Sch Med Mt Sinai, Mt Sinai St Lukes Hosp, Dept Med, Div Diabet & Nutr, New York, NY 10029 USA. [Matti-Orozco, Brenda; Young, Edwin; Albu, Jeanine B.] Icahn Sch Med Mt Sinai, Mt Sinai St Lukes Hosp, Dept Med, Div Gen Med, New York, NY 10029 USA. [Matti-Orozco, Brenda; Young, Edwin; Albu, Jeanine B.] Icahn Sch Med Mt Sinai, Mt Sinai Roosevelt Hosp, New York, NY 10029 USA. [Li, Xuan] CUNY, Res Fdn, New York, NY 10021 USA. [Gregg, Edward W.; Ali, Mohammed K.; Bullard, Kai McKeever] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. RP Albu, JB (reprint author), Mt Sinai St Lukes Hosp, Dept Med, Div Endocrinol Diabet & Nutr, 1111 Amsterdam Ave, New York, NY 10025 USA.; Albu, JB (reprint author), Mt Sinai Roosevelt Hosp, 1111 Amsterdam Ave, New York, NY 10025 USA. EM JAlbu@chpnet.org FU CDC [U58-DP002717]; NIH/NIDDK [U58-DP002717] FX This study was funded jointly by the CDC and NIH/NIDDK under U58-DP002717. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the National Institutes of Health. NR 33 TC 1 Z9 1 U1 1 U2 2 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD FEB PY 2016 VL 22 IS 2 BP 143 EP 150 DI 10.4158/EP15866.OR PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DO7NB UT WOS:000377968200003 PM 26484404 ER PT J AU Murrill, CS Bingham, T Lauby, J Liu, KL Wheeler, D Carballo-Dieguez, A Marks, G Millett, GA AF Murrill, Christopher S. Bingham, Trista Lauby, Jennifer Liu, Kai-lih Wheeler, Darrell Carballo-Dieguez, Alex Marks, Gary Millett, Gregorio A. TI Respondent-Driven Sampling in a Multi-Site Study of Black and Latino Men Who Have Sex with Men SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION LA English DT Article DE Respondent-driven sampling; HIV; Field experiences; Men who have sex with men ID HIDDEN POPULATIONS; HIV; SURVEILLANCE; RECRUITMENT; RISK AB Purpose: Respondent-driven sampling (RDS) was used to recruit four samples of Black and Latino men who have sex with men (MSM) in three metropolitan areas to measure HIV prevalence and sexual and drug use behaviors. We compared demographic and behavioral risk characteristics of participants across sites, assessed the extent to which the RDS statistical adjustment procedure provides estimates that differ from the crude results, and summarized our experiences using RDS. Methods: From June 2005 to March 2006 a total of 2,235 MSM were recruited and interviewed: 614 Black MSM and 516 Latino MSM in New York City, 540 Black MSM in Philadelphia, and 565 Latino MSM in Los Angeles County. Crude point estimates for demographic characteristics, behavioral risk factors and HIV prevalence were calculated for each of the four samples. RDS Analysis Tool was used to obtain population-based estimates of each sampled population's characteristics. Results: RDS adjusted estimates were similar to the crude estimates for each study sample on demographic characteristics such as age, income, education and employment status. Adjusted estimates of the prevalence of risk behaviors were lower than the crude estimates, and for three of the study samples, the adjusted HIV prevalence estimates were lower than the crude estimates. However, even the adjusted HIV prevalence estimates were higher than what has been previously estimated for these groups of MSM in these cities. Each site faced unique circumstances in implementing RDS. Conclusions: Our experience in using RDS among Black and Latino MSM resulted in diverse recruitment patterns and uncertainties in the estimated HIV prevalence and risk behaviors by study site. C1 [Murrill, Christopher S.; Marks, Gary; Millett, Gregorio A.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE MS E-98, Atlanta, GA 30333 USA. [Bingham, Trista] Los Angeles Cty Dept Publ Hlth, Div HIV & STD Programs, Los Angeles, CA USA. [Lauby, Jennifer] Publ Hlth Management Corp, Philadelphia, PA USA. [Liu, Kai-lih] Human Dev Res Cambodia, Phnom Penh, Cambodia. [Wheeler, Darrell] Loyola Univ Chicago, Grad Sch Social Work, Chicago, IL USA. [Carballo-Dieguez, Alex] New York State Psychiat Inst & Hosp, HIV Ctr Clin & Behav Studies, New York, NY 10032 USA. [Carballo-Dieguez, Alex] Columbia Univ, New York, NY 10027 USA. RP Murrill, CS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE MS E-98, Atlanta, GA 30333 USA. EM csm5@cdc.gov FU U.S. Centers for Disease Control and Prevention FX This study was funded through a cooperative agreement from the U.S. Centers for Disease Control and Prevention. The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 23 TC 0 Z9 0 U1 1 U2 1 PU NATL MED ASSOC PI WASHINGON PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA SN 0027-9684 EI 1943-4693 J9 J NATL MED ASSOC JI J. Natl. Med. Assoc. PD FEB PY 2016 VL 108 IS 1 BP 69 EP 76 DI 10.1016/j.jnma.2015.12.009 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DO3MB UT WOS:000377684600010 PM 26928490 ER PT J AU Bernstein, KT Chow, JM Pathela, P Gift, TL AF Bernstein, Kyle T. Chow, Joan M. Pathela, Preeti Gift, Thomas L. TI Bacterial Sexually Transmitted Disease Screening Outside the Clinic-Implications for the Modern Sexually Transmitted Disease Program SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID CHLAMYDIA-TRACHOMATIS INFECTION; COST-EFFECTIVENESS ANALYSIS; JUVENILE DETENTION CENTERS; NEISSERIA-GONORRHOEAE; SAN-FRANCISCO; VAGINAL SWABS; CORRECTIONAL FACILITIES; NONCLINICAL SETTINGS; INCARCERATED MEN; HIV PREVALENCE AB Background: The development of noninvasive nucleic acid amplification tests for chlamydia and gonorrhea has facilitated innovation in moving sexually transmitted disease (STD) screening to nonclinical settings. However, limited data are available to inform local STD programs on evidence-based approaches to STD screening in nonclinical settings in the United States. Methods: We conducted a systematic review of the literature published since 2000 related to chlamydia, gonorrhea, and syphilis screening in US correctional settings, bathhouses and sex venues, self-collected at-home testing, and other nonclinical sites. Results: Sixty-four articles met eligibility criteria and were reviewed. Although data on testing volume and positivity were available, there were scarce data on the proportion of new positives treated and the programmatic costs for the various screening programs. Screening in correctional settings identified a sizable amount of asymptomatic infections. The value and sustainability of screening in the other nonclinical settings examined was not clear from the published literature. Conclusions: Local and state health departments should explore the development of sustainable jail and juvenile detention screening programs for STDs. Furthermore, local programs should pilot outreach and home-based STD screening programs to determine if they are identifying asymptomatic persons who would not have otherwise been found. Local programs are encouraged to present and publish their findings related to non clinic-based screening to enhance the limited body of literature; data on the proportion of new infections treated and the local program costs are needed. C1 [Bernstein, Kyle T.; Gift, Thomas L.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Chow, Joan M.] Calif Dept Publ Hlth, Sexually Transmitted Dis Control Branch, Richmond, CA USA. [Pathela, Preeti] Bur STD Control, New York City Dept Hlth & Mental Hyg, New York, NY USA. RP Bernstein, KT (reprint author), CDC NCHHSTP DSTDP, 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA. EM Kio8@cdc.gov NR 71 TC 0 Z9 0 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2016 VL 43 SU 1 BP S42 EP S52 DI 10.1097/OLQ.0000000000000343 PG 11 WC Infectious Diseases SC Infectious Diseases GA DN7MV UT WOS:000377261200007 PM 26779687 ER PT J AU Brookmeyer, KA Hogben, M Kinsey, J AF Brookmeyer, Kathryn A. Hogben, Matthew Kinsey, Jennine TI The Role of Behavioral Counseling in Sexually Transmitted Disease Prevention Program Settings SO SEXUALLY TRANSMITTED DISEASES LA English DT Review ID SERVICES-TASK-FORCE; CONTROLLED-TRIAL; HIGH-RISK; RANDOMIZED-TRIAL; HIV-PREVENTION; UNITED-STATES; PRIMARY-CARE; CONDOM USE; INTERVENTIONS; INFECTIONS AB Background: Behavioral counseling for sexually transmitted disease (STD) prevention is recommended for persons at risk, and the body of evidence yields numerous interventions that have STD preventive efficacy. What is needed is a review of the subset of these interventions that could be feasible in clinical settings, especially settings in STD prevention programs. Methods: We reviewed existing systematic reviews of the literature and abstracted from them studies that fit the following criteria in that the interventions: (1) used no more than 60 minutes of contact time in Ito 2 sessions, (2) were individual level and face to face, (3) took place in a clinical setting, (4) had STD outcomes available, (5) were based in the United States, (6) were peer reviewed, and (7) had a control group. Results: From 6 reviews (published 2006-2014) covering 91 studies, we found 13 analyses representing 11 intervention studies that fit the selection criteria. Of these 13, 5 returned lower STD rates in the intervention group at follow-up; one study reported a higher rate of STD in one subset of the intervention group (men who have sex with men). Studies with effects on STD at follow-up were quite similar to studies across populations, settings, and follow-up periods, although successful interventions were more likely to demonstrate behavioral effects as well (5/5 vs. 2/5 among 10 interventions measuring behavior change). Conclusions: Counseling is likely to benefit some STD clinic attendees, although unlikely to benefit men who have sex with men. The balance of costs and benefits of implementing behavioral counseling in STD programs is unclear, but feasibility would be improved if behavioral counseling were implemented in the context of other prevention efforts. Because populations outside typical STD clinic settings could also benefit, programs may exercise a valuable role through partnerships. C1 [Brookmeyer, Kathryn A.; Hogben, Matthew; Kinsey, Jennine] Ctr Dis Control & Prevent, DSTDP, Atlanta, GA 30333 USA. RP Brookmeyer, KA (reprint author), Ctr Dis Control & Prevent, Mail Stop E-44, Atlanta, GA 30333 USA. EM kbrookmeyer@cdc.gov FU Intramural CDC HHS [CC999999] NR 37 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2016 VL 43 SU 1 BP S102 EP S112 DI 10.1097/OLQ.0000000000000327 PG 11 WC Infectious Diseases SC Infectious Diseases GA DN7MV UT WOS:000377261200012 PM 26779681 ER PT J AU Carter, MW Wu, H Cohen, S Hightow-Weidman, L Lecher, SL Peters, PJ AF Carter, Marion W. Wu, Hsiu Cohen, Stephanie Hightow-Weidman, Lisa Lecher, Shirley Lee Peters, Philip J. TI Linkage and Referral to HIV and Other Medical and Social Services: A Focused Literature Review for Sexually Transmitted Disease Prevention and Control Programs SO SEXUALLY TRANSMITTED DISEASES LA English DT Review ID STD CLINIC PATIENTS; UNITED-STATES; INFECTED PERSONS; CARE SETTINGS; HEALTH-CARE; INTERVENTION SERVICES; EMERGENCY-DEPARTMENT; SURVEILLANCE DATA; AFRICAN-AMERICAN; SEEKING CARE AB Background: Sexually transmitted disease (STD) program and clinic staff play an important role in providing linkage and referrals to programs and services that address the complex medical and psychosocial needs of their clients. We synthesized recent published literature related to effective practices for linkage to care for HIV and referral to other medical and social services. Methods: Three PubMed searches were conducted to identify relevant studies published since 2004 on (1) linkage to HIV care, (2) referral within STD clinical contexts, and (3) (review articles only) referral practices among all medical specialties. Systematic review procedures were not used. Results: Thirty-three studies were included in this review. Studies highlight the limited value of passive referral practices and the increased effectiveness of active referral and linkage practices. Numerous studies on linkage to HIV care suggest that case management approaches, cultural -linguistic concordance between linkage staff and clients, and structural features such as colocation facilitate timely linkage to care. Integration of other medical and social services such as family planning and alcohol screening services into STD settings may be optimal but resource -intensive. Active referral practices such as having a written referral protocols and agreements, using information technology to help transfer information between providers, and making appointments for clients may offer some benefit. Few studies included information on program costs associated with linkage and referral. Conclusions: Recent literature provides some guideposts for STD program and clinical staff to use in determining their approach to helping link and refer clients to needed care. Much experience with these issues within STD services remains unpublished, and key gaps in the literature remain. C1 [Carter, Marion W.] CDC, Div STD Prevent, 1600 Clifton Rd,MS-E-80, Atlanta, GA 30333 USA. [Wu, Hsiu; Lecher, Shirley Lee; Peters, Philip J.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Cohen, Stephanie] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Hightow-Weidman, Lisa] Univ N Carolina, Sch Med, Chapel Hill, NC USA. RP Carter, MW (reprint author), CDC, Div STD Prevent, 1600 Clifton Rd,MS-E-80, Atlanta, GA 30333 USA. NR 52 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2016 VL 43 SU 1 BP S76 EP S82 DI 10.1097/OLQ.0000000000000290 PG 7 WC Infectious Diseases SC Infectious Diseases GA DN7MV UT WOS:000377261200010 PM 26779689 ER PT J AU Carter, MW AF Carter, Marion W. TI Program Evaluation for Sexually Transmitted Disease Programs: In Support of Effective Interventions SO SEXUALLY TRANSMITTED DISEASES LA English DT Review ID NEW-YORK-CITY; HEALTH; NOTIFICATION; IMPROVEMENT; CHLAMYDIA; IMPACT AB Program evaluation is a key tool for gathering evidence about the value and effectiveness of sexually transmitted disease (STD) prevention programs and interventions. Drawing from published literature, the Centers for Disease Control and Prevention evaluation framework, and program examples, this article lays out some of the key principles of program evaluation for STD program staff. The purpose is to offer STD program staff a stronger basis for talking about, planning, conducting, and advocating for evaluation within their respective program contexts. C1 [Carter, Marion W.] Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS-E-80, Atlanta, GA 30333 USA. RP Carter, MW (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS-E-80, Atlanta, GA 30333 USA. EM acq0@cdc.gov NR 13 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2016 VL 43 SU 1 BP S11 EP S17 DI 10.1097/OLQ.0000000000000281 PG 7 WC Infectious Diseases SC Infectious Diseases GA DN7MV UT WOS:000377261200004 PM 26779682 ER PT J AU Friedman, AL Kachur, RE Noar, SM McFarlane, M AF Friedman, Allison L. Kachur, Rachel E. Noar, Seth M. McFarlane, Mary TI Health Communication and Social Marketing Campaigns for Sexually Transmitted Disease Prevention and Control: What Is the Evidence of their Effectiveness? SO SEXUALLY TRANSMITTED DISEASES LA English DT Review ID HIGH-SENSATION-SEEKING; IDENTIFIED LATINO MEN; MASS-MEDIA CAMPAIGNS; LOS-ANGELES-COUNTY; HIV-PREVENTION; SYPHILIS PREVENTION; BISEXUAL MEN; UNITED-STATES; YOUNG-ADULTS; NYC CONDOM AB Background: Despite the ubiquity of sex in the media, a culture of silence surrounds sexual health in the United States, serving as a barrier to sexually transmitted disease (STD) prevention, testing, and treatment. Campaigns can increase STD-related knowledge, communication, and protective behaviors. This review assesses the effectiveness of STD prevention and testing campaigns in the United States to inform the field on their use as a strategy for affecting behavior change. Methods: A comprehensive literature search was conducted to identify original research articles, published between 2000 and 2014, which report on US media campaigns promoting community- or population-level STD testing or prevention behaviors and are evaluated for impact on one or more behavioral outcomes. Titles and abstracts were independently reviewed by 2 researchers. Results: The review yielded 26 articles representing 16 unique STD testing and/or prevention campaigns. Most campaigns were developed using formative research and social marketing or behavioral theory. Most campaigns (68.75%) used posttest -only or pretest-posttest designs without comparison groups for evaluation; only 5 campaigns used control groups, and these proved challenging (i.e., achieving necessary exposure and avoiding contamination). Nearly all campaigns found differences between exposed and unexposed individuals on one or more key behavioral outcomes. Several campaigns found dose -response relationships. Among evaluations with uncontaminated control groups whose campaigns achieved sufficient exposure, sustained campaign effects were observed among targeted populations. Conclusions: Current findings suggest that campaigns can impact targeted STD-related behaviors and add to the evidence that greater exposure is associated with greater behavior change. C1 [Friedman, Allison L.; Kachur, Rachel E.; McFarlane, Mary] Ctr Dis Control & Prevent, Div STD Prevent, CDC, Atlanta, GA 30333 USA. [Noar, Seth M.] Univ N Carolina, Sch Journalism & Mass Commun, Chapel Hill, NC 27515 USA. RP Friedman, AL (reprint author), Ctr Dis Control & Prevent, CDC, 1600 Clifton Rd,NE Mail Stop E-44, Atlanta, GA 30333 USA. EM alf8@cdc.gov NR 72 TC 1 Z9 1 U1 9 U2 18 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2016 VL 43 SU 1 BP S83 EP S101 DI 10.1097/OLQ.0000000000000286 PG 19 WC Infectious Diseases SC Infectious Diseases GA DN7MV UT WOS:000377261200011 PM 26779691 ER PT J AU Gift, TL Aral, SO AF Gift, Thomas L. Aral, Sevgi O. TI Predicting the Marginal Impact of Interventions-Issues and Challenges SO SEXUALLY TRANSMITTED DISEASES LA English DT Editorial Material ID CONTROLLED-TRIAL; HIV; PREVENTION; SEX; EPIDEMICS; EFFICACY; RISK; TRANSMISSION; UNCERTAINTY; SENSITIVITY AB Assessing the impact of interventions individually and in combination with other interventions is an an important part of developing and implementing an optimal mix of activities for sexually transmitted disease (STD) prevention.1-2 Identifying outcomes of interest is one of the first steps and designing evaluations to determine the impact of the interventions on those outcomes follows.3 However, quantifying the marginal impact of interventions can be challenging, given the multiple confounding factors that can be present due to other programs, changes in the epidemiological context, and population-level trends in mixing or risk behavior that may be unrecognized or unquantified.(4,6) We identify some of the issues that may complicate the estimation of intervention impact and that may affect the impact that interventions have on the outcomes of interest to STD prevention programs. Much of what we know about program and intervention effectiveness comes from research studies. Randomized controlled trials (RCTs) are widely considered to be the gold standard in determining intervention effect,7 although quality observational studies often yield results that are generally comparable.(8) Randomized controlled trials by design focus on limited controlled differences in interventions to best assess the impact of the interventions on the outcome or outcomes of interest. In observational studies, the investigators have less control but attempt to collect data sufficient to analyze the impact of the interventions being analyzed.(3) With both types of studies, key issues for programmatic translation include scalability and the ability to target the interventions to relevant populations.(4,9) Modeling studies also contribute to the body of knowledge around program effectiveness, but modeling studies typically draw data for model inputs from RCTs, observational studies, and other literature. Well-designed modeling studies include sensitivity analyses; these often vary a small group of parameters individually or together, or vary larger sets of parameters randomly, such as with Monte Carlo simulation (or a modification, such as Latin hypercube sampling).(10,12) Whether limited or comprehensive, sensitivity analyses generally vary parameters over their ranges. If some of the parameters influence others in ways that are not explicitly accounted for in the model, sensitivity analyses relying on random variation may lead to misleading conclusions about the range of outcomes likely to be associated with the program or intervention when implemented. Although interventions are often studied in isolation, there may be crossover effects that impact their effectiveness. Interventions may have synergistic or antagonistic effects on each other. Interventions that are synergistic achieve a greater impact on outcomes when implemented together than the sum of the outcomes that would result from implementing either separately.13 Interventions that are antagonistic toward each other have less impact when combined than the sum of implementing them individually. These concepts can be defined mathematically, and interventions may meet the definition either additively, multiplicatively, or both.(13,14) However, the effect of synergistic or antagonistic impacts can be intuitively understood. For example, condoms are recommended to prevent STD and HIV transmission. Although not often a formal public health intervention, seroadaptive behaviors such as serosorting or seropositioning are sometimes used by men who have sex with men to reduce HIV transmission risk.(15,16) However, condom use is lower in men using seroadaptive practices.(17,19) Therefore, seroadaption may have an antagonistic effect on the marginal impact of an intervention designed to increase condom usage. If seroadaptive behaviors are increasing over time, the marginal impact of a condom promotion intervention may diminish.(20) The impact of seroadaptive behaviors may not just overlap with condoms; it may reduce the effectiveness of interventions designed to increase condom usage. Synergies may be found with interventions that can achieve the same outcomes but that do not directly impact each other. For example, interventions designed to improve the HIV care continuum may be enhanced by promoting STD screening in persons who are HIV infected.(21) Receipt of STD services provides another opportunity to maintain high levels of HIV care. Patients not in care may be motivated by an intervention to seek STD screening, at which time they can be reengaged in care. Sexually transmitted disease screening together with other HIV retention and linkage interventions may lead to more patients achieving viral suppression than the sum of what they could do if implemented separately. C1 [Gift, Thomas L.; Aral, Sevgi O.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Gift, TL (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-80, Atlanta, GA 30333 USA. EM tgift@cdc.gov NR 36 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2016 VL 43 SU 1 BP S8 EP S10 DI 10.1097/OLQ.0000000000000330 PG 3 WC Infectious Diseases SC Infectious Diseases GA DN7MV UT WOS:000377261200003 PM 26779690 ER PT J AU Hogben, M Collins, D Hoots, B O'Connor, K AF Hogben, Matthew Collins, Dayne Hoots, Brooke O'Connor, Kevin TI Partner Services in Sexually Transmitted Disease Prevention Programs: A Review SO SEXUALLY TRANSMITTED DISEASES LA English DT Review ID CHLAMYDIAL INFECTION; GONORRHEA INCIDENCE; REFERRAL SERVICES; SEX PARTNERS; NOTIFICATION; HIV; THERAPY; STD; NETWORKS; HEALTH AB Background: Partner services have been a mainstay of public health sexually transmitted disease (STD) prevention programs for decades. The principal goals are to interrupt transmission and reduce STD morbidity and sequelae. In this article, we review current literature with the goal of informing STD prevention programs. Methods: We searched the literature for systematic reviews. We found 9 reviews published between 2005 and 2014 (covering 108 studies). The reviews varied by study inclusion criteria (e.g., study methods, geographic location, and infections). We abstracted major conclusions and recommendations from the reviews. Results: Conclusions and recommendations were divided into patient referral interventions and provider referral interventions. For patient referral, there was evidence supporting the use of expedited partner therapy and interactive counseling, but not purely didactic instruction. Provider referral through Disease Intervention Specialists was efficacious and particularly well supported for HW For other studies, modeling data and testing outcomes showed that partner notification in general reached high prevalence populations. Reviews also suggested more focus on using technology and population-level implementation strategies. However, partner services may not be the most efficient means to reach infected persons. Conclusions: Partner services programs constitute a large proportion of program STD prevention activities. Value is maximized by balancing a portfolio of patient and provider referral interventions and by blending partner notification interventions with other STD prevention interventions in overall partner services program structure. Sexually transmitted disease prevention needs program-level research and development to generate this portfolio. C1 [Hogben, Matthew; Collins, Dayne; O'Connor, Kevin] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Hoots, Brooke] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Hogben, M (reprint author), Ctr Dis Control & Prevent, Mail Stop E-44, Atlanta, GA 30333 USA. EM mhogben@cdc.gov FU Intramural CDC HHS [CC999999] NR 56 TC 2 Z9 2 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2016 VL 43 SU 1 BP S53 EP S62 DI 10.1097/OLQ.0000000000000328 PG 10 WC Infectious Diseases SC Infectious Diseases GA DN7MV UT WOS:000377261200008 PM 26779688 ER PT J AU Kroeger, K Torrone, E Nelson, R AF Kroeger, Karen Torrone, Elizabeth Nelson, Robert TI Assessment: A Core Function for Implementing Effective Interventions in Sexually Transmitted Disease Control Programs SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID NEW-YORK-CITY; INFECTIONS; US; GONORRHEA; SEX; SURVEILLANCE; DISPARITIES; POLICIES; NETWORK; CONTEXT AB Assessment is a core function in sexually transmitted disease (STD) prevention and control programs. Assessment is more than reviewing case report data; it includes taking into consideration an array of data of various sources and types to be able to respond to emerging disease threats, align human and financial resources, and plan for the future. In this article, we outline key assessment domains, data sources, activities, and methods for STD programs. We present an illustrative case study of how assessment can be used to identify effective interventions for STD control. C1 Ctr Dis Control & Prevent, Div STD Prevent & Surveillance, Natl Ctr HIV AIDS, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Data Management Branch, Natl Ctr HIV AIDS, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS, Atlanta, GA 30333 USA. RP Kroeger, K (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E-44, Atlanta, GA 30333 USA. EM knk2@cdc.gov NR 31 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2016 VL 43 SU 1 BP S3 EP S7 DI 10.1097/OLQ.0000000000000285 PG 5 WC Infectious Diseases SC Infectious Diseases GA DN7MV UT WOS:000377261200002 PM 26779686 ER PT J AU Leichliter, JS Seiler, N Wohlfeiler, D AF Leichliter, Jami S. Seiler, Naomi Wohlfeiler, Dan TI Sexually Transmitted Disease Prevention Policies in the United States: Evidence and Opportunities SO SEXUALLY TRANSMITTED DISEASES LA English DT Review ID EXPEDITED PARTNER THERAPY; FAMILY-PLANNING CLINICS; PUBLIC-HEALTH; CHLAMYDIAL INFECTIONS; PATIENT; CARE; COMMUNITY; SERVICES; IMPACT; WOMEN AB Policies are an important part of public health interventions, including in the area of sexually transmitted disease (STD) prevention. Similar to other tools used in public health, policies are often evaluated to determine their usefulness. Therefore, we conducted a nonsystematic review of policy evidence for STD prevention. Our review considers assessments or evaluations of STD prevention specific policies, health care system policies, and other, broader policies that have the potential to impact STD prevention through social determinants of health. We also describe potential policy opportunity in these areas. It should be noted that we found gaps in policy evidence for some areas; thus, additional research would be useful for public health policy interventions for STD prevention. C1 [Leichliter, Jami S.] Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E-44, Atlanta, GA 30333 USA. [Seiler, Naomi] George Washington Univ, Dept Hlth Policy & Management, Milken Inst Sch Publ Hlth, Washington, DC USA. [Wohlfeiler, Dan] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Leichliter, JS (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E-44, Atlanta, GA 30333 USA. EM jleichliter@cdc.gov FU Intramural CDC HHS [CC999999] NR 62 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2016 VL 43 SU 1 BP S113 EP S121 DI 10.1097/OLQ.0000000000000289 PG 9 WC Infectious Diseases SC Infectious Diseases GA DN7MV UT WOS:000377261200013 PM 26779683 ER PT J AU Lewis, FMT Dittus, P Salmon, ME Nsuami, MJ AF Lewis, Felicia M. T. Dittus, Patricia Salmon, Melinda E. Nsuami, M. Jacques TI School-Based Sexually Transmitted Disease Screening: Review and Programmatic Guidance SO SEXUALLY TRANSMITTED DISEASES LA English DT Review ID FAMILY-PLANNING CLINICS; FRANCISCO HIGH-SCHOOLS; PUBLIC HIGH-SCHOOLS; CHLAMYDIA-TRACHOMATIS; COST-EFFECTIVENESS; NEISSERIA-GONORRHOEAE; NEW-ORLEANS; HIGH-RISK; ADOLESCENTS; INFECTION AB School-based sexually transmitted disease (STD) screening (SBSS) was designed to provide chlamydia and gonorrhea testing, treatment, and counseling to adolescents in a school setting to overcome some of the difficulties of screening in this population. To inform STD control programs and other entities on decision making about potentially implementing this intervention, we reviewed existing published and gray literature on SBSS from 1998 to 2014. Although they are work -intensive to establish, school -based STD screening programs are a feasible and costeffective way of testing large numbers of male and female adolescents for chlamydia and gonorrhea, and to provide counseling and treatment to almost all those who are found infected. School -based STD screening programs do not seem to reduce prevalence in either the school or the general adolescent population, although there are currently relatively few studies on large-scale SBSS. More research in this field is needed. C1 [Lewis, Felicia M. T.; Dittus, Patricia; Salmon, Melinda E.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Lewis, Felicia M. T.; Salmon, Melinda E.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Nsuami, M. Jacques] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. RP Lewis, FMT (reprint author), CDC, Philadelphia Dept Publ Hlth, Philadelphia, PA USA. EM felicia.lewis@phila.gov NR 47 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2016 VL 43 SU 1 BP S18 EP S27 DI 10.1097/OLQ.0000000000000283 PG 10 WC Infectious Diseases SC Infectious Diseases GA DN7MV UT WOS:000377261200005 PM 26779684 ER PT J AU Peterman, TA Carter, MW AF Peterman, Thomas A. Carter, Marion W. TI Effective Interventions to Reduce Sexually Transmitted Disease: Introduction to the Special Issue SO SEXUALLY TRANSMITTED DISEASES LA English DT Editorial Material ID IMPLEMENTATION; PROGRAM AB When the US National Gonorrhea Control Program was launched in 1973, it added a layer of complexity toprograms that had previously focused almost entirely on syphilis.' Now, there are more than 35 sexually transmitted or transmissible pathogens,2 and counting only 8 of them, the prevalence was estimated to be 110 million in the United States in 2008.3 Although interventions to control these infections still fit into the general categories outlined by Parran4 in the 1930s, there are now more options and approaches, including vaccination, preexposure prophylaxis, treatment, education, screening, providing condoms, and more. These interventions are accomplished using partners from community -based organizations, federally qualified health centers, departments of corrections, schools, private providers, and business partners like MTV. The mix of sexually transmitted disease (STD) and potential control strategies varies across populations so programs are quite different in Maine, Montana, Miami, and Memphis. It is now common for programs to be pulled in multiple directions. Compared with the complexity of navigating through all the issues faced by programs, the goal of this special issue was simple: to summarize the published evidence for effectiveness of various kinds of interventions to control STD, with today's STD program staff in mind. What does the latest evidence say is more (or less) effective for meeting a program's goals? How does the literature suggest programs can accomplish more while spending less? We sought to develop a menu of options to help programs identify effective interventions that meet their needs. The published literature was helpful in some ways, but not in others. One problem authors faced while preparing the menu was that few of the publications on interventions included any cost information, and when costs were included, they were calculated so differently that they could not be compared across studies. In addition, the benefits of the interventions were hard to compare. For example, some articles reported the percent of persons screened who tested positive, but the articles lacked details about how many were newly identified infections, how many were treated, or how much onward transmission was prevented. Furthermore, the cost and benefits of an intervention depend on the context and on other interventions that are already in place. Authors also faced the common problem of summarizing evidence from studies with varying levels of rigor and potential bias. Finally, how does a program balance interventions across the mix of policy, screening, partner services, and community outreach? This is the challenge of program science. 5,6 Although this special issue does not solve the problem of balancing screening with social marketing, it does help identify which screening approaches work best, and it identifies key components of successful social marketing, among other findings. The issue includes 3 overview articles and 9 articles focused on a range of STD interventions. The overview articles provide high-level summaries of 3 cross-cutting programmatic concerns: assessment, program evaluation, and predicting the impact of interventions. Those articles offer frameworks for conceptualizing these issues and provide practical information to help STD program staff use them in their work. The articles focused on STD interventions include traditional approaches such as partner notification and screening programs in clinical settings, schools, and outreach settings, as well as broader interventions such as social marketing, behavioral counseling, linkage and referral to care, and policy interventions. In all cases, the recent literature offers some helpful guideposts for STD programs today. Programs have different needs, and readers have different interests, so highlights of these articles will be highly reader dependent. Here are a few notable findings: C1 [Peterman, Thomas A.; Carter, Marion W.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Peterman, TA (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Mailstop E02,1600 Clifton Rd, Atlanta, GA 30333 USA. EM tap1@cdc.gov NR 8 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2016 VL 43 SU 1 BP S1 EP S2 DI 10.1097/OLQ.0000000000000373 PG 2 WC Infectious Diseases SC Infectious Diseases GA DN7MV UT WOS:000377261200001 PM 26771401 ER PT J AU Taylor, MM Frasure-Williams, J Burnett, P Park, IU AF Taylor, Melanie M. Frasure-Williams, Jessica Burnett, Phyllis Park, Ina U. TI Interventions to Improve Sexually Transmitted Disease Screening in Clinic-Based Settings SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; CHLAMYDIA-TRACHOMATIS INFECTION; GENERAL-PRACTICE; PRIMARY-CARE; YOUNG-WOMEN; ASYMPTOMATIC SYPHILIS; UNITED-STATES; HIV-INFECTION; EDUCATIONAL INTERVENTION; HEALTH PRACTICE AB Background: The asymptomatic nature and suboptimal screening rates of sexually transmitted diseases (STD) call for implementation of successful interventions to improve screening in community-based clinic settings with attention to cost and resources. Methods: We used MEDLINE to systematically review comparative analyses of interventions to improve STD (chlamydia, gonorrhea, or syphilis) screening or rescreening in clinic -based settings that were published between January 2000 and January 2014. Absolute differences in the percent of the target population screened between comparison groups or relative percent increase in the number of tests or patients tested were used to score the interventions as highly effective (>20% increase) or moderately effective (5%-19% increase) in improving screening. Published cost of the interventions was described where available and, when not available, was estimated. Results: Of the 4566 citations reviewed, 38 articles describing 42 interventions met the inclusion criteria. Of the 42 interventions, 16 (38.1%) were categorized as highly effective and 14 (33.3%) as moderately effective. Effective low-cost interventions (<$1000) included the strategic placement of specimen collection materials or automatic collection of STD specimens as part of a routine visit (7 highly effective and 1 moderately effective) and the use of electronic health records (EHRs; 3 highly effective and 4 moderately effective). Patient reminders for screening or rescreening (via text, telephone, and postcards) were highly effective (3) or moderately effective (2) and low or moderate cost (<$1001-10,000). Interventions with dedicated clinic staff to improve STD screening were highly effective (2) or moderately effective in improving STD screening (1) but high cost ($10,001 $100,000). Conclusions: Successful interventions include changing clinic flow to routinely collect specimens for testing, using EHR screening reminders, and reminding patients to get screened or rescreened. These strategies can be tailored to different clinic settings to improve screening at a low cost. C1 [Taylor, Melanie M.; Burnett, Phyllis] Ctr Dis Control & Prevent, Div STD Prevent, CDC, Atlanta, GA USA. [Taylor, Melanie M.] Arizona Dept Hlth Serv, STD Program, Phoenix, AZ 85007 USA. [Frasure-Williams, Jessica; Park, Ina U.] Calif Dept Publ Hlth, STD Control Branch, Div Communicable Dis Control, Ctr Infect Dis, Sacramento, CA USA. [Burnett, Phyllis] Baltimore Dept Publ Hlth, Baltimore, MD USA. RP Taylor, MM (reprint author), CDC NCHHSTP DSTDP, 1645 East Roosevelt, Phoenix, AZ 85006 USA. EM MDT7@CDC.GOV NR 64 TC 2 Z9 2 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2016 VL 43 SU 1 BP S28 EP S41 DI 10.1097/OLQ.0000000000000294 PG 14 WC Infectious Diseases SC Infectious Diseases GA DN7MV UT WOS:000377261200006 PM 26779685 ER PT J AU Berg, CJ Smith, SA Bascombe, TM Maglakelidze, N Starua, L Topuridze, M AF Berg, Carla J. Smith, Samantha A. Bascombe, Ta Misha Maglakelidze, Nino Starua, Lela Topuridze, Marina TI Smoke-Free Public Policies and Voluntary Policies in Personal Settings in Tbilisi, Georgia: A Qualitative Study SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article ID FOCUS GROUPS; FREE HOMES; ACCEPTABILITY; POPULATION; INTERVIEWS; COUNTRIES; EXPOSURE; DISEASE; BURDEN; ADULTS C1 [Berg, Carla J.] Emory Univ, Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. [Smith, Samantha A.] Army Publ Hlth Ctr, Hlth Promot & Wellness Directorate, 8506 Dawnridge Dr, Houston, TX 77071 USA. [Bascombe, Ta Misha] Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30322 USA. [Maglakelidze, Nino; Starua, Lela; Topuridze, Marina] Natl Ctr Dis Control, 9 M Asatiani St, GA-0177 Tbilisi, Rep of Georgia. RP Berg, CJ (reprint author), Emory Univ, Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM cjberg@emory.edu; s.smith012@gmail.com; tsbascombe@gmail.com; nmaglakelidze@yahoo.com; lela.sturua@ncdc.ge; topuridzemarina@gmail.com FU National Cancer Institute [K07 CA139114]; Georgia Cancer Coalition; Council for International Exchange of Scholars Fulbright Scholars Program FX This research was supported by the National Cancer Institute (K07 CA139114; PI: Carla J. Berg), the Georgia Cancer Coalition (PI: Carla J. Berg), and the Council for International Exchange of Scholars Fulbright Scholars Program. We would like to thank the Georgia National Center for Disease Control and Public Health for their scientific input and technical support in conducting this research and Tbilisi State Medical University for hosting Carla J. Berg during her tenure as a Fulbright Scholar in Georgia. NR 35 TC 0 Z9 0 U1 2 U2 2 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD FEB PY 2016 VL 13 IS 2 AR 156 DI 10.3390/ijerph13020156 PG 11 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DG2ME UT WOS:000371900500032 PM 26821035 ER PT J AU Loo, JD Hyseni, L Ouda, R Koske, S Nyagol, R Sadumah, I Bashin, M Sage, M Bruce, N Pilishvili, T Stanistreet, D AF Loo, Jennifer D. Hyseni, Lirije Ouda, Rosebel Koske, Selline Nyagol, Ronald Sadumah, Ibrahim Bashin, Michelle Sage, Mike Bruce, Nigel Pilishvili, Tamara Stanistreet, Debbi TI User Perspectives of Characteristics of Improved Cookstoves from a Field Evaluation in Western Kenya SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article ID COOKING PRACTICES; INTERVENTIONS C1 [Loo, Jennifer D.; Pilishvili, Tamara] Ctr Dis Control & Prevent, Resp Dis Branch, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop C-25, Atlanta, GA 30329 USA. [Hyseni, Lirije; Bruce, Nigel; Stanistreet, Debbi] Univ Liverpool, Dept Publ Hlth & Policy, Inst Psychol Hlth & Soc, Liverpool L69 3GB, Merseyside, England. [Ouda, Rosebel; Koske, Selline; Nyagol, Ronald; Sadumah, Ibrahim] Safe Water & AIDS Project, Res Unit, Kisumu 40100, Kenya. [Bashin, Michelle] Inst Publ Hlth, Oakland, CA 94607 USA. [Sage, Mike] Global Alliance Clean Cookstoves, Washington, DC 20006 USA. RP Loo, JD (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop C-25, Atlanta, GA 30329 USA. EM JLoo@cdc.gov; L.Hyseni@liverpool.ac.uk; rozzypats@gmail.com; chepkwemoiselin@yahoo.com; ronotien0@yahoo.com; sirahimahs@gmail.com; mbashin@phi.org; mikesage44@gmail.com; ngb@liverpool.ac.uk; tdp4@cdc.gov; D.L.Stanistreet@liverpool.ac.uk NR 20 TC 3 Z9 3 U1 5 U2 8 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD FEB PY 2016 VL 13 IS 2 AR 167 DI 10.3390/ijerph13020167 PG 14 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DG2ME UT WOS:000371900500006 PM 26828505 ER PT J AU Claes, F Morzaria, SP Donis, RO AF Claes, Filip Morzaria, Subhash P. Donis, Ruben O. TI Emergence and dissemination of clade 2.3.4.4 H5Nx influenza viruses - how is the Asian HPAI H5 lineage maintained SO CURRENT OPINION IN VIROLOGY LA English DT Article ID PATHOGENIC AVIAN INFLUENZA; MIGRATORY BIRDS; SOUTH-KOREA; GENETIC-CHARACTERIZATION; A(H5N8) VIRUS; WILD BIRDS; A H5N2; CHINA; REASSORTANT; POULTRY AB Highly pathogenic avian influenza (HPAI) A(H5N1) viruses containing the A/goose/Guangdong/96-like (GD/96) HA genes circulated in birds from four continents in the course of 2015 (Jan to Sept). A new HA Glade, termed 2.3.4.4, emerged around 2010-2011 in China and revealed a novel propensity to reassort with NA subtypes other than N1, unlike dozens of earlier clades. Two subtypes, H5N6 and H5N8, have spread to countries in Asia (H5N6), Europe and North America (H5N8). Infections by clade 2.3.4.4 viruses are characterized by low virulence in poultry and some wild birds, contributing to wide geographical dissemination of the viruses via poultry trade and wild bird migration. C1 [Claes, Filip] Food & Agr Org United Nations FAO, Reg Off Asia & Pacific, Bangkok, Thailand. [Morzaria, Subhash P.] Food & Agr Org United Nations FAO, Viale Terme Di Caracalla, I-00153 Rome, Italy. [Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. RP Claes, F (reprint author), Food & Agr Org United Nations FAO, Reg Off Asia & Pacific, Bangkok, Thailand.; Donis, RO (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. EM Filip.Claes@fao.org; rdonis@cdc.gov FU USAID Emerging Pandemic Threat programme (EPT) FX We would like to thank all our colleagues at FAO headquarters and FAO-ECTAD (Emergency Center for Transboundary Animal Diseases) offices around the world for their insights and discussions about the topic of this review. The information used in the paper is derived from the work supported by the USAID Emerging Pandemic Threat programme (EPT), and the authors would like to thank them for their continued support. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the Food and Agriculture Organization of the United Nations. NR 39 TC 10 Z9 11 U1 4 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1879-6257 J9 CURR OPIN VIROL JI Curr. Opin. Virol. PD FEB PY 2016 VL 16 BP 158 EP 163 DI 10.1016/j.coviro.2016.02.005 PG 6 WC Virology SC Virology GA DK2AK UT WOS:000374716800023 PM 26991931 ER PT J AU Reniers, G Wamukoya, M Urassa, M Nyaguara, A Nakiyingi-Miiro, J Lutalo, T Hosegood, V Gregson, S Gomez-Olive, X Geubbels, E Crampin, AC Wringe, A Waswa, L Tollman, S Todd, J Slaymaker, E Serwadda, D Price, A Oti, S Nyirenda, MJ Nabukalu, D Nyamukapa, C Nalugoda, F Mugurungi, O Mtenga, B Mills, L Michael, D McLean, E McGrath, N Martin, E Marston, M Maquins, S Levira, F Kyobutungi, C Kwaro, D Kasamba, I Kanjala, C Kahn, K Kabudula, C Herbst, K Gareta, D Eaton, JW Clark, SJ Church, K Chihana, M Calvert, C Beguy, D Asiki, G Amri, S Abdul, R Zaba, B AF Reniers, Georges Wamukoya, Marylene Urassa, Mark Nyaguara, Amek Nakiyingi-Miiro, Jessica Lutalo, Tom Hosegood, Vicky Gregson, Simon Gomez-Olive, Xavier Geubbels, Eveline Crampin, Amelia C. Wringe, Alison Waswa, Laban Tollman, Stephen Todd, Jim Slaymaker, Emma Serwadda, David Price, Alison Oti, Samuel Nyirenda, Moffat J. Nabukalu, Dorean Nyamukapa, Constance Nalugoda, Fred Mugurungi, Owen Mtenga, Baltazar Mills, Lisa Michael, Denna McLean, Estelle McGrath, Nuala Martin, Emmanuel Marston, Milly Maquins, Sewe Levira, Francis Kyobutungi, Catherine Kwaro, Daniel Kasamba, Ivan Kanjala, Chifundo Kahn, Kathleen Kabudula, Chodziwadziwa Herbst, Kobus Gareta, Dickman Eaton, Jeffrey W. Clark, Samuel J. Church, Kathryn Chihana, Menard Calvert, Clara Beguy, Donatien Asiki, Gershim Amri, Shamte Abdul, Ramadhani Zaba, Basia TI Data Resource Profile: Network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA Network) SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article ID DEMOGRAPHIC SURVEILLANCE SYSTEM; SUB-SAHARAN AFRICA; SPECTRUM PROJECTION PACKAGE; GENERALIZED HIV EPIDEMICS; MIDDLE-INCOME COUNTRIES; ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; RURAL UGANDA; MORTALITY; HEALTH C1 [Reniers, Georges; Crampin, Amelia C.; Wringe, Alison; Todd, Jim; Slaymaker, Emma; Price, Alison; Nyirenda, Moffat J.; McLean, Estelle; Marston, Milly; Kanjala, Chifundo; Kabudula, Chodziwadziwa; Church, Kathryn; Calvert, Clara; Zaba, Basia] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England. [Reniers, Georges; Gomez-Olive, Xavier; Tollman, Stephen; Kahn, Kathleen; Kabudula, Chodziwadziwa; Clark, Samuel J.] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. [Wamukoya, Marylene; Oti, Samuel; Kyobutungi, Catherine; Beguy, Donatien] African Populat & Hlth Res Ctr, Nairobi, Kenya. [Urassa, Mark; Mtenga, Baltazar; Michael, Denna] Tanzania Natl Inst Med Res, Tazama Project, Mwanza, Tanzania. [Nyaguara, Amek; Mills, Lisa; Maquins, Sewe; Kwaro, Daniel] Kenya Govt Med Res Ctr, Kisumu, Kenya. [Nyaguara, Amek; Mills, Lisa; Maquins, Sewe; Kwaro, Daniel] Ctr Dis Control, Kisumu, Kenya. [Nakiyingi-Miiro, Jessica; Waswa, Laban; Kasamba, Ivan; Asiki, Gershim] MRC, UVRI Uganda Res Unit AIDS, Entebbe, Uganda. [Lutalo, Tom; Serwadda, David; Nabukalu, Dorean; Nalugoda, Fred] Uganda Virus Res Inst, Rakai Hlth Sci Program, Rakai, Uganda. [Serwadda, David] Makerere Univ, Sch Publ Hlth, Kampala, Uganda. [Hosegood, Vicky; McGrath, Nuala; Herbst, Kobus; Gareta, Dickman] Africa Ctr Populat Hlth, Mtubatuba, South Africa. [Hosegood, Vicky; McGrath, Nuala] Univ Southampton, Dept Social Stat & Demog, Southampton, Hants, England. [Gregson, Simon; Nyamukapa, Constance; Mugurungi, Owen] Manicaland Ctr Publ Hlth Res, Harare, Zimbabwe. [Gregson, Simon; Nyamukapa, Constance; Eaton, Jeffrey W.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England. [Geubbels, Eveline; Levira, Francis; Amri, Shamte; Abdul, Ramadhani] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Crampin, Amelia C.; Price, Alison; Nyirenda, Moffat J.; McLean, Estelle; Martin, Emmanuel; Chihana, Menard] Malawi Epidemiol & Intervent Res Unit, Lilongwe, Malawi. [Tollman, Stephen; Kahn, Kathleen] Umea Univ, Ctr Global Hlth Res, Umea, Sweden. [Mugurungi, Owen] Zimbabwe Minist Hlth & Child Care, Harare, Zimbabwe. [Mills, Lisa] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Clark, Samuel J.] Univ Washington, Dept Sociol, Seattle, WA 98195 USA. RP Reniers, G (reprint author), London Sch Hyg & Trop Med, Dept Populat Hlth, Keppel St, London WC1E 7HT, England. EM georges.reniers@lshtm.ac.uk OI Eaton, Jeffrey/0000-0001-7728-728X; Price, Alison/0000-0002-3891-3337 FU Wellcome Trust [085477/Z/08/Z]; Wellcome Trust; Bill and Melinda Gates Foundation [BMGF-OPP1082114]; UNAIDS; WHO FX The core funding for the network comes from the Wellcome Trust (085477/Z/08/Z), and is administered by the London School of Hygiene and Tropical Medicine (LSHTM). At its inception in 2005, the network consisted of six study sites. The network is now in its second Wellcome Trust funding cycle and has grown to 10 study sites. Additional funding has been received from the Bill and Melinda Gates Foundation (2013, BMGF-OPP1082114) for monitoring HIV-related mortality in the era of ART, and the Nuffield Foundation (2012) for studying the effects of HIV on children and adolescents. UNAIDS and WHO have supported various ALPHA Network meetings and publications. NR 49 TC 2 Z9 2 U1 4 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 EI 1464-3685 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD FEB PY 2016 VL 45 IS 1 BP 83 EP 93 DI 10.1093/ije/dyv343 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DJ5ER UT WOS:000374230100016 PM 26968480 ER PT J AU Lesko, CR Cole, SR Hall, HI Westreich, D Miller, WC Eron, JJ Li, JM Mugavero, MJ AF Lesko, Catherine R. Cole, Stephen R. Hall, H. Irene Westreich, Daniel Miller, William C. Eron, Joseph J. Li, Jianmin Mugavero, Michael J. CA CNICS Investigators TI The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11 SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE HIV; antiretroviral therapy; survival analysis; mortality; effect modification; external validity; generalizability ID MARGINAL STRUCTURAL MODELS; HUMAN-IMMUNODEFICIENCY-VIRUS; INVERSE PROBABILITY WEIGHTS; CLINICAL-TRIALS; TARGET POPULATIONS; UNITED-STATES; MEDICAL-CARE; AIDS; INFERENCE; INFECTION AB Background: Although antiretroviral therapy ( ART) is known to be protective against HIV- related mortality, the expected magnitude of effect is unclear because existing estimates of the effect of ART may not directly generalize to recently HIV- diagnosed persons. Methods: In this study, we estimated 5-year mortality risks for immediate versus no ART initiation among patients (n = 12 547) in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) using the complement of adjusted Kaplan-Meier survival functions. We subsequently standardized estimates to persons diagnosed with HIV in the USA between 2009 and 2011, who were enumerated using national surveillance data. Results: The 5-year mortality, had all patients in the CNICS immediately initiated ART, was 10.6% [95% confidence interval (CI): 9.3%, 11.9%] compared with 28.3% (95% CI: 19.1%, 37.5%) had ART initiation been delayed at least 5 years. The 5-year mortality risk difference due to ART among patients in the CNICS was -17.7% (95% CI: -27.0%, -8.4%). Based on methods for generalizing an estimate from a study sample to a different target population, the expected risk difference due to ART initiation among recently HIV-diagnosed persons in the USA was -19.1% (95% CI: -30.5%, -7.8%). Conclusions: Immediate ART initiation substantially lowers mortality among persons in the CNICS and this benefit is expected to be similar among persons recently diagnosed with HIV in the USA. We demonstrate a method by which concerns about generalizability can be addressed and evaluated quantitatively. C1 [Lesko, Catherine R.; Cole, Stephen R.; Westreich, Daniel; Miller, William C.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA. [Lesko, Catherine R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Hall, H. Irene; Li, Jianmin] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Miller, William C.; Eron, Joseph J.] Univ N Carolina, Div Infect Dis, Dept Med, Chapel Hill, NC 27515 USA. [Mugavero, Michael J.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. RP Lesko, CR (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA.; Lesko, CR (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. EM clesko2@jhu.edu FU CNICS [R24 AI067039]; National Institute of Health [R01 AI100654, DP2 HD084070, R01 AI103661]; University of North Carolina at Chapel Hill Center for AIDS Research (CFAR); NIH [P30 AI50410] FX The CNICS is supported by R24 AI067039. C.L., S.R.C. and DW were supported in part by National Institute of Health grant R01 AI100654. D.W. was also supported in part by National Institute of Health grant DP2 HD084070. S.R.C., D.W. and J.J.E. were supported in part by the University of North Carolina at Chapel Hill Center for AIDS Research (CFAR) and by NIH-funded program P30 AI50410. M.J.M. was supported in part by National Institute of Health grant R01 AI103661. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 49 TC 4 Z9 4 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 EI 1464-3685 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD FEB PY 2016 VL 45 IS 1 BP 140 EP 150 DI 10.1093/ije/dyv352 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DJ5ER UT WOS:000374230100021 PM 26772869 ER PT J AU Thomas, TK Ritter, T Bruden, D Bruce, M Byrd, K Goldberger, R Dobson, J Hickel, K Smith, J Hennessy, T AF Thomas, T. K. Ritter, T. Bruden, D. Bruce, M. Byrd, K. Goldberger, R. Dobson, J. Hickel, K. Smith, J. Hennessy, T. TI Impact of providing in-home water service on the rates of infectious diseases: results from four communities in Western Alaska SO JOURNAL OF WATER AND HEALTH LA English DT Article DE in-home piped water; water quantity; water-washed diseases ID RESPIRATORY-TRACT; NATIVE CHILDREN; HOSPITALIZATIONS; POPULATION; OUTBREAK; SKIN AB Approximately 20% of rural Alaskan homes lack in-home piped water; residents haul water to their homes. The limited quantity of water impacts the ability to meet basic hygiene needs. We assessed rates of infections impacted by water quality (waterborne, e.g. gastrointestinal infections) and quantity (water-washed, e.g. skin and respiratory infections) in communities transitioning to in-home piped water. Residents of four communities consented to a review of medical records 3 years before and after their community received piped water. We selected health encounters with ICD-9CM codes for respiratory, skin and gastrointestinal infections. We calculated annual illness episodes for each infection category after adjusting for age. We obtained 5,477 person-years of observation from 1032 individuals. There were 9,840 illness episodes with at least one ICD-9CM code of interest; 8,155 (83%) respiratory, 1,666 (17%) skin, 241 (2%) gastrointestinal. Water use increased from an average 1.5 gallons/capita/day (g/c/d) to 25.7 g/c/d. There were significant (P-value < 0.05) declines in respiratory (16, 95% confidence interval (CI): 11-21%), skin (20, 95% CI: 10-30%), and gastrointestinal infections (38, 95% CI: 13-55%). We demonstrated significant declines in respiratory, skin and gastrointestinal infections among individuals who received in-home piped water. This study reinforces the importance of adequate quantities of water for health. C1 [Thomas, T. K.; Ritter, T.; Goldberger, R.; Hickel, K.; Smith, J.] Alaska Native Tribal Hlth Consortium, 3900 Ambassador Dr, Anchorage, AK 99508 USA. [Bruden, D.; Bruce, M.; Byrd, K.; Hennessy, T.] Ctr Dis Control & Prevent, Arctic Invest Program, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. [Dobson, J.] Yukon Kuskokwim Hlth Corp, POB 528, Bethel, AK 99559 USA. RP Thomas, TK (reprint author), Alaska Native Tribal Hlth Consortium, 3900 Ambassador Dr, Anchorage, AK 99508 USA. EM tkthomas@anthc.org FU Centers for Disease Control; Alaska Native Tribal Health Consortium FX Funding and material support for the study were obtained from Centers for Disease Control and the Alaska Native Tribal Health Consortium. NR 24 TC 5 Z9 5 U1 2 U2 4 PU IWA PUBLISHING PI LONDON PA ALLIANCE HOUSE, 12 CAXTON ST, LONDON SW1H0QS, ENGLAND SN 1477-8920 J9 J WATER HEALTH JI J. Water Health PD FEB PY 2016 VL 14 IS 1 BP 132 EP 141 DI 10.2166/wh.2015.110 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health; Microbiology; Water Resources SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Microbiology; Water Resources GA DJ7RT UT WOS:000374409600013 PM 26837837 ER PT J AU Croston, TL Nayak, AP Lemons, AR Goldsmith, WT Kashon, ML Germolec, DM Beezhold, DH Green, BJ AF Croston, Tara L. Nayak, Ajay P. Lemons, Angela R. Goldsmith, W. Travis Kashon, Michael L. Germolec, Dori M. Beezhold, Donald H. Green, Brett J. TI Pulmonary MicroRNA Expression Profiles Associated with Subchronic Aspergillus fumigatus Exposure SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 04-07, 2016 CL Los Angeles, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Croston, Tara L.; Nayak, Ajay P.; Lemons, Angela R.; Green, Brett J.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Goldsmith, W. Travis] NIOSH, Engn & Control Technol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Kashon, Michael L.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Germolec, Dori M.] Natl Inst Environm Hlth Sci, Toxicol Branch, Div Natl Toxicol Program, Res Triangle Pk, NC USA. [Beezhold, Donald H.] NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2016 VL 137 IS 2 SU S MA 889 BP AB272 EP AB272 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA DK6BI UT WOS:000375005404085 ER PT J AU Green, BJ Lemons, AR Park, Y Cox-Ganser, JM Park, JH AF Green, Brett J. Lemons, Angela R. Park, Yeonmi Cox-Ganser, Jean M. Park, Ju-Hyeong TI Internal Transcribed Spacer rRNA Gene Sequencing Analysis of Dustborne Fungi in a Water-Damaged Office Building SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 04-07, 2016 CL Los Angeles, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Green, Brett J.; Lemons, Angela R.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Park, Yeonmi; Cox-Ganser, Jean M.; Park, Ju-Hyeong] NIOSH, Field Studies Branch, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2016 VL 137 IS 2 SU S MA 593 BP AB181 EP AB181 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA DK6BI UT WOS:000375005403039 ER PT J AU Hsu, J Chen, J Mirabelli, MC AF Hsu, Joy Chen, Jessica Mirabelli, Maria C. TI Risk Factors Associated with Asthma-Related Hospitalizations Among Older Adults SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 04-07, 2016 CL Los Angeles, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Hsu, Joy; Mirabelli, Maria C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Chen, Jessica] Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2016 VL 137 IS 2 SU S MA 33 BP AB11 EP AB11 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA DK6BI UT WOS:000375005400034 ER PT J AU Lemons, AR Hogan, MB Gault, RA Holland, KJ Sobek, E Olsen-Wilson, KA Green, BJ AF Lemons, Angela R. Hogan, Mary Beth Gault, Ruth A. Holland, Kathleen J. Sobek, Edward Olsen-Wilson, Kimberly A. Green, Brett J. TI Fungal Metagenomic Analysis of Indoor Evaporative Cooler Environments in the Great Basin Desert Region SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 04-07, 2016 CL Los Angeles, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Lemons, Angela R.; Green, Brett J.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Hogan, Mary Beth; Olsen-Wilson, Kimberly A.] Univ Nevada, Sch Med, Dept Pediat, Las Vegas, NV 89154 USA. [Gault, Ruth A.] Univ Nevada, Sch Med, Dept Microbiol & Immunol, Reno, NV 89557 USA. [Holland, Kathleen J.] Indiana Univ, Dept Pediat, Indianapolis, IN 46204 USA. [Sobek, Edward] Assured Bio Labs, Oak Ridge, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2016 VL 137 IS 2 SU S MA 592 BP AB181 EP AB181 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA DK6BI UT WOS:000375005403038 ER PT J AU Nayak, AP Croston, TL Lemons, AR Goldsmith, WT Kashon, ML Germolec, DM Beezhold, DH Green, BJ AF Nayak, Ajay P. Croston, Tara L. Lemons, Angela R. Goldsmith, W. Travis Kashon, Michael L. Germolec, Dori M. Beezhold, Donald H. Green, Brett J. TI The Murine Pulmonary Proteomic Profile Associated with Allergic Aspergillus Fumigatus Exposure SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 04-07, 2016 CL Los Angeles, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Nayak, Ajay P.; Green, Brett J.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Croston, Tara L.; Lemons, Angela R.] NIOSH, CDC, ACIB, Morgantown, WV USA. [Goldsmith, W. Travis] NIOSH, Engn & Control Technol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Kashon, Michael L.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Germolec, Dori M.] NIEHS, Toxicol Program, Div Natl Toxicol Program, POB 12233, Res Triangle Pk, NC 27709 USA. [Beezhold, Donald H.] NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2016 VL 137 IS 2 SU S MA 594 BP AB181 EP AB181 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA DK6BI UT WOS:000375005403040 ER PT J AU Li, CY Balluz, LS Vaidyanathan, A Wen, XJ Hao, YP Qualters, JR AF Li, Chaoyang Balluz, Lina S. Vaidyanathan, Ambarish Wen, Xiao-Jun Hao, Yongping Qualters, Judith R. TI Long-Term Exposure to Ozone and Life Expectancy in the United States, 2002 to 2008 SO MEDICINE LA English DT Article ID POSTNEONATAL INFANT-MORTALITY; AIR-POLLUTION; DEVELOPMENTAL TRAJECTORIES; TIME-SERIES; HEALTH; METAANALYSIS; HUMANS; SYSTEM; PM2.5; RISK AB Long-term exposure to ground-level ozone is associated with increased risk of morbidity and mortality. The association remains uncertain between long-term exposure to ozone and life expectancy. We assessed the associations between seasonal mean daily 8-hour maximum (8-hr max) ozone concentrations measured during the ozone monitoring seasons and life expectancy at birth in 3109 counties of the conterminous U.S. during 2002 to 2008. We used latent class growth analysis to identify latent classes of counties that had distinct mean levels and rates of change in ozone concentrations over the 7-year period and used linear regression analysis to determine differences in life expectancy by ozone levels. We identified 3 classes of counties with distinct seasonal mean daily 8-hr max ozone concentrations and rates of change. When compared with the counties with the lowest ozone concentrations, the counties with the highest ozone concentrations had 1.7- and 1.4-year lower mean life expectancy in males and females (both P<0.0001), respectively. The associations remained statistically significant after controlling for potential confounding effects of seasonal mean PM2.5 concentrations and other selected environmental, demographic, socio-economic, and health-related factors (both P<0.0001). A 5ppb higher ozone concentration was associated with 0.25 year lower life expectancy in males (95% CI: -0.30 to -0.19) and 0.21 year in females (95% CI: -0.25 to -0.17). We identified 3 classes of counties with distinct mean levels and rates of change in ozone concentrations. Our findings suggest that long-term exposure to a higher ozone concentration may be associated with a lower life expectancy. C1 [Li, Chaoyang; Balluz, Lina S.; Vaidyanathan, Ambarish; Qualters, Judith R.] Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA USA. [Wen, Xiao-Jun] Natl Ctr Global Heath, Div Global HIV AIDS, Atlanta, GA USA. [Hao, Yongping] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Li, CY (reprint author), Ctr Dis Control & Prevent, 1825 Century Ctr Blvd,MS E-98, Atlanta, GA 30345 USA. EM cli@cdc.gov NR 37 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD FEB PY 2016 VL 95 IS 7 AR e2474 DI 10.1097/MD.0000000000002474 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DK2ZA UT WOS:000374782900002 PM 26886595 ER PT J AU Mansfield, C Tangka, FKL Ekwueme, DU Smith, JL Guy, GP Li, CY Hauber, AB AF Mansfield, Carol Tangka, Florence K. L. Ekwueme, Donatus U. Smith, Judith Lee Guy, Gery P., Jr. Li, Chunyu Hauber, A. Brett TI Stated Preference for Cancer Screening: A Systematic Review of the Literature, 1990-2013 SO PREVENTING CHRONIC DISEASE LA English DT Review ID DISCRETE-CHOICE EXPERIMENT; COLORECTAL-CANCER; CONJOINT-ANALYSIS; PATIENT PREFERENCES; PUBLIC PREFERENCES; DECISION-MAKING; CERVICAL-CANCER; TESTS; PARTICIPATION; CLARIFICATION AB Introduction Stated-preference methods provide a systematic approach to quantitatively assess the relative preferences for features of cancer screening tests. We reviewed stated-preference studies for breast, cervical, and colorectal cancer screening to identify the types of attributes included, the use of questions to assess uptake, and whether gaps exist in these areas. The goal of our review is to inform research on the design and promotion of public health programs to increase cancer screening. Methods Using the PubMed and EconLit databases, we identified studies published in English from January 1990 through July 2013 that measured preferences for breast, cervical, and colorectal cancer screening test attributes using conjoint analysis or a discrete-choice experiment. We extracted data on study characteristics and results. We categorized studies by whether attributes evaluated included screening test, health care delivery characteristics, or both. Results Twenty-two studies met the search criteria. Colorectal cancer was the most commonly studied cancer of the 3. Fifteen studies examined only screening test attributes (efficacy, process, test characteristics, and cost). Two studies included only health care delivery attributes (information provided, staff characteristics, waiting time, and distance to facility). Five studies examined both screening test and health care delivery attributes. Overall, cancer screening test attributes had a significant effect on a patient's selection of a cancer screening test, and health care delivery attributes had mixed effects on choice. Conclusion A growing number of studies examine preferences for cancer screening tests. These studies consistently find that screening test attributes, such as efficacy, process, and cost, are significant determinants of choice. Fewer studies have examined the effect of health care delivery attributes on choice, and the results from these studies are mixed. There is a need for additional studies on the barriers to cancer screening uptake, including health care delivery attributes, and the effect of education materials on preferences. C1 [Tangka, Florence K. L.] Ctr Dis Control & Prevent, 4770 Buford Hwy NE,MS F-76, Atlanta, GA 30341 USA. [Mansfield, Carol; Hauber, A. Brett] RTI Int, RTI Hlth Solut, Res Triangle Pk, NC USA. [Ekwueme, Donatus U.; Smith, Judith Lee; Guy, Gery P., Jr.; Li, Chunyu] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Tangka, FKL (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,MS F-76, Atlanta, GA 30341 USA. EM ftangka@cdc.gov FU Centers for Disease Control and Prevention [200-2008-27958, 0025] FX Funding was provided by the Centers for Disease Control and Prevention (Contract No. 200-2008-27958, Task order 0025); we have no financial disclosures. We thank Linda Chamiec-Case for her help in assembling the data for this study. NR 45 TC 0 Z9 0 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD FEB PY 2016 VL 13 AR E27 DI 10.5888/pcd13.150433 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DK8TV UT WOS:000375202100012 PM 26916898 ER PT J AU Schauer, GL Malarcher, A Mann, N Fabrikant, J Zhang, L Babb, S AF Schauer, Gillian L. Malarcher, Ann Mann, Nathan Fabrikant, Jesse Zhang, Lei Babb, Stephen TI How Tobacco Quitline Callers in 38 US States Reported Hearing About Quitline Services, 2010-2013 SO PREVENTING CHRONIC DISEASE LA English DT Article ID UNITED-STATES; CESSATION QUITLINES; EDUCATION CAMPAIGN; SMOKING-CESSATION; WEBSITE VISITORS; ADULTS; IMPACT AB Introduction Telephone-based tobacco quitlines are an evidence-based intervention, but little is known about how callers hear about quitlines and whether variations exist by demographics or state. This study assessed trends in "how-heard-abouts" (HHAs) in 38 states. Methods Data came from the Centers for Disease Control and Prevention's (CDC's) National Quitline Data Warehouse, which stores nonidentifiable data collected from individual callers at quitline registration and reported quarterly by states. Callers were asked how they heard about the quitline; responses were grouped into the following categories: media, health professional, family or friends, and "other." We examined trends from 2010 through 2013 (N = 1,564,437) using multivariable models that controlled for seasonality and the impact of CDC's national tobacco education campaign, Tips From Former Smokers (Tips). Using data from 2013 only, we assessed HHAs variation by demographics (sex, age, race/ethnicity, education) and state in a 38-state sample (n = 378,935 callers). Results From 2010 through 2013, the proportion of HHAs through media increased; however, this increase was not significant when we controlled for calendar quarters in which Tips aired. The proportion of HHAs through health professionals increased, whereas those through family or friends decreased. In 2013, HHAs occurred as follows: media, 45.1%; health professionals, 27.5%, family or friends, 17.0%, and other, 10.4%. Media was the predominant HHA among quitline callers of all demographic groups, followed by health professionals (except among people aged 18-24 years). Large variations in source of HHAs were observed by state. Conclusion Most quitline callers in the 38-state sample heard about quitlines through the media or health care professionals. Variations in source of HHAs exist across states; implementation of best-practice quitline promotional strategies is critical to maximize reach. C1 [Schauer, Gillian L.; Malarcher, Ann; Zhang, Lei; Babb, Stephen] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-79, Atlanta, GA 30341 USA. [Mann, Nathan; Fabrikant, Jesse] RTI Int, Res Triangle Pk, NC USA. RP Schauer, GL (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-79, Atlanta, GA 30341 USA. EM gschauer@cdc.gov NR 30 TC 0 Z9 0 U1 2 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD FEB PY 2016 VL 13 AR E17 DI 10.5888/pcd13.150325 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DK8TV UT WOS:000375202100002 PM 26851336 ER PT J AU Zemtsova, GE Killmaster, LF Montgomery, M Schumacher, L Burrows, M Levin, ML AF Zemtsova, Galina E. Killmaster, Lindsay F. Montgomery, Merrill Schumacher, Lauren Burrows, Matt Levin, Michael L. TI First Report of Rickettsia Identical to R. slovaca in Colony-Originated D. variabilis in the United States: Detection, Laboratory Animal Model, and Vector Competence of Ticks SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE R. slovaca; D. variabilis; Vector competence; Animal model ID FEVER GROUP RICKETTSIA; RHIPICEPHALUS-SANGUINEUS TICKS; MOUNTAIN-SPOTTED-FEVER; NEWLY RECOGNIZED CAUSE; GULF-COAST TICKS; DERMACENTOR-VARIABILIS; BORNE RICKETTSIOSES; GENE; IDENTIFICATION; IXODIDAE AB Ticks of the genus Dermacentor are known vectors of rickettsial pathogens in both the Old World and New World. In North America, Dermacentor variabilis and D. andersoni are vectors of Rickettsia rickettsii, while in Europe, D. marginatus and D. reticulatus transmit R. slovaca and R. raoultii, respectively. Neither the presence of R. slovaca in the Americas nor the ability of American tick species to maintain this pathogen have been reported. Here we describe detection of Rickettsia genetically identical to R. slovaca in D. variabilis, its molecular characterization, assessment of pathogenicity to guinea pigs, and vector competence of D. variabilis ticks. Ticks from a laboratory colony of D. variabilis, established from wild ticks and maintained on naive NZW rabbits, tested positive for spotted fever group (SFG) Rickettsia by PCR. Analysis of 17 kDa gltA, rpoB, ompA, ompB, and sca4 genes revealed 100% identity to R. slovaca sequences available in the GenBank. New Zealand white rabbits fed upon by infected ticks seroconverted to SFG Rickettsia. Guinea pigs inoculated with the Rickettsia culture or infested by the infected ticks developed antibodies to SFG Rickettsia. The intensity of clinical signs and immune response were dependent on dose and route of infection. The identified Rickettsia was detected in all life stages of D. variabilis ticks, confirming transstadial and transovarial transmission. Thirty-six percent of uninfected larvae co-fed with infected nymphs on guinea pigs were PCR-positive and able to pass rickettsia to at least 11.7% of molted nymphs. To our knowledge, this is a first report of identification of a European pathogen R. slovaca or a highly similar agent in the American dog tick, D. variabilis. Considering pathogenicity of R. slovaca in humans, further laboratory and field studies are warranted to assess the relevance of the above findings to the public health and epidemiology of SFG rickettsioses in the United States. C1 [Zemtsova, Galina E.; Killmaster, Lindsay F.; Montgomery, Merrill; Schumacher, Lauren; Burrows, Matt; Levin, Michael L.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, 1600 Clifton Rd Northeast,MS G-13, Atlanta, GA 30329 USA. RP Zemtsova, GE (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, 1600 Clifton Rd Northeast,MS G-13, Atlanta, GA 30329 USA. EM gzemtsova@cdc.gov NR 34 TC 2 Z9 2 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2016 VL 16 IS 2 BP 77 EP 84 DI 10.1089/vbz.2015.1844 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DK9QQ UT WOS:000375266700002 PM 26808054 ER PT J AU Goodman, RA Ling, SM Briss, PA Parrish, RG Salive, ME Finke, BS AF Goodman, Richard A. Ling, Shari M. Briss, Peter A. Parrish, R. Gibson Salive, Marcel E. Finke, Bruce S. TI Multimorbidity Patterns in the United States: Implications for Research and Clinical Practice SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Editorial Material ID CARDIOVASCULAR-DISEASE; HEALTH; PREVALENCE; ADULTS; COMORBIDITIES; DEPRESSION; STRATEGIES; GUIDELINES; ARTHRITIS C1 [Goodman, Richard A.] US Dept HHS, Off Assistant Secretary Hlth, Washington, DC 20201 USA. [Goodman, Richard A.; Briss, Peter A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K40,4770 Buford Highway NE, Atlanta, GA 30341 USA. [Ling, Shari M.] Ctr Medicare, Baltimore, MD USA. [Ling, Shari M.] Ctr Medicaid Serv, Baltimore, MD USA. [Goodman, Richard A.; Parrish, R. Gibson] Publ Hlth Informat Inst, Decatur, GA USA. [Salive, Marcel E.] NIA, NIH, Bethesda, MD 20892 USA. [Ling, Shari M.; Finke, Bruce S.] Indian Hlth Serv, Nashville Area, Nashville, TN USA. RP Briss, PA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K40,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM pxb5@cdc.gov NR 40 TC 4 Z9 4 U1 3 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD FEB PY 2016 VL 71 IS 2 BP 215 EP 220 DI 10.1093/gerona/glv199 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DJ4XY UT WOS:000374212600009 PM 26714567 ER PT J AU August, EM Steinmetz, E Gavin, L Rivera, MI Pazol, K Moskosky, S Weik, T Ku, L AF August, Euna M. Steinmetz, Erika Gavin, Lorrie Rivera, Maria I. Pazol, Karen Moskosky, Susan Weik, Tasmeen Ku, Leighton TI Projecting the Unmet Need and Costs for Contraception Services After the Affordable Care Act SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HEALTH-CARE; INSURANCE-COVERAGE; REFORM; IMPACT; CONFIDENTIALITY; MASSACHUSETTS; PREGNANCIES; GOVERNMENT; MEDICAID; CHILDREN AB Objectives. We estimated the number of women of reproductive age in need who would gain coverage for contraceptive services after implementation of the Affordable Care Act, the extent to which there would remain a need for publicly funded programs that provide contraceptive services, and how that need would vary on the basis of state Medicaid expansion decisions. Methods. We used nationally representative American Community Survey data (2009), to estimate the insurance status for women in Massachusetts and derived the numbers of adult women at or below 250% of the federal poverty level and adolescents in need of confidential services. We extrapolated findings to simulate the impact of the Affordable Care Act nationally and by state, adjusting for current Medicaid expansion and state Medicaid Family Planning Expansion Programs. Results. The number of low-income women at risk for unintended pregnancy is expected to decrease from 5.2 million in 2009 to 2.5 million in 2016, based on states' current Medicaid expansion plans. Conclusions. The Affordable Care Act increases women's insurance coverage and improves access to contraceptive services. However, for women who remain uninsured, publicly funded family planning programs may still be needed. C1 [August, Euna M.; Rivera, Maria I.; Pazol, Karen] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. [Steinmetz, Erika; Ku, Leighton] George Washington Univ, Ctr Hlth Policy Res, Washington, DC USA. [Gavin, Lorrie; Moskosky, Susan; Weik, Tasmeen] Off Populat Affairs, Washington, DC USA. RP August, EM (reprint author), Ctr Dis Control & Prevent, Prevent Commun Branch, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-49, Atlanta, GA 30333 USA. EM eaugust@cdc.gov OI Ku, Leighton/0000-0002-6154-9289 NR 40 TC 2 Z9 2 U1 1 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD FEB PY 2016 VL 106 IS 2 BP 334 EP 341 DI 10.2105/AJPH.2015.302928 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DI3VY UT WOS:000373429000040 PM 26691128 ER PT J AU Crawford, S Boulet, SL Jamieson, DJ Stone, C Mullen, J Kissin, DM AF Crawford, Sara Boulet, Sheree L. Jamieson, Denise J. Stone, Carol Mullen, Jewel Kissin, Dmitry M. TI Assisted reproductive technology use, embryo transfer practices, and birth outcomes after infertility insurance mandates: New Jersey and Connecticut SO FERTILITY AND STERILITY LA English DT Article DE Infertility insurance mandate; embryo transfer; multiple births; assisted reproductive technology (ART); in vitro fertilization (IVF) ID MULTIPLE BIRTHS; COVERAGE; PREGNANCIES; FERTILITY; IMPACT AB Objective: To explore whether recently enacted infertility mandates including coverage for assisted reproductive technology (ART) treatment in New Jersey (2001) and Connecticut (2005) increased ART use, improved embryo transfer practices, and decreased multiple birth rates. Design: Retrospective cohort study using data from the National ART Surveillance System. We explored trends in ART use, embryo transfer practices and birth outcomes, and compared changes in practices and outcomes during a 2-year period before and after passing the mandate between mandate and non-mandate states. Setting: Not applicable. Patient(s): Cycles of ART performed in the United States between 1996 and 2013. Intervention(s): Infertility insurancemandates including coverage for ART treatment passed in New Jersey (2001) and Connecticut (2005). Main Outcome Measures(s): Number of ART cycles performed, number of embryos transferred, multiple live birth rates. Result(s): Both New Jersey and Connecticut experienced an increase in ART use greater than the non-mandate states. The mean number of embryos transferred decreased significantly in New Jersey and Connecticut; however, the magnitudes were not significantly different from non-mandate states. There was no significant change in ART birth outcomes in either mandate state except for an increase in live births in Connecticut; the magnitude was not different from non-mandate states. Conclusion(s): The infertility insurance mandates passed in New Jersey and Connecticut were associated with increased ART treatment use but not a decrease in the number of embryos transferred or the rate of multiples; however, applicability of the mandates was limited. (C) 2016 by American Society for Reproductive Medicine. C1 [Crawford, Sara; Boulet, Sheree L.; Jamieson, Denise J.; Kissin, Dmitry M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS F-74, Atlanta, GA 30341 USA. [Stone, Carol; Mullen, Jewel] Connecticut Dept Publ Hlth, Hartford, CT USA. RP Crawford, S (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS F-74, Atlanta, GA 30341 USA. EM sgv0@cdc.gov FU Intramural CDC HHS [CC999999] NR 22 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD FEB PY 2016 VL 105 IS 2 BP 347 EP 355 DI 10.1016/j.fertnstert.2015.10.009 PG 9 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DI3NR UT WOS:000373405900021 PM 26515377 ER PT J AU Chang, J Boulet, SL Jeng, G Flowers, L Kissin, DM AF Chang, Jeani Boulet, Sheree L. Jeng, Gary Flowers, Lisa Kissin, Dmitry M. TI Outcomes of in vitro fertilization with preimplantation genetic diagnosis: an analysis of the United States Assisted Reproductive Technology Surveillance Data, 2011-2012 SO FERTILITY AND STERILITY LA English DT Article DE Aneuploidy; chromosomal abnormality; genetic; in vitro fertilization; preimplantation genetic diagnosis ID BLASTOCYST TRANSFER; MATERNAL AGE; MORPHOLOGY; WOMEN; PGD AB Objective: To assess the characteristics of IVF cycles for which preimplantation genetic diagnosis (PGD) was used and to evaluate indications for PGD and treatment outcomes associated with this procedure as compared with cycles without PGD with the data from the U.S. National ART Surveillance System. Design: Retrospective cohort study. Setting: None. Patient(s): Fresh autologous cycles that involved transfer of at least one embryo at blastocyst when available. Intervention(s): None. Main Outcome Measure(s): PGD indications and age-specific reproductive outcomes. Result(s): There were a total of 97,069 non-PGD cycles and 9,833 PGD cycles: 55.6% were performed for aneuploidy screening (PGD Aneuploidy), 29.1% for other reasons (PGD Other), and 15.3% for genetic testing (PGD Genetic). In comparison to non-PGD cycles, PGD Aneuploidy cycles showed a decreased odds of miscarriage among women 35-37 years (adjusted odds ratio [aOR] 0.62; 95% CI, 0.45-0.87) and women >37 years (aOR 0.55; 95% CI, 0.43-0.70); and an increased odds of clinical pregnancy (aOR 1.18; 95% CI, 1.05-1.34), live-birth delivery (aOR 1.43; 95% CI, 1.26-1.62), and multiple-birth delivery (aOR 1.98; 95% CI, 1.52-2.57) among women >37 years. Conclusion(s): Aneuploidy screening was the most common indication for PGD. Use of PGD was not observed to be associated with an increased odds of clinical pregnancy or live birth for women <35 years. PGD for aneuploidy was associated with a decreased odds of miscarriage for women >35 years, but an increased odds of a live-birth and a multiple live-birth delivery among women >37 years. (C) 2016 by American Society for Reproductive Medicine. C1 [Chang, Jeani; Boulet, Sheree L.; Jeng, Gary; Flowers, Lisa; Kissin, Dmitry M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Chang, J (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway NE,Mailstop F-74, Atlanta, GA 30341 USA. EM jchang@cdc.gov FU Intramural CDC HHS [CC999999] NR 27 TC 12 Z9 12 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD FEB PY 2016 VL 105 IS 2 BP 394 EP 400 DI 10.1016/j.fertnstert.2015.10.018 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DI3NR UT WOS:000373405900027 PM 26551441 ER PT J AU Crawford, S Boulet, SL Mneimneh, AS Perkins, KM Jamieson, DJ Zhang, YJ Kissin, DM AF Crawford, Sara Boulet, Sheree L. Mneimneh, Allison S. Perkins, Kiran M. Jamieson, Denise J. Zhang, Yujia Kissin, Dmitry M. TI Costs of achieving live birth from assisted reproductive technology: a comparison of sequential single and double embryo transfer approaches SO FERTILITY AND STERILITY LA English DT Article DE Sequential single embryo transfer (SET); double embryo transfer (DET); assisted reproductive technology (ART); in vitro fertilization (IVF); infertility ID IN-VITRO FERTILIZATION; ELECTIVE SINGLE; TWINS; AUSTRALIA; COVERAGE; OUTCOMES; CYCLES; IMPACT; IVF AB Objective: To assess treatment and pregnancy/infant-associated medical costs and birth outcomes for assisted reproductive technology (ART) cycles in a subset of patients using elective double embryo (ET) and to project the difference in costs and outcomes had the cycles instead been sequential single ETs (fresh followed by frozen if the fresh ET did not result in live birth). Design: Retrospective cohort study using 2012 and 2013 data from the National ART Surveillance System. Setting: Infertility treatment centers. Patient(s): Fresh, autologous double ETs performed in 2012 among ART patients younger than 35 years of age with no prior ART use who cryopreserved at least one embryo. Intervention(s): Sequential single and double ETs. Main Outcome Measure(s): Actual live birth rates and estimated ART treatment and pregnancy/infant-associated medical costs for double ET cycles started in 2012 and projected ART treatment and pregnancy/infant-associated medical costs if the double ET cycles had been performed as sequential single ETs. Result(s): The estimated total ART treatment and pregnancy/infant-associated medical costs were $ 580.9 million for 10,001 double ETs started in 2012. If performed as sequential single ETs, estimated costs would have decreased by $ 195.0 million to $ 386.0 million, and live birth rates would have increased from 57.7%-68.0%. Conclusion(s): Sequential single ETs, when clinically appropriate, can reduce total ART treatment and pregnancy/infant-associated medical costs by reducing multiple births without lowering live birth rates. (C) 2016 by American Society for Reproductive Medicine. C1 [Crawford, Sara; Boulet, Sheree L.; Mneimneh, Allison S.; Perkins, Kiran M.; Jamieson, Denise J.; Zhang, Yujia; Kissin, Dmitry M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Crawford, S (reprint author), 4770 Buford Highway NE,MS F-74, Atlanta, GA 30341 USA. EM sgv0@cdc.gov FU Intramural CDC HHS [CC999999] NR 29 TC 2 Z9 2 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD FEB PY 2016 VL 105 IS 2 BP 444 EP 450 DI 10.1016/j.fertnstert.2015.10.032 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DI3NR UT WOS:000373405900034 PM 26604068 ER PT J AU Dunville, RL Liddon, N Dittus, P AF Dunville, Richard L. Liddon, Nicole Dittus, Patricia TI POTENTIAL NEW DIRECTIONS FOR SCHOOL-BASED STD SCREENING PROGRAMS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Dunville, Richard L.; Liddon, Nicole; Dittus, Patricia] Ctr Dis Control & Prevent, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2016 VL 58 IS 2 SU S MA 203 BP S106 EP S106 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DI3VW UT WOS:000373428800204 ER PT J AU Harper, C Dittus, P Ethier, K AF Harper, Christopher Dittus, Patricia Ethier, Kathleen TI ASSOCIATIONS BETWEEN MARIJUANA USE AND 15 INDICATORS OF SEXUAL RISK AND SEXUAL HEALTH SERVICE USE SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Harper, Christopher; Dittus, Patricia; Ethier, Kathleen] Ctr Dis Control & Prevent, Washington, DC USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2016 VL 58 IS 2 SU S MA 209 BP S109 EP S110 PG 4 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DI3VW UT WOS:000373428800210 ER PT J AU Harper, CR Liddon, N Dunville, R Habel, M AF Harper, Christopher R. Liddon, Nicole Dunville, Richard Habel, Melissa TI ADDRESSING DISPARITIES IN STD/HIV RISK THROUGH SCHOOL-BASED HEALTH SERVICES SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Harper, Christopher R.; Liddon, Nicole; Dunville, Richard; Habel, Melissa] Ctr Dis Control & Prevent, Morgantown, WV USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2016 VL 58 IS 2 SU S MA 96 BP S51 EP S52 PG 4 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DI3VW UT WOS:000373428800097 ER PT J AU Johns, MM Jayne, PE Steiner, RJ AF Johns, Michelle M. Jayne, Paula E. Steiner, Riley J. TI DIFFERENCES IN SOURCES OF SEXUAL HEALTH INFORMATION BY SEXUAL ORIENTATION: FINDINGS FROM A NATIONALLY REPRESENTATIVE SAMPLE OF ADOLESCENTS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Johns, Michelle M.; Jayne, Paula E.; Steiner, Riley J.] Ctr Dis Control & Prevent, Washington, DC USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2016 VL 58 IS 2 SU S MA 199 BP S104 EP S104 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DI3VW UT WOS:000373428800200 ER PT J AU Liddon, N Carver, L Robin, L Harper, C Herbert, A Murray, C Altman, L Lesesne, C AF Liddon, Nicole Carver, Lisa Robin, Leah Harper, Christopher Herbert, Andrew Murray, Colleen Altman, Lara Lesesne, Catherine TI SCHOOLS TO CLINICS: CONNECTING STUDENTS TO STD/HIV SERVICE PROVIDERS USING GYT SOCIAL MARKETING CAMPAIGN SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Liddon, Nicole; Robin, Leah; Harper, Christopher] Ctr Dis Control & Prevent, Washington, DC USA. [Carver, Lisa; Herbert, Andrew; Murray, Colleen; Lesesne, Catherine] ICF Int, Washington, DC USA. [Altman, Lara] Chicago Publ Sch, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2016 VL 58 IS 2 SU S MA 194 BP S101 EP S102 PG 4 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DI3VW UT WOS:000373428800195 ER PT J AU Marcell, AV Gibbs, S Howard, S Pilgrim, NA Jennings, J Sanders, R Page, KR Dittus, PJ Loosier, P AF Marcell, Arik V. Gibbs, Susannah Howard, Shalynn Pilgrim, Nanlesta A. Jennings, Jacky Sanders, Renata Page, Kathleen R. Dittus, Patricia J. Loosier, Penny TI COMMUNITY-BASED YOUTH-SERVING PROFESSIONALS' PROVISION OF SEXUAL AND REPRODUCTIVE HEALTH INFORMATION AND RESOURCES TO YOUNG MEN AND ASSOCIATED FACTORS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Marcell, Arik V.; Gibbs, Susannah; Howard, Shalynn; Jennings, Jacky; Sanders, Renata; Page, Kathleen R.] Johns Hopkins, Baltimore, MD USA. [Pilgrim, Nanlesta A.] Populat Council, Baltimore, MD USA. [Dittus, Patricia J.; Loosier, Penny] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2016 VL 58 IS 2 SU S MA 75 BP S40 EP S41 PG 4 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DI3VW UT WOS:000373428800076 ER PT J AU Sharma, A Wang, LY Dunville, R Kearns, R Rosenberg, E Sullivan, P AF Sharma, Akshay Wang, Li Yan Dunville, Richard Kearns, Rachel Rosenberg, Eli Sullivan, Patrick TI HIV AND STD TESTING BEHAVIOR AMONG YOUNG MEN WHO HAVE SEX WITH MEN: ANALYSIS OF POOLED YOUTH RISK BEHAVIOR SURVEY DATA, 2005-2013 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Sharma, Akshay; Kearns, Rachel; Rosenberg, Eli; Sullivan, Patrick] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Wang, Li Yan; Dunville, Richard] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2016 VL 58 IS 2 SU S MA 153 BP S80 EP S80 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DI3VW UT WOS:000373428800154 ER PT J AU Steiner, RJ Haardoerfer, R Harper, C Dittus, P Sales, J AF Steiner, Riley J. Haardoerfer, Regine Harper, Christopher Dittus, Patricia Sales, Jessica TI PARENT-ADOLESCENT COMMUNICATION ABOUT SEXUAL HEALTH AND ADOLESCENT SEXUAL RISK: A LATENT CLASS ANALYSIS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Steiner, Riley J.; Harper, Christopher; Dittus, Patricia] Ctr Dis Control & Prevent, Washington, DC USA. [Haardoerfer, Regine; Sales, Jessica] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2016 VL 58 IS 2 SU S MA 193 BP S101 EP S101 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DI3VW UT WOS:000373428800194 ER PT J AU Steiner, RJ Liddon, N Swartzendruber, AL Rasberry, CN Sales, JM AF Steiner, Riley J. Liddon, Nicole Swartzendruber, Andrea L. Rasberry, Catherine N. Sales, Jessica M. TI LONG-ACTING REVERSIBLE CONTRACEPTION (LARC) AND CONDOM USE AMONG FEMALE US HIGH SCHOOL STUDENTS: IMPLICATIONS FOR STI PREVENTION IN THE CONTEXT OF ADOLESCENT LARC SCALE-UP SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Steiner, Riley J.; Liddon, Nicole; Rasberry, Catherine N.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. [Swartzendruber, Andrea L.; Sales, Jessica M.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2016 VL 58 IS 2 SU S MA 10 BP S5 EP S6 PG 4 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DI3VW UT WOS:000373428800011 ER PT J AU Vandenberg, AE Hunter, RH Anderson, LA Bryant, LL Hooker, SP Satariano, WA AF Vandenberg, Ann E. Hunter, Rebecca H. Anderson, Lynda A. Bryant, Lucinda L. Hooker, Steven P. Satariano, William A. TI Walking and Walkability: Is Wayfinding a Missing Link? Implications for Public Health Practice SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE physical activity; built environment ID PHYSICAL-ACTIVITY RECOMMENDATIONS; OLDER-ADULTS; BUILT ENVIRONMENT; INDIVIDUAL-DIFFERENCES; GENDER-DIFFERENCES; SPATIAL KNOWLEDGE; SEX-DIFFERENCES; VIRTUAL ENVIRONMENT; ALZHEIMERS-DISEASE; URBAN ENVIRONMENTS AB Background: Research on walking and walkability has yet to focus on wayfinding, the interactive, problem-solving process by which people use environmental information to locate themselves and navigate through various settings. Methods: We reviewed the literature on outdoor pedestrian-oriented wayfinding to examine its relationship to walking and walkability, 2 areas of importance to physical activity promotion. Results: Our findings document that wayfinding is cognitively demanding and can compete with other functions, including walking itself. Moreover, features of the environment can either facilitate or impede wayfinding, just as environmental features can influence walking. Conclusions: Although there is still much to be learned about wayfinding and walking behaviors, our review helps frame the issues and lays out the importance of this area of research and practice. C1 [Vandenberg, Ann E.] Emory Univ, Dept Med, Atlanta, GA 30322 USA. [Hunter, Rebecca H.] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC USA. [Anderson, Lynda A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Bryant, Lucinda L.] Univ Colorado, Dept Community & Behav Hlth, Colorado Sch Publ Hlth, Aurora, CO USA. [Hooker, Steven P.] Arizona State Univ, Exercise Sci & Hlth Promot Program, Phoenix, AZ USA. [Satariano, William A.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. RP Vandenberg, AE (reprint author), Emory Univ, Dept Med, Atlanta, GA 30322 USA. EM avanden@emory.edu NR 119 TC 0 Z9 0 U1 7 U2 8 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 EI 1543-5474 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD FEB PY 2016 VL 13 IS 2 BP 189 EP 197 DI 10.1123/jpah.2014-0577 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DI3FB UT WOS:000373382800009 PM 25965057 ER PT J AU Michael, SL Coffield, E Lee, SM Fulton, JE AF Michael, Shannon L. Coffield, Edward Lee, Sarah M. Fulton, Janet E. TI Variety, Enjoyment, and Physical Activity Participation Among High School Students SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE adolescents; youth; guidelines; recommendations ID ADOLESCENT GIRLS; DETERMINANTS; BEHAVIOR; CHILDREN; EDUCATION; EXERCISE; GENDER AB Background: Federal guidelines state that youth should participate in a variety of physical activity (PA) they find enjoyable. Little is known, however, about how variety and enjoyment are associated with PA participation among adolescents. Methods: Data came from the 2010 National Youth Physical Activity and Nutrition Survey, a nationally representative survey of adolescents. Path analysis was used to examine the association of a variety of self-reported PA, defined as the number of activities and activity types (ie, team sports/weightlifting, individual activities, and other competitive/recreational sports), on self-reported PA enjoyment and participation. The analysis also examined whether enjoyment mediates the association between a variety of PA and participation. Separate models were estimated for boys and girls. Results: Number of activities was associated with increased PA enjoyment and participation. For boys and girls, team sports/weightlifting was associated with increased participation, and individual activities were indirectly associated with increased participation through enjoyment. For boys, team sports/weightlifting was indirectly related with participation. Conclusions: These findings suggest that participation in a variety of PA is associated with increased PA enjoyment and participation. Providing opportunities for adolescents to engage in a variety of activities might help them identify PA they enjoy and facilitate lifelong PA habits. C1 [Michael, Shannon L.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Michael, Shannon L.; Coffield, Edward; Lee, Sarah M.] Ctr Dis Control & Prevent, Sch Hlth Branch, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Fulton, Janet E.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Michael, SL (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. EM sot2@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 1 Z9 1 U1 4 U2 9 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 EI 1543-5474 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD FEB PY 2016 VL 13 IS 2 BP 223 EP 230 DI 10.1123/jpah.2014-0551 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DI3FB UT WOS:000373382800013 PM 26107142 ER PT J AU Gjeltema, JL Troan, B Muehlenbachs, A Liu, L Da Silva, AJ Qvarnstrom, Y Tobias, JR Loomis, MR De Voe, RS AF Gjeltema, Jenessa L. Troan, Brigid Muehlenbachs, Atis Liu, Lindy Da Silva, Alexandre J. Qvarnstrom, Yvonne Tobias, Jeremy R. Loomis, Michael R. De Voe, Ryan S. TI Amoebic meningoencephalitis and disseminated infection caused by Balamuthia mandrillaris in a Western lowland gorilla (Gorilla gorilla gorilla) SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Article ID RIBOSOMAL-RNA GENE; LEPTOMYXID-AMEBA; PCR ASSAY; ENCEPHALITIS; AGENT; IMMUNOCOMPETENT; IMMUNODEFICIENT; DIAGNOSIS; ANIMALS; HUMANS AB CASE DESCRIPTION A 22-year-old male gorilla (Gorilla gorilla gorilla) housed in a zoo was evaluated for signs of lethargy, head-holding, and cervical stiffness followed by development of neurologic abnormalities including signs of depression, lip droop, and tremors. CLINICAL FINDINGS Physical examination under general anesthesia revealed a tooth root abscess and suboptimal body condition. A CBC and serum biochemical analysis revealed mild anemia, neutrophilia and eosinopenia consistent with a stress leukogram, and signs consistent with dehydration. Subsequent CSF analysis revealed lymphocytic pleocytosis and markedly increased total protein concentration. TREATMENT AND OUTCOME Despite treatment with antimicrobials, steroids, and additional supportive care measures, the gorilla's condition progressed to an obtunded mentation with grand mal seizures over the course of 10 days. Therefore, the animal was euthanized and necropsy was performed. Multifocal areas of malacia and hemorrhage were scattered throughout the brain; on histologic examination, these areas consisted of necrosis and hemorrhage associated with mixed inflammation, vascular necrosis, and intralesional amoebic trophozoites.Tan foci were also present in the kidneys and pancreas. Immunohistochemical testing positively labeled free-living amoebae within the brain, kidneys, eyes, pancreas, heart, and pulmonary capillaries. Subsequent PCR assay of CSF and frozen kidney samples identified the organism as Balamuthia mandrillaris, confirming a diagnosis of amoebic meningoencephalitis. CLINICAL RELEVANCE Infection with B mandrillaris has been reported to account for 2.8% of captive gorilla deaths in North America over the past 19 years. Clinicians working with gorillas should have a high index of suspicion for this diagnosis when evaluating and treating animals with signs of centrally localized neurologic disease. C1 [Gjeltema, Jenessa L.] N Carolina State Univ, Coll Vet Med, Dept Clin Sci, 4700 Hillsborough St, Raleigh, NC 27606 USA. [Troan, Brigid; Tobias, Jeremy R.] N Carolina State Univ, Coll Vet Med, Dept Hlth & Pathobiol, 4700 Hillsborough St, Raleigh, NC 27606 USA. [Gjeltema, Jenessa L.; Troan, Brigid; Loomis, Michael R.; De Voe, Ryan S.] N Carolina State Univ, Coll Vet Med, Environm Med Consortium, 4700 Hillsborough St, Raleigh, NC 27606 USA. [Gjeltema, Jenessa L.; Troan, Brigid; Loomis, Michael R.] North CaroIina Zoo, 4401 Zoo Pkwy, Asheboro, NC 27205 USA. [Muehlenbachs, Atis; Liu, Lindy] CDC, Infect Dis Pathol Branch, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd, Atlanta, GA 30333 USA. [Da Silva, Alexandre J.; Qvarnstrom, Yvonne] CDC, Parasit Dis Branch, 1600 Clifton Rd, Atlanta, GA 30333 USA. [De Voe, Ryan S.] Disneys Anim Kingdom, Dept Anim Hlth, 2901 Osceola Pkwy, Orlando, FL 32830 USA. [Gjeltema, Jenessa L.] Univ Calif Davis, Sch Vet Med, Zool Med Serv, Davis, CA 95616 USA. RP Loomis, MR (reprint author), N Carolina State Univ, Coll Vet Med, Environm Med Consortium, 4700 Hillsborough St, Raleigh, NC 27606 USA.; Loomis, MR (reprint author), North CaroIina Zoo, 4401 Zoo Pkwy, Asheboro, NC 27205 USA. EM Mike.loomis@nczoo.org NR 44 TC 0 Z9 0 U1 0 U2 1 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 EI 1943-569X J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD FEB 1 PY 2016 VL 248 IS 3 BP 315 EP 321 PG 7 WC Veterinary Sciences SC Veterinary Sciences GA DI0UX UT WOS:000373213900018 PM 26799111 ER PT J AU DeGrauw, X Annest, JL Stevens, JA Xu, LK Coronado, V AF DeGrauw, Xinyao Annest, Joseph L. Stevens, Judy A. Xu, Likang Coronado, Victor TI Unintentional injuries treated in hospital emergency departments among persons aged 65 years and older, United States, 2006-2011 SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE Unintentional injury; Older adults; Elderly; Emergency department; Falls ID FALLS; ADULTS; POPULATION; HEALTH AB Introduction: With the aging of the United States population, unintentional injuries among older adults, and especially falls-related injuries, are an increasing public health concern. Methods: We analyzed emergency department (ED) data from the Nationwide Emergency Department Sample, 2006-2011. We examined unintentional injury trends by 5-year age groups, sex, mechanism, body region, discharge disposition, and primary payer. For 2011, we estimated the medical costs of unintentional injury and the distribution of primary payers, plus rates by injury mechanisms and body regions injured by 5-year age groups. Results: From 2006 to 2011, the age-adjusted annual rate of unintentional injury-related ED visits among persons aged 65 years increased significantly from 7987 to 8163, per 100,000 population. In 2011, 65% of injuries were due to falls. Rates for fall-related injury ED visits increased with age and the highest rate was among those aged >= 100. Each year, about 85% of unintentional injury-related ED visits in this population were expected to be paid by Medicare. In 2011, the estimated lifetime medical cost of unintentional injury-related ED visits among those aged years was $40 billion. Conclusion: Increasing rates of ED-treated unintentional injuries, driven mainly by falls among older adults, will challenge our health care system and increase the economic burden on our society. Prevention efforts to reduce falls and resulting injuries among adults aged >= 65 years have the potential to increase wellbeing and reduce health care spending, especially the costs covered by Medicare. Practical applications: With the aging of the U.S. population, unintentional injuries, and especially fall-related injuries, will present a growing challenge to our health care system as well as an increasing economic burden. To counteract this trend, we must implement effective public health strategies, such as increasing knowledge about fall risk factors and broadly disseminating evidence-based injury and fall prevention programs in both clinical and community settings. (C) 2015 National Safety Council and Elsevier Ltd. All rights reserved. C1 [DeGrauw, Xinyao] Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA. [Annest, Joseph L.; Stevens, Judy A.; Xu, Likang; Coronado, Victor] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway,F-62, Atlanta, GA 30341 USA. RP Stevens, JA (reprint author), 4770 Buford Highway,F-62, Atlanta, GA 30341 USA. EM jas2@cdc.gov NR 24 TC 0 Z9 0 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 EI 1879-1247 J9 J SAFETY RES JI J. Saf. Res. PD FEB PY 2016 VL 56 BP 105 EP 109 DI 10.1016/j.jsr.2015.11.002 PG 5 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA DH6YS UT WOS:000372938600015 PM 26875172 ER PT J AU Cassidy, T Worrell, CM Little, K Prakash, A Patra, I Rout, J Fox, LM AF Cassidy, Tali Worrell, Caitlin M. Little, Kristen Prakash, Aishya Patra, Inakhi Rout, Jonathan Fox, LeAnne M. TI Experiences of a Community-Based Lymphedema Management Program for Lymphatic Filariasis in Odisha State, India: An Analysis of Focus Group Discussions with Patients, Families, Community Members and Program Volunteers SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID BANCROFTIAN FILARIASIS; SOUTHERN ETHIOPIA; NORTHERN ETHIOPIA; GLOBAL PROGRAM; PODOCONIOSIS; IMPACT; DISEASE; BURDEN; STIGMA; ELEPHANTIASIS AB Background Globally 68 million people are infected with lymphatic filariasis (LF), 17 million of whom have lymphedema. This study explores the effects of a lymphedema management program in Odisha State, India on morbidity and psychosocial effects associated with lymphedema. Methodology/Principal Findings Focus groups were held with patients (eight groups, separated by gender), their family members (eight groups), community members (four groups) and program volunteers (four groups) who had participated in a lymphedema management program for the past three years. Significant social, physical, and economic difficulties were described by patients and family members, including marriageability, social stigma, and lost workdays. However, the positive impact of the lymphedema management program was also emphasized, and many family and community members indicated that community members were accepting of patients and had some improved understanding of the etiology of the disease. Program volunteers and community members stressed the role that the program had played in educating people, though interestingly, local explanations and treatments appear to coexist with knowledge of biomedical treatments and the mosquito vector. Conclusions/Significance Local and biomedical understandings of disease can co-exist and do not preclude individuals from participating in biomedical interventions, specifically lymphedema management for those with lymphatic filariasis. There is a continued need for gender-specific psychosocial support groups to address issues particular to men and women as well as a continued need for improved economic opportunities for LF-affected patients. There is an urgent need to scale up LF-related morbidity management programs to reduce the suffering of people affected by LF. C1 [Cassidy, Tali] Univ Cape Town, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa. [Worrell, Caitlin M.; Little, Kristen; Fox, LeAnne M.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Parasit Dis Branch, Atlanta, GA USA. [Prakash, Aishya; Patra, Inakhi; Rout, Jonathan] Churchs Auxiliary Social Act, Pusa Rd, New Delhi, India. RP Cassidy, T (reprint author), Univ Cape Town, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa. EM talicassidy@gmail.com FU IMA World Health; Centers for Disease Control and Prevention FX The funding for this work was provided by IMA World Health and the Centers for Disease Control and Prevention. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Centers for Diseases Control and Prevention. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 0 Z9 0 U1 4 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD FEB PY 2016 VL 10 IS 2 AR e0004424 DI 10.1371/journal.pntd.0004424 PG 15 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DH1TH UT WOS:000372567300040 PM 26849126 ER PT J AU Fouts, DE Matthias, MA Adhikarla, H Adler, B Amorim-Santos, L Berg, DE Bulach, D Buschiazzo, A Chang, YF Galloway, RL Haake, DA Haft, DH Hartskeerl, R Ko, AI Levett, PN Matsunaga, J Mechaly, AE Monk, JM Nascimento, ALT Nelson, KE Palsson, B Peacock, SJ Picardeau, M Ricaldi, JN Thaipandungpanit, J Wunder, EA Yang, XF Zhang, JJ Vinetz, JM AF Fouts, Derrick E. Matthias, Michael A. Adhikarla, Haritha Adler, Ben Amorim-Santos, Luciane Berg, Douglas E. Bulach, Dieter Buschiazzo, Alejandro Chang, Yung-Fu Galloway, Renee L. Haake, David A. Haft, Daniel H. Hartskeerl, Rudy Ko, Albert I. Levett, Paul N. Matsunaga, James Mechaly, Ariel E. Monk, Jonathan M. Nascimento, Ana L. T. Nelson, Karen E. Palsson, Bernhard Peacock, Sharon J. Picardeau, Mathieu Ricaldi, Jessica N. Thaipandungpanit, Janjira Wunder, Elsio A., Jr. Yang, X. Frank Zhang, Jun-Jie Vinetz, Joseph M. TI What Makes a Bacterial Species Pathogenic?: Comparative Genomic Analysis of the Genus Leptospira SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID COMPLEMENT REGULATOR C4BP; FAINEI SEROVAR HURSTBRIDGE; VIRULENCE-ASSOCIATED GENES; OUTER-MEMBRANE PROTEINS; LPS BIOSYNTHETIC LOCI; DNA-DNA HYBRIDIZATION; SIGNAL PEPTIDASE-II; L-GLUTAMATE OXIDASE; ESCHERICHIA-COLI; BORRELIA-BURGDORFERI AB Leptospirosis, caused by spirochetes of the genus Leptospira, is a globally widespread, neglected and emerging zoonotic disease. While whole genome analysis of individual pathogenic, intermediately pathogenic and saprophytic Leptospira species has been reported, comprehensive cross-species genomic comparison of all known species of infectious and non-infectious Leptospira, with the goal of identifying genes related to pathogenesis and mammalian host adaptation, remains a key gap in the field. Infectious Leptospira, comprised of pathogenic and intermediately pathogenic Leptospira, evolutionarily diverged from non-infectious, saprophytic Leptospira, as demonstrated by the following computational biology analyses: 1) the definitive taxonomy and evolutionary relatedness among all known Leptospira species; 2) genomically-predicted metabolic reconstructions that indicate novel adaptation of infectious Leptospira to mammals, including sialic acid biosynthesis, pathogen-specific porphyrin metabolism and the first-time demonstration of cobalamin (B12) autotrophy as a bacterial virulence factor; 3) CRISPR/Cas systems demonstrated only to be present in pathogenic Leptospira, suggesting a potential mechanism for this clade's refractoriness to gene targeting; 4) finding Leptospira pathogen-specific specialized protein secretion systems; 5) novel virulence-related genes/gene families such as the Virulence Modifying (VM) (PF07598 paralogs) proteins and pathogen-specific adhesins; 6) discovery of novel, pathogen-specific protein modification and secretion mechanisms including unique lipoprotein signal peptide motifs, Sec-independent twin arginine protein secretion motifs, and the absence of certain canonical signal recognition particle proteins from all Leptospira; and 7) and demonstration of infectious Leptospira-specific signal-responsive gene expression, motility and chemotaxis systems. By identifying large scale changes in infectious (pathogenic and intermediately pathogenic) vs. non-infectious Leptospira, this work provides new insights into the evolution of a genus of bacterial pathogens. This work will be a comprehensive roadmap for understanding leptospirosis pathogenesis. More generally, it provides new insights into mechanisms by which bacterial pathogens adapt to mammalian hosts. C1 [Fouts, Derrick E.; Haft, Daniel H.; Nelson, Karen E.] J Craig Venter Inst, Rockville, MD USA. [Matthias, Michael A.; Berg, Douglas E.; Vinetz, Joseph M.] Univ Calif San Diego, Sch Med, Div Infect Dis, Dept Med, La Jolla, CA 92093 USA. [Adhikarla, Haritha; Amorim-Santos, Luciane; Ko, Albert I.; Wunder, Elsio A., Jr.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA. [Adler, Ben] Monash Univ, Dept Microbiol, Australian Res Council, Ctr Excellence Struct & Funct Microbial Gen, Clayton, Vic 3168, Australia. [Amorim-Santos, Luciane; Ko, Albert I.; Wunder, Elsio A., Jr.] Fundacao Oswaldo Cruz MS, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil. [Bulach, Dieter] Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic, Australia. [Buschiazzo, Alejandro; Mechaly, Ariel E.] Inst Pasteur, Lab Mol & Struct Microbiol, Montevideo, Uruguay. [Buschiazzo, Alejandro] Inst Pasteur, Dept Struct Biol & Chem, Paris, France. [Chang, Yung-Fu] Cornell Univ, Coll Vet Med, Dept Populat Med & Diagnost Sci, Ithaca, NY 14853 USA. [Galloway, Renee L.] Ctr Dis Control & Prevent, BSPB, DHCPP, NCEZID,OID,CDC,DHHS, Atlanta, GA USA. [Haake, David A.; Matsunaga, James] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Haake, David A.; Matsunaga, James] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Hartskeerl, Rudy] Royal Trop Inst KIT, WHO FAO OIE, Amsterdam, Netherlands. [Hartskeerl, Rudy] Royal Trop Inst KIT, Natl Collaborating Ctr Reference & Res Leptospiro, KIT Biomed Res, Amsterdam, Netherlands. [Levett, Paul N.] Govt Saskatchewan, Dis Control Lab Regina, Saskatoon, SK, Canada. [Monk, Jonathan M.; Palsson, Bernhard] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA. [Nascimento, Ana L. T.] Inst Butantan, Ctr Biotecnol, Sao Paulo, SP, Brazil. [Nascimento, Ana L. T.] Univ Sao Paulo, Programa Interunidades Biotecnol, Inst Ciencias Biomed, Sao Paulo, SP, Brazil. [Peacock, Sharon J.] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England. [Picardeau, Mathieu] Inst Pasteur, Biol Spirochetes Unit, Natl Reference Ctr, Paris, France. [Picardeau, Mathieu] WHO Collaborating Ctr Leptospirosis, Paris, France. [Ricaldi, Jessica N.; Vinetz, Joseph M.] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Fac Med Alberto Hurtado, Lima, Peru. [Thaipandungpanit, Janjira] Mahidol Univ, Fac Trop Med, Bangkok, Thailand. [Yang, X. Frank; Zhang, Jun-Jie] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA. [Vinetz, Joseph M.] Univ Peruana Cayetano Heredia, Inst Med Alexander von Humboldt, Lima, Peru. RP Fouts, DE (reprint author), J Craig Venter Inst, Rockville, MD USA.; Fouts, DE; Vinetz, JM (reprint author), Univ Calif San Diego, Sch Med, Div Infect Dis, Dept Med, La Jolla, CA 92093 USA.; Vinetz, JM (reprint author), Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Fac Med Alberto Hurtado, Lima, Peru.; Vinetz, JM (reprint author), Univ Peruana Cayetano Heredia, Inst Med Alexander von Humboldt, Lima, Peru. EM dfouts@jcvi.org; jvinetz@ucsd.edu RI Ko, Albert/P-2343-2015; Wunder, Elsio/C-2733-2013; zhang, junjie/P-2376-2015; OI zhang, junjie/0000-0002-5108-2072; Nascimento, Ana Lucia /0000-0003-4851-0870; Mechaly, Ariel/0000-0002-5305-7495 FU federal funds from National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200900007C]; U.S. Public Health Service [U19AI115658, R01AI108276, D43TW007120, K24AI068903, R21AI115273, R01AI052473, R25TW009338, U01AI088752, R01TW009504, R01AI121207]; ANII (Uruguay) [FSA_1_2013_1_12557, ALI_1_2014_1_4982] FX This project has been funded in whole or part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under Contract Number HHSN272200900007C. This work was also supported in part by the following U.S. Public Health Service grants: U19AI115658 (JMV), R01AI108276 (JMV), D43TW007120 (JMV), K24AI068903 (JMV), R21AI115273 (MAM), R01AI052473 (AIK), U01AI088752 (AIK), R25TW009338 (AIK), R01TW009504 (AIK), and R01AI121207 (AIK). In addition, support to the A. Buschiazzo team was provided in part by grants FSA_1_2013_1_12557 and ALI_1_2014_1_4982 from ANII (Uruguay). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 214 TC 13 Z9 13 U1 9 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD FEB PY 2016 VL 10 IS 2 AR e0004403 DI 10.1371/journal.pntd.0004403 PG 57 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DH1TH UT WOS:000372567300024 PM 26890609 ER PT J AU Johnson, TL Landguth, EL Stone, EF AF Johnson, Tammi L. Landguth, Erin L. Stone, Emily F. TI Modeling Relapsing Disease Dynamics in a Host-Vector Community SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID WEST-NILE-VIRUS; INFECTIOUS-DISEASES; BORRELIA-HERMSII; NORTH-AMERICA; FEVER; BIODIVERSITY; ECOLOGY; TRANSMISSION; PROTEIN; HEALTH AB Vector-borne diseases represent a threat to human and wildlife populations and mathematical models provide a means to understand and control epidemics involved in complex host-vector systems. The disease model studied here is a host-vector system with a relapsing class of host individuals, used to investigate tick-borne relapsing fever (TBRF). Equilibrium analysis is performed for models with increasing numbers of relapses and multiple hosts and the disease reproduction number, R-0, is generalized to establish relationships with parameters that would result in the elimination of the disease. We show that host relapses in a single competent host-vector system is needed to maintain an endemic state. We show that the addition of an incompetent second host with no relapses increases the number of relapses needed for maintaining the pathogen in the first competent host system. Further, coupling of the system with hosts of differing competencies will always reduce R-0, making it more difficult for the system to reach an endemic state. C1 [Johnson, Tammi L.; Landguth, Erin L.] Univ Montana, Div Biol Sci, Missoula, MT 59812 USA. [Stone, Emily F.] Univ Montana, Dept Math Sci, Missoula, MT 59812 USA. [Johnson, Tammi L.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. RP Johnson, TL (reprint author), Univ Montana, Div Biol Sci, Missoula, MT 59812 USA.; Johnson, TL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. EM uzj6@cdc.gov FU Montana Ecology of Infectious Diseases IGERT Program (NSF IGERT) [0501628]; National Instituted of Health Pre-doctoral Intramural Research and Training Award (IRTA) FX TLJ and ELL received graduate stipend support from the Montana Ecology of Infectious Diseases IGERT Program (NSF IGERT Grant #0501628; William Holben, PI). TLJ also received graduate stipend support from the National Instituted of Health Pre-doctoral Intramural Research and Training Award (IRTA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 2 Z9 2 U1 3 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD FEB PY 2016 VL 10 IS 2 AR e0004428 DI 10.1371/journal.pntd.0004428 PG 14 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DH1TH UT WOS:000372567300043 PM 26910884 ER PT J AU Pant, BP Bhatta, RC Chaudhary, JSP Awasthi, S Mishra, S Sharma, S Cuddapah, PA Gwyn, SE Stoller, NE Martin, DL Keenan, JD Lietman, TM Gaynor, BD AF Pant, Bidya Prasad Bhatta, Ramesh C. Chaudhary, J. S. P. Awasthi, Suresh Mishra, Sailesh Sharma, Shekhar Cuddapah, Puja A. Gwyn, Sarah E. Stoller, Nicole E. Martin, Diana L. Keenan, Jeremy D. Lietman, Thomas M. Gaynor, Bruce D. TI Control of Trachoma from Achham District, Nepal: A Cross-Sectional Study from the Nepal National Trachoma Program SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID OCULAR CHLAMYDIA-TRACHOMATIS; CLUSTER-RANDOMIZED TRIAL; SEVERELY AFFECTED COMMUNITIES; MASS ANTIBIOTIC-TREATMENT; INFECTIOUS TRACHOMA; AZITHROMYCIN; ELIMINATION; PREVALENCE; REDUCTION; ETHIOPIA AB Background The WHO seeks to control trachoma as a public health problem in endemic areas. Achham District in western Nepal was found to have TF (trachoma follicular) above 20% in a 2006 government survey, triggering 3 annual mass drug administrations finishing in 2010. Here we assess the level of control that has been achieved using surveillance for clinical disease, ocular chlamydia trachomatis infection, and serology for antibodies against chlamydia trachomatis protein antigens. Methods We conducted a cross-sectional survey of children aged 1-9 years in communities in Achham District in early 2014 including clinical examination validated with photographs, conjunctival samples for Chlamydia trachomatis (Amplicor PCR), and serological testing for antibodies against chlamydia trachomatis protein antigens pgp3 and CT694 using the Luminex platform. Findings In 24 randomly selected communities, the prevalence of trachoma (TF and/or TI) in 1-9 year olds was 3/1124 (0.3%, 95% CI 0.1 to 0.8%), and the prevalence of ocular chlamydia trachomatis infection was 0/1124 (0%, 95% CI 0 to 0.3%). In 18 communities selected because they had the highest prevalence of trachoma in a previous survey, the prevalence of TF and/or TI was 7/716 (1.0%, 95% CI 0.4 to 2.0%) and the prevalence of ocular chlamydia trachomatis infection was 0/716 (0%, 95% CI 0 to 0.5%). In 3 communities selected for serological testing, the prevalence of trachoma was 0/68 (0%, 95% CI 0 to 5.3%), the prevalence of ocular chlamydia trachomatis infection was 0/68 (0%, 95% CI 0 to 0.5%), the prevalence of antibodies against chlamydia trachomatis protein antigen pgp3 was 1/68 (1.5%, 95% CI 0.04% to 7.9%), and the prevalence of antibodies against chlamydia trachomatis protein antigen CT694 was 0/68 (0%, 95% CI 0 to 5.3%). Conclusion/Significance This previously highly endemic district in Nepal has little evidence of recent clinical disease, chlamydia trachomatis infection, or serological evidence of trachoma, suggesting that epidemiological control has been achieved. C1 [Pant, Bidya Prasad; Bhatta, Ramesh C.; Chaudhary, J. S. P.; Awasthi, Suresh] Geta Eye Hosp, Dhangadhi, Nepal. [Mishra, Sailesh; Sharma, Shekhar] Nepal Netra Jyoti Sangh, Kathmandu, Nepal. [Cuddapah, Puja A.; Stoller, Nicole E.; Keenan, Jeremy D.; Lietman, Thomas M.; Gaynor, Bruce D.] Univ Calif San Francisco, FI Proctor Fdn, San Francisco, CA 94143 USA. [Gwyn, Sarah E.; Martin, Diana L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Keenan, Jeremy D.; Lietman, Thomas M.; Gaynor, Bruce D.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA. [Lietman, Thomas M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Gaynor, BD (reprint author), Univ Calif San Francisco, FI Proctor Fdn, San Francisco, CA 94143 USA.; Gaynor, BD (reprint author), Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA. EM bdgaynor@gmail.com FU National Institutes of Health [NIH/NEI K23 EYO19881-01, NIH/NCRR/OD UCSF-CTSI KL2 RR024130] FX BDG: This work was supported by the National Institutes of Health (NIH/NEI K23 EYO19881-01 and NIH/NCRR/OD UCSF-CTSI KL2 RR024130). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 4 Z9 4 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD FEB PY 2016 VL 10 IS 2 AR e0004462 DI 10.1371/journal.pntd.0004462 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DH1TH UT WOS:000372567300067 PM 26871898 ER PT J AU Respicio-Kingry, LB Yockey, BM Acayo, S Kaggwa, J Apangu, T Kugeler, KJ Eisen, RJ Griffith, KS Mead, PS Schriefer, ME Petersen, JM AF Respicio-Kingry, Laurel B. Yockey, Brook M. Acayo, Sarah Kaggwa, John Apangu, Titus Kugeler, Kiersten J. Eisen, Rebecca J. Griffith, Kevin S. Mead, Paul S. Schriefer, Martin E. Petersen, Jeannine M. TI Two Distinct Yersinia pestis Populations Causing Plague among Humans in the West Nile Region of Uganda SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID GENOME REARRANGEMENTS; UNITED-STATES; PHYLOGEOGRAPHY; EVOLUTION; STRAINS; EPIDEMIOLOGY; TRANSMISSION; DIVERSITY; EXPANSION; SEQUENCES AB Background Plague is a life-threatening disease caused by the bacterium, Yersinia pestis. Since the 1990s, Africa has accounted for the majority of reported human cases. In Uganda, plague cases occur in the West Nile region, near the border with Democratic Republic of Congo. Despite the ongoing risk of contracting plague in this region, little is known about Y. pestis genotypes causing human disease. Methodology/Principal Findings During January 2004-December 2012, 1,092 suspect human plague cases were recorded in the West Nile region of Uganda. Sixty-one cases were culture-confirmed. Recovered Y. pestis isolates were analyzed using three typing methods, single nucleotide polymorphisms (SNPs), pulsed field gel electrophoresis (PFGE), and multiple variable number of tandem repeat analysis (MLVA) and subpopulations analyzed in the context of associated geographic, temporal, and clinical data for source patients. All three methods separated the 61 isolates into two distinct 1. ANT lineages, which persisted throughout the 9 year period and were associated with differences in elevation and geographic distribution. Conclusions/Significance We demonstrate that human cases of plague in the West Nile region of Uganda are caused by two distinct 1. ANT genetic subpopulations. Notably, all three typing methods used, SNPs, PFGE, and MLVA, identified the two genetic subpopulations, despite recognizing different mutation types in the Y. pestis genome. The geographic and elevation differences between the two subpopulations is suggestive of their maintenance in highly localized enzootic cycles, potentially with differing vector-host community composition. This improved understanding of Y. pestis subpopulations in the West Nile region will be useful for identifying ecologic and environmental factors associated with elevated plague risk. C1 [Respicio-Kingry, Laurel B.; Yockey, Brook M.; Kugeler, Kiersten J.; Eisen, Rebecca J.; Griffith, Kevin S.; Mead, Paul S.; Schriefer, Martin E.; Petersen, Jeannine M.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Bacterial Dis Branch, Ft Collins, CO USA. [Acayo, Sarah; Kaggwa, John; Apangu, Titus] Uganda Virus Res Inst, Entebbe, Uganda. RP Petersen, JM (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Bacterial Dis Branch, Ft Collins, CO USA. EM nzp0@cdc.gov NR 34 TC 2 Z9 2 U1 4 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD FEB PY 2016 VL 10 IS 2 AR e0004360 DI 10.1371/journal.pntd.0004360 PG 14 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DH1TH UT WOS:000372567300009 PM 26866815 ER PT J AU Sharp, TM Garcia, BR Perez-Padilla, J Galloway, RL Guerra, M Ryff, KR Haberling, D Ramakrishnan, S Shadomy, S Blau, D Tomashek, KM Bower, WA AF Sharp, Tyler M. Garcia, Brenda Rivera Perez-Padilla, Janice Galloway, Renee L. Guerra, Marta Ryff, Kyle R. Haberling, Dana Ramakrishnan, Sharada Shadomy, Sean Blau, Dianna Tomashek, Kay M. Bower, William A. TI Early Indicators of Fatal Leptospirosis during the 2010 Epidemic in Puerto Rico SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID ACUTE-RENAL-FAILURE; RISK-FACTORS; PULMONARY HEMORRHAGE; DENGUE-FEVER; WEST-INDIES; PREDICTORS; OUTBREAK; BARBADOS; MORTALITY; DISEASE AB Background Leptospirosis is a potentially fatal bacterial zoonosis that is endemic throughout the tropics and may be misdiagnosed as dengue. Delayed hospital admission of leptospirosis patients is associated with increased mortality. Methodology/Principal Findings During a concurrent dengue/leptospirosis epidemic in Puerto Rico in 2010, suspected dengue patients that tested dengue-negative were tested for leptospirosis. Fatal and non-fatal hospitalized leptospirosis patients were matched 1: 1-3 by age. Records from all medical visits were evaluated for factors associated with fatal outcome. Among 175 leptospirosis patients identified (4.7 per 100,000 residents), 26 (15%) were fatal. Most patients were older males and had illness onset during the rainy season. Fatal case patients first soughtmedical care earlier than non-fatal control patients (2.5 vs. 5 days post-illness onset [DPO], p < 0.01), but less frequently first sought care at a hospital (52.4% vs. 92.2%, p < 0.01). Although fatal cases were more often diagnosed with leptospirosis at first medical visit (43.9% vs. 9.6%, p = 0.01), they were admitted to the hospital no earlier than non-fatal controls (4.5 vs. 6 DPO, p = 0.31). Cases less often developed fever (p = 0.03), but more often developed jaundice, edema, leg pain, hemoptysis, and had a seizure (p <= 0.03). Multivariable analysis of laboratory values from first medical visit associated with fatal outcome included increased white blood cell (WBC) count with increased creatinine (p = 0.001), and decreased bicarbonate with either increased WBC count, increased creatinine, or decreased platelet count (p < 0.001). Conclusions/Significance Patients with fatal leptospirosis sought care earlier, but were not admitted for care any earlier than non-fatal patients. Combinations of routine laboratory values predictive of fatal outcome should be considered in admission decision-making for patients with suspected leptospirosis. C1 [Sharp, Tyler M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Sharp, Tyler M.; Perez-Padilla, Janice; Tomashek, Kay M.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR USA. [Garcia, Brenda Rivera; Ryff, Kyle R.] Puerto Rico Dept Hlth, San Juan, PR USA. [Galloway, Renee L.; Guerra, Marta; Haberling, Dana; Ramakrishnan, Sharada; Shadomy, Sean; Bower, William A.] Ctr Dis Control & Prevent, Div High Consequence Pathogens, Bacterial Special Pathogens Branch, Atlanta, GA USA. [Blau, Dianna] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Infect Dis Pathol Branch, Atlanta, GA USA. RP Sharp, TM (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA.; Sharp, TM (reprint author), Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR USA. EM tsharp@cdc.gov FU U.S. Centers for Disease Control and Prevention; Puerto Rico Department of Health FX This study was supported by the U.S. Centers for Disease Control and Prevention and Puerto Rico Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD FEB PY 2016 VL 10 IS 2 AR e0004482 DI 10.1371/journal.pntd.0004482 PG 15 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DH1TH UT WOS:000372567300077 PM 26914210 ER PT J AU Frank, EA Carreira, VS Birch, ME Yadav, JS AF Frank, Evan A. Carreira, Vinicius S. Birch, M. Eileen Yadav, Jagjit S. TI Carbon Nanotube and Asbestos Exposures Induce Overlapping but Distinct Profiles of Lung Pathology in Non-Swiss Albino CF-1 Mice SO TOXICOLOGIC PATHOLOGY LA English DT Article DE carbon nanotubes; crocidolite asbestos; fiber toxicology; comparative pathology; lung; mouse ID MADE VITREOUS FIBERS; CROCIDOLITE ASBESTOS; PULMONARY INFLAMMATION; ALVEOLAR MACROPHAGES; LIBBY AMPHIBOLE; MOUSE LUNG; IN-VITRO; FIBROSIS; INHALATION; RATS AB Carbon nanotubes (CNTs) are emerging as important occupational and environmental toxicants owing to their increasing prevalence and potential to be inhaled as airborne particles. CNTs are a concern because of their similarities to asbestos, which include fibrous morphology, high aspect ratio, and biopersistence. Limitations in research models have made it difficult to experimentally ascertain the risk of CNT exposures to humans and whether these may lead to lung diseases classically associated with asbestos, such as mesothelioma and fibrosis. In this study, we sought to comprehensively compare profiles of lung pathology in mice following repeated exposures to multiwall CNTs or crocidolite asbestos (CA). We show that both exposures resulted in granulomatous inflammation and increased interstitial collagen; CA exposures caused predominantly bronchoalveolar hyperplasia, whereas CNT exposures caused alveolar hyperplasia of type II pneumocytes (T2Ps). T2Ps isolated from CNT-exposed lungs were found to have upregulated proinflammatory genes, including interleukin 1 ss (IL-1 ss), in contrast to those from CA exposed. Immunostaining in tissue showed that while both toxicants increased IL-1 ss protein expression in lung cells, T2P-specific IL-1 ss increases were greater following CNT exposure. These results suggest related but distinct mechanisms of action by CNTs versus asbestos which may lead to different outcomes in the 2 exposure types. C1 [Frank, Evan A.; Carreira, Vinicius S.; Yadav, Jagjit S.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Div Environm Genet & Mol Toxicol, Cincinnati, OH 45267 USA. [Birch, M. Eileen] NIOSH, Cincinnati, OH 45226 USA. RP Yadav, JS (reprint author), Univ Cincinnati, Coll Med, Kettering Lab Complex, 160 Panzeca Way, Cincinnati, OH 45267 USA. EM jagjit.yadav@uc.edu FU National Institutes of Health/National Institute for Environmental Health Sciences Center for Environmental Genetics (CEG) [2P30ES006096-16A1]; Gene-Environment Interactions Training Program (GEITP) fellowship [T32ES016646]; National Institute of Occupational Safety and Health/Education and Research Center (ERC) [T42OH008432-07]; University of Cincinnati FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institutes of Health/National Institute for Environmental Health Sciences Center for Environmental Genetics (CEG) funds [2P30ES006096-16A1 to JSY], Gene-Environment Interactions Training Program (GEITP) fellowship [T32ES016646 to EAF], and National Institute of Occupational Safety and Health/Education and Research Center (ERC) funding [T42OH008432-07 to EAF], and the University of Cincinnati funds (to JSY). NR 49 TC 0 Z9 0 U1 1 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0192-6233 EI 1533-1601 J9 TOXICOL PATHOL JI Toxicol. Pathol. PD FEB PY 2016 VL 44 IS 2 BP 211 EP 225 DI 10.1177/0192623315620587 PG 15 WC Pathology; Toxicology SC Pathology; Toxicology GA DH0KL UT WOS:000372473000006 PM 26839332 ER PT J AU Mijatovic-Rustempasic, S Roy, S Teel, EN Weinberg, GA Payne, DC Parashar, UD Bowen, MD AF Mijatovic-Rustempasic, Slavica Roy, Sunando Teel, Elizabeth N. Weinberg, Geoffrey A. Payne, Daniel C. Parashar, Umesh D. Bowen, Michael D. TI Full genome characterization of the first G3P[24] rotavirus strain detected in humans provides evidence of interspecies reassortment and mutational saturation in the VP7 gene SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID GROUP-A ROTAVIRUS; TRANSMISSION EVENTS; UNITED-STATES; DIVERSITY; VACCINATION; IMPACT; CLASSIFICATION; SURVEILLANCE; GENOTYPE; SEROTYPE AB During the 2008-2009 rotavirus season of the Centers for Disease Control and Prevention New Vaccine Surveillance Network, one case of paediatric acute gastroenteritis associated with a rotavirus G14P[24] strain was identified. This was the first detection of the genotype G14 and P[24] in humans, and the first detection of the G14P[24] combination. To gain an insight into the origins and the evolution of this strain, we determined the complete ORF sequences of all 11 genes. A majority of the genes identified were similar to the simian strain TUCH, except for the VP1 and VP7 genes that clustered only distantly with the bovine and equine strains, respectively. In addition, this strain carried AU-1-like NSP2 and NSP4 genes. Using codon-partitioning and protein-based phylogenetic approaches, we determined that the VP7 genotype of strain 2009727118 was actually G3; therefore, the proposed full genomic classification of the 2009727118 strain is G3-P[24]-I9-R2-C3-M3-A9-N3-T3-E3-H6. These findings indicate the possibility that the 2009727118 strain originated by interspecies transmission and multiple reassortment events involving human, bovine and equine rotaviruses, resulting in the introduction of some genes into the genome of simian rotaviruses. Additionally, we found evidence of mutational saturation in the third codon position of the VP7 ORF which presented an issue with homoplasy in phylogenetic analyses. C1 [Mijatovic-Rustempasic, Slavica; Roy, Sunando; Teel, Elizabeth N.; Payne, Daniel C.; Parashar, Umesh D.; Bowen, Michael D.] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. [Weinberg, Geoffrey A.] Univ Rochester, Dept Pediat, Sch Med & Dent, 601 Elmwood Ave,Box 690, Rochester, NY 14642 USA. RP Bowen, MD (reprint author), Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM mkb6@cdc.gov FU Intramural CDC HHS [CC999999] NR 35 TC 2 Z9 2 U1 1 U2 5 PU MICROBIOLOGY SOC PI LONDON PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND SN 0022-1317 EI 1465-2099 J9 J GEN VIROL JI J. Gen. Virol. PD FEB PY 2016 VL 97 BP 389 EP 402 DI 10.1099/jgv.0.000349 PN 2 PG 14 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA DG4ST UT WOS:000372063600015 PM 26590163 ER PT J AU Conley, LJ Bush, TJ Darragh, TM Palefsky, JM Unger, ER Patel, P Steinau, M Kojic, EM Martin, H Overton, ET Cu-Uvin, S Hammer, J Henry, K Wood, K Brooks, JT AF Conley, Lois J. Bush, Timothy J. Darragh, Teresa M. Palefsky, Joel M. Unger, Elizabeth R. Patel, Pragna Steinau, Martin Kojic, E. Milu Martin, Harold Overton, E. Turner Cu-Uvin, Susan Hammer, John Henry, Keith Wood, Kathleen Brooks, John T. CA SUN Study Grp TI Incidence and Predictors of Abnormal Anal Cytology Findings Among HIV-Infected Adults Receiving Contemporary Antiretroviral Therapy SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE abnormal anal cytology; HPV; HIV; incidence; persistence ID SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN-PAPILLOMAVIRUS INFECTION; AIDS-DEFINING CANCERS; CHLAMYDIA-TRACHOMATIS; RISK-FACTORS; HIGH PREVALENCE; UNITED-STATES; BISEXUAL MEN; POSITIVE MEN; NEOPLASIA AB Background. Anal cancer rates are higher for human immunodeficiency virus (HIV)-infected adults than for uninfected adults. Limited published data exist characterizing the incidence of precursor lesions detected by anal cytology. Methods.The Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy was a prospective cohort of 700 HIV-infected participants in 4 US cities. At baseline and annually thereafter, each participant completed a behavioral questionnaire, and healthcare professionals collected anorectal swabs for cytologic examination and human papillomavirus (HPV) detection and genotyping. Results.Among 243 participants with negative baseline results of anal cytology, 37% developed abnormal cytology findings (incidence rate, 13.9 cases/100 person-years of follow-up; 95% confidence interval [CI], 11.3-16.9) over a median follow-up duration of 2.1 years. Rates among men having sex with men, among women, and among men having sex with women were 17.9 cases/person-years of follow-up (95% CI, 13.9-22.7), 9.4 cases/person-years of follow-up (95% CI, 5.6-14.9), and 8.9 cases/person-years of follow-up (95% CI, 4.8-15.6), respectively. In multivariable analysis, the number of persistent high-risk HPV types (adjusted hazard ratio [aHR], 1.17; 95% CI, 1.01-1.36), persistent high-risk HPV types except 16 or 18 (aHR, 2.46; 95% CI, 1.31-4.60), and persistent types 16 or 18 (aHR, 3.90; 95% CI, 1.78-8.54) remained associated with incident abnormalities. Conclusions.The incidence of abnormal anal cytology findings was high and more likely to develop among persons with persistent high-risk HPV. C1 [Conley, Lois J.; Bush, Timothy J.; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Darragh, Teresa M.; Palefsky, Joel M.; Unger, Elizabeth R.; Steinau, Martin] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Darragh, Teresa M.; Palefsky, Joel M.; Unger, Elizabeth R.; Steinau, Martin] Univ Calif San Francisco, Providence, RI USA. [Kojic, E. Milu; Cu-Uvin, Susan] Miriam Hosp, Providence, RI 02906 USA. [Martin, Harold] Pk Nicollet Clin, Minneapolis, MN USA. [Overton, E. Turner] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Hammer, John] Denver Infect Dis Consultants, Denver, CO USA. [Henry, Keith] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Wood, Kathleen] Cerner, Vienna, VA USA. [Martin, Harold] Gilead Sci, Foster City, CA USA. RP Conley, LJ (reprint author), Ctr Dis Control & Prevent, DHAP NCHHSTP, 1600 Clifton Rd NE,Mailstop E-45, Atlanta, GA 30333 USA. EM ljc2@cdc.gov OI Unger, Elizabeth/0000-0002-2925-5635 FU CDC [200-2002-00610, 200-2002-00611, 200-2002-00612, 200-2002-00613, 200-2007-3633, 200-2007-23634, 200-2007-23635, 200-2007-23636] FX This work was supported by the CDC (contracts 200-2002-00610, 200-2002-00611, 200-2002-00612, 200-2002-00613, 200-2007-3633, 200-2007-23634, 200-2007-23635, and 200-2007-23636). NR 50 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2016 VL 213 IS 3 BP 351 EP 360 DI 10.1093/infdis/jiv408 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DG9XB UT WOS:000372436000005 PM 26268855 ER PT J AU Maslanka, SE Luquez, C Dykes, JK Tepp, WH Pier, CL Pellett, S Raphael, BH Kalb, SR Barr, JR Rao, A Johnson, EA AF Maslanka, Susan E. Luquez, Carolina Dykes, Janet K. Tepp, William H. Pier, Christina L. Pellett, Sabine Raphael, Brian H. Kalb, Suzanne R. Barr, John R. Rao, Agam Johnson, Eric A. TI A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE botulinum toxin; Clostridium botulinum; serotype; botulism; neutralization; neuronal cell-based assay ID INTERNATIONAL STANDARDS; INFANT BOTULISM; ANTIBODIES; TOXIN; ASSAY; DIVERSITY AB Botulism is a potentially fatal paralytic disease caused by the action of botulinum neurotoxin (BoNT) on nerve cells. There are 7 known serotypes (A-G) of BoNT and up to 40 genetic variants. Clostridium botulinum strain IBCA10-7060 was recently reported to produce BoNT serotype B (BoNT/B) and a novel BoNT, designated as BoNT/H. The BoNT gene (bont) sequence of BoNT/H was compared to known bont sequences. Genetic analysis suggested that BoNT/H has a hybrid-like structure containing regions of similarity to the structures of BoNT/A1 and BoNT/F5. This novel BoNT was serologically characterized by the mouse neutralization assay and a neuronal cell-based assay. The toxic effects of this hybrid-like BoNT were completely eliminated by existing serotype A antitoxins, including those contained in multivalent therapeutic antitoxin products that are the mainstay of human botulism treatment. C1 [Maslanka, Susan E.; Luquez, Carolina; Dykes, Janet K.; Raphael, Brian H.; Kalb, Suzanne R.; Barr, John R.; Rao, Agam] Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30329 USA. [Tepp, William H.; Pier, Christina L.; Pellett, Sabine; Johnson, Eric A.] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA. RP Maslanka, SE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM smaslanka@cdc.gov OI Raphael, Brian/0000-0003-2778-2623 FU Office of Public Health Preparedness and Response, CDC; National Institute of Allergy and Infectious Diseases [R01AI095274] FX This work was supported by the Office of Public Health Preparedness and Response, CDC (to S. E. M., C. L., J. K. D., B. H. R., S. R. K., J. R. B., and A. R.); and the National Institute of Allergy and Infectious Diseases (R01AI095274 to W. H. T., C. L. P., S. P., and E. A. J.). NR 42 TC 15 Z9 15 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2016 VL 213 IS 3 BP 379 EP 385 DI 10.1093/infdis/jiv327 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DG9XB UT WOS:000372436000008 PM 26068781 ER PT J AU Gutman, J Taylor, S Meshnick, SR ter Kuile, FO AF Gutman, Julie Taylor, Steve Meshnick, Steven R. ter Kuile, Feiko O. TI Defending the Use of Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment for Malaria in Pregnancy: A Short-Sighted Strategy Reply SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter ID RESISTANT PLASMODIUM-FALCIPARUM; CONTROLLED-TRIAL; BIRTH-WEIGHT; WOMEN; INFECTION; OUTCOMES; THERAPY; AFRICA C1 [Gutman, Julie] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,Mailstop A06, Atlanta, GA 30322 USA. [Taylor, Steve] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Taylor, Steve; Meshnick, Steven R.] Univ N Carolina, Chapel Hill, NC USA. [ter Kuile, Feiko O.] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England. RP Gutman, J (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,Mailstop A06, Atlanta, GA 30322 USA. EM jgutman@cdc.gov FU Intramural CDC HHS [CC999999] NR 13 TC 0 Z9 0 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2016 VL 213 IS 3 BP 497 EP 498 DI 10.1093/infdis/jiv421 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DG9XB UT WOS:000372436000023 PM 26290609 ER PT J AU Wilson, RJ Ryerson, AB Singh, SD King, JB AF Wilson, Reda J. Ryerson, A. Blythe Singh, Simple D. King, Jessica B. TI Cancer Incidence in Appalachia, 2004-2011 SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID PROSTATE-CANCER; UNITED-STATES; CARCINOMA MORTALITY; RACIAL DISPARITIES; INCIDENCE RATES; THYROID-CANCER; FOLLOW-UP; WOMEN; MEN; BREAST AB Background: Limited literature is available about cancer in the Appalachian Region. This is the only known analysis of all cancers for Appalachia and non-Appalachia covering 100% of the US population. Appalachian cancer incidence and trends were evaluated by state, sex, and race and compared with those found in non-Appalachian regions. Methods: US counties were identified as Appalachian or non-Appalachian. Age-adjusted cancer incidence rates, standard errors, and confidence intervals were calculated using the most recent data from the United States Cancer Statistics for 2004 to 2011. Results: Generally, Appalachia carries a higher cancer burden compared with non-Appalachia, particularly for tobacco-related cancers. For all cancer sites combined, Appalachia has higher rates regardless of sex, race, or region. The Appalachia and non-Appalachia cancer incidence gap has narrowed, with the exception of oral cavity and pharynx, larynx, lung and bronchus, and thyroid cancers. Conclusions: Higher cancer incidence continues in Appalachia and appears at least in part to reflect high tobacco use and potential differences in socioeconomic status, other risk factors, patient health care utilization, or provider practices. It is important to continue to evaluate this population to monitor results from screening and early detection programs, understand behavioral risk factors related to cancer incidence, increase efforts to reduce tobacco use and increase cancer screening, and identify other areas where effective interventions may mediate disparities. Impact: Surveillance and evaluation of special populations provide means to monitor screening and early detection programs, understand behavioral risk factors, and increase efforts to reduce tobacco use to mediate disparities. (C) 2016 AACR. C1 [Wilson, Reda J.; Ryerson, A. Blythe; Singh, Simple D.; King, Jessica B.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Wilson, RJ (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,Mail Stop F-76, Chamblee, GA 30341 USA. EM rwilson1@cdc.gov FU Division of Cancer Prevention and Control at the National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention FX This work was supported by the Division of Cancer Prevention and Control at the National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (all authors). NR 41 TC 3 Z9 3 U1 2 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD FEB PY 2016 VL 25 IS 2 BP 250 EP 258 DI 10.1158/1055-9965.EPI-15-0946 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DG6DS UT WOS:000372173000004 PM 26819264 ER PT J AU Liao, YL Siegel, PZ White, S Dulin, R Taylor, A AF Liao, Youlian Siegel, Paul Z. White, Shannon Dulin, Rick Taylor, April TI Improving actions to control high blood pressure in Hispanic communities - Racial and Ethnic Approaches to Community Health Across the US Project, 2009-2012 SO PREVENTIVE MEDICINE LA English DT Article DE Community intervention; Hispanic; Hypertension; Health disparity ID HYPERTENSION; INTERVENTION; DISPARITIES; ADULTS AB Background. Compared with the general population in the United States (U.S.), Hispanics with hypertension are less likely to be aware of their condition, to take antihypertensive medication, and to adopt healthy lifestyles to control high blood pressure. We examined whether a multi-community intervention successfully increased the prevalence of actions to control hypertension among Hispanics. Methods. Annual survey from 2009-2012 was conducted in six Hispanic communities in the Racial and Ethnic Approaches to Community Health (REACH) ACTOSS the U.S. project. The survey used address based sampling design that matched the geographies of intervention program. Results. Age- and sex-standardized prevalences of taking hypertensive medication, changing eating habits, cutting down on salt, and reducing alcohol use significantly increased among Hispanics with self-reported hypertension in REACH communities. The 3-year relative percent increases were 5.8, 6.8, 7.9, and 35.2% for the four indicators, respectively. These favorable (healthier) trends occurred in both foreign-born and U.S.-born Hispanics. Conclusion. This large community-based participatory intervention resulted in more Hispanic residents in the communities taking actions to control high blood pressure. Published by Elsevier Inc. C1 [Liao, Youlian; Siegel, Paul Z.; White, Shannon; Dulin, Rick] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Community Hlth, Atlanta, GA USA. [Taylor, April] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. RP Liao, YL (reprint author), Ctr Dis Control & Prevent, Div Community Hlth, 4770 Buford Hwy NE,MS F-73, Atlanta, GA 30341 USA. EM ycl1@cdc.gov FU Intramural CDC HHS [CC999999] NR 18 TC 1 Z9 1 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD FEB PY 2016 VL 83 BP 11 EP 15 DI 10.1016/j.ypmed.2015.11.027 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DG2XD UT WOS:000371933200003 PM 26656406 ER PT J AU Wong, SPY Vig, EK Taylor, JS Burrows, NR Liu, CF Williams, DE Hebert, PL O'Hare, AM AF Wong, Susan P. Y. Vig, Elizabeth K. Taylor, Janelle S. Burrows, Nilka R. Liu, Chuan-Fen Williams, Desmond E. Hebert, Paul L. O'Hare, Ann M. TI Timing of Initiation of Maintenance Dialysis A Qualitative Analysis of the Electronic Medical Records of a National Cohort of Patients From the Department of Veterans Affairs SO JAMA INTERNAL MEDICINE LA English DT Article ID DECISION-MAKING; HEALTH-CARE; KIDNEY-DISEASE; SURVIVAL; COMORBIDITY; MORTALITY; HARMFUL; TRENDS; START; AGE AB IMPORTANCE There is often considerable uncertainty about the optimal time to initiate maintenance dialysis in individual patients and little medical evidence to guide this decision. OBJECTIVE To gain a better understanding of the factors influencing the timing of initiation of dialysis in clinical practice. DESIGN, SETTING, AND PARTICIPANTS A qualitative analysis was conducted using the electronic medical records from the Department of Veterans Affairs (VA) of a national random sample of 1691 patients for whom the decision to initiate maintenance dialysis occurred in the VA between January 1, 2000, and December 31, 2009. Data analysis took place from June 1 to November 30, 2014. MAIN OUTCOMES AND MEASURES Central themes related to the timing of initiation of dialysis as documented in patients' electronic medical records. RESULTS Of the 1691 patients, 1264 (74.7%) initiated dialysis as inpatients and 1228 (72.6%) initiated dialysis with a hemodialysis catheter. Cohort members met with a nephrologist during an outpatient clinic visit a median of 3 times (interquartile range, 0-6) in the year prior to initiation of dialysis. The mean (SD) estimated glomerular filtration rate at the time of initiation for cohort members was 10.4 (5.7) mL/min/1.73m(2). The timing of initiation of dialysis reflected the complex interplay of at least 3 interrelated and dynamic processes. The first was physician practices, which ranged from practices intended to prepare patients for dialysis to those intended to forestall the need for dialysis by managing the signs and symptoms of uremia with medical interventions. The second process was sources of momentum. Initiation of dialysis was often precipitated by clinical events involving acute illness or medical procedures. In these settings, the imperative to treat often seemed to override patient choice. The third process was patient-physician dynamics. Interactions between patients and physicians were sometimes adversarial, and physician recommendations to initiate dialysis sometimes seemed to conflict with patient priorities. CONCLUSIONS AND RELEVANCE The initiation of maintenance dialysis reflects the care practices of individual physicians, sources of momentum for initiation of dialysis, interactions between patients and physicians, and the complex interplay of these dynamic processes over time. Our findings suggest opportunities to improve communication between patients and physicians and to better align these processes with patients' values, goals, and preferences. C1 [Wong, Susan P. Y.; Vig, Elizabeth K.; O'Hare, Ann M.] Univ Washington, Dept Med, 1959 NE Pacific St,POB 356521, Seattle, WA 98195 USA. [Vig, Elizabeth K.; O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Dept Med, Seattle, WA USA. [Taylor, Janelle S.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. [Burrows, Nilka R.] Ctr Dis Control & Prevent, Chron Kidney Dis Initiat, Div Diabet Translat, Atlanta, GA USA. [Liu, Chuan-Fen; Hebert, Paul L.] VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev Ctr Innovat, Washington, DC USA. [Liu, Chuan-Fen; Hebert, Paul L.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Williams, Desmond E.] Ctr Dis Control & Prevent, Liberia Country Off, Div Global Hlth Protect, Atlanta, GA USA. RP Wong, SPY (reprint author), Univ Washington, Dept Med, 1959 NE Pacific St,POB 356521, Seattle, WA 98195 USA. EM spywong@uw.edu FU United States Department of Veterans Affairs [VA IIR 09-094]; VA Puget Sound Healthcare System [IAA 15FED1505101-0001]; Centers for Disease Control and Prevention [IAA 15FED1505101-0001]; Clinical Scientist in Nephrology Fellowship from the American Kidney Fund; Department of Veterans Affairs Health Services Research and Development Service; National Institutes of Health FX This study was supported by grant VA IIR 09-094 from the United States Department of Veterans Affairs and by Interagency Agreement IAA 15FED1505101-0001 between the VA Puget Sound Healthcare System and the Centers for Disease Control and Prevention. Dr Wong is supported by the Clinical Scientist in Nephrology Fellowship from the American Kidney Fund. Drs O'Hare, Hebert, and Liu reported having received research funding from the Department of Veterans Affairs Health Services Research and Development Service. Dr O'Hare also reported having received research funding from the National Institutes of Health and an honorarium from the American Society of Nephrology. NR 36 TC 7 Z9 7 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2016 VL 176 IS 2 BP 228 EP 235 DI 10.1001/jamainternmed.2015.7412 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DD0RR UT WOS:000369627600017 PM 26809745 ER PT J AU Oluoch, T Katana, A Kwaro, D Santas, X Langat, P Mwalili, S Muthusi, K Okeyo, N Ojwang, JK Cornet, R Abu-Hanna, A de Keizer, N AF Oluoch, Tom Katana, Abraham Kwaro, Daniel Santas, Xenophon Langat, Patrick Mwalili, Samuel Muthusi, Kimeu Okeyo, Nicky Ojwang, James K. Cornet, Ronald Abu-Hanna, Ameen de Keizer, Nicolette TI Effect of a clinical decision support system on early action on immunological treatment failure in patients with HIV in Kenya: a cluster randomised controlled trial SO LANCET HIV LA English DT Article ID ANTIRETROVIRAL-THERAPY; PERFORMANCE; MANAGEMENT; SETTINGS; VALUES; HEALTH; CARE AB Background A clinical decision support system (CDSS) is a computer program that applies a set of rules to data stored in electronic health records to off er actionable recommendations. We aimed to establish whether a CDSS that supports detection of immunological treatment failure among patients with HIV taking antiretroviral therapy (ART) would improve appropriate and timely action. Methods We did this prospective, cluster randomised controlled trial in adults and children (aged >= 18 months) who were eligible for, and receiving, ART at HIV clinics in Siaya County, western Kenya. Health facilities were randomly assigned (1: 1), via block randomisation (block size of two) with a computer-generated random number sequence, to use electronic health records either alone (control) or with CDSS (intervention). Facilities were matched by type and by number of patients enrolled in HIV care. The primary outcome measure was the difference between groups in the proportion of patients who experienced immunological treatment failure and had a documented clinical action. We used generalised linear mixed models with random effects to analyse clustered data. This trial is registered with ClinicalTrials.gov, number NCT01634802. Findings Between Sept 1, 2012, and Jan 31, 2014, 13 clinics, comprising 41 062 patients, were randomly assigned to the control group (n=6) or the intervention group (n=7). Data collection at each site took 12 months. Among patients eligible for ART, 10 358 (99%) of 10 478 patients were receiving ART at control sites and 10 991 (99%) of 11 028 patients were receiving ART at intervention sites. Of these patients, 1125 (11%) in the control group and 1342 (12%) in the intervention group had immunological treatment failure, of whom 332 (30%) and 727 (54%), respectively, received appropriate action. The likelihood of clinicians taking appropriate action on treatment failure was higher with CDSS alerts than with no decision support system (adjusted odds ratio 3.18, 95% CI 1.02-9.87). Interpretation CDSS significantly improved the likelihood of appropriate and timely action on immunological treatment failure. We expect our findings will be generalisable to virological monitoring of patients with HIV receiving ART once countries implement the 2015 WHO recommendation to scale up viral load monitoring. C1 [Oluoch, Tom; Katana, Abraham; Mwalili, Samuel; Ojwang, James K.] US Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Nairobi, Kenya. [Santas, Xenophon] US Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Atlanta, GA USA. [Kwaro, Daniel; Langat, Patrick; Okeyo, Nicky] Kenya Govt Med Res Ctr, CDC Collaborat Program, Kisumu, Kenya. [Muthusi, Kimeu] Univ Calif San Francisco, Nairobi, Kenya. [Cornet, Ronald; Abu-Hanna, Ameen; de Keizer, Nicolette] Univ Amsterdam, Acad Med Ctr, Dept Med Informat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. [Cornet, Ronald] Linkoping Univ, Dept Biomed Engn, Linkoping, Sweden. RP Oluoch, T (reprint author), US Ctr Dis Control & Prevent, Div Global HIV AIDS, Nairobi 00621, Kenya. EM toluoch@cdc.gov RI Cornet, Ronald/G-8375-2012 OI Cornet, Ronald/0000-0002-1704-5980 FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention (CDC), Division of Global HIV/AIDS, under a KEMRI-CDC Cooperative Agreement [GH000048-04] FX We thank the Director of Kenya Medical Research Institute (KEMRI) and his staff for the approval of this study and for reviewing and approving the manuscript for publication. We also thank all the staff at the 13 clinics in Siaya County that supported the data collection for this study. This study was funded by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention (CDC), Division of Global HIV/AIDS, under a KEMRI-CDC Cooperative Agreement (number GH000048-04). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, the Agency for Toxic Substances and Disease Registry, or KEMRI. NR 29 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 2352-3018 J9 LANCET HIV JI Lancet HIV PD FEB PY 2016 VL 3 IS 2 BP E76 EP E84 DI 10.1016/S2352-3018(15)00242-8 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DG1NL UT WOS:000371834700007 PM 26847229 ER PT J AU Zaza, S Koonin, LM Ajao, A Nystrom, SV Branson, R Patel, A Bray, B Iademarco, MF AF Zaza, Stephanie Koonin, Lisa M. Ajao, Adebola Nystrom, Scott V. Branson, Richard Patel, Anita Bray, Bruce Iademarco, Michael F. TI A Conceptual Framework for Allocation of Federally Stockpiled Ventilators During Large-Scale Public Health Emergencies SO HEALTH SECURITY LA English DT Article ID MASS CRITICAL-CARE; MECHANICAL VENTILATORS; DEFINITIVE CARE; CRITICALLY-ILL; UNITED-STATES; JANUARY 26-27; TASK-FORCE; INFLUENZA; DISASTER; RESOURCES AB Some types of public health emergencies could result in large numbers of patients with respiratory failure who need mechanical ventilation. Federal public health planning has included needs assessment and stockpiling of ventilators. However, additional federal guidance is needed to assist states in further allocating federally supplied ventilators to individual hospitals to ensure that ventilators are shipped to facilities where they can best be used during an emergency. A major consideration in planning is a hospital's ability to absorb additional ventilators, based on available space and staff expertise. A simple pro rata plan that does not take these factors into account might result in suboptimal use or unused scarce resources. This article proposes a conceptual framework that identifies the steps in planning and an important gap in federal guidance regarding the distribution of stockpiled mechanical ventilators during an emergency. C1 [Zaza, Stephanie] CDC, Ctr Dis Control & Prevent, Natl Ctr HIV AIDS STD Viral Hepatitis & TB Preven, Div Adolescent & Sch Hlth, Atlanta, GA 30333 USA. [Zaza, Stephanie; Koonin, Lisa M.] CDC, Off Infect Dis, Influenza Coordinat Unit, Atlanta, GA 30333 USA. [Ajao, Adebola] US FDA, Off Med Policy Initiat, Div Clin Trials Qual, Silver Spring, MD USA. [Nystrom, Scott V.] Off Policy & Planning, Div Med Countermeasure Strategy & Requirements, Washington, DC USA. [Nystrom, Scott V.] Dept Hlth & Human Serv, Preparedness & Response, Washington, DC USA. [Branson, Richard] Univ Cincinnati, Surg, Cincinnati, OH USA. [Patel, Anita] CDC, Off Publ Hlth Preparedness & Response, Div Strateg Natl Stockpile, Atlanta, GA 30333 USA. [Bray, Bruce] Emory Univ Hosp, Dept Resp Care, 1364 Clifton Rd NE, Atlanta, GA 30322 USA. [Bray, Bruce] Emory Univ Hosp, Dept EKG, 1364 Clifton Rd NE, Atlanta, GA 30322 USA. [Bray, Bruce] Emory Univ Hosp, Dept Neurophysiol, 1364 Clifton Rd NE, Atlanta, GA 30322 USA. [Bray, Bruce] Emory Univ Hosp, Dept Pulm Funct & Blood Gas Labs, 1364 Clifton Rd NE, Atlanta, GA 30322 USA. [Iademarco, Michael F.] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Koonin, LM (reprint author), Ctr Dis Control & Prevent, Influenza Coordinat Unit, 1600 Clifton Rd NE,Mailstop A28, Atlanta, GA 30329 USA. EM lmk1@cdc.gov NR 32 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2326-5094 EI 2326-5108 J9 HEALTH SECUR JI Health Secur. PD FEB 1 PY 2016 VL 14 IS 1 BP 1 EP 6 DI 10.1089/hs.2015.0043 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DF4QN UT WOS:000371334800001 PM 26828799 ER PT J AU Agaku, IT Singh, T Rolle, I Olalekan, AY King, BA AF Agaku, Israel T. Singh, Tushar Rolle, Italia Olalekan, Ayo-Yusuf King, Brian A. TI Prevalence and Determinants of Secondhand Smoke Exposure Among Middle and High School Students SO PEDIATRICS LA English DT Article ID UNITED-STATES; ELECTRONIC CIGARETTES; CARBONYL-COMPOUNDS; US MIDDLE; VAPORS; CARS AB BACKGROUND: Secondhand smoke (SHS) causes disease and death among nonsmokers. Private settings are major sources of exposure for children. We assessed prevalence and determinants of self-reported SHS exposure in homes and vehicles, as well as school, work, and indoor/outdoor public areas, among US students in grades 6 through 12. METHODS: Data were from the 2013 National Youth Tobacco Survey (n = 18 406). Self-reported SHS exposure within the past 7 days was assessed overall and by extent of smoke-free home and vehicle rules among never users of 10 tobacco product types. Descriptive statistics were used to compare estimates, and adjusted prevalence ratios were calculated to assess determinants of SHS exposure. RESULTS: Among never tobacco users, 48.0% reported SHS exposure in 1 or more locations, including 15.5% in the home, 14.7% in a vehicle, 16.8% at school, 27.1% at work, and 35.2% in an indoor/outdoor public area. Home exposure was 8.5%, 55.3%, and 79.4% among never tobacco users with complete, partial, or no smoke-free home rules, respectively (P < .05). Vehicle exposure was 7.1%, 44.8%, and 70.2% among never tobacco users with complete, partial, or no smoke-free vehicle rules, respectively (P < .05). Factors associated with higher prevalence ratio of SHS exposure included current tobacco use, truant behavior, and having tobacco using household members/friends CONCLUSIONS: Approximately half of US students in grades 6 through 12 reported exposure to SHS in 2013. Smoke-free home and vehicle rules, coupled with intensified implementation and enforcement of comprehensive smoke-free laws, could help protect youth from this preventable health hazard. C1 [Agaku, Israel T.; Singh, Tushar; Rolle, Italia; King, Brian A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS F-79, Atlanta, GA 30341 USA. [Olalekan, Ayo-Yusuf] Sefako Makgatho Hlth Sci Univ, Pretoria, South Africa. RP Agaku, IT (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS F-79, Atlanta, GA 30341 USA. EM iagaku@cdc.gov NR 34 TC 0 Z9 0 U1 5 U2 9 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD FEB PY 2016 VL 137 IS 2 AR e20151985 DI 10.1542/peds.2015-1985 PG 9 WC Pediatrics SC Pediatrics GA DF5LA UT WOS:000371392000022 PM 26755696 ER PT J AU Allison, MA Hurley, LP Markowitz, L Crane, LA Brtnikova, M Beaty, BL Snow, M Cory, J Stokley, S Roark, J Kempe, A AF Allison, Mandy A. Hurley, Laura P. Markowitz, Lauri Crane, Lori A. Brtnikova, Michaela Beaty, Brenda L. Snow, Megan Cory, Janine Stokley, Shannon Roark, Jill Kempe, Allison TI Primary Care Physicians' Perspectives About HPV Vaccine SO PEDIATRICS LA English DT Article ID HUMAN-PAPILLOMAVIRUS VACCINATION; IMMUNIZATION PRACTICES ACIP; UNITED-STATES; PROVIDER RECOMMENDATION; ADOLESCENT VACCINES; ADVISORY-COMMITTEE; DECISION-SUPPORT; HEALTH; INITIATION; ATTITUDES AB BACKGROUND AND OBJECTIVES: Because physicians' practices could be modified to reduce missed opportunities for human papillomavirus (HPV) vaccination, our goal was to: (1) describe self-reported practices regarding recommending the HPV vaccine; (2) estimate the frequency of parental deferral of HPV vaccination; and (3) identify characteristics associated with not discussing it. METHODS: A national survey among pediatricians and family physicians (FP) was conducted between October 2013 and January 2014. Using multivariable analysis, characteristics associated with not discussing HPV vaccination were examined. RESULTS: Response rates were 82% for pediatricians (364 of 442) and 56% for FP (218 of 387). For 11-12 year-old girls, 60% of pediatricians and 59% of FP strongly recommend HPV vaccine; for boys, 52% and 41% ostrongly recommen. More than one-half reported >= 25% of parents deferred HPV vaccination. At the 11-12 year well visit, 84% of pediatricians and 75% of FP frequently/always discuss HPV vaccination. Compared with physicians who frequently/always discuss, those who occasionally/rarely discuss(18%) were more likely to be FP (adjusted odds ratio [aOR]: 2.0 [95% confidence interval (CI): 1.1-3.5), be male (aOR: 1.8 [95% CI: 1.1-3.1]), disagree that parents will accept HPV vaccine if discussed with other vaccines (aOR: 2.3 [95% CI: 1.3-4.2]), report that 25% to 49% (aOR: 2.8 [95% CI: 1.1-6.8]) or >= 50% (aOR: 7.8 [95% CI: 3.4-17.6]) of parents defer, and express concern about waning immunity (aOR: 3.4 [95% CI: 1.8-6.4]). CONCLUSIONS: Addressing physicians' perceptions about parental acceptance of HPV vaccine, the possible advantages of discussing HPV vaccination with other recommended vaccines, and concerns about waning immunity could lead to increased vaccination rates. C1 [Allison, Mandy A.; Brtnikova, Michaela; Kempe, Allison] Univ Colorado, Dept Pediat, Anschutz Med Campus, Aurora, CO USA. [Allison, Mandy A.; Hurley, Laura P.; Crane, Lori A.; Brtnikova, Michaela; Beaty, Brenda L.; Snow, Megan; Kempe, Allison] Univ Colorado, Adult & Child Ctr Hlth Outcomes Res & Delivery Sc, Anschutz Med Campus, Aurora, CO USA. [Crane, Lori A.] Univ Colorado, Colorado Sch Publ Hlth, Anschutz Med Campus, Aurora, CO USA. [Crane, Lori A.] Childrens Hosp Colorado, Aurora, CO USA. [Hurley, Laura P.] Denver Hlth, Div Internal Med, Denver, CO USA. [Markowitz, Lauri] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Cory, Janine; Stokley, Shannon; Roark, Jill] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Allison, MA (reprint author), Gen Acad Pediat, Mail Stop F443,13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA. FU Centers for Disease Control and Prevention SIP through the Rocky Mountain Prevention Research Center [5U48DP0011938]; Centers for Disease Control and Prevention PEP through the Association of American Medical Colleges, Washington, District of Columbia [MM-1040-08/08] FX Funded by a grant from the Centers for Disease Control and Prevention SIP (5U48DP0011938) through the Rocky Mountain Prevention Research Center. Funded by a grant from the Centers for Disease Control and Prevention PEP (MM-1040-08/08) through the Association of American Medical Colleges, Washington, District of Columbia. NR 30 TC 10 Z9 10 U1 4 U2 6 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD FEB PY 2016 VL 137 IS 2 AR e20152488 DI 10.1542/peds.2015-2488 PG 9 WC Pediatrics SC Pediatrics GA DF5LA UT WOS:000371392000031 PM 26729738 ER PT J AU Chung, JR Flannery, B Thompson, MG Gaglani, M Jackson, ML Monto, AS Nowalk, MP Talbot, HK Treanor, JJ Belongia, EA Murthy, K Jackson, LA Petrie, JG Zimmerman, RK Griffin, MR McLean, HQ Fry, AM AF Chung, Jessie R. Flannery, Brendan Thompson, Mark G. Gaglani, Manjusha Jackson, Michael L. Monto, Arnold S. Nowalk, Mary Patricia Talbot, H. Keipp Treanor, John J. Belongia, Edward A. Murthy, Kempapura Jackson, Lisa A. Petrie, Joshua G. Zimmerman, Richard K. Griffin, Marie R. McLean, Huong Q. Fry, Alicia M. TI Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine SO PEDIATRICS LA English DT Article ID IMMUNIZATION PRACTICES ACIP; TEST-NEGATIVE DESIGN; ADVISORY-COMMITTEE; UNITED-STATES; YOUNG-CHILDREN; CONFIRMED INFLUENZA; RECOMMENDATIONS; PREVENTION; VIRUS; EFFICACY AB BACKGROUND: Few observational studies have evaluated the relative effectiveness of live attenuated (LAIV) and inactivated (IIV) influenza vaccines against medically attended laboratory-confirmed influenza. METHODS: We analyzed US Influenza Vaccine Effectiveness Network data from participants aged 2 to 17 years during 4 seasons (2010-2011 through 2013-2014) to compare relative effectiveness of LAIV and IIV against influenza-associated illness. Vaccine receipt was confirmed via provider/electronic medical records or immunization registry. We calculated the ratio (odds) of influenza-positive to influenza-negative participants among those age-appropriately vaccinated with either LAIV or IIV for the corresponding season. We examined relative effectiveness of LAIV and IIV by using adjusted odds ratios (ORs) and 95% confidence intervals (CIs) from logistic regression. RESULTS: Of 6819 participants aged 2 to 17 years, 2703 were age-appropriately vaccinated with LAIV (n = 637) or IIV (n = 2066). Odds of influenza were similar for LAIV and IIV recipients during 3 seasons (2010-2011 through 2012-2013). In 2013-2014, odds of influenza were significantly higher among LAIV recipients compared with IIV recipients 2 to 8 years old (OR 5.36; 95% CI, 2.37 to 12.13). Participants vaccinated with LAIV or IIV had similar odds of illness associated with influenza A/H3N2 or B. LAIV recipients had greater odds of illness due to influenza A/H1N1pdm09 in 2010-2011 and 2013-2014. CONCLUSIONS: We observed lower effectiveness of LAIV compared with IIV against influenza A/H1N1pdm09 but not A(H3N2) or B among children and adolescents, suggesting poor performance related to the LAIV A/H1N1pdm09 viral construct. C1 [Chung, Jessie R.] Atlanta Res & Educ Fdn Inc, Atlanta, GA USA. [Chung, Jessie R.; Flannery, Brendan; Thompson, Mark G.; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30333 USA. [Gaglani, Manjusha; Murthy, Kempapura] Texas A&M Univ, Coll Med, Baylor Scott & White Hlth, Hlth Sci Ctr, Temple, TX 76508 USA. [Jackson, Michael L.; Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA. [Monto, Arnold S.; Petrie, Joshua G.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Nowalk, Mary Patricia; Zimmerman, Richard K.] Univ Pittsburgh, Sch Hlth Sci, Pittsburgh, PA USA. [Nowalk, Mary Patricia; Zimmerman, Richard K.] UPMC, Sch Hlth Sci, Pittsburgh, PA USA. [Talbot, H. Keipp; Griffin, Marie R.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Treanor, John J.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA. [Belongia, Edward A.; McLean, Huong Q.] Marshfield Clin Res Fdn, Marshfield, WI USA. RP Chung, JR (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30333 USA. EM uwp0@cdc.gov OI Zimmerman, Richard/0000-0001-5941-6092 FU Centers for Disease Control and Prevention; University of Michigan [U01 IP000170, U01 IP000474]; Group Health Research Institute [U01 IP000466]; Marshfield Clinic Research Foundation [U01 IP000183, U01 IP000471]; University of Pittsburgh [U01 IP000467]; Baylor Scott and White Health [U01 IP000473]; Vanderbilt University [U01 IP000184]; University of Rochester [U01 IP000172]; National Institutes of Health [UL1 RR024153, UL1TR000005]; National Institutes of Health (NIH) FX Supported by the Centers for Disease Control and Prevention through cooperative agreements with the University of Michigan (U01 IP000170, U01 IP000474), Group Health Research Institute (U01 IP000466), Marshfield Clinic Research Foundation (U01 IP000183, U01 IP000471), University of Pittsburgh (U01 IP000467), Baylor Scott and White Health (U01 IP000473), Vanderbilt University (U01 IP000184), and the University of Rochester (U01 IP000172). At the University of Pittsburgh, the project was also supported by the National Institutes of Health through grants UL1 RR024153 and UL1TR000005. Funded by the National Institutes of Health (NIH). NR 37 TC 11 Z9 11 U1 1 U2 7 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD FEB PY 2016 VL 137 IS 2 AR e20153279 DI 10.1542/peds.2015-3279 PG 10 WC Pediatrics SC Pediatrics GA DF5LA UT WOS:000371392000049 PM 26738884 ER PT J AU Faherty, LJ Rasmussen, SA Lurie, N AF Faherty, Laura J. Rasmussen, Sonja A. Lurie, Nicole TI Planning for Research on Children During Public Health Emergencies SO PEDIATRICS LA English DT Article ID DISASTERS AB The recent Ebola epidemic exposed critical knowledge gaps about the disease and its impact on different populations, particularly children, which hindered the public health and medical response. For instance, unanswered questions remain about the natural history of Ebola virus disease in young children and its transmissibility in breast milk. Other emerging infectious diseases, such as Middle East Respiratory Syndrome (MERS), remind us that there will always be another pathogen lurking around the corner. Public health emergencies (PHEs) resulting from natural disasters are increasing in ferocity and frequency. (1) How can we ensure that we address our current knowledge gaps to better prepare for future disasters? Awareness of the need to integrate scientific research into PHE response is growing, (2) but the discussion of research involving children has been limited. Although several efforts have addressed the unique physical and socio-emotional needs of children in PHEs, (3,4) pediatric research during PHEs has been lacking, resulting in significant knowledge gaps for children compared to adults. Conducting research, especially in children, without interfering with the PHE response is challenging. The present article discusses the importance of including children in PHE research and proposes components of a robust infrastructure that need to be in place to facilitate this research. C1 [Faherty, Laura J.] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. [Faherty, Laura J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Ctr Surveillance Epidemiol Lab Serv, Atlanta, GA USA. [Lurie, Nicole] US Dept HHS, Off Assistant Secretary Preparedness & Response, Washington, DC 20201 USA. RP Faherty, LJ (reprint author), Blockley Hall,13th Floor,Room 1310, Philadelphia, PA 19104 USA. EM lajohns@mail.med.upenn.edu NR 8 TC 0 Z9 0 U1 2 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD FEB PY 2016 VL 137 IS 2 AR e20153611 DI 10.1542/peds.2015-3611 PG 4 WC Pediatrics SC Pediatrics GA DF5LA UT WOS:000371392000053 PM 26729740 ER PT J AU Reidy, DE Kearns, MC Houry, D Valle, LA Holland, KM Marshall, KJ AF Reidy, Dennis E. Kearns, Megan C. Houry, Debra Valle, Linda A. Holland, Kristin M. Marshall, Khiya J. TI Dating Violence and Injury Among Youth Exposed to Violence SO PEDIATRICS LA English DT Article ID INTIMATE PARTNER VIOLENCE; AT-RISK YOUTH; PREVENTION PROGRAM; HIGH-SCHOOL; SEX-DIFFERENCES; AGGRESSION; GENDER; MIDDLE; PERPETRATION; TRAJECTORIES AB OBJECTIVES To assess gender differences in the proportion of adolescents reporting teen dating violence (TDV) and the frequency of TDV at multiple age points across adolescence in a high-risk sample of youth with previous exposure to violence. METHODS: A cross-sectional, high-risk sample of boys and girls (n = 1149) ages 11 to 17 years completed surveys assessing TDV and self-defense. Indices of TDV included perpetration and victimization scales of controlling behaviors, psychological TDV, physical TDV, sexual TDV, fear/intimidation, and injury. RESULTS: More girls reported perpetrating psychological and physical TDV, whereas twice as many boys reported sexual TDV perpetration. More girls reported fear/intimidation victimization than boys. When comparing the frequency of TDV across adolescence, boys reported more sexual TDV victimization at younger ages, and girls demonstrated a trend toward more victimization at older ages. Likewise, younger boys reported more fear/intimidation and injury perpetration and injury victimization than younger girls. However, by age 17, girls reported more injury perpetration than boys, and reports of injury victimization and use of self-defense did not differ. Notably, despite potential parity in injury, girls consistently reported more fear/intimidation victimization associated with TDV. CONCLUSIONS: Contrary to data suggesting that girls experience far more sexual TDV and injury, these data suggest that at specific times during adolescence, boys among high-risk populations may be equally at risk for victimization. However, the psychological consequences (fear) are greater for girls. These findings suggest a need to tailor strategies to prevent TDV based on both age-and gender-specific characteristics in high-risk populations. C1 [Reidy, Dennis E.; Kearns, Megan C.; Valle, Linda A.; Holland, Kristin M.; Marshall, Khiya J.] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. [Houry, Debra] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Reidy, DE (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. EM dreidy@cdc.gov FU Centers for Disease Control and Prevention [200-2010-34099] FX Supported by Centers for Disease Control and Prevention Contract #200-2010-34099. NR 37 TC 0 Z9 0 U1 4 U2 8 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD FEB PY 2016 VL 137 IS 2 DI 10.1542/peds.2015-2627 PG 8 WC Pediatrics SC Pediatrics GA DF5LA UT WOS:000371392000034 ER PT J AU Van Handel, M Kann, L Olsen, EO Dietz, P AF Van Handel, Michelle Kann, Laura Olsen, Emily O'Malley Dietz, Patricia TI HIV Testing Among US High School Students and Young Adults SO PEDIATRICS LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED-DISEASES; RISK BEHAVIOR SURVEILLANCE; UNITED-STATES; PREGNANT-WOMEN; ADOLESCENTS; SERVICES; HEALTH; CARE; PREVENTION AB BACKGROUND: We assessed HIV testing trends among high school students and young adults. METHODS: We analyzed National Youth Risk Behavior Survey (YRBS) and Behavioral Risk Factor Surveillance System (BRFSS) data to assess HIV testing prevalence among high school students and young adults aged 18 to 24, respectively. Logistic regression models for each sample stratified by gender and race/ethnicity were estimated to assess trends in the percentages ever tested, with year as a continuous linear variable. We report absolute differences in HIV testing prevalence and model results for 2005-2013 (YRBS) and 2011-2013 (BRFSS). RESULTS: During the study periods, an average of 22% of high school students (17% of male and 27% of female students) who ever had sexual intercourse and 33% of young adults reported ever being tested for HIV. Among high school students, no change was detected in HIV testing prevalence during 2005-2013, regardless of gender or race/ethnicity. Among young adult males, an average of 27% had ever been tested, and no significant changes were detected overall or by race/ethnicity during 2011-2013. Significant decreases in testing prevalence were detected during 2011-2013 among young adult females overall (from 42.4% to 39.5%), young adult white females (from 37.2% to 33.9%), and young adult black females (from 68.9% to 59.9%). CONCLUSIONS: HIV testing prevalence was low among high school students and young adults. No increase in testing among young adult males and decreased testing among young adult black females is concerning given their higher risk of HIV infection. C1 [Van Handel, Michelle; Dietz, Patricia] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,Mail Stop E-59, Atlanta, GA 30333 USA. [Kann, Laura; Olsen, Emily O'Malley] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30333 USA. RP Van Handel, M (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,Mail Stop E-59, Atlanta, GA 30333 USA. EM ioq4@cdc.gov NR 34 TC 3 Z9 3 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD FEB PY 2016 VL 137 IS 2 DI 10.1542/peds.2015-2700 PG 9 WC Pediatrics SC Pediatrics GA DF5LA UT WOS:000371392000036 ER PT J AU Hald, T Angulo, F Bin Hamzah, WM Bellinger, D Black, R de Silva, N Dopfer, D Havelaar, A Gibb, H Kasuga, F Lake, R Rokni, MB Speybroeck, N Aspinall, W Cooke, R Hoffmann, S Devleesschauwer, B Pires, SM AF Hald, Tine Angulo, Fred Bin Hamzah, Wan Mansor Bellinger, David Black, Robert de Silva, Nilanthi Doepfer, Doerte Havelaar, Arie Gibb, Herman Kasuga, Fumiko Lake, Rob Rokni, Muhammad B. Speybroeck, Niko Aspinall, Willy Cooke, Roger Hoffmann, Sandra Devleesschauwer, Brecht Pires, Sara M. CA World Hlth Org Foodborne Epidemiology Reference G Source Attribution Task Force TI Research Synthesis Methods in an Age of Globalized Risks: Lessons from the Global Burden of Foodborne Disease Expert Elicitation SO RISK ANALYSIS LA English DT Editorial Material DE Disease burden; expert elicitation; expert judgment; exposure estimates; foodborne illness; research synthesis; source attribution; systematic review; uncertainty quantification ID ADJUSTED LIFE YEARS; PATHOGENS; JUDGMENT; MODEL; FOOD AB We live in an age that increasingly calls for national or regional management of global risks. This article discusses the contributions that expert elicitation can bring to efforts to manage global risks and identifies challenges faced in conducting expert elicitation at this scale. In doing so it draws on lessons learned from conducting an expert elicitation as part of the World Health Organizations (WHO) initiative to estimate the global burden of foodborne disease; a study commissioned by the Foodborne Disease Epidemiology Reference Group (FERG). Expert elicitation is designed to fill gaps in data and research using structured, transparent methods. Such gaps are a significant challenge for global risk modeling. Experience with the WHO FERG expert elicitation shows that it is feasible to conduct an expert elicitation at a global scale, but that challenges do arise, including: defining an informative, yet feasible geographical structure for the elicitation; defining what constitutes expertise in a global setting; structuring international, multidisciplinary expert panels; and managing demands on experts' time in the elicitation. This article was written as part of a workshop, Methods for Research Synthesis: A Cross-Disciplinary Approach held at the Harvard Center for Risk Analysis on October 13, 2013. C1 [Hald, Tine; Pires, Sara M.] Tech Univ Denmark, Natl Food Inst, Lyngby, Denmark. [Angulo, Fred] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Bin Hamzah, Wan Mansor] Malaysian Minist Hlth, Dis Control Div, Kuala Lumpur, Malaysia. [Bellinger, David] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. [Black, Robert] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. [de Silva, Nilanthi] Univ Kelaniya, Fac Med, Kelaniya, Sri Lanka. [Doepfer, Doerte] Univ Wisconsin Madison, Sch Vet Med, Madison, WI USA. [Havelaar, Arie; Devleesschauwer, Brecht] Univ Florida, Emerging Pathogens Inst, Gainesville, FL 32611 USA. [Gibb, Herman] Gibb Epidemiol Consulting LLC, Arlington, VA USA. [Kasuga, Fumiko] Japanese Minist Hlth Labour & Welfare, Natl Inst Hlth Sci, Tokyo, Japan. [Lake, Rob] Inst Environm Sci & Res ESR Ltd, Tokyo, Japan. [Rokni, Muhammad B.] Teheran Univ Med Sci, Tehran, Iran. [Speybroeck, Niko] Catholic Univ Louvain, Louvain, Belgium. [Aspinall, Willy] Univ Bristol, Bristol BS8 1TH, Avon, England. [Aspinall, Willy] Aspinall & Associates, Louvain, Belgium. [Cooke, Roger] Resources Future Inc, Louvain, Belgium. [Hoffmann, Sandra] USDA, Econ Res Serv, Washington, DC USA. RP Hoffmann, S (reprint author), USDA, Econ Res Serv, Washington, DC USA. EM shoffmann@ers.usda.gov FU World Health Organization FX This study was commissioned and paid for by the World Health Organization. Copyright in the original work on which this article is based belongs to WHO. The authors have been given permission to publish this article. NR 49 TC 0 Z9 0 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0272-4332 EI 1539-6924 J9 RISK ANAL JI Risk Anal. PD FEB PY 2016 VL 36 IS 2 BP 191 EP 202 DI 10.1111/risa.12385 PG 12 WC Public, Environmental & Occupational Health; Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods SC Public, Environmental & Occupational Health; Mathematics; Mathematical Methods In Social Sciences GA DF3JJ UT WOS:000371239800002 ER PT J AU Denu, RA Hampton, JM Currey, A Anderson, RT Cress, RD Fleming, ST Lipscomb, J Sabatino, SA Wu, XC Wilson, JF Trentham-Dietz, A AF Denu, Ryan A. Hampton, John M. Currey, Adam Anderson, Roger T. Cress, Rosemary D. Fleming, Steven T. Lipscomb, Joseph Sabatino, Susan A. Wu, Xiao-Cheng Wilson, J. Frank Trentham-Dietz, Amy TI Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer SO CANCER EPIDEMIOLOGY LA English DT Article DE Inflammatory breast cancer; Breast cancer; Guideline; Healthcare disparities; Epidemiology ID INTERNATIONAL EXPERT PANEL; END RESULTS PROGRAM; PATHOLOGICAL DEFINITION; CARCINOMA INCIDENCE; OLDER WOMEN; SURVIVAL; THERAPY; EPIDEMIOLOGY; SURVEILLANCE; CHEMOTHERAPY AB Purpose: Inflammatory breast cancer (IBC) is an aggressive subtype of breast cancer for which treatments vary, so we sought to identify factors that affect the receipt of guideline-concordant care. Methods: Patients diagnosed with IBC in 2004 were identified from the Breast and Prostate Cancer Data Quality and Patterns of Care Study, containing information from cancer registries in seven states. Variation in guideline-concordant care for IBC, based on National Comprehensive Cancer Network (NCCN) guidelines, was assessed according to patient, physician, and hospital characteristics. Results: Of the 107 IBC patients in the study without distant metastasis at the time of diagnosis, only 25.8% received treatment concordant with guidelines. Predictors of non-concordance included patient age (>= 70 years), non-white race, normal body mass index (BMI 18.5-25 kg/m(2)), patients with physicians graduating from medical school >15 years prior, and smaller hospital size (<200 beds). IBC patients survived longer if they received guideline-concordant treatment based on either 2003 (p = 0.06) or 2013 (p = 0.06) NCCN guidelines. Conclusions: Targeting factors associated with receipt of care that is not guideline-concordant may reduce survival disparities in IBC patients. Prompt referral for neoadjuvant chemotherapy and post-operative radiation therapy is also crucial. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Denu, Ryan A.] Univ Wisconsin, Med Scientist Training Program, 6068 WIMR,1111 Highland Ave, Madison, WI 53705 USA. [Hampton, John M.] Univ Wisconsin, Carbone Canc Ctr, 610 Walnut St,Room 307,WARF Bldg, Madison, WI 53726 USA. [Currey, Adam; Wilson, J. Frank] Med Coll Wisconsin, Dept Radiat Oncol, 8701 W Watertown Plank Rd, Milwaukee, WI 53226 USA. [Anderson, Roger T.] Penn State Univ, Div Hlth Serv Res, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA. [Cress, Rosemary D.] Univ Calif Davis, Inst Publ Hlth, Canc Registry Greater Calif, Dept Publ Hlth Sci,Sch Med, One Shields Ave,Med Sci 1C, Davis, CA 95616 USA. [Fleming, Steven T.] Univ Kentucky, Coll Publ Hlth, 111 Washington Ave, Lexington, KY 40536 USA. [Lipscomb, Joseph] Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA. [Lipscomb, Joseph] Emory Univ, Winship Canc Inst, 1518 Clifton Rd, Atlanta, GA 30322 USA. [Sabatino, Susan A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Wu, Xiao-Cheng] LSU, Hlth Sci Ctr, Sch Publ Hlth, 2020 Gravier St,3rd Floor, New Orleans, LA 70112 USA. [Trentham-Dietz, Amy] Univ Wisconsin, Dept Populat Hlth Sci, Carbone Canc Ctr, 610 Walnut St,Room 307,WARF Bldg, Madison, WI 53726 USA. RP Trentham-Dietz, A (reprint author), Univ Wisconsin, Dept Populat Hlth Sci, Carbone Canc Ctr, 610 Walnut St,Room 307,WARF Bldg, Madison, WI 53726 USA. EM trentham@wisc.edu OI Denu, Ryan/0000-0001-9698-9201 FU University of Wisconsin Medical Scientist Training Program [T32GM008692]; NIH [P30CA014520]; [U01DP000261] FX The data used for this publication were collected by the CDC National Program of Cancer Registries Patterns of Care Study for Female Breast and Prostate Cancers through cooperative agreements with the participating state cancer registries including grant U01DP000261 to JFW. RAD is supported by the University of Wisconsin Medical Scientist Training Program (T32GM008692). This article was written on behalf of the Patterns of Care Study BP Group. This study was also supported in part by NIH grant P30CA014520. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 44 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1877-7821 EI 1877-783X J9 CANCER EPIDEMIOL JI Cancer Epidemiol. PD FEB PY 2016 VL 40 BP 7 EP 14 DI 10.1016/j.canep.2015.11.003 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DD8HM UT WOS:000370167000002 PM 26605428 ER PT J AU Winskell, K Miller, KS Allen, KA Obong'o, CO AF Winskell, Kate Miller, Kim S. Allen, Kristi Ann Obong'o, Christopher O. TI Guiding and supporting adolescents living with HIV in sub-Saharan Africa: The development of a curriculum for family and community members SO CHILDREN AND YOUTH SERVICES REVIEW LA English DT Article DE Adolescents living with HIV; Curriculum development; Parenting; ART adherence; Secondary prevention ID ANTIRETROVIRAL THERAPY; SOUTHERN AFRICA; CHILDREN; NEEDS; DISCLOSURE; ADHERENCE; ZIMBABWE; HEALTH; UGANDA; ZAMBIA AB Although HIV-related deaths declined globally by 30% between 2005 and 2012, those among adolescents living with HIV (ALHIV) rose by 50%. This discrepancy is primarily due to failure to address the specific needs of ALHIV and resulting poor clinical outcomes related to late diagnosis and poor adherence to antiretroviral therapy. The Families Matter' Program (FMP) is an evidence-based intervention for parents and caregivers of 9-12 year-olds that promotes positive parenting practices and effective parent-child communication about sexuality and sexual risk reduction. It is delivered to groups of participants at the community level through a series of six weekly three-hour sessions. Recognizing family and community members' need for guidance on issues specific to ALHIV, we developed a seventh FMP session to address their needs. Key themes treated in the curriculum for this session include: stigma and mental health, disclosure, ART adherence and self-care, and responsible sexual relationships. In developing the curriculum, we drew on narratives about growing up with HIV contributed by young Africans to a 2013 scriptwriting competition. We describe the data-driven process of developing this curriculum with a view to informing the development of much-needed interventions to serve this vulnerable population. (c) 2015 Published by Elsevier Ltd. C1 [Winskell, Kate; Allen, Kristi Ann] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Miller, Kim S.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, 1600 Clifton Rd,NE,Mailstop E-04, Atlanta, GA 30333 USA. [Obong'o, Christopher O.] Univ Memphis, Sch Publ Hlth, Memphis, TN 38111 USA. RP Winskell, K (reprint author), Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. EM swinske@emoty.edu; kmiller@cdc.gov; kristi.ann.allen@emory.edu; obongoc@gmail.com FU President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC); Dutch Foreign Ministry through The Global Dialogues Trust; Global Dialogues Trust FX The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). This project has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC). Research on the Global Dialogues narratives was supported by funding to Kate Winskell from the Dutch Foreign Ministry through The Global Dialogues Trust. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the Dutch Foreign Ministry or of The Global Dialogues Trust. Kate Winskell's spouse serves as a paid consultant to The Global Dialogues Trust. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies. Special thanks to research assistant Kristina Countryman. NR 37 TC 1 Z9 1 U1 2 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0190-7409 EI 1873-7765 J9 CHILD YOUTH SERV REV JI Child. Youth Serv. Rev. PD FEB PY 2016 VL 61 BP 253 EP 260 DI 10.1016/j.childyouth.2015.12.017 PG 8 WC Family Studies; Social Work SC Family Studies; Social Work GA DE2LJ UT WOS:000370458500031 PM 27141147 ER PT J AU Xu, FJ Moorman, AC Tong, X Gordon, SC Rupp, LB Lu, M Teshale, EH Spradling, PR Boscarino, JA Trinacty, CM Schmidt, MA Holmberg, SD AF Xu, Fujie Moorman, Anne C. Tong, Xin Gordon, Stuart C. Rupp, Loralee B. Lu, Mei Teshale, Eyasu H. Spradling, Philip R. Boscarino, Joseph A. Trinacty, Connie M. Schmidt, Mark A. Holmberg, Scott D. CA Chronic Hepatitis Cohort Study CHe TI All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE hepatitis C; hepatic decompensation; hepatocellular carcinoma; mortality; cirrhosis ID SUSTAINED VIROLOGICAL RESPONSE; VIRAL-HEPATITIS; UNITED-STATES; LIVER-DISEASE; CARE; THERAPY; COHORT; PEGINTERFERON; POPULATION; FIBROSIS AB Background. A key question in care of patients with chronic hepatitis C virus (HCV) infection is beginning treatment immediately vs delaying treatment. Risks of mortality and disease progression in "real world" settings are important to assess the implications of delaying HCV treatment. Methods. This was a cohort study of HCV patients identified from 4 integrated health systems in the United States who had liver biopsies during 2001-2012. The probabilities of death and progression to hepatocellular carcinoma, hepatic decompensation (hepatic encephalopathy, esophageal varices, ascites, or portal hypertension) or liver transplant were estimated over 1, 2, or 5 years by fibrosis stage (Metavir F0-F4) determined by biopsy at beginning of observation. Results. Among 2799 HCV-monoinfected patients who had a qualifying liver biopsy, the mean age at the time of biopsy was 50.7 years. The majority were male (58.9%) and non-Hispanic white (66.9%). Over a mean observation of 5.0 years, 261 (9.3%) patients died and 34 (1.2%) received liver transplants. At 5 years after biopsy, the estimated risk of progression to hepatic decompensation or hepatocellular carcinoma was 37.2% in stage F4, 19.6% in F3, 4.7% in F2, and 2.3% in F0-F1 patients. Baseline biopsy stage F3 or F4 and platelet count below normal were the strongest predictors of progression to hepatic decompensation or hepatocellular carcinoma. Conclusions. The risks of death and progression to liver failure varied greatly by fibrosis stage. Clinicians and policy makers could use these progression risk data in prioritization and in determining the timing of treatment for patients in early stages of liver disease. C1 [Xu, Fujie; Moorman, Anne C.; Tong, Xin; Teshale, Eyasu H.; Spradling, Philip R.; Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,MS-G-37, Atlanta, GA 30333 USA. [Gordon, Stuart C.; Rupp, Loralee B.; Lu, Mei] Henry Ford Hlth Syst, Detroit, MI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. [Trinacty, Connie M.] Kaiser Permanente Hawaii, Honolulu, HI USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Portland, OR USA. RP Xu, FJ (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,MS-G-37, Atlanta, GA 30333 USA. EM fax1@gmail.com FU CDC Foundation; AbbVie; Gilead Sciences; Janssen Pharmaceuticals, Inc; Genentech, a member of the Roche Group; Vertex Pharmaceuticals; Bristol-Myers Squibb FX CHeCS was funded by the CDC Foundation, which currently receives grants from AbbVie, Gilead Sciences, and Janssen Pharmaceuticals, Inc. Past funders include Genentech, a member of the Roche Group, and Vertex Pharmaceuticals. Past partial funders include Bristol-Myers Squibb. Granting corporations do not have access to CHeCS data and do not contribute to data analysis or writing of manuscripts. NR 25 TC 6 Z9 6 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2016 VL 62 IS 3 BP 289 EP 297 DI 10.1093/cid/civ860 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DD8VS UT WOS:000370205600007 PM 26417034 ER PT J AU Desai, M Gutman, J Taylor, SM Wiegand, RE Khairallah, C Kayentao, K Ouma, P Coulibaly, SO Kalilani, L Mace, KE Arinaitwe, E Mathanga, DP Doumbo, O Otieno, K Edgar, D Chaluluka, E Kamuliwo, M Ades, V Skarbinski, J Shi, YP Magnussen, P Meshnick, S ter Kuile, FO AF Desai, Meghna Gutman, Julie Taylor, Steve M. Wiegand, Ryan E. Khairallah, Carole Kayentao, Kassoum Ouma, Peter Coulibaly, Sheick O. Kalilani, Linda Mace, Kimberly E. Arinaitwe, Emmanuel Mathanga, Don P. Doumbo, Ogobara Otieno, Kephas Edgar, Dabira Chaluluka, Ebbie Kamuliwo, Mulakwa Ades, Veronica Skarbinski, Jacek Shi, Ya Ping Magnussen, Pascal Meshnick, Steve ter Kuile, Feiko O. TI Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE malaria in pregnancy; sulfadoxine-pyrimethamine resistance; intermittent preventive treatment; effectiveness ID PLASMODIUM-FALCIPARUM; MACHINGA DISTRICT; PROPENSITY SCORE; WESTERN KENYA; WOMEN; AFRICA; METAANALYSIS; TANZANIA; EFFICACY; OUTCOMES AB Background. Owing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan Africa, monitoring the effectiveness of intermittent preventive therapy in pregnancy (IPTp) with SP is crucial. Methods. Between 2009 and 2013, both the efficacy of IPTp-SP at clearing existing peripheral malaria infections and the effectiveness of IPTp-SP at reducing low birth weight (LBW) were assessed among human immunodeficiency virus-uninfected participants in 8 sites in 6 countries. Sites were classified as high, medium, or low resistance after measuring parasite mutations conferring SP resistance. An individual-level prospective pooled analysis was conducted. Results. Among 1222 parasitemic pregnant women, overall polymerase chain reaction-uncorrected and -corrected failure rates by day 42 were 21.3% and 10.0%, respectively (39.7% and 21.1% in high-resistance areas; 4.9% and 1.1% in low-resistance areas). Median time to recurrence decreased with increasing prevalence of Pfdhps-K540E. Among 6099 women at delivery, IPTp-SP was associated with a 22% reduction in the risk of LBW (prevalence ratio [PR], 0.78; 95% confidence interval [CI], .69-.88; P < .001). This association was not modified by insecticide-treated net use or gravidity, and remained significant in areas with high SP resistance (PR, 0.81; 95% CI, .67-.97; P = .02). Conclusions. The efficacy of SP to clear peripheral parasites and prevent new infections during pregnancy is compromised in areas with >90% prevalence of Pfdhps-K540E. Nevertheless, in these high-resistance areas, IPTp-SP use remains associated with increases in birth weight and maternal hemoglobin. The effectiveness of IPTp in eastern and southern Africa is threatened by further increases in SP resistance and reinforces the need to evaluate alternative drugs and strategies for the control of malaria in pregnancy. C1 [Desai, Meghna; Gutman, Julie; Wiegand, Ryan E.; Mace, Kimberly E.; Skarbinski, Jacek; Shi, Ya Ping] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE,Mail Stop A-06, Atlanta, GA 30322 USA. [Desai, Meghna; Ouma, Peter; Otieno, Kephas] Kenya Govt Med Res Ctr, Malaria Branch, Ctr Global Hlth Res, Kisumu, Kenya. [Taylor, Steve M.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC USA. [Taylor, Steve M.; Meshnick, Steve] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Khairallah, Carole; Kayentao, Kassoum; ter Kuile, Feiko O.] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool, Merseyside, England. [Kayentao, Kassoum; Doumbo, Ogobara] Univ Sci Tech & Technol Bamako, Malaria Res & Training Ctr, Bamako, Mali. [Coulibaly, Sheick O.; Edgar, Dabira] Univ Ouagadougou, Ouagadougou, Burkina Faso. [Kalilani, Linda; Mathanga, Don P.; Chaluluka, Ebbie] Univ Malawi, Coll Med, Blantyre, Malawi. [Arinaitwe, Emmanuel] Infect Dis Res Collaborat, Kampala, Uganda. [Kamuliwo, Mulakwa] Natl Malaria Control Ctr, Lusaka, Zambia. [Ades, Veronica] NYU, Langone Med Ctr, New York, NY USA. [Magnussen, Pascal] Univ Copenhagen, Fac Hlth & Med Sci, Ctr Med Parasitol, DK-1168 Copenhagen, Denmark. RP Desai, M (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE,Mail Stop A-06, Atlanta, GA 30322 USA. EM mdesai@cdc.gov OI Ades, Veronica/0000-0002-9163-7511; ter Kuile, Feiko/0000-0003-3663-5617 FU CDC; US President's Malaria Initiative; USAID; Malaria in Pregnancy Consortium through Bill & Melinda Gates Foundation [46099]; European Developing Countries Clinical Trials Partnership [IP.2007.31080.003] FX This work was supported by the CDC; the US President's Malaria Initiative; USAID; and the Malaria in Pregnancy Consortium, which is funded through a grant from the Bill & Melinda Gates Foundation (grant number 46099) to the Liverpool School of Tropical Medicine and the European Developing Countries Clinical Trials Partnership (grant number IP.2007.31080.003). NR 38 TC 7 Z9 7 U1 1 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2016 VL 62 IS 3 BP 323 EP 333 DI 10.1093/cid/civ881 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DD8VS UT WOS:000370205600012 PM 26486699 ER PT J AU Smithgall, M Vargas, CY Reed, C Finelli, L LaRussa, P Larson, EL Saiman, L Stockwell, MS AF Smithgall, Marie Vargas, Celibell Y. Reed, Carrie Finelli, Lyn LaRussa, Philip Larson, Elaine L. Saiman, Lisa Stockwell, Melissa S. TI Influenza Vaccine Effectiveness in a Low-Income, Urban Community Cohort SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza; vaccine effectiveness; community-based ID SEASONAL INFLUENZA; UNITED-STATES AB In this community-based cohort study of 275 primarily low-income, urban households in New York City, overall 2013-2014 influenza vaccine effectiveness (VE) was 62.5% (95% confidence interval, 21.7%-82.0%). VE point estimates were highest against 2009 H1N1 and for those who were vaccinated in 2013-2014 but not in 2012-2013. C1 [Smithgall, Marie] Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA. [Vargas, Celibell Y.; LaRussa, Philip; Saiman, Lisa; Stockwell, Melissa S.] Columbia Univ, Dept Pediat, New York, NY 10032 USA. [Reed, Carrie; Finelli, Lyn] Ctr Dis Control & Prevent, Atlanta, GA USA. [Larson, Elaine L.] Columbia Univ, Sch Nursing, New York, NY 10032 USA. [Larson, Elaine L.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA. [Saiman, Lisa] Columbia Univ, NewYork Presbyterian Hosp, Dept Infect Prevent & Control, New York, NY 10032 USA. [Stockwell, Melissa S.] Columbia Univ, Dept Populat & Family Hlth, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Stockwell, Melissa S.] NewYork Presbyterian Hosp, New York, NY USA. RP Stockwell, MS (reprint author), Columbia Univ, Div Child & Adolescent Hlth, Dept Pediat, 622 W 168th St,VC 417, New York, NY 10032 USA. EM mss2112@columbia.edu FU CDC [U01IP000618]; National Institutes of Health [5T35HL007616-34] FX This work was supported by the CDC (grant number U01IP000618) and the National Institutes of Health (grant number 5T35HL007616-34). NR 12 TC 0 Z9 0 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2016 VL 62 IS 3 BP 358 EP 360 DI 10.1093/cid/civ867 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DD8VS UT WOS:000370205600016 PM 26420801 ER PT J AU Fonjungo, PN Boeras, DI Zeh, C Alexander, H Parekh, BS Nkengasong, JN AF Fonjungo, Peter N. Boeras, Debrah I. Zeh, Clement Alexander, Heather Parekh, Bharat S. Nkengasong, John N. TI Access and Quality of HIV-Related Point-of-Care Diagnostic Testing in Global Health Programs SO CLINICAL INFECTIOUS DISEASES LA English DT Review DE point-of-care testing; access; quality assurance; policy; evaluation ID RESOURCE-LIMITED SETTINGS; DRIED TUBE SPECIMENS; XPERT MTB/RIF; DEVELOPING-COUNTRIES; SOUTH-AFRICA; TUBERCULOSIS; MALARIA; SYPHILIS; CLINICS; PANELS AB Access to point-of-care testing (POCT) improves patient care, especially in resource-limited settings where laboratory infrastructure is poor and the bulk of the population lives in rural settings. However, because of challenges in rolling out the technology and weak quality assurance measures, the promise of human immunodeficiency virus (HIV)-related POCT in resource-limited settings has not been fully exploited to improve patient care and impact public health. Because of these challenges, the Joint United Nations Programme on HIV/AIDS (UNAIDS), in partnership with other organizations, recently launched the Diagnostics Access Initiative. Expanding HIV programs, including the "test and treat" strategies and the newly established UNAIDS 90-90-90 targets, will require increased access to reliable and accurate POCT results. In this review, we examine various components that could improve access and uptake of quality-assured POC tests to ensure coverage and public health impact. These components include evaluation, policy, regulation, and innovative approaches to strengthen the quality of POCT. C1 [Fonjungo, Peter N.; Boeras, Debrah I.; Alexander, Heather; Parekh, Bharat S.; Nkengasong, John N.] US Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Zeh, Clement] US Ctr Dis Control & Prevent, HIV Res Branch, Kisumu, Kenya. RP Fonjungo, PN (reprint author), Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Ctr Global Hlth, 1600 Clifton Rd NE,MS G19, Atlanta, GA 30333 USA. EM pfonjungo@cdc.gov FU President's Emergency Plan for AIDS Relief through the CDC FX This work was supported by the President's Emergency Plan for AIDS Relief through the CDC. NR 41 TC 3 Z9 3 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2016 VL 62 IS 3 BP 369 EP 374 DI 10.1093/cid/civ866 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DD8VS UT WOS:000370205600019 PM 26423384 ER PT J AU Garg, S Thongcharoen, P Praphasiri, P Chitwarakorn, A Sathirapanya, P Fernandez, S Rungrojcharoenkit, K Chonwattana, W Mock, PA Sukwicha, W Katz, JM Widdowson, MA Curlin, ME Gibbons, RV Holtz, TH Dawood, FS Olsen, SJ AF Garg, Shikha Thongcharoen, Prasert Praphasiri, Prabda Chitwarakorn, Anupong Sathirapanya, Pornchai Fernandez, Stefan Rungrojcharoenkit, Kamonthip Chonwattana, Wannee Mock, Philip A. Sukwicha, Wichuda Katz, Jacqueline M. Widdowson, Marc-Alain Curlin, Marcel E. Gibbons, Robert V. Holtz, Timothy H. Dawood, Fatimah S. Olsen, Sonja J. TI Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza; vaccine; HIV; immunogenicity; intradermal ID A H1N1 VACCINE; ANTIBODY-RESPONSE; HIV-1-INFECTED PATIENTS; IMMUNE-RESPONSE; CLINICAL-TRIAL; SPLIT VIRION; DOUBLE-BLIND; ADULTS; EFFICACY; INDIVIDUALS AB Background. Individuals infected with human immunodeficiency virus (HIV) are at increased risk for severe influenza, yet immune responses to standard-dose intramuscular (IM) influenza vaccine are suboptimal in this population. Intradermal (ID) delivery of influenza vaccine might improve immune response through enhanced stimulation of dendritic cells. Methods. We conducted a randomized, double-blind, controlled trial to compare the immunogenicity of off-label standard-dose (15 mu g) ID vs standard-dose (15 mu g) IM inactive influenza vaccine in HIV-infected men in Bangkok, Thailand. The primary study outcome was seroconversion (minimum titer of 1:40 and >= 4-fold rise in antibody titer) at 1 month postvaccination based on serum hemagglutination inhibition antibody titers against each vaccine strain. Adverse events (AEs) in the 7 days following vaccination were also assessed. Results. We enrolled 400 HIV-infected participants; 200 were randomly assigned to receive IM and 200 ID vaccine. Vaccine arms were well-balanced with respect to age, CD4 cell count, HIV RNA load, and antiretroviral treatment. Percentage of seroconversion to all (ID 14% vs IM 15%; P=.8) or at least 1 (ID 69% vs IM 68%; P=.7) of the 3 vaccine strains did not differ significantly between ID vs IM vaccine recipients. A higher proportion of participants who received ID vaccine had mild injection-site AEs compared with participants who received IM vaccine (77% vs 27%). Conclusions. There were no significant differences in the immunogenicity of standard-dose ID vs IM influenza vaccine in this HIV-infected population in Thailand. Additional strategies to enhance immune responses to influenza vaccine among HIV-infected persons are needed. C1 [Garg, Shikha; Curlin, Marcel E.; Holtz, Timothy H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Garg, Shikha; Katz, Jacqueline M.; Widdowson, Marc-Alain; Dawood, Fatimah S.; Olsen, Sonja J.] Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30329 USA. [Praphasiri, Prabda; Chonwattana, Wannee; Mock, Philip A.; Sukwicha, Wichuda; Curlin, Marcel E.; Holtz, Timothy H.; Olsen, Sonja J.] Ctr Dis Control & Prevent, Thailand Minist Publ Health US CDC Collaborat, Atlanta, GA USA. [Chitwarakorn, Anupong] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. [Fernandez, Stefan; Rungrojcharoenkit, Kamonthip; Gibbons, Robert V.] Armed Forces Res Inst Med Sci, Bangkok 10400, Thailand. [Thongcharoen, Prasert; Sathirapanya, Pornchai] Siriraj Hosp, Bangkok, Thailand. RP Garg, S (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30329 USA. EM izj7@cdc.gov FU CDC [5U01GH000152] FX This work was supported by the CDC (cooperative agreement 5U01GH000152). NR 43 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2016 VL 62 IS 3 BP 383 EP 391 DI 10.1093/cid/civ884 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DD8VS UT WOS:000370205600021 PM 26486702 ER PT J AU Goldsmith, S McIntyre, S Smithers-Sheedy, H Blair, E Cans, C Watson, L Yeargin-Allsopp, M AF Goldsmith, Shona McIntyre, Sarah Smithers-Sheedy, Hayley Blair, Eve Cans, Christine Watson, Linda Yeargin-Allsopp, Marshalyn CA Australian Cerebral Palsy Register TI An international survey of cerebral palsy registers and surveillance systems SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY LA English DT Article ID CLASSIFICATION-SYSTEM; PREVENTION PROGRAM; RISK-FACTORS; CHILDREN; PREVALENCE; RELIABILITY; CLASSIFY; COLLABORATION; DISLOCATION; ABILITY AB Aim To describe cerebral palsy (CP) surveillance programmes and identify similarities and differences in governance and funding, aims and scope, definition, inclusion/exclusion criteria, ascertainment and data collection, to enhance the potential for research collaboration. Method Representatives from 38 CP surveillance programmes were invited to participate in an online survey and submit their data collection forms. Descriptive statistics were used to summarize information submitted. Results Twenty-seven surveillance programmes participated (25 functioning registers, two closed owing to lack of funding). Their aims spanned five domains: resource for CP research, surveillance, aetiology/prevention, service planning, and information provision (in descending order of frequency). Published definitions guided decision making for the definition of CP and case eligibility for most programmes. Consent, case identification, and data collection methods varied widely. Ten key data items were collected by all programmes and a further seven by at least 80% of programmes. All programmes reported an interest in research collaboration. Interpretation Despite variability in methodologies, similarities exist across programmes in terms of their aims, definitions, and data collected. These findings will facilitate harmonization of data and collaborative research efforts, which are so necessary on account of the heterogeneity and relatively low prevalence of CP. C1 [Goldsmith, Shona; McIntyre, Sarah; Smithers-Sheedy, Hayley] Univ Sydney, Cerebral Palsy Alliance, Sydney, NSW 2006, Australia. [McIntyre, Sarah; Blair, Eve; Watson, Linda] Univ Western Australia, Telethon Kids Inst, Perth, WA 6009, Australia. [Cans, Christine] Grenoble Univ, CHU Grenoble, RHEOP ThEMAS, Grenoble, France. [Watson, Linda] Dept Hlth Western Australia, Perth, WA, Australia. [Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Dev Disabil Branch, Atlanta, GA USA. RP Goldsmith, S (reprint author), Cerebral Palsy Alliance, POB 6427, Frenchs Forest, NSW 2086, Australia. EM sgoldsmith@cerebralpalsy.org.au FU Research Foundation, Cerebral Palsy Alliance FX We acknowledge and thank Kim Van Naarden Braun, Deborah Christensen, and Alyson Goodman for their comments on the draft version of this paper. The supplement was funded by the Research Foundation, Cerebral Palsy Alliance. A list of contributors is given in Appendix S1 (online supporting information). NR 25 TC 1 Z9 1 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0012-1622 EI 1469-8749 J9 DEV MED CHILD NEUROL JI Dev. Med. Child Neurol. PD FEB PY 2016 VL 58 SU 2 SI SI BP 11 EP 17 DI 10.1111/dmcn.12999 PG 7 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA DD9OM UT WOS:000370255300004 PM 26781543 ER PT J AU Hammer, LB Johnson, RC Crain, TL Bodner, T Kossek, EE Davis, KD Kelly, EL Buxton, OM Karuntzos, G Chosewood, LC Berkman, L AF Hammer, Leslie B. Johnson, Ryan C. Crain, Tori L. Bodner, Todd Kossek, Ellen Ernst Davis, Kelly D. Kelly, Erin L. Buxton, Orfeu M. Karuntzos, Georgia Chosewood, L. Casey Berkman, Lisa TI Intervention Effects on Safety Compliance and Citizenship Behaviors: Evidence From the Work, Family, and Health Study SO JOURNAL OF APPLIED PSYCHOLOGY LA English DT Article DE group-randomized trial; work-family conflict; family supportive supervisor behavior; safety compliance; organizational citizenship behavior ID SUPPORTIVE SUPERVISOR BEHAVIORS; GROUP-RANDOMIZED TRIALS; JOB DECISION LATITUDE; ORGANIZATIONAL JUSTICE; MULTIDIMENSIONAL MEASURE; WORKPLACE INTERVENTION; RESOURCES-MODEL; SOCIAL SUPPORT; LABOR UNION; CONFLICT AB We tested the effects of a work-family intervention on employee reports of safety compliance and organizational citizenship behaviors in 30 health care facilities using a group-randomized trial. Based on conservation of resources theory and the work-home resources model, we hypothesized that implementing a work-family intervention aimed at increasing contextual resources via supervisor support for work and family, and employee control over work time, would lead to improved personal resources and increased employee performance on the job in the form of self-reported safety compliance and organizational citizenship behaviors. Multilevel analyses used survey data from 1,524 employees at baseline and at 6-month and 12-month postintervention follow-ups. Significant intervention effects were observed for safety compliance at the 6-month, and organizational citizenship behaviors at the 12-month, follow-ups. More specifically, results demonstrate that the intervention protected against declines in employee self-reported safety compliance and organizational citizenship behaviors compared with employees in the control facilities. The hypothesized mediators of perceptions of family-supportive supervisor behaviors, control over work time, and work-family conflict (work-to-family conflict, family-to-work conflict) were not significantly improved by the intervention. However, baseline perceptions of family-supportive supervisor behaviors, control over work time, and work-family climate were significant moderators of This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly. the intervention effect on the self-reported safety compliance and organizational citizenship behavior outcomes. C1 [Hammer, Leslie B.; Crain, Tori L.; Bodner, Todd] Portland State Univ, Dept Psychol, 1721 SW Broadway St, Portland, OR 97207 USA. [Johnson, Ryan C.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA. [Kossek, Ellen Ernst] Purdue Univ, Krannert Sch Management, W Lafayette, IN 47907 USA. [Davis, Kelly D.] Penn State Univ, Human Dev & Family Studies, University Pk, PA 16802 USA. [Kelly, Erin L.] Univ Minnesota, Dept Sociol, Minneapolis, MN 55455 USA. [Buxton, Orfeu M.] Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA. [Buxton, Orfeu M.] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA USA. [Karuntzos, Georgia] RTI Int, Res Triangle Pk, NC USA. [Chosewood, L. Casey] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth NIOSH, Atlanta, GA USA. [Berkman, Lisa] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. [Crain, Tori L.] Colorado State Univ, Dept Psychol, Ft Collins, CO 80523 USA. [Davis, Kelly D.] Oregon State Univ, Corvallis, OR 97331 USA. [Kelly, Erin L.] MIT, Sloan Sch Management, Cambridge, MA 02139 USA. RP Hammer, LB (reprint author), Portland State Univ, Dept Psychol, 1721 SW Broadway St, Portland, OR 97207 USA. EM hammerl@pdx.edu FU National Institutes of Health and the Centers for Disease Control and Prevention: Eunice Kennedy Shriver National Institute of Child Health and Human Development [U01HD051217, U01HD051218, U01HD051256, U01HD051276]; National Institute on Aging [U01AG027669]; National Heart, Lung, and Blood Institute [R01HL107240]; Office of Behavioral and Social Sciences Research; National Institute for Occupational Safety and Health [U01OH008788, U01HD059773]; William T. Grant Foundation; Alfred P. Sloan Foundation; Administration for Children and Families FX This research was conducted as part of the Work, Family and Health Network (www.WorkFamilyHealthNetwork.org), which is funded by a cooperative agreement through the National Institutes of Health and the Centers for Disease Control and Prevention: Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant # U01HD051217, U01HD051218, U01HD051256, U01HD051276); National Institute on Aging (Grant # U01AG027669); the National Heart, Lung, and Blood Institute (R01HL107240); Office of Behavioral and Social Sciences Research; and National Institute for Occupational Safety and Health (Grant # U01OH008788, U01HD059773). Grants from the William T. Grant Foundation, Alfred P. Sloan Foundation, and the Administration for Children and Families have provided additional funding. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of these institutes and offices. Special acknowledgment goes to Extramural Staff Science Collaborator, Rosalind Berkowitz King, PhD, and Lynne Casper, PhD, for design of the original Workplace, Family, Health and Well-Being Network Initiative. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of these institutes and offices. NR 87 TC 3 Z9 3 U1 14 U2 29 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-9010 EI 1939-1854 J9 J APPL PSYCHOL JI J. Appl. Psychol. PD FEB PY 2016 VL 101 IS 2 BP 190 EP 208 DI 10.1037/ap10000047 PG 19 WC Psychology, Applied; Management SC Psychology; Business & Economics GA DD8IN UT WOS:000370169900003 PM 26348479 ER PT J AU Head, MG Lopman, BA AF Head, Michael G. Lopman, Benjamin A. TI Norovirus in 2016-Emesis Aplenty but Clear Signs of Progress SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE norovirus; norwalk; calicivirus ID SYSTEMATIC ANALYSIS; GASTROENTERITIS; ENGLAND; DISEASE AB The key theme emerging from the articles in this supplement is that burden of norovirus in the United Kingdom and elsewhere is substantial and that new tools for prevention, diagnosis, and treatment are required. Basic understanding of norovirus biology continues to accelerate, but parallel increases in capacity and research funding are going to be needed to translate this knowledge into clinical trials and translational research that can result in public health gains. C1 [Head, Michael G.] UCL, Farr Inst Hlth Informat, 222 Euston Rd, London NW1 2DA, England. [Head, Michael G.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England. [Lopman, Benjamin A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA. RP Head, MG (reprint author), UCL, Farr Inst Hlth Informat, 222 Euston Rd, London NW1 2DA, England.; Head, MG (reprint author), Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England. EM m.head@ucl.ac.uk OI Head, Michael/0000-0003-1189-0531 NR 14 TC 0 Z9 0 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2016 VL 213 SU 1 BP S1 EP S2 DI 10.1093/infdis/jiv409 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DE0FR UT WOS:000370300800001 PM 26744425 ER PT J AU Sadique, Z Lopman, B Cooper, BS Edmunds, WJ AF Sadique, Zia Lopman, Ben Cooper, Ben S. Edmunds, W. John TI Cost-effectiveness of Ward Closure to Control Outbreaks of Norovirus Infection in United Kingdom National Health Service Hospitals SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE norovirus; outbreak; ward closure; cost-effectiveness ID ENGLAND; GASTROENTERITIS; MANAGEMENT; IMPACT; WALES AB Background. Norovirus is the most common cause of outbreaks of acute gastroenteritis in National Health Service hospitals in the United Kingdom. Wards (units) are often closed to new admissions to stop the spread of the virus, but there is limited evidence describing the cost-effectiveness of ward closure. Methods. An economic analysis based on the results from a large, prospective, active-surveillance study of gastroenteritis outbreaks in hospitals and from an epidemic simulation study compared alternative ward closure options evaluated at different time points since first infection, assuming different efficacies of ward closure. Results. A total of 232 gastroenteritis outbreaks occurring in 14 hospitals over a 1-year period were analyzed. The risk of a new outbreak in a hospital is significantly associated with the number of admission, general medical, and long-stay wards that are concurrently affected but is less affected by the level of community transmission. Ward closure leads to higher costs but reduces the number of new outbreaks by 6%-56% and the number of clinical cases by 1%-55%, depending on the efficacy of the intervention. The incremental cost per outbreak averted varies from 10 pound 000 ($14 000) to 306 pound 000 ($428 000), and the cost per case averted varies from 500 pound ($700) to 61 pound 000 ($85 000). The cost-effectiveness of ward closure decreases as the efficacy of the intervention increases, and the cost-effectiveness increases with the timing of the intervention. The efficacy of ward closure is critical from a cost-effectiveness perspective. Conclusions. Ward closure may be cost-effective, particularly if targeted to high-throughput units. C1 [Sadique, Zia; Edmunds, W. John] London Sch Hyg & Trop Med, London WC1, England. [Lopman, Ben] Publ Hlth England, London, England. [Cooper, Ben S.] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Nuffield Dept Clin Med, Oxford OX1 2JD, England. [Cooper, Ben S.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand. [Lopman, Ben] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA. RP Sadique, Z (reprint author), London Sch Hyg & Trop Med, London WC1, England.; Sadique, Z (reprint author), London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, 15-17 Tavistock Pl, London WC1H 9SH, England. EM zia.sadique@lshtm.ac.uk OI Cooper, Ben/0000-0002-9445-7217 FU POLYMOD (an EU FP6) [SP22-CT-2004-502084] FX This work was supported by POLYMOD (an EU FP6-funded program; contract SP22-CT-2004-502084). NR 17 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2016 VL 213 SU 1 BP S19 EP S26 DI 10.1093/infdis/jiv410 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DE0FR UT WOS:000370300800006 PM 26744428 ER PT J AU Sorensen, G Nagler, EM Hashimoto, D Dennerlein, JT Theron, JV Stoddard, AM Buxton, O Wallace, LM Kenwood, C Nelson, CC Tamers, SL Grant, MP Wagner, G AF Sorensen, Glorian Nagler, Eve M. Hashimoto, Dean Dennerlein, Jack T. Theron, Julie V. Stoddard, Anne M. Buxton, Orfeu Wallace, Lorraine M. Kenwood, Christopher Nelson, Candace C. Tamers, Sara L. Grant, Michael P. Wagner, Gregory TI Implementing an Integrated Health Protection/Health Promotion Intervention in the Hospital Setting Lessons Learned From the Be Well, Work Well Study SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID PATIENT-CARE WORKERS; LOW-BACK-PAIN; PROOF-OF-CONCEPT; MUSCULOSKELETAL PAIN; REGISTERED NURSES; SLEEP DEFICIENCY; PSYCHOLOGICAL DISTRESS; OCCUPATIONAL INJURIES; FAMILY CONFLICT; RISK-FACTOR AB Objective:This study reports findings from a proof-of-concept trial designed to examine the feasibility and estimates the efficacy of the Be Well, Work Well workplace intervention.Methods:The intervention included consultation for nurse managers to implement changes on patient-care units and educational programming for patient-care staff to facilitate improvements in safety and health behaviors. We used a mixed-methods approach to evaluate feasibility and efficacy.Results:Using findings from process tracking and qualitative research, we observed challenges to implementing the intervention due to the physical demands, time constraints, and psychological strains of patient care. Using survey data, we found no significant intervention effects.Conclusions:Beyond educating individual workers, systemwide initiatives that respond to conditions of work might be needed to transform the workplace culture and broader milieu in support of worker health and safety. C1 [Sorensen, Glorian; Nagler, Eve M.; Theron, Julie V.; Wallace, Lorraine M.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02215 USA. [Dennerlein, Jack T.; Wagner, Gregory] Harvard Univ, Dept Environm Hlth, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Sorensen, Glorian; Nagler, Eve M.; Nelson, Candace C.; Grant, Michael P.] Harvard Univ, Dept Social & Behav Sci, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Hashimoto, Dean] Partners HealthCare, Boston, MA USA. [Hashimoto, Dean] Boston Coll, Sch Law, Newton, MA USA. [Hashimoto, Dean; Buxton, Orfeu] Harvard Univ, Sch Med, Boston, MA USA. [Dennerlein, Jack T.] Northeastern Univ, Bouve Coll Hlth Sci, Boston, MA 02115 USA. [Buxton, Orfeu] Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA. [Buxton, Orfeu] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Kenwood, Christopher] New England Res Inst, 9 Galen St, Watertown, MA 02172 USA. [Tamers, Sara L.] Ctr Dis Control & Prevent, Off Total Worker Hlth Coordinat & Res Support, NIOSH, Washington, DC USA. [Wagner, Gregory] Ctr Dis Control & Prevent, Off Director, NIOSH, Washington, DC USA. RP Sorensen, G (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM glorian_sorensen@dfci.harvard.edu FU National Institute for Occupational Safety and Health for Harvard T.H. Chan School of Public Health Center for Work, Health and Well-being [U19 OH008861] FX This work was supported by a grant from the National Institute for Occupational Safety and Health (U19 OH008861) for the Harvard T.H. Chan School of Public Health Center for Work, Health and Well-being. NR 64 TC 1 Z9 1 U1 2 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD FEB PY 2016 VL 58 IS 2 BP 185 EP 194 DI 10.1097/JOM.0000000000000592 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD8VH UT WOS:000370204500011 PM 26849263 ER PT J AU Husain, MJ Khondker, BH AF Husain, Muhammad Jami Khondker, Bazlul Haque TI Tobacco-free Economy: A SAM-based Multiplier Model to Quantify the Impact of Changes in Tobacco Demand in Bangladesh SO MARGIN-JOURNAL OF APPLIED ECONOMIC RESEARCH LA English DT Article DE Social Accounting Matrix; Bangladesh SAM; Tobacco Consumption; Tobacco-free Economy; Multiplier Model; Multiplier Values; Input-Output Tables; Demand-driven Interventions ID ACCOUNTING MATRIX FRAMEWORK AB In Bangladesh, where tobacco use is pervasive, reducing tobacco use is economically beneficial. This article uses the latest Bangladesh social accounting matrix (SAM) multiplier model to quantify the economy-wide impact of demand-driven changes in tobacco cultivation, bidi industries and cigarette industries. First, we compute various income multiplier values (i.e., backward linkages) for all production activities in the economy to quantify the impact of changes in demand for the corresponding products on gross output for 86 activities, demand for 86 commodities, returns to 4 factors of production and income for 8 household groups. Next, we rank tobacco production activities by income multiplier values relative to other sectors. Finally, we present three hypothetical 'tobacco-free economy' scenarios by diverting demand from tobacco products into other sectors of the economy and by quantifying the economy-wide impact. The simulation exercises with three different tobacco-free scenarios show that, compared to the baseline values, total sectoral output increases by 0.92, 1.3 and 0.75 per cent. The corresponding increases in the total factor returns (i.e., gross domestic product, GDP) are 1.57, 1.75 and 1.75 per cent. Similarly, total household income increases by 1.40, 1.58 and 1.55 per cent. C1 [Husain, Muhammad Jami] Ctr Dis Control & Prevent, Global Tobacco Control Branch, Off Smoking & Hlth, Atlanta, GA USA. [Khondker, Bazlul Haque] Univ Dhaka, Econ, Dhaka 1000, Bangladesh. RP Husain, MJ (reprint author), Ctr Dis Control & Prevent, Global Tobacco Control Branch, Off Smoking & Hlth, Atlanta, GA USA. EM MHusain@cdc.gov; bazlul.khondker@gmail.com NR 25 TC 0 Z9 0 U1 1 U2 2 PU SAGE PUBLICATIONS INDIA PVT LTD PI NEW DELHI PA B-1-I-1 MOHAN CO-OPERATIVE INDUSTRIAL AREA, MATHURA RD, POST BAG NO 7, NEW DELHI 110 044, INDIA SN 0973-8010 EI 0973-8029 J9 MARGIN JI Margin PD FEB PY 2016 VL 10 IS 1 BP 55 EP 85 DI 10.1177/0973801015612665 PG 31 WC Economics SC Business & Economics GA DE3YA UT WOS:000370565200003 ER PT J AU Hale, GL Zaki, SR Day, SM AF Hale, Gillian L. Zaki, Sherif R. Day, Sarah M. TI Yersinia Pestis Osteomyelitis: An Underreported Complication of Plague SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 12-18, 2016 CL Seattle, WA SP US & Canadian Acad Pathol C1 Ctr Dis Control & Prevent, Atlanta, GA USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2016 VL 29 SU 2 MA 1538 BP 389A EP 389A PG 1 WC Pathology SC Pathology GA DE0GI UT WOS:000370302503012 ER PT J AU Ng, D Jones, T Paddock, C AF Ng, Dianna Jones, Tara Paddock, Christopher TI Histologic Features and Immunohistochemical Characterization of Inflammatory Infiltrates in Eschar Biopsy Specimens from Patients with Rickettsia parkeri Rickettsiosis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 12-18, 2016 CL Seattle, WA SP US & Canadian Acad Pathol C1 [Ng, Dianna; Jones, Tara; Paddock, Christopher] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2016 VL 29 SU 2 MA 1541 BP 390A EP 390A PG 1 WC Pathology SC Pathology GA DE0GI UT WOS:000370302503015 ER PT J AU Mujugira, A Celum, C Tappero, JW Ronald, A Mugo, N Baeten, JM AF Mujugira, Andrew Celum, Connie Tappero, Jordan W. Ronald, Allan Mugo, Nelly Baeten, Jared M. TI Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED ADULTS; FREE STATE PROVINCE; SUB-SAHARAN AFRICA; SOUTH-AFRICA; MEDICATION ADHERENCE; INITIATION; OUTCOMES; COUPLES; BARRIERS AB Background: Antiretroviral therapy (ART) markedly reduces the risk of HIV-1 transmission in serodiscordant partnerships. We previously found that younger age and higher CD4 counts were associated with delayed initiation of ART by HIV-1-infected partners in serodiscordant partnerships. Among those initiating ART, we sought to explore whether those same factors were associated with failure to achieve viral suppression. Methods: In a prospective study of HIV-1-infected persons who had a known heterosexual HIV-1-uninfected partner in Kenya and Uganda [Partners Pre-Exposure Prophylaxis (PrEP) Study], we used Cox proportional hazards regression to evaluate correlates of viral nonsuppression (HIV-1 RNA >80 copies/ml). Results: Of 1,035 HIV-1-infected participants initiating ART, 867 (84%) achieved viral suppression: 77% by 6 months and 86% by 12 months. Younger age [adjusted hazard ratio (aHR) 1.05 for every 5 years younger; p=.006], lower pretreatment CD4 count (aHR 1.26; p=.009 for 250 compared with >250 cells/l), and higher pretreatment HIV-1 RNA quantity (aHR 1.21 per log(10); p<.001) independently predicted failure to achieve viral suppression. Following initial viral suppression, 8.8% (76/867) experienced virologic rebound (HIV-1 RNA >200 copies/ml): 6.3% and 11.5% by 6 and 12 months after initial suppression, respectively. Age was the only factor associated with increased risk of virologic rebound (aHR 1.33 for every 5 years younger; p=.005). Conclusions: For HIV-1-infected persons in serodiscordant couples, younger age was associated with delayed ART initiation, failure to achieve viral suppression, and increased risk of virologic rebound. Motivating ART initiation and early adherence is a key to achieving and sustaining viral suppression. C1 [Mujugira, Andrew; Celum, Connie; Mugo, Nelly; Baeten, Jared M.] Univ Washington, Dept Global Hlth, Seattle, WA 98104 USA. [Mujugira, Andrew; Celum, Connie; Baeten, Jared M.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA. [Celum, Connie; Baeten, Jared M.] Univ Washington, Dept Med, Seattle, WA 98104 USA. [Tappero, Jordan W.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. [Ronald, Allan] Univ Manitoba, Dept Med, Winnipeg, MB, Canada. [Ronald, Allan] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada. [Mugo, Nelly] Kenya Govt Med Res Ctr, Clin Res Ctr, Nairobi, Kenya. RP Mujugira, A (reprint author), Univ Washington, Int Clin Res Ctr, Dept Global Hlth, Box 359927,325 Ninth Ave, Seattle, WA 98104 USA. EM mujugira@uw.edu FU Bill & Melinda Gates Foundation [OPP47674]; National Institute of Mental Health of the US National Institutes of Health [R01 MH095507] FX This study was supported through research grants from the Bill & Melinda Gates Foundation (Grant OPP47674) and the National Institute of Mental Health of the US National Institutes of Health (Grant R01 MH095507). NR 65 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD FEB 1 PY 2016 VL 32 IS 2 BP 148 EP 154 DI 10.1089/aid.2015.0296 PG 7 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DD2NY UT WOS:000369760500007 PM 26670218 ER PT J AU Watson, M Thomas, CC Massetti, GM McKenna, S Gershenwald, JE Laird, S Iskander, J Lushniak, B AF Watson, M. Thomas, C. C. Massetti, G. M. McKenna, S. Gershenwald, J. E. Laird, S. Iskander, J. Lushniak, B. TI CDC Grand Rounds: Prevention and Control of Skin Cancer SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID UNITED-STATES; CUTANEOUS MELANOMA; US ADULTS; TRENDS; PREVALENCE C1 [Watson, M.; Thomas, C. C.; Massetti, G. M.] CDC, Canc Prevent Div, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [McKenna, S.] Arizona Dept Hlth Serv, Arizona SunWise Skin Canc Prevent Program, Phoenix, AZ 85007 USA. [Gershenwald, J. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Laird, S.; Iskander, J.] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA. [Lushniak, B.] US Dept HHS, Off Surgeon Gen, Washington, DC USA. RP Watson, M (reprint author), CDC, Canc Prevent Div, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM mwatson2@cdc.gov NR 17 TC 1 Z9 1 U1 3 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD FEB PY 2016 VL 16 IS 2 BP 717 EP 720 DI 10.1111/ajt.13720 PG 4 WC Surgery; Transplantation SC Surgery; Transplantation GA DD3WL UT WOS:000369853900040 PM 26824446 ER PT J AU Dong, J Yu, XQ Porter, DW Battelli, LA Kashon, ML Ma, Q AF Dong, Jie Yu, Xiaoqing Porter, Dale W. Battelli, Lori A. Kashon, Michael L. Ma, Qiang TI Common and distinct mechanisms of induced pulmonary fibrosis by particulate and soluble chemical fibrogenic agents SO ARCHIVES OF TOXICOLOGY LA English DT Article DE Pulmonary fibrosis; Genome-wide gene expression; Inflammation; Silica; Bleomycin; Paraquat ID SECRETORY LEUCOPROTEASE INHIBITOR; GELATINASE-ASSOCIATED LIPOCALIN; WALLED CARBON NANOTUBES; ACUTE KIDNEY INJURY; TENASCIN-C; LUNG FIBROSIS; MATRIX METALLOPROTEINASES; CRYSTALLINE SILICA; INFLAMMATION; OSTEOPONTIN AB Pulmonary fibrosis results from the excessive deposition of collagen fibers and scarring in the lungs with or without an identifiable cause. The mechanism(s) underlying lung fibrosis development is poorly understood, and effective treatment is lacking. Here we compared mouse lung fibrosis induced by pulmonary exposure to prototypical particulate (crystalline silica) or soluble chemical (bleomycin or paraquat) fibrogenic agents to identify the underlying mechanisms. Young male C57BL/6J mice were given silica (2 mg), bleomycin (0.07 mg), or paraquat (0.02 mg) by pharyngeal aspiration. All treatments induced significant inflammatory infiltration and collagen deposition, manifesting fibrotic foci in silica-exposed lungs or diffuse fibrosis in bleomycin or paraquat-exposed lungs on day 7 post-exposure, at which time the lesions reached their peaks and represented a junction of transition from an acute response to chronic fibrosis. Lung genome-wide gene expression was analyzed, and differential gene expression was confirmed by quantitative RT-PCR, immunohistochemistry, and immunoblotting for representative genes to demonstrate their induced expression and localization in fibrotic lungs. Canonical signaling pathways, gene ontology, and upstream transcription networks modified by each agent were identified. In particular, these inducers elicited marked proliferative responses; at the same time, silica preferentially activated innate immune functions and the defense against foreign bodies, whereas bleomycin and paraquat boosted responses related to cell adhesion, platelet activation, extracellular matrix remodeling, and wound healing. This study identified, for the first time, the shared and unique genes, signaling pathways, and biological functions regulated by particulate and soluble chemical fibrogenic agents during lung fibrosis, providing insights into the mechanisms underlying human lung fibrotic diseases. C1 [Dong, Jie; Ma, Qiang] NIOSH, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,Ctr Dis Control & Prevent, Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA. [Yu, Xiaoqing] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT 06520 USA. [Porter, Dale W.; Battelli, Lori A.] NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Kashon, Michael L.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Ma, Q (reprint author), NIOSH, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,Ctr Dis Control & Prevent, Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM qam1@cdc.gov FU National Institute for Occupational Safety and Health, Health Effects Laboratory Division FX This work was funded to Q.M. by National Institute for Occupational Safety and Health, Health Effects Laboratory Division. NR 48 TC 6 Z9 7 U1 4 U2 9 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0340-5761 EI 1432-0738 J9 ARCH TOXICOL JI Arch. Toxicol. PD FEB PY 2016 VL 90 IS 2 BP 385 EP 402 DI 10.1007/s00204-015-1589-3 PG 18 WC Toxicology SC Toxicology GA DD8SD UT WOS:000370196300013 PM 26345256 ER PT J AU Blanco, RM dos Santos, LF Galloway, RL Romero, EC AF Blanco, Roberta Morozetti dos Santos, Luis Fernando Galloway, Renee Lynn Romero, Eliete Carlo TI Is the microagglutination test (MAT) good for predicting the infecting serogroup for leptospirosis in Brazil? SO COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES LA English DT Article DE Leptospirosis; Microscopic agglutination test; Leptospira spp.; Zoonosis ID SAO-PAULO; IDENTIFICATION AB Leptospirosis is a zoonotic infection caused by pathogenic members of the genus Leptospira spp. Knowledge of the prevalent serovars and their maintenance hosts is essential to understand the disease. The aim of this study was to evaluate the ability of serology by the microscopic agglutination test (MAT) to predict the serogroups compared with results of identification of leptospires in Sao Paulo, Brazil. MAT correctly assigned the serogroup of the infecting isolate in 49/52 cases (94.23%). The serogroup Icterohaemorrhagiae was the predominant serogroup (88.46%). This study showed the usefulness of the MAT to correctly identify the infecting serogroup with a good overall agreement between the serologically-identified infecting serogroup and by identification of the isolate and can be used in epidemiological surveys in Sao Paulo. However, it should be complemented by the identification of Leptospira isolates. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Blanco, Roberta Morozetti; dos Santos, Luis Fernando; Romero, Eliete Carlo] Adolfo Lutz Inst, Ctr Bacteriol, Sao Paulo, SP, Brazil. [Galloway, Renee Lynn] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Atlanta, GA USA. RP Romero, EC (reprint author), Adolfo Lutz Inst, Ctr Bacteriol, Sao Paulo, SP, Brazil. EM eliete_romero@yahoo.com.br NR 13 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0147-9571 EI 1878-1667 J9 COMP IMMUNOL MICROB JI Comp. Immunol. Microbiol. Infect. Dis. PD FEB PY 2016 VL 44 BP 34 EP 36 DI 10.1016/j.cimid.2015.12.003 PG 3 WC Immunology; Microbiology; Veterinary Sciences SC Immunology; Microbiology; Veterinary Sciences GA DD8IC UT WOS:000370168700006 PM 26851592 ER PT J AU Thurman, DJ Kobau, R Luo, YH Helmers, SL Zack, MM AF Thurman, David J. Kobau, Rosemarie Luo, Yao-Hua Helmers, Sandra L. Zack, Matthew M. TI Health-care access among adults with epilepsy: The US National Health Interview Survey, 2010 and 2013 SO EPILEPSY & BEHAVIOR LA English DT Article DE Epilepsy; Epidemiology; Surveillance; United States; Insurance; Access to care ID SELF-REPORTED EPILEPSY; PSYCHOLOGICAL DISTRESS; DISPARITIES; STATES; SURVEILLANCE; POPULATION; PREVALENCE; MEDICAID; IMPACT AB Introduction: Community-based and other epidemiologic studies within the United States have identified substantial disparities in health care among adults with epilepsy. However, few data analyses addressing their health-care access are representative of the entire United States. This study aimed to examine national survey data about adults with epilepsy and to identify barriers to their health care. Materials and methods: We analyzed data from U.S. adults in the 2010 and the 2013 National Health Interview Surveys, multistage probability samples with supplemental questions on epilepsy. We defined active epilepsy as a history of physician-diagnosed epilepsy either currently under treatment or accompanied by seizures during the preceding year. We employed SAS-callable SUDAAN software to obtain weighted estimates of population proportions and rate ratios (RRs) adjusted for sex, age, and race/ethnicity. Results: Compared to adults reporting no history of epilepsy, adults reporting active epilepsy were significantly more likely to be insured under Medicaid (RR = 3.58) and less likely to have private health insurance (RR = 0.58). Adults with active epilepsy were also less likely to be employed (RR = 0.53) and much more likely to report being disabled (RR = 6.14). They experience greater barriers to health-care access including an inability to afford medication (RR = 2.40), mental health care (RR = 3.23), eyeglasses (RR = 2.36), or dental care (RR = 1.98) and are more likely to report transportation as a barrier to health care (RR = 5.28). Conclusions: These reported substantial disparities in, and barriers to, access to health care for adults with active epilepsy are amenable to intervention. Published by Elsevier Inc. C1 [Thurman, David J.; Helmers, Sandra L.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Kobau, Rosemarie; Luo, Yao-Hua; Zack, Matthew M.] Ctr Dis Control & Prevent, Epilepsy Program, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Kobau, R (reprint author), CDC, Epilepsy Program, 4770 Buford Highway NE,MS K78, Atlanta, GA 30341 USA. EM rkobau@cdc.gov FU Intramural CDC HHS [CC999999] NR 29 TC 6 Z9 6 U1 1 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD FEB PY 2016 VL 55 BP 184 EP 188 DI 10.1016/j.yebeh.2015.10.028 PG 5 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA DD1ML UT WOS:000369685700033 PM 26627980 ER PT J AU Cogliati, M Zani, A Rickerts, V McCormick, I Desnos-Ollivier, M Velegraki, A Escandon, P Ichikawa, T Ikeda, R Bienvenu, AL Tintelnot, K Tore, O Akcaglar, S Lockhart, S Tortorano, AM Varma, A AF Cogliati, Massinio Zani, Alberto Rickerts, Volker McCormick, Ilka Desnos-Ollivier, Marie Velegraki, Aristea Escandon, Patricia Ichikawa, Tomoe Ikeda, Reiko Bienvenu, Anne-Lise Tintelnot, Kathrin Tore, Okan Akcaglar, Sevim Lockhart, Shawn Tortorano, Anna Maria Varma, Ashok TI Multilocus sequence typing analysis reveals that Cryptococcus neoformans var. neoformans is a recombinant population SO FUNGAL GENETICS AND BIOLOGY LA English DT Article DE Cryptococcus; C. neoformans var. neoformans; C neoformans var. grubii; MLST; Recombination ID SPECIES COMPLEX; MATING-TYPE; MOLECULAR EPIDEMIOLOGY; GATTII; PCR; SEROTYPES; GENOTYPE; THAILAND AB Cryptococcus neoformans var. neoformans (serotype D) represents about 30% of the clinical isolates in Europe and is present less frequently in the other continents. It is the prevalent etiological agent in primary cutaneous cryptococcosis as well as in cryptococcal skin lesions of disseminated cryptococcosis. Very little is known about the genotypic diversity of this Cryptococcus subtype. The aim of this study was to investigate the genotypic diversity among a set of clinical and environmental C. neoformans var. neoformans isolates and to evaluate the relationship between genotypes, geographical origin and clinical manifestations. A total of 83 globally collected C neoformans var. neoformans isolates from Italy, Germany, France, Belgium, Denmark, Greece, Turkey, Thailand, Japan, Colombia, and the USA, recovered from different sources (primary and secondary cutaneous cryptococcosis, disseminated cryptococcosis, the environment, and animals), were included in the study. All isolates were confirmed to belong to genotype VNIV by molecular typing and they were further investigated by MLST analysis. Maximum likelihood phylogenetic as well as network analysis strongly suggested the existence of a recombinant rather than a clonal population structure. Geographical origin and source of isolation were not correlated with a specific MLST genotype. The comparison with a set of outgroup C neoformans var. grubii isolates provided clear evidence that the two varieties have different population structures. (C) 2016 Elsevier Inc. All rights reserved. C1 [Cogliati, Massinio; Zani, Alberto; Tortorano, Anna Maria] Univ Milan, Lab Micol Med, Dip Sci Biomed Salute, Via Pascal 36, I-20133 Milan, Italy. [Rickerts, Volker; McCormick, Ilka; Tintelnot, Kathrin] Robert Koch Inst, Sect Mycol, Berlin, Germany. [Desnos-Ollivier, Marie] Inst Pasteur, Ctr Natl Reference Mycoses Invas & Antifong, Unite Mycol, Paris, France. [Velegraki, Aristea] Univ Athens, Sch Med, Dept Microbiol, Athens 11528, Greece. [Escandon, Patricia] Inst Nacl Salud, Microbiol Grp, Bogota, Colombia. [Ichikawa, Tomoe; Ikeda, Reiko] Meiji Pharmaceut Univ, Dept Microbial Sci & Host Def, Tokyo, Japan. [Bienvenu, Anne-Lise] Hosp Civils Lyon, Inst Parasitol & Mycol Med, Lyon, France. [Bienvenu, Anne-Lise] Univ Lyon, Malaria Res Unit, Lyon, France. [Varma, Ashok] NIAID, Mol Microbiol Sect, Lab Clin Infect Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Tore, Okan; Akcaglar, Sevim] Uludag Univ, Sch Med, Dept Med Microbiol, Bursa, Turkey. [Lockhart, Shawn] Ctr Dis Control & Prevent, Mycot Dis Branch, Antifungal & Fungal Reference Labs, Atlanta, GA USA. RP Cogliati, M (reprint author), Univ Milan, Lab Micol Med, Dip Sci Biomed Salute, Via Pascal 36, I-20133 Milan, Italy. EM massimo.cogliati@unimi.it OI Tortorano, Anna Maria/0000-0003-2093-8250 FU Intramural NIH HHS [Z99 AI999999]; NCRR NIH HHS [P41 RR001646] NR 39 TC 3 Z9 3 U1 2 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1087-1845 EI 1096-0937 J9 FUNGAL GENET BIOL JI Fungal Genet. Biol. PD FEB PY 2016 VL 87 BP 22 EP 29 DI 10.1016/j.fgb.2016.01.003 PG 8 WC Genetics & Heredity; Mycology SC Genetics & Heredity; Mycology GA DD2UW UT WOS:000369778700003 PM 26768709 ER PT J AU Cochi, SL Hegg, L Kaur, A Pandak, C Jafari, H AF Cochi, Stephen L. Hegg, Lea Kaur, Anjali Pandak, Carol Jafari, Hamid TI The Global Polio Eradication Initiative: Progress, Lessons Learned, And Polio Legacy Transition Planning SO HEALTH AFFAIRS LA English DT Editorial Material ID POLIOMYELITIS ERADICATION; SMALLPOX; NIGERIA AB The world is closer than ever to achieving global polio eradication, with record-low polio cases in 2015 and the impending prospect of a polio-free Africa. Tens of millions of volunteers, social mobilizers, and health workers have participated in the Global Polio Eradication Initiative. The program contributes to efforts to deliver other health benefits, including health systems strengthening. As the initiative nears completion after more than twenty-five years, it becomes critical to document and transition the knowledge, lessons learned, assets, and infrastructure accumulated by the initiative to address other health goals and priorities. The primary goals of this process, known as polio legacy transition planning, are both to protect a polio-free world and to ensure that investments in polio eradication will contribute to other health goals after polio is completely eradicated. The initiative is engaged in an extensive transition process of consultations and planning at the global, regional, and country levels. A successful completion of this process will result in a well-planned and -managed conclusion of the initiative that will secure the global public good gained by ending one of the world's most devastating diseases and ensure that these investments provide public health benefits for years to come. C1 [Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. [Hegg, Lea] Bill & Melinda Gates Fdn, Seattle, WA USA. [Kaur, Anjali] United Nations Childrens Fund, Polio Team, New York, NY USA. [Pandak, Carol] Rotary Int, PolioPlus, Evanston, IL USA. [Jafari, Hamid] WHO, Global Polio Eradicat Initiat, CH-1211 Geneva, Switzerland. RP Cochi, SL (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. EM slc1@cdc.gov FU Centers for Disease Control and Prevention (CDC); Bill & Melinda Gates Foundation; United Nations Children's Fund (UNICEF); Rotary International; World Health Organization (WHO) FX This work was supported by the Centers for Disease Control and Prevention (CDC), the Bill & Melinda Gates Foundation, the United Nations Children's Fund (UNICEF), Rotary International, and the World Health Organization (WHO). The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the CDC, the Bill & Melinda Gates Foundation, UNICEF, Rotary International, or the WHO. NR 13 TC 2 Z9 3 U1 2 U2 8 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD FEB PY 2016 VL 35 IS 2 BP 277 EP 283 DI 10.1377/hlthaff.2015.1104 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DD1QU UT WOS:000369697200016 PM 26858381 ER PT J AU Biellik, R Davidkin, I Esposito, S Lobanov, A Kojouharova, M Pfaff, G Santos, JI Simpson, J Ben Mamou, M Butler, R Deshevoi, S Huseynov, S Jankovic, D Shefer, A AF Biellik, Robin Davidkin, Iria Esposito, Susanna Lobanov, Andrey Kojouharova, Mira Pfaff, Guenter Santos, Jose Ignacio Simpson, John Ben Mamou, Myriam Butler, Robb Deshevoi, Sergei Huseynov, Shahin Jankovic, Dragan Shefer, Abigail TI Slow Progress In Finalizing Measles And Rubella Elimination In The European Region SO HEALTH AFFAIRS LA English DT Article AB All countries in the World Health Organization European Region committed to eliminating endemic transmission of measles and rubella by 2015, and disease incidence has decreased dramatically. However, there was little progress between 2012 and 2013, and the goal will likely not be achieved on time. Genuine political commitment, increased technical capacity, and greater public awareness are urgently needed, especially in Western Europe. C1 [Biellik, Robin] WHO, CH-1211 Geneva, Switzerland. [Davidkin, Iria] Natl Inst Hlth & Welf, Viral Infect Unit, Helsinki, Finland. [Esposito, Susanna] Univ Milan, Pediat Highly Intens Care Unit, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy. [Lobanov, Andrey] WHO, Moscow, Russia. [Kojouharova, Mira] Minist Hlth, Natl Ctr Infect & Parasit Dis, Sofia, Bulgaria. [Pfaff, Guenter] Baden Wurttemberg State Hlth Off, Dept Epidemiol & Hlth Reporting, Stuttgart, Germany. [Santos, Jose Ignacio] Univ Nacl Autonoma Mexico, Fac Med, Mexico City 04510, DF, Mexico. [Simpson, John] Publ Hlth England, Div Emergency Preparedness Resilience & Response, Salisbury, England. [Ben Mamou, Myriam] WHO Reg Off Europe, Div Communicable Dis Hlth Secur & Environm, Measles & Rubella Lab, Copenhagen, Denmark. [Butler, Robb; Deshevoi, Sergei; Huseynov, Shahin; Jankovic, Dragan; Shefer, Abigail] WHO Reg Off Europe, Div Communicable Dis Hlth Secur & Environm, Copenhagen, Denmark. [Shefer, Abigail] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. EM rbiellik@gmail.com RI Esposito, Susanna/K-3475-2016; Huseynov, Shahin/D-6930-2017 OI Esposito, Susanna/0000-0003-4103-2837; Huseynov, Shahin/0000-0002-2412-2833 FU World Health Organization [001] NR 11 TC 1 Z9 1 U1 0 U2 2 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD FEB PY 2016 VL 35 IS 2 BP 322 EP 326 DI 10.1377/hlthaff.2015.1055 PG 5 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DD1QU UT WOS:000369697200022 PM 26858387 ER PT J AU Andrus, JK Cochi, SL Cooper, LZ Klein, JD AF Andrus, Jon Kim Cochi, Stephen L. Cooper, Louis Z. Klein, Jonathan D. TI Combining Global Elimination Of Measles And Rubella With Strengthening Of Health Systems In Developing Countries SO HEALTH AFFAIRS LA English DT Editorial Material ID ROUTINE IMMUNIZATION; ERADICATION; VACCINATION; IMPACT; CARE AB Global efforts to eliminate measles and rubella can be combined with other actions to accelerate the strengthening of health systems in developing countries. However, there are several challenges standing in the way of successfully combining measles and rubella vaccination campaigns with health systems strengthening. Those challenges include the following: achieving universal vaccine coverage while integrating the initiative with other primary care strategies and developing the necessary health system resilience to confront emergencies, ensuring epidemiological and laboratory surveillance of vaccine-preventable diseases, developing the human resources needed to effectively manage and implement national strategies, increasing community demand for health services, and obtaining long-term political support. We describe lessons learned from the successful elimination of measles and rubella in the Americas and elsewhere that strive to strengthen national health systems to both improve vaccine uptake and confront emerging threats. The elimination of measles and rubella provides opportunities for nations to strengthen health systems and thus to both reduce inequities and ensure national health security. C1 [Andrus, Jon Kim] Sabin Vaccine Inst, Washington, DC USA. [Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. [Cooper, Louis Z.] Columbia Univ, Dept Pediat, New York, NY 10027 USA. [Klein, Jonathan D.] Amer Acad Pediat, Elk Grove Village, IL USA. RP Andrus, JK (reprint author), Sabin Vaccine Inst, Washington, DC USA. EM Jon.Andrus@sabin.org NR 29 TC 1 Z9 1 U1 1 U2 10 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD FEB PY 2016 VL 35 IS 2 BP 327 EP 333 DI 10.1377/hlthaff.2015.1005 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DD1QU UT WOS:000369697200023 PM 26858388 ER PT J AU Kissoon, N Uyeki, TM AF Kissoon, Niranjan Uyeki, Timothy M. TI Sepsis and the Global Burden of Disease in Children SO JAMA PEDIATRICS LA English DT Editorial Material ID SYSTEMATIC ANALYSIS; SEPTIC SHOCK; MORTALITY C1 [Kissoon, Niranjan] Univ British Columbia, Dept Pediat, Div Crit Care, British Columbia Childrens Hosp, 4480 Oak St,Room B245, Vancouver, BC V6H 3V4, Canada. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Kissoon, N (reprint author), Univ British Columbia, Dept Pediat, Div Crit Care, British Columbia Childrens Hosp, 4480 Oak St,Room B245, Vancouver, BC V6H 3V4, Canada. EM nkissoon@cw.bc.ca NR 7 TC 4 Z9 4 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD FEB PY 2016 VL 170 IS 2 BP 107 EP 108 DI 10.1001/jamapediatrics.2015.3241 PG 2 WC Pediatrics SC Pediatrics GA DD1AT UT WOS:000369654000006 PM 26661465 ER PT J AU Bradley, RD Mauldin, MR AF Bradley, Robert D. Mauldin, Matthew R. TI Molecular data indicate a cryptic species in Neotoma albigula (Cricetidae: Neotominae) from northwestern Mexico SO JOURNAL OF MAMMALOGY LA English DT Article DE cryptic species; cytochrome-b gene; genetic species; Neotoma; N. albigula complex ID CYTOCHROME-B SEQUENCES; GENUS NEOTOMA; DNA-SEQUENCES; MAMMALS; PHYLOGENETICS; SYSTEMATICS; MITOCHONDRIAL; RODENTIA; TREES AB DNA sequences from the mitochondrial cytochrome-b gene were obtained from 41 specimens of Neotoma albigula from the southwestern United States and northwestern Mexico. Phylogenetic analyses depicted that samples of N. a. melanura from southern Sonora and northern Sinaloa formed a clade separate from representatives of the other sampled subspecies of N. albigula (albigula, laplataensis, mearnsi, seri, sheldoni, and venusta). Genetic distances detected between these clades (7.41%) approached divergence levels reported for other sister species of woodrats and indicated that N. a. melanura is presumably a cryptic and genetically differentiated species relative to N. albigula. Analyses of DNA sequences from a nuclear gene (intron 2 of the alcohol dehydrogenase gene, Adh1-I2) indicated that samples of N. a. melanura formed a separate, monophyletic clade relative to the remainder of N. albigula. Further, habitat, geographic distinctions, and morphological differences were apparent between members of the 2 clades. Together, those data support the elevation of N. a. melanura to species status. C1 [Bradley, Robert D.; Mauldin, Matthew R.] Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA. [Bradley, Robert D.] Texas Tech Univ Museum, Nat Sci Res Lab, Lubbock, TX 79409 USA. [Mauldin, Matthew R.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. RP Bradley, RD (reprint author), Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA.; Bradley, RD (reprint author), Texas Tech Univ Museum, Nat Sci Res Lab, Lubbock, TX 79409 USA. EM robert.bradley@ttu.edu NR 44 TC 0 Z9 0 U1 3 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2372 EI 1545-1542 J9 J MAMMAL JI J. Mammal. PD FEB PY 2016 VL 97 IS 1 BP 187 EP 199 DI 10.1093/jmammal/gyv169 PG 13 WC Zoology SC Zoology GA DC5AP UT WOS:000369232600019 ER PT J AU Massetti, GM Ragan, KR Thomas, CC Ryerson, AB AF Massetti, Greta M. Ragan, Kathleen R. Thomas, Cheryll C. Ryerson, A. Blythe TI Public Health Opportunities for Promoting Health Equity in Cancer Prevention and Control in LGBT Populations SO LGBT HEALTH LA English DT Article DE cancer prevention and control; health equity; LGBT health; public health AB Advances in cancer prevention, detection, and treatment have led to reductions in morbidity and premature mortality and improvements in quality of life. However, not all Americans have benefited equally from these advances, and certain populations experience continued disparities in cancer care. Although research and public health efforts have highlighted the experiences of some groups, other populations have been relatively understudied, such as lesbian, gay, bisexual, and transgender (LGBT) individuals. Public health efforts in surveillance, research, programs, and partnerships can provide opportunities to advance health equity for LGBT at the population level and lead to better health outcomes for LGBT individuals with cancer. C1 [Massetti, Greta M.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,MS K76, Atlanta, GA 30341 USA. RP Massetti, GM (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,MS K76, Atlanta, GA 30341 USA. EM gmassetti@cdc.gov OI Massetti, Greta/0000-0002-3813-9839 FU U.S. Department of Energy; CDC FX The authors thank Ena Wanliss for her suggestions and input in the original conceptualization of the manuscript. This research was supported in part by an appointment (K. Ragan) to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an inter-agency agreement between the U.S. Department of Energy and CDC. NR 20 TC 1 Z9 1 U1 3 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2325-8292 EI 2325-8306 J9 LGBT HEALTH JI LGBT Health PD FEB PY 2016 VL 3 IS 1 SI SI BP 11 EP 14 DI 10.1089/lgbt.2015.0109 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD0PY UT WOS:000369623100004 ER PT J AU Lee, E Toprani, A Begier, E Genovese, R Madsen, A Gambatese, M AF Lee, Erica Toprani, Amita Begier, Elizabeth Genovese, Richard Madsen, Ann Gambatese, Melissa TI Implications for Improving Fetal Death Vital Statistics: Connecting Reporters' Self-Identified Practices and Barriers to Third Trimester Fetal Death Data Quality in New York City SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Fetal death; Vital statistics; Stillbirth; Data collection; Perinatal mortality ID RISK-FACTORS; ETHNIC DISPARITIES; STILLBIRTHS; MORTALITY; VALIDITY; HEALTH AB Objectives Perinatal mortality prevention strategies that target fetal deaths often utilize vital records data sets shown to contain critical quality deficiencies. To understand the causes of deficient data, we linked survey responses of fetal death reporters with facility fetal death data quality indicators. Methods In 2011, we surveyed the person most responsible for fetal death reporting at New York City healthcare facilities on their attitudes, barriers, and practices regarding reporting. We compared responses by 2 facility data quality indicators (data completeness and ill-defined cause of fetal death) for third trimester fetal death registrations using Chi squared tests. Results Thirty-nine of 50 facilities completed full questionnaires (78 % response rate); responding facilities reported 84 % (n = 11,891) of all 2011 fetal deaths, including 329 third trimester fetal deaths. Facilities citing a parts per thousand yen1 reporting barrier were approximately five times more likely to have incomplete third trimester registrations than facilities citing no substantial barriers (37.5 vs 7.9 %; RR 4.7; 95 % CI [1.6-14.2]). Reported barriers included onerous reporting requirements (n = 10; 26 %) and competing physician priorities (n = 11; 28 %). Facilities citing difficulty involving physicians in reporting were more likely to report fetal deaths with nonspecific cause-of-death information (70.9 vs 56.6 %; RR 1.3; 95 % CI [1.1-1.5]). Conclusions Self-reported challenges correlate with completeness and accuracy of reported fetal death data, suggesting that such barriers are likely contributing to low quality data. We identified several improvement opportunities, including in-depth training and reducing the information collected, especially for early fetal deaths (< 20 weeks' gestation), the majority of events reported. C1 [Lee, Erica; Toprani, Amita; Begier, Elizabeth; Genovese, Richard; Madsen, Ann; Gambatese, Melissa] New York City Dept Hlth & Mental Hyg, Bur Vital Stat, 125 Worth St,Room 219B,CN 7, New York, NY 10013 USA. [Toprani, Amita] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RP Lee, E (reprint author), New York City Dept Hlth & Mental Hyg, Bur Vital Stat, 125 Worth St,Room 219B,CN 7, New York, NY 10013 USA. EM elee7@health.nyc.gov NR 26 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD FEB PY 2016 VL 20 IS 2 BP 337 EP 346 DI 10.1007/s10995-015-1833-8 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD3FK UT WOS:000369807300013 PM 26518007 ER PT J AU Vuong, J Collard, JM Whaley, MJ Bassira, I Seidou, I Diarra, S Ouedraogo, RT Kambire, D Taylor, TH Sacchi, C Mayer, LW Wang, X AF Vuong, Jeni Collard, Jean-Marc Whaley, Melissa J. Bassira, Issaka Seidou, Issaka Diarra, Seydou Ouedraogo, Rasmata T. Kambire, Dinanibe Taylor, Thomas H., Jr. Sacchi, Claudio Mayer, Leonard W. Wang, Xin TI Development of Real-Time PCR Methods for the Detection of Bacterial Meningitis Pathogens without DNA Extraction SO PLOS ONE LA English DT Article ID NUCLEIC-ACID AMPLIFICATION; CHILDREN YOUNGER; IDENTIFICATION; HAEMOPHILUS; BURDEN; ASSAYS; TESTS; BLOOD AB Neisseria meningitidis (Nm), Haemophilus influenzae (Hi), and Streptococcus pneumoniae (Sp) are the lead causes of bacterial meningitis. Detection of these pathogens from clinical specimens using traditional real-time PCR (rt-PCR) requires DNA extraction to remove the PCR inhibitors prior to testing, which is time consuming and labor intensive. In this study, five species-specific (Nm-sodC and -ctrA, Hi-hpd# 1 and -hpd#3 and Sp-lytA) and six serogroup- specific rt-PCR tests (A, B, C, W, X, Y) targeting Nm capsular genes were evaluated in the two direct rt-PCR methods using PerfeCTa and 5x Omni that do not require DNA extraction. The sensitivity and specify of the two direct rt-PCR methods were compared to TaqMan traditional rt-PCR, the current standard rt-PCR method for the detection of meningitis pathogens. The LLD for all 11 rt-PCR tests ranged from 6,227 to 272,229 CFU/ml for TaqMan, 1,824-135,982 for 5x Omni, and 168-6,836 CFU/ml for PerfeCTa. The diagnostic sensitivity using TaqMan ranged from 89.2%-99.6%, except for NmB-csb, which was 69.7%. For 5x Omni, the sensitivity varied from 67.1% to 99.8%, with three tests below 90%. The sensitivity of these tests using PerfeCTa varied from 89.4% to 99.8%. The specificity ranges of the 11 tests were 98.0-99.9%, 97.5-99.9%, and 92.9-99.9% for TaqMan, 5x Omni, and PerfeCTa, respectively. PerfeCTa direct rt-PCR demonstrated similar or better sensitivity compared to 5x Omni direct rt-PCR or TaqMan traditional rt-PCR. Since the direct rt-PCR method does not require DNA extraction, it reduces the time and cost for processing CSF specimens, increases testing throughput, decreases the risk of cross-contamination, and conserves precious CSF. The direct rt-PCR method will be beneficial to laboratories with high testing volume. C1 [Vuong, Jeni; Whaley, Melissa J.; Taylor, Thomas H., Jr.; Mayer, Leonard W.; Wang, Xin] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA USA. [Collard, Jean-Marc] Sci Inst Publ Hlth, Brussels, Belgium. [Collard, Jean-Marc; Bassira, Issaka; Seidou, Issaka] Ctr Rech Med & Sanit, Niamey, Niger. [Diarra, Seydou] Inst Natl Rech Sante Publ, Bamako, Mali. [Ouedraogo, Rasmata T.; Kambire, Dinanibe] Ctr Hosp Univ Pediat Charles De Gaulle, Ouagadougou, Burkina Faso. [Sacchi, Claudio] Adolfo Lutz Inst, Sao Paulo, Brazil. RP Wang, X (reprint author), Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA USA. EM gqe8@cdc.gov NR 15 TC 3 Z9 3 U1 2 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 1 PY 2016 VL 11 IS 2 AR e0147765 DI 10.1371/journal.pone.0147765 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DC9NL UT WOS:000369548200032 PM 26829233 ER PT J AU Paredes-Esquivel, C Lenhart, A del Rio, R Leza, MM Estrugo, M Chalco, E Casanova, W Miranda, MA AF Paredes-Esquivel, Claudia Lenhart, Audrey del Rio, Ricardo Leza, M. M. Estrugo, M. Chalco, Enrique Casanova, Wilma Angel Miranda, Miguel TI The impact of indoor residual spraying of deltamethrin on dengue vector populations in the Peruvian Amazon SO ACTA TROPICA LA English DT Article DE Dengue; Mosquitoes; Aedes aegypti; Indoor residual spraying; IRS; Vector-control ID INSECTICIDE-TREATED CURTAINS; AEDES-AEGYPTI DIPTERA; RANDOMIZED-TRIAL; CULICIDAE; TRANSMISSION; THAILAND; MEXICO AB Dengue is an important public health problem in the Amazon area of Peru, resulting in significant morbidity each year. As in other areas of the world, ultra-low volume (ULV) application of insecticides is the main strategy to reduce adult populations of the dengue vector Aedes aegypti, despite growing evidence of its limitations as a single control method. This study investigated the efficacy of deltamethrin S.C. applied through indoor residual spraying (IRS) of dwellings in reducing A. aegypti populations. The residual effect of the insecticide was tested by monthly bioassays on the three most common indoor surfaces found in the Amazon area: painted wood, unpainted wood and brick. The results showed that in an area with moderate levels of A. aegypti infestation, IRS dramatically reduced all immature indices the first week after deltamethrin IRS application and the adult index from 18.5 to 3.1, four weeks after intervention (p <0.05). Even though housing conditions facilitated reinfestation with A. aegypti (100% of the houses have open roof eaves, 31.5% lack sewage systems, and 60.4% collected rain in open containers), indices remained low compared to baseline 16 weeks after insecticide application. Bioassays showed that deltamethrin S.C. caused mortalities >80% 8 weeks after application on all types of surfaces. The residual effect of the insecticide was greater on brick than on wooden walls (p<0.05). Our results demonstrate that IRS can have both an immediate and sustained effect on reducing adult and immature A. aegypti populations and should be considered as an adult mosquito control strategy by dengue vector control programs. (C) 2015 Elsevier B.V. All rights reserved. C1 [Paredes-Esquivel, Claudia; del Rio, Ricardo; Leza, M. M.; Estrugo, M.; Angel Miranda, Miguel] Univ Balearic Isl, Zool Lab, Ctra Valldemossa Km 7-5, Palma De Mallorca 07122, Spain. [Lenhart, Audrey] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Chalco, Enrique; Casanova, Wilma] Minist Salud Peru, Direcc Reg Salud Loreto, Lima, Peru. RP Paredes-Esquivel, C (reprint author), Univ Balearic Isl, Zool Lab, Ctra Valldemossa Km 7-5, Palma De Mallorca 07122, Spain. EM claudia.paredes@uib.es RI Paredes, Claudia/F-2340-2016; Leza, M. Mar/F-5537-2016 OI Paredes, Claudia/0000-0002-9196-3069; Leza, M. Mar/0000-0002-0134-0221 FU Govern de les Illes Balears; Oficina de Cooperacio al Desenvolupament i Solidaritat of the University of the Balearic Islands FX This study was funded by the Govern de les Illes Balears. We would like to thank to the Oficina de Cooperacio al Desenvolupament i Solidaritat of the University of the Balearic Islands, for their support. We would also like to thank Amy Morrison and Helvio Astete, from NAMRU-6 in Iquitos for their extremely valuable technical advice and support. NR 37 TC 3 Z9 4 U1 3 U2 13 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0001-706X EI 1873-6254 J9 ACTA TROP JI Acta Trop. PD FEB PY 2016 VL 154 BP 139 EP 144 DI 10.1016/j.actatropica.2015.10.020 PG 6 WC Parasitology; Tropical Medicine SC Parasitology; Tropical Medicine GA DC4PO UT WOS:000369203000018 PM 26571068 ER PT J AU Moisi, JC Moore, M Carvalho, MD Sow, SO Siludjai, D Knoll, MD Tapia, M Baggett, HC AF Moisi, Jennifer C. Moore, Matthew Carvalho, Maria da Gloria Sow, Samba O. Siludjai, Duangkamon Knoll, Maria Deloria Tapia, Milagritos Baggett, Henry C. CA LEAP Study Investigators TI Enhanced Diagnosis of Pneumococcal Bacteremia Using Antigen- and Molecular-Based Tools on Blood Specimens in Mali and Thailand: A Prospective Surveillance Study SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID PNEUMONIAE URINARY ANTIGEN; POLYMERASE-CHAIN-REACTION; RESPIRATORY-TRACT INFECTIONS; SEQUENTIAL MULTIPLEX PCR; STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; CAPSULAR SEROTYPES; IMMUNOCHROMATOGRAPHIC TEST; GAMBIAN CHILDREN; RAPID DIAGNOSIS AB Prior antibiotic use, contamination, limited blood volume, and processing delays reduce yield of blood cultures for detection of Streptococcus pneumoniae. We performed immunochromatographic testing (ICT) on broth from incubated blood culture bottles and real-time lytA polymerase chain reaction (PCR) on broth and whole blood and compared findings to blood culture in patients with suspected bacteremia. We selected 383 patients in Mali and 586 patients in Thailand based on their blood culture results: 75 and 31 were positive for pneumococcus, 100 and 162 were positive for other pathogens, and 208 and 403 were blood culture negative, respectively. ICT and PCR of blood culture broth were at least 87% sensitive and 97% specific compared with blood culture; whole blood PCR was 75-88% sensitive and 96-100% specific. Pneumococcal yields in children < 5 years of age increased from 2.9% to 10.7% in Mali with > 99% of additional cases detected by whole blood PCR, and from 0.07% to 5.1% in Thailand with two-thirds of additional cases identified by ICT. Compared with blood culture, ICT and lytA PCR on cultured broth were highly sensitive and specific but their ability to improve pneumococcal identification varied by site. Further studies of these tools are needed before widespread implementation. C1 Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Baltimore, MD USA. Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. Ctr Vaccins Dev, Bamako, Mali. US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA. RP Moisi, JC (reprint author), Agence Med Prevent, 21 Blvd Pasteur, F-75015 Paris, France. EM jennifer.moisi@polytechnique.org NR 39 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2016 VL 94 IS 2 BP 267 EP 275 DI 10.4269/ajtmh.15-0431 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA DC8JK UT WOS:000369465500005 PM 26643535 ER PT J AU Dahlgren, FS Heitman, KN Behravesh, CB AF Dahlgren, F. Scott Heitman, Kristen Nichols Behravesh, Casey Barton TI Undetermined Human Ehrlichiosis and Anaplasmosis in the United States, 2008-2012: A Catch-All for Passive Surveillance SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID AMBLYOMMA-AMERICANUM; NATIONAL SURVEILLANCE; INCREASING INCIDENCE; TRANSMISSION; CHAFFEENSIS; IXODIDAE; EWINGII; VECTOR AB Human ehrlichiosis and anaplasmosis are potentially severe illnesses endemic in the United States. Several bacterial agents are known causes of these diseases: Ehrlichia chaffeensis, Ehrlichia ewingii, Ehrlichia muris-like agent, Panola Mountain Ehrlichia species, and Anaplasma phagocytophilum. Because more than one agent may be present in one area, cases of human ehrlichiosis and anaplasmosis may be reported as "human ehrlichiosis/anaplasmosis undetermined" when the available evidence does not suggest an etiology to the species level. Here, we present a brief summary of these undetermined cases with onset of symptoms from 2008 to 2012 reported to two passive surveillance systems in the United States. The reported incidence rate during this time was 0.52 cases per million person-years. Many cases (24%) had positive polymerase chain reaction results. Enhanced surveillance in an area where several of these etiologic agents are endemic may provide a better understanding of the epidemiology of ehrlichiosis and anaplasmosis in the United States. C1 [Dahlgren, F. Scott; Heitman, Kristen Nichols; Behravesh, Casey Barton] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, 1600 Clifton Rd NE,MS A-30, Atlanta, GA 30329 USA. RP Dahlgren, FS (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, 1600 Clifton Rd NE,MS A-30, Atlanta, GA 30329 USA. EM iot0@cdc.gov FU Centers for Disease Control and Prevention FX This study was supported by the Centers for Disease Control and Prevention as well as by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the Centers for Disease Control and Prevention. NR 14 TC 0 Z9 0 U1 1 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2016 VL 94 IS 2 BP 299 EP 301 DI 10.4269/ajtmh.15-0691 PG 3 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA DC8JK UT WOS:000369465500010 PM 26621564 ER PT J AU Hause, AM Perez-Padilla, J Horiuchi, K Han, GS Hunsperger, E Aiwazian, J Margolis, HS Tomashek, KM AF Hause, Anne M. Perez-Padilla, Janice Horiuchi, Kalanthe Han, George S. Hunsperger, Elizabeth Aiwazian, Jonathan Margolis, Harold S. Tomashek, Kay M. TI Epidemiology of Dengue among Children Aged < 18 Months-Puerto Rico, 1999-2011 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ANTIBODY-DEPENDENT ENHANCEMENT; VIRUS-INFECTION; HEMORRHAGIC-FEVER; IGG SUBCLASSES; INFANTS; DIAGNOSIS; DISEASE; ASSAY AB Dengue, a mosquito-borne viral illness caused by dengue virus types (DENY)-1 to DENV-4, is endemic in Puerto Rico. Severe dengue usually occurs in individuals previously infected with DENY or among infants born to previously infected mothers. To describe clinical features of dengue in infants, we retrospectively characterized dengue patients aged < 18 months reported to the Passive Dengue Surveillance System (PDSS) during 1999-2011. To determine frequency of signs, symptoms, and disease severity, case report forms and medical records were evaluated for patients who tested positive for dengue by reverse transcriptase polymerase chain reaction or anti-DENY immunoglobulin M enzyme-linked immunosorbent assay. Of 4,178 reported patients aged < 18 months, 813 (19%) were laboratory positive. Of these, most had fever (92%), rash (53%), bleeding manifestations (52%), and thrombocytopenia (52%). Medical records were available for 145 (31%) of 472 hospitalized patients, of which 40% had dengue, 23% had dengue with warning signs, and 33% had severe dengue. Mean age of patients with severe dengue was 8 months. Anti-DENY immunoglobulin G (IgG) titers were not statistically different in patients with (50%) and without (59%) severe dengue. In this study, one-third of DENY-infected infants met the severe dengue case definition. The role of maternal anti-DENY IgG in development of severe disease warrants further study in prospective cohorts of mother-infant pairs. C1 [Hause, Anne M.; Perez-Padilla, Janice; Horiuchi, Kalanthe; Han, George S.; Hunsperger, Elizabeth; Aiwazian, Jonathan; Margolis, Harold S.; Tomashek, Kay M.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR USA. RP Perez-Padilla, J (reprint author), Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1324 Calle Canada, San Juan, PR 00920 USA. EM jperez@cdc.gov NR 25 TC 1 Z9 1 U1 0 U2 7 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2016 VL 94 IS 2 BP 404 EP 408 DI 10.4269/ajtmh.15.0382 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA DC8JK UT WOS:000369465500027 PM 26711519 ER PT J AU Bower, H Grass, JE Veltus, E Brault, A Campbell, S Basile, AJ Wang, D Paddock, CD Erickson, BR Salzer, JS Belser, J Chege, E Seneca, D Saffa, G Stroeher, U Decroo, T Caleo, GM AF Bower, Hilary Grass, Julian E. Veltus, Emily Brault, Aaron Campbell, Shelley Basile, Alison Jane Wang, David Paddock, Christopher D. Erickson, Bobbie R. Salzer, Johanna S. Belser, Jessica Chege, Eunice Seneca, Dean Saffa, Gbessay Stroeher, Ute Decroo, Tom Caleo, Grazia M. TI Delivery of an Ebola Virus-Positive Stillborn Infant in a Rural Community Health Center, Sierra Leone, 2015 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article AB We report the case of an Ebola virus (EBOV) RNA negative pregnant woman who delivered an EBOV RNA positive stillborn infant at a community health center in rural Sierra Leone, 1 month after the mother's last possible exposure. The mother was later found to be immunoglobulins M and G positive indicating previous infection. The apparent absence of Ebola symptoms and not recognizing that the woman had previous contact with an Ebola patient led health workers performing the delivery to wear only minimal personal protection, potentially exposing them to a high risk of EBOV infection. This case emphasizes the importance of screening for epidemiological risk factors as well as classic and atypical symptoms of Ebola when caring for pregnant women, even once they have passed the typical time frame for exposure and incubation expected in nonpregnant adults. It also illustrates the need for healthcare workers to use appropriate personal protection equipment when caring for pregnant women in an Ebola setting. C1 Medecins Sans Frontieres Operat Ctr Amsterdam, MSF Ebola Management Ctr Project, Bo, Sierra Leone. Ctr Dis Control & Prevent, Atlanta, GA USA. Ctr Dis Control & Prevent, Ft Collins, CO USA. World Hlth Org, Bo, Sierra Leone. Sierra Leone Minist Hlth & Sanitat, Dist Hlth Management Team Surveillance Unit, Bo, Sierra Leone. Medecins Sans Frontieres Operat Ctr Brussels, Luxembourg Operat Res Unit, Brussels, Belgium. Medecins Sans Frontieres Operat Ctr Amsterdam, Mansons Unit, London, England. RP Bower, H (reprint author), Medecins Sans Frontieres Operat Ctr Amsterdam, Plantage Middenlaan 14, NL-1018 DD Amsterdam, Netherlands. EM hilarybower@gmail.com OI Bower, Hilary/0000-0002-1541-6637; Decroo, Tom/0000-0002-1205-1484 FU World Health Organization [001] NR 7 TC 6 Z9 6 U1 1 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2016 VL 94 IS 2 BP 417 EP 419 DI 10.4269/ajtmh.15-0619 PG 3 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA DC8JK UT WOS:000369465500030 PM 26556830 ER PT J AU Slayton, RB Murphy, JL Morris, J Faith, SH Oremo, J Odhiambo, A Ayers, T Feinman, SJ Brown, AC Quick, RE AF Slayton, Rachel B. Murphy, Jennifer L. Morris, Jamae Faith, Sitnah Hamidah Oremo, Jared Odhiambo, Aloyce Ayers, Tracy Feinman, Shawna J. Brown, Allison C. Quick, Robert E. TI A Cluster Randomized Controlled Evaluation of the Health Impact of a Novel Antimicrobial Hand Towel on the Health of Children Under 2 Years Old in Rural Communities in Nyanza Province, Kenya SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID HYGIENE BEHAVIORS; DIARRHEA; WATER; RISK; CONTAMINATION; VARIABILITY AB To assess the health impact of reusable, antimicrobial hand towels, we conducted a cluster randomized, yearlong field trial. At baseline, we surveyed mothers, and gave four towels plus hygiene education to intervention households and education alone to controls. At biweekly home visits, we asked about infections in children < 2 years old and tested post-handwashing hand rinse samples of 20% of mothers for Escherichia coli. At study's conclusion, we tested 50% of towels for E. coli. Baseline characteristics between 188 intervention and 181 control households were similar. Intervention and control children had similar rates of diarrhea (1.47 versus 1.48, P = 0.99), respiratory infections (1.38 versus 1.48, P = 0.92), skin infections (1.76 versus 1.79, P = 0.81), and subjective fever (2.62 versus 3.40, P = 0.04) per 100 person-visits. Post-handwashing hand contamination was similar; 67% of towels exhibited E. coli contamination. Antimicrobial hand towels became contaminated over time, did not improve hand hygiene, or prevent diarrhea, respiratory infections, or skin infections. C1 Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. Safe Water & AIDS Project, Kisumu, Kenya. RP Slayton, RB (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA. EM via3@cdc.gov OI Brown, Allison/0000-0003-0011-0309 FU CDC Foundation FX This study was supported by the CDC Foundation that received a donation from the towel manufacturer, Vestergaard-Frandsen. NR 15 TC 0 Z9 0 U1 2 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2016 VL 94 IS 2 BP 437 EP 444 DI 10.4269/ajtmh.14-0566 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA DC8JK UT WOS:000369465500033 PM 26643530 ER PT J AU Bergholz, TM den Bakker, HC Katz, LS Silk, BJ Jackson, KA Kucerova, Z Joseph, LA Turnsek, M Gladney, LM Halpin, JL Xavier, K Gossack, J Ward, TJ Frace, M Tarrc, CL AF Bergholz, Teresa M. den Bakker, Henk C. Katz, Lee S. Silk, Benjamin J. Jackson, Kelly A. Kucerova, Zuzana Joseph, Lavin A. Turnsek, Maryann Gladney, Lori M. Halpin, Jessica L. Xavier, Karen Gossack, Joseph Ward, Todd J. Frace, Michael Tarrc, Cheryl L. TI Determination of Evolutionary Relationships of Outbreak-Associated Listeria monocytogenes Strains of Serotypes 1/2a and 1/2b by Whole-Genome Sequencing SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID SINGLE NUCLEOTIDE POLYMORPHISMS; MOBILE GENETIC ELEMENTS; MULTISTATE OUTBREAK; UNITED-STATES; INVASIVE LISTERIOSIS; MAXIMUM-LIKELIHOOD; PASTEURIZED MILK; EPIDEMIC CLONES; GASTROENTERITIS; SURVEILLANCE AB We used whole-genome sequencing to determine evolutionary relationships among 20 outbreak-associated clinical isolates of Listeria monocytogenes serotypes 1/2a and 1/2b. Isolates from 6 of 11 outbreaks fell outside the clonal groups or "epidemic clones" that have been previously associated with outbreaks, suggesting that epidemic potential may be widespread in L. monocytogenes and is not limited to the recognized epidemic clones. Pairwise comparisons between epidemiologically related isolates within clonal complexes showed that genome-level variation differed by 2 orders of magnitude between different comparisons, and the distribution of point mutations (core versus accessory genome) also varied. In addition, genetic divergence between one closely related pair of isolates from a single outbreak was driven primarily by changes in phage regions. The evolutionary analysis showed that the changes could be attributed to horizontal gene transfer; members of the diverse bacterial community found in the production facility could have served as the source of novel genetic material at some point in the production chain. The results raise the question of how to best utilize information contained within the accessory genome in outbreak investigations. The full magnitude and complexity of genetic changes revealed by genome sequencing could not be discerned from traditional subtyping methods, and the results demonstrate the challenges of interpreting genetic variation among isolates recovered from a single outbreak. Epidemiological information remains critical for proper interpretation of nucleotide and structural diversity among isolates recovered during outbreaks and will remain so until we understand more about how various population histories influence genetic variation. C1 [Bergholz, Teresa M.] N Dakota State Univ, Fargo, ND 58105 USA. [den Bakker, Henk C.] Cornell Univ, Ithaca, NY USA. [Katz, Lee S.; Silk, Benjamin J.; Jackson, Kelly A.; Kucerova, Zuzana; Joseph, Lavin A.; Turnsek, Maryann; Gladney, Lori M.; Halpin, Jessica L.; Frace, Michael; Tarrc, Cheryl L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Xavier, Karen; Gossack, Joseph] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Ward, Todd J.] ARS, USDA, Peoria, IL USA. [den Bakker, Henk C.] Texas Tech Univ, Lubbock, TX 79409 USA. RP Tarrc, CL (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM ctarr@cdc.gov RI Bergholz, Teresa/A-2815-2010 OI Bergholz, Teresa/0000-0002-3976-5858 FU USDA NIFA Special Research Grants [2008-34459-19043, 2009-34459-19750] FX T.M.B. and H.C.D.B. thank M. Wiedmann for support from USDA NIFA Special Research Grants 2008-34459-19043 and 2009-34459-19750. NR 54 TC 9 Z9 9 U1 3 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 EI 1098-5336 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD FEB PY 2016 VL 82 IS 3 BP 928 EP 938 DI 10.1128/AEM.02440-15 PG 11 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA DC7BR UT WOS:000369373800017 PM 26590286 ER PT J AU Velasquez, GE Cegielski, JP Murray, MB Yagui, MJA Asencios, LL Bayona, JN Bonilla, CA Jave, HO Yale, G Suarez, CZ Sanchez, E Rojas, C Atwood, SS Contreras, CC Cruz, JS Shin, SS AF Velasquez, Gustavo E. Cegielski, J. Peter Murray, Megan B. Yagui, Martin J. A. Asencios, Luis L. Bayona, Jaime N. Bonilla, Cesar A. Jave, Hector O. Yale, Gloria Suarez, Carmen Z. Sanchez, Eduardo Rojas, Christian Atwood, Sidney S. Contreras, Carmen C. Cruz, Janeth Santa Shin, Sonya S. TI Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study SO BMC INFECTIOUS DISEASES LA English DT Article DE Tuberculosis; Human immunodeficiency virus; Clinical outcomes; Mortality; Prospective cohort study; Operational research ID MULTIDRUG-RESISTANT TUBERCULOSIS; ANTIRETROVIRAL THERAPY; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; INFECTED ADULTS; RISK-FACTORS; OUTCOMES; PROGRAM; IMPLEMENTATION; PREDICTORS AB Background: Human immunodeficiency virus (HIV)-associated tuberculosis deaths have decreased worldwide over the past decade. We sought to evaluate the effect of HIV status on tuberculosis mortality among patients undergoing treatment for tuberculosis in Lima, Peru, a low HIV prevalence setting. Methods: We conducted a prospective cohort study of patients treated for tuberculosis between 2005 and 2008 in two adjacent health regions in Lima, Peru (Lima Ciudad and Lima Este). We constructed a multivariate Cox proportional hazards model to evaluate the effect of HIV status on mortality during tuberculosis treatment. Results: Of 1701 participants treated for tuberculosis, 136 (8.0 %) died during tuberculosis treatment. HIV-positive patients constituted 11.0 % of the cohort and contributed to 34.6 % of all deaths. HIV-positive patients were significantly more likely to die (25.1 vs. 5.9 %, P < 0.001) and less likely to be cured (28.3 vs. 39.4 %, P = 0.003). On multivariate analysis, positive HIV status (hazard ratio [HR] = 6.06; 95 % confidence interval [CI], 3.96-9.27), unemployment (HR = 2.24; 95 % CI, 1.55-3.25), and sputum acid-fast bacilli smear positivity (HR = 1.91; 95 % CI, 1.10-3.31) were significantly associated with a higher hazard of death. Conclusions: We demonstrate that positive HIV status was a strong predictor of mortality among patients treated for tuberculosis in the early years after Peru started providing free antiretroviral therapy. As HIV diagnosis and antiretroviral therapy provision are more widely implemented for tuberculosis patients in Peru, future operational research should document the changing profile of HIV-associated tuberculosis mortality. C1 [Velasquez, Gustavo E.; Shin, Sonya S.] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA. [Velasquez, Gustavo E.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Velasquez, Gustavo E.; Shin, Sonya S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Cegielski, J. Peter] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Murray, Megan B.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA. [Murray, Megan B.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Murray, Megan B.; Atwood, Sidney S.; Shin, Sonya S.] Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA. [Yagui, Martin J. A.] Inst Nacl Salud, Oficina Gen Invest & Transferencia Tecnol, Lima, Peru. [Yagui, Martin J. A.] Univ Nacl Mayor San Marcos, Dept Acad Med Prevent & Salud Publ, Lima 14, Peru. [Asencios, Luis L.] Inst Nacl Salud, Lab Nacl Referencia Micobacterias, Lima, Peru. [Bayona, Jaime N.] World Bank Grp, Hlth Nutr & Populat, Washington, DC USA. [Bonilla, Cesar A.; Jave, Hector O.] Minist Salud Peru, Estrategia Sanitaria Nacl Prevenc & Control TB, Lima, Peru. [Yale, Gloria] Direcc Salud V Lima Ciudad, Programa Control TB, Lima, Peru. [Suarez, Carmen Z.] Direcc Salud IV Lima Este, Programa Control TB, Lima, Peru. [Sanchez, Eduardo] Hosp Nacl Hipolito Unanue, Serv Enfermedades Infecciosas & Trop, Lima, Peru. [Rojas, Christian] Inst Nacl Cardiovasc Carlos Alberto Peschiera Car, Serv Neumol, Lima, Peru. [Contreras, Carmen C.; Cruz, Janeth Santa; Shin, Sonya S.] Partners Hlth Socios Salud, Lima, Peru. RP Velasquez, GE (reprint author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA.; Velasquez, GE (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. EM gvelasquez@bwh.harvard.edu OI Velasquez, Gustavo/0000-0003-1438-0692 FU Bill and Melinda Gates Foundation; U.S. Centers for Disease Control and Prevention; National Institute of Allergy and Infectious Diseases at the National Institutes of Health [K23 AI054591, T32 AI007433]; Infectious Diseases Society of America; Heiser Foundation; Division of Global Health Equity at Brigham and Women's Hospital FX This publication was supported by the Bill and Melinda Gates Foundation; the U.S. Centers for Disease Control and Prevention; the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (grant numbers K23 AI054591 to SSS and T32 AI007433 to GEV); the Infectious Diseases Society of America; and the Heiser Foundation. GEV received support for publication costs from the Division of Global Health Equity at Brigham and Women's Hospital. The content is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. Centers for Disease Control and Prevention, the National Institutes of Health, or the institutions with which the authors are affiliated. The funding sources played no role in the design, collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication. NR 34 TC 0 Z9 0 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD FEB 1 PY 2016 VL 16 AR 45 DI 10.1186/s12879-016-1375-8 PG 11 WC Infectious Diseases SC Infectious Diseases GA DC6YA UT WOS:000369364300001 PM 26831140 ER PT J AU Kalman, LV Agundez, JAG Appell, ML Black, JL Bell, GC Boukouvala, S Bruckner, C Bruford, E Caudle, K Coulthard, SA Daly, AK Del Tredici, AL den Dunnen, JT Drozda, K Everts, RE Flockhart, D Freimuth, RR Gaedigk, A Hachad, H Hartshorne, T Ingelman-Sundberg, M Klein, TE Lauschke, VM Maglott, DR McLeod, HL McMillin, GA Meyer, UA Muller, DJ Nickerson, DA Oetting, WS Pacanowski, M Pratt, VM Relling, MV Roberts, A Rubinstein, WS Sangkuhl, K Schwab, M Scott, SA Sim, SC Thirumaran, RK Toji, LH Tyndale, RF van Schaik, RHN Whirl-Carrillo, M Yeo, KTJ Zanger, UM AF Kalman, L. V. Agundez, J. A. G. Appell, M. Lindqvist Black, J. L. Bell, G. C. Boukouvala, S. Bruckner, C. Bruford, E. Caudle, K. Coulthard, S. A. Daly, A. K. Del Tredici, A. L. den Dunnen, J. T. Drozda, K. Everts, R. E. Flockhart, D. Freimuth, R. R. Gaedigk, A. Hachad, H. Hartshorne, T. Ingelman-Sundberg, M. Klein, T. E. Lauschke, V. M. Maglott, D. R. McLeod, H. L. McMillin, G. A. Meyer, U. A. Mueller, D. J. Nickerson, D. A. Oetting, W. S. Pacanowski, M. Pratt, V. M. Relling, M. V. Roberts, A. Rubinstein, W. S. Sangkuhl, K. Schwab, M. Scott, S. A. Sim, S. C. Thirumaran, R. K. Toji, L. H. Tyndale, R. F. van Schaik, R. H. N. Whirl-Carrillo, M. Yeo, K. T. J. Zanger, U. M. TI Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Article ID PERSONALIZED MEDICINE; IMPLEMENTATION CONSORTIUM; MOLECULAR-PATHOLOGY; VKORC1 HAPLOTYPES; CLINICAL-PRACTICE; DRUG DEVELOPMENT; INFORMATION; PERSPECTIVE; ASSOCIATION; TRANSPORTER AB This article provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using different nomenclature systems. In addition, PGx analysis may detect different sets of variants for each gene, which can affect interpretation of results. This practice has caused confusion and may thereby impede the adoption of clinical PGx testing. Standardization is critical to move PGx forward. C1 [Kalman, L. V.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Agundez, J. A. G.] Univ Extremadura, Dept Pharmacol, Caceres, Spain. [Appell, M. Lindqvist] Linkoping Univ, Fac Med & Hlth Sci, Dept Med & Hlth Sci, Div Drug Res, Linkoping, Sweden. [Black, J. L.; Freimuth, R. R.] Mayo Clin, Rochester, MN USA. [Bell, G. C.; McLeod, H. L.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Boukouvala, S.] Democritus Univ Thrace, Dept Mol Biol & Genet, Alexandroupolis, Greece. [Bruckner, C.] Affymetrix, Santa Clara, CA USA. [Bruford, E.] European Mol Biol Lab, EMBL EBI, HUGO Gene Nomenclature Comm, Wellcome Genome Campus, Hinxton, England. [Caudle, K.; Relling, M. V.] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA. [Coulthard, S. A.; Daly, A. K.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Del Tredici, A. L.] Millennium Hlth LLC, San Diego, CA USA. [den Dunnen, J. T.] Leiden Univ, Med Ctr, Dept Human Genet & Clin Genet, Leiden, Netherlands. [Drozda, K.; Pacanowski, M.] US FDA, Silver Spring, MD USA. [Everts, R. E.] Agena Biosci, San Diego, CA USA. [Flockhart, D.; Pratt, V. M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Gaedigk, A.] Univ Missouri, Childrens Mercy Kansas City, Div Clin Pharmacol & Therapeut Innovat, Kansas City, MO 64110 USA. [Gaedigk, A.] Univ Missouri, Sch Med, Kansas City, MO 64108 USA. [Hachad, H.] Translat Software, Bellevue, WA USA. [Hartshorne, T.] Thermo Fisher Sci, Dept Genet Anal, San Francisco, CA USA. [Ingelman-Sundberg, M.; Lauschke, V. M.; Sim, S. C.] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden. [Klein, T. E.; Sangkuhl, K.; Whirl-Carrillo, M.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA. [Maglott, D. R.; Rubinstein, W. S.] Natl Lib Med, NIH, Natl Ctr Biotechnol Informat, Bethesda, MD USA. [McMillin, G. A.] Univ Utah, Salt Lake City, UT USA. [McMillin, G. A.] ARUP Labs, Salt Lake City, UT USA. [Meyer, U. A.] Univ Basel, Basel, Switzerland. [Mueller, D. J.] Univ Toronto, Dept Psychiat, CAMH, Toronto, ON, Canada. [Nickerson, D. A.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Oetting, W. S.] Univ Minnesota, Dept Expt & Clin Pharmacol, Minneapolis, MN USA. [Roberts, A.] Aegis Sci Corp, Nashville, TN USA. [Schwab, M.; Zanger, U. M.] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Auerbachstr 112, Stuttgart, Germany. [Schwab, M.; Zanger, U. M.] Univ Hosp, Dept Clin Pharmacol, Tubingen, Germany. [Scott, S. A.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Thirumaran, R. K.] Genelex Corp, Seattle, WA USA. [Toji, L. H.] Coriell Inst Med Res, Camden, NJ USA. [Tyndale, R. F.] Univ Toronto, CAMH, Toronto, ON, Canada. [Tyndale, R. F.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Tyndale, R. F.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada. [van Schaik, R. H. N.] Erasmus MC, Dept Clin Chem, Int Federat Clin Chem IFCC Task Force Pharmacogen, Rotterdam, Netherlands. [Yeo, K. T. J.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA. RP Kalman, LV (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM LKalman@cdc.gov RI Agundez, Jose/A-5503-2008; Mueller, Daniel/L-4159-2016; Zanger, Ulrich/A-9364-2012; Daly, Ann/H-3144-2011; OI Mueller, Daniel/0000-0003-4978-4400; Zanger, Ulrich/0000-0002-5276-2002; Daly, Ann/0000-0002-7321-0629; Agundez, Jose/0000-0001-6895-9160; Bruford, Elspeth/0000-0002-8380-5247; Lauschke, Volker/0000-0002-1140-6204 FU Intramural CDC HHS [CC999999]; NCI NIH HHS [P30 CA021765]; NHGRI NIH HHS [U01 HG007762, U01HG007762, U41 HG003345, U41HG003345]; NIDA NIH HHS [R01 DA035736]; NIGMS NIH HHS [R24GM115264, 2 R01 GM088076-05, K23 GM104401, R01 GM088076, R24 GM061374, R24 GM115264, R24 GM61374, U19 GM061388, U19 GM61388]; Wellcome Trust [099129/Z/12/Z] NR 54 TC 8 Z9 9 U1 6 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9236 EI 1532-6535 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD FEB PY 2016 VL 99 IS 2 BP 172 EP 185 DI 10.1002/cpt.280 PG 14 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DC9HW UT WOS:000369533100020 PM 26479518 ER PT J AU Lyapustina, T Rutkow, L Chang, HY Daubresse, M Ramji, AF Faul, M Stuart, EA Alexander, GC AF Lyapustina, Tatyana Rutkow, Lainie Chang, Hsien-Yen Daubresse, Matthew Ramji, Alim F. Faul, Mark Stuart, Elizabeth A. Alexander, G. Caleb TI Effect of a "pill mill" law on opioid prescribing and utilization: The case of Texas SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Prescription pain medication; Pill mill law; Prescription drug monitoring; Time series analysis ID DRUG-MONITORING PROGRAM; NONMALIGNANT PAIN; OVERDOSE; DEATHS; INTERVENTIONS; DIAGNOSIS; FLORIDA; IMPACT; STATES AB Background: States have attempted to reduce prescription opioid abuse through strengthening the regulation of pain management clinics; however, the effect of such measures remains unclear. We quantified the impact of Texas's September 2010 "pill mill" law on opioid prescribing and utilization. Methods: We used the IMS Health LRx LifeLink database to examine anonymized, patient-level pharmacy claims for a closed cohort of individuals filling prescription opioids in Texas between September 2009 and August 2011. Our primary outcomes were derived at a monthly level and included: (1) average morphine equivalent dose (MED) per transaction; (2) aggregate opioid volume; (3) number of opioid prescriptions; and (4) quantity of opioid pills dispensed. We compared observed values with the counterfactual, which we estimated from pre-intervention levels and trends. Results: Texas's pill mill law was associated with declines in average MED per transaction (-0.57 mg/month, 95% confidence interval [CI] -1.09, -0.057), monthly opioid volume (-9.99 kg/month, CI -12.86, -7.11), monthly number of opioid prescriptions (-12,200 prescriptions/month, CI -15,300, -9,150) and monthly quantity of opioid pills dispensed (-714,000 pills/month, CI -877,000, -550,000). These reductions reflected decreases of 8.1-24.3% across the outcomes at one year compared with the counterfactual, and they were concentrated among prescribers and patients with the highest opioid prescribing and utilization at baseline. Conclusions: Following the implementation of Texas's 2010 pill mill law, there were clinically significant reductions in opioid dose, volume, prescriptions and pills dispensed within the state, which were limited to individuals with higher levels of baseline opioid prescribing and utilization. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Lyapustina, Tatyana; Ramji, Alim F.] Johns Hopkins Sch Med, 733 N Broadway, Baltimore, MD 21205 USA. [Rutkow, Lainie; Chang, Hsien-Yen; Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway St, Baltimore, MD 21205 USA. [Daubresse, Matthew; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St W6027, Baltimore, MD 21205 USA. [Daubresse, Matthew; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, 615 N Wolfe St W6035, Baltimore, MD 21205 USA. [Faul, Mark] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy,NE Mail Stop MS F-63, Atlanta, GA 30341 USA. [Alexander, G. Caleb] Johns Hopkins Med, Div Gen Internal Med, 1800 Orleans St, Baltimore, MD 21287 USA. [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Hampton House,624 N Broadway,8th Floor, Baltimore, MD 21205 USA. [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, 615 N Wolfe St, Baltimore, MD 21205 USA. RP Lyapustina, T (reprint author), Johns Hopkins Sch Med, 733 N Broadway, Baltimore, MD 21205 USA. EM tlyapus1@jhmi.edu FU Centers for Disease Control and Prevention (CDC) [U01CE002499]; Johns Hopkins Institute for Clinical and Translational Research (ICTR) from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH) [TL1TR001078]; NIH Roadmap for Medical Research FX This manuscript was supported by the Centers for Disease Control and Prevention (CDC) under Cooperative Agreement U01CE002499. CDC personnel participated in the analysis and interpretation of the data, as well as preparation of the manuscript and final approval of the manuscript prior to publication. The opinions and conclusions expressed are solely of the author(s) and should not be construed as representing the opinions of CDC or any agency of the Federal Government.; This manuscript was additionally supported by the Johns Hopkins Institute for Clinical and Translational Research (ICTR) which is funded in part by Grant Number TL1TR001078 from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS or NIH. NR 27 TC 3 Z9 3 U1 2 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD FEB 1 PY 2016 VL 159 BP 190 EP 197 DI 10.1016/j.drugalcdep.2015.12.025 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DC8LX UT WOS:000369472200025 PM 26778760 ER PT J AU Hao, YP Strosnider, H Balluz, L Qualters, JR AF Hao, Yongping Strosnider, Heather Balluz, Lina Qualters, Judith R. TI Geographic Variation in the Association between Ambient Fine Particulate Matter (PM2.5) and Term Low Birth Weight in the United States SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID AIR-POLLUTION; PRETERM BIRTH; RESIDENTIAL-MOBILITY; PREGNANCY OUTCOMES; PRENATAL EXPOSURE; CALIFORNIA; INFANTS; HEALTH; RISK; CONSTITUENTS AB BACKGROUND: Studies on the association between prenatal exposure to fine particulate matter <= 2.5 mu m in aerodynamic diameter (PM2.5) and term low birth weight (LBW) have resulted in inconsistent findings. Most studies were conducted in snapshots of small geographic areas and no national study exists. OBJECTIVES: We investigated geographic variation in the associations between ambient PM2.5 during pregnancy and term LBW in the contiguous United States. METHODS: A total of 3,389,450 term singleton births in 2002 (37-44weeks gestational age and birth weight of 1,000-5,500g) were linked to daily PM2.5 via imputed birth days. We generated average daily PM2.5 during the entire pregnancy and each trimester. Multi-level logistic regression models with county-level random effects were used to evaluate the associations between term LBW and PM2.5 during pregnancy. RESULTS: Without adjusting for covariates, the odds of term LBW increased 2% [odds ratio (OR) = 1.02; 95% CI: 1.00, 1.03] for every 5-mu g/m(3) increase in PM2.5 exposure during the second trimester only, which remained unchanged after adjusting for county-level poverty (OR = 1.02; 95% CI: 1.01, 1.04). The odds did change to null after adjusting for individual-level predictors (OR = 1.00; 95% CI: 0.99, 1.02). Multi-level analyses, stratified by census division, revealed significant positive associations of term LBW and PM2.5 exposure (during the entire pregnancy or a specific trimester) in three census divisions of the United States: Middle Atlantic, East North Central, and West North Central, and significant negative association in the Mountain division. CONCLUSIONS: Our study provided additional evidence on the associations between PM2.5 exposure during pregnancy and term LBW from a national perspective. The magnitude and direction of the estimated associations between PM2.5 exposure and term LBW varied by geographic locations in the United States. C1 [Hao, Yongping; Strosnider, Heather; Balluz, Lina; Qualters, Judith R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Hwy NE,MS-F-60, Atlanta, GA 30341 USA. RP Hao, YP (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Hwy NE,MS-F-60, Atlanta, GA 30341 USA. EM yhao@cdc.gov NR 45 TC 5 Z9 5 U1 6 U2 15 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD FEB PY 2016 VL 124 IS 2 BP 250 EP 255 DI 10.1289/ehp.1408798 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA DC6NX UT WOS:000369337900019 PM 26046626 ER EF